<SEC-DOCUMENT>0001159036-24-000037.txt : 20240507
<SEC-HEADER>0001159036-24-000037.hdr.sgml : 20240507
<ACCEPTANCE-DATETIME>20240507160958
ACCESSION NUMBER:		0001159036-24-000037
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		82
CONFORMED PERIOD OF REPORT:	20240331
FILED AS OF DATE:		20240507
DATE AS OF CHANGE:		20240507

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HALOZYME THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001159036
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				880488686
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32335
		FILM NUMBER:		24921902

	BUSINESS ADDRESS:	
		STREET 1:		12390 EL CAMINO REAL
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		(858) 794-8889

	MAIL ADDRESS:	
		STREET 1:		12390 EL CAMINO REAL
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HALOZYME THERAPEUTICS INC
		DATE OF NAME CHANGE:	20040312

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GLOBAL YACHT SERVICES INC
		DATE OF NAME CHANGE:	20010912
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>halo-20240331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:17e6b7b2-f6c0-4a96-9180-046700296928,g:1765a142-e24e-49b0-883b-7a52af9d0516,d:56f00e77098e4077b277260135e70ed7-->
<html xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:halo="http://www.halozyme.com/20240331" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>halo-20240331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-25">0001159036</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-26">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-27">2024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-28">Q1</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-29">12/31</ix:nonNumeric><ix:nonNumeric contextRef="c-3" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="f-420">http://fasb.org/us-gaap/2023#PrepaidExpenseAndOtherAssetsCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-3" name="us-gaap:DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration" id="f-422">http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-3" name="us-gaap:DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration" id="f-424">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-129" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="f-557">P7Y</ix:nonNumeric><ix:nonNumeric contextRef="c-224" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-821">328</ix:nonNumeric><ix:nonNumeric contextRef="c-228" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-822">460</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="halo-20240331.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:CollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:CollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>halo:product</xbrli:measure></xbrli:unit><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">halo:ArgenxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">halo:TakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">halo:JanssenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">halo:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>halo:segment</xbrli:measure></xbrli:unit><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="security"><xbrli:measure>halo:security</xbrli:measure></xbrli:unit><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:ProprietaryProductsSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:ProprietaryProductsSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:BulkrHuPH20Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:BulkrHuPH20Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DevicePartneredProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DevicePartneredProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:EventBasedDevelopmentAndRegulatoryMilestoneAndOtherFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:EventBasedDevelopmentAndRegulatoryMilestoneAndOtherFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DeviceLicensingAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DeviceLicensingAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:LicenseFeesAndEventBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">halo:OthercollaboratorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2024-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DevicePartneredProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DevicePartneredProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:CollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:CollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:ProductSalesOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:ProductSalesOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ResearchEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ResearchEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:AutoInjectorTechnologyPlatformMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:AutoInjectorTechnologyPlatformMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:XYOSTEDProprietaryProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:XYOSTEDProprietaryProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="trading_day"><xbrli:measure>halo:trading_day</xbrli:measure></xbrli:unit><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="businessday"><xbrli:measure>halo:businessDay</xbrli:measure></xbrli:unit><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="halo:AnnualInterestPaymentPeriodAxis">halo:DebtInstrumentInterestPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="halo:AnnualInterestPaymentPeriodAxis">halo:DebtInstrumentInterestPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="halo:AnnualInterestPaymentPeriodAxis">halo:DebtInstrumentInterestPeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="halo:AnnualInterestPaymentPeriodAxis">halo:DebtInstrumentInterestPeriodFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="halo:VariableRateComponentAxis">halo:VariableRateComponentOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="halo:VariableRateComponentAxis">halo:VariableRateComponentTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="halo:VariableRateComponentAxis">halo:VariableRateComponentTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:RSURSAandPRSUawardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:RSURSAandPRSUawardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">halo:A2021ESPPPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">halo:A2021ESPPPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">halo:A2021ESPPPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:RestrictedStockUnitsAndPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:RestrictedStockUnitsAndPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">halo:AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">halo:AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">halo:A2024CapitalReturnProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:RestrictStockUnitsPerformanceSharesAndESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:RestrictStockUnitsPerformanceSharesAndESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">halo:HelenTorleyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">halo:HelenTorleyPriorPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">halo:HelenTorleyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">halo:HelenTorleyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">halo:HelenTorleyPriorPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">halo:HelenTorleyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">halo:HelenTorleyMarch2024PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">halo:HelenTorleyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">halo:HelenTorleyMarch2024PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">halo:NicoleLaBrosseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">halo:NicoleLaBrosseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i56f00e77098e4077b277260135e70ed7_1"></div><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Mark One)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.861%"><tr><td style="width:1.0%"/><td style="width:4.756%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.044%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="f-2">&#9746;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">March&#160;31, 2024</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.861%"><tr><td style="width:1.0%"/><td style="width:4.756%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.044%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="f-4">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-32335</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><img src="halo-20240331_g1.jpg" alt="Halo Logo updated.jpg" style="height:75px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">_______________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">HALOZYME THERAPEUTICS, INC.</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Exact name of registrant as specified in its charter</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">_______________________________________</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.861%"><tr><td style="width:1.0%"/><td style="width:48.533%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.486%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">88-0488686</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">12390 El Camino Real</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">92130</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">San Diego</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Zip Code)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-12">California</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-13">858</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-14">794-8889</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(Former name, former address and former fiscal year, if changed since last report)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.277%"><tr><td style="width:1.0%"/><td style="width:33.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.010%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.104%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-15">Common Stock, $0.001 par value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-16">HALO</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-17">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-18">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-19">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.:</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.277%"><tr><td style="width:1.0%"/><td style="width:31.925%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.213%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.633%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-20">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer&#160;&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="f-21">&#9744;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-22">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="f-23">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The number of outstanding shares of the registrant&#8217;s common stock, par value $0.001 per share, was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-24">127,274,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> as of April&#160;30, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="height:22.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i56f00e77098e4077b277260135e70ed7_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HALOZYME THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160; </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:8.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:81.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.123%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i56f00e77098e4077b277260135e70ed7_13">PART&#160;I &#8212; FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i56f00e77098e4077b277260135e70ed7_16">Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i56f00e77098e4077b277260135e70ed7_19">Condensed Consolidated Balance Sheets (Unaudited) - March 31, 2024 and December 31, 2023</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i56f00e77098e4077b277260135e70ed7_19">3</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i56f00e77098e4077b277260135e70ed7_22">Condensed Consolidated Statements of Income (Unaudited) - Three Months Ended March 31, 2024 and 2023</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i56f00e77098e4077b277260135e70ed7_22">4</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i56f00e77098e4077b277260135e70ed7_25">Condensed Consolidated Statements of Comprehensive Income (Unaudited) - Three Months Ended March 31, 2024 and 2023</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i56f00e77098e4077b277260135e70ed7_25">5</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i56f00e77098e4077b277260135e70ed7_28">Condensed Consolidated Statements of Cash Flows (Unaudited) - Three Months Ended March 31, 2024 and 2023</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i56f00e77098e4077b277260135e70ed7_28">6</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i56f00e77098e4077b277260135e70ed7_31">Condensed Consolidated Statements of Stockholders&#8217; Equity (Unaudited) - Three Months Ended March 31, 2024 and 2023</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i56f00e77098e4077b277260135e70ed7_31">7</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i56f00e77098e4077b277260135e70ed7_34">Notes to Condensed Consolidated Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i56f00e77098e4077b277260135e70ed7_37">8</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i56f00e77098e4077b277260135e70ed7_76">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i56f00e77098e4077b277260135e70ed7_76">35</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i56f00e77098e4077b277260135e70ed7_94">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i56f00e77098e4077b277260135e70ed7_94">52</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i56f00e77098e4077b277260135e70ed7_97">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i56f00e77098e4077b277260135e70ed7_97">52</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i56f00e77098e4077b277260135e70ed7_100">PART&#160;II &#8212; OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i56f00e77098e4077b277260135e70ed7_103">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i56f00e77098e4077b277260135e70ed7_103">53</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i56f00e77098e4077b277260135e70ed7_106">Risk Factors</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i56f00e77098e4077b277260135e70ed7_106">53</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i56f00e77098e4077b277260135e70ed7_109">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i56f00e77098e4077b277260135e70ed7_109">53</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i56f00e77098e4077b277260135e70ed7_112">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i56f00e77098e4077b277260135e70ed7_112">53</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i56f00e77098e4077b277260135e70ed7_115">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i56f00e77098e4077b277260135e70ed7_115">53</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i56f00e77098e4077b277260135e70ed7_118">Other Information</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i56f00e77098e4077b277260135e70ed7_118">53</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i56f00e77098e4077b277260135e70ed7_121">Exhibits</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i56f00e77098e4077b277260135e70ed7_121">54</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i56f00e77098e4077b277260135e70ed7_124">SIGNATURES</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i56f00e77098e4077b277260135e70ed7_124">55</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i56f00e77098e4077b277260135e70ed7_13"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I &#8212; FINANCIAL INFORMATION</span></div><div id="i56f00e77098e4077b277260135e70ed7_16"></div><div style="padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. &#160;&#160;&#160;&#160;Financial Statements</span></div><div id="i56f00e77098e4077b277260135e70ed7_19"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HALOZYME THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:71.587%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.827%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.677%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-30">164,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-31">118,370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities, available-for-sale</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="f-32">298,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="f-33">217,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net and contract assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="halo:AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="f-34">195,902</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="halo:AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="f-35">234,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-36">168,541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-37">127,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-38">45,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-39">48,613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-40">873,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-41">746,424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="halo:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-42">78,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="halo:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-43">74,944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-44">17,319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-45">17,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-46">416,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-47">416,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-48">455,116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-49">472,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="f-50">616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-51">4,386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-52">1,841,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-53">1,733,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-54">13,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-55">11,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-56">118,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-57">100,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-58">131,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-59">112,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-60">1,500,879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-61">1,499,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-62">31,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-63">37,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-64">1,663,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-65">1,649,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 11)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-3" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-66"/></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-67"/></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock - $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-68"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-69">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-70"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-71">20,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="6" id="f-72"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="6" id="f-73"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="f-74"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="f-75">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares </span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;issued and outstanding</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock - $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-78"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-79">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-80"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-81">300,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-82"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-83">127,186</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-84"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-85">126,770</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March&#160;31, 2024 and December&#160;31, 2023, respectively</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-86">127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-87">127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-88">11,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-89">2,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-90">1,486</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-91">9,278</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-92">167,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-93">90,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-94">177,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-95">83,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-96">1,841,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-97">1,733,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i56f00e77098e4077b277260135e70ed7_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HALOZYME THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-98">120,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-99">99,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-100">58,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-101">60,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues under collaborative agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-102">16,703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-103">1,709</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-104">195,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-105">162,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-106">28,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-107">35,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangibles</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-108">17,763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-109">17,835</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-110">19,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-111">17,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-112">35,134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-113">37,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-114">100,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-115">108,341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-116">95,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-117">53,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment and other income, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-118">4,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-119">2,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-120">4,507</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-121">4,543</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-122">96,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-123">52,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-124">19,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-125">12,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-126">76,823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-127">39,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-128">0.61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-129">0.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-130">0.60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-131">0.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-132">126,941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-133">135,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-134">128,887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-135">137,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i56f00e77098e4077b277260135e70ed7_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HALOZYME THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.921%"><tr><td style="width:1.0%"/><td style="width:70.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.865%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.843%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.718%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-136">76,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-137">39,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized (loss) gain on marketable securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-138">313</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-139">924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="f-140">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="f-141">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on derivative instruments, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="halo:OtherComprehensiveIncomeLossCashFlowHedgeUnrealizedHoldingGainLossBeforeAdjustmentAfterTax" format="ixt:num-dot-decimal" scale="3" id="f-142">8,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="halo:OtherComprehensiveIncomeLossCashFlowHedgeUnrealizedHoldingGainLossBeforeAdjustmentAfterTax" format="ixt:fixed-zero" scale="3" id="f-143">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gain on derivative instruments, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="3" id="f-144">518</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:fixed-zero" scale="3" id="f-145">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-146">84,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-147">40,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i56f00e77098e4077b277260135e70ed7_28"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HALOZYME THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.475%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-148">76,823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-149">39,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-150">9,874</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-151">7,966</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-152">2,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-153">2,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-154">17,763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-155">17,835</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="f-156">1,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="f-157">1,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of premium on marketable securities, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="f-158">2,365</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="f-159">917</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gain on marketable securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" scale="3" id="f-160">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" format="ixt:fixed-zero" scale="3" id="f-161">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease payments deferred</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="halo:DeferredRentPayments" scale="3" id="f-162">220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="halo:DeferredRentPayments" scale="3" id="f-163">320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="f-164">1,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="f-165">3,874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net and other contract assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-166">38,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-167">36,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-168">40,233</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-169">7,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-170">4,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-171">8,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-172">18,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-173">24,006</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-174">129,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-175">86,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-176">198,763</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-177">109,919</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-178">119,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-179">61,134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-180">3,545</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-181">11,377</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-182">82,681</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-183">60,162</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of 2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:fixed-zero" scale="3" id="f-184">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="f-185">13,483</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-186">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-187">150,083</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement, net of proceeds from issuance of common stock under equity incentive plans</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-188">489</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-189">1,048</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="f-190">489</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-191">164,614</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-192">46,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-193">137,812</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-194">118,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-195">234,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-196">164,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-197">96,883</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental disclosure of non-cash investing and financing activities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts accrued for purchases of property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="f-198">1,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-199">390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-200">1,242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="f-201">406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock issued for conversion of 2024 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="3" id="f-202">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:StockIssued1" scale="3" id="f-203">125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i56f00e77098e4077b277260135e70ed7_31"></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HALOZYME THERAPEUTICS, INC.</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.749%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2024</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Comprehensive (Loss) Income</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Retained Earnings </span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">BALANCE AS OF DECEMBER 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-204">126,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-205">127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-206">2,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-207">9,278</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-208">90,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-209">83,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-210">9,874</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-211">9,874</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock and performance stock units, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="f-212">416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-213">489</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-214">489</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-215">7,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-216">7,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-217">76,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-218">76,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">BALANCE AS OF MARCH 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-219">127,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-220">127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-221">11,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-222">1,486</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-223">167,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-224">177,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Comprehensive (Loss) Income</span></div></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Retained Earnings </span></div></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">BALANCE AS OF DECEMBER 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-225">135,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-226">135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-227">27,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-228">922</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-229">143,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-230">169,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-231">7,966</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-232">7,966</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Issuance of common stock for the conversion of the 2024 Convertible Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-31" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" id="f-233">289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="f-234">126</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="f-235">126</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock and performance stock units, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-31" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="f-236">384</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-237">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-238">1,049</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-239">1,048</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-31" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" format="ixt:num-dot-decimal" scale="3" id="f-240">4,165</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="3" id="f-241">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="3" id="f-242">34,159</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="3" id="f-243">117,138</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="3" id="f-244">151,301</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" scale="3" id="f-245">946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" scale="3" id="f-246">946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-247">39,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-248">39,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">BALANCE AS OF MARCH 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-34" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-249">131,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-250">132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-251">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-252">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-253">65,694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-254">65,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i56f00e77098e4077b277260135e70ed7_34"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div id="i56f00e77098e4077b277260135e70ed7_37"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HALOZYME THERAPEUTICS, INC.</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:NatureOfOperations" id="f-255" continuedAt="f-255-1" escape="true">Organization and Business </ix:nonNumeric></span></div><ix:continuation id="f-255-1"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the innovators of ENHANZE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> drug delivery technology (&#8220;ENHANZE&#8221;) with our proprietary enzyme, rHuPH20, our commercially validated solution is used to facilitate the subcutaneous (&#8220;SC&#8221;) delivery of injected drugs and fluids with the goal of reducing the treatment burden for patients. We license our technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with our partners&#8217; proprietary compounds. We also develop, manufacture and commercialize, for ourselves or with our partners, drug-device combination products using our advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ENHANZE partners&#8217; approved products and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. rHuPH20 works by breaking down hyaluronan (&#8220;HA&#8221;), a naturally occurring carbohydrate that is a major component of the extracellular matrix of the SC space. This temporarily reduces the barrier to bulk fluid flow allowing for improved and more rapid SC delivery of high dose, high volume injectable biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids. We refer to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as ENHANZE. We license our ENHANZE technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the SC route of administration. In the development of proprietary intravenous (&#8220;IV&#8221;) drugs combined with our ENHANZE technology, data has been generated supporting the potential for ENHANZE to reduce patient treatment burden, as a result of shorter duration of SC administration with ENHANZE compared to IV administration. ENHANZE may enable fixed-dose SC dosing compared to weight-based dosing typically required for IV administration, extend the dosing interval for drugs that are already administered subcutaneously and potentially allow for lower rates of infusion-related reactions.&#160;ENHANZE may enable more flexible treatment options such as home administration by a healthcare professional or potentially the patient or caregiver. Lastly, certain proprietary drugs co-formulated with ENHANZE have been granted additional exclusivity, extending the patent life of the product beyond the patent expiry of the proprietary IV drug.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have ENHANZE collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (&#8220;Roche&#8221;), Takeda Pharmaceuticals International AG and Baxalta US Inc. (&#8220;Takeda&#8221;), Pfizer Inc. (&#8220;Pfizer&#8221;), Janssen Biotech, Inc. (&#8220;Janssen&#8221;), AbbVie, Inc. (&#8220;AbbVie&#8221;), Eli Lilly and Company (&#8220;Lilly&#8221;), Bristol-Myers Squibb Company (&#8220;BMS&#8221;), argenx BVBA (&#8220;argenx&#8221;), ViiV Healthcare (the global specialist HIV Company majority owned by GlaxoSmithKline) (&#8220;ViiV&#8221;), Chugai Pharmaceutical Co., Ltd. (&#8220;Chugai&#8221;) and Acumen Pharmaceuticals, Inc. (&#8220;Acumen&#8221;). In addition to receiving upfront licensing fees from our ENHANZE collaborations, we are entitled to receive event and sales-based milestone payments, revenues from the sale of bulk rHuPH20 and royalties from commercial sales of approved partner products co-formulated with ENHANZE. We currently earn royalties from sales of <ix:nonFraction unitRef="product" contextRef="c-1" decimals="INF" name="halo:RoyaltiesReceivedNumberOfProductsSold" format="ixt-sec:numwordsen" scale="0" id="f-256">seven</ix:nonFraction> commercial products including sales of <ix:nonFraction unitRef="product" contextRef="c-38" decimals="INF" name="halo:RoyaltiesReceivedNumberOfProductsSold" format="ixt-sec:numwordsen" scale="0" id="f-257"><ix:nonFraction unitRef="product" contextRef="c-39" decimals="INF" name="halo:RoyaltiesReceivedNumberOfProductsSold" format="ixt-sec:numwordsen" scale="0" id="f-258"><ix:nonFraction unitRef="product" contextRef="c-40" decimals="INF" name="halo:RoyaltiesReceivedNumberOfProductsSold" format="ixt-sec:numwordsen" scale="0" id="f-259">one</ix:nonFraction></ix:nonFraction></ix:nonFraction> commercial product from each of the Takeda, Janssen and argenx collaborations and <ix:nonFraction unitRef="product" contextRef="c-41" decimals="INF" name="halo:RoyaltiesReceivedNumberOfProductsSold" format="ixt-sec:numwordsen" scale="0" id="f-260">four</ix:nonFraction> commercial products products from the Roche collaboration. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have commercialized auto-injector products with several pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (&#8220;Teva&#8221;) and Otter Pharmaceuticals, LLC (&#8220;Otter&#8221;). We have development programs including auto-injectors with Idorsia Pharmaceuticals Ltd. (&#8220;Idorsia&#8221;).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial portfolio of proprietary products includes Hylenex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, utilizing rHuPH20, and XYOSTED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> utilizing our auto-injector technology.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except where specifically noted or the context otherwise requires, references to &#8220;Halozyme,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; and &#8220;us&#8221; in these notes to our condensed consolidated financial statements refer to Halozyme Therapeutics, Inc. and each of its directly and indirectly wholly owned subsidiaries as disclosed in Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i56f00e77098e4077b277260135e70ed7_40"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-261" continuedAt="f-261-1" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="f-261-1" continuedAt="f-261-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-262" escape="true"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim unaudited condensed consolidated financial statements have been prepared for purposes of and in accordance with United States generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and with the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) related to a quarterly report on Form 10-Q. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for a complete set of financial statements. These condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December&#160;31, 2023, filed with the SEC on February&#160;20, 2024. The unaudited financial information for the interim periods presented herein reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operations for the periods presented, with such adjustments consisting only of normal recurring adjustments. Operating results for interim periods are not necessarily indicative of the operating results for an entire fiscal year.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-263" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements include the accounts of Halozyme Therapeutics, Inc. and our wholly owned subsidiaries, Halozyme, Inc. and Antares Pharma, Inc., and Antares Pharma, Inc.&#8217;s wholly owned Swiss subsidiaries, Antares Pharma IPL AG and Antares Pharma AG. All intercompany accounts and transactions have been eliminated.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-264" continuedAt="f-264-1" escape="true"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-264-1">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that we believe to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from our estimates</ix:continuation>.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents and Marketable Securities </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" id="f-265" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of highly liquid investments, readily convertible to cash, which mature within 90 days or less from the date of purchase. As of March&#160;31, 2024, our cash and cash equivalents consisted of money market funds, bank certificate of deposits, U.S. treasury securities and demand deposits at commercial banks.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:MarketableSecuritiesPolicy" id="f-266" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities are investments with original maturities of more than 90 days from the date of purchase that are specifically identified to fund current operations. Marketable securities are considered available-for-sale. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date which reflects management&#8217;s intention to use the proceeds from the sale of these investments to fund our operations, as necessary. Such available-for-sale investments are carried at fair value with unrealized gains and losses recorded in other comprehensive income and included as a separate component of stockholders&#8217; equity. The cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in investment and other income, net in our condensed consolidated statements of income. We use the specific identification method for calculating realized gains and losses on marketable securities sold. None of the realized gains and losses and declines in value that were judged to be as a result of credit loss on marketable securities, if any, are included in investment and other income, net in our condensed consolidated statements of income.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="f-267" continuedAt="f-267-1" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authoritative guidance for fair value measurements establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments include cash equivalents, available-for-sale marketable securities, accounts receivable, prepaid expenses and other assets, accounts payable, accrued expenses and long-term debt. Fair value estimates of these instruments are made at a specific point in time based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore, cannot be determined with precision. The carrying amount of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. </span></div></ix:nonNumeric></ix:continuation><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-261-2" continuedAt="f-261-3"><ix:continuation id="f-267-1"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale marketable securities consist of asset-backed securities, corporate debt securities, U.S. Treasury securities, agency bonds and commercial paper, and are measured at fair value using Level 1 and Level 2 inputs. Level 2 financial instruments are valued using market prices on less active markets and proprietary pricing valuation models with observable inputs, including interest rates, yield curves, maturity dates, issue dates, settlement dates, reported trades, broker-dealer quotes, issue spreads, benchmark securities or other market related data. We obtain the fair value of Level 2 investments from our investment manager, who obtains these fair values from a third-party pricing source. We validate the fair values of Level 2 financial instruments provided by our investment manager by comparing these fair values to a third-party pricing source.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="f-268" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable, net</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable is recorded at the invoiced amount and is non-interest bearing. Accounts receivable is recorded net of estimated prompt pay discounts, distribution fees and chargebacks. We believe the risk of accounts being uncollectible is minimal; therefore, <ix:nonFraction unitRef="usd" contextRef="c-4" decimals="INF" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:fixed-zero" scale="0" id="f-269"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="INF" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:fixed-zero" scale="0" id="f-270">no</ix:nonFraction></ix:nonFraction> significant allowances for doubtful accounts were established as of March&#160;31, 2024 and December&#160;31, 2023.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryPolicyTextBlock" id="f-271" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Inventories are reviewed periodically for potential excess, dated or obsolete status. We evaluate the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the price we expect to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-272" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into operating leases primarily for real estate and automobiles. These leases have contractual terms which range from <ix:nonNumeric contextRef="c-42" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-273">3</ix:nonNumeric> years to <ix:nonNumeric contextRef="c-43" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-274">12</ix:nonNumeric> years. We determine if an arrangement contains a lease at inception. Right of use (&#8220;ROU&#8221;) assets and liabilities resulting from operating leases are included in property and equipment, accrued expenses and other long-term liabilities on our condensed consolidated balance sheets. Operating lease ROU assets and liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the discount rate to calculate the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. Our leases often include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that we will exercise that option. Short-term leases with an initial term of 12 months or less are not recorded on our condensed consolidated balance sheet. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have lease agreements with lease and non-lease components, which are generally accounted for separately. For certain leases, such as automobiles, we account for the lease and non-lease components as a single lease component.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-275" continuedAt="f-275-1" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-275-1">Property and equipment, including ROU assets are recorded at cost, less accumulated depreciation and amortization. Equipment is depreciated using the straight-line method over its estimated useful life ranging from <ix:nonNumeric contextRef="c-42" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-276">three years</ix:nonNumeric> to <ix:nonNumeric contextRef="c-43" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-277"><ix:nonNumeric contextRef="c-43" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-278">ten years</ix:nonNumeric></ix:nonNumeric> and leasehold improvements are amortized using the straight-line method over the estimated useful life of the asset or the lease term, whichever is shorter.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentImpairment" id="f-279" continuedAt="f-279-1" escape="true"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-279-1">We account for long-lived assets in accordance with authoritative guidance for impairment or disposal of long-lived assets. Long-lived assets are reviewed for events or changes in circumstances, which indicate that their carrying value may not be recoverable.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="f-280" escape="true"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income is defined as the change in equity during the period from transactions and other events and circumstances from non-owner sources.</span></div></ix:nonNumeric></ix:continuation><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-261-3" continuedAt="f-261-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtPolicyTextBlock" id="f-281" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Notes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Convertible Notes, the 2027 Convertible Notes and the 2028 Convertible Notes (collectively, the &#8220;Convertible Notes&#8221;) are accounted for in accordance with authoritative guidance for debt and derivatives. We evaluate all the embedded conversion options contained in the Convertible Notes to determine if there are embedded features that require bifurcation as a derivative as required by U.S. GAAP. Based on our analysis, we account for each of our Convertible Notes as single units of accounting, a liability, because we concluded that the conversion features do not require bifurcation as a derivative under embedded derivative authoritative guidance.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:DerivativesMethodsOfAccountingHedgingDerivatives" id="f-282" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flow Hedges - Currency Risks</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the second quarter of 2023, we entered into a cash flow hedging program to mitigate foreign currency exchange risk associated with forecasted royalty revenue denominated in Swiss francs. Under the program, we can hedge these forecasted royalties up to a maximum of <ix:nonNumeric contextRef="c-44" name="us-gaap:DerivativeTermOfContract" format="ixt-sec:durwordsen" id="f-283">four years</ix:nonNumeric> into the future. We hedge these cash flow exposures to reduce the risk of our earnings and cash flows being adversely affected by fluctuations in exchange rates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the hedge accounting treatment, all hedging relationships are formally documented at the inception of the hedge and are highly effective in offsetting changes to future cash flows on hedged transactions. Both at inception of the hedge and on an ongoing basis, we assess whether the foreign currency forward contracts are highly effective in offsetting changes in cash flows of hedged items on a prospective and retrospective basis. If we determine a (i) foreign currency forward contract is not highly effective as a cash flow hedge, (ii) foreign currency forward contract has ceased to be a highly effective hedge or (iii) forecasted transaction is no longer probable of occurring, we would discontinue hedge accounting treatment prospectively. We measure effectiveness based on the change in fair value of the forward currency forward contract and the fair value of the hypothetical foreign currency forward contract with terms that match the critical terms of the risk being hedged. No portion of our foreign currency forward contracts were excluded from the assessment of hedge effectiveness. As of March&#160;31, 2024, all hedges were determined to be highly effective. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets or liabilities associated with our hedging contracts are recorded at fair market value in prepaid expense and other current assets, accrued expenses, or other long-term liabilities, respectively, in our condensed consolidated balance sheets. Gains and losses related to changes in the fair market value of these hedging contracts are recorded as a component of accumulated other comprehensive income (loss) (&#8220;AOCI&#8221;) within stockholder&#8217;s equity in our condensed consolidated balance sheets and reclassified to royalty revenue in our condensed consolidated statements of income in the same period as the recognition of the underlying hedged transaction. In the event the underlying forecasted transaction does not occur, or it becomes probable that it will not occur, within the defined hedge period, we reclassify the gains or losses on the related cash flow hedge from AOCI to royalties revenue in our condensed consolidated statements of income. Settlements from the cash flow hedge are included in operating activities on the condensed consolidated statements of cash flows. Since the fair market value of these hedging contracts is derived from current market rates, the hedging contracts are classified as derivative financial instruments. We do not use derivatives for speculative or trading purposes. As of March&#160;31, 2024, amounts expected to be recognized as a net gain out of AOCI into our condensed consolidated statements of income during the next 12 months are not material.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationsPolicy" id="f-284" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the acquisition method of accounting, we allocate the fair value of the total consideration transferred to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the date of acquisition. These valuations require us to make estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill. Costs incurred to complete a business combination, such as legal and other professional fees, are expensed as incurred.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the initial accounting for a business combination is incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date. We record these adjustments to the provisional amounts with a corresponding offset to goodwill. Any adjustments identified after the measurement period are recorded in our condensed consolidated statements of income.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill, Intangible Assets and Other Long-Lived Asset</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="f-285" continuedAt="f-285-1" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets acquired, including intangible assets and in-process research and development (&#8220;IPR&amp;D&#8221;), and liabilities assumed are measured at fair value as of the acquisition date. Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of the net assets acquired. Intangible assets acquired in a business combination that are used for IPR&amp;D activities are considered indefinite lived until the completion or abandonment of the associated research and development efforts. Upon reaching the end of the relevant research and development project (i.e., upon commercialization), the IPR&amp;D </span></div></ix:nonNumeric></ix:continuation><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-261-4" continuedAt="f-261-5"><ix:continuation id="f-285-1"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">asset is amortized over its estimated useful life. If the relevant research and development project is abandoned, the IPR&amp;D asset is expensed in the period of abandonment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and IPR&amp;D are not amortized; however, they are reviewed for impairment at least annually during the second quarter, or more frequently if an event occurs indicating the potential for impairment. Goodwill and IPR&amp;D are considered to be impaired if the carrying value of the reporting unit or IPR&amp;D asset exceeds its respective fair value.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform our goodwill impairment analysis at the reporting unit level, which aligns with our reporting and operating segment structure and availability of discrete financial information. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair values of our reporting unit is less than the carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and our overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amounts, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair value of the reporting unit with the carrying value, including goodwill. If the carrying amount of the reporting unit exceeds the fair value, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative goodwill impairment test.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our identifiable intangible assets with finite useful lives are typically comprised of acquired device technologies and product rights. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#8217; respective estimated useful lives.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" id="f-286" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform regular reviews to determine if any event has occurred that may indicate intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to the net book value, significant changes in the ability of a particular asset to generate positive cash flows for our strategic business objectives, and the pattern of utilization of a particular asset.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-287" continuedAt="f-287-1" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate revenues from payments received (i) as royalties from licensing our ENHANZE technology and other royalty arrangements, (ii) under collaborative agreements and (iii) from sales of our proprietary and partnered products. We recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, we perform the following five steps: (i) identify the promised goods or services in the contract; (ii) identify the performance obligations in the contract, including whether they are distinct in the context of the contract; (iii) determine the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ENHANZE and Device Royalties</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our ENHANZE collaboration and license agreements, our partners will pay us royalties at an on average mid-single digit percent rate of their sales if products under the collaboration are commercialized. All amounts owed to us are noncancelable after the underlying triggering event occurs, and nonrefundable once paid. Unless terminated earlier in accordance with its terms, collaborations generally continue in effect until the last to expire royalty payment term, as determined on a product by product and country by country basis, with each royalty term starting on the first commercial sale of that product and ending the later of: (i) a specified period or term set forth in the agreement or (ii) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration. In general, when there are no valid claims of a specified patent developed under the collaboration covering the product in a given country, the royalty rate is reduced for those sales in that country upon the expiration of our patents covering rHuPH20. Janssen&#8217;s patents covering DARZALEX SC do not impact the timing for this royalty reduction. Partners may terminate the agreement prior to expiration for any reason in its entirety or on a target-by-target basis generally upon <ix:nonNumeric contextRef="c-1" name="halo:RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice" format="ixt-sec:durday" id="f-288">90</ix:nonNumeric> days prior written notice to us.&#160;Upon any such termination, the license granted to partners (in total or with respect to the terminated target, as applicable) will terminate provided; however, that in the event of expiration of the agreement (as opposed to a termination), the on-going licenses granted may become perpetual, non-exclusive and fully paid. Sales-based milestones and royalties are recognized in the period the underlying sales or milestones occur. We do not receive final royalty reports from our ENHANZE partners until after we complete our financial statements for a prior quarter. Therefore, we recognize revenue based on estimates of the royalty earned, which are based on internal estimates and available preliminary reports provided by our partners. We will record adjustments in the following quarter, if necessary, when final royalty reports are received. To date, we have not recorded any material adjustments.</span></div></ix:nonNumeric></ix:continuation><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-287-1" continuedAt="f-287-2"><ix:continuation id="f-261-5" continuedAt="f-261-6"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also earn royalties in connection with several of our licenses granted under license and development arrangements with our device partners. These royalties are based upon a percentage of commercial sales of partnered products with rates ranging from mid-single digits to low double digits and are tiered based on levels of net sales. These sales-based royalties, for which the license was deemed the predominant element to which the royalties relate, are estimated and recognized in the period in which the partners&#8217; commercial sales occur. The royalties are generally reported and payable to us within 45 to 60 days after the end of the period in which the commercial sales are made. We base our estimates of royalties earned on actual sales information from our partners when available or estimated, prescription sales from external sources and estimated net selling price. We will record adjustments in the following quarter, if necessary, when final royalty reports are received. To date, we have not recorded any material adjustments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue under ENHANZE and Device Collaborative Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ENHANZE Collaboration and License Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under these agreements, we grant the collaboration partner a worldwide license to develop and commercialize products using our ENHANZE technology to combine our patented rHuPH20 enzyme with their proprietary biologics directed at up to a specified number of targets. Targets are usually licensed on an exclusive, global basis. Targets selected subsequent to inception of the arrangement generally require payment of an additional license fee. The collaboration partner is responsible for all development, manufacturing, clinical, regulatory, sales and marketing costs for any products developed under the agreement. We are responsible for supply of bulk rHuPH20 based on the collaboration partner&#8217;s purchase orders, and may also be separately engaged to perform research and development services. While these collaboration agreements are similar in that they originate from the same framework, each one is the result of an arms-length negotiation and thus may vary from one to the other.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally collect an upfront license payment from collaboration partners, and are also entitled to receive event-based payments subject to collaboration partners&#8217; achievement of specified development, regulatory and sales-based milestones. In several agreements, collaboration partners pay us annual fees to maintain their exclusive license rights if they are unable to advance product development to specified stages. We earn separate fees for bulk rHuPH20 supplies and research and development services. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although these agreements are in form identified as collaborative agreements, we concluded for accounting purposes they represent contracts with customers and are not subject to accounting literature on collaborative arrangements. This is because we grant to partners licenses to our intellectual property and provide supply of bulk rHuPH20 and research and development services which are all outputs of our ongoing activities, in exchange for respective consideration. Under these collaborative agreements, our partners lead development of assets, and we do not share in significant financial risks of their development or commercialization activities. Accordingly, we concluded our collaborative agreements are appropriately accounted for pursuant to U.S. GAAP. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under all of our ENHANZE collaborative agreements, we have identified licenses to use functional intellectual property as the only performance obligation. The intellectual property underlying the license is our proprietary ENHANZE technology which represents application of rHuPH20 to facilitate delivery of drugs. Each of the licenses grants the partners rights to use our intellectual property as it exists and is identified on the effective date of the license, because there is no ongoing development of the ENHANZE technology required. Therefore, we recognize revenue from licenses at the point when the license becomes effective and the partner has received access to our intellectual property, usually at the inception of the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When partners can select additional targets to add to the licenses granted, we consider these rights to be options. We evaluate whether such options contain material rights, i.e. have exercise prices that are discounted compared to what we would charge for a similar license to a new partner. The exercise price of these options includes a combination of the target selection fees, event-based milestone payments and royalties. When these amounts in aggregate are not offered at a discount that exceeds discounts available to other customers, we conclude the option does not contain a material right, and we consider grants of additional licensing rights upon option exercises to be separate contracts (target selection contracts).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, we provide indemnification and protection of licensed intellectual property for our customers. These provisions are part of assurance that the licenses meet the agreements&#8217; representations and are not obligations to provide goods or services.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also fulfill purchase orders for supply of bulk rHuPH20 and perform research and development services pursuant to project authorization forms for our partners, which represent separate contracts. In addition to our licenses, we price our supply of bulk rHuPH20 and research and development services at our regular selling prices, called standalone selling prices (&#8220;SSP&#8221;). Therefore, our partners do not have material rights to order these items at prices not reflective of SSP. Refer to the discussion below regarding recognition of revenue for these separate contracts.</span></div></ix:continuation></ix:continuation><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-287-2" continuedAt="f-287-3"><ix:continuation id="f-261-6" continuedAt="f-261-7"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction price for a contract represents the amount to which we are entitled in exchange for providing goods and services to the customer. Transaction price does not include amounts subject to uncertainties unless it is probable that there will be no significant reversal of revenue when the uncertainty is resolved. Apart from the upfront license payment (or target selection fees in the target selection contracts), all other fees we may earn under our collaborative agreements are subject to significant uncertainties of product development. Achievement of many of the event-based development and regulatory milestones may not be probable until such milestones are actually achieved. This generally relates to milestones such as obtaining marketing authorization approvals. With respect to other development milestones, e.g., dosing of a first patient in a clinical trial, achievement could be considered probable prior to its actual occurrence, based on the progress towards commencement of the trial. In order to evaluate progress towards commencement of a trial, we assess the status of activities leading up to our partner&#8217;s initiation of a trial such as feedback received from the applicable regulatory authorities, completion of Investigational New Drug (&#8220;IND&#8221;) or equivalent filings, readiness and availability of drug, readiness of study sites and our partner&#8217;s commitment of resources to the program. We do not include any amounts subject to uncertainties in the transaction price until it is probable that the amount will not result in a significant reversal of revenue in the future. At the end of each reporting period, we re-evaluate the probability of achievement of such milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When target exchange rights are held by partners, and the amounts attributed to these rights are not refundable, they are included in the transaction price. However, they are recorded as deferred revenues because we have a potential performance obligation to provide a new target upon an exchange right being exercised. These amounts are recognized in revenue when the right of exchange expires or is exercised.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because our agreements have one type of performance obligation (licenses) which are typically all transferred at the same time at agreement inception, allocation of transaction price often is not required. However, allocation is required when licenses for some of the individual targets are subject to rights of exchange, because revenue associated with these targets cannot be recognized. When allocation is needed, we perform an allocation of the upfront amount based on relative SSP of licenses for individual targets. We determine license SSP using an income-based valuation approach utilizing risk-adjusted discounted cash flow projections of the estimated return a licensor would receive. When amounts subject to uncertainties, such as milestones and royalties, are included in the transaction price, we attribute them to the specific individual target licenses which generate such milestone or royalty amounts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also estimate SSP of bulk rHuPH20 and research and development services, to determine that our partners do not have material rights to order them at discounted prices. For supplies of bulk rHuPH20, because we effectively act as a contract manufacturer to our partners, we estimate and charge SSP based on the typical contract manufacturer margins consistent with all of our partners. We determine SSP of research and development services based on a fully-burdened labor rate. Our rates are comparable to those we observe in other collaborative agreements. We also have a history of charging similar rates to all of our partners. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront amounts allocated to licenses to individual targets are recognized as revenue when the license is transferred to the partner, as discussed above, if the license is not subject to exchange rights, or when the exchange right expires or is exercised. Development milestones and other fees are recognized in revenue when they are included in the transaction price, because by that time, we have already transferred the related license to the partner. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In contracts to provide research and development services, such services represent the only performance obligation. The fees are charged based on hours worked by our employees and the fixed contractual rate per hour, plus third-party pass-through costs, on a monthly basis. We recognize revenues as the related services are performed based on the amounts billed, as the partner consumes the benefit of research and development work simultaneously as we perform these services, and the amounts billed reflect the value of these services to the customer. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Device License, Development and Supply Arrangements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have several license, development and supply arrangements with pharmaceutical partners, under which we grant a license to our device technology and provide research and development services that often involve multiple performance obligations and highly-customized deliverables. For such arrangements, we identify each of the promised goods and services within the contract and the distinct performance obligations at inception of the contract and allocate consideration to each performance obligation based on relative SSP, which is generally determined based on the expected cost plus mark-up. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the contract includes an enforceable right to payment for performance completed to date and performance obligations are satisfied over time, we recognize revenue over the development period using either the input or output method depending on which is most appropriate given the nature of the distinct deliverable. For other contracts that do not contain an enforceable right to payment for performance completed to date, revenue is recognized when control of the product is transferred to the customer. Factors that may indicate transfer of control has occurred include the transfer of legal title, transfer of physical possession, the customer has obtained the significant risks and rewards of ownership of the assets, and we have a present right to payment. </span></div></ix:continuation></ix:continuation><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-287-3" continuedAt="f-287-4"><ix:continuation id="f-261-7" continuedAt="f-261-8"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our payment terms for development contracts may include an upfront payment equal to a percentage of the total contract value with the remaining portion to be billed upon completion and transfer of the individual deliverables or satisfaction of the individual performance obligations. We record a contract liability for cash received in advance of performance, which is presented within deferred revenue and deferred revenue, long-term in our condensed consolidated balance sheets and recognized as revenue in our condensed consolidated statements of income when the associated performance obligations have been satisfied. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License fees and milestones received in exchange for the grant of a license to our functional intellectual property, such as patented technology and know-how in connection with a partnered development arrangement, are generally recognized at inception of the arrangement, or over the development period depending on the facts and circumstances, as the license is generally not distinct from the non-licensed goods or services to be provided under the contract. Milestone payments that are contingent upon the occurrence of future events are evaluated and recorded at the most likely amount, and to the extent that it is probable that a significant reversal of revenue will not occur when the associated uncertainty is resolved.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 4,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion on our collaborative arrangements.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales, Net</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Proprietary Product Sales</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial portfolio of proprietary products includes XYOSTED and Hylenex recombinant which we sell primarily to wholesale pharmaceutical distributors and specialty pharmacies, who sell the products to hospitals, retail chain drug stores and other end-user customers. Sales to wholesalers are made pursuant to purchase orders subject to the terms of a master agreement, and delivery of individual packages of products represents performance obligations under each purchase order. We use contract manufacturers to produce our proprietary products and third-party logistics (&#8220;3PL&#8221;) vendors to process and fulfill orders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We concluded we are the principal in the sales to wholesalers because we control access to services rendered by both vendors and direct their activities. We have no significant obligations to wholesalers to generate pull-through sales.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized when control has transferred to the customer, which is typically upon delivery, at the net selling price, which reflects the variable consideration for which reserves and sales allowances are established for estimated returns, wholesale distribution fees, prompt payment discounts, government rebates and chargebacks, plan rebate arrangements and patient discount and support programs. We recognize revenue from product sales and related cost of sales upon product delivery to the wholesaler location. At that time, the wholesalers take control of the product as they take title, bear the risk of loss of ownership, and have an enforceable obligation to pay us. They also have the ability to direct sales of product to their customers on terms and at prices they negotiate. Although wholesalers have product return rights, we do not believe they have a significant incentive to return the product to us.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of certain reserves and sales allowances requires us to make a number of judgements and estimates to reflect our best estimate of the transaction price and the amount of consideration to which we believe we would be ultimately entitled to receive. The expected value is determined based on unit sales data, contractual terms with customers and third-party payers, historical and estimated future percentage of rebates incurred on sales, historical and future insurance plan billings, any new or anticipated changes in programs or regulations that would impact the amount of the actual rebates, customer purchasing patterns, product expiration dates and levels of inventory in the distribution channel. The estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, rebates and customer co-pay support programs are included in accrued expenses and accounts receivable, net in our condensed consolidated balance sheets upon recognition of revenue from product sales. We monitor actual product returns, chargebacks, discounts and fees subsequent to the sale. If these amounts differ from our estimates, we make adjustments to these allowances, which are applied to increase or reduce product sales revenue and earnings in the period of adjustment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling prices initially billed to wholesalers are subject to discounts for prompt payment and subsequent chargebacks when wholesalers sell our products at negotiated discounted prices to members of certain group purchasing organizations (&#8220;GPOs&#8221;), Pharmacy Benefit Managers (&#8220;PBMs&#8221;) and government programs. We also pay quarterly distribution fees to certain wholesalers for inventory reporting and chargeback processing, and to PBMs and GPOs as administrative fees for services and for access to their members. We concluded the benefits received in exchange for these fees are not distinct from our sales of our products, and accordingly we apply these amounts to reduce revenues. Wholesalers also have rights to return unsold product nearing or past the expiration date. Because of the shelf life of our products and our lengthy return period, there may be a significant period of time between when the product is shipped and when we issue credits on returned product. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the transaction price when we receive each purchase order taking into account the expected reductions of the selling price initially billed to the wholesaler arising from all of the above factors. We have compiled historical experience and data to estimate future returns and chargebacks of our products and the impact of the other discounts and fees we pay. When estimating these adjustments to the transaction price, we reduce it sufficiently to be able to assert that it is probable that there will be no significant reversal of revenue when the ultimate adjustment amounts are known.</span></div></ix:continuation></ix:continuation><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-287-4"><ix:continuation id="f-261-8" continuedAt="f-261-9"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each purchase order contains only one type of product, and is usually shipped to the wholesaler in a single shipment. Therefore, allocation of the transaction price to individual packages is not required.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the orders placed by wholesalers, we incur costs such as commissions to our sales representatives. However, as revenue from product sales is recognized upon delivery to the wholesaler, which occurs shortly after we receive a purchase order, we do not capitalize these commissions and other costs, based on application of the practical expedient allowed within the applicable guidance. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Partnered Product Sales</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bulk rHuPH20</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell bulk rHuPH20 to partners for use in research and development and, subsequent to receiving marketing approval, we sell it for use in collaboration commercial products. Sales are made pursuant to purchase orders subject to the terms of the collaborative agreement or a supply agreement, and delivery of units of bulk rHuPH20 represent performance obligations under each purchase order. We provide a standard warranty that the product conforms to specifications. We use contract manufacturers to produce bulk rHuPH20 and have concluded we are the principal in the sales to partners. The transaction price for each purchase order of bulk rHuPH20 is fixed based on the cost of production plus a contractual markup, and is not subject to adjustments. Allocation of the transaction price to individual quantities of the product is usually not required because each order contains only one type of product.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue from the sale of bulk rHuPH20 as product sales and related cost of sales upon transfer of title to our partners. At that time, the partners take control of the product, bear the risk of loss of ownership, and have an enforceable obligation to pay us. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Devices</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to several license, development, supply and distribution arrangements with pharmaceutical partners, under which we produce and are the exclusive supplier of certain products, devices and/or components. Revenue is recognized when or as control of the goods transfers to the customer as discussed below.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the exclusive supplier of OTREXUP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to Otter. Because this product is custom manufactured with no alternative use and we have a contractual right to payment for performance completed to date, control is continuously transferred to the customer as the product is produced pursuant to firm purchase orders. Revenue is recognized over time using the output method based on the contractual selling price and number of units produced. The amount of revenue recognized in excess of the amount shipped/billed to the customer, if any, is recorded as contract assets in our condensed consolidated balance sheets due to the short-term nature in which the amount is ultimately expected to be billed and collected from the customer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other device partnered product sales are recognized at the point in time in which control is transferred to the customer, which is typically upon shipment. Sales terms and pricing are governed by the respective supply and distribution agreements, and there is generally no right of return. Revenue is recognized at the transaction price, which includes the contractual per unit selling price and estimated variable consideration, such as volume-based pricing arrangements or profit-sharing arrangements, if any. We recognize revenue, including the estimated variable consideration we expect to receive for contract margin on future commercial sales, upon shipment of the goods to our partner. The estimated variable consideration is recognized at an amount we believe is not subject to significant reversal of revenue based on historical experience and is adjusted at each reporting period if the most likely amount of expected consideration changes or becomes fixed.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales consists primarily of raw materials, third-party manufacturing costs, fill and finish costs, freight costs, internal costs and manufacturing overhead associated with the production of proprietary and partnered products. Cost of sales also consists of the write-down of excess, dated and obsolete inventories and the write-off of inventories that do not meet certain product specifications, if any.</span></div></ix:continuation></ix:continuation><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-261-9" continuedAt="f-261-10"><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-289" escape="true"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include salaries and benefits, allocation of facilities and other overhead expenses, research related manufacturing services, contract services, and other outside expenses related to manufacturing, preclinical and regulatory activities and our partner development platforms. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to our research and development efforts and have no alternative future uses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as expense as the related goods are delivered or the related services are performed or such time when we do not expect the goods to be delivered or services to be performed.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-290" escape="true"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record compensation expense associated with stock options, restricted stock units (&#8220;RSUs&#8221;), performance stock units (&#8220;PSUs&#8221;) and shares issued under our employee stock purchase plan (&#8220;ESPP&#8221;) in accordance with the authoritative guidance for share-based compensation. The cost of employee services received in exchange for an award of an equity instrument is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense on a straight-line basis over the requisite service period of the award. Share-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed. Forfeitures are recognized as a reduction of share-based compensation expense as they occur.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-291" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide for income taxes using the liability method. Under this method, deferred income tax assets and liabilities are determined based on the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases at each reporting period. We measure deferred tax assets and liabilities using enacted tax rates for the year in which the differences are expected to reverse. Significant judgment is required by management to determine our provision for income taxes, our deferred tax assets and liabilities, and any associated valuation allowances recorded against our net deferred tax assets, which are based on complex and evolving tax regulations. Deferred tax assets (&#8220;DTA&#8221;) and other tax benefits are recorded when they are more likely than not to be realized. On a quarterly basis, we assess the need for valuation allowance on our DTAs, weighing all positive and negative evidence, to assess if it is more-likely-than-not that some or all of our DTAs will be realized. We recorded a provision for income taxes of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-292">19.2</ix:nonFraction> million using an effective tax rate of <ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-293">20</ix:nonFraction>% for the three months ended March&#160;31, 2024. The difference between our effective tax rate and the U.S. federal statutory rate of 21% is primarily due to state income taxes, research and development credit generations, tax benefits on the Foreign Derived Intangible Income Deduction (&#8220;FDII&#8221;) (net of reserves), tax detriments on 162(m) and other share-based compensation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-294" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate our business in <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-295">one</ix:nonFraction> operating segment, which includes all activities related to the research, development and commercialization of our proprietary enzymes and devices. This segment also includes revenues and expenses related to (i)&#160;research and development and manufacturing activities conducted under our collaborative agreements with third parties, and (ii)&#160;product sales of proprietary and partnered products. The chief operating decision-maker (&#8220;CODM&#8221;), our Chief Executive Officer (&#8220;CEO&#8221;), reviews the operating results on an aggregate basis and manages the operations as a single operating segment.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:3pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-296" escape="true"><ix:continuation id="f-261-10"><div style="margin-top:3pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adoption and Pending Adoption of Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a brief description of recently issued accounting standards, those adopted in the current period and those not yet adopted:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"><tr><td style="width:1.0%"/><td style="width:17.852%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.570%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.631%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.570%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.154%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.570%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.688%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.878%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.787%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Standard</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Adoption Method</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Effect on the Financial<br/>Statements or Other Significant Matters</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The new standard is intended to improve annual and interim reportable segment disclosure requirements regardless of number of reporting units, primarily through enhanced disclosures of significant expenses. The amendment requires public entities to disclose significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit and loss.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Annual periods beginning after December 15, 2023 (our 2024 Form 10-K), and interim periods within fiscal years beginning after December 15, 2024 (our Q1 2025 Form 10-Q) - Early adoption is permitted, including adoption in an interim period<br/></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Retrospective</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are currently evaluating the impact of the standard on our consolidated financial statements and related disclosures.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The new guidance includes amendments that further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Annual periods beginning after December 15, 2024 (our 2025 Form 10-K) - Early adoption is permitted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prospective or Retrospective</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are currently evaluating the impact of the standard on our consolidated financial statements and related disclosures.</span></td></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="i56f00e77098e4077b277260135e70ed7_46"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-297" continuedAt="f-297-1" escape="true">Fair Value Measurement</ix:nonNumeric></span></div><ix:continuation id="f-297-1" continuedAt="f-297-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="f-298" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale marketable securities consisted of the following (in thousands):</span></div><div style="margin-top:11pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:52.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.779%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-299">2,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-300">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-301">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-302">2,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-303">43,118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-304">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-305">64</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-306">43,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-307">239,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-308">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-309">106</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-310">239,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-311">9,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-312">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-313">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-314">9,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-315">4,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-316">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-317">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-318">4,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities, available-for-sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-319">298,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-320">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-321">197</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-322">298,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:52.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.779%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-323">3,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-324">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-325">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-326">3,504</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-327">6,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-328">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-329">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-330">6,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-331">175,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-332">200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-333">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-334">176,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-335">16,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-336">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-337">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-338">16,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-339">15,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-340">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-341">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-342">15,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities, available-for-sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-343">217,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-344">201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-345">46</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-346">217,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, <ix:nonFraction unitRef="security" contextRef="c-3" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="f-347">33</ix:nonFraction> available-for-sale marketable securities with a fair market value of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="f-348">215.5</ix:nonFraction> million were in a gross unrealized loss position of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-349">0.2</ix:nonFraction>&#160;million. Based on our review of these marketable securities, we believe <ix:nonFraction unitRef="usd" contextRef="c-3" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" format="ixt:fixed-zero" scale="0" id="f-350">none</ix:nonFraction> of the unrealized loss is as a result of a credit loss as of&#160;March&#160;31, 2024 because we do not intend to sell these securities and it is not more-likely-than-not that we will be required to sell these securities before the recovery of their amortized cost basis.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="f-351" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of our contractual maturities of available-for-sale debt securities were as follows (in thousands):</span></div><div style="margin-top:11pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:67.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.063%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="f-352">235,059</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="f-353">197,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year but within five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="f-354">63,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="f-355">19,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total estimated fair value of contractual maturities, available-for-sale</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-356">298,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-357">217,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-297-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="f-358" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes, by major security type, our cash equivalents and available-for-sale marketable securities measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"/><td style="width:29.421%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.329%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.329%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.967%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.329%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.329%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.337%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Estimated Fair Value</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Estimated Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-359">20,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-360">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-361">20,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-362">22,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-363">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-364">22,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-365">30,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-366">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-367">30,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-368">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-369">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-370">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale marketable <br/>&#160;&#160;&#160;securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-371">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-372">2,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-373">2,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-374">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-375">3,504</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-376">3,504</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-377">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-378">43,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-379">43,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-380">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-381">6,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-382">6,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-383">239,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-384">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-385">239,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-386">176,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-387">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-388">176,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-389">9,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-390">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-391">9,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-392">16,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-393">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-394">16,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-395">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-396">4,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-397">4,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-398">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-399">15,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-400">15,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency hedging contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="f-401">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="f-402">1,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="f-403">1,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="f-404">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="f-405">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="f-406">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-407">298,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-408">51,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-409">350,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-410">216,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-411">25,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-412">241,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency hedging contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="f-413">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:DerivativeLiabilities" scale="3" id="f-414">478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:DerivativeLiabilities" scale="3" id="f-415">478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="f-416">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-417">9,480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-418">9,480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Based on observable market transactions of spot currency rates, forward currency rates or equivalently-termed instruments. Carrying amounts of the financial assets and liabilities are equal to the fair value. As of March&#160;31, 2024, the derivative assets and liabilities recorded within prepaid expenses and other current assets, prepaid expense and other assets and other long-term liabilities in our condensed consolidated balance sheets were $<span style="-sec-ix-hidden:f-420"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-419">1.3</ix:nonFraction> million</span>, $<span style="-sec-ix-hidden:f-422"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-421">0.3</ix:nonFraction> million</span> and $<span style="-sec-ix-hidden:f-424"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-423">0.5</ix:nonFraction> million</span>, respectively.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had <ix:nonFraction unitRef="usd" contextRef="c-97" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt-sec:numwordsen" scale="6" id="f-425"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt-sec:numwordsen" scale="6" id="f-426">no</ix:nonFraction></ix:nonFraction> available for sale securities that were classified within Level 3 as of March&#160;31, 2024 and December&#160;31, 2023.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="i56f00e77098e4077b277260135e70ed7_49"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="f-427" continuedAt="f-427-1" escape="true">Revenue</ix:nonNumeric></span></div><ix:continuation id="f-427-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="f-428" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our disaggregated revenues were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"><tr><td style="width:1.0%"/><td style="width:78.869%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.570%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.144%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.570%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.147%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-429">120,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-430">99,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proprietary product sales</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-431">35,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-432">27,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bulk rHuPH20 sales</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-433">10,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-434">22,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Device partnered product sales</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-435">12,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-436">10,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-437">58,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-438">60,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues under collaborative agreements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Event-based development and regulatory milestones and other fees</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-439">14,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-440">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Device licensing and development revenue</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-441">2,703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-442">1,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues under collaborative agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-443">16,703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-444">1,709</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-445">195,879</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-446">162,143</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024, we recognized revenue related to licenses granted to partners in prior periods in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-5" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:num-dot-decimal" scale="6" id="f-447">134.6</ix:nonFraction> million. This amount represents royalties earned in the current period in addition to $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="f-448">14.0</ix:nonFraction>&#160;million of variable consideration in the contracts where uncertainties were resolved and the development milestones are expected to be achieved or were achieved. We also recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="f-449">0.1</ix:nonFraction>&#160;million during the three months ended March&#160;31, 2024 that had been included in accrued expense and other long-term liabilities in our condensed consolidated balance sheets as of December&#160;31, 2023. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="f-450" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, other contract assets and deferred revenues (contract liabilities) from contracts with customers, including partners, consisted of the following (in thousands): </span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"/><td style="width:75.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.859%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-451">185,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-452">233,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other contract assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ContractWithCustomerAssetGrossCurrent" format="ixt:num-dot-decimal" scale="3" id="f-453">10,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerAssetGrossCurrent" scale="3" id="f-454">956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-455">4,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-456">4,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, the amounts included in the transaction price of our contracts with customers, including collaboration partners, and allocated to goods and services not yet provided were $<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="f-457">77.3</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-5" name="halo:RevenueRemainingPerformanceObligationsUnfulfilledProductPurchaseOrdersAmount" format="ixt:num-dot-decimal" scale="6" id="f-458">72.7</ix:nonFraction> million relates to unfulfilled product purchase orders and $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-459">4.6</ix:nonFraction>&#160;million has been collected and is reported as accrued expense and other long-term liabilities in our condensed consolidated balance sheets. The unfulfilled product purchase orders are estimated to be delivered by the end of 2024. Of the total deferred revenues of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-460">4.6</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="f-461">1.2</ix:nonFraction> million is expected to be used by our customers within the next <ix:nonNumeric contextRef="c-112" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durmonth" id="f-462">12</ix:nonNumeric> months. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized contract assets of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:ContractWithCustomerAssetGrossCurrent" format="ixt:num-dot-decimal" scale="6" id="f-463">10.6</ix:nonFraction> million as of March&#160;31, 2024, which related to development milestones deemed probable of receipt for intellectual property licenses granted to partners in prior periods and for goods or services when control has transferred to the customer, and corresponding revenue is recognized on an over time basis but is not yet billable to the customer in accordance with the terms of the contract.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="i56f00e77098e4077b277260135e70ed7_55"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="f-464" continuedAt="f-464-1" escape="true">Certain Balance Sheet Items</ix:nonNumeric></span></div><ix:continuation id="f-464-1" continuedAt="f-464-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="f-465" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net and contract assets consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:68.485%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from product sales to partners</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:AccountsReceivableGrossCurrent" format="ixt:num-dot-decimal" scale="3" id="f-466">27,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:AccountsReceivableGrossCurrent" format="ixt:num-dot-decimal" scale="3" id="f-467">58,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from revenues under collaborative agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:AccountsReceivableGrossCurrent" format="ixt:num-dot-decimal" scale="3" id="f-468">2,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:AccountsReceivableGrossCurrent" format="ixt:num-dot-decimal" scale="3" id="f-469">16,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from royalty payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:AccountsReceivableGrossCurrent" format="ixt:num-dot-decimal" scale="3" id="f-470">115,413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:AccountsReceivableGrossCurrent" format="ixt:num-dot-decimal" scale="3" id="f-471">118,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from other product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="us-gaap:AccountsReceivableGrossCurrent" format="ixt:num-dot-decimal" scale="3" id="f-472">46,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="us-gaap:AccountsReceivableGrossCurrent" format="ixt:num-dot-decimal" scale="3" id="f-473">47,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ContractWithCustomerAssetGrossCurrent" format="ixt:num-dot-decimal" scale="3" id="f-474">10,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerAssetGrossCurrent" scale="3" id="f-475">956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts receivable and contract assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="halo:AccountsReceivableAndContractWithCustomerAssetBeforeAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="f-476">202,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="halo:AccountsReceivableAndContractWithCustomerAssetBeforeAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="f-477">240,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for distribution fees and discounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="halo:AccountsReceivableAndContractWithCustomerAssetAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="f-478">6,209</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="halo:AccountsReceivableAndContractWithCustomerAssetAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="f-479">6,747</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts receivable, net and contract assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="halo:AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="f-480">195,902</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="halo:AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="f-481">234,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="f-482" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:68.485%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-483">29,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-484">23,646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-485">43,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-486">34,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-487">95,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-488">69,930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-489">168,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-490">127,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfOtherAssetsTableTextBlock" id="f-491" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:68.485%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid manufacturing expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-492">36,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-493">36,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-494">13,847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-495">12,902</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-496">12,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-497">16,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-498">63,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-499">66,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Long-term portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-500">17,319</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-501">17,816</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other assets, current</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-502">45,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-503">48,613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid manufacturing expenses include raw materials, slot reservation fees and other amounts paid to contract manufacturing organizations.&#160;Such amounts are reclassified to work-in-process inventory as materials are used or the contract manufacturing organization services are complete.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-504" continuedAt="f-504-1" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div></ix:nonNumeric><div style="text-align:center;text-indent:22.5pt"><ix:continuation id="f-504-1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:68.485%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-505">8,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-506">8,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-507">36,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-508">32,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer and office equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-509">10,888</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-510">9,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-511">7,124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-512">6,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-513">63,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-514">57,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-515">21,180</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-516">19,661</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-517">41,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-518">38,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use of assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-519">36,185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-520">36,836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="halo:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-521">78,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="halo:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-522">74,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">                            </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense was approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-523">2.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-524">2.6</ix:nonFraction> million, inclusive of ROU asset amortization of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="6" id="f-525">1.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="6" id="f-526">1.4</ix:nonFraction> million for the three months ended March&#160;31, 2024 and 2023, respectively. </span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-464-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-527" escape="true"><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:68.485%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and payroll taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-528">10,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-529">17,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued outsourced manufacturing expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="halo:AccruedOutsourcedManufacturingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-530">27,456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="halo:AccruedOutsourcedManufacturingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-531">12,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:TaxesPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-532">19,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:TaxesPayableCurrent" scale="3" id="f-533">963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product returns and sales allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ContractWithCustomerRefundLiability" format="ixt:num-dot-decimal" scale="3" id="f-534">39,941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerRefundLiability" format="ixt:num-dot-decimal" scale="3" id="f-535">41,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-536">20,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-537">33,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-538">31,763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-539">32,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-540">149,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-541">138,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less long-term portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="halo:AccruedLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-542">31,201</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="halo:AccruedLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-543">37,720</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses, current</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-544">118,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-545">100,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expense associated with the accretion of the lease liabilities was approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="halo:OperatingLeaseAccretionOfLiability" format="ixt:num-dot-decimal" scale="6" id="f-546">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="halo:OperatingLeaseAccretionOfLiability" format="ixt:num-dot-decimal" scale="6" id="f-547">0.7</ix:nonFraction> million for the three months ended March&#160;31, 2024 and 2023, respectively. Total lease expense for the three months ended March&#160;31, 2024 and 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-548">2.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-549">2.1</ix:nonFraction> million, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts related to leases for the three months ended March&#160;31, 2024 and 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="f-550">1.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="f-551">1.7</ix:nonFraction> million, respectively.</span></div></ix:continuation><div style="margin-top:12pt;text-indent:22.5pt"><span><br/></span></div><div style="text-align:center;text-indent:22.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="i56f00e77098e4077b277260135e70ed7_58"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="f-552" continuedAt="f-552-1" escape="true">Goodwill and Intangible Assets</ix:nonNumeric></span></div><ix:continuation id="f-552-1"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfGoodwillTextBlock" id="f-553" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the activity impacting goodwill is presented below (in thousands):</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"><tr><td style="width:1.0%"/><td style="width:84.592%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-554">416,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustment</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:fixed-zero" scale="3" id="f-555">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-556">416,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our acquired intangible assets are amortized using the straight-line method over their estimated useful lives of <span style="-sec-ix-hidden:f-557">seven</span> to <ix:nonNumeric contextRef="c-130" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:durwordsen" id="f-558">ten years</ix:nonNumeric>. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="f-559" continuedAt="f-559-1" escape="true">The following table shows the cost, accumulated amortization and weighted average useful life in years for our acquired intangible assets as of March&#160;31, 2024 (in thousands).</ix:nonNumeric></span></div><ix:continuation id="f-559-1"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"><tr><td style="width:1.0%"/><td style="width:47.650%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.118%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.993%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.893%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.993%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.893%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.998%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Useful Life </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auto Injector technology platform</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-131" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="f-560">7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-561">402,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-562">106,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-563">295,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XYOSTED proprietary product</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-133" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="f-564">10</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-565">136,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-566">25,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-567">110,937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived intangibles, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-568">538,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-569">131,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-570">406,416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ATRS-1902 (IPR&amp;D)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-571">48,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangibles, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-572">455,116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="f-573" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated future annual amortization of finite-lived intangible assets is shown in the following table (in thousands). Actual amortization expense to be reported in future periods could differ from these estimates as a result of acquisitions, divestitures, and asset impairments, among other factors.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"/><td style="width:82.561%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.010%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="f-574">53,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-575">71,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-576">71,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="f-577">71,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="f-578">71,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="halo:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="f-579">68,934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-580">406,416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="i56f00e77098e4077b277260135e70ed7_61"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:LongTermDebtTextBlock" id="f-581" continuedAt="f-581-1" escape="true">Long-Term Debt, Net</ix:nonNumeric></span></div><ix:continuation id="f-581-1" continuedAt="f-581-2"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-135" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-582">1.00</ix:nonFraction>% Convertible Notes due 2028</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, we completed the sale of $<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-583">720.0</ix:nonFraction>&#160;million in aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="c-135" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-584">1.00</ix:nonFraction>% Convertible Senior Notes due 2028 (the &#8220;2028 Convertible Notes&#8221;). The net proceeds in connection with the issuance of the 2028 Convertible Notes, after deducting the initial purchasers&#8217; fee of $<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-5" name="us-gaap:DebtInstrumentFeeAmount" format="ixt:num-dot-decimal" scale="6" id="f-585">18.0</ix:nonFraction>&#160;million, was approximately $<ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-5" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="f-586">702.0</ix:nonFraction>&#160;million. We also incurred additional debt issuance costs totaling $<ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="f-587">1.0</ix:nonFraction>&#160;million. Debt issuance costs and the initial purchasers&#8217; fee are presented as a debt discount.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2028 Convertible Notes pay interest semi-annually in arrears on February 15th and August 15th of each year at an annual rate of <ix:nonFraction unitRef="number" contextRef="c-135" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-588">1.00</ix:nonFraction>%. The 2028 Convertible Notes are general unsecured obligations and rank senior in right of payment to all indebtedness that is expressly subordinated in right of payment to the 2028 Convertible Notes, rank equally in right of payment with all existing and future liabilities that are not so subordinated, are effectively junior to any secured indebtedness to the extent of the value of the assets securing such indebtedness, and are structurally subordinated to all indebtedness and other liabilities (including trade payables) of our current or future subsidiaries. The 2028 Convertible Notes have a maturity date of August 15, 2028.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their 2028 Convertible Notes at their option only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on December 31, 2022, if the last reported sale price per share of common stock exceeds <ix:nonFraction unitRef="number" contextRef="c-137" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="f-589">130</ix:nonFraction>% of the conversion price for each of at least <ix:nonFraction unitRef="trading_day" contextRef="c-137" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="f-590">20</ix:nonFraction> trading days during the <ix:nonFraction unitRef="trading_day" contextRef="c-137" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="f-591">30</ix:nonFraction> consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the <ix:nonFraction unitRef="businessday" contextRef="c-138" decimals="INF" name="halo:DebtInstrumentConvertibleThresholdConsecutiveBusinessDays" format="ixt-sec:numwordsen" scale="0" id="f-592">five</ix:nonFraction> consecutive business days immediately after any <ix:nonFraction unitRef="trading_day" contextRef="c-138" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" format="ixt-sec:numwordsen" scale="0" id="f-593">five</ix:nonFraction> consecutive trading day period (such <ix:nonFraction unitRef="trading_day" contextRef="c-138" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" format="ixt-sec:numwordsen" scale="0" id="f-594">five</ix:nonFraction> consecutive trading day period, the &#8220;measurement period&#8221;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than <ix:nonFraction unitRef="number" contextRef="c-138" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="f-595">98</ix:nonFraction>% of the product of the last reported sale price per share of our common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on our common stock, as described in the offering memorandum for the 2028 Convertible Notes; (4) if we call such notes for redemption; and (5) at any time from, and including, February 15, 2028 until the close of business on the second scheduled trading day immediately before the maturity date. As of March&#160;31, 2024, the 2028 Convertible Notes were not convertible.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, we will pay cash for the settlement of principal, and for the premium, if applicable, we will pay cash, deliver shares of common stock or a combination of cash and shares of common stock, at our election. The initial conversion rate for the 2028 Convertible Notes is <ix:nonFraction unitRef="number" contextRef="c-136" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="f-596">17.8517</ix:nonFraction> shares of common stock per $1,000 in principal amount of 2028 Convertible Notes, equivalent to a conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="c-135" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-597">56.02</ix:nonFraction> per share of our common stock. The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued or unpaid interest.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, we were in compliance with all covenants and there was no material adverse change in our business, operations or financial condition. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capped Call Transactions</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the offering of the 2028 Convertible Notes, we entered into capped call transactions with certain counterparties (the &#8220;Capped Call Transactions&#8221;). The Capped Call Transactions are expected generally to reduce potential dilution to holders of our common stock upon conversion of the 2028 Convertible Notes or at our election (subject to certain conditions) offset any cash payments we are required to make in excess of the principal amount of such converted 2028 Convertible Notes. The cap price of the Capped Call Transactions is initially $<ix:nonFraction unitRef="usdPerShare" contextRef="c-139" decimals="4" name="halo:DebtInstrumentCapCallTransactionCapPricePerShare" scale="0" id="f-598">75.4075</ix:nonFraction> per share of common stock, representing a premium of <ix:nonFraction unitRef="number" contextRef="c-140" decimals="INF" name="halo:SaleOfStockPremiumOverLastReportedSalePricePercentage" scale="-2" id="f-599">75</ix:nonFraction>% above the last reported sale price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-141" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-600">43.09</ix:nonFraction> per share of common stock on August 15, 2022, and is subject to certain adjustments under the terms of the Capped Call Transactions. As of March&#160;31, 2024, no capped calls had been exercised.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to their terms, the capped calls qualify for classification within stockholders&#8217; equity in our condensed consolidated balance sheets, and their fair value is not remeasured and adjusted as long as they continue to qualify for stockholders&#8217; equity classification. We paid approximately $<ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-5" name="halo:PaymentForCappedCallTransactions" format="ixt:num-dot-decimal" scale="6" id="f-601">69.1</ix:nonFraction>&#160;million for the Capped Calls, including applicable transaction costs, which was recorded as a reduction to additional paid-in capital in our condensed consolidated balance sheets. The Capped Call Transactions are separate transactions entered into by us with the capped call Counterparties, are not part of the terms of the Convertible Notes, and do not affect any holder&#8217;s rights under the Convertible Notes. Holders of the Convertible Notes do not have any rights with respect to the Capped Call Transactions.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-581-2" continuedAt="f-581-3"><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-142" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-602">0.25</ix:nonFraction>% Convertible Notes due 2027</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, we completed the sale of $<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-603">805.0</ix:nonFraction>&#160;million in aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="c-142" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-604">0.25</ix:nonFraction>% Convertible Senior Notes due 2027 (the &#8220;2027 Convertible Notes&#8221;). The net proceeds in connection with the issuance of the 2027 Convertible Notes, after deducting the initial purchasers&#8217; fee of $<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-5" name="us-gaap:DebtInstrumentFeeAmount" format="ixt:num-dot-decimal" scale="6" id="f-605">20.1</ix:nonFraction>&#160;million, was approximately $<ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="f-606">784.9</ix:nonFraction>&#160;million. We also incurred additional debt issuance costs totaling $<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="f-607">0.4</ix:nonFraction>&#160;million. Debt issuance costs and the initial purchasers&#8217; fee are presented as a debt discount.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2027 Convertible Notes pay interest semi-annually in arrears on March 1st and September 1st of each year at an annual rate of <ix:nonFraction unitRef="number" contextRef="c-142" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-608">0.25</ix:nonFraction>%. The 2027 Convertible Notes are general unsecured obligations and rank senior in right of payment to all indebtedness that is expressly subordinated in right of payment to the 2027 Convertible Notes, rank equally in right of payment with all existing and future liabilities that are not so subordinated, are effectively junior to any secured indebtedness to the extent of the value of the assets securing such indebtedness and are structurally subordinated to all indebtedness and other liabilities (including trade payables) of our current or future subsidiaries. The 2027 Convertible Notes have a maturity date of March 1, 2027.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their 2027 Convertible Notes at their option only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on June 30, 2021, if the last reported sale price per share of common stock exceeds <ix:nonFraction unitRef="number" contextRef="c-145" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="f-609">130</ix:nonFraction>% of the conversion price for each of at least <ix:nonFraction unitRef="trading_day" contextRef="c-145" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="f-610">20</ix:nonFraction> trading days during the <ix:nonFraction unitRef="trading_day" contextRef="c-145" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="f-611">30</ix:nonFraction> consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the <ix:nonFraction unitRef="businessday" contextRef="c-146" decimals="INF" name="halo:DebtInstrumentConvertibleThresholdConsecutiveBusinessDays" format="ixt-sec:numwordsen" scale="0" id="f-612">five</ix:nonFraction> consecutive business days immediately after any <ix:nonFraction unitRef="trading_day" contextRef="c-146" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" format="ixt-sec:numwordsen" scale="0" id="f-613">five</ix:nonFraction> consecutive trading day period (such <ix:nonFraction unitRef="trading_day" contextRef="c-146" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" format="ixt-sec:numwordsen" scale="0" id="f-614">five</ix:nonFraction> consecutive trading day period, the &#8220;measurement period&#8221;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than <ix:nonFraction unitRef="number" contextRef="c-146" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="f-615">98</ix:nonFraction>% of the product of the last reported sale price per share of our common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on our common stock, as described in the offering memorandum for the 2027 Convertible Notes; (4) if we call such notes for redemption; and (5) at any time from, and including, September 1, 2026 until the close of business on the scheduled trading day immediately before the maturity date. As of March&#160;31, 2024, the 2027 Convertible Notes were not convertible.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, we will pay cash for the settlement of principal and for the premium, if applicable, we will pay cash, deliver shares of common stock or a combination of cash and shares of common stock, at our election. The initial conversion rate for the 2027 Convertible Notes is <ix:nonFraction unitRef="number" contextRef="c-144" decimals="4" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="f-616">12.9576</ix:nonFraction> shares of common stock per $1,000 in principal amount of 2027 Convertible Notes, equivalent to a conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="c-142" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-617">77.17</ix:nonFraction> per share of our common stock. The conversion rate is subject to adjustment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, we were in compliance with all covenants and there was no material adverse change in our business, operations or financial condition. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-147" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-618">1.25</ix:nonFraction>% Convertible Notes due 2024</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we completed the sale of $<ix:nonFraction unitRef="usd" contextRef="c-147" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-619">460.0</ix:nonFraction> million in aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="c-147" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-620">1.25</ix:nonFraction>% Convertible Senior Notes due 2024 (the &#8220;2024 Convertible Notes&#8221;). The net proceeds in connection with the issuance of the 2024 Convertible Notes, after deducting the initial purchasers&#8217; fee of $<ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-5" name="us-gaap:DebtInstrumentFeeAmount" format="ixt:num-dot-decimal" scale="6" id="f-621">12.7</ix:nonFraction>&#160;million, was approximately $<ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-5" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="f-622">447.3</ix:nonFraction> million. We also incurred debt issuance cost totaling $<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="f-623">0.3</ix:nonFraction>&#160;million. Debt issuance costs and the initial purchasers&#8217; fee were presented as a debt discount.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we notified the note holders of our irrevocable election to settle the principal of the 2024 Convertible Notes in cash and for the premium, to deliver shares of common stock. The conversion rate for the 2024 Convertible Notes was <ix:nonFraction unitRef="number" contextRef="c-150" decimals="4" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="f-624">41.9208</ix:nonFraction> shares of common stock per $1,000 in principal amount of 2024 Convertible Notes, equivalent to a conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="c-151" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-625">23.85</ix:nonFraction> per share of our common stock. The conversion rate was subject to adjustment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, we issued a notice for the redemption of 2024 Convertible Notes. Holders of the notes could convert their notes at any time prior to the close of the business day prior to the redemption date. In March 2023, holders of the notes elected to convert the 2024 Convertible Notes in full. In connection with the conversion, we paid approximately $<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="6" id="f-626">13.5</ix:nonFraction> million in cash which included principal and accrued interest, and issued <ix:nonFraction unitRef="shares" contextRef="c-152" decimals="INF" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="f-627">288,886</ix:nonFraction> shares of our common stock representing the intrinsic value based on the contractual conversion rate.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="f-628" escape="true"><ix:continuation id="f-581-3" continuedAt="f-581-4"><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Carrying Amounts of our Convertible Notes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount and fair value of our Convertible Notes were as follows (in thousands). </span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"><tr><td style="width:1.0%"/><td style="width:69.570%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.474%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="f-629">805,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="f-630">805,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="f-631">720,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="f-632">720,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total principal amount</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="f-633">1,525,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="f-634">1,525,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="f-635">10,094</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="f-636">10,950</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="f-637">14,027</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="f-638">14,802</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total unamortized debt discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="f-639">24,121</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="f-640">25,752</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-641">794,906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-642">794,050</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-643">705,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-644">705,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carrying amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-645">1,500,879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-646">1,499,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value based on trading levels (Level 2):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="f-647">714,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="f-648">695,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="f-649">702,403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="f-650">670,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of outstanding notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="f-651">1,416,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="f-652">1,366,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization per period of debt discount (in years):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-153" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" format="ixt-sec:duryear" id="f-653">2.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-154" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" format="ixt-sec:duryear" id="f-654">3.2</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-155" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" format="ixt-sec:duryear" id="f-655">4.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-156" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" format="ixt-sec:duryear" id="f-656">4.6</ix:nonNumeric></span></td></tr></table></div></ix:continuation></ix:nonNumeric><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><ix:continuation id="f-581-4" continuedAt="f-581-5"><ix:nonNumeric contextRef="c-1" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" id="f-657" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of interest expense and the effective interest rates for each of our Convertible Notes (in thousands).</span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.011%"><tr><td style="width:1.0%"/><td style="width:77.305%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.464%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.368%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.464%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.699%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Coupon interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" format="ixt:fixed-zero" scale="3" id="f-658">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" scale="3" id="f-659">36</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" scale="3" id="f-660">503</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" scale="3" id="f-661">503</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" format="ixt:num-dot-decimal" scale="3" id="f-662">1,800</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" format="ixt:num-dot-decimal" scale="3" id="f-663">1,800</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total coupon interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" format="ixt:num-dot-decimal" scale="3" id="f-664">2,303</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" format="ixt:num-dot-decimal" scale="3" id="f-665">2,339</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:fixed-zero" scale="3" id="f-666">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="f-667">24</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="f-668">856</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="f-669">850</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="f-670">775</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="f-671">764</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortization of debt discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="f-672">1,631</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="f-673">1,638</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:fixed-zero" scale="3" id="f-674">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="us-gaap:InterestExpenseDebt" scale="3" id="f-675">60</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-676">1,359</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-677">1,353</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-678">2,575</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-679">2,564</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-680">3,934</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-681">3,977</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective interest rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-165" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-682">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-166" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-683">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-167" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-684">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-168" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-685">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revolving Credit and Term Loan Facilities (May 2022)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, we entered into a credit agreement, which was subsequently amended in August 2022 (the &#8220;Amendment&#8221;), with Bank of America, N.A., as Administrative Agent, Swing Line Lender and an L/C Issuer, and the other lenders and L/C Issuers party thereto (the &#8220;2022 Credit Agreement), evidencing a credit facility (the &#8220;2022 Facility&#8221;) that provides for (i) a $<ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-686">575</ix:nonFraction>&#160;million revolving credit facility (the &#8220;Revolving Credit Facility&#8221;) and (ii) a $<ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-687">250</ix:nonFraction>&#160;million term loan facility (the &#8220;Term Facility&#8221;). Concurrently, with the entry into the Amendment, we repaid the entire outstanding Term Loan Facility and repaid all outstanding loans under the Revolving Credit Facility under the 2022 Credit Agreement. The 2022 Facility will mature on November 30, 2026 unless either the Revolving Credit Facility or the Term Facility is extended prior to such date in accordance with the 2022 Credit Agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Facility requires quarterly scheduled repayments of the term loans in each of the first, second, third and fourth years following the closing in annual amounts equal to <ix:nonFraction unitRef="number" contextRef="c-171" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-688">2.50</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="c-172" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-689">5.00</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="c-173" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-690">7.50</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-174" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-691">10.00</ix:nonFraction>% of the initial principal amount of the term loans, respectively. The term loans are also subject to mandatory prepayments from the proceeds of certain asset sales, subject to our right to reinvest the proceeds thereof.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2022 Facility bear interest, at our option, at a rate equal to an applicable margin plus: (a) the applicable Term Secured Overnight Financing Rate (&#8220;SOFR&#8221;) (which includes a SOFR adjustment of <ix:nonFraction unitRef="number" contextRef="c-175" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-692">0.10</ix:nonFraction>%), or (b) a base rate determined by reference to the highest of (1) the federal funds effective rate plus <ix:nonFraction unitRef="number" contextRef="c-176" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-693">0.50</ix:nonFraction>%, (2) the Bank of America prime rate, (3) the Term SOFR rate for an interest period of one month plus <ix:nonFraction unitRef="number" contextRef="c-177" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-694">1.10</ix:nonFraction>%, and (4) <ix:nonFraction unitRef="number" contextRef="c-178" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-695">1.00</ix:nonFraction>%. The margin for the 2022 Facility ranges, based on our consolidated total net leverage ratio, from <ix:nonFraction unitRef="number" contextRef="c-179" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-696">0.25</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-180" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-697">1.25</ix:nonFraction>% in the case of base rate loans and from <ix:nonFraction unitRef="number" contextRef="c-181" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-698">1.25</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-182" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-699">2.25</ix:nonFraction>% in the case of Term SOFR rate loans. In addition to paying interest on the outstanding principal under the Facility, we will pay (i) a commitment fee in respect of the unutilized commitments thereunder and (ii) customary letter of credit fees and agency fees. The commitment fees range from <ix:nonFraction unitRef="number" contextRef="c-183" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="f-700">0.15</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-184" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="f-701">0.35</ix:nonFraction>% per annum based on our consolidated net leverage ratio.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-581-5"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, the Revolving Credit Facility was undrawn. We incurred a total of $<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-5" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="6" id="f-702">3.6</ix:nonFraction>&#160;million in third-party costs related to the 2022 Credit Agreement which are recorded as debt issuance cost within prepaid expenses and other assets in our condensed consolidated balance sheets. As of March&#160;31, 2024, the unamortized debt issuance cost related to the revolving credit facility was $<ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="f-703">2.1</ix:nonFraction> million.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="i56f00e77098e4077b277260135e70ed7_64"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-704" continuedAt="f-704-1" escape="true">Share-based Compensation</ix:nonNumeric></span></div><ix:continuation id="f-704-1" continuedAt="f-704-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-705" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarized share-based compensation expense included in our condensed consolidated statements of income related to share-based awards (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:79.143%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.018%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.021%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-706">3,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-707">3,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-708">6,529</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-709">4,865</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-710">9,874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-711">7,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="f-712" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense by type of share-based award was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"/><td style="width:79.351%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.922%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.925%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-713">4,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-714">3,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs, PSUs and ESPP</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-715">5,575</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-716">4,511</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-717">9,874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-718">7,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We granted stock options to purchase approximately <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="6" id="f-719">0.5</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="c-11" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="6" id="f-720">1.2</ix:nonFraction> million shares of common stock during the three months ended March&#160;31, 2024 and 2023, respectively. The exercise price of stock options granted is equal to the closing price of the common stock on the date of grant. The fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option pricing model (&#8220;Black-Scholes Model&#8221;). Expected volatility is based on historical volatility of our common stock. The expected term of options granted is based on analyses of historical employee termination rates and option exercises. The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The dividend yield assumption is based on the expectation of no future dividend payments. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-721" continuedAt="f-721-1" escape="true">The assumptions used in the Black-Scholes Model were as follows:</ix:nonNumeric></span></div><ix:continuation id="f-721-1"><div style="margin-top:5pt;text-align:center;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"/><td style="width:67.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-129" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="f-722">40.02</ix:nonFraction> - <ix:nonFraction unitRef="number" contextRef="c-130" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="f-723">40.08</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-195" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="f-724">39.68</ix:nonFraction> - <ix:nonFraction unitRef="number" contextRef="c-196" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="f-725">39.98</ix:nonFraction>%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-726">5.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-11" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-727">4.8</ix:nonNumeric></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-728">3.80</ix:nonFraction> - <ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-729">4.28</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-11" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-730">3.48</ix:nonFraction> - <ix:nonFraction unitRef="number" contextRef="c-11" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-731">4.27</ix:nonFraction>%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-732">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-11" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-733">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, our Board of Directors approved our 2021 ESPP and our stockholders approved the plan in May 2021. The ESPP enables eligible employees to purchase shares of our common stock at the end of each offering period at a price equal to <ix:nonFraction unitRef="number" contextRef="c-197" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="f-734">85</ix:nonFraction>% of the fair market value of the shares on the first business day or the last business day of the offering period, whichever is lower. Share purchases are funded through payroll deduction of at least <ix:nonFraction unitRef="number" contextRef="c-198" decimals="INF" name="halo:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" scale="-2" id="f-735">1</ix:nonFraction>% and up to <ix:nonFraction unitRef="number" contextRef="c-198" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="f-736">15</ix:nonFraction>% of an employee&#8217;s compensation for each payroll period, and no employee may purchase shares under the ESPP that exceeds $<ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-3" name="halo:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" format="ixt:num-dot-decimal" scale="0" id="f-737">25,000</ix:nonFraction> worth of our common stock for a calendar year. As of March&#160;31, 2024, <ix:nonFraction unitRef="shares" contextRef="c-199" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-738">2,604,222</ix:nonFraction> shares were available for future purchase. The offering period is generally for a <ix:nonNumeric contextRef="c-197" name="halo:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" format="ixt-sec:durwordsen" id="f-739">six-month</ix:nonNumeric> period and the first offering period commenced on June 16, 2021. Offering periods shall commence on or about the sixteenth day of June and December of each year and end on or about the fifteenth day of the next December and June, respectively, occurring thereafter. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" id="f-740" escape="true"><ix:continuation id="f-704-2"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total unrecognized estimated compensation cost by type of award and the weighted-average remaining requisite service period over which such expense is expected to be recognized was as follows (in thousands, unless otherwise noted):</span></div><div style="margin-top:5pt;text-align:center;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.643%"><tr><td style="width:1.0%"/><td style="width:66.158%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.030%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrecognized<br/>Expense</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Recognition Period</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="3" id="f-741">42,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-191" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-742">2.70</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="3" id="f-743">56,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-202" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-744">3.05</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="3" id="f-745">11,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-204" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-746">2.30</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="f-747">118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-206" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-748">0.21</ix:nonNumeric></span></td></tr></table></div></ix:continuation></ix:nonNumeric><div style="text-align:center;text-indent:24.75pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="i56f00e77098e4077b277260135e70ed7_67"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-749" continuedAt="f-749-1" escape="true">Stockholders&#8217; Equity </ix:nonNumeric></span></div><ix:continuation id="f-749-1"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024 and 2023, we issued an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-191" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-750">154,556</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-192" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-751">143,931</ix:nonFraction> shares of common stock, respectively, in connection with the exercises of stock options at a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-191" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-752">17.47</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-192" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-753">16.87</ix:nonFraction> per share, respectively, for net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="f-754">2.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="f-755">2.4</ix:nonFraction> million, respectively. For the three months ended March&#160;31, 2024 and 2023, we issued <ix:nonFraction unitRef="shares" contextRef="c-207" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="f-756">262,195</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-208" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="f-757">239,919</ix:nonFraction> shares of common stock, respectively, upon vesting of certain RSUs and PSUs for which the RSU and PSU holders surrendered <ix:nonFraction unitRef="shares" contextRef="c-207" decimals="INF" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-758">88,825</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-208" decimals="INF" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-759">70,733</ix:nonFraction> RSUs and PSUs, respectively, to pay for minimum withholding taxes totaling approximately $<ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="f-760">6.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="f-761">6.5</ix:nonFraction> million, respectively. Stock options and unvested restricted units totaling approximately <ix:nonFraction unitRef="shares" contextRef="c-209" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="6" id="f-762">8.7</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="c-210" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="6" id="f-763">7.8</ix:nonFraction> million shares of our common stock were outstanding as of March&#160;31, 2024 and December&#160;31, 2023, respectively. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchases</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Board of Directors authorized a second capital return program to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-5" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="f-764">750.0</ix:nonFraction>&#160;million of outstanding stock over a <ix:nonNumeric contextRef="c-212" name="us-gaap:StockRepurchaseProgramPeriodInForce1" format="ixt-sec:durwordsen" id="f-765">three-year</ix:nonNumeric> period. During 2021, we repurchased <ix:nonFraction unitRef="shares" contextRef="c-213" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-766">3.9</ix:nonFraction>&#160;million shares of common stock for $<ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-767">150.0</ix:nonFraction>&#160;million at an average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-213" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="f-768">38.51</ix:nonFraction>. During 2022, we repurchased <ix:nonFraction unitRef="shares" contextRef="c-214" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-769">4.5</ix:nonFraction>&#160;million shares of common stock for $<ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-770">200.0</ix:nonFraction>&#160;million at an average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-214" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="f-771">44.44</ix:nonFraction>. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accelerated the initiation of our planned 2024 share repurchases and in November 2023, we entered into an Accelerated Share Repurchase (&#8220;ASR&#8221;) agreement with Bank of America, N.A. to accelerate the remaining $<ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-772">250.0</ix:nonFraction>&#160;million of share repurchases under the approved capital return program. Pursuant to the agreement, at the inception of the ASR, we paid $<ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-5" sign="-" name="us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt" format="ixt:num-dot-decimal" scale="6" id="f-773">250.0</ix:nonFraction>&#160;million to Bank of America, N.A. and took initial delivery of <ix:nonFraction unitRef="shares" contextRef="c-215" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-774">5.5</ix:nonFraction>&#160;million shares. All shares repurchased under our capital return programs have been retired and have resumed their status of authorized and unissued shares. We continued to execute share repurchases during the three months ended March 31, 2024 under our ASR agreement with Bank of America, N.A.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, excluding the shares we received under the ASR, we have repurchased a total of <ix:nonFraction unitRef="shares" contextRef="c-217" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-775">12.6</ix:nonFraction>&#160;million shares for $<ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-776">500.0</ix:nonFraction>&#160;million at an average price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-217" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="f-777">39.81</ix:nonFraction> under our $<ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-6" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="f-778">750</ix:nonFraction>&#160;million <ix:nonNumeric contextRef="c-212" name="us-gaap:StockRepurchaseProgramPeriodInForce1" format="ixt-sec:durwordsen" id="f-779">3-year</ix:nonNumeric> share repurchase plan.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2024, our Board of Directors authorized a new capital return program to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-5" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="f-780">750.0</ix:nonFraction>&#160;million of our outstanding common stock.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span><br/></span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="i56f00e77098e4077b277260135e70ed7_70"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-781" continuedAt="f-781-1" escape="true">Earnings per share</ix:nonNumeric></span></div><ix:continuation id="f-781-1" continuedAt="f-781-2"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is computed by dividing net income for the period by the weighted average number of common shares outstanding during the period, without consideration for common stock equivalents. Outstanding stock options, unvested RSUs, unvested PSUs, common shares expected to be issued under our ESPP and the Convertible Notes are considered common stock equivalents and are only included in the calculation of diluted earnings per common share when net income is reported and their effect is dilutive. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive common shares issuable upon vesting of stock options, RSUs and PSUs are determined using the average share price for each period under the treasury stock method. Potentially dilutive common shares issuable upon conversion of the Convertible Notes are determined using the if-converted method. Since we have committed to settle the principal amount of the Convertible Notes in cash upon conversion only, the number of shares for the conversion spread will be included as a dilutive common stock equivalent. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-782" continuedAt="f-782-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the numerators and the denominators of the basic and diluted earnings per share computations is as follows (in thousands, except per share amounts):</span></ix:nonNumeric></div><ix:continuation id="f-782-1"><div style="margin-top:11pt;text-align:center;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:77.307%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.547%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.316%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-783">76,823</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-784">39,615</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding for basic earnings per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-785">126,941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-786">135,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive potential common stock outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-191" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="f-787">1,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-192" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="f-788">2,173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs, PSUs and ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-219" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="f-789">339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-220" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="f-790">468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-221" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="f-791">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-222" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="f-792">232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding for diluted earnings per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-793">128,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-794">137,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-795">0.61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-796">0.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-797">0.60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-798">0.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-799" continuedAt="f-799-1" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares which have been excluded from the calculation of diluted earnings per common share because their effect was anti-dilutive include the following (shares in millions):</span></div><div style="margin-top:11pt;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"/><td style="width:77.640%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.429%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.821%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.589%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-800">28.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-801">26.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><ix:continuation id="f-799-1" continuedAt="f-799-2"><ix:continuation id="f-781-2" continuedAt="f-781-3"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-799-2"><ix:continuation id="f-781-3">    The anti-dilutive securities include outstanding stock options, unvested RSUs, unvested PSUs, common shares expected to be issued under our ESPP and Convertible Notes</ix:continuation></ix:continuation>.</span></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="i56f00e77098e4077b277260135e70ed7_73"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-802" continuedAt="f-802-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="f-802-1"><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of our business. Any of these claims could subject us to costly legal expenses and, while we generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage or our policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on our condensed consolidated statements of income and balance sheets. Additionally, any such claims, whether or not successful, could damage our reputation and business. We currently are not a party to any legal proceedings, the adverse outcome of which, in our opinion, individually or in the aggregate, would have a material adverse effect on our condensed consolidated statements of income or balance sheets.</span></div></ix:continuation><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="i56f00e77098e4077b277260135e70ed7_76"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. &#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div id="i56f00e77098e4077b277260135e70ed7_79"></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> used in this Quarterly Report on Form 10-Q, unless the context suggests otherwise, references to &#8220;Halozyme,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;ours,&#8221; and &#8220;us&#8221; refer to Halozyme Therapeutics, Inc., its wholly owned subsidiaries, Halozyme, Inc., Antares Pharma Inc., and Antares Pharma Inc.&#8217;s wholly owned subsidiaries, Antares Pharma IPL AG and Antares Pharma AG. References to &#8220;Notes&#8221; refer to the notes to the condensed consolidated financial statements included herein (refer to Item 1 of Part I).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following information should be read in conjunction with the condensed consolidated financial statements and notes thereto included in Item&#160;1 of this Quarterly Report on Form 10-Q, as well as the audited financial statements and notes thereto and Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations for the year ended December&#160;31, 2023, included in our Annual Report on Form 10-K for the year ended December&#160;31, 2023. Past financial or operating performance is not necessarily a reliable indicator of future performance, and our historical performance should not be used to anticipate results or future period trends.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, provisions of Section 21E of the securities and Exchange Act, as amended, and Section 27A of the Securities Act of 1933, as amended.. All statements in this report other than statements of historical fact, included herein, including without limitation those regarding our future product development and regulatory events and goals, product collaborations, our business intentions and financial statements and anticipated results, are, or may be deemed to be, forward-looking statements. Words such as &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;seek,&#8221; &#8220;estimate,&#8221; &#8220;think,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;continue,&#8221; &#8220;potential,&#8221; &#8220;likely,&#8221; &#8220;opportunity,&#8221; &#8220;project&#8221; and similar expressions or variations of such words are intended to identify forward-looking statements, but are not the exclusive means of identifying forward-looking statements in this Quarterly Report on Form 10-Q. Additionally, statements concerning future matters such as the development or regulatory approval of new partner products, enhancements of existing products or technologies, timing and success of the launch of new products by us and our partners, third-party performance under key collaboration agreements, the ability of our bulk drug and device part manufacturers to provide adequate supply for our partners, revenue, expense, cash burn levels and our ability to make timely repayments of debt, anticipated amounts and timing of share repurchases, anticipated profitability and expected trends and other statements regarding our plans and matters that are not historical are forward-looking statements. Such statements reflect management&#8217;s current forecast of certain aspects of our future business, are based on currently available operating, financial and competitive information and are subject to various risks, uncertainties and assumptions that could cause actual results to differ materially from those anticipated or implied in our forward-looking statements due to a number of factors including, but not limited to, those set forth below under the section entitled &#8220;Risks Factors&#8221; and elsewhere in this Quarterly Report on Form 10-Q and our most recent Annual Report on Form 10-K. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this Quarterly Report on Form 10-Q. We undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the innovators of ENHANZE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> drug delivery technology (&#8220;ENHANZE&#8221;) with our proprietary enzyme rHuPH20, our commercially validated solution is used to facilitate the subcutaneous (&#8220;SC&#8221;) delivery of injected drugs and fluids, with the goal of reducing the treatment burden for patients. We license our technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with our partners&#8217; proprietary compounds. We also develop, manufacture and commercialize, for ourselves or with our partners, drug-device combination products using our advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ENHANZE partners&#8217; approved products and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. rHuPH20 works by breaking down hyaluronan (&#8220;HA&#8221;), a naturally occurring carbohydrate that is a major component of the extracellular matrix of the SC space. This temporarily reduces the barrier to bulk fluid flow allowing for improved and more rapid SC delivery of high dose, high volume injectable biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids. We refer to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as ENHANZE. We license our ENHANZE technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the SC route of administration. In the development of proprietary intravenous (&#8220;IV&#8221;) drugs combined with our ENHANZE technology, data have been generated supporting the potential for ENHANZE to reduce patient treatment burden, as a result of shorter duration of SC administration with ENHANZE compared to IV administration. ENHANZE may enable fixed-dose SC dosing compared to weight-based dosing typically required for IV administration, extend the dosing interval for drugs that are already administered subcutaneously and potentially allow for lower rates of infusion-related reactions. ENHANZE may enable more flexible treatment options such as home administration by a healthcare professional or potentially the patient or caregiver. Lastly, certain proprietary drugs co-formulated with ENHANZE have been granted additional exclusivity, extending the patent life of the product beyond the patent expiry of the proprietary IV drug.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have ENHANZE collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (&#8220;Roche&#8221;), Takeda Pharmaceuticals International AG and Baxalta US Inc. (&#8220;Takeda&#8221;), Pfizer Inc. (&#8220;Pfizer&#8221;), Janssen Biotech, Inc. (&#8220;Janssen&#8221;), AbbVie, Inc. (&#8220;AbbVie&#8221;), Eli Lilly and Company (&#8220;Lilly&#8221;), Bristol Myers Squibb Company (&#8220;BMS&#8221;), argenx BVBA (&#8220;argenx&#8221;), ViiV Healthcare (the global specialist HIV Company majority owned by GlaxoSmithKline) (&#8220;ViiV&#8221;), Chugai Pharmaceutical Co., Ltd. (&#8220;Chugai&#8221;) and Acumen Pharmaceuticals, Inc. (&#8220;Acumen&#8221;). In addition to receiving upfront licensing fees from our ENHANZE collaborations, we are entitled to receive event and sales-based milestone payments, revenues from the sale of bulk rHuPH20 and royalties from commercial sales of approved partner products co-formulated with ENHANZE. We currently earn royalties from the sales of seven commercial products including sales of one commercial product from each of the Takeda, Janssen and argenx collaborations and four commercial products from the Roche collaboration. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have commercialized auto-injector products with several pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (&#8220;Teva&#8221;) and Otter Pharmaceuticals, LLC (&#8220;Otter&#8221;). We have development programs including auto-injectors with Idorsia Pharmaceuticals Ltd. (&#8220;Idorsia&#8221;).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial portfolio of proprietary products includes Hylenex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, utilizing rHuPH20, and our specialty product XYOSTED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, utilizing our auto-injector technology.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our first quarter of 2024 and recent key events are as follows:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Partners</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In May 2024, BMS announced that the U.S. Food and Drug Administration (&#8220;FDA&#8221;) accepted its Biologics License Application (&#8220;BLA&#8221;) for the subcutaneous formulation of Opdivo (nivolumab) co-formulated with ENHANZE, resulting in a $15.0 million milestone payment. The FDA assigned a Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) goal date of February 28, 2025.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In April 2024, Roche announced that European Medicines Agency&#8217;s Committee for Medicinal Products for Human Use has recommended the approval of Ocrevus (ocrelizumab) SC for its multiple sclerosis (&#8220;MS&#8221;) indications. A final decision on its approval from the European Commission (&#8220;EC&#8221;) is expected mid-2024.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In April 2024, Roche announced that the FDA has accepted the submission of orcelizumab SC with potential approval in September 2024.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In April 2024, Roche&#8217;s Mabthera SC was approved by the China National Medical Products Administration (&#8220;NMPA&#8221;) to treat diffuse large B-cell lymphoma (&#8220;DLBCL&#8221;).</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In March 2024, ViiV initiated a Phase 1 study of VH4524184 with ENHANZE to evaluate the safety, tolerability, and pharmacokinetics in healthy adults.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In the first quarter of 2024, argenx initiated two registrational studies evaluating efgartigimod with ENHANZE administered by pre-filled syringe in subjects with thyroid eye disease (&#8220;TED&#8221;).</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In February 2024, argenx announced that the FDA had accepted for priority review a supplemental Biologics License Application (&#8220;sBLA&#8221;) for VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of chronic inflammatory demyelinating polyneuropathy (&#8220;CIDP&#8221;). The application has been granted a PDUFA action date of June 21, 2024.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In February 2024, Takeda submitted a New Drug Application (&#8220;NDA&#8221;) in Japan seeking approval for TAK-771, subcutaneous 10% human immunoglobulin with ENHANZE, for treatment of primary immunodeficiency.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In January 2024, Janssen announced submission of a sBLA to the FDA seeking approval of a new indication for DARZALEX FASPRO in combination with bortezomib, lenalidomide and dexamethasone (&#8220;D-VRd&#8221;) for induction and consolidation treatment and with lenalidomide (&#8220;D-R&#8221;) for maintenance treatment of adult patients who are newly diagnosed with multiple myeloma (&#8220;NDMM&#8221;) and are eligible for autologous stem cell transplant (&#8220;ASCT&#8221;).</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In January 2024, Roche received EC marketing authorization for Tecentriq SC for all approved indications of Tecentriq IV for multiple cancer types.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In January 2024, Takeda received FDA and EC approval for HYQVIA for the treatment of CIDP. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In January 2024, argenx received regulatory approval in Japan for VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) co-formulated with ENHANZE for the treatment of adult patients with generalized myasthenia gravis (&#8220;gMG&#8221;) including options for self-administration, and in April 2024, VYVDURA was made available to patients resulting in $14.0 million in total milestone payments.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In February 2024, our Board of Directors authorized our third capital return program to repurchase up to $750.0 million of our outstanding common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product and Product Candidates</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The following table summarizes our marketed proprietary products and product candidates under development and our marketed partnered products and product candidates under development with our partners:</span></div><div style="text-indent:18pt"><img src="halo-20240331_g2.jpg" alt="Slide 1.jpg" style="height:815px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><img src="halo-20240331_g3.jpg" alt="slide 2.jpg" style="height:672px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="margin-top:9pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-top:9pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Proprietary Products and Product Candidates</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hylenex Recombinant (hyaluronidase human injection)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market and sell Hylenex recombinant which is a formulation of rHuPH20 that facilitates SC administration for achieving hydration, increases the dispersion and absorption of other injected drugs and, in SC urography, to improve resorption of radiopaque agents. Hylenex recombinant is currently the number one prescribed branded hyaluronidase. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">XYOSTED (testosterone enanthate) Injection</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market and sell our proprietary product XYOSTED for SC administration of testosterone replacement therapy (&#8220;TRT&#8221;) in adult males for conditions associated with a deficiency or absence of endogenous testosterone (primary or hypogonadism). XYOSTED is the only FDA-approved SC testosterone enanthate product for once-weekly, at-home self-administration and is approved and marketed in the United States (&#8220;U.S.&#8221;) in three dosage strengths, 50 mg, 75 mg and 100 mg.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ATRS - 1902</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an ongoing program to develop a proprietary drug device combination product for the endocrinology market, for patients who require additional supplemental hydrocortisone, identified as ATRS-1902. The development program uses a novel proprietary auto-injector platform to deliver a liquid stable formulation of hydrocortisone. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, we submitted an investigational new drug (&#8220;IND&#8221;) application with the FDA for the initiation of a Phase 1 clinical study of ATRS-1902 for adrenal crisis rescue. The IND application included the protocol for an initial clinical study to compare the pharmacokinetics (&#8220;PK&#8221;) profile of our novel formulation of hydrocortisone versus Solu-Cortef</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is an anti-inflammatory glucocorticoid and is the current standard of care for the management of acute adrenal crises.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the FDA accepted our IND for ATRS-1902 enabling us to initiate our Phase 1 clinical study. The Phase 1 clinical study, designed to evaluate the safety, tolerability and PK of a liquid stable formulation of hydrocortisone, was initiated in September 2021. The study was a cross-over design to establish the PK profile of ATRS-1902 (100 mg) compared to Solu-Cortef (100 mg), the reference-listed drug, in 32 healthy adults. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, we announced the positive results from the Phase 1 clinical study and were granted Fast Track designation by the FDA. The positive results supported the advancement of our ATRS-1902 development program to a pivotal study for the treatment of acute adrenal insufficiency, using our Vai novel proprietary rescue pen platform to deliver a liquid stable formulation of hydrocortisone. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Partnered Products</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ENHANZE Collaborations</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Roche Collaboration</span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2006, we and Roche entered into a collaboration and license agreement under which Roche obtained a worldwide license to develop and commercialize product combinations of rHuPH20 and up to twelve Roche target compounds (the &#8220;Roche Collaboration&#8221;). Under this agreement, Roche elected a total of eight targets, two of which are exclusive. </span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2013, Roche launched a SC formulation of Herceptin (trastuzumab) (Herceptin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SC) in Europe for the treatment of patients with HER2-positive breast cancer followed by launches in additional countries. This formulation utilizes our ENHANZE technology and is administered in two to five minutes, compared to 30 to 90 minutes with the standard IV form. Herceptin SC has since received approval in Canada, the U.S. (under the brand name Herceptin Hylecta&#8482;) and China. </span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the FDA approved the fixed-dose combination of Perjeta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pertuzumab) and Herceptin for SC injection (Phesgo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) utilizing ENHANZE technology for the treatment of patients with HER2-positive breast cancer. Phesgo has since received approval in Europe and China. In September 2023, Chugai (a Member of the Roche Group) announced that it had obtained regulatory approval for Phesgo from the Ministry of Health, Labour and Welfare (&#8220;MHLW&#8221;) in Japan. We will receive royalties for Phesgo sales in Japan as part of our licensing agreement with Roche.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2014, Roche launched MabThera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SC in Europe for the treatment of patients with common forms of non-Hodgkin lymphoma (&#8220;NHL&#8221;), followed by launches in additional countries. This formulation utilizes our ENHANZE technology and is administered in approximately five minutes compared to the approximate 1.5 to 4 hour IV infusion. In May 2016, Roche announced that the European Medicines Agency (&#8220;EMA&#8221;) approved MabThera SC to treat patients with chronic lymphocytic leukemia (&#8220;CLL&#8221;). In June 2017, the FDA-approved Genentech&#8217;s RITUXAN HYCELA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a combination of rituximab using ENHANZE technology (approved and marketed under the MabThera SC brand in countries outside the U.S. and Canada), for CLL and two types of NHL, follicular lymphoma and diffuse large B-cell lymphoma. In March 2018, Health Canada approved a combination of rituximab and ENHANZE (approved and marketed under the brand name RITUXAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SC) for patients with CLL. In April 2024, Roche&#8217;s Mabthera SC was approved by the China NMPA to treat DLBCL.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017 and October 2018, we entered into agreements with Roche to develop and commercialize additional exclusive targets using ENHANZE technology. The upfront license payment may be followed by event-based payments subject to Roche&#8217;s achievement of specified development, regulatory and sales-based milestones. In addition, Roche will pay royalties to us if products under the collaboration are commercialized.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, Roche initiated a Phase 1b/2 study in patients with non-small cell lung cancer (&#8220;NSCLC&#8221;) for TECENTRIQ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (atezolizumab) using ENHANZE technology, followed by initiation of a Phase 3 study in December 2020. In August 2022, Roche announced that the Phase 3 study met its co-primary endpoints showing non-inferior levels of Tecentriq in the blood PK, when injected subcutaneously, compared with IV infusion, in cancer immunotherapy-na&#239;ve patients with advanced or metastatic NSCLC for whom prior platinum therapy has failed. The safety profile of the SC formulation was consistent with that of IV Tecentriq. In August 2023, Roche announced the approval of Tecentriq SC with ENHANZE by the Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;) in Great Britain. In January 2024, Roche received EC marketing authorization for Tecentriq SC for all approved indications of Tecentriq IV. Roche is expecting Tecentriq SC approval in the U.S. in September 2024 and is planning to launch soon after. Tecentriq SC enables SC delivery in approximately seven minutes, compared with 30-60 minutes for IV infusion.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, Roche initiated a Phase 1 study evaluating ocrelizumab SC with ENHANZE technology in subjects with MS, followed by initiation of a Phase 3 study in April 2022. In July 2023, Roche announced that the Phase 3 OCARINA 2 trial evaluating ocrelizumab SC with ENHANZE as a twice a year 10-minute SC injection met its primary and secondary endpoints in patients with relapsing forms of MS or primary progressive MS (&#8220;RMS&#8221; or &#8220;PPMS&#8221;). In April 2024, Roche announced the EMA and FDA have both accepted the submissions for ocrelizumab SC with ENHANZE, with approval anticipated mid-2024 in the EMA and in September 2024 for the FDA.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, Roche nominated a new undisclosed exclusive target to be studied using ENHANZE technology. In November 2021, Roche initiated a Phase 1 study with the undisclosed target and ENHANZE.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2007, we and Takeda entered into a collaboration and license agreement under which Takeda obtained a worldwide, exclusive license to develop and commercialize product combinations of rHuPH20 with GAMMAGARD LIQUID (HYQVIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) (the &#8220;Takeda Collaboration&#8221;). HYQVIA is indicated for the treatment of primary immunodeficiency disorders associated with defects in the immune system.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2013, the EC granted Takeda marketing authorization in all EU Member States for the use of HYQVIA as replacement therapy for adult patients with primary and secondary immunodeficiencies. Takeda launched HYQVIA in the first EU country in July 2013 and has continued to launch in additional countries. In May 2016, Takeda announced that HYQVIA received a marketing authorization from the EC for a pediatric indication.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2014, HYQVIA was approved by the FDA for treatment of adult patients with primary immunodeficiency in the U.S. HYQVIA is the first SC immune globulin (&#8220;IG&#8221;) treatment approved for adult primary immunodeficiency patients with a dosing regimen requiring only one infusion up to once per month (every three to four weeks) and one injection site per infusion in most patients, to deliver a full therapeutic dose of IG.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, Takeda announced the EMA approved a label update for HYQVIA broadening its use and making it the first and only facilitated SC immunoglobulin replacement therapy in adults, adolescents and children with an expanded range of secondary immunodeficiencies (&#8220;SID&#8221;).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, Takeda initiated a Phase 1 single-dose, single-center, open-label, three-arm study to assess the tolerability and safety of immune globulin SC (human), 20% solution with ENHANZE (TAK-881) at various infusion rates in healthy adult subjects. In October 2023, Takeda initiated a Phase 2/3 study to evaluate PK, safety, and tolerability of subcutaneous administration of TAK-881 in adult and pediatric participants with Primary Immunodeficiency Diseases (&#8220;PIDD&#8221;).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, Takeda announced positive topline results from a pivotal Phase 3 trial evaluating HYQVIA, for maintenance treatment of CIDP. In June 2023, Takeda announced positive full results from a pivotal Phase 3 trial evaluating HYQVIA for maintenance treatment of CIDP and confirmed regulatory applications were under review in the U.S. and EU for HYQVIA use as a maintenance therapy in adults with stable CIDP. In January 2024, Takeda received FDA and EC approval for HYQVIA for the treatment of CIDP.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, Takeda announced that the FDA-approved the sBLA to expand the use of HYQVIA to treat primary immunodeficiency in children. In February 2024, Takeda submitted a NDA in Japan seeking approval for TAK-771, subcutaneous 10% human immunoglobulin with ENHANZE, for treatment of primary immunodeficiency.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pfizer Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2012, we and Pfizer entered into a collaboration and license agreement, under which Pfizer has the worldwide license to develop and commercialize products combining our rHuPH20 enzyme with Pfizer proprietary biologics in primary care and specialty care indications. Pfizer has elected five targets and has returned two targets. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Janssen Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2014, we and Janssen entered into a collaboration and license agreement, under which Janssen has the worldwide license to develop and commercialize products combining our rHuPH20 enzyme with Janssen proprietary biologics directed to up to five targets. Targets may be selected on an exclusive basis. Janssen elected CD38 and initiated several Phase 3 studies, Phase 2 studies and Phase 1 studies of DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(daratumumab), directed at CD38, using ENHANZE technology in patients with amyloidosis, smoldering myeloma and multiple myeloma.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In May 2020, Janssen launched the commercial sale of DARZALEX FASPRO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (DARZALEX utilizing ENHANZE technology) in four regimens across five indications in multiple myeloma patients, including newly diagnosed, transplant-ineligible patients as well as relapsed or refractory patients. As a fixed-dose formulation, DARZALEX FASPRO can be administered over three to five minutes, significantly less time than DARZALEX IV which requires multi-hour infusions. In June 2020, we announced that Janssen received European marketing authorization and launched the commercial sale of DARZALEX SC utilizing ENHANZE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the EU. Subsequent to these approvals, Janssen received several additional regulatory approvals for additional indications and patient populations in the U.S., EU, Japan and China. Beginning with the U.S., Janssen has marketing authorization for DARZALEX FASPRO in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplant, in combination with bortezomib, cyclophosphamide and dexamethasone (&#8220;D-VCd&#8221;) for the treatment of adult patients with newly diagnosed AL amyloidosis, in combination with pomalidomide and dexamethasone (&#8220;D-Pd&#8221;) for patients with multiple myeloma after first or subsequent relapse, and in combination with Kyprolis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (carfilzomib) and dexamethasone for patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy. In the EU, Janssen has marketing authorization for DARZALEX SC in combination with D-VCd in newly diagnosed adult patients with AL amyloidosis and in combination with D-Pd in adult patients with relapsed or refractory multiple myeloma. In Japan, Janssen has marketing authorization for the SC formulation of DARZALEX (known as DARZQURO in Japan) for the treatment of multiple myeloma and systemic AL amyloidosis. In China, Janssen has marketing authorization for DARZALEX SC for the treatment of primary light chain amyloidosis, in combination with D-VCd in newly diagnosed patients. In January 2024, Janssen announced submission of a sBLA to the FDA seeking approval of a new indication for DARZALEX FASPRO in combination with D-VRd for induction and consolidation treatment and with D-R for maintenance treatment of adult patients who are NDMM and are eligible for ASCT.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, Janssen elected epidermal growth factor receptor (&#8220;EGFR&#8221;) and mesenchymal-epithelial transition factor (&#8220;cMET&#8221;) as a bispecific antibody (amivantamab) target on an exclusive basis, which is being studied in solid tumors. In September 2022, following a Phase 1 study, Janssen initiated a Phase 3 study of lazertinib and amivantamab with ENHANZE in patients with EGFR-mutated advanced or metastatic non-small cell lung cancer (PALOMA-3). In November 2022, Janssen initiated a Phase 2 study of amivantamab with ENHANZE in multiple regimens in patients with advanced or metastatic solid tumors including EGFR-mutated non-small cell lung cancer (PALOMA-2). In January 2024, Janssen noted its intention to submit applications in the U.S. and EU seeking approval of a SC formulation for amivantamab SC during 2024. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, Janssen elected the target human immunodeficiency virus (&#8220;HIV&#8221;) reverse transcriptase limited to non-nucleoside reverse transcriptase inhibitors. In December 2021, Janssen initiated a Phase 1 clinical trial combining rilpivirine and ENHANZE. In 2023, Janssen discontinued the rilpivirine program with ENHANZE.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AbbVie Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2015, we and AbbVie entered into a collaboration and license agreement, under which AbbVie has the worldwide license to develop and commercialize products combining our rHuPH20 enzyme with AbbVie proprietary biologics directed to up to nine targets. Targets may be selected on an exclusive basis. </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lilly Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2015, we and Lilly entered into a collaboration and license agreement, under which Lilly has the worldwide license to develop and commercialize products combining our rHuPH20 enzyme with Lilly proprietary biologics. Lilly currently has the right to select up to three targets. Targets may be selected on an exclusive basis. Lilly has elected two targets on an exclusive basis and one target on a semi-exclusive basis.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BMS Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, we and BMS entered into a collaboration and license agreement, which became effective in November 2017, under which BMS had the worldwide license to develop and commercialize products combining our rHuPH20 enzyme with BMS products directed at up to eleven targets. Targets may be selected on an exclusive basis or non-exclusive basis. BMS has designated multiple immuno-oncology targets including programmed death 1 (&#8220;PD-1&#8221;) and has an option to select three additional targets by November 2024. In October 2019, BMS initiated a Phase 1 study of relatlimab, an anti-LAG-3 antibody, in combination with nivolumab using ENHANZE technology. In May 2021, BMS initiated a Phase 3 of nivolumab using ENHANZE technology for patients with advanced or metastatic clear cell renal cell carcinoma (CheckMate-67T), leveraging data and insights from Phase 1/2 CA209-8KX study in patients with solid tumors. In October 2023, BMS reported positive top-line data from the Phase 3 CheckMate-67T trial evaluating a SC formulation of Opdivo (nivolumab) with ENHANZE in patients with advanced or metastatic clear cell renal cell carcinoma (&#8220;ccRCC&#8221;) who have received prior systemic therapy. The study met its co-primary PK endpoints and a key secondary endpoint. In May 2024, BMS announced that the FDA accepted its BLA for the subcutaneous formulation of Opdivo (nivolumab) co-formulated with ENHANZE and assigned a PDUFA goal date of February 28, 2025.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, BMS initiated a Phase 3 trial to demonstrate the drug exposure levels of nivolumab and relatlimab fixed-dose combination with ENHANZE is not inferior to IV administration in participants with previously untreated metastatic or unresectable melanoma (RELATIVITY-127).</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">argenx Collaboration </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we and argenx entered into an agreement for the right to develop and commercialize one exclusive target, the human neonatal Fc receptor FcRn, which includes argenx&#8217;s lead asset efgartigimod (ARGX-113), and an option to select two additional targets using ENHANZE technology. In May 2019, argenx nominated a second target to be studied using ENHANZE technology, a human complement factor C2 associated with the product candidate ARGX-117, which is being developed to treat severe autoimmune diseases in Multifocal Motor Neuropathy (&#8220;MMN&#8221;). In October 2020, we and argenx entered into an agreement to expand the collaboration relationship, adding three targets for a total of up to six targets under the collaboration. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, argenx announced the FDA approval of efgartigimod (VYVGART</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for the treatment of gMG for the IV dosing regimen. In March 2022, argenx announced that data from argenx&#8217;s phase 3 ADAPT-SC study evaluating SC efgartigimod utilizing ENHANZE (1000mg efgartigimod-PH20) for the treatment of gMG achieved the primary endpoint of total IgG reduction from baseline at day 29, demonstrating statistical non-inferiority to VYVGART (efgartigimod alfa-fcab) IV formulation in gMG patients. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, argenx received FDA approval under the brand name VYVGART</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Hytrulo for the injection with ENHANZE for SC use of treatment of gMG in adult patients who are anti-acetylcholine receptor (&#8220;AChR&#8221;) antibody positive. In November 2023, argenx received EC approval of VYVGART SC for the treatment of gMG, which also provides the option for patient self-administration. In January 2024, argenx received Japan approval for VYVDURA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (efgartigimod alfa and hyaluronidase-qvfc) co-formulated with ENHANZE for the treatment of adult patients with gMG including options for self-administration. argenx also expects the regulatory decision on approval of VYVGART SC for gMG in China through Zai Lab by the end of 2024. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023, argenx reported positive data from the ADHERE study evaluating VYVGART</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Hytrulo with ENHANZE in adults with CIDP. In February 2024, argenx announced that the FDA had accepted for priority review a sBLA for VYVGART Hytrulo for the treatment of CIDP. The application has been granted a PDUFA action date of June 21, 2024. argenx also expects to submit VYVGART SC for CIDP for regulatory approval in Japan, Europe, China and Canada in 2024. In September 2023, Zai Lab limited (argenx commercial partner for China) announced the CDE of the National Medical Products Administration (&#8220;NMPA&#8221;) granted Breakthrough Therapy Designation for efgartigimod SC for the treatment of patients with CIDP.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">argenx is currently conducting the following studies with the goal of expanding approved indications for efgartigimod with ENHANZE: Phase 2/3 (ALKIVIA) study in active idiopathic inflammatory myopathy (Myositis) and two registrational studies in TED. Evaluation is ongoing to determine the path forward in BALLAD study evaluating efgartigimod in bullous pemphigoid (BP) with an update expected in 2024.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ViiV Healthcare Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, we and ViiV entered into a global collaboration and license agreement that gives ViiV exclusive access to our ENHANZE technology for four specific small and large molecule targets for the treatment and prevention of HIV. These targets are integrase inhibitors, reverse transcriptase inhibitors limited to nucleoside reverse transcriptase inhibitors (&#8220;NRTI&#8221;) and nucleoside reverse transcriptase translocation inhibitors (&#8220;NRTTIs&#8221;), capsid inhibitors and broadly neutralising monoclonal antibodies (&#8220;bNAbs&#8221;), that bind to the gp120 CD4 binding site. In December 2021, ViiV initiated enrollment of a Phase 1 study to evaluate cabotegravir administered subcutaneously with ENHANZE. In March 2024, ViiV presented the results of the Phase 1 study of cabotegravir and communicated their decision to no longer pursue cabotegravir 200mg/ml SC plus rHuPH20 for long term dosing. In February 2022, ViiV initiated enrollment of a Phase 1 study to evaluate the safety and PKs of N6LS, a broadly neutralizing antibody, administered subcutaneously with ENHANZE technology. In June 2022, ViiV initiated enrollment of a Phase 1 single dose escalation study to evaluate PKs, safety and tolerability of long-acting cabotegravir administered subcutaneously with ENHANZE technology. In August 2023, ViiV initiated a Phase 2b study to evaluate the efficacy, safety, PKs and tolerability of VH3810109 (N6LS) administered subcutaneously with rHuPH20 in combination with cabotegravir. In the third quarter of 2023, ViiV initiated a Phase 1 study with ENHANZE for an undisclosed program. In March 2024, ViiV initiated a Phase 1 study of VH4524184 with ENHANZE to evaluate the safety, tolerability, and pharmacokinetics in healthy adults.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Chugai Collaboration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, we and Chugai entered into a global collaboration and license agreement that gives Chugai exclusive access to ENHANZE technology for an undisclosed target. Chugai intends to explore the potential use of ENHANZE for a Chugai drug candidate. In May 2022, Chugai initiated a Phase 1 study to evaluate the PKs, pharmacodynamics, and safety of targeted antibody administered subcutaneously with ENHANZE.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acumen Collaboration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, we and Acumen entered into a global collaboration and non-exclusive license agreement that provides Acumen access to ENHANZE for a single target. Acumen intends to explore the potential use of ENHANZE for ACU193, Acumen&#8217;s clinical stage monoclonal antibody candidate to target Amyloid-&#946; Oligomers for the treatment of early Alzheimer&#8217;s disease. In March 2024, Acumen announced plans to initiate a Phase 2 IV study for ACU193 in the first half of 2024 and a Phase 1 SC study for ACU193 in mid-2024.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Device and Other Drug Product Collaborations</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Teva License, Development and Supply Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2006, we entered into an exclusive license, development and supply agreement with Teva for an epinephrine auto- injector product to be marketed in the U.S. and Canada. We are the exclusive supplier of the device, which we developed, for Teva&#8217;s generic Epinephrine Injection USP products, indicated for emergency treatment of severe allergic reactions including those that are life threatening (anaphylaxis) in adults and certain pediatric patients. Teva&#8217;s Epinephrine Injection, utilizing our patented VIBEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> injection technology, was approved by the FDA as a generic drug product with an AB rating, meaning that it is therapeutically equivalent to the branded products EpiPen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and EpiPen Jr</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and therefore, subject to state law, substitutable at the pharmacy. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2007, we entered into a license, development and supply agreement with Teva under which we developed and supply a disposable pen injector for teriparatide. Under the agreement, we received an upfront payment and development milestones, and are entitled to receive royalties on net product sales by Teva in territories where commercialized. We are the exclusive supplier of the multi-dose pen, which we developed, used in Teva&#8217;s generic teriparatide injection product. In 2020, Teva launched Teriparatide Injection, the generic version of Eli Lilly&#8217;s branded product Forsteo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> featuring our multi-dose pen platform, for commercial sale in several countries outside of the U.S. In November 2023, Teva announced FDA approval of the generic version of Forteo, featuring our multi-dose auto-injector pen platform for the treatment of osteoporosis among certain women and men.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pfizer Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, we entered into a development agreement with Pfizer to jointly develop a combination drug device rescue pen utilizing the QuickShot auto-injector and an undisclosed Pfizer drug. Pfizer has provided the intellectual property rights for further development of the product to us and has retained an option to assist in the marketing, distribution and sale if we complete development of the product and submit for regulatory approval. We are continuing to evaluate the next steps for this program.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Idorsia Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we entered into a global agreement with Idorsia to develop a novel, drug-device product containing selatogrel. A new chemical entity, selatogrel is being developed for the treatment of a suspected acute myocardial infarction (&#8220;AMI&#8221;) in adult patients with a history of AMI. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024, the recruitment of the Phase 3 study with selatogrel for acute myocardial infarction had reached approximately 6,000 patients.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Otter Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we entered into a supply agreement with Otter to manufacture the VIBEX auto-injection system device, designed and developed to incorporate a pre-filled syringe for delivery of methotrexate, assemble, package, label and supply the final OTREXUP product and related samples to Otter at cost plus mark-up. Otter is responsible for manufacturing, formulation and testing of methotrexate and the corresponding pre-filled syringe for assembly with the device manufactured by us, along with the commercialization and distribution of OTREXUP. OTREXUP is a SC methotrexate injection for once weekly self-administration with an easy-to-use, single dose, disposable auto injector, indicated for adults with severe active rheumatoid arthritis (&#8220;RA&#8221;), children with active polyarticular juvenile idiopathic arthritis and adults with severe recalcitrant psoriasis. Further, we entered into a license agreement with Otter in which we granted Otter a worldwide, exclusive, fully paid-up license to certain patents relating to OTREXUP that may also relate to our other products for Otter to commercialize and otherwise exploit OTREXUP in the field as defined in the license agreement.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><div id="i56f00e77098e4077b277260135e70ed7_82"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Three Months Ended March&#160;31, 2024 Compared to Three Months Ended March&#160;31, 2023 </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Royalties were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.497%"><tr><td style="width:1.0%"/><td style="width:46.072%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.177%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.177%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.177%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.182%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase / (Decrease)</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollar</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,593&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,640&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,953&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in royalties was primarily driven by continued sales uptake of DARZALEX SC by Janssen and Phesgo by Roche in all geographies and the launch of Vyvgart by argenx, partially offset by slightly lower sales of Herceptin SC and MabThera SC by Roche. We expect royalty revenue to continue to grow as a result of our 2020 and 2023 ENHANZE partner product launches, offsetting the ongoing impact from IV biosimilars on pricing of mature partner products delivered SC with ENHANZE and the impact of a royalty rate reduction in March of 2024 for certain sales of DARZALEX SC outside of the U.S.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Product sales, net were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"/><td style="width:47.014%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.459%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.363%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.459%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.363%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.459%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.363%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.855%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.365%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase / (Decrease)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollar </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proprietary product sales</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,254&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,961&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,293&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bulk rHuPH20 sales</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,069&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,558)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Device partnered product sales</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,818&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,054&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,583&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,794&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,211)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in product sales, net was primarily due to lower sales of bulk rHuPH20 due to the timing of shipment to our partners, partially offset by contributions from our proprietary and device partnered products. We expect sales of our proprietary products will grow in future years as we continue to gain market share in the TRT market. We expect product sales of bulk rHuPH20 and device partnered products to fluctuate in future periods based on the needs of our partners.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues Under Collaborative Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Revenues under collaborative agreements were as follows (in thousands): </span></div><div style="margin-top:5pt;text-align:center;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:46.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.415%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.415%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.415%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.012%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.418%"/><td style="width:0.1%"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase / (Decrease)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollar </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage</span></div></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upfront license fees, license fees for the election of additional targets, event-based payments, license maintenance fees and amortization of deferred upfront and other license fees:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Event-based development milestones and regulatory milestones and other fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Device licensing and development revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues under collaborative agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,703&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,709&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,994&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in revenues under collaborative agreements was primarily due to the timing of milestones driven by partner activities. Revenue from upfront licenses fees, license fees for the election of additional targets, license maintenance fees and other license fees and event-based payments vary from period to period based on our ENHANZE collaboration activity. We expect these revenues to continue to fluctuate in future periods based on our partners&#8217; ability to meet various clinical and regulatory milestones set forth in such agreements and our ability to obtain new collaborative agreements.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"/><td style="width:46.276%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.497%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.628%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.497%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.628%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.497%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.628%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase / (Decrease)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollar </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,329&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,170&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,841)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangibles</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,835&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,979&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,223)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales consists primarily of raw materials, third-party manufacturing costs, fill and finish costs, freight costs, internal costs and manufacturing overhead associated with the production of our proprietary products, device partnered products and bulk rHuPH20. The decrease in cost of sales was primarily due to lower bulk rHuPH20 sales, partially offset by higher proprietary product sales. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization of intangibles</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangibles consists primarily of expense associated with the amortization of acquired device technologies and product rights. Amortization of intangibles expense remained flat year over year.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Research and development expenses consist of external costs, salaries and benefits and allocation of facilities and other overhead expenses related to research manufacturing, preclinical and regulatory activities related to our collaborations, and our development platforms. The increase in research and development expense was primarily due to planned investments in ENHANZE.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Selling, general and administrative (&#8220;SG&amp;A&#8221;) expenses consist primarily of salaries and related costs for personnel in executive, selling and administrative functions as well as professional fees for legal and accounting, business development, commercial operations support for proprietary products and alliance management and marketing support for our collaborations. The decrease in SG&amp;A expense was primarily due to reductions in commercial marketing expense, partially offset by increased compensation expense.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investment and other income (expense)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Investment and other income (expense), net was as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"><tr><td style="width:1.0%"/><td style="width:47.436%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.878%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.302%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.610%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.878%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.610%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.878%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase / (Decrease)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollar </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment and other income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,993&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,979&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,014&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment and other income (expense), net consists primarily of interest income on our cash, cash-equivalent and marketable securities. The increase in investment and other income, net was primarily due to a significant increase in market interest rates as well as an increase in the average invested balance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Interest expense was as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.029%"><tr><td style="width:1.0%"/><td style="width:49.207%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.592%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.592%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.592%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase / (Decrease)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollar </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,507&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,543&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense consists primarily of costs related to our convertible notes and revolving credit facility. Interest expense remained flat year over year.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Income taxes were as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:46.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.489%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.574%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.489%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.574%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.489%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.574%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.578%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase / (Decrease)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollar </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,205&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,623&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,582&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in income tax expense was primarily due to higher income before taxes recognized during the current quarter. Our annual effective tax rate is estimated to be approximately 20% for 2024, which differs from the U.S. federal statutory rate due to state income taxes, nondeductible executive compensation, research and development credit generation and the reduced rate on foreign export sales. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><div id="i56f00e77098e4077b277260135e70ed7_88"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal sources of liquidity are our existing cash, cash equivalents and available-for-sale marketable securities. As of March&#160;31, 2024, we had cash, cash equivalents and marketable securities of $463.5 million. We believe that our current cash, cash equivalents and marketable securities will be sufficient to fund our operations for at least the next twelve months. We expect to fund our operations going forward with existing cash resources, anticipated revenues from our existing collaborative agreements and cash that we may raise through future transactions. We may raise cash through any one of the following financing vehicles: (i) new collaborative agreements; (ii) expansions or revisions to existing collaborative relationships; (iii) private financings; (iv) other equity or debt financings; (v) monetizing assets; and/or (vi) the public offering of securities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may, in the future, draw on our existing line of credit or offer and sell additional equity, debt securities and warrants to purchase any of such securities, either individually or in units to raise capital for additional working capital, capital expenditures, share repurchases, acquisitions or for other general corporate purposes. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"/><td style="width:59.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.132%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.132%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.135%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,427&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,964&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,463&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82,681)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,162)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,519)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(489)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(164,614)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,257&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137,812)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,069&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in net cash provided by operations was primarily due to an increase in revenue and a reduction in working capital spend.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in net cash used in investing activities was primarily due an increase in net purchases of marketable securities, partially offset by a decrease in capital spend for property and equipment.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in net cash used in financing activities was primarily due to the repurchase of $150.1 million in common stock in the prior year and $13.5 million in cash paid on the conversion of our 2024 Convertible Notes in the prior year. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchases</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, our Board of Directors approved a share repurchase program to repurchase up to $750.0 million of our outstanding common stock which is expected to be completed in the second quarter of 2024. In February 2024, our Board of Directors authorized a new capital return program to repurchase up to $750.0 million of our outstanding common stock. Refer to Note 9, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stockholders&#8217; Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of our condensed consolidated financial statements for additional information regarding our share repurchases.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Term Debt</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">1.00% Convertible Notes due 2028</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, we completed the sale of $720.0&#160;million in aggregate principal amount of 1.00% Convertible Senior Notes due 2028 (the &#8220;2028 Convertible Notes&#8221;). The net proceeds in connection with the issuance of the 2028 Convertible Notes, after deducting the initial purchasers&#8217; fee of $18.0&#160;million, was approximately $702.0&#160;million. We also incurred additional debt issuance costs totaling $1.0&#160;million. Debt issuance costs and the initial purchasers&#8217; fee are presented as a debt discount.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2028 Convertible Notes pay interest semi-annually in arrears on February 15th and August 15th of each year at an annual rate of 1.00%. The 2028 Convertible Notes are general unsecured obligations and rank senior in right of payment to all indebtedness that is expressly subordinated in right of payment to the 2028 Convertible Notes, rank equally in right of payment with all existing and future liabilities that are not so subordinated, are effectively junior to any secured indebtedness to the extent of the value of the assets securing such indebtedness and are structurally subordinated to all indebtedness and other liabilities (including trade payables) of our current or future subsidiaries. The 2028 Convertible Notes have a maturity date of August 15, 2028.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their 2028 Convertible Notes at their option only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on December 31, 2022, if the last reported sale price per share of common stock exceeds 130% of the conversion price for each of at least 20 trading days during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the five consecutive business days immediately after any five consecutive trading day period (such five consecutive trading day period, the &#8220;measurement period&#8221;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of our common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on our common stock, as described in the offering memorandum for the 2028 Convertible Notes; (4) if we call such notes for redemption; and (5) at any time from, and including, February 15, 2028 until the close of business on the second scheduled trading day immediately before the maturity date. As of March&#160;31, 2024, the 2028 Convertible Notes were not convertible.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, we will pay cash for the settlement of principal, and for the premium, if applicable, we will pay cash, deliver shares of common stock or a combination of cash and shares of common stock, at our election. The initial conversion rate for the 2028 Convertible Notes is 17.8517 shares of common stock per $1,000 in principal amount of 2028 Convertible Notes, equivalent to a conversion price of approximately $56.02 per share of our common stock. The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued or unpaid interest.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capped Call Transactions</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the offering of the 2028 Convertible Notes, we entered into capped call transactions with certain counterparties (the &#8220;Capped Call Transactions&#8221;). The Capped Call Transactions are expected generally to reduce potential dilution to holders of our common stock upon conversion of the 2028 Convertible Notes or at our election (subject to certain conditions) offset any cash payments we are required to make in excess of the principal amount of such converted 2028 Convertible Notes. The cap price of the Capped Call Transactions is initially $75.4075 per share of common stock, representing a premium of 75% above the last reported sale price of $43.09 per share of common stock on August 15, 2022, and is subject to certain adjustments under the terms of the Capped Call Transactions. As of March&#160;31, 2024, no capped calls had been exercised.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to their terms, the capped calls qualify for classification within stockholders&#8217; equity in our condensed consolidated balance sheets, and their fair value is not remeasured and adjusted as long as they continue to qualify for stockholders&#8217; equity classification. We paid approximately $69.1&#160;million for the Capped Calls, including applicable transaction costs, which was recorded as a reduction to additional paid-in capital in our condensed consolidated balance sheets. The Capped Call Transactions are separate transactions entered into by us with the capped call Counterparties, are not part of the terms of the Convertible Notes, and do not affect any holder&#8217;s rights under the Convertible Notes. Holders of the Convertible Notes do not have any rights with respect to the Capped Call Transactions.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">0.25% Convertible Notes due 2027</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, we completed the sale of $805.0&#160;million in aggregate principal amount of 0.25% Convertible Senior Notes due 2027 (the &#8220;2027 Convertible Notes&#8221;). The net proceeds in connection with the issuance of the 2027 Convertible Notes, after deducting the initial purchasers&#8217; fee of $20.1&#160;million, was approximately $784.9&#160;million. We also incurred additional debt issuance costs totaling $0.4&#160;million. Debt issuance costs and the initial purchasers&#8217; fee are presented as a debt discount.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2027 Convertible Notes pay interest semi-annually in arrears on March 1st and September 1st of each year at an annual rate of 0.25%. The 2027 Convertible Notes are general unsecured obligations and rank senior in right of payment to all indebtedness that is expressly subordinated in right of payment to the 2027 Convertible Notes, will rank equally in right of payment with all existing and future liabilities that are not so subordinated, are effectively junior to any secured indebtedness to the extent of the value of the assets securing such indebtedness and are structurally subordinated to all indebtedness and other liabilities (including trade payables) of our current or future subsidiaries. The 2027 Convertible Notes have a maturity date of March 1, 2027.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their 2027 Convertible Notes at their option only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on June 30, 2021, if the last reported sale price per share of common stock exceeds 130% of the conversion price for each of at least 20 trading days during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the five consecutive business days immediately after any five consecutive trading day period (such five consecutive trading day period, the &#8220;measurement period&#8221;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of our common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on our common stock, as described in the offering memorandum for the 2027 Convertible Notes; (4) if we call such notes for redemption; and (5) at any time from, and including, September 1, 2026 until the close of business on the scheduled trading day immediately before the maturity date. As of March&#160;31, 2024, the 2027 Convertible Notes were not convertible.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, we will pay cash for the settlement of principal, and for the premium, if applicable, we will pay cash, deliver shares of common stock or a combination of cash and shares of common stock, at our election. The initial conversion rate for the 2027 Convertible Notes is 12.9576 shares of common stock per $1,000 in principal amount of 2027 Convertible Notes, equivalent to a conversion price of approximately $77.17 per share of our common stock. The conversion rate is subject to adjustment.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">1.25% Convertible Notes due 2024</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we completed the sale of $460.0 million in aggregate principal amount of 1.25% Convertible Senior Notes due 2024 (the &#8220;2024 Convertible Notes&#8221;). The net proceeds in connection with the issuance of the 2024 Convertible Notes, after deducting the initial purchasers&#8217; fee of $12.7&#160;million, was approximately $447.3 million. We also incurred debt issuance cost totaling $0.3&#160;million. Debt issuance costs and the initial purchasers&#8217; fee were presented as a debt discount.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we notified the note holders of our irrevocable election to settle the principal of the 2024 Convertible Notes in cash and for the premium, to deliver shares of common stock. The conversion rate for the 2024 Convertible Notes was 41.9208 shares of common stock per $1,000 in principal amount of 2024 Convertible Notes, equivalent to a conversion price of approximately $23.85 per share of our common stock. The conversion rate was subject to adjustment. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, we issued a notice for the redemption of 2024 Convertible Notes. Holders of the notes could convert their notes at any time prior to the close of the business day prior to the redemption date. In March 2023, holders of the notes elected to convert the 2024 Convertible Notes in full. In connection with the conversion, we paid approximately $13.5 million in cash which included principal and accrued interest, and issued 288,886 shares of our common stock representing the intrinsic value based on the contractual conversion rate.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revolving Credit and Term Loan Facilities (May 2022)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, we entered into a credit agreement, which was subsequently amended in August 2022 (the &#8220;Amendment&#8221;), with Bank of America, N.A., as Administrative Agent, Swing Line Lender and an L/C Issuer, and the other lenders and L/C Issuers party thereto (the &#8220;2022 Credit Agreement), evidencing a credit facility (the &#8220;2022 Facility&#8221;) that provides for (i) a $575 million revolving credit facility (the &#8220;Revolving Credit Facility&#8221;) and (ii) a $250 million term loan facility (the &#8220;Term Facility&#8221;). Concurrently, with the entry into the Amendment, we repaid the entire outstanding Term Loan Facility and repaid all outstanding loans under the Revolving Credit Facility under the 2022 Credit Agreement. The 2022 Facility will mature on November 30, 2026 unless either the Revolving Credit Facility or the Term Facility is extended prior to such date in accordance with the 2022 Credit Agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Facility requires quarterly scheduled repayments of the term loans in each of the first, second, third and fourth years following the closing in annual amounts equal to 2.50%, 5.00%, 7.50% and 10.00% of the initial principal amount of the term loans, respectively. The term loans are also subject to mandatory prepayments from the proceeds of certain asset sales, subject to our right to reinvest the proceeds thereof.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2022 Facility bear interest, at our option, at a rate equal to an applicable margin plus: (a) the applicable Term Secured Overnight Financing Rate (&#8220;SOFR&#8221;) (which includes a SOFR adjustment of 0.10%), or (b) a base rate determined by reference to the highest of (1) the federal funds effective rate plus 0.50%, (2) the Bank of America prime rate, (3) the Term SOFR rate for an interest period of one month plus 1.10%, and (4) 1.00%. The margin for the 2022 Facility ranges, based on our consolidated total net leverage ratio, from 0.25% to 1.25% in the case of base rate loans and from 1.25% to 2.25% in the case of Term SOFR rate loans. In addition to paying interest on the outstanding principal under the 2022 Facility, we will pay (i) a commitment fee in respect of the unutilized commitments thereunder and (ii) customary letter of credit fees and agency fees. The commitment fees range from 0.15% to 0.35% per annum based on our consolidated net leverage ratio.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of March&#160;31, 2024, the revolving credit facility was undrawn. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional Capital Requirements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our expected working capital and other capital requirements are described in &#8220;Part II, Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2023. As of March&#160;31, 2024, there have been no material changes to our expected working capital and other capital requirements described in our Annual Report on Form 10-K for the year ended December&#160;31, 2023.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion and analysis of our financial condition and results of operations are based on our condensed consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). The preparation of our condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant accounting policies are described in Part II, Item 8, Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2023. The accounting policies and estimates that are most critical to a full understanding and evaluation of our reported financial results are described in Part II, Item 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of our Annual Report on Form 10-K for the year ended December&#160;31, 2023. There were no material changes to our critical accounting policies or estimates during the three months ended March&#160;31, 2024.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of our condensed consolidated financial statements for a discussion of recent accounting pronouncements and their effect, if any.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><div id="i56f00e77098e4077b277260135e70ed7_94"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:15.02pt">Quantitative and Qualitative Disclosures About Market Risk </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in our market risks during the quarter ended March&#160;31, 2024.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, our cash equivalents and marketable securities consisted of investments in money market funds, asset-backed securities, U.S. Treasury securities, corporate debt securities, agency bonds and commercial paper. These investments were made in accordance with our investment policy which specifies the categories, allocations, and ratings of securities we may consider for investment. The primary objective of our investment activities is to preserve principal while at the same time maximizing the income we receive without significantly increasing risk. Some of the financial instruments that we invest in could be subject to market risk. This means that a change in prevailing interest rates may cause the value of the instruments to fluctuate. For example, if we purchase a security that was issued with a fixed interest rate and the prevailing interest rate later rises, the value of that security may decline. Based on our current investment portfolio as of March&#160;31, 2024, we do not believe that our results of operations would be materially impacted by an immediate change of 10% in interest rates. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hedge a portion of foreign currency exchange risk associated with forecasted royalties revenue denominated in Swiss francs to reduce the risk of our earnings and cash flows being adversely affected by fluctuations in exchange rates. These transactions are designated and qualify as cash flow hedges. The cash flow hedges are carried at fair value with mark-to-market gains and losses recorded within AOCI in our condensed consolidated balance sheets and reclassified to royalty revenue in our condensed consolidated statements of income in the same period as the recognition of the underlying hedged transaction. We do not issue derivatives, derivative commodity instruments or other financial instruments for speculative trading purposes. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, we do not believe our cash, cash equivalents and marketable securities have significant risk of default or illiquidity. We made this determination based on discussions with our investment advisors and a review of our holdings. While we believe our cash, cash equivalents and marketable securities do not contain excessive risk, we cannot provide absolute assurance that in the future our investments will not be subject to adverse changes in market value. All of our cash equivalents and marketable securities are recorded at fair market value.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div id="i56f00e77098e4077b277260135e70ed7_97"></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:15.02pt">Controls and Procedures</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the timelines specified in the Securities and Exchange Commission&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decision regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can only provide reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended. Based on this evaluation, our principal executive officer and our principal financial officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes in our internal control over financial reporting that occurred during the quarter ended March&#160;31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><div id="i56f00e77098e4077b277260135e70ed7_100"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II &#8211; OTHER INFORMATION</span></div><div id="i56f00e77098e4077b277260135e70ed7_103"></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:15.02pt">Legal Proceedings</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of our business. Any of these claims could subject us to costly legal expenses and, while we generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage or our policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on our condensed consolidated statements of income and balance sheets. Additionally, any such claims, whether or not successful, could damage our reputation and business. We currently are not a party to any legal proceedings, the adverse outcome of which, in our opinion, individually or in the aggregate, would have a material adverse effect on our condensed consolidated statements of income or balance sheets.</span></div><div id="i56f00e77098e4077b277260135e70ed7_106"></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:7.8pt">Risk Factors </span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There have been no material changes to the risk factors set forth under Part I, Item 1A. &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2023.</span></div><div id="i56f00e77098e4077b277260135e70ed7_109"></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:15.02pt">Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In December 2021, the Board of Directors authorized a capital return program to repurchase up to $750.0 million of outstanding stock over a three-year period. We accelerated the initiation of our planned 2024 share repurchases and in November 2023, we entered into an ASR agreement with Bank of America, N.A. to accelerate the remaining $250.0 million of share repurchases under the approved capital return program. Pursuant to the agreement, at the inception of the ASR, we paid $250.0 million to Bank of America, N.A. and took initial delivery of 5.5 million shares. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2024, our Board of Directors authorized a new capital return program to repurchase up to $750.0 million of our outstanding common stock.</span></div><div id="i56f00e77098e4077b277260135e70ed7_112"></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:15.02pt">Defaults Upon Senior Securities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i56f00e77098e4077b277260135e70ed7_115"></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:15.02pt">Mine Safety Disclosures</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i56f00e77098e4077b277260135e70ed7_118"></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:15.02pt">Other Information</span></div><ix:nonNumeric contextRef="c-1" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-803" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fiscal quarter ended ended March&#160;31, 2024, the following officers adopted or terminated any Rule 10b5-1 trading arrangement (as such terms are defined pursuant to Item 408(a) of Regulation S-K) as noted in the table below.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"><tr><td style="width:1.0%"/><td style="width:19.779%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.427%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.427%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.947%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.427%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.202%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.427%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.319%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.427%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.830%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.196%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.119%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Arrangement</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name and Title</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Action</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rule 10b5-1*</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-804"><ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-805">Non-Rule 10b5-1**</ix:nonNumeric></ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Shares To Be Sold</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration Date</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-223" name="ecd:TrdArrIndName" id="f-806">Helen Torley</ix:nonNumeric></span></div><div><span><br/></span></div></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-224" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-true" id="f-807">Termination</ix:nonNumeric></span></div></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-224" name="ecd:TrdArrTerminationDate" id="f-808">1/30/2024</ix:nonNumeric></span></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></div></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-225" decimals="-3" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-809">500,000</ix:nonFraction>&#160;</span></td><td rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Terminated</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-223" name="ecd:TrdArrIndTitle" id="f-810">President and Chief Executive Officer</ix:nonNumeric></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-226" name="ecd:TrdArrIndName" id="f-811">Helen Torley</ix:nonNumeric></span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-226" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-812">Adoption</ix:nonNumeric></span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-226" name="ecd:TrdArrAdoptionDate" id="f-813">3/22/2024</ix:nonNumeric></span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="2" rowspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-227" decimals="-3" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-814">110,000</ix:nonFraction>&#160;</span></td><td rowspan="2" style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The earlier of 02/13/2025 or date all shares are sold</span></div></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-226" name="ecd:TrdArrIndTitle" id="f-815">President and Chief Executive Officer</ix:nonNumeric></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-228" name="ecd:TrdArrIndName" id="f-816">Nicole LaBrosse</ix:nonNumeric></span></div></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-228" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-817">Adoption</ix:nonNumeric></span></div></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-228" name="ecd:TrdArrAdoptionDate" id="f-818">3/22/2024</ix:nonNumeric></span></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></div></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-229" decimals="-3" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-819">35,000</ix:nonFraction>&#160;</span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></div></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The earlier of 06/25/2025 or date all shares are sold</span></div></td></tr><tr style="height:35pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-228" name="ecd:TrdArrIndTitle" id="f-820">Senior Vice President and Chief Financial Officer</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Non-Rule 10b5-1 trading arrangement&#8221; as defined in Item 408(c) of Regulation S-K under the Exchange Act.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The duration of the trading arrangement was until May 30, 2024, or earlier if all transaction under the trading arrangement had been completed. At the time of termination, no shares had been sold under the trading arrangement.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Represents a sale of common shares acquired upon exercise of stock options with ten-year term expiring in 2025.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><div id="i56f00e77098e4077b277260135e70ed7_121"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:12pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:15.02pt">Exhibits</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.375%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1159036/000115903624000031/exhibit31amendedandrestate.htm">Amended and Restated Certificate of Incorporation of Halozyme Therapeutics, Inc. (filed as Exhibit 3.1 to the Company&#8217;s Form 8-K filed April 26, 2024 and incorporated herein by reference)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1159036/000115903621000056/ex31-amendedandrestatedbyl.htm">Bylaws, as amended (filed as Exhibit 3.1 to the Company&#8217;s Form 8-K filed December 10, 2021 and incorporated herein by reference)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000119312521063401/d587130dex41.htm">Indenture, dated March 1, 2021, between Halozyme Therapeutics, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee (</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000056/ex31-amendedandrestatedbyl.htm">filed as Exhibit 4.1 to the Company&#8217;s Form 8-K filed March 1, 2021 and incorporated herein by reference</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1159036/000119312521063401/d587130dex41.htm">)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000119312521063401/d587130dex42.htm">Form of Note, dated March 1, 2021, between Halozyme Therapeutics, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee, (</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000056/ex31-amendedandrestatedbyl.htm">filed as Exhibit 4.2 to the Company&#8217;s Form 8-K filed March 1, 2021 and incorporated herein by reference</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1159036/000119312521063401/d587130dex42.htm">)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000119312522224202/d391138dex41.htm">Indenture, dated August 18, 2022, between Halozyme Therapeutics, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee, (</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000056/ex31-amendedandrestatedbyl.htm">filed as Exhibit 4.1 to the Company&#8217;s Form 8-K filed August 18, 2022 and incorporated herein by reference</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1159036/000119312522224202/d391138dex41.htm">)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000119312522224202/d391138dex41.htm">Form of Note, dated August 18, 2022, between Halozyme Therapeutics, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee, (included within Exhibit 4.1) (</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000056/ex31-amendedandrestatedbyl.htm">filed as Exhibit 4.2 to the Company&#8217;s Form 8-K filed August 18, 2022 and incorporated herein by reference</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1159036/000119312522224202/d391138dex41.htm">)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex31110qq120234.htm">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (filed herewith)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex31210qq12024.htm">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (filed herewith)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex3210qq12024.htm">Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (furnished herewith)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Instance Document - the instance document does not appear in the interactive Data File because its XBRL tags are embedded within the Inline XBRL document (filed herewith)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline Taxonomy Extension Schema Document (filed herewith)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline Taxonomy Extension Calculation Linkbase Document (filed herewith)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline Taxonomy Extension Definition Linkbase Document (filed herewith)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline Taxonomy Extension Label Linkbase Document (filed herewith)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline Taxonomy Extension Presentation Linkbase Document (filed herewith)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) (filed herewith)</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:2.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:81.478%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:justify;text-indent:-4.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:-4.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:-4.5pt"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><div id="i56f00e77098e4077b277260135e70ed7_124"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:6.084%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.920%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.210%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Halozyme Therapeutics, Inc.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 7, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;Helen I. Torley, M.B. Ch.B., M.R.C.P.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Helen I. Torley, M.B. Ch.B., M.R.C.P.<br/>President and Chief Executive Officer<br/>(Principal Executive Officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 7, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Nicole LaBrosse</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nicole LaBrosse<br/>Senior Vice President and Chief Financial Officer<br/>(Principal Financial and Accounting Officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ex31110qq120234.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i2d3e3460d90349debb575b06da24252e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Helen I. Torley, M.B. Ch.B., M.R.C.P., Chief Executive Officer of Halozyme Therapeutics, Inc. certify that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">I have reviewed this Quarterly Report on Form 10-Q of Halozyme Therapeutics, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">The Registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.74pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.17pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.74pt">evaluated the effectiveness of the Registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.17pt">disclosed in this report any change in the Registrant&#8217;s internal control over financial reporting that occurred during the Registrant&#8217;s most recent fiscal quarter (the Registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">The Registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant&#8217;s auditors and the audit committee of the Registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.74pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.17pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:7.099%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.768%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.773%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 7, 2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Helen I. Torley, M.B. Ch.B., M.R.C.P.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Helen I. Torley, M.B. Ch.B., M.R.C.P</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ex31210qq12024.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i872321a3a49c42b6967f4dfe70a4a284_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Nicole LaBrosse, Chief Financial Officer of Halozyme Therapeutics, Inc. certify that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">I have reviewed this Quarterly Report on Form 10-Q of Halozyme Therapeutics, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">The Registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.74pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.17pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.74pt">evaluated the effectiveness of the Registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.17pt">disclosed in this report any change in the Registrant&#8217;s internal control over financial reporting that occurred during the Registrant&#8217;s most recent fiscal quarter (the Registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">The Registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant&#8217;s auditors and the audit committee of the Registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.74pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.17pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:6.074%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.922%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 7, 2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Nicole LaBrosse</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nicole LaBrosse</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>4
<FILENAME>ex3210qq12024.htm
<DESCRIPTION>EX-32
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i3928cb3c18534dd8b22851f13249d397_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Halozyme Therapeutics, Inc. (the &#8220;Registrant&#8221;) on Form 10-Q for the quarter ended March&#160;31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Helen I. Torley, M.B. Ch.B., M.R.C.P., Chief Executive Officer of the Registrant, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge&#58;</font></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m)&#59; and</font></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.773%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 7, 2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Helen I. Torley, M.B. Ch.B., M.R.C.P.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Helen I. Torley, M.B. Ch.B., M.R.C.P.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Halozyme Therapeutics, Inc. (the &#8220;Registrant&#8221;) on Form 10-Q for the quarter ended March&#160;31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Nicole LaBrosse, Chief Financial Officer of the Registrant, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge&#58;</font></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m)&#59; and</font></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.774%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 7, 2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Nicole LaBrosse</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nicole LaBrosse</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>halo-20240331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:17e6b7b2-f6c0-4a96-9180-046700296928,g:1765a142-e24e-49b0-883b-7a52af9d0516-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:halo="http://www.halozyme.com/20240331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.halozyme.com/20240331">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="halo-20240331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="halo-20240331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="halo-20240331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="halo-20240331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.halozyme.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>0000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>0000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofIncomeUnaudited" roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited">
        <link:definition>0000004 - Statement - Condensed Consolidated Statements of Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited">
        <link:definition>0000005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>0000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquityUnaudited" roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited">
        <link:definition>0000007 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBusiness" roleURI="http://www.halozyme.com/role/OrganizationandBusiness">
        <link:definition>0000008 - Disclosure - Organization and Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurement" roleURI="http://www.halozyme.com/role/FairValueMeasurement">
        <link:definition>0000010 - Disclosure - Fair Value Measurement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenue" roleURI="http://www.halozyme.com/role/Revenue">
        <link:definition>0000011 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItems" roleURI="http://www.halozyme.com/role/CertainBalanceSheetItems">
        <link:definition>0000012 - Disclosure - Certain Balance Sheet Items</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssets" roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssets">
        <link:definition>0000013 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtNet" roleURI="http://www.halozyme.com/role/LongTermDebtNet">
        <link:definition>0000014 - Disclosure - Long-Term Debt, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensation" roleURI="http://www.halozyme.com/role/SharebasedCompensation">
        <link:definition>0000015 - Disclosure - Share-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.halozyme.com/role/StockholdersEquity">
        <link:definition>0000016 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Earningspershare" roleURI="http://www.halozyme.com/role/Earningspershare">
        <link:definition>0000017 - Disclosure - Earnings per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.halozyme.com/role/CommitmentsandContingencies">
        <link:definition>0000018 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementTables" roleURI="http://www.halozyme.com/role/FairValueMeasurementTables">
        <link:definition>9954472 - Disclosure - Fair Value Measurement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueTables" roleURI="http://www.halozyme.com/role/RevenueTables">
        <link:definition>9954473 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsTables" roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsTables">
        <link:definition>9954474 - Disclosure - Certain Balance Sheet Items (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsTables" roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsTables">
        <link:definition>9954475 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtNetTables" roleURI="http://www.halozyme.com/role/LongTermDebtNetTables">
        <link:definition>9954476 - Disclosure - Long-Term Debt, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensationTables" roleURI="http://www.halozyme.com/role/SharebasedCompensationTables">
        <link:definition>9954477 - Disclosure - Share-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningspershareTables" roleURI="http://www.halozyme.com/role/EarningspershareTables">
        <link:definition>9954478 - Disclosure - Earnings per share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBusinessDetails" roleURI="http://www.halozyme.com/role/OrganizationandBusinessDetails">
        <link:definition>9954479 - Disclosure - Organization and Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAccountsReceivablenetDetails" roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivablenetDetails">
        <link:definition>9954480 - Disclosure - Summary of Significant Accounting Policies -Accounts Receivable, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesLeasesDetails" roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails">
        <link:definition>9954481 - Disclosure - Summary of Significant Accounting Policies - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPropertyandEquipmentnetDetails" roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentnetDetails">
        <link:definition>9954482 - Disclosure - Summary of Significant Accounting Policies -Property and Equipment, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesCashFlowHedgesCurrencyRisksDetails" roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesCashFlowHedgesCurrencyRisksDetails">
        <link:definition>9954483 - Disclosure - Summary of Significant Accounting Policies - Cash Flow Hedges - Currency Risks (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesRevenueandCostofProductSalesDetails" roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesRevenueandCostofProductSalesDetails">
        <link:definition>9954484 - Disclosure - Summary of Significant Accounting Policies - Revenue and Cost of Product Sales (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesIncomeTaxesDetails" roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails">
        <link:definition>9954485 - Disclosure - Summary of Significant Accounting Policies - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSegmentInformationDetails" roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails">
        <link:definition>9954486 - Disclosure - Summary of Significant Accounting Policies - Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails" roleURI="http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails">
        <link:definition>9954487 - Disclosure - Fair Value Measurement - Components of Available-for-sale Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementNarrativeDetails" roleURI="http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails">
        <link:definition>9954488 - Disclosure - Fair Value Measurement - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementContractualMaturitiesofAvailableforsaleDebtSecuritiesDetails" roleURI="http://www.halozyme.com/role/FairValueMeasurementContractualMaturitiesofAvailableforsaleDebtSecuritiesDetails">
        <link:definition>9954489 - Disclosure - Fair Value Measurement - Contractual Maturities of Available-for-sale Debt Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>9954490 - Disclosure - Fair Value Measurement - Assets Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueDisaggregatedRevenuesDetails" roleURI="http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails">
        <link:definition>9954491 - Disclosure - Revenue - Disaggregated Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueNarrativeDetails" roleURI="http://www.halozyme.com/role/RevenueNarrativeDetails">
        <link:definition>9954492 - Disclosure - Revenue - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueNarrativeDetails_1" roleURI="http://www.halozyme.com/role/RevenueNarrativeDetails_1">
        <link:definition>9954492 - Disclosure - Revenue - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueAccountsReceivableOtherContractAssetsandContractLiabilitiesDetails" roleURI="http://www.halozyme.com/role/RevenueAccountsReceivableOtherContractAssetsandContractLiabilitiesDetails">
        <link:definition>9954493 - Disclosure - Revenue - Accounts Receivable, Other Contract Assets and Contract Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsAccountsReceivablenetDetails" roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails">
        <link:definition>9954494 - Disclosure - Certain Balance Sheet Items - Accounts Receivable, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsInventoriesDetails" roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails">
        <link:definition>9954495 - Disclosure - Certain Balance Sheet Items - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails" roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails">
        <link:definition>9954496 - Disclosure - Certain Balance Sheet Items - Prepaid Expenses and Other Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails_1" roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails_1">
        <link:definition>9954496 - Disclosure - Certain Balance Sheet Items - Prepaid Expenses and Other Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsPropertyandEquipmentnetDetails" roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails">
        <link:definition>9954497 - Disclosure - Certain Balance Sheet Items - Property and Equipment, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsAccruedExpensesDetails" roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails">
        <link:definition>9954498 - Disclosure - Certain Balance Sheet Items - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsAccruedExpensesDetails_1" roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails_1">
        <link:definition>9954498 - Disclosure - Certain Balance Sheet Items - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsGoodwillRollforwardDetails" roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsGoodwillRollforwardDetails">
        <link:definition>9954499 - Disclosure - Goodwill and Intangible Assets - Goodwill Rollforward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsAdditionalDetails" roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalDetails">
        <link:definition>9954500 - Disclosure - Goodwill and Intangible Assets - Additional (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsIntangibleAssetsDetails" roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails">
        <link:definition>9954501 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsFutureAmortizationDetails" roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails">
        <link:definition>9954502 - Disclosure - Goodwill and Intangible Assets - Future Amortization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtNetNarrativeDetails" roleURI="http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails">
        <link:definition>9954503 - Disclosure - Long-Term Debt, Net - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtNetCarryingAmountofConvertibleNotesDetails" roleURI="http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails">
        <link:definition>9954504 - Disclosure - Long-Term Debt, Net - Carrying Amount of Convertible Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtNetComponentsofInterestExpenseDetails" roleURI="http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails">
        <link:definition>9954505 - Disclosure - Long-Term Debt, Net - Components of Interest Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensationSharebasedCompensationExpenseDetails" roleURI="http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails">
        <link:definition>9954506 - Disclosure - Share-based Compensation - Share-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensationNarrativeDetails" roleURI="http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails">
        <link:definition>9954507 - Disclosure - Share-based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails" roleURI="http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails">
        <link:definition>9954508 - Disclosure - Share-based Compensation - Assumptions Used in the Black-Scholes Model (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails" roleURI="http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails">
        <link:definition>9954509 - Disclosure - Share-based Compensation - Unrecognized Estimated Compensation Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.halozyme.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>9954510 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningspershareComputationDetails" roleURI="http://www.halozyme.com/role/EarningspershareComputationDetails">
        <link:definition>9954511 - Disclosure - Earnings per share - Computation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningspershareAntidilutiveSecuritiesDetails" roleURI="http://www.halozyme.com/role/EarningspershareAntidilutiveSecuritiesDetails">
        <link:definition>9954512 - Disclosure - Earnings per share - Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="halo_TermLoanFacilityMember" abstract="true" name="TermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" abstract="false" name="PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_AnnualInterestPaymentPeriodAxis" abstract="true" name="AnnualInterestPaymentPeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="halo_HelenTorleyMember" abstract="true" name="HelenTorleyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_OtherComprehensiveIncomeLossCashFlowHedgeUnrealizedHoldingGainLossBeforeAdjustmentAfterTax" abstract="false" name="OtherComprehensiveIncomeLossCashFlowHedgeUnrealizedHoldingGainLossBeforeAdjustmentAfterTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_OthercollaboratorsMember" abstract="true" name="OthercollaboratorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="halo_A2021ESPPPlanMember" abstract="true" name="A2021ESPPPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="halo_VariableRateComponentAxis" abstract="true" name="VariableRateComponentAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="halo_OperatingLeaseAccretionOfLiability" abstract="false" name="OperatingLeaseAccretionOfLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_DebtInstrumentCapCallTransactionCapPricePerShare" abstract="false" name="DebtInstrumentCapCallTransactionCapPricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="halo_PaymentForCappedCallTransactions" abstract="false" name="PaymentForCappedCallTransactions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_A025ConvertibleSeniorNotesDue2027Member" abstract="true" name="A025ConvertibleSeniorNotesDue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="halo_A2024CapitalReturnProgramMember" abstract="true" name="A2024CapitalReturnProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_DeferredRentPayments" abstract="false" name="DeferredRentPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_AutoInjectorTechnologyPlatformMember" abstract="true" name="AutoInjectorTechnologyPlatformMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="halo_VariableRateComponentOneMember" abstract="true" name="VariableRateComponentOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="halo_ArgenxMember" abstract="true" name="ArgenxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="halo_HelenTorleyMarch2024PlanMember" abstract="true" name="HelenTorleyMarch2024PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="halo_DebtInstrumentInterestPeriodThreeMember" abstract="true" name="DebtInstrumentInterestPeriodThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="halo_ManufacturingEquipmentMember" abstract="true" name="ManufacturingEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="halo_DeviceLicensingAndDevelopmentMember" abstract="true" name="DeviceLicensingAndDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="halo_RestrictStockUnitsPerformanceSharesAndESPPMember" abstract="true" name="RestrictStockUnitsPerformanceSharesAndESPPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="halo_CollaborativeAgreementsMember" abstract="true" name="CollaborativeAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="halo_ComputerAndOfficeEquipmentMember" abstract="true" name="ComputerAndOfficeEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="halo_VariableRateComponentDomain" abstract="true" name="VariableRateComponentDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="halo_StockOptionsAndRestrictedStockUnitsMember" abstract="true" name="StockOptionsAndRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="halo_EventBasedDevelopmentAndRegulatoryMilestoneAndOtherFeesMember" abstract="true" name="EventBasedDevelopmentAndRegulatoryMilestoneAndOtherFeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays" abstract="false" name="DebtInstrumentConvertibleThresholdConsecutiveBusinessDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="halo_ProprietaryProductsSalesMember" abstract="true" name="ProprietaryProductsSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="halo_RevenueRemainingPerformanceObligationsUnfulfilledProductPurchaseOrdersAmount" abstract="false" name="RevenueRemainingPerformanceObligationsUnfulfilledProductPurchaseOrdersAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent" abstract="false" name="AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_AcceleratedShareRepurchaseAgreementMember" abstract="true" name="AcceleratedShareRepurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems" abstract="true" name="ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="halo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" abstract="false" name="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_XYOSTEDProprietaryProductMember" abstract="true" name="XYOSTEDProprietaryProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="halo_SaleOfStockPremiumOverLastReportedSalePricePercentage" abstract="false" name="SaleOfStockPremiumOverLastReportedSalePricePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="halo_ResearchEquipmentMember" abstract="true" name="ResearchEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="halo_AccruedOutsourcedManufacturingExpenses" abstract="false" name="AccruedOutsourcedManufacturingExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_DebtInstrumentInterestPeriodFourMember" abstract="true" name="DebtInstrumentInterestPeriodFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable" abstract="true" name="ScheduleofSharebasedCompensationArrangementsValuationInputsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="halo_LicenseFeesAndEventBasedMember" abstract="true" name="LicenseFeesAndEventBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="halo_VariableRateComponentTwoMember" abstract="true" name="VariableRateComponentTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="halo_DebtInstrumentInterestPeriodOneMember" abstract="true" name="DebtInstrumentInterestPeriodOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="halo_RSURSAandPRSUawardsMember" abstract="true" name="RSURSAandPRSUawardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="halo_AccruedLiabilitiesNoncurrent" abstract="false" name="AccruedLiabilitiesNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_BulkrHuPH20Member" abstract="true" name="BulkrHuPH20Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="halo_JanssenMember" abstract="true" name="JanssenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="halo_A100ConvertibleSeniorNotesDue2028Member" abstract="true" name="A100ConvertibleSeniorNotesDue2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="halo_TakedaMember" abstract="true" name="TakedaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="halo_A1.25ConvertibleSeniorNotesdue2024Member" abstract="true" name="A1.25ConvertibleSeniorNotesdue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="halo_AnnualInterestPaymentPeriodDomain" abstract="true" name="AnnualInterestPaymentPeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="halo_RoyaltiesReceivedNumberOfProductsSold" abstract="false" name="RoyaltiesReceivedNumberOfProductsSold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="halo_NicoleLaBrosseMember" abstract="true" name="NicoleLaBrosseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_RestrictedStockUnitsAndPerformanceSharesMember" abstract="true" name="RestrictedStockUnitsAndPerformanceSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_CreditAgreementMember" abstract="true" name="CreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="halo_AccountsReceivableAndContractWithCustomerAssetBeforeAllowanceForCreditLossCurrent" abstract="false" name="AccountsReceivableAndContractWithCustomerAssetBeforeAllowanceForCreditLossCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_RocheMember" abstract="true" name="RocheMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="halo_DebtInstrumentInterestPeriodTwoMember" abstract="true" name="DebtInstrumentInterestPeriodTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="halo_HelenTorleyPriorPlanMember" abstract="true" name="HelenTorleyPriorPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice" abstract="false" name="RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="halo_AccountsReceivableAndContractWithCustomerAssetAllowanceForCreditLossCurrent" abstract="false" name="AccountsReceivableAndContractWithCustomerAssetAllowanceForCreditLossCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="halo_ProductSalesOtherMember" abstract="true" name="ProductSalesOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_DevicePartneredProductsMember" abstract="true" name="DevicePartneredProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>halo-20240331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:17e6b7b2-f6c0-4a96-9180-046700296928,g:1765a142-e24e-49b0-883b-7a52af9d0516-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="halo-20240331.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_44f80797-ebdd-4ad9-9789-ba00b656cac8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_2b12f6ba-9e02-4412-b761-c68b0d475ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_44f80797-ebdd-4ad9-9789-ba00b656cac8" xlink:to="loc_us-gaap_AccountsPayableCurrent_2b12f6ba-9e02-4412-b761-c68b0d475ac9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_d29899ec-5af5-4199-8695-e1de0b75be6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_44f80797-ebdd-4ad9-9789-ba00b656cac8" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_d29899ec-5af5-4199-8695-e1de0b75be6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_2bd884c3-f976-494d-b982-b583789bb1aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_83d33d80-e735-4b71-a2c9-ebbabcff77a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2bd884c3-f976-494d-b982-b583789bb1aa" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_83d33d80-e735-4b71-a2c9-ebbabcff77a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b1cd674d-c0e1-434c-ae43-60a92c7a8634" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2bd884c3-f976-494d-b982-b583789bb1aa" xlink:to="loc_us-gaap_LiabilitiesCurrent_b1cd674d-c0e1-434c-ae43-60a92c7a8634" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_32f080a3-1336-444a-a43a-d960d3865eec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2bd884c3-f976-494d-b982-b583789bb1aa" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_32f080a3-1336-444a-a43a-d960d3865eec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e2e50349-d587-4142-8034-bc36ff0b84c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_3d4fecb9-2016-49ef-a63e-007a6300485c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e2e50349-d587-4142-8034-bc36ff0b84c1" xlink:to="loc_us-gaap_PreferredStockValue_3d4fecb9-2016-49ef-a63e-007a6300485c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_174d1b4c-65b1-470a-bfd4-a0c836f327a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e2e50349-d587-4142-8034-bc36ff0b84c1" xlink:to="loc_us-gaap_CommonStockValue_174d1b4c-65b1-470a-bfd4-a0c836f327a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_d6351e5c-dd39-4dc6-8901-b19494e2a3fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e2e50349-d587-4142-8034-bc36ff0b84c1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_d6351e5c-dd39-4dc6-8901-b19494e2a3fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ef87b564-20ea-45c2-85dc-15ab86135020" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e2e50349-d587-4142-8034-bc36ff0b84c1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ef87b564-20ea-45c2-85dc-15ab86135020" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_124dcc73-96be-4512-bc79-f9ecc475654b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e2e50349-d587-4142-8034-bc36ff0b84c1" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_124dcc73-96be-4512-bc79-f9ecc475654b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_9208f6a8-f064-4888-a7ba-5401551ffcae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_370cb32d-6b5c-4ae9-87d8-2ba2efee9c48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9208f6a8-f064-4888-a7ba-5401551ffcae" xlink:to="loc_us-gaap_AssetsCurrent_370cb32d-6b5c-4ae9-87d8-2ba2efee9c48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_89323161-17e3-42c4-b773-e5af963c5ea0" xlink:href="halo-20240331.xsd#halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9208f6a8-f064-4888-a7ba-5401551ffcae" xlink:to="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_89323161-17e3-42c4-b773-e5af963c5ea0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_589bdc1b-c4cf-44d2-878c-a57770cadf67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9208f6a8-f064-4888-a7ba-5401551ffcae" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_589bdc1b-c4cf-44d2-878c-a57770cadf67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f486a1e7-d85e-40eb-b41f-09f4ca83585b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9208f6a8-f064-4888-a7ba-5401551ffcae" xlink:to="loc_us-gaap_Goodwill_f486a1e7-d85e-40eb-b41f-09f4ca83585b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_232f25b9-9504-488f-a0cd-d2a1d7e0dcfe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9208f6a8-f064-4888-a7ba-5401551ffcae" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_232f25b9-9504-488f-a0cd-d2a1d7e0dcfe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_44c0a4e0-8bb9-44d0-aa67-9cd10d0199c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9208f6a8-f064-4888-a7ba-5401551ffcae" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_44c0a4e0-8bb9-44d0-aa67-9cd10d0199c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a73da951-42ac-431c-aa1c-e31cc7625ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7c0075db-56f6-42a2-8a54-3d2dbf4a5210" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a73da951-42ac-431c-aa1c-e31cc7625ae8" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7c0075db-56f6-42a2-8a54-3d2dbf4a5210" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_574440b0-2c27-4f0c-8147-8368af4a92cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a73da951-42ac-431c-aa1c-e31cc7625ae8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_574440b0-2c27-4f0c-8147-8368af4a92cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent_c10f39f5-f646-42f9-b40c-2a2e6954a51c" xlink:href="halo-20240331.xsd#halo_AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a73da951-42ac-431c-aa1c-e31cc7625ae8" xlink:to="loc_halo_AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent_c10f39f5-f646-42f9-b40c-2a2e6954a51c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_1411176b-1f1d-4881-b660-b268ed33afe5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a73da951-42ac-431c-aa1c-e31cc7625ae8" xlink:to="loc_us-gaap_InventoryNet_1411176b-1f1d-4881-b660-b268ed33afe5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_eee92e11-6b5f-4e71-865a-cce3db84fcd4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a73da951-42ac-431c-aa1c-e31cc7625ae8" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_eee92e11-6b5f-4e71-865a-cce3db84fcd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_fd6dbee0-140c-46e7-b0f1-83bd5bfcbdbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_308c07f1-f82c-4ad2-8aa4-fbcdb039e1f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_fd6dbee0-140c-46e7-b0f1-83bd5bfcbdbf" xlink:to="loc_us-gaap_Liabilities_308c07f1-f82c-4ad2-8aa4-fbcdb039e1f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_72ee6000-2328-4bb1-9982-62fe4d95480e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_fd6dbee0-140c-46e7-b0f1-83bd5bfcbdbf" xlink:to="loc_us-gaap_StockholdersEquity_72ee6000-2328-4bb1-9982-62fe4d95480e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_a2a895f9-869e-40bd-902d-5d01d9f54d19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_fd6dbee0-140c-46e7-b0f1-83bd5bfcbdbf" xlink:to="loc_us-gaap_CommitmentsAndContingencies_a2a895f9-869e-40bd-902d-5d01d9f54d19" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="simple" xlink:href="halo-20240331.xsd#CondensedConsolidatedStatementsofIncomeUnaudited"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_7ebd2772-08d1-4c35-8210-f6dfb09f6787" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_160d320b-5c1a-4587-a6e2-1794ee27c79f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_7ebd2772-08d1-4c35-8210-f6dfb09f6787" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_160d320b-5c1a-4587-a6e2-1794ee27c79f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8fd5d3fa-83bb-4830-a75c-a0348ec0f5e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_7ebd2772-08d1-4c35-8210-f6dfb09f6787" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8fd5d3fa-83bb-4830-a75c-a0348ec0f5e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c7669541-4268-4447-b179-e7cdca6b5af9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_7ebd2772-08d1-4c35-8210-f6dfb09f6787" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c7669541-4268-4447-b179-e7cdca6b5af9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_60859283-4361-4dd0-a04d-efc3eb5a3e91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_7ebd2772-08d1-4c35-8210-f6dfb09f6787" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_60859283-4361-4dd0-a04d-efc3eb5a3e91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_187064ca-9e36-48bd-bf4d-f7ce5eb1b4ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cb9912d1-3d50-49e8-ade3-b62741789e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_187064ca-9e36-48bd-bf4d-f7ce5eb1b4ff" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cb9912d1-3d50-49e8-ade3-b62741789e7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a238d4e8-4406-4633-b7ef-6988717364f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_187064ca-9e36-48bd-bf4d-f7ce5eb1b4ff" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a238d4e8-4406-4633-b7ef-6988717364f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3cb346b0-dfe6-40a1-8380-cb61ecc77d17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_88e32e72-a7a1-4ca9-bbdc-f8a05c62d7f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_3cb346b0-dfe6-40a1-8380-cb61ecc77d17" xlink:to="loc_us-gaap_CostsAndExpenses_88e32e72-a7a1-4ca9-bbdc-f8a05c62d7f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_287a8114-4113-43d3-9e7f-7908abdbf2e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_3cb346b0-dfe6-40a1-8380-cb61ecc77d17" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_287a8114-4113-43d3-9e7f-7908abdbf2e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b1efcf36-f96d-44f7-91a3-2d26f171212c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b8641f07-a65a-4601-8e26-398caabc208f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b1efcf36-f96d-44f7-91a3-2d26f171212c" xlink:to="loc_us-gaap_OperatingIncomeLoss_b8641f07-a65a-4601-8e26-398caabc208f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_0a320627-939b-4f80-85c3-0e1d2d569cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b1efcf36-f96d-44f7-91a3-2d26f171212c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_0a320627-939b-4f80-85c3-0e1d2d569cd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_6a57f0b1-ab1e-4081-8b6c-453067c8ba94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b1efcf36-f96d-44f7-91a3-2d26f171212c" xlink:to="loc_us-gaap_InterestExpense_6a57f0b1-ab1e-4081-8b6c-453067c8ba94" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="simple" xlink:href="halo-20240331.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_e4bb7f34-e12e-4d93-8f5f-e4cccd3ea8e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5f8f7e98-8e06-445c-9846-b19f34418538" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_e4bb7f34-e12e-4d93-8f5f-e4cccd3ea8e9" xlink:to="loc_us-gaap_NetIncomeLoss_5f8f7e98-8e06-445c-9846-b19f34418538" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_3791aba7-34aa-4236-b67f-bb1a79a7f744" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_e4bb7f34-e12e-4d93-8f5f-e4cccd3ea8e9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_3791aba7-34aa-4236-b67f-bb1a79a7f744" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_f60fa001-5a5e-4eed-9e09-7a34e81edb0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_e4bb7f34-e12e-4d93-8f5f-e4cccd3ea8e9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_f60fa001-5a5e-4eed-9e09-7a34e81edb0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_OtherComprehensiveIncomeLossCashFlowHedgeUnrealizedHoldingGainLossBeforeAdjustmentAfterTax_d275b89a-b5e0-42d7-a985-11dc88f3f48c" xlink:href="halo-20240331.xsd#halo_OtherComprehensiveIncomeLossCashFlowHedgeUnrealizedHoldingGainLossBeforeAdjustmentAfterTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_e4bb7f34-e12e-4d93-8f5f-e4cccd3ea8e9" xlink:to="loc_halo_OtherComprehensiveIncomeLossCashFlowHedgeUnrealizedHoldingGainLossBeforeAdjustmentAfterTax_d275b89a-b5e0-42d7-a985-11dc88f3f48c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_01f265db-721c-4c1b-834f-37941091a5a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_e4bb7f34-e12e-4d93-8f5f-e4cccd3ea8e9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_01f265db-721c-4c1b-834f-37941091a5a1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="halo-20240331.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_861fcec3-aff5-42c9-ab22-02406730c115" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_948e1802-7f23-4abd-ba54-b90df886689a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_861fcec3-aff5-42c9-ab22-02406730c115" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_948e1802-7f23-4abd-ba54-b90df886689a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_261c5021-5c79-47aa-a76f-e7e65be7318e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_861fcec3-aff5-42c9-ab22-02406730c115" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_261c5021-5c79-47aa-a76f-e7e65be7318e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_980ab61f-6cc3-4777-8210-3849619383c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_861fcec3-aff5-42c9-ab22-02406730c115" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_980ab61f-6cc3-4777-8210-3849619383c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b85a4e09-bfc1-4b09-954e-1ad2f7d0e0b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_398e932a-ac0d-439b-9200-2f36427876ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b85a4e09-bfc1-4b09-954e-1ad2f7d0e0b1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_398e932a-ac0d-439b-9200-2f36427876ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8c3597f2-41e3-4199-b8e9-93299a945a98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b85a4e09-bfc1-4b09-954e-1ad2f7d0e0b1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8c3597f2-41e3-4199-b8e9-93299a945a98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_953e7088-29cc-4210-a299-71c39184a71c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b85a4e09-bfc1-4b09-954e-1ad2f7d0e0b1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_953e7088-29cc-4210-a299-71c39184a71c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f0387599-0544-40a6-9feb-e54ef7668fb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_f58738e9-94d7-472e-bad0-a0cbccd79a69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f0387599-0544-40a6-9feb-e54ef7668fb6" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_f58738e9-94d7-472e-bad0-a0cbccd79a69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_bc1ea92c-b012-4a92-b0c7-346c7e508890" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f0387599-0544-40a6-9feb-e54ef7668fb6" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_bc1ea92c-b012-4a92-b0c7-346c7e508890" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_99778cb2-b3fd-4546-bce2-a84b34f828e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f0387599-0544-40a6-9feb-e54ef7668fb6" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_99778cb2-b3fd-4546-bce2-a84b34f828e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1785a77e-04af-4c81-a093-a4486310f429" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cea47327-7ad4-4903-bd2a-fccc67a8ca28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1785a77e-04af-4c81-a093-a4486310f429" xlink:to="loc_us-gaap_NetIncomeLoss_cea47327-7ad4-4903-bd2a-fccc67a8ca28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_591d99f3-67b0-49c9-a34f-77f23f705f64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1785a77e-04af-4c81-a093-a4486310f429" xlink:to="loc_us-gaap_ShareBasedCompensation_591d99f3-67b0-49c9-a34f-77f23f705f64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_7af25f4a-d11e-4872-a2e1-c0e3f1429616" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1785a77e-04af-4c81-a093-a4486310f429" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_7af25f4a-d11e-4872-a2e1-c0e3f1429616" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_7b78232e-7d59-49db-85ea-bfbbad67e8ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1785a77e-04af-4c81-a093-a4486310f429" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_7b78232e-7d59-49db-85ea-bfbbad67e8ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_48352d85-0eb5-4cd1-9c02-ef95f2505118" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1785a77e-04af-4c81-a093-a4486310f429" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_48352d85-0eb5-4cd1-9c02-ef95f2505118" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_36f640c1-5f13-4a6a-8fc6-a01008cbe105" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1785a77e-04af-4c81-a093-a4486310f429" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_36f640c1-5f13-4a6a-8fc6-a01008cbe105" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_b283de7d-2700-4e35-a979-a5435d530480" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1785a77e-04af-4c81-a093-a4486310f429" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_b283de7d-2700-4e35-a979-a5435d530480" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4e95279c-0741-41c4-9f84-5c174d7fb1b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1785a77e-04af-4c81-a093-a4486310f429" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4e95279c-0741-41c4-9f84-5c174d7fb1b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_cd534528-9eaa-456a-a6d7-6bcbb021049f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1785a77e-04af-4c81-a093-a4486310f429" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_cd534528-9eaa-456a-a6d7-6bcbb021049f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_c2eb813f-31a5-4427-b43e-c85a9b67ed74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1785a77e-04af-4c81-a093-a4486310f429" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_c2eb813f-31a5-4427-b43e-c85a9b67ed74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_5645606d-0491-49d4-8f4e-783bf3689b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1785a77e-04af-4c81-a093-a4486310f429" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_5645606d-0491-49d4-8f4e-783bf3689b2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_0b1ec243-8622-41ce-a8bf-8371a87abe98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1785a77e-04af-4c81-a093-a4486310f429" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_0b1ec243-8622-41ce-a8bf-8371a87abe98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DeferredRentPayments_ff6bc9fe-dc20-4704-8c66-e729b0482074" xlink:href="halo-20240331.xsd#halo_DeferredRentPayments"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1785a77e-04af-4c81-a093-a4486310f429" xlink:to="loc_halo_DeferredRentPayments_ff6bc9fe-dc20-4704-8c66-e729b0482074" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_329a7401-efde-4d9d-aef7-ed62193c4d34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_55d8f9db-a7fb-4819-8972-f273f0267f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_329a7401-efde-4d9d-aef7-ed62193c4d34" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_55d8f9db-a7fb-4819-8972-f273f0267f9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_98dc1180-e87e-4b58-9707-223172f6dec1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_329a7401-efde-4d9d-aef7-ed62193c4d34" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_98dc1180-e87e-4b58-9707-223172f6dec1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_464851af-f20f-42dc-950f-2feeff0c6160" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_329a7401-efde-4d9d-aef7-ed62193c4d34" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_464851af-f20f-42dc-950f-2feeff0c6160" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/FairValueMeasurementContractualMaturitiesofAvailableforsaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#FairValueMeasurementContractualMaturitiesofAvailableforsaleDebtSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/FairValueMeasurementContractualMaturitiesofAvailableforsaleDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_90295edc-b310-4b72-b768-a10b574f221b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d7dc26ca-30d9-47d4-a67a-ade0d7c3e015" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_90295edc-b310-4b72-b768-a10b574f221b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d7dc26ca-30d9-47d4-a67a-ade0d7c3e015" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_c2eca23c-2753-4b86-8393-bbc2c345b0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_90295edc-b310-4b72-b768-a10b574f221b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_c2eca23c-2753-4b86-8393-bbc2c345b0f8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_f292b4d0-da4e-41b0-be6b-db996f864687" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_98cc5b89-4241-4918-b985-beb1d3c7b6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_f292b4d0-da4e-41b0-be6b-db996f864687" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_98cc5b89-4241-4918-b985-beb1d3c7b6ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_6e73cfe3-355e-41d2-ab59-18fdcaeef564" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_f292b4d0-da4e-41b0-be6b-db996f864687" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_6e73cfe3-355e-41d2-ab59-18fdcaeef564" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_aadb4d58-9551-41fa-aa8b-07dad4d01fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_f292b4d0-da4e-41b0-be6b-db996f864687" xlink:to="loc_us-gaap_DerivativeAssets_aadb4d58-9551-41fa-aa8b-07dad4d01fe5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#CertainBalanceSheetItemsAccountsReceivablenetDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_halo_AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent_bb7583ef-b28a-4dc1-8dcc-803b0891364b" xlink:href="halo-20240331.xsd#halo_AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AccountsReceivableAndContractWithCustomerAssetBeforeAllowanceForCreditLossCurrent_bdfbfde1-a1ca-4fc1-8378-a4b72c8eb721" xlink:href="halo-20240331.xsd#halo_AccountsReceivableAndContractWithCustomerAssetBeforeAllowanceForCreditLossCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_halo_AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent_bb7583ef-b28a-4dc1-8dcc-803b0891364b" xlink:to="loc_halo_AccountsReceivableAndContractWithCustomerAssetBeforeAllowanceForCreditLossCurrent_bdfbfde1-a1ca-4fc1-8378-a4b72c8eb721" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AccountsReceivableAndContractWithCustomerAssetAllowanceForCreditLossCurrent_acd3e0a5-822e-406e-a93d-09df72dc0075" xlink:href="halo-20240331.xsd#halo_AccountsReceivableAndContractWithCustomerAssetAllowanceForCreditLossCurrent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_halo_AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent_bb7583ef-b28a-4dc1-8dcc-803b0891364b" xlink:to="loc_halo_AccountsReceivableAndContractWithCustomerAssetAllowanceForCreditLossCurrent_acd3e0a5-822e-406e-a93d-09df72dc0075" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AccountsReceivableAndContractWithCustomerAssetBeforeAllowanceForCreditLossCurrent_48dcadfb-e837-4e70-b2b0-43d9ff30c598" xlink:href="halo-20240331.xsd#halo_AccountsReceivableAndContractWithCustomerAssetBeforeAllowanceForCreditLossCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_ef1d8d0e-c7d9-4df8-9210-1b997645c9e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_halo_AccountsReceivableAndContractWithCustomerAssetBeforeAllowanceForCreditLossCurrent_48dcadfb-e837-4e70-b2b0-43d9ff30c598" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_ef1d8d0e-c7d9-4df8-9210-1b997645c9e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetGrossCurrent_faa0658e-8437-4950-99a3-b0f191e900f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetGrossCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_halo_AccountsReceivableAndContractWithCustomerAssetBeforeAllowanceForCreditLossCurrent_48dcadfb-e837-4e70-b2b0-43d9ff30c598" xlink:to="loc_us-gaap_ContractWithCustomerAssetGrossCurrent_faa0658e-8437-4950-99a3-b0f191e900f2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#CertainBalanceSheetItemsInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_d55dca8d-c8b7-4a05-9617-9a9119cfdca2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_0ef7eba4-02b5-4489-a38f-07ef40be0f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_d55dca8d-c8b7-4a05-9617-9a9119cfdca2" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_0ef7eba4-02b5-4489-a38f-07ef40be0f2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_fdf8b2ab-13d8-4eec-af56-34d347025932" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_d55dca8d-c8b7-4a05-9617-9a9119cfdca2" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_fdf8b2ab-13d8-4eec-af56-34d347025932" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_eeb54b2a-c963-4351-895e-79968376b232" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_d55dca8d-c8b7-4a05-9617-9a9119cfdca2" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_eeb54b2a-c963-4351-895e-79968376b232" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_6f8cba72-aab6-4f09-9257-d9a38a6d912b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_c906b19f-7e56-47e8-8d0e-82df29dc24cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_6f8cba72-aab6-4f09-9257-d9a38a6d912b" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_c906b19f-7e56-47e8-8d0e-82df29dc24cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e0c7876f-97af-4d8d-beae-bfdae8312ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_6f8cba72-aab6-4f09-9257-d9a38a6d912b" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e0c7876f-97af-4d8d-beae-bfdae8312ea2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails_1" xlink:type="simple" xlink:href="halo-20240331.xsd#CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails_1"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_dcb54894-7eeb-4e70-8a5c-ab41895507c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_2cbb2d75-c0e7-403f-a56a-191a2c35e0a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_dcb54894-7eeb-4e70-8a5c-ab41895507c2" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_2cbb2d75-c0e7-403f-a56a-191a2c35e0a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_ab9c4cd8-93cf-4dd0-b221-81919989e821" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_dcb54894-7eeb-4e70-8a5c-ab41895507c2" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_ab9c4cd8-93cf-4dd0-b221-81919989e821" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_ac85e726-c6c1-4ab8-8157-8a7ed3989be8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_dcb54894-7eeb-4e70-8a5c-ab41895507c2" xlink:to="loc_us-gaap_OtherAssets_ac85e726-c6c1-4ab8-8157-8a7ed3989be8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#CertainBalanceSheetItemsPropertyandEquipmentnetDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_261df721-cdc7-4dea-ac64-b4c7c5a4703e" xlink:href="halo-20240331.xsd#halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0a265d57-0e54-4215-8092-16afa2446584" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_261df721-cdc7-4dea-ac64-b4c7c5a4703e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0a265d57-0e54-4215-8092-16afa2446584" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1c9a387d-5409-4160-8b7c-2d13ebab4142" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_261df721-cdc7-4dea-ac64-b4c7c5a4703e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_1c9a387d-5409-4160-8b7c-2d13ebab4142" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1562b785-5066-4648-a170-09fb94d16be9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_bf554afc-33b4-4f72-8d05-e73852ef8293" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_1562b785-5066-4648-a170-09fb94d16be9" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_bf554afc-33b4-4f72-8d05-e73852ef8293" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1c48883e-e6b3-48de-a2d4-e626c1b8acfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_1562b785-5066-4648-a170-09fb94d16be9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1c48883e-e6b3-48de-a2d4-e626c1b8acfd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#CertainBalanceSheetItemsAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_060006f5-dfe1-4e41-89f9-6831d1f8a15d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_5cffcea6-ecc7-4e08-8960-5825769617da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_060006f5-dfe1-4e41-89f9-6831d1f8a15d" xlink:to="loc_us-gaap_TaxesPayableCurrent_5cffcea6-ecc7-4e08-8960-5825769617da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AccruedOutsourcedManufacturingExpenses_74b000f8-b292-4914-9f60-f6b6eeacab32" xlink:href="halo-20240331.xsd#halo_AccruedOutsourcedManufacturingExpenses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_060006f5-dfe1-4e41-89f9-6831d1f8a15d" xlink:to="loc_halo_AccruedOutsourcedManufacturingExpenses_74b000f8-b292-4914-9f60-f6b6eeacab32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f04e4e00-c763-4264-aa85-9620e5f98155" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_060006f5-dfe1-4e41-89f9-6831d1f8a15d" xlink:to="loc_us-gaap_OperatingLeaseLiability_f04e4e00-c763-4264-aa85-9620e5f98155" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiability_aa429a37-9519-4a71-8d43-da7d3f76840f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerRefundLiability"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_060006f5-dfe1-4e41-89f9-6831d1f8a15d" xlink:to="loc_us-gaap_ContractWithCustomerRefundLiability_aa429a37-9519-4a71-8d43-da7d3f76840f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_09aeb94a-8b20-4821-9160-58f81ca4fb1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_060006f5-dfe1-4e41-89f9-6831d1f8a15d" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_09aeb94a-8b20-4821-9160-58f81ca4fb1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_c76c0ba9-f03f-445a-91e3-dd306247fef2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_060006f5-dfe1-4e41-89f9-6831d1f8a15d" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_c76c0ba9-f03f-445a-91e3-dd306247fef2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails_1" xlink:type="simple" xlink:href="halo-20240331.xsd#CertainBalanceSheetItemsAccruedExpensesDetails_1"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_fc79d2e9-7928-4cd4-95cd-b5012b541571" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AccruedLiabilitiesNoncurrent_db6ba61c-bf95-4f6a-98ca-c9838c46e3a2" xlink:href="halo-20240331.xsd#halo_AccruedLiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_fc79d2e9-7928-4cd4-95cd-b5012b541571" xlink:to="loc_halo_AccruedLiabilitiesNoncurrent_db6ba61c-bf95-4f6a-98ca-c9838c46e3a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_9b07dcfe-9a7f-45f9-88b4-fcf5aa078087" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_fc79d2e9-7928-4cd4-95cd-b5012b541571" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_9b07dcfe-9a7f-45f9-88b4-fcf5aa078087" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#GoodwillandIntangibleAssetsIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d695190b-9e51-4cb4-97ee-96ea9d0b339d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_20668885-49d9-4ebf-9fae-d2e92b270111" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d695190b-9e51-4cb4-97ee-96ea9d0b339d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_20668885-49d9-4ebf-9fae-d2e92b270111" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_b7e5481c-2258-40ab-a9d5-2bf2c339f2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d695190b-9e51-4cb4-97ee-96ea9d0b339d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_b7e5481c-2258-40ab-a9d5-2bf2c339f2a9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#GoodwillandIntangibleAssetsFutureAmortizationDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5a236bdb-7d0b-4a7e-95f8-be9d843ce36f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_7f572c47-74ff-491d-8636-a61a5faff1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5a236bdb-7d0b-4a7e-95f8-be9d843ce36f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_7f572c47-74ff-491d-8636-a61a5faff1b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_e54a2abc-f5c5-4675-bfb4-ad94a994a903" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5a236bdb-7d0b-4a7e-95f8-be9d843ce36f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_e54a2abc-f5c5-4675-bfb4-ad94a994a903" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_5c45fed4-df7e-4bf0-9e6f-84698fb7fe9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5a236bdb-7d0b-4a7e-95f8-be9d843ce36f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_5c45fed4-df7e-4bf0-9e6f-84698fb7fe9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_0233e518-dc24-4fd0-bab4-d95cb9059ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5a236bdb-7d0b-4a7e-95f8-be9d843ce36f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_0233e518-dc24-4fd0-bab4-d95cb9059ea8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_116ba264-9516-447d-9a32-4dcbd681d7c8" xlink:href="halo-20240331.xsd#halo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5a236bdb-7d0b-4a7e-95f8-be9d843ce36f" xlink:to="loc_halo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_116ba264-9516-447d-9a32-4dcbd681d7c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_23777b0f-5d10-4a35-9644-6b9f4452cf54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5a236bdb-7d0b-4a7e-95f8-be9d843ce36f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_23777b0f-5d10-4a35-9644-6b9f4452cf54" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#LongTermDebtNetCarryingAmountofConvertibleNotesDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_2352acfa-6fac-4928-bb0e-0fb8e5e692dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_74bb65a2-b48e-4aa5-998a-5b622bbd8e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_2352acfa-6fac-4928-bb0e-0fb8e5e692dd" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_74bb65a2-b48e-4aa5-998a-5b622bbd8e5d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/EarningspershareComputationDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#EarningspershareComputationDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/EarningspershareComputationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e407a4a1-60b7-4f35-952d-a289a33693e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8fee6d60-28f1-441a-8398-c0f01b93f984" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e407a4a1-60b7-4f35-952d-a289a33693e1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8fee6d60-28f1-441a-8398-c0f01b93f984" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_bcb6e66b-98cb-4df6-812f-73501a831748" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e407a4a1-60b7-4f35-952d-a289a33693e1" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_bcb6e66b-98cb-4df6-812f-73501a831748" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>halo-20240331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:17e6b7b2-f6c0-4a96-9180-046700296928,g:1765a142-e24e-49b0-883b-7a52af9d0516-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="simple" xlink:href="halo-20240331.xsd#CondensedConsolidatedStatementsofIncomeUnaudited"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b08ae9b3-0715-4c0e-8dc6-8c1d30356998" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5f71299c-13f0-498c-9555-e66d549a8366" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_b08ae9b3-0715-4c0e-8dc6-8c1d30356998" xlink:to="loc_us-gaap_StatementTable_5f71299c-13f0-498c-9555-e66d549a8366" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_609353ac-0d62-4584-9e9f-eeda87b91baf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_5f71299c-13f0-498c-9555-e66d549a8366" xlink:to="loc_srt_ProductOrServiceAxis_609353ac-0d62-4584-9e9f-eeda87b91baf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_609353ac-0d62-4584-9e9f-eeda87b91baf_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_609353ac-0d62-4584-9e9f-eeda87b91baf" xlink:to="loc_srt_ProductsAndServicesDomain_609353ac-0d62-4584-9e9f-eeda87b91baf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_00481f19-1654-4f20-b69f-f908ffa38d10" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_609353ac-0d62-4584-9e9f-eeda87b91baf" xlink:to="loc_srt_ProductsAndServicesDomain_00481f19-1654-4f20-b69f-f908ffa38d10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_d5cf6dde-dcc5-45a5-aa41-b6400de292a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_00481f19-1654-4f20-b69f-f908ffa38d10" xlink:to="loc_us-gaap_RoyaltyMember_d5cf6dde-dcc5-45a5-aa41-b6400de292a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_d54c0369-fe47-44fe-80c1-650485de0144" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_00481f19-1654-4f20-b69f-f908ffa38d10" xlink:to="loc_us-gaap_ProductMember_d54c0369-fe47-44fe-80c1-650485de0144" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_CollaborativeAgreementsMember_fdf0e258-112d-419f-8208-559c058c4f4d" xlink:href="halo-20240331.xsd#halo_CollaborativeAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_00481f19-1654-4f20-b69f-f908ffa38d10" xlink:to="loc_halo_CollaborativeAgreementsMember_fdf0e258-112d-419f-8208-559c058c4f4d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_cad2960f-e8a6-4038-af2d-e73e9068f56f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b08ae9b3-0715-4c0e-8dc6-8c1d30356998" xlink:to="loc_us-gaap_RevenuesAbstract_cad2960f-e8a6-4038-af2d-e73e9068f56f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e2e8b421-2038-4912-8186-9c87a33f9507" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_cad2960f-e8a6-4038-af2d-e73e9068f56f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e2e8b421-2038-4912-8186-9c87a33f9507" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_10e1e87f-a46e-4fed-874a-fba87d4953e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b08ae9b3-0715-4c0e-8dc6-8c1d30356998" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_10e1e87f-a46e-4fed-874a-fba87d4953e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_72749ba5-e9e6-4687-8743-92e2644af072" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_10e1e87f-a46e-4fed-874a-fba87d4953e7" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_72749ba5-e9e6-4687-8743-92e2644af072" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_187597a4-c0e9-4045-bc6d-6becdef697e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_10e1e87f-a46e-4fed-874a-fba87d4953e7" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_187597a4-c0e9-4045-bc6d-6becdef697e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_2eccb5d6-c3af-45a7-b4e1-62563fc015c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_10e1e87f-a46e-4fed-874a-fba87d4953e7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_2eccb5d6-c3af-45a7-b4e1-62563fc015c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a4b7e0dc-bcda-444d-a319-cf2c18a18bd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_10e1e87f-a46e-4fed-874a-fba87d4953e7" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a4b7e0dc-bcda-444d-a319-cf2c18a18bd6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_0551a726-31d6-41e3-948b-c434df3e6e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_10e1e87f-a46e-4fed-874a-fba87d4953e7" xlink:to="loc_us-gaap_CostsAndExpenses_0551a726-31d6-41e3-948b-c434df3e6e3c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_40b2d3de-d6bd-4125-b67f-3fd1d656682d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b08ae9b3-0715-4c0e-8dc6-8c1d30356998" xlink:to="loc_us-gaap_OperatingIncomeLoss_40b2d3de-d6bd-4125-b67f-3fd1d656682d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_36dfbe06-61cb-415a-8cb3-e7ffdc2f906e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b08ae9b3-0715-4c0e-8dc6-8c1d30356998" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_36dfbe06-61cb-415a-8cb3-e7ffdc2f906e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_4b6d7e1c-e9f7-4fc0-8a1b-c0f620607614" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_36dfbe06-61cb-415a-8cb3-e7ffdc2f906e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_4b6d7e1c-e9f7-4fc0-8a1b-c0f620607614" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_947c866f-d622-42f5-9a81-17d515af934c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_36dfbe06-61cb-415a-8cb3-e7ffdc2f906e" xlink:to="loc_us-gaap_InterestExpense_947c866f-d622-42f5-9a81-17d515af934c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0c1be247-260f-4e59-8ed5-85f93e82b016" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b08ae9b3-0715-4c0e-8dc6-8c1d30356998" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0c1be247-260f-4e59-8ed5-85f93e82b016" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_be3a5464-50c2-4a6f-aa26-e4d2c3bdcf87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b08ae9b3-0715-4c0e-8dc6-8c1d30356998" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_be3a5464-50c2-4a6f-aa26-e4d2c3bdcf87" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_558e16a9-9717-474d-9459-5c947559f6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b08ae9b3-0715-4c0e-8dc6-8c1d30356998" xlink:to="loc_us-gaap_NetIncomeLoss_558e16a9-9717-474d-9459-5c947559f6ec" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c306ac00-39c6-4326-a98c-44a3378ff557" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b08ae9b3-0715-4c0e-8dc6-8c1d30356998" xlink:to="loc_us-gaap_EarningsPerShareAbstract_c306ac00-39c6-4326-a98c-44a3378ff557" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_a6773906-86ed-4316-aac7-18ac064368fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c306ac00-39c6-4326-a98c-44a3378ff557" xlink:to="loc_us-gaap_EarningsPerShareBasic_a6773906-86ed-4316-aac7-18ac064368fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_c76d9238-589d-459b-bf68-70054642f1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c306ac00-39c6-4326-a98c-44a3378ff557" xlink:to="loc_us-gaap_EarningsPerShareDiluted_c76d9238-589d-459b-bf68-70054642f1b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_265bb600-113f-4a5f-91a1-9d1cfe627425" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b08ae9b3-0715-4c0e-8dc6-8c1d30356998" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_265bb600-113f-4a5f-91a1-9d1cfe627425" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ade74e9e-0202-4eb7-abb0-bb074b046350" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_265bb600-113f-4a5f-91a1-9d1cfe627425" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ade74e9e-0202-4eb7-abb0-bb074b046350" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bb3dae29-a5c6-4f77-b963-dd70a7378d46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_265bb600-113f-4a5f-91a1-9d1cfe627425" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bb3dae29-a5c6-4f77-b963-dd70a7378d46" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" xlink:type="simple" xlink:href="halo-20240331.xsd#CondensedConsolidatedStatementsofStockholdersEquityUnaudited"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b3bf8bae-6077-4e45-8002-ad478693ef93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2fa8c63d-e915-4843-98af-5ec01e55dd4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_b3bf8bae-6077-4e45-8002-ad478693ef93" xlink:to="loc_us-gaap_StatementTable_2fa8c63d-e915-4843-98af-5ec01e55dd4a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ec188b13-71d6-4ebe-ba96-f3810f984f20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2fa8c63d-e915-4843-98af-5ec01e55dd4a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ec188b13-71d6-4ebe-ba96-f3810f984f20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ec188b13-71d6-4ebe-ba96-f3810f984f20_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ec188b13-71d6-4ebe-ba96-f3810f984f20" xlink:to="loc_us-gaap_EquityComponentDomain_ec188b13-71d6-4ebe-ba96-f3810f984f20_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_944f9113-4963-4bc8-913f-fb0024821397" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ec188b13-71d6-4ebe-ba96-f3810f984f20" xlink:to="loc_us-gaap_EquityComponentDomain_944f9113-4963-4bc8-913f-fb0024821397" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_692fde6f-0fd2-47ad-9bec-253d4d050d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_944f9113-4963-4bc8-913f-fb0024821397" xlink:to="loc_us-gaap_CommonStockMember_692fde6f-0fd2-47ad-9bec-253d4d050d1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_c10536b6-49a6-4f89-8222-7f8dc57e930a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_944f9113-4963-4bc8-913f-fb0024821397" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_c10536b6-49a6-4f89-8222-7f8dc57e930a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_450cd986-4af6-467e-abba-d91e012d5ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_944f9113-4963-4bc8-913f-fb0024821397" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_450cd986-4af6-467e-abba-d91e012d5ca6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_a3f742db-c013-43d6-b25c-93b8043fd80e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_944f9113-4963-4bc8-913f-fb0024821397" xlink:to="loc_us-gaap_RetainedEarningsMember_a3f742db-c013-43d6-b25c-93b8043fd80e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2efc2c4b-0f11-47b2-8f9d-c12586479250" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b3bf8bae-6077-4e45-8002-ad478693ef93" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2efc2c4b-0f11-47b2-8f9d-c12586479250" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_20760742-6f78-4f63-b98a-4d02460703ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2efc2c4b-0f11-47b2-8f9d-c12586479250" xlink:to="loc_us-gaap_SharesOutstanding_20760742-6f78-4f63-b98a-4d02460703ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_45bf261b-56f7-481a-9551-5d569bd1211b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2efc2c4b-0f11-47b2-8f9d-c12586479250" xlink:to="loc_us-gaap_StockholdersEquity_45bf261b-56f7-481a-9551-5d569bd1211b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_cd998c59-e93f-49fc-bd56-4022f29f3b0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2efc2c4b-0f11-47b2-8f9d-c12586479250" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_cd998c59-e93f-49fc-bd56-4022f29f3b0e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0909d592-e990-4ea9-92a4-54832004996a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2efc2c4b-0f11-47b2-8f9d-c12586479250" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0909d592-e990-4ea9-92a4-54832004996a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_efcb581a-d471-430e-ab3b-80c579437d75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2efc2c4b-0f11-47b2-8f9d-c12586479250" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_efcb581a-d471-430e-ab3b-80c579437d75" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6f6f5cad-ad5b-4b0f-81a7-91b0ffcd6246" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2efc2c4b-0f11-47b2-8f9d-c12586479250" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6f6f5cad-ad5b-4b0f-81a7-91b0ffcd6246" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_e556ab3d-e636-4637-84ef-69129a125c10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2efc2c4b-0f11-47b2-8f9d-c12586479250" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_e556ab3d-e636-4637-84ef-69129a125c10" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_09d9a018-fe96-45f6-9589-eb14bcbd64d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2efc2c4b-0f11-47b2-8f9d-c12586479250" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_09d9a018-fe96-45f6-9589-eb14bcbd64d4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_fd13c0a1-e656-4a96-9873-63ed9e08ed80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2efc2c4b-0f11-47b2-8f9d-c12586479250" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_fd13c0a1-e656-4a96-9873-63ed9e08ed80" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_91620269-39e1-48b8-8597-ba60d4bb0169" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2efc2c4b-0f11-47b2-8f9d-c12586479250" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_91620269-39e1-48b8-8597-ba60d4bb0169" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_685550be-e1fe-4fe9-83f3-35d92daa73d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2efc2c4b-0f11-47b2-8f9d-c12586479250" xlink:to="loc_us-gaap_NetIncomeLoss_685550be-e1fe-4fe9-83f3-35d92daa73d6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_76a24e51-1af3-41df-b2a5-07bd61433448" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_42c5e498-3a01-41e9-9e7f-53732b666792" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/OrganizationandBusinessDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#OrganizationandBusinessDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/OrganizationandBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9d498a6-b13f-4b1e-96a0-c5ac39a40c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9e1f248d-d8a6-4c2d-82a8-bb0923c29acc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9d498a6-b13f-4b1e-96a0-c5ac39a40c6b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9e1f248d-d8a6-4c2d-82a8-bb0923c29acc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_74e2e288-7093-4274-a1c2-154a70d10e9c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9e1f248d-d8a6-4c2d-82a8-bb0923c29acc" xlink:to="loc_srt_CounterpartyNameAxis_74e2e288-7093-4274-a1c2-154a70d10e9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_74e2e288-7093-4274-a1c2-154a70d10e9c_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_74e2e288-7093-4274-a1c2-154a70d10e9c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_74e2e288-7093-4274-a1c2-154a70d10e9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_58098f10-5c67-43a7-aca5-68a4e2e000c9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_74e2e288-7093-4274-a1c2-154a70d10e9c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_58098f10-5c67-43a7-aca5-68a4e2e000c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_TakedaMember_b586679c-2861-4d58-99d6-cda264c314eb" xlink:href="halo-20240331.xsd#halo_TakedaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_58098f10-5c67-43a7-aca5-68a4e2e000c9" xlink:to="loc_halo_TakedaMember_b586679c-2861-4d58-99d6-cda264c314eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_JanssenMember_77c40d70-2cf7-4c24-ab3d-746c94e4e70c" xlink:href="halo-20240331.xsd#halo_JanssenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_58098f10-5c67-43a7-aca5-68a4e2e000c9" xlink:to="loc_halo_JanssenMember_77c40d70-2cf7-4c24-ab3d-746c94e4e70c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ArgenxMember_ba08fc39-4693-43b9-b46a-a1bf1469ec43" xlink:href="halo-20240331.xsd#halo_ArgenxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_58098f10-5c67-43a7-aca5-68a4e2e000c9" xlink:to="loc_halo_ArgenxMember_ba08fc39-4693-43b9-b46a-a1bf1469ec43" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RocheMember_a007a761-55cf-48b4-9b56-59e1d8b1eea5" xlink:href="halo-20240331.xsd#halo_RocheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_58098f10-5c67-43a7-aca5-68a4e2e000c9" xlink:to="loc_halo_RocheMember_a007a761-55cf-48b4-9b56-59e1d8b1eea5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RoyaltiesReceivedNumberOfProductsSold_3a628a9e-cb20-4294-aa7d-2ab1419b870e" xlink:href="halo-20240331.xsd#halo_RoyaltiesReceivedNumberOfProductsSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9d498a6-b13f-4b1e-96a0-c5ac39a40c6b" xlink:to="loc_halo_RoyaltiesReceivedNumberOfProductsSold_3a628a9e-cb20-4294-aa7d-2ab1419b870e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#SummaryofSignificantAccountingPoliciesLeasesDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_61b6f2e7-f7ee-43fc-8e3a-8fc248e9ec41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_11bdf2bb-f644-47ce-ab9b-5c7bd4b5cb85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_61b6f2e7-f7ee-43fc-8e3a-8fc248e9ec41" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_11bdf2bb-f644-47ce-ab9b-5c7bd4b5cb85" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_63ad638a-d8f2-42c7-a874-31efa54edd6d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_11bdf2bb-f644-47ce-ab9b-5c7bd4b5cb85" xlink:to="loc_srt_RangeAxis_63ad638a-d8f2-42c7-a874-31efa54edd6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_63ad638a-d8f2-42c7-a874-31efa54edd6d_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_63ad638a-d8f2-42c7-a874-31efa54edd6d" xlink:to="loc_srt_RangeMember_63ad638a-d8f2-42c7-a874-31efa54edd6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_509a0953-054c-428f-a303-dc492040d70e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_63ad638a-d8f2-42c7-a874-31efa54edd6d" xlink:to="loc_srt_RangeMember_509a0953-054c-428f-a303-dc492040d70e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_64a621d2-5219-4c64-8699-4b760c7c4f00" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_509a0953-054c-428f-a303-dc492040d70e" xlink:to="loc_srt_MinimumMember_64a621d2-5219-4c64-8699-4b760c7c4f00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_326d6b3e-2713-447c-9cff-c945bc5d7b8b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_509a0953-054c-428f-a303-dc492040d70e" xlink:to="loc_srt_MaximumMember_326d6b3e-2713-447c-9cff-c945bc5d7b8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_2e9198c0-ff72-4044-b66b-864ce09ace9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_61b6f2e7-f7ee-43fc-8e3a-8fc248e9ec41" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_2e9198c0-ff72-4044-b66b-864ce09ace9c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentnetDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#SummaryofSignificantAccountingPoliciesPropertyandEquipmentnetDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentnetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_29e82a51-d84a-44c7-af88-b488187ec056" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8951f826-37c9-40c7-9ed2-c929a0894596" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_29e82a51-d84a-44c7-af88-b488187ec056" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8951f826-37c9-40c7-9ed2-c929a0894596" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_efb4e5b6-c0b2-4a25-b74b-1b0ddfc1b870" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8951f826-37c9-40c7-9ed2-c929a0894596" xlink:to="loc_srt_RangeAxis_efb4e5b6-c0b2-4a25-b74b-1b0ddfc1b870" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_efb4e5b6-c0b2-4a25-b74b-1b0ddfc1b870_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_efb4e5b6-c0b2-4a25-b74b-1b0ddfc1b870" xlink:to="loc_srt_RangeMember_efb4e5b6-c0b2-4a25-b74b-1b0ddfc1b870_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_849c4802-a107-4868-84a4-4473f1c8b8a1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_efb4e5b6-c0b2-4a25-b74b-1b0ddfc1b870" xlink:to="loc_srt_RangeMember_849c4802-a107-4868-84a4-4473f1c8b8a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_de9e92ef-b88e-4d27-931c-456b010f769d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_849c4802-a107-4868-84a4-4473f1c8b8a1" xlink:to="loc_srt_MinimumMember_de9e92ef-b88e-4d27-931c-456b010f769d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_236d43b9-82d9-4ded-bb4d-b1de08591c85" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_849c4802-a107-4868-84a4-4473f1c8b8a1" xlink:to="loc_srt_MaximumMember_236d43b9-82d9-4ded-bb4d-b1de08591c85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_9d648be8-a9e9-484a-afe7-5cce03160fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_29e82a51-d84a-44c7-af88-b488187ec056" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_9d648be8-a9e9-484a-afe7-5cce03160fc2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesCashFlowHedgesCurrencyRisksDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#SummaryofSignificantAccountingPoliciesCashFlowHedgesCurrencyRisksDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesCashFlowHedgesCurrencyRisksDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_c38682c8-a432-435c-a07c-ed6ce13844aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_95ad931d-99a1-4fb2-9f85-bdeeef80cc6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_c38682c8-a432-435c-a07c-ed6ce13844aa" xlink:to="loc_us-gaap_DerivativeTable_95ad931d-99a1-4fb2-9f85-bdeeef80cc6e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7d048014-3564-4de5-87b5-4ce9d9a7371e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_95ad931d-99a1-4fb2-9f85-bdeeef80cc6e" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7d048014-3564-4de5-87b5-4ce9d9a7371e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_7d048014-3564-4de5-87b5-4ce9d9a7371e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7d048014-3564-4de5-87b5-4ce9d9a7371e" xlink:to="loc_us-gaap_HedgingRelationshipDomain_7d048014-3564-4de5-87b5-4ce9d9a7371e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_25cd261a-7cc0-44c7-8d3e-015be069ea89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7d048014-3564-4de5-87b5-4ce9d9a7371e" xlink:to="loc_us-gaap_HedgingRelationshipDomain_25cd261a-7cc0-44c7-8d3e-015be069ea89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_da65852f-871b-4930-8aa4-2a80dce0c17a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_25cd261a-7cc0-44c7-8d3e-015be069ea89" xlink:to="loc_us-gaap_CashFlowHedgingMember_da65852f-871b-4930-8aa4-2a80dce0c17a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_529ba929-28ee-48c0-8fc0-f477a523c44e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_95ad931d-99a1-4fb2-9f85-bdeeef80cc6e" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_529ba929-28ee-48c0-8fc0-f477a523c44e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_529ba929-28ee-48c0-8fc0-f477a523c44e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_529ba929-28ee-48c0-8fc0-f477a523c44e" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_529ba929-28ee-48c0-8fc0-f477a523c44e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_ef6bb067-8e50-4cd5-a6f4-831abf352881" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_529ba929-28ee-48c0-8fc0-f477a523c44e" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_ef6bb067-8e50-4cd5-a6f4-831abf352881" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_293fe1bc-ff7b-41c9-a771-0a9b2fdab0cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_ef6bb067-8e50-4cd5-a6f4-831abf352881" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_293fe1bc-ff7b-41c9-a771-0a9b2fdab0cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_3f0cd66a-1286-4409-99c3-b715aa334293" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_c38682c8-a432-435c-a07c-ed6ce13844aa" xlink:to="loc_us-gaap_DerivativeTermOfContract_3f0cd66a-1286-4409-99c3-b715aa334293" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f3848996-d383-4e8f-8527-7b155913afe2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_012c148b-854e-4647-a5dd-f9fd61ce664e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f3848996-d383-4e8f-8527-7b155913afe2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_012c148b-854e-4647-a5dd-f9fd61ce664e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_50c2fb3b-e9dc-45ab-b780-fe3e0c29c03c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_012c148b-854e-4647-a5dd-f9fd61ce664e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_50c2fb3b-e9dc-45ab-b780-fe3e0c29c03c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_50c2fb3b-e9dc-45ab-b780-fe3e0c29c03c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_50c2fb3b-e9dc-45ab-b780-fe3e0c29c03c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_50c2fb3b-e9dc-45ab-b780-fe3e0c29c03c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7fe8d086-9749-4d15-a3b4-bd568830b91a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_50c2fb3b-e9dc-45ab-b780-fe3e0c29c03c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7fe8d086-9749-4d15-a3b4-bd568830b91a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_b83a6029-bf67-4ac9-89be-204f82287088" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7fe8d086-9749-4d15-a3b4-bd568830b91a" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_b83a6029-bf67-4ac9-89be-204f82287088" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_ae46744e-8a3f-446c-97e7-fa94627eede3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7fe8d086-9749-4d15-a3b4-bd568830b91a" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_ae46744e-8a3f-446c-97e7-fa94627eede3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_fda96b75-193d-4235-93bf-1cb94579f5f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7fe8d086-9749-4d15-a3b4-bd568830b91a" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_fda96b75-193d-4235-93bf-1cb94579f5f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember_6f67b146-3362-4493-b933-6e48d9a8eb00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7fe8d086-9749-4d15-a3b4-bd568830b91a" xlink:to="loc_us-gaap_AgencySecuritiesMember_6f67b146-3362-4493-b933-6e48d9a8eb00" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_ba217f25-ce26-4d20-8081-7835444c3af5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7fe8d086-9749-4d15-a3b4-bd568830b91a" xlink:to="loc_us-gaap_CommercialPaperMember_ba217f25-ce26-4d20-8081-7835444c3af5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_a823979d-f63e-4e10-9d89-5091fd2ded13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f3848996-d383-4e8f-8527-7b155913afe2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_a823979d-f63e-4e10-9d89-5091fd2ded13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8db02277-92f1-4391-8d48-75ebb348c32a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f3848996-d383-4e8f-8527-7b155913afe2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8db02277-92f1-4391-8d48-75ebb348c32a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9c7a8c2a-706e-4c08-b175-bb62427347f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f3848996-d383-4e8f-8527-7b155913afe2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9c7a8c2a-706e-4c08-b175-bb62427347f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_584ac3f6-4757-4167-b195-66886b4e88cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f3848996-d383-4e8f-8527-7b155913afe2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_584ac3f6-4757-4167-b195-66886b4e88cc" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#FairValueMeasurementNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3844fa68-cd75-47a2-ab42-21ce3f511b10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6ab3ad5d-77b0-40fc-b8e5-05ca5940f981" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3844fa68-cd75-47a2-ab42-21ce3f511b10" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6ab3ad5d-77b0-40fc-b8e5-05ca5940f981" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_285ae8f9-f3e3-4c84-9391-2c8ec23028f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6ab3ad5d-77b0-40fc-b8e5-05ca5940f981" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_285ae8f9-f3e3-4c84-9391-2c8ec23028f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_285ae8f9-f3e3-4c84-9391-2c8ec23028f4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_285ae8f9-f3e3-4c84-9391-2c8ec23028f4" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_285ae8f9-f3e3-4c84-9391-2c8ec23028f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_749264fe-750c-4972-92f9-a13ed70a3ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_285ae8f9-f3e3-4c84-9391-2c8ec23028f4" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_749264fe-750c-4972-92f9-a13ed70a3ca4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_4c65d4a0-ed0b-4bb7-801a-172ad1b1a917" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_749264fe-750c-4972-92f9-a13ed70a3ca4" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_4c65d4a0-ed0b-4bb7-801a-172ad1b1a917" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_f537950d-54a0-452d-8b29-7b9b1c80603e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3844fa68-cd75-47a2-ab42-21ce3f511b10" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_f537950d-54a0-452d-8b29-7b9b1c80603e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_6b408b58-911d-417a-9c8f-b64831dc0fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3844fa68-cd75-47a2-ab42-21ce3f511b10" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_6b408b58-911d-417a-9c8f-b64831dc0fd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7ee70a2f-836d-4cd9-8ce1-8783244538b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3844fa68-cd75-47a2-ab42-21ce3f511b10" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7ee70a2f-836d-4cd9-8ce1-8783244538b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_a554251a-21a2-4981-9b8e-00d476c97f67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3844fa68-cd75-47a2-ab42-21ce3f511b10" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_a554251a-21a2-4981-9b8e-00d476c97f67" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_5ebe47b9-1ce8-4d13-944a-9672ad86f6ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3844fa68-cd75-47a2-ab42-21ce3f511b10" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_5ebe47b9-1ce8-4d13-944a-9672ad86f6ba" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_802198c4-c783-4672-be76-a3771454a504" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a5dce32f-0043-4bb2-b7ee-525e8144c593" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_802198c4-c783-4672-be76-a3771454a504" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a5dce32f-0043-4bb2-b7ee-525e8144c593" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1dba06c8-70da-4c07-9ae4-66cb40fc7f70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a5dce32f-0043-4bb2-b7ee-525e8144c593" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1dba06c8-70da-4c07-9ae4-66cb40fc7f70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1dba06c8-70da-4c07-9ae4-66cb40fc7f70_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1dba06c8-70da-4c07-9ae4-66cb40fc7f70" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1dba06c8-70da-4c07-9ae4-66cb40fc7f70_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0758a658-5609-40f5-9bcd-6e55e6db10cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1dba06c8-70da-4c07-9ae4-66cb40fc7f70" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0758a658-5609-40f5-9bcd-6e55e6db10cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_a699431c-b40b-4d7a-9674-82123e43b35c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0758a658-5609-40f5-9bcd-6e55e6db10cb" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_a699431c-b40b-4d7a-9674-82123e43b35c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9cbd0ea2-a60e-4f7d-b534-3fa2c818868a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0758a658-5609-40f5-9bcd-6e55e6db10cb" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_9cbd0ea2-a60e-4f7d-b534-3fa2c818868a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_724ad22a-80cd-475c-9cd4-f5f7acd60a57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a5dce32f-0043-4bb2-b7ee-525e8144c593" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_724ad22a-80cd-475c-9cd4-f5f7acd60a57" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_724ad22a-80cd-475c-9cd4-f5f7acd60a57_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_724ad22a-80cd-475c-9cd4-f5f7acd60a57" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_724ad22a-80cd-475c-9cd4-f5f7acd60a57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_06a7ccc9-9882-41ef-a246-ff0b052619fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_724ad22a-80cd-475c-9cd4-f5f7acd60a57" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_06a7ccc9-9882-41ef-a246-ff0b052619fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2f0c31d2-0610-4fa9-9e91-abea89f81d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_06a7ccc9-9882-41ef-a246-ff0b052619fc" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2f0c31d2-0610-4fa9-9e91-abea89f81d7a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_cad0e92f-4b82-44f7-b834-d2ed6f2d8bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_06a7ccc9-9882-41ef-a246-ff0b052619fc" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_cad0e92f-4b82-44f7-b834-d2ed6f2d8bb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_9db2d5f0-ae42-45a1-bca8-d666c0696769" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a5dce32f-0043-4bb2-b7ee-525e8144c593" xlink:to="loc_us-gaap_FinancialInstrumentAxis_9db2d5f0-ae42-45a1-bca8-d666c0696769" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9db2d5f0-ae42-45a1-bca8-d666c0696769_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9db2d5f0-ae42-45a1-bca8-d666c0696769" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9db2d5f0-ae42-45a1-bca8-d666c0696769_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7bba414b-89f6-4e45-813e-c884170799a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9db2d5f0-ae42-45a1-bca8-d666c0696769" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7bba414b-89f6-4e45-813e-c884170799a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_fd1c4747-12dc-4a6e-9916-bd482cb8c70f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7bba414b-89f6-4e45-813e-c884170799a9" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_fd1c4747-12dc-4a6e-9916-bd482cb8c70f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_19977649-7131-4cd5-b92c-4f887907dc79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7bba414b-89f6-4e45-813e-c884170799a9" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_19977649-7131-4cd5-b92c-4f887907dc79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_bdfdbff2-6402-42af-9c72-e1ab232603cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7bba414b-89f6-4e45-813e-c884170799a9" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_bdfdbff2-6402-42af-9c72-e1ab232603cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember_30adecf5-934d-471a-8dd1-e32dd190120a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7bba414b-89f6-4e45-813e-c884170799a9" xlink:to="loc_us-gaap_AgencySecuritiesMember_30adecf5-934d-471a-8dd1-e32dd190120a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_8fc971fe-49fd-4182-9f09-24d2163173cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7bba414b-89f6-4e45-813e-c884170799a9" xlink:to="loc_us-gaap_CommercialPaperMember_8fc971fe-49fd-4182-9f09-24d2163173cb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_73f79759-d0eb-4590-8052-08e4ff4e6dba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a5dce32f-0043-4bb2-b7ee-525e8144c593" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_73f79759-d0eb-4590-8052-08e4ff4e6dba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_73f79759-d0eb-4590-8052-08e4ff4e6dba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_73f79759-d0eb-4590-8052-08e4ff4e6dba" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_73f79759-d0eb-4590-8052-08e4ff4e6dba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_f4083177-db2f-4ce0-bbd1-3fbcb8c63fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_73f79759-d0eb-4590-8052-08e4ff4e6dba" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_f4083177-db2f-4ce0-bbd1-3fbcb8c63fe3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_f6e30ca6-539b-4e61-916b-b39d8fc09158" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_f4083177-db2f-4ce0-bbd1-3fbcb8c63fe3" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_f6e30ca6-539b-4e61-916b-b39d8fc09158" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_1a85e6d8-0af9-4bbb-86de-0246c4179af3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_802198c4-c783-4672-be76-a3771454a504" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_1a85e6d8-0af9-4bbb-86de-0246c4179af3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d3fd0ad5-7e71-45fd-bb0e-15cffc4be7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_1a85e6d8-0af9-4bbb-86de-0246c4179af3" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d3fd0ad5-7e71-45fd-bb0e-15cffc4be7c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_5d5c2eba-2ec4-41a6-9557-1205be4da718" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_1a85e6d8-0af9-4bbb-86de-0246c4179af3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_5d5c2eba-2ec4-41a6-9557-1205be4da718" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_3e1eeecf-a624-4dbd-9739-6bb5a61f3892" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_1a85e6d8-0af9-4bbb-86de-0246c4179af3" xlink:to="loc_us-gaap_DerivativeAssets_3e1eeecf-a624-4dbd-9739-6bb5a61f3892" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_9461bf00-344f-4fde-a143-8aab0ae26af3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_1a85e6d8-0af9-4bbb-86de-0246c4179af3" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_9461bf00-344f-4fde-a143-8aab0ae26af3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_b8a08fba-15b3-4412-9b11-53c1bbe9d553" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_802198c4-c783-4672-be76-a3771454a504" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_b8a08fba-15b3-4412-9b11-53c1bbe9d553" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_7984e2d2-66d7-4e4f-ad2f-14fa9798874c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_b8a08fba-15b3-4412-9b11-53c1bbe9d553" xlink:to="loc_us-gaap_DerivativeLiabilities_7984e2d2-66d7-4e4f-ad2f-14fa9798874c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_223d91d8-c1f8-4ebd-82c5-73ff2a0fac50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_802198c4-c783-4672-be76-a3771454a504" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_223d91d8-c1f8-4ebd-82c5-73ff2a0fac50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_7480f5c0-731f-4789-b33e-7baaf19cf560" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_802198c4-c783-4672-be76-a3771454a504" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_7480f5c0-731f-4789-b33e-7baaf19cf560" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_b6656b0d-cf6b-4f28-95bc-bcc417cad519" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_802198c4-c783-4672-be76-a3771454a504" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_b6656b0d-cf6b-4f28-95bc-bcc417cad519" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_51b704ac-3d0d-4f14-a8f3-81aa3e3b3a48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_802198c4-c783-4672-be76-a3771454a504" xlink:to="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_51b704ac-3d0d-4f14-a8f3-81aa3e3b3a48" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration_50acceb6-3e8d-46e4-b4f1-703367036858" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_802198c4-c783-4672-be76-a3771454a504" xlink:to="loc_us-gaap_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration_50acceb6-3e8d-46e4-b4f1-703367036858" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration_0d0f1f54-c64d-48b2-96dd-8747bb0b2d86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_802198c4-c783-4672-be76-a3771454a504" xlink:to="loc_us-gaap_DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration_0d0f1f54-c64d-48b2-96dd-8747bb0b2d86" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#RevenueDisaggregatedRevenuesDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_8a7e5b94-6064-49d1-89b6-daa18fba2c38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_537efb5f-25f3-450b-b09a-5837e6240701" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8a7e5b94-6064-49d1-89b6-daa18fba2c38" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_537efb5f-25f3-450b-b09a-5837e6240701" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_faf6085e-146e-4610-abbe-5cbda216cb40" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_537efb5f-25f3-450b-b09a-5837e6240701" xlink:to="loc_srt_ProductOrServiceAxis_faf6085e-146e-4610-abbe-5cbda216cb40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_faf6085e-146e-4610-abbe-5cbda216cb40_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_faf6085e-146e-4610-abbe-5cbda216cb40" xlink:to="loc_srt_ProductsAndServicesDomain_faf6085e-146e-4610-abbe-5cbda216cb40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c8623c69-ef42-4589-a083-b9fe21e9e1b8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_faf6085e-146e-4610-abbe-5cbda216cb40" xlink:to="loc_srt_ProductsAndServicesDomain_c8623c69-ef42-4589-a083-b9fe21e9e1b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_d8bdd1b3-92fd-480d-93d2-df2730b9c9ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c8623c69-ef42-4589-a083-b9fe21e9e1b8" xlink:to="loc_us-gaap_RoyaltyMember_d8bdd1b3-92fd-480d-93d2-df2730b9c9ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_b22fafe3-179c-4bde-8991-adf286e6e637" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c8623c69-ef42-4589-a083-b9fe21e9e1b8" xlink:to="loc_us-gaap_ProductMember_b22fafe3-179c-4bde-8991-adf286e6e637" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ProprietaryProductsSalesMember_e7c15b10-edbf-4e5c-93c3-f801f75bf30b" xlink:href="halo-20240331.xsd#halo_ProprietaryProductsSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_b22fafe3-179c-4bde-8991-adf286e6e637" xlink:to="loc_halo_ProprietaryProductsSalesMember_e7c15b10-edbf-4e5c-93c3-f801f75bf30b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BulkrHuPH20Member_6e8fb03d-6d91-47bc-a8e7-105a9865e5e6" xlink:href="halo-20240331.xsd#halo_BulkrHuPH20Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_b22fafe3-179c-4bde-8991-adf286e6e637" xlink:to="loc_halo_BulkrHuPH20Member_6e8fb03d-6d91-47bc-a8e7-105a9865e5e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DevicePartneredProductsMember_1d5ebeb2-d66e-42b9-b199-642fe7bd7f53" xlink:href="halo-20240331.xsd#halo_DevicePartneredProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_b22fafe3-179c-4bde-8991-adf286e6e637" xlink:to="loc_halo_DevicePartneredProductsMember_1d5ebeb2-d66e-42b9-b199-642fe7bd7f53" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_CollaborativeAgreementsMember_45271125-ebb5-47f8-996a-19d96bc85130" xlink:href="halo-20240331.xsd#halo_CollaborativeAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c8623c69-ef42-4589-a083-b9fe21e9e1b8" xlink:to="loc_halo_CollaborativeAgreementsMember_45271125-ebb5-47f8-996a-19d96bc85130" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_EventBasedDevelopmentAndRegulatoryMilestoneAndOtherFeesMember_ac97cce9-0d66-443c-bd5e-7dd572de13f9" xlink:href="halo-20240331.xsd#halo_EventBasedDevelopmentAndRegulatoryMilestoneAndOtherFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_CollaborativeAgreementsMember_45271125-ebb5-47f8-996a-19d96bc85130" xlink:to="loc_halo_EventBasedDevelopmentAndRegulatoryMilestoneAndOtherFeesMember_ac97cce9-0d66-443c-bd5e-7dd572de13f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DeviceLicensingAndDevelopmentMember_b112d057-c3b2-4c7f-b21d-a9916a5e899e" xlink:href="halo-20240331.xsd#halo_DeviceLicensingAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_CollaborativeAgreementsMember_45271125-ebb5-47f8-996a-19d96bc85130" xlink:to="loc_halo_DeviceLicensingAndDevelopmentMember_b112d057-c3b2-4c7f-b21d-a9916a5e899e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e6982695-477e-4df7-93df-024e0b1c1bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8a7e5b94-6064-49d1-89b6-daa18fba2c38" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e6982695-477e-4df7-93df-024e0b1c1bc2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/RevenueNarrativeDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#RevenueNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/RevenueNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_d97e5034-0be2-486c-81d7-a8043494d771" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_9c65fa08-bbe7-4fd0-ace8-17ab877386ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d97e5034-0be2-486c-81d7-a8043494d771" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_9c65fa08-bbe7-4fd0-ace8-17ab877386ff" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f0b1c023-9c2f-4030-8697-baaa7d4882cd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9c65fa08-bbe7-4fd0-ace8-17ab877386ff" xlink:to="loc_srt_ProductOrServiceAxis_f0b1c023-9c2f-4030-8697-baaa7d4882cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f0b1c023-9c2f-4030-8697-baaa7d4882cd_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f0b1c023-9c2f-4030-8697-baaa7d4882cd" xlink:to="loc_srt_ProductsAndServicesDomain_f0b1c023-9c2f-4030-8697-baaa7d4882cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c78a3203-9ef5-4292-9008-efe117346709" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f0b1c023-9c2f-4030-8697-baaa7d4882cd" xlink:to="loc_srt_ProductsAndServicesDomain_c78a3203-9ef5-4292-9008-efe117346709" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_LicenseFeesAndEventBasedMember_89e66fcb-1e80-4c0a-99cc-ca93a775e442" xlink:href="halo-20240331.xsd#halo_LicenseFeesAndEventBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c78a3203-9ef5-4292-9008-efe117346709" xlink:to="loc_halo_LicenseFeesAndEventBasedMember_89e66fcb-1e80-4c0a-99cc-ca93a775e442" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_4a38e358-3854-41e4-a44f-29c14f7cc7bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c78a3203-9ef5-4292-9008-efe117346709" xlink:to="loc_us-gaap_ProductMember_4a38e358-3854-41e4-a44f-29c14f7cc7bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_44a7d734-ed2a-49b9-be5a-c28fabbbe1b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9c65fa08-bbe7-4fd0-ace8-17ab877386ff" xlink:to="loc_us-gaap_TypeOfArrangementAxis_44a7d734-ed2a-49b9-be5a-c28fabbbe1b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_44a7d734-ed2a-49b9-be5a-c28fabbbe1b9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_44a7d734-ed2a-49b9-be5a-c28fabbbe1b9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_44a7d734-ed2a-49b9-be5a-c28fabbbe1b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3365078c-8566-4dde-accc-e163fd7f3dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_44a7d734-ed2a-49b9-be5a-c28fabbbe1b9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3365078c-8566-4dde-accc-e163fd7f3dc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_OthercollaboratorsMember_f46a1d23-933e-4a1e-a385-d2bb99016ac8" xlink:href="halo-20240331.xsd#halo_OthercollaboratorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3365078c-8566-4dde-accc-e163fd7f3dc0" xlink:to="loc_halo_OthercollaboratorsMember_f46a1d23-933e-4a1e-a385-d2bb99016ac8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_f31bc888-e004-4ca6-a5aa-7e266a5c1a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9c65fa08-bbe7-4fd0-ace8-17ab877386ff" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_f31bc888-e004-4ca6-a5aa-7e266a5c1a2e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_f5a0c659-b6a0-46d5-9355-b3b49da267f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d97e5034-0be2-486c-81d7-a8043494d771" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_f5a0c659-b6a0-46d5-9355-b3b49da267f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_3aa3fa2d-5fc3-47bd-8f66-cb32207c099a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d97e5034-0be2-486c-81d7-a8043494d771" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_3aa3fa2d-5fc3-47bd-8f66-cb32207c099a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_edacba0b-65a5-462a-95e4-8e2bd545ddf9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d97e5034-0be2-486c-81d7-a8043494d771" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_edacba0b-65a5-462a-95e4-8e2bd545ddf9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_c7610b5f-eb12-4e5a-83dc-eb8b952682b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d97e5034-0be2-486c-81d7-a8043494d771" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_c7610b5f-eb12-4e5a-83dc-eb8b952682b0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RevenueRemainingPerformanceObligationsUnfulfilledProductPurchaseOrdersAmount_b2da247e-d98a-4c1a-aabd-500736000cfa" xlink:href="halo-20240331.xsd#halo_RevenueRemainingPerformanceObligationsUnfulfilledProductPurchaseOrdersAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d97e5034-0be2-486c-81d7-a8043494d771" xlink:to="loc_halo_RevenueRemainingPerformanceObligationsUnfulfilledProductPurchaseOrdersAmount_b2da247e-d98a-4c1a-aabd-500736000cfa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_cf831757-efa9-4c4f-809e-8a860a6943ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d97e5034-0be2-486c-81d7-a8043494d771" xlink:to="loc_us-gaap_ContractWithCustomerLiability_cf831757-efa9-4c4f-809e-8a860a6943ab" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_5045fed2-cef1-497e-9ac8-908367bc7130" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d97e5034-0be2-486c-81d7-a8043494d771" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_5045fed2-cef1-497e-9ac8-908367bc7130" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetGrossCurrent_2673461b-6785-4096-a8b8-e85d72960d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetGrossCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d97e5034-0be2-486c-81d7-a8043494d771" xlink:to="loc_us-gaap_ContractWithCustomerAssetGrossCurrent_2673461b-6785-4096-a8b8-e85d72960d4e" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/RevenueNarrativeDetails_1" xlink:type="simple" xlink:href="halo-20240331.xsd#RevenueNarrativeDetails_1"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/RevenueNarrativeDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_d97e5034-0be2-486c-81d7-a8043494d771" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_9c65fa08-bbe7-4fd0-ace8-17ab877386ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d97e5034-0be2-486c-81d7-a8043494d771" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_9c65fa08-bbe7-4fd0-ace8-17ab877386ff" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f0b1c023-9c2f-4030-8697-baaa7d4882cd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9c65fa08-bbe7-4fd0-ace8-17ab877386ff" xlink:to="loc_srt_ProductOrServiceAxis_f0b1c023-9c2f-4030-8697-baaa7d4882cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f0b1c023-9c2f-4030-8697-baaa7d4882cd_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f0b1c023-9c2f-4030-8697-baaa7d4882cd" xlink:to="loc_srt_ProductsAndServicesDomain_f0b1c023-9c2f-4030-8697-baaa7d4882cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c78a3203-9ef5-4292-9008-efe117346709" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f0b1c023-9c2f-4030-8697-baaa7d4882cd" xlink:to="loc_srt_ProductsAndServicesDomain_c78a3203-9ef5-4292-9008-efe117346709" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_LicenseFeesAndEventBasedMember_89e66fcb-1e80-4c0a-99cc-ca93a775e442" xlink:href="halo-20240331.xsd#halo_LicenseFeesAndEventBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c78a3203-9ef5-4292-9008-efe117346709" xlink:to="loc_halo_LicenseFeesAndEventBasedMember_89e66fcb-1e80-4c0a-99cc-ca93a775e442" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_4a38e358-3854-41e4-a44f-29c14f7cc7bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c78a3203-9ef5-4292-9008-efe117346709" xlink:to="loc_us-gaap_ProductMember_4a38e358-3854-41e4-a44f-29c14f7cc7bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_44a7d734-ed2a-49b9-be5a-c28fabbbe1b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9c65fa08-bbe7-4fd0-ace8-17ab877386ff" xlink:to="loc_us-gaap_TypeOfArrangementAxis_44a7d734-ed2a-49b9-be5a-c28fabbbe1b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_44a7d734-ed2a-49b9-be5a-c28fabbbe1b9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_44a7d734-ed2a-49b9-be5a-c28fabbbe1b9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_44a7d734-ed2a-49b9-be5a-c28fabbbe1b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3365078c-8566-4dde-accc-e163fd7f3dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_44a7d734-ed2a-49b9-be5a-c28fabbbe1b9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3365078c-8566-4dde-accc-e163fd7f3dc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_OthercollaboratorsMember_f46a1d23-933e-4a1e-a385-d2bb99016ac8" xlink:href="halo-20240331.xsd#halo_OthercollaboratorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3365078c-8566-4dde-accc-e163fd7f3dc0" xlink:to="loc_halo_OthercollaboratorsMember_f46a1d23-933e-4a1e-a385-d2bb99016ac8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_f5a0c659-b6a0-46d5-9355-b3b49da267f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d97e5034-0be2-486c-81d7-a8043494d771" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_f5a0c659-b6a0-46d5-9355-b3b49da267f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_3aa3fa2d-5fc3-47bd-8f66-cb32207c099a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d97e5034-0be2-486c-81d7-a8043494d771" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_3aa3fa2d-5fc3-47bd-8f66-cb32207c099a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_edacba0b-65a5-462a-95e4-8e2bd545ddf9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d97e5034-0be2-486c-81d7-a8043494d771" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_edacba0b-65a5-462a-95e4-8e2bd545ddf9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_c7610b5f-eb12-4e5a-83dc-eb8b952682b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d97e5034-0be2-486c-81d7-a8043494d771" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_c7610b5f-eb12-4e5a-83dc-eb8b952682b0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RevenueRemainingPerformanceObligationsUnfulfilledProductPurchaseOrdersAmount_b2da247e-d98a-4c1a-aabd-500736000cfa" xlink:href="halo-20240331.xsd#halo_RevenueRemainingPerformanceObligationsUnfulfilledProductPurchaseOrdersAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d97e5034-0be2-486c-81d7-a8043494d771" xlink:to="loc_halo_RevenueRemainingPerformanceObligationsUnfulfilledProductPurchaseOrdersAmount_b2da247e-d98a-4c1a-aabd-500736000cfa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_cf831757-efa9-4c4f-809e-8a860a6943ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d97e5034-0be2-486c-81d7-a8043494d771" xlink:to="loc_us-gaap_ContractWithCustomerLiability_cf831757-efa9-4c4f-809e-8a860a6943ab" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_5045fed2-cef1-497e-9ac8-908367bc7130" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d97e5034-0be2-486c-81d7-a8043494d771" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_5045fed2-cef1-497e-9ac8-908367bc7130" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetGrossCurrent_2673461b-6785-4096-a8b8-e85d72960d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetGrossCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d97e5034-0be2-486c-81d7-a8043494d771" xlink:to="loc_us-gaap_ContractWithCustomerAssetGrossCurrent_2673461b-6785-4096-a8b8-e85d72960d4e" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#CertainBalanceSheetItemsAccountsReceivablenetDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_b0b9c703-94b2-4244-b4d8-878301700dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_4ea6c496-c00e-4c6a-b53a-f70706803db6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_b0b9c703-94b2-4244-b4d8-878301700dbe" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_4ea6c496-c00e-4c6a-b53a-f70706803db6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_dba86945-d80d-41a2-aa82-ba599afd7564" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_4ea6c496-c00e-4c6a-b53a-f70706803db6" xlink:to="loc_srt_ProductOrServiceAxis_dba86945-d80d-41a2-aa82-ba599afd7564" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_dba86945-d80d-41a2-aa82-ba599afd7564_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_dba86945-d80d-41a2-aa82-ba599afd7564" xlink:to="loc_srt_ProductsAndServicesDomain_dba86945-d80d-41a2-aa82-ba599afd7564_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5d452b7c-00dc-4bca-ba43-b416ddb43f6f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_dba86945-d80d-41a2-aa82-ba599afd7564" xlink:to="loc_srt_ProductsAndServicesDomain_5d452b7c-00dc-4bca-ba43-b416ddb43f6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DevicePartneredProductsMember_dda89d7e-54d1-441e-8979-8c6b5781991e" xlink:href="halo-20240331.xsd#halo_DevicePartneredProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5d452b7c-00dc-4bca-ba43-b416ddb43f6f" xlink:to="loc_halo_DevicePartneredProductsMember_dda89d7e-54d1-441e-8979-8c6b5781991e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_CollaborativeAgreementsMember_93e5d4d7-e685-44ea-9f36-e348bf6f701d" xlink:href="halo-20240331.xsd#halo_CollaborativeAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5d452b7c-00dc-4bca-ba43-b416ddb43f6f" xlink:to="loc_halo_CollaborativeAgreementsMember_93e5d4d7-e685-44ea-9f36-e348bf6f701d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_a7729ec4-db0e-485b-b8e3-c960874a973d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5d452b7c-00dc-4bca-ba43-b416ddb43f6f" xlink:to="loc_us-gaap_RoyaltyMember_a7729ec4-db0e-485b-b8e3-c960874a973d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ProductSalesOtherMember_b9bf8899-fb2e-4f3a-9972-29fd8a32ef54" xlink:href="halo-20240331.xsd#halo_ProductSalesOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5d452b7c-00dc-4bca-ba43-b416ddb43f6f" xlink:to="loc_halo_ProductSalesOtherMember_b9bf8899-fb2e-4f3a-9972-29fd8a32ef54" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_33d37ab3-4cb3-4f4b-aced-890e1ce43daa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_b0b9c703-94b2-4244-b4d8-878301700dbe" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_33d37ab3-4cb3-4f4b-aced-890e1ce43daa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetGrossCurrent_28382da5-d91f-4514-a978-98b680094f29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetGrossCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_b0b9c703-94b2-4244-b4d8-878301700dbe" xlink:to="loc_us-gaap_ContractWithCustomerAssetGrossCurrent_28382da5-d91f-4514-a978-98b680094f29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AccountsReceivableAndContractWithCustomerAssetBeforeAllowanceForCreditLossCurrent_559c0b34-4000-4f2b-af30-fcd242c2cc96" xlink:href="halo-20240331.xsd#halo_AccountsReceivableAndContractWithCustomerAssetBeforeAllowanceForCreditLossCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_b0b9c703-94b2-4244-b4d8-878301700dbe" xlink:to="loc_halo_AccountsReceivableAndContractWithCustomerAssetBeforeAllowanceForCreditLossCurrent_559c0b34-4000-4f2b-af30-fcd242c2cc96" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AccountsReceivableAndContractWithCustomerAssetAllowanceForCreditLossCurrent_e5d127b1-cb54-457c-a7ef-69b031ed6939" xlink:href="halo-20240331.xsd#halo_AccountsReceivableAndContractWithCustomerAssetAllowanceForCreditLossCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_b0b9c703-94b2-4244-b4d8-878301700dbe" xlink:to="loc_halo_AccountsReceivableAndContractWithCustomerAssetAllowanceForCreditLossCurrent_e5d127b1-cb54-457c-a7ef-69b031ed6939" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent_6b2ce132-9a61-4686-9d2a-284bbcda30ec" xlink:href="halo-20240331.xsd#halo_AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_b0b9c703-94b2-4244-b4d8-878301700dbe" xlink:to="loc_halo_AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent_6b2ce132-9a61-4686-9d2a-284bbcda30ec" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#CertainBalanceSheetItemsPropertyandEquipmentnetDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5e207bbf-ebf4-411a-a416-9d48ca393e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_df655e4a-22c7-4a14-8684-0e9e2006bde2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5e207bbf-ebf4-411a-a416-9d48ca393e9e" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_df655e4a-22c7-4a14-8684-0e9e2006bde2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_66cae749-4480-40aa-8795-3f234c579881" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_df655e4a-22c7-4a14-8684-0e9e2006bde2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_66cae749-4480-40aa-8795-3f234c579881" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_66cae749-4480-40aa-8795-3f234c579881_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_66cae749-4480-40aa-8795-3f234c579881" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_66cae749-4480-40aa-8795-3f234c579881_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_716b19a3-fae4-4051-bf9e-03a4b5af5123" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_66cae749-4480-40aa-8795-3f234c579881" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_716b19a3-fae4-4051-bf9e-03a4b5af5123" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ResearchEquipmentMember_1ea5cd55-186b-4205-90e9-ef2bf46ef948" xlink:href="halo-20240331.xsd#halo_ResearchEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_716b19a3-fae4-4051-bf9e-03a4b5af5123" xlink:to="loc_halo_ResearchEquipmentMember_1ea5cd55-186b-4205-90e9-ef2bf46ef948" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ManufacturingEquipmentMember_f9dd1ebd-eb52-4ae6-9a72-33da8754857c" xlink:href="halo-20240331.xsd#halo_ManufacturingEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_716b19a3-fae4-4051-bf9e-03a4b5af5123" xlink:to="loc_halo_ManufacturingEquipmentMember_f9dd1ebd-eb52-4ae6-9a72-33da8754857c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ComputerAndOfficeEquipmentMember_324afaec-e4cc-45c9-b2b1-9a18294343c6" xlink:href="halo-20240331.xsd#halo_ComputerAndOfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_716b19a3-fae4-4051-bf9e-03a4b5af5123" xlink:to="loc_halo_ComputerAndOfficeEquipmentMember_324afaec-e4cc-45c9-b2b1-9a18294343c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_cb01ef5b-ef6e-4736-bee7-7cb830358607" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_716b19a3-fae4-4051-bf9e-03a4b5af5123" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_cb01ef5b-ef6e-4736-bee7-7cb830358607" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_e9b65045-3365-490d-9f62-73964dc6851c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5e207bbf-ebf4-411a-a416-9d48ca393e9e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_e9b65045-3365-490d-9f62-73964dc6851c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b474b4ae-776e-4a80-ab07-eaf3833de9bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5e207bbf-ebf4-411a-a416-9d48ca393e9e" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b474b4ae-776e-4a80-ab07-eaf3833de9bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_692fc55e-aa75-46e7-8e5e-a61c6635fa2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5e207bbf-ebf4-411a-a416-9d48ca393e9e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_692fc55e-aa75-46e7-8e5e-a61c6635fa2a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6a8f81b9-0818-40df-9184-657dd1a74d97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5e207bbf-ebf4-411a-a416-9d48ca393e9e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6a8f81b9-0818-40df-9184-657dd1a74d97" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_0d69a493-2571-44b6-b28b-de749b993917" xlink:href="halo-20240331.xsd#halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5e207bbf-ebf4-411a-a416-9d48ca393e9e" xlink:to="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_0d69a493-2571-44b6-b28b-de749b993917" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_50ac4de7-8384-47ad-9abc-8b0d2f123d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5e207bbf-ebf4-411a-a416-9d48ca393e9e" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_50ac4de7-8384-47ad-9abc-8b0d2f123d4b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_26e151f8-bf60-4e66-b2b2-f11b483b60f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5e207bbf-ebf4-411a-a416-9d48ca393e9e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_26e151f8-bf60-4e66-b2b2-f11b483b60f2" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#GoodwillandIntangibleAssetsAdditionalDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_19817e88-a036-4170-b398-fecc79f292b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7585db2b-e0ce-4e97-ac83-99024b2692ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_19817e88-a036-4170-b398-fecc79f292b5" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7585db2b-e0ce-4e97-ac83-99024b2692ae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ae165932-e813-4b62-94ba-dc6ccd498eaa" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7585db2b-e0ce-4e97-ac83-99024b2692ae" xlink:to="loc_srt_RangeAxis_ae165932-e813-4b62-94ba-dc6ccd498eaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ae165932-e813-4b62-94ba-dc6ccd498eaa_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ae165932-e813-4b62-94ba-dc6ccd498eaa" xlink:to="loc_srt_RangeMember_ae165932-e813-4b62-94ba-dc6ccd498eaa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7af43159-8b8f-4be7-9814-a48ce6ddb33a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ae165932-e813-4b62-94ba-dc6ccd498eaa" xlink:to="loc_srt_RangeMember_7af43159-8b8f-4be7-9814-a48ce6ddb33a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_402b82ba-256f-4276-83c6-23da1aee5a73" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7af43159-8b8f-4be7-9814-a48ce6ddb33a" xlink:to="loc_srt_MinimumMember_402b82ba-256f-4276-83c6-23da1aee5a73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ade37b12-ce70-489e-a760-7a9dc8d52895" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7af43159-8b8f-4be7-9814-a48ce6ddb33a" xlink:to="loc_srt_MaximumMember_ade37b12-ce70-489e-a760-7a9dc8d52895" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_e045678a-1ad1-4626-9fd6-b29404c75154" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_19817e88-a036-4170-b398-fecc79f292b5" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_e045678a-1ad1-4626-9fd6-b29404c75154" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#GoodwillandIntangibleAssetsIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_efb84010-1ca3-44d5-9938-146788138266" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_97810f31-53ea-472d-9c24-40c3fa5361fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_efb84010-1ca3-44d5-9938-146788138266" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_97810f31-53ea-472d-9c24-40c3fa5361fb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c1f2008f-4709-45df-9d1d-06155bdf8cef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_97810f31-53ea-472d-9c24-40c3fa5361fb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c1f2008f-4709-45df-9d1d-06155bdf8cef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c1f2008f-4709-45df-9d1d-06155bdf8cef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c1f2008f-4709-45df-9d1d-06155bdf8cef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c1f2008f-4709-45df-9d1d-06155bdf8cef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_73876f1d-b77e-4b59-9656-3d5c037a679f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c1f2008f-4709-45df-9d1d-06155bdf8cef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_73876f1d-b77e-4b59-9656-3d5c037a679f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AutoInjectorTechnologyPlatformMember_decf1350-b861-4abc-9a75-4cee0c2fd4e0" xlink:href="halo-20240331.xsd#halo_AutoInjectorTechnologyPlatformMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_73876f1d-b77e-4b59-9656-3d5c037a679f" xlink:to="loc_halo_AutoInjectorTechnologyPlatformMember_decf1350-b861-4abc-9a75-4cee0c2fd4e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_XYOSTEDProprietaryProductMember_5c27f336-df46-44ab-a26c-c973109887ad" xlink:href="halo-20240331.xsd#halo_XYOSTEDProprietaryProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_73876f1d-b77e-4b59-9656-3d5c037a679f" xlink:to="loc_halo_XYOSTEDProprietaryProductMember_5c27f336-df46-44ab-a26c-c973109887ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_74d98acd-6a9f-4a66-87c1-bea58595721c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_efb84010-1ca3-44d5-9938-146788138266" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_74d98acd-6a9f-4a66-87c1-bea58595721c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_77112387-9cea-4463-802b-074506f71e65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_efb84010-1ca3-44d5-9938-146788138266" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_77112387-9cea-4463-802b-074506f71e65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a059809b-f570-4d44-a553-3f2b674e5fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_efb84010-1ca3-44d5-9938-146788138266" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a059809b-f570-4d44-a553-3f2b674e5fe2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_bb48207f-74a8-4c74-9922-80c0d5137483" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_efb84010-1ca3-44d5-9938-146788138266" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_bb48207f-74a8-4c74-9922-80c0d5137483" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_9da8ca6f-ca18-4987-8bd0-5b565521a97c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_efb84010-1ca3-44d5-9938-146788138266" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_9da8ca6f-ca18-4987-8bd0-5b565521a97c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_805b6163-de4d-4919-8fd9-717a3cb514ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_efb84010-1ca3-44d5-9938-146788138266" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_805b6163-de4d-4919-8fd9-717a3cb514ee" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#LongTermDebtNetNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ab381bde-8376-4b94-b8c0-6bbaeb548c07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_45da4622-135a-4b64-a1c0-ce6afeef463d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ab381bde-8376-4b94-b8c0-6bbaeb548c07" xlink:to="loc_us-gaap_DebtInstrumentTable_45da4622-135a-4b64-a1c0-ce6afeef463d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c3e51902-4126-409d-964c-5cf3d4c64ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_45da4622-135a-4b64-a1c0-ce6afeef463d" xlink:to="loc_us-gaap_DebtInstrumentAxis_c3e51902-4126-409d-964c-5cf3d4c64ec8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c3e51902-4126-409d-964c-5cf3d4c64ec8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_c3e51902-4126-409d-964c-5cf3d4c64ec8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c3e51902-4126-409d-964c-5cf3d4c64ec8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f6999d24-1e87-4b17-a989-bc50d831ab0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_c3e51902-4126-409d-964c-5cf3d4c64ec8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f6999d24-1e87-4b17-a989-bc50d831ab0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A100ConvertibleSeniorNotesDue2028Member_ccebe56a-516e-464b-823a-11b6f468b1b9" xlink:href="halo-20240331.xsd#halo_A100ConvertibleSeniorNotesDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f6999d24-1e87-4b17-a989-bc50d831ab0c" xlink:to="loc_halo_A100ConvertibleSeniorNotesDue2028Member_ccebe56a-516e-464b-823a-11b6f468b1b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A025ConvertibleSeniorNotesDue2027Member_f2a5912b-ac3c-4d04-8bc3-7cf4127ba025" xlink:href="halo-20240331.xsd#halo_A025ConvertibleSeniorNotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f6999d24-1e87-4b17-a989-bc50d831ab0c" xlink:to="loc_halo_A025ConvertibleSeniorNotesDue2027Member_f2a5912b-ac3c-4d04-8bc3-7cf4127ba025" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A1.25ConvertibleSeniorNotesdue2024Member_29e22fdb-efd9-406d-ab57-01bae822dd67" xlink:href="halo-20240331.xsd#halo_A1.25ConvertibleSeniorNotesdue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f6999d24-1e87-4b17-a989-bc50d831ab0c" xlink:to="loc_halo_A1.25ConvertibleSeniorNotesdue2024Member_29e22fdb-efd9-406d-ab57-01bae822dd67" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_CreditAgreementMember_e2e1e68d-d36b-4814-aa79-80f08d766f21" xlink:href="halo-20240331.xsd#halo_CreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f6999d24-1e87-4b17-a989-bc50d831ab0c" xlink:to="loc_halo_CreditAgreementMember_e2e1e68d-d36b-4814-aa79-80f08d766f21" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3fa85c72-9ae6-4d7c-92e3-9634f9c66524" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_45da4622-135a-4b64-a1c0-ce6afeef463d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3fa85c72-9ae6-4d7c-92e3-9634f9c66524" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3fa85c72-9ae6-4d7c-92e3-9634f9c66524_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3fa85c72-9ae6-4d7c-92e3-9634f9c66524" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3fa85c72-9ae6-4d7c-92e3-9634f9c66524_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_42a5520e-78bf-49ca-8bd4-78bd3dc5b05d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3fa85c72-9ae6-4d7c-92e3-9634f9c66524" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_42a5520e-78bf-49ca-8bd4-78bd3dc5b05d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_d908d269-2589-42f2-84dd-d321efe9b08b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_42a5520e-78bf-49ca-8bd4-78bd3dc5b05d" xlink:to="loc_us-gaap_ConvertibleDebtMember_d908d269-2589-42f2-84dd-d321efe9b08b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_TermLoanFacilityMember_c74629f2-a516-41a1-861c-70b3c5052d2c" xlink:href="halo-20240331.xsd#halo_TermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_42a5520e-78bf-49ca-8bd4-78bd3dc5b05d" xlink:to="loc_halo_TermLoanFacilityMember_c74629f2-a516-41a1-861c-70b3c5052d2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_66e2bf8e-0447-411c-ba84-e303ac95cafb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_45da4622-135a-4b64-a1c0-ce6afeef463d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_66e2bf8e-0447-411c-ba84-e303ac95cafb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_66e2bf8e-0447-411c-ba84-e303ac95cafb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_66e2bf8e-0447-411c-ba84-e303ac95cafb" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_66e2bf8e-0447-411c-ba84-e303ac95cafb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_ff7d3253-1eea-4453-9656-509dc10a90ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_66e2bf8e-0447-411c-ba84-e303ac95cafb" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_ff7d3253-1eea-4453-9656-509dc10a90ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_f321165f-3044-4ae6-b744-ff5b51b7d9c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_ff7d3253-1eea-4453-9656-509dc10a90ec" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_f321165f-3044-4ae6-b744-ff5b51b7d9c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_f319a97f-e110-406e-bef7-e9a74cb437e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_ff7d3253-1eea-4453-9656-509dc10a90ec" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_f319a97f-e110-406e-bef7-e9a74cb437e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_026829a3-072f-421f-96c9-64f0d2a77df9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_45da4622-135a-4b64-a1c0-ce6afeef463d" xlink:to="loc_us-gaap_VariableRateAxis_026829a3-072f-421f-96c9-64f0d2a77df9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_026829a3-072f-421f-96c9-64f0d2a77df9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_026829a3-072f-421f-96c9-64f0d2a77df9" xlink:to="loc_us-gaap_VariableRateDomain_026829a3-072f-421f-96c9-64f0d2a77df9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_2e9933ba-85f2-44f2-b35f-b8107e4dbeba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_026829a3-072f-421f-96c9-64f0d2a77df9" xlink:to="loc_us-gaap_VariableRateDomain_2e9933ba-85f2-44f2-b35f-b8107e4dbeba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_53deceaf-87b1-4a7f-b632-65f96176e6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_2e9933ba-85f2-44f2-b35f-b8107e4dbeba" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_53deceaf-87b1-4a7f-b632-65f96176e6ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_0431c560-fdf5-4e55-acf1-5f9e99dd8466" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_2e9933ba-85f2-44f2-b35f-b8107e4dbeba" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_0431c560-fdf5-4e55-acf1-5f9e99dd8466" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_be9a9293-a31c-422b-b39f-4d90cd241a69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_2e9933ba-85f2-44f2-b35f-b8107e4dbeba" xlink:to="loc_us-gaap_BaseRateMember_be9a9293-a31c-422b-b39f-4d90cd241a69" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cbc0a3b2-4161-4775-8b66-96f08b0fc5d4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_45da4622-135a-4b64-a1c0-ce6afeef463d" xlink:to="loc_srt_RangeAxis_cbc0a3b2-4161-4775-8b66-96f08b0fc5d4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cbc0a3b2-4161-4775-8b66-96f08b0fc5d4_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_cbc0a3b2-4161-4775-8b66-96f08b0fc5d4" xlink:to="loc_srt_RangeMember_cbc0a3b2-4161-4775-8b66-96f08b0fc5d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_32e889f7-df29-40aa-b3cb-14783b963db7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_cbc0a3b2-4161-4775-8b66-96f08b0fc5d4" xlink:to="loc_srt_RangeMember_32e889f7-df29-40aa-b3cb-14783b963db7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8e5a200a-e6f0-4b15-94c0-20394925b077" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_32e889f7-df29-40aa-b3cb-14783b963db7" xlink:to="loc_srt_MinimumMember_8e5a200a-e6f0-4b15-94c0-20394925b077" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e8a723b8-19de-4910-8059-b499d125ed83" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_32e889f7-df29-40aa-b3cb-14783b963db7" xlink:to="loc_srt_MaximumMember_e8a723b8-19de-4910-8059-b499d125ed83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_f31de8e1-f5ea-4f34-b8bd-55097afda20b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_45da4622-135a-4b64-a1c0-ce6afeef463d" xlink:to="loc_us-gaap_CreditFacilityAxis_f31de8e1-f5ea-4f34-b8bd-55097afda20b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_f31de8e1-f5ea-4f34-b8bd-55097afda20b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_f31de8e1-f5ea-4f34-b8bd-55097afda20b" xlink:to="loc_us-gaap_CreditFacilityDomain_f31de8e1-f5ea-4f34-b8bd-55097afda20b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_7189a399-05aa-4b1a-a6a3-4ee07559f390" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_f31de8e1-f5ea-4f34-b8bd-55097afda20b" xlink:to="loc_us-gaap_CreditFacilityDomain_7189a399-05aa-4b1a-a6a3-4ee07559f390" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_9c0f6dec-64ea-41d1-88b7-a6020f7bb52c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_7189a399-05aa-4b1a-a6a3-4ee07559f390" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_9c0f6dec-64ea-41d1-88b7-a6020f7bb52c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AnnualInterestPaymentPeriodAxis_ac008b69-0199-4885-a029-e7b78099f1d8" xlink:href="halo-20240331.xsd#halo_AnnualInterestPaymentPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_45da4622-135a-4b64-a1c0-ce6afeef463d" xlink:to="loc_halo_AnnualInterestPaymentPeriodAxis_ac008b69-0199-4885-a029-e7b78099f1d8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AnnualInterestPaymentPeriodDomain_ac008b69-0199-4885-a029-e7b78099f1d8_default" xlink:href="halo-20240331.xsd#halo_AnnualInterestPaymentPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_halo_AnnualInterestPaymentPeriodAxis_ac008b69-0199-4885-a029-e7b78099f1d8" xlink:to="loc_halo_AnnualInterestPaymentPeriodDomain_ac008b69-0199-4885-a029-e7b78099f1d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AnnualInterestPaymentPeriodDomain_c4779b36-a6df-4103-971a-1a5da327860c" xlink:href="halo-20240331.xsd#halo_AnnualInterestPaymentPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_halo_AnnualInterestPaymentPeriodAxis_ac008b69-0199-4885-a029-e7b78099f1d8" xlink:to="loc_halo_AnnualInterestPaymentPeriodDomain_c4779b36-a6df-4103-971a-1a5da327860c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentInterestPeriodOneMember_2ae2b432-34fc-4189-8c16-179022383ee2" xlink:href="halo-20240331.xsd#halo_DebtInstrumentInterestPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_AnnualInterestPaymentPeriodDomain_c4779b36-a6df-4103-971a-1a5da327860c" xlink:to="loc_halo_DebtInstrumentInterestPeriodOneMember_2ae2b432-34fc-4189-8c16-179022383ee2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentInterestPeriodTwoMember_b098c8d2-bcc0-4184-978b-39da99a77532" xlink:href="halo-20240331.xsd#halo_DebtInstrumentInterestPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_AnnualInterestPaymentPeriodDomain_c4779b36-a6df-4103-971a-1a5da327860c" xlink:to="loc_halo_DebtInstrumentInterestPeriodTwoMember_b098c8d2-bcc0-4184-978b-39da99a77532" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentInterestPeriodThreeMember_7c9d2a80-427e-41ef-adff-7ec91f1134cd" xlink:href="halo-20240331.xsd#halo_DebtInstrumentInterestPeriodThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_AnnualInterestPaymentPeriodDomain_c4779b36-a6df-4103-971a-1a5da327860c" xlink:to="loc_halo_DebtInstrumentInterestPeriodThreeMember_7c9d2a80-427e-41ef-adff-7ec91f1134cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentInterestPeriodFourMember_6a500dce-ad56-41bd-bf58-2399941a1084" xlink:href="halo-20240331.xsd#halo_DebtInstrumentInterestPeriodFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_AnnualInterestPaymentPeriodDomain_c4779b36-a6df-4103-971a-1a5da327860c" xlink:to="loc_halo_DebtInstrumentInterestPeriodFourMember_6a500dce-ad56-41bd-bf58-2399941a1084" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentAxis_9738459b-e8b6-4704-bfa5-8329470d45f1" xlink:href="halo-20240331.xsd#halo_VariableRateComponentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_45da4622-135a-4b64-a1c0-ce6afeef463d" xlink:to="loc_halo_VariableRateComponentAxis_9738459b-e8b6-4704-bfa5-8329470d45f1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentDomain_9738459b-e8b6-4704-bfa5-8329470d45f1_default" xlink:href="halo-20240331.xsd#halo_VariableRateComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_halo_VariableRateComponentAxis_9738459b-e8b6-4704-bfa5-8329470d45f1" xlink:to="loc_halo_VariableRateComponentDomain_9738459b-e8b6-4704-bfa5-8329470d45f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentDomain_68d4a88a-8670-44f0-b62f-6269d160f40f" xlink:href="halo-20240331.xsd#halo_VariableRateComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_halo_VariableRateComponentAxis_9738459b-e8b6-4704-bfa5-8329470d45f1" xlink:to="loc_halo_VariableRateComponentDomain_68d4a88a-8670-44f0-b62f-6269d160f40f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentOneMember_f0070773-af50-4885-a62c-7bbbc5736281" xlink:href="halo-20240331.xsd#halo_VariableRateComponentOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_VariableRateComponentDomain_68d4a88a-8670-44f0-b62f-6269d160f40f" xlink:to="loc_halo_VariableRateComponentOneMember_f0070773-af50-4885-a62c-7bbbc5736281" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentTwoMember_17e304f7-e30a-4fab-a441-1f98c6085669" xlink:href="halo-20240331.xsd#halo_VariableRateComponentTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_VariableRateComponentDomain_68d4a88a-8670-44f0-b62f-6269d160f40f" xlink:to="loc_halo_VariableRateComponentTwoMember_17e304f7-e30a-4fab-a441-1f98c6085669" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_220b3e62-6039-4beb-817b-084c9f422834" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ab381bde-8376-4b94-b8c0-6bbaeb548c07" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_220b3e62-6039-4beb-817b-084c9f422834" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_d2819480-0498-4143-bb9e-c2a34dc7b666" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ab381bde-8376-4b94-b8c0-6bbaeb548c07" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_d2819480-0498-4143-bb9e-c2a34dc7b666" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_3b336fd1-5dfd-4071-b407-ccc22ec1b94c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ab381bde-8376-4b94-b8c0-6bbaeb548c07" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_3b336fd1-5dfd-4071-b407-ccc22ec1b94c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_daaf5217-8a7f-4c13-987d-2b54c11967c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ab381bde-8376-4b94-b8c0-6bbaeb548c07" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_daaf5217-8a7f-4c13-987d-2b54c11967c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_e0350011-2f00-40c1-9c44-1deef725c3da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ab381bde-8376-4b94-b8c0-6bbaeb548c07" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_e0350011-2f00-40c1-9c44-1deef725c3da" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_27cce5bb-252f-4320-b952-373bfa000f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ab381bde-8376-4b94-b8c0-6bbaeb548c07" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_27cce5bb-252f-4320-b952-373bfa000f7e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_3ef7de36-6ef4-4f59-8c91-f9ebaa2bc617" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ab381bde-8376-4b94-b8c0-6bbaeb548c07" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_3ef7de36-6ef4-4f59-8c91-f9ebaa2bc617" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_2877a043-fa37-4149-9fa8-4b99b2af6963" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ab381bde-8376-4b94-b8c0-6bbaeb548c07" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_2877a043-fa37-4149-9fa8-4b99b2af6963" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays_8c75dcaa-bcc6-4ad2-9f29-e2280819b1df" xlink:href="halo-20240331.xsd#halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ab381bde-8376-4b94-b8c0-6bbaeb548c07" xlink:to="loc_halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays_8c75dcaa-bcc6-4ad2-9f29-e2280819b1df" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_bd7b06eb-c135-48a3-afa0-7ece7dfdde2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ab381bde-8376-4b94-b8c0-6bbaeb548c07" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_bd7b06eb-c135-48a3-afa0-7ece7dfdde2a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_810df83e-458c-4522-a279-0b8262e94f27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ab381bde-8376-4b94-b8c0-6bbaeb548c07" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_810df83e-458c-4522-a279-0b8262e94f27" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentCapCallTransactionCapPricePerShare_d12c26fb-1f6b-4499-89fc-270377557989" xlink:href="halo-20240331.xsd#halo_DebtInstrumentCapCallTransactionCapPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ab381bde-8376-4b94-b8c0-6bbaeb548c07" xlink:to="loc_halo_DebtInstrumentCapCallTransactionCapPricePerShare_d12c26fb-1f6b-4499-89fc-270377557989" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_SaleOfStockPremiumOverLastReportedSalePricePercentage_bc1e472b-a943-4bd9-be47-ecde2894c7df" xlink:href="halo-20240331.xsd#halo_SaleOfStockPremiumOverLastReportedSalePricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ab381bde-8376-4b94-b8c0-6bbaeb548c07" xlink:to="loc_halo_SaleOfStockPremiumOverLastReportedSalePricePercentage_bc1e472b-a943-4bd9-be47-ecde2894c7df" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_81930344-e700-4dbc-8d83-d2031e9efcbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ab381bde-8376-4b94-b8c0-6bbaeb548c07" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_81930344-e700-4dbc-8d83-d2031e9efcbe" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_PaymentForCappedCallTransactions_b8429052-e0c4-4712-b181-b472f65ea76a" xlink:href="halo-20240331.xsd#halo_PaymentForCappedCallTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ab381bde-8376-4b94-b8c0-6bbaeb548c07" xlink:to="loc_halo_PaymentForCappedCallTransactions_b8429052-e0c4-4712-b181-b472f65ea76a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_f3132a89-8a81-4ff1-acd0-e597dcf74ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ab381bde-8376-4b94-b8c0-6bbaeb548c07" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_f3132a89-8a81-4ff1-acd0-e597dcf74ac3" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_4681ad3b-7233-4dbc-a9ad-9b67480958a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ab381bde-8376-4b94-b8c0-6bbaeb548c07" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_4681ad3b-7233-4dbc-a9ad-9b67480958a7" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ea10ded6-9321-4e11-b7d7-428f629e7438" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ab381bde-8376-4b94-b8c0-6bbaeb548c07" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ea10ded6-9321-4e11-b7d7-428f629e7438" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_8dcebb7c-d921-4d29-90a2-c131141eaa87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ab381bde-8376-4b94-b8c0-6bbaeb548c07" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_8dcebb7c-d921-4d29-90a2-c131141eaa87" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_310f79d0-2bf8-4583-8f11-c645cb2dd5c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ab381bde-8376-4b94-b8c0-6bbaeb548c07" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_310f79d0-2bf8-4583-8f11-c645cb2dd5c5" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_90494db3-859f-4d59-a20c-6e05dc916f98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ab381bde-8376-4b94-b8c0-6bbaeb548c07" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_90494db3-859f-4d59-a20c-6e05dc916f98" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_33e74ba7-e586-4eb4-9248-51626f91ed47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ab381bde-8376-4b94-b8c0-6bbaeb548c07" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_33e74ba7-e586-4eb4-9248-51626f91ed47" xlink:type="arc" order="21"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#LongTermDebtNetCarryingAmountofConvertibleNotesDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_78e85926-0adc-48be-bbc1-2e76f100848f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_5ed31473-ed53-4582-9d40-0dfe885aea54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_78e85926-0adc-48be-bbc1-2e76f100848f" xlink:to="loc_us-gaap_DebtInstrumentTable_5ed31473-ed53-4582-9d40-0dfe885aea54" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_6e645951-6d32-49e5-80d6-0da4810a65a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5ed31473-ed53-4582-9d40-0dfe885aea54" xlink:to="loc_us-gaap_DebtInstrumentAxis_6e645951-6d32-49e5-80d6-0da4810a65a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6e645951-6d32-49e5-80d6-0da4810a65a8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_6e645951-6d32-49e5-80d6-0da4810a65a8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6e645951-6d32-49e5-80d6-0da4810a65a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bfa5cd6f-a742-4acf-b7db-ef92b1f56328" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_6e645951-6d32-49e5-80d6-0da4810a65a8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bfa5cd6f-a742-4acf-b7db-ef92b1f56328" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A025ConvertibleSeniorNotesDue2027Member_8d815816-6073-4742-8f04-caa13a5fcf0a" xlink:href="halo-20240331.xsd#halo_A025ConvertibleSeniorNotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bfa5cd6f-a742-4acf-b7db-ef92b1f56328" xlink:to="loc_halo_A025ConvertibleSeniorNotesDue2027Member_8d815816-6073-4742-8f04-caa13a5fcf0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A100ConvertibleSeniorNotesDue2028Member_e903e965-8334-49ca-a4cb-17c03d5352dd" xlink:href="halo-20240331.xsd#halo_A100ConvertibleSeniorNotesDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bfa5cd6f-a742-4acf-b7db-ef92b1f56328" xlink:to="loc_halo_A100ConvertibleSeniorNotesDue2028Member_e903e965-8334-49ca-a4cb-17c03d5352dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_e7e71b2b-c158-4db1-9266-066cb062ccde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_78e85926-0adc-48be-bbc1-2e76f100848f" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_e7e71b2b-c158-4db1-9266-066cb062ccde" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_658a6e6c-01a5-489d-bcc9-1096190e5a31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_78e85926-0adc-48be-bbc1-2e76f100848f" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_658a6e6c-01a5-489d-bcc9-1096190e5a31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_9503df57-e1bc-452f-9075-7e4355e37f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_78e85926-0adc-48be-bbc1-2e76f100848f" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_9503df57-e1bc-452f-9075-7e4355e37f8f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_aef09b7f-be8e-44c5-bb75-d891be3c531e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_78e85926-0adc-48be-bbc1-2e76f100848f" xlink:to="loc_us-gaap_LongTermDebt_aef09b7f-be8e-44c5-bb75-d891be3c531e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_6ac51de8-d32f-42e0-b403-d721aaa563d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_78e85926-0adc-48be-bbc1-2e76f100848f" xlink:to="loc_us-gaap_DebtInstrumentFairValue_6ac51de8-d32f-42e0-b403-d721aaa563d5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_55ac03eb-8fa9-4d09-9e15-7936b028ddee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_78e85926-0adc-48be-bbc1-2e76f100848f" xlink:to="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_55ac03eb-8fa9-4d09-9e15-7936b028ddee" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#LongTermDebtNetComponentsofInterestExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_f2d25297-a6aa-4a8d-b580-94940595d364" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_aa6b546b-aa20-4e28-9dd0-d871f403b21b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f2d25297-a6aa-4a8d-b580-94940595d364" xlink:to="loc_us-gaap_DebtInstrumentTable_aa6b546b-aa20-4e28-9dd0-d871f403b21b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_23125723-cf05-443d-8a1f-127232cc73fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_aa6b546b-aa20-4e28-9dd0-d871f403b21b" xlink:to="loc_us-gaap_DebtInstrumentAxis_23125723-cf05-443d-8a1f-127232cc73fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_23125723-cf05-443d-8a1f-127232cc73fa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_23125723-cf05-443d-8a1f-127232cc73fa" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_23125723-cf05-443d-8a1f-127232cc73fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_23d5d4a0-7bb1-4129-a95e-f47b92e30337" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_23125723-cf05-443d-8a1f-127232cc73fa" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_23d5d4a0-7bb1-4129-a95e-f47b92e30337" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A1.25ConvertibleSeniorNotesdue2024Member_42fad6b6-5db0-4da8-9e15-2680089543d8" xlink:href="halo-20240331.xsd#halo_A1.25ConvertibleSeniorNotesdue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_23d5d4a0-7bb1-4129-a95e-f47b92e30337" xlink:to="loc_halo_A1.25ConvertibleSeniorNotesdue2024Member_42fad6b6-5db0-4da8-9e15-2680089543d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A025ConvertibleSeniorNotesDue2027Member_61668a44-6119-46f9-9a2e-4732c55983e9" xlink:href="halo-20240331.xsd#halo_A025ConvertibleSeniorNotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_23d5d4a0-7bb1-4129-a95e-f47b92e30337" xlink:to="loc_halo_A025ConvertibleSeniorNotesDue2027Member_61668a44-6119-46f9-9a2e-4732c55983e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A100ConvertibleSeniorNotesDue2028Member_62ea4c7b-24a9-474b-8c3d-5af0e444dfb6" xlink:href="halo-20240331.xsd#halo_A100ConvertibleSeniorNotesDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_23d5d4a0-7bb1-4129-a95e-f47b92e30337" xlink:to="loc_halo_A100ConvertibleSeniorNotesDue2028Member_62ea4c7b-24a9-474b-8c3d-5af0e444dfb6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1d714364-436b-4268-9ebd-b4a784a60da8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_aa6b546b-aa20-4e28-9dd0-d871f403b21b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1d714364-436b-4268-9ebd-b4a784a60da8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1d714364-436b-4268-9ebd-b4a784a60da8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1d714364-436b-4268-9ebd-b4a784a60da8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1d714364-436b-4268-9ebd-b4a784a60da8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e329fdd7-2737-464b-8a1d-9c7c4b43e62f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1d714364-436b-4268-9ebd-b4a784a60da8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e329fdd7-2737-464b-8a1d-9c7c4b43e62f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_a497abb1-ba0a-4661-80b1-71ebd34100d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e329fdd7-2737-464b-8a1d-9c7c4b43e62f" xlink:to="loc_us-gaap_ConvertibleDebtMember_a497abb1-ba0a-4661-80b1-71ebd34100d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_d2a43b90-5fcf-4a24-9f39-404cb9777437" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f2d25297-a6aa-4a8d-b580-94940595d364" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_d2a43b90-5fcf-4a24-9f39-404cb9777437" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_cbeaee1d-782d-4199-be2c-964ac487b7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f2d25297-a6aa-4a8d-b580-94940595d364" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_cbeaee1d-782d-4199-be2c-964ac487b7ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_8ff36f97-06b3-43b0-b182-2c600a955e42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f2d25297-a6aa-4a8d-b580-94940595d364" xlink:to="loc_us-gaap_InterestExpenseDebt_8ff36f97-06b3-43b0-b182-2c600a955e42" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_9a64b03e-fdcd-40f1-ad54-226947584a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f2d25297-a6aa-4a8d-b580-94940595d364" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_9a64b03e-fdcd-40f1-ad54-226947584a9f" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#SharebasedCompensationSharebasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_840f61d6-92bb-4343-84d2-a9264072eb4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4405748f-7f1f-4e95-9570-7d8755168a46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_840f61d6-92bb-4343-84d2-a9264072eb4e" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4405748f-7f1f-4e95-9570-7d8755168a46" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_36e4fa9d-cdd4-45bb-a170-72959fd6b49d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4405748f-7f1f-4e95-9570-7d8755168a46" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_36e4fa9d-cdd4-45bb-a170-72959fd6b49d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_36e4fa9d-cdd4-45bb-a170-72959fd6b49d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_36e4fa9d-cdd4-45bb-a170-72959fd6b49d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_36e4fa9d-cdd4-45bb-a170-72959fd6b49d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_63943d7c-6ccf-491d-96ad-2551907feb56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_36e4fa9d-cdd4-45bb-a170-72959fd6b49d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_63943d7c-6ccf-491d-96ad-2551907feb56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2c773efc-d3c6-4b9f-985b-d374d8f2eced" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_63943d7c-6ccf-491d-96ad-2551907feb56" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2c773efc-d3c6-4b9f-985b-d374d8f2eced" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_70b4af9e-83e1-48c9-a9b2-40d314d2c499" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_63943d7c-6ccf-491d-96ad-2551907feb56" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_70b4af9e-83e1-48c9-a9b2-40d314d2c499" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bcf2171b-34bb-4ba3-94b9-99c9a949237b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4405748f-7f1f-4e95-9570-7d8755168a46" xlink:to="loc_us-gaap_AwardTypeAxis_bcf2171b-34bb-4ba3-94b9-99c9a949237b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bcf2171b-34bb-4ba3-94b9-99c9a949237b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_bcf2171b-34bb-4ba3-94b9-99c9a949237b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bcf2171b-34bb-4ba3-94b9-99c9a949237b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a6eb39c7-e730-4b56-a5ff-5c42c82eda52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_bcf2171b-34bb-4ba3-94b9-99c9a949237b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a6eb39c7-e730-4b56-a5ff-5c42c82eda52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f7cdfd56-7086-4ea5-9e46-84c23ab41f71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a6eb39c7-e730-4b56-a5ff-5c42c82eda52" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f7cdfd56-7086-4ea5-9e46-84c23ab41f71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RSURSAandPRSUawardsMember_cdcda707-0ed5-45b8-b19e-da2b15186489" xlink:href="halo-20240331.xsd#halo_RSURSAandPRSUawardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a6eb39c7-e730-4b56-a5ff-5c42c82eda52" xlink:to="loc_halo_RSURSAandPRSUawardsMember_cdcda707-0ed5-45b8-b19e-da2b15186489" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6f0f87e5-d59f-48f6-87b9-fe1dc5e4ddc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_840f61d6-92bb-4343-84d2-a9264072eb4e" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6f0f87e5-d59f-48f6-87b9-fe1dc5e4ddc9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#SharebasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4adf41ad-c98a-4537-9261-7308962cd20b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dc373bc1-204a-4a79-b2a7-6affb52a0607" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4adf41ad-c98a-4537-9261-7308962cd20b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dc373bc1-204a-4a79-b2a7-6affb52a0607" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f5eac0b9-9605-459f-ad20-f3248a1031dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dc373bc1-204a-4a79-b2a7-6affb52a0607" xlink:to="loc_us-gaap_AwardTypeAxis_f5eac0b9-9605-459f-ad20-f3248a1031dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f5eac0b9-9605-459f-ad20-f3248a1031dc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f5eac0b9-9605-459f-ad20-f3248a1031dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f5eac0b9-9605-459f-ad20-f3248a1031dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df9363d4-4086-4e75-818e-4c565d65bd48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f5eac0b9-9605-459f-ad20-f3248a1031dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df9363d4-4086-4e75-818e-4c565d65bd48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_9088d327-f92e-4c41-9315-7b22393a8b79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df9363d4-4086-4e75-818e-4c565d65bd48" xlink:to="loc_us-gaap_EmployeeStockOptionMember_9088d327-f92e-4c41-9315-7b22393a8b79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RSURSAandPRSUawardsMember_073f1b72-85d0-4f32-9c29-709fdebb6f60" xlink:href="halo-20240331.xsd#halo_RSURSAandPRSUawardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df9363d4-4086-4e75-818e-4c565d65bd48" xlink:to="loc_halo_RSURSAandPRSUawardsMember_073f1b72-85d0-4f32-9c29-709fdebb6f60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_4a539ea4-3598-44d5-aa91-787684d2a753" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df9363d4-4086-4e75-818e-4c565d65bd48" xlink:to="loc_us-gaap_EmployeeStockMember_4a539ea4-3598-44d5-aa91-787684d2a753" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_094de255-ba7e-4328-b117-71ead6a8705b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dc373bc1-204a-4a79-b2a7-6affb52a0607" xlink:to="loc_us-gaap_PlanNameAxis_094de255-ba7e-4328-b117-71ead6a8705b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_094de255-ba7e-4328-b117-71ead6a8705b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_094de255-ba7e-4328-b117-71ead6a8705b" xlink:to="loc_us-gaap_PlanNameDomain_094de255-ba7e-4328-b117-71ead6a8705b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_3c814820-7247-405b-bc5f-96b132c10e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_094de255-ba7e-4328-b117-71ead6a8705b" xlink:to="loc_us-gaap_PlanNameDomain_3c814820-7247-405b-bc5f-96b132c10e5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A2021ESPPPlanMember_8b35fd4e-5c2d-4cda-879b-86cb6a209fc0" xlink:href="halo-20240331.xsd#halo_A2021ESPPPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3c814820-7247-405b-bc5f-96b132c10e5d" xlink:to="loc_halo_A2021ESPPPlanMember_8b35fd4e-5c2d-4cda-879b-86cb6a209fc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_248c739e-2381-4ce7-b7d9-719ac2590b98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4adf41ad-c98a-4537-9261-7308962cd20b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_248c739e-2381-4ce7-b7d9-719ac2590b98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_0b9e6421-3e56-4f3f-855a-82f1c67aa26e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4adf41ad-c98a-4537-9261-7308962cd20b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_0b9e6421-3e56-4f3f-855a-82f1c67aa26e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate_2708f7a9-30fc-44b9-8832-1c348b6f61ba" xlink:href="halo-20240331.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4adf41ad-c98a-4537-9261-7308962cd20b" xlink:to="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate_2708f7a9-30fc-44b9-8832-1c348b6f61ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_f99d5042-6eea-4a23-9de3-6dedc6a4604a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4adf41ad-c98a-4537-9261-7308962cd20b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_f99d5042-6eea-4a23-9de3-6dedc6a4604a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_2bf1451f-8ed9-47cb-81f0-4fd29fa12216" xlink:href="halo-20240331.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4adf41ad-c98a-4537-9261-7308962cd20b" xlink:to="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_2bf1451f-8ed9-47cb-81f0-4fd29fa12216" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7c3e53d5-a230-4e01-adfe-7268ad84ec2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4adf41ad-c98a-4537-9261-7308962cd20b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7c3e53d5-a230-4e01-adfe-7268ad84ec2c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_6f9bc57f-bf88-44d3-967a-62342de9dacd" xlink:href="halo-20240331.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4adf41ad-c98a-4537-9261-7308962cd20b" xlink:to="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_6f9bc57f-bf88-44d3-967a-62342de9dacd" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_57bf4f03-7189-48c2-8b8b-11050eb0bae8" xlink:href="halo-20240331.xsd#halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable_7ea82d73-f096-4693-b725-27c4d6af29cd" xlink:href="halo-20240331.xsd#halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_57bf4f03-7189-48c2-8b8b-11050eb0bae8" xlink:to="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable_7ea82d73-f096-4693-b725-27c4d6af29cd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_762d085b-185f-4333-8bb6-4c48d4bd9a64" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable_7ea82d73-f096-4693-b725-27c4d6af29cd" xlink:to="loc_srt_RangeAxis_762d085b-185f-4333-8bb6-4c48d4bd9a64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_762d085b-185f-4333-8bb6-4c48d4bd9a64_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_762d085b-185f-4333-8bb6-4c48d4bd9a64" xlink:to="loc_srt_RangeMember_762d085b-185f-4333-8bb6-4c48d4bd9a64_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_831d9d6a-0546-44b7-9241-74e09e41006e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_762d085b-185f-4333-8bb6-4c48d4bd9a64" xlink:to="loc_srt_RangeMember_831d9d6a-0546-44b7-9241-74e09e41006e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_37b13c75-16bb-4c2f-9ed8-441c37139c28" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_831d9d6a-0546-44b7-9241-74e09e41006e" xlink:to="loc_srt_MinimumMember_37b13c75-16bb-4c2f-9ed8-441c37139c28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1f4dc48d-19b3-4726-aed6-335dae35dd3d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_831d9d6a-0546-44b7-9241-74e09e41006e" xlink:to="loc_srt_MaximumMember_1f4dc48d-19b3-4726-aed6-335dae35dd3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_1d06597f-7b5f-418d-957e-96664d58a7b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_57bf4f03-7189-48c2-8b8b-11050eb0bae8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_1d06597f-7b5f-418d-957e-96664d58a7b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9201183f-7ee6-4485-a92f-d937f94d2527" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_57bf4f03-7189-48c2-8b8b-11050eb0bae8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9201183f-7ee6-4485-a92f-d937f94d2527" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_116c07e3-ee00-4b49-9137-574af1171bfe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_57bf4f03-7189-48c2-8b8b-11050eb0bae8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_116c07e3-ee00-4b49-9137-574af1171bfe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_7fb357a7-5646-4b09-b716-dd7154740a16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_57bf4f03-7189-48c2-8b8b-11050eb0bae8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_7fb357a7-5646-4b09-b716-dd7154740a16" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_74620584-2419-4aa6-a30a-9164db12bb20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_57bf4f03-7189-48c2-8b8b-11050eb0bae8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_74620584-2419-4aa6-a30a-9164db12bb20" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c033c7f-c608-4939-89b4-a4f5a076e31b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_79ca65d8-ab3d-4466-8a5b-d073b93cdf6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c033c7f-c608-4939-89b4-a4f5a076e31b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_79ca65d8-ab3d-4466-8a5b-d073b93cdf6b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b3c81768-cceb-4d3f-a24a-2d4047e6a54e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_79ca65d8-ab3d-4466-8a5b-d073b93cdf6b" xlink:to="loc_us-gaap_AwardTypeAxis_b3c81768-cceb-4d3f-a24a-2d4047e6a54e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b3c81768-cceb-4d3f-a24a-2d4047e6a54e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b3c81768-cceb-4d3f-a24a-2d4047e6a54e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b3c81768-cceb-4d3f-a24a-2d4047e6a54e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f1f358c-9436-4efd-a8f2-3c1b6360f21f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b3c81768-cceb-4d3f-a24a-2d4047e6a54e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f1f358c-9436-4efd-a8f2-3c1b6360f21f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7260ce0c-3374-42e0-bfc0-e2f5222d7f66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f1f358c-9436-4efd-a8f2-3c1b6360f21f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7260ce0c-3374-42e0-bfc0-e2f5222d7f66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e6364348-5f4a-4d81-b197-9572f017a236" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f1f358c-9436-4efd-a8f2-3c1b6360f21f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e6364348-5f4a-4d81-b197-9572f017a236" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_c32959b5-a62a-45e5-9f59-b92adbf405f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f1f358c-9436-4efd-a8f2-3c1b6360f21f" xlink:to="loc_us-gaap_PerformanceSharesMember_c32959b5-a62a-45e5-9f59-b92adbf405f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_a22edab9-f716-455a-9ab0-9f2569f63d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f1f358c-9436-4efd-a8f2-3c1b6360f21f" xlink:to="loc_us-gaap_EmployeeStockMember_a22edab9-f716-455a-9ab0-9f2569f63d9e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_8eed62df-5bc8-4da3-886e-bb63fb1020dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c033c7f-c608-4939-89b4-a4f5a076e31b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_8eed62df-5bc8-4da3-886e-bb63fb1020dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_56a45ff7-31e0-4def-abf2-9217f0d1b292" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c033c7f-c608-4939-89b4-a4f5a076e31b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_56a45ff7-31e0-4def-abf2-9217f0d1b292" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4876fe32-0f06-4bce-9203-e2b6f1753cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_21ec367e-10c2-4dec-be17-59db4c982531" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4876fe32-0f06-4bce-9203-e2b6f1753cc9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_21ec367e-10c2-4dec-be17-59db4c982531" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_118163b7-9dee-4e80-84f6-0c510700d791" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_21ec367e-10c2-4dec-be17-59db4c982531" xlink:to="loc_us-gaap_AwardTypeAxis_118163b7-9dee-4e80-84f6-0c510700d791" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_118163b7-9dee-4e80-84f6-0c510700d791_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_118163b7-9dee-4e80-84f6-0c510700d791" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_118163b7-9dee-4e80-84f6-0c510700d791_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b6193fa8-af2a-4450-8589-faece9cc730c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_118163b7-9dee-4e80-84f6-0c510700d791" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b6193fa8-af2a-4450-8589-faece9cc730c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ce4b5334-9ac4-47ca-b626-06edb047267f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b6193fa8-af2a-4450-8589-faece9cc730c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ce4b5334-9ac4-47ca-b626-06edb047267f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RestrictedStockUnitsAndPerformanceSharesMember_952df324-d408-49e2-801a-f05dc34404e6" xlink:href="halo-20240331.xsd#halo_RestrictedStockUnitsAndPerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b6193fa8-af2a-4450-8589-faece9cc730c" xlink:to="loc_halo_RestrictedStockUnitsAndPerformanceSharesMember_952df324-d408-49e2-801a-f05dc34404e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_StockOptionsAndRestrictedStockUnitsMember_17663e9b-8826-4b5e-b7b1-0770dfb89245" xlink:href="halo-20240331.xsd#halo_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b6193fa8-af2a-4450-8589-faece9cc730c" xlink:to="loc_halo_StockOptionsAndRestrictedStockUnitsMember_17663e9b-8826-4b5e-b7b1-0770dfb89245" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_cc608e1f-4b39-450f-8567-997f2f8a9ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_21ec367e-10c2-4dec-be17-59db4c982531" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_cc608e1f-4b39-450f-8567-997f2f8a9ae0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_cc608e1f-4b39-450f-8567-997f2f8a9ae0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_cc608e1f-4b39-450f-8567-997f2f8a9ae0" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_cc608e1f-4b39-450f-8567-997f2f8a9ae0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_49a15e20-1340-49e3-9a16-d6b7e044748c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_cc608e1f-4b39-450f-8567-997f2f8a9ae0" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_49a15e20-1340-49e3-9a16-d6b7e044748c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AcceleratedShareRepurchaseAgreementMember_5db8c8e5-110b-4663-b6ad-16c277d14f5f" xlink:href="halo-20240331.xsd#halo_AcceleratedShareRepurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_49a15e20-1340-49e3-9a16-d6b7e044748c" xlink:to="loc_halo_AcceleratedShareRepurchaseAgreementMember_5db8c8e5-110b-4663-b6ad-16c277d14f5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A2024CapitalReturnProgramMember_dbe4ca9c-671b-40a1-be01-61462fdf09c5" xlink:href="halo-20240331.xsd#halo_A2024CapitalReturnProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_49a15e20-1340-49e3-9a16-d6b7e044748c" xlink:to="loc_halo_A2024CapitalReturnProgramMember_dbe4ca9c-671b-40a1-be01-61462fdf09c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_29ddf2ba-3f5c-4018-b01c-e43bc77c2f81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4876fe32-0f06-4bce-9203-e2b6f1753cc9" xlink:to="loc_us-gaap_StockholdersEquityAbstract_29ddf2ba-3f5c-4018-b01c-e43bc77c2f81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c150f61f-1729-4671-a2ab-f5843e1e0a28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29ddf2ba-3f5c-4018-b01c-e43bc77c2f81" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c150f61f-1729-4671-a2ab-f5843e1e0a28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_457a7e43-8125-4c94-a9d5-6c3d212a74ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29ddf2ba-3f5c-4018-b01c-e43bc77c2f81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_457a7e43-8125-4c94-a9d5-6c3d212a74ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_09478f9c-b3f6-4211-a24a-b47b87a9a159" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29ddf2ba-3f5c-4018-b01c-e43bc77c2f81" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_09478f9c-b3f6-4211-a24a-b47b87a9a159" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_461602f3-be82-4eb8-a9ea-974889f9daf3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29ddf2ba-3f5c-4018-b01c-e43bc77c2f81" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_461602f3-be82-4eb8-a9ea-974889f9daf3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_20b415f8-5c65-4c7a-b4c0-2ff46b7596fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29ddf2ba-3f5c-4018-b01c-e43bc77c2f81" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_20b415f8-5c65-4c7a-b4c0-2ff46b7596fd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_0236a373-8a5f-4c8a-b20f-9de337882de6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29ddf2ba-3f5c-4018-b01c-e43bc77c2f81" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_0236a373-8a5f-4c8a-b20f-9de337882de6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_138f4ea8-12e6-4d88-98e3-ef52fc95828a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29ddf2ba-3f5c-4018-b01c-e43bc77c2f81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_138f4ea8-12e6-4d88-98e3-ef52fc95828a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_6f9bbf87-4399-4e37-9d56-9cc6f6048315" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29ddf2ba-3f5c-4018-b01c-e43bc77c2f81" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_6f9bbf87-4399-4e37-9d56-9cc6f6048315" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramPeriodInForce1_806e4002-04ab-4a48-8d3b-01da487dbcd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramPeriodInForce1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29ddf2ba-3f5c-4018-b01c-e43bc77c2f81" xlink:to="loc_us-gaap_StockRepurchaseProgramPeriodInForce1_806e4002-04ab-4a48-8d3b-01da487dbcd2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_f234ad2f-bcc4-4b55-bf4c-b85c48278a81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29ddf2ba-3f5c-4018-b01c-e43bc77c2f81" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_f234ad2f-bcc4-4b55-bf4c-b85c48278a81" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_e4c0f50e-d64d-4c3d-88a1-305021845f18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29ddf2ba-3f5c-4018-b01c-e43bc77c2f81" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_e4c0f50e-d64d-4c3d-88a1-305021845f18" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_3edfb1e8-50d6-418d-96e1-467f7d10f99b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29ddf2ba-3f5c-4018-b01c-e43bc77c2f81" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_3edfb1e8-50d6-418d-96e1-467f7d10f99b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_1c0f740c-c28e-4094-92ea-08cada5e8cad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29ddf2ba-3f5c-4018-b01c-e43bc77c2f81" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_1c0f740c-c28e-4094-92ea-08cada5e8cad" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/EarningspershareComputationDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#EarningspershareComputationDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/EarningspershareComputationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems_bce6ad63-beb5-4bc7-846e-9c7c4dd77215" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_bdb7bcf9-4c7b-4b37-81cf-e4fd4a0880ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_bce6ad63-beb5-4bc7-846e-9c7c4dd77215" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_bdb7bcf9-4c7b-4b37-81cf-e4fd4a0880ab" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_861b3ce6-1421-46b5-a7d4-1c26d1fa28b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_bdb7bcf9-4c7b-4b37-81cf-e4fd4a0880ab" xlink:to="loc_us-gaap_AwardTypeAxis_861b3ce6-1421-46b5-a7d4-1c26d1fa28b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_861b3ce6-1421-46b5-a7d4-1c26d1fa28b4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_861b3ce6-1421-46b5-a7d4-1c26d1fa28b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_861b3ce6-1421-46b5-a7d4-1c26d1fa28b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7de5431c-ce1e-4982-a09a-5a74e3398bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_861b3ce6-1421-46b5-a7d4-1c26d1fa28b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7de5431c-ce1e-4982-a09a-5a74e3398bfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d01deafc-7009-4ca7-9937-75a8825f48e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7de5431c-ce1e-4982-a09a-5a74e3398bfb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d01deafc-7009-4ca7-9937-75a8825f48e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RestrictStockUnitsPerformanceSharesAndESPPMember_99e75fbc-3b64-4378-9711-f4d8818d5c06" xlink:href="halo-20240331.xsd#halo_RestrictStockUnitsPerformanceSharesAndESPPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7de5431c-ce1e-4982-a09a-5a74e3398bfb" xlink:to="loc_halo_RestrictStockUnitsPerformanceSharesAndESPPMember_99e75fbc-3b64-4378-9711-f4d8818d5c06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8fcc95fb-4843-4446-af5e-5e9e059e4f46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_bdb7bcf9-4c7b-4b37-81cf-e4fd4a0880ab" xlink:to="loc_us-gaap_DebtInstrumentAxis_8fcc95fb-4843-4446-af5e-5e9e059e4f46" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8fcc95fb-4843-4446-af5e-5e9e059e4f46_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_8fcc95fb-4843-4446-af5e-5e9e059e4f46" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8fcc95fb-4843-4446-af5e-5e9e059e4f46_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a3a0e209-cb33-40da-af40-8be89df1b0e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_8fcc95fb-4843-4446-af5e-5e9e059e4f46" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a3a0e209-cb33-40da-af40-8be89df1b0e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_ccdbd8f7-2605-4305-b720-0da246013b81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a3a0e209-cb33-40da-af40-8be89df1b0e6" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_ccdbd8f7-2605-4305-b720-0da246013b81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_38a34b7d-7605-4d07-adf1-749ec2b901a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_bce6ad63-beb5-4bc7-846e-9c7c4dd77215" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_38a34b7d-7605-4d07-adf1-749ec2b901a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_dfd95c4f-5ccb-40ad-b661-ba5e379bb048" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_38a34b7d-7605-4d07-adf1-749ec2b901a9" xlink:to="loc_us-gaap_NetIncomeLoss_dfd95c4f-5ccb-40ad-b661-ba5e379bb048" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_91682c6d-2b80-445a-b252-90886cdadbea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_bce6ad63-beb5-4bc7-846e-9c7c4dd77215" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_91682c6d-2b80-445a-b252-90886cdadbea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_69af07bf-5672-42d5-b223-b97e416302ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_91682c6d-2b80-445a-b252-90886cdadbea" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_69af07bf-5672-42d5-b223-b97e416302ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_cf39fb35-fb93-4408-9c16-12e8478cbdd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_91682c6d-2b80-445a-b252-90886cdadbea" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_cf39fb35-fb93-4408-9c16-12e8478cbdd0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_44864326-747b-45f9-819b-1a7b0314cd3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_cf39fb35-fb93-4408-9c16-12e8478cbdd0" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_44864326-747b-45f9-819b-1a7b0314cd3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_68bb64f6-5a2f-433f-8d4e-5d42a1c35303" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_cf39fb35-fb93-4408-9c16-12e8478cbdd0" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_68bb64f6-5a2f-433f-8d4e-5d42a1c35303" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_d0def7ba-6459-4339-b0a8-21dda4a29705" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_bce6ad63-beb5-4bc7-846e-9c7c4dd77215" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_d0def7ba-6459-4339-b0a8-21dda4a29705" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_6465efde-8e0d-48e6-83c5-97b1723b201f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_d0def7ba-6459-4339-b0a8-21dda4a29705" xlink:to="loc_us-gaap_EarningsPerShareBasic_6465efde-8e0d-48e6-83c5-97b1723b201f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_497218c7-b32a-40b3-aa67-95fa6f5c2f87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_d0def7ba-6459-4339-b0a8-21dda4a29705" xlink:to="loc_us-gaap_EarningsPerShareDiluted_497218c7-b32a-40b3-aa67-95fa6f5c2f87" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#TradingArrangmentsOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_HelenTorleyPriorPlanMember_d4b1c46c-9040-4bc7-8b11-79ab72643936" xlink:href="halo-20240331.xsd#halo_HelenTorleyPriorPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_halo_HelenTorleyPriorPlanMember_d4b1c46c-9040-4bc7-8b11-79ab72643936" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_HelenTorleyMarch2024PlanMember_cdede9e8-7c69-47c9-9bd6-3936a47253fd" xlink:href="halo-20240331.xsd#halo_HelenTorleyMarch2024PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_halo_HelenTorleyMarch2024PlanMember_cdede9e8-7c69-47c9-9bd6-3936a47253fd" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTypeOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RSURSAandPRSUawardsMember_e886b5e3-d9eb-4eed-b592-e2f7b199f02f" xlink:href="halo-20240331.xsd#halo_RSURSAandPRSUawardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_halo_RSURSAandPRSUawardsMember_e886b5e3-d9eb-4eed-b592-e2f7b199f02f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockMember" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_PerformanceSharesMember" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RestrictedStockUnitsAndPerformanceSharesMember_77b73cfc-0826-4ea6-b2fa-e0627723028b" xlink:href="halo-20240331.xsd#halo_RestrictedStockUnitsAndPerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_halo_RestrictedStockUnitsAndPerformanceSharesMember_77b73cfc-0826-4ea6-b2fa-e0627723028b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_StockOptionsAndRestrictedStockUnitsMember_0f7a8e74-8c56-487f-9dec-9084f80a6ecd" xlink:href="halo-20240331.xsd#halo_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_halo_StockOptionsAndRestrictedStockUnitsMember_0f7a8e74-8c56-487f-9dec-9084f80a6ecd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RestrictStockUnitsPerformanceSharesAndESPPMember_7dddd3c0-a6c5-487e-a2c4-d2615df5a876" xlink:href="halo-20240331.xsd#halo_RestrictStockUnitsPerformanceSharesAndESPPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_halo_RestrictStockUnitsPerformanceSharesAndESPPMember_7dddd3c0-a6c5-487e-a2c4-d2615df5a876" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#IndividualsOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_HelenTorleyMember_a6e5aa33-1a73-482e-9f86-dfcd352cd95e" xlink:href="halo-20240331.xsd#halo_HelenTorleyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_halo_HelenTorleyMember_a6e5aa33-1a73-482e-9f86-dfcd352cd95e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_NicoleLaBrosseMember_b0105b5e-f93c-4f21-bc0e-f9a29e3c8b53" xlink:href="halo-20240331.xsd#halo_NicoleLaBrosseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_halo_NicoleLaBrosseMember_b0105b5e-f93c-4f21-bc0e-f9a29e3c8b53" xlink:type="arc" order="3"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>halo-20240331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:17e6b7b2-f6c0-4a96-9180-046700296928,g:1765a142-e24e-49b0-883b-7a52af9d0516-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_halo_DeferredRentPayments_a3d93036-e6a4-4273-88ac-0c0643133425_negatedLabel_en-US" xlink:label="lab_halo_DeferredRentPayments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Lease payments deferred</link:label>
    <link:label id="lab_halo_DeferredRentPayments_label_en-US" xlink:label="lab_halo_DeferredRentPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Rent Payments</link:label>
    <link:label id="lab_halo_DeferredRentPayments_documentation_en-US" xlink:label="lab_halo_DeferredRentPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Rent Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DeferredRentPayments" xlink:href="halo-20240331.xsd#halo_DeferredRentPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_DeferredRentPayments" xlink:to="lab_halo_DeferredRentPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_2ab704ad-bd5d-4e5c-8a30-1745ad86811d_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_58859d28-12e7-4ad5-9eb7-6b2d9760d3fc_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales and maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_ef39f8d1-0c0a-45b5-b826-4a25460ae83f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of accrued expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_d98b8df0-cda5-486c-a062-9c1c8873ec23_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_3f2dff36-be44-4c99-9adc-ee15430d0a3c_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total accrued expenses, current</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_b0858ec5-2885-433e-8a28-bbaaeb90560d_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e1c2910f-f872-4d9d-92f0-e0643ec5890e_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit facility, maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_828ff482-f6f1-421b-823f-0f8c1bd82b77_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_52311d85-3f39-4d91-8549-7571b7f96a2e_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_0ac77f5b-8327-484b-ba2f-0a640e980387_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible, threshold consecutive trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d78f4fa7-35f9-44ce-875c-4bf4b0bd277e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_69d62118-6e23-4bca-837a-8b95145686ce_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, remaining performance obligation, expected timing</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_e078fc1e-0d0b-49fd-80f3-c092ca4ae5d7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_8664891c-e75d-4267-9101-f1ccc74d1e94_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_d5cac595-20e5-46ce-a72c-57bd3cbaf149_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ComputerAndOfficeEquipmentMember_3ce3fd0d-a6a5-4f94-9a2a-868d0bdadc56_terseLabel_en-US" xlink:label="lab_halo_ComputerAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer and office equipment</link:label>
    <link:label id="lab_halo_ComputerAndOfficeEquipmentMember_label_en-US" xlink:label="lab_halo_ComputerAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer and Office Equipment [Member]</link:label>
    <link:label id="lab_halo_ComputerAndOfficeEquipmentMember_documentation_en-US" xlink:label="lab_halo_ComputerAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Computer and office equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ComputerAndOfficeEquipmentMember" xlink:href="halo-20240331.xsd#halo_ComputerAndOfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ComputerAndOfficeEquipmentMember" xlink:to="lab_halo_ComputerAndOfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentImpairment_bc81d725-3c96-4efc-ad43-8ae3edb8ca0c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentImpairment_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Impairment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentImpairment" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_e61feac5-ecfe-4ce3-8be0-37a20463b582_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PSUs</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedLineItems_20dc27d3-ad04-465b-9033-b57455151ce5_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedLineItems_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems" xlink:to="lab_us-gaap_EarningsPerShareDilutedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_307adb58-6733-473b-b18d-ce1b91d528c8_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_f40f5119-865e-4843-af48-20cc8cd89879_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_9da1438d-4ac1-4bb8-8248-a42e7311e2b3_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 11)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsCurrent_0b04ecdb-17a7-41ea-bc6d-1b40951af94d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative asset, current</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsCurrent" xlink:to="lab_us-gaap_DerivativeAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_0e769398-fb40-4739-be27-3574da031b02_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_38666a49-a345-4125-a604-f2344211119f_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_18d2b9d0-0f97-4ed4-8761-9c595bb2d6ce_terseLabel_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum contribution amount</link:label>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_label_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount</link:label>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_documentation_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:href="halo-20240331.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:to="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_80d2aa36-a366-46e0-aa2c-be3b08255be7_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized variable consideration and other uncertainties satisfied</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_2c29f66a-837f-4537-9e46-b769e9a6c98e_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_StockOptionsAndRestrictedStockUnitsMember_0b79ad29-7973-4338-b419-08e88694b903_terseLabel_en-US" xlink:label="lab_halo_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options and restricted units</link:label>
    <link:label id="lab_halo_StockOptionsAndRestrictedStockUnitsMember_label_en-US" xlink:label="lab_halo_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Options And Restricted Stock Units [Member]</link:label>
    <link:label id="lab_halo_StockOptionsAndRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_halo_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Options And Restricted Stock Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_StockOptionsAndRestrictedStockUnitsMember" xlink:href="halo-20240331.xsd#halo_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_StockOptionsAndRestrictedStockUnitsMember" xlink:to="lab_halo_StockOptionsAndRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_15104683-d561-47e0-b070-41464cc2eee4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_8b39b95a-09f3-4779-b16e-8505f47afec2_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock issued during period, shares, restricted stock award, net of forfeitures (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_9189bc39-66c5-4b50-90ab-09ed302c0985_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_2be05f86-2bcb-4a9f-9bae-83dcae71da97_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_ae70e1b1-7a65-41f6-a489-812f89e3aff8_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_469199c6-992f-441d-b42e-8f0da9584d78_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock - $0.001 par value; 20,000 shares authorized; no shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_OperatingLeaseAccretionOfLiability_222a9d01-f217-4844-8b67-88f392daf972_terseLabel_en-US" xlink:label="lab_halo_OperatingLeaseAccretionOfLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense associated with accretion of lease liabilities</link:label>
    <link:label id="lab_halo_OperatingLeaseAccretionOfLiability_label_en-US" xlink:label="lab_halo_OperatingLeaseAccretionOfLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Accretion Of Liability</link:label>
    <link:label id="lab_halo_OperatingLeaseAccretionOfLiability_documentation_en-US" xlink:label="lab_halo_OperatingLeaseAccretionOfLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Accretion Of Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_OperatingLeaseAccretionOfLiability" xlink:href="halo-20240331.xsd#halo_OperatingLeaseAccretionOfLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_OperatingLeaseAccretionOfLiability" xlink:to="lab_halo_OperatingLeaseAccretionOfLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_8af97353-f326-4ac8-9cdc-7682ccd0ea93_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_HelenTorleyMarch2024PlanMember_label_en-US" xlink:label="lab_halo_HelenTorleyMarch2024PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Helen Torley March 2024 Plan [Member]</link:label>
    <link:label id="lab_halo_HelenTorleyMarch2024PlanMember_documentation_en-US" xlink:label="lab_halo_HelenTorleyMarch2024PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Helen Torley March 2024 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_HelenTorleyMarch2024PlanMember" xlink:href="halo-20240331.xsd#halo_HelenTorleyMarch2024PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_HelenTorleyMarch2024PlanMember" xlink:to="lab_halo_HelenTorleyMarch2024PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_e005751f-96a2-4718-86e3-9e6564f136b0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_93a8f493-d082-4a7f-b274-de1fbb4034c8_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_94b3ad48-5a99-4829-b650-ac119efaad3e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_427b6c33-6a5d-4322-b43b-738140a7f8da_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_DevicePartneredProductsMember_7fa6e185-1ea1-444e-b205-a0519239186d_terseLabel_en-US" xlink:label="lab_halo_DevicePartneredProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Device partnered product sales</link:label>
    <link:label id="lab_halo_DevicePartneredProductsMember_label_en-US" xlink:label="lab_halo_DevicePartneredProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Device Partnered Products [Member]</link:label>
    <link:label id="lab_halo_DevicePartneredProductsMember_documentation_en-US" xlink:label="lab_halo_DevicePartneredProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Device Partnered Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DevicePartneredProductsMember" xlink:href="halo-20240331.xsd#halo_DevicePartneredProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_DevicePartneredProductsMember" xlink:to="lab_halo_DevicePartneredProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_ec0d803b-7621-4893-8268-f52ce69977d8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9545f838-3c4f-48ea-aec4-0d284383ea95_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Outstanding stock options and restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_CreditAgreementMember_960faba5-8bee-4081-8b84-ff109f333d50_terseLabel_en-US" xlink:label="lab_halo_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Agreement</link:label>
    <link:label id="lab_halo_CreditAgreementMember_label_en-US" xlink:label="lab_halo_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:label id="lab_halo_CreditAgreementMember_documentation_en-US" xlink:label="lab_halo_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_CreditAgreementMember" xlink:href="halo-20240331.xsd#halo_CreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_CreditAgreementMember" xlink:to="lab_halo_CreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_a7fbf25f-88d3-45fe-ae3a-11106dc5016b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_92b9c3e2-bbeb-4252-bf20-ad787d551022_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale marketable securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_02d3d846-00f9-48bd-8895-1ab97033641c_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total estimated fair value of contractual maturities, available-for-sale</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Excluding Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_490164cd-756a-4743-9e71-3422f8e35779_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:to="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_4177fb60-ea70-4040-b243-89bdd642d710_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_AnnualInterestPaymentPeriodAxis_cb7e6098-69d7-4818-9e3d-33b255f26d69_terseLabel_en-US" xlink:label="lab_halo_AnnualInterestPaymentPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual Interest Payment Period [Axis]</link:label>
    <link:label id="lab_halo_AnnualInterestPaymentPeriodAxis_label_en-US" xlink:label="lab_halo_AnnualInterestPaymentPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annual Interest Payment Period [Axis]</link:label>
    <link:label id="lab_halo_AnnualInterestPaymentPeriodAxis_documentation_en-US" xlink:label="lab_halo_AnnualInterestPaymentPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Annual Interest Payment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AnnualInterestPaymentPeriodAxis" xlink:href="halo-20240331.xsd#halo_AnnualInterestPaymentPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_AnnualInterestPaymentPeriodAxis" xlink:to="lab_halo_AnnualInterestPaymentPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_79372da0-93ce-4c3f-a101-130bb952c3ba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_7d38a1c9-3fe7-44ba-ab8f-f47d417b3b29_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_d1bb56b7-0028-455c-a9c3-47e049276f7a_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_64eaf724-f2fb-4db9-aec1-fc20df67c842_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_6c0dc955-3c9b-4bcd-8ffe-e19b88e0792b_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets and Other Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_0c52f5f1-a463-4219-9150-9cd2bb19bb6e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_bc6bf91a-5847-4daf-9542-d2c6c3eaa425_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SOFR</link:label>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_label_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:to="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_84cec16c-7b39-4fc3-a06b-41a5e77f7bc5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_ad265e5e-4df7-4094-89da-e0025cdef171_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ProductSalesOtherMember_dacf509d-6a3a-445a-9e96-676d8575f6f0_terseLabel_en-US" xlink:label="lab_halo_ProductSalesOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other product sales</link:label>
    <link:label id="lab_halo_ProductSalesOtherMember_label_en-US" xlink:label="lab_halo_ProductSalesOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Sales, Other [Member]</link:label>
    <link:label id="lab_halo_ProductSalesOtherMember_documentation_en-US" xlink:label="lab_halo_ProductSalesOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Product Sales, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ProductSalesOtherMember" xlink:href="halo-20240331.xsd#halo_ProductSalesOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ProductSalesOtherMember" xlink:to="lab_halo_ProductSalesOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ResearchEquipmentMember_84e2e594-45c8-4567-9830-d35fb516c189_terseLabel_en-US" xlink:label="lab_halo_ResearchEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research equipment</link:label>
    <link:label id="lab_halo_ResearchEquipmentMember_label_en-US" xlink:label="lab_halo_ResearchEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Equipment [Member]</link:label>
    <link:label id="lab_halo_ResearchEquipmentMember_documentation_en-US" xlink:label="lab_halo_ResearchEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ResearchEquipmentMember" xlink:href="halo-20240331.xsd#halo_ResearchEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ResearchEquipmentMember" xlink:to="lab_halo_ResearchEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3998f8f4-fd92-4485-9393-21aacf1affe2_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_acb4fdd2-1dad-4154-9eb1-f24b6ca3d470_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_a361c327-e65b-40ce-b9ef-b7935f7276bb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayment of 2024 Convertible Notes</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_a31dda9d-93ce-485b-8f1d-32d21e64fde8_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_48ab8b01-dca1-46c5-8020-25e100ab04ca_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total amortization of debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_0687aadf-c817-40af-8ffb-63da3f2af10e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_36f2bca1-5382-4e2c-8c07-4ca719fb554a_terseLabel_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fed Funds Rate</link:label>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_label_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fed Funds Effective Rate Overnight Index Swap Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:to="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_4982409e-f209-4102-8c7f-b45ecc4306e7_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_OtherComprehensiveIncomeLossCashFlowHedgeUnrealizedHoldingGainLossBeforeAdjustmentAfterTax_271ef857-f213-4043-87e0-c2359c412b6e_terseLabel_en-US" xlink:label="lab_halo_OtherComprehensiveIncomeLossCashFlowHedgeUnrealizedHoldingGainLossBeforeAdjustmentAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain on derivative instruments, net</link:label>
    <link:label id="lab_halo_OtherComprehensiveIncomeLossCashFlowHedgeUnrealizedHoldingGainLossBeforeAdjustmentAfterTax_label_en-US" xlink:label="lab_halo_OtherComprehensiveIncomeLossCashFlowHedgeUnrealizedHoldingGainLossBeforeAdjustmentAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Unrealized Holding Gain (Loss), Before Adjustment, after Tax</link:label>
    <link:label id="lab_halo_OtherComprehensiveIncomeLossCashFlowHedgeUnrealizedHoldingGainLossBeforeAdjustmentAfterTax_documentation_en-US" xlink:label="lab_halo_OtherComprehensiveIncomeLossCashFlowHedgeUnrealizedHoldingGainLossBeforeAdjustmentAfterTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Unrealized Holding Gain (Loss), Before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_OtherComprehensiveIncomeLossCashFlowHedgeUnrealizedHoldingGainLossBeforeAdjustmentAfterTax" xlink:href="halo-20240331.xsd#halo_OtherComprehensiveIncomeLossCashFlowHedgeUnrealizedHoldingGainLossBeforeAdjustmentAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_OtherComprehensiveIncomeLossCashFlowHedgeUnrealizedHoldingGainLossBeforeAdjustmentAfterTax" xlink:to="lab_halo_OtherComprehensiveIncomeLossCashFlowHedgeUnrealizedHoldingGainLossBeforeAdjustmentAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_2786a27a-4e45-45d8-92ef-6bc759c49731_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_cb4304c7-0804-45e1-b567-8295ad3c85d3_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_af7c4086-d878-4f69-9676-e3db05d732f7_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity (deficit) (textual)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_89f01147-cfc7-4fb7-9baf-a5563ca8bc1e_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a1386d04-1ff0-4b36-8fc1-2b78729df624_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized loss position of debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_bdcab518-0b8e-4fb0-961f-f987034453a2_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of shares of common stock issued as a result of stock option exercises (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_3231440c-85c8-477e-91a0-2ac9114cddee_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenues</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_NicoleLaBrosseMember_label_en-US" xlink:label="lab_halo_NicoleLaBrosseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nicole LaBrosse [Member]</link:label>
    <link:label id="lab_halo_NicoleLaBrosseMember_documentation_en-US" xlink:label="lab_halo_NicoleLaBrosseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nicole LaBrosse</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_NicoleLaBrosseMember" xlink:href="halo-20240331.xsd#halo_NicoleLaBrosseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_NicoleLaBrosseMember" xlink:to="lab_halo_NicoleLaBrosseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ManufacturingEquipmentMember_d0b3e76b-1e92-47ef-8153-82cd7c99ad14_terseLabel_en-US" xlink:label="lab_halo_ManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Manufacturing equipment</link:label>
    <link:label id="lab_halo_ManufacturingEquipmentMember_label_en-US" xlink:label="lab_halo_ManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Manufacturing Equipment [Member]</link:label>
    <link:label id="lab_halo_ManufacturingEquipmentMember_documentation_en-US" xlink:label="lab_halo_ManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Manufacturing Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ManufacturingEquipmentMember" xlink:href="halo-20240331.xsd#halo_ManufacturingEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ManufacturingEquipmentMember" xlink:to="lab_halo_ManufacturingEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1f3d86ab-771c-4268-96ef-3c6a86b3b841_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of reconciliation of numerators and denominators of basic and diluted computations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_9d1af131-0eab-47e5-ae7c-57678ddbd9aa_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_61b989f1-de39-4930-bf1b-b716e00b2591_verboseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average useful life (in years)</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_bac8e8b3-86a9-43b1-b99d-874648b3858b_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Useful Life (in years)</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_e3675793-0414-46ba-9316-7ec49f61bfa1_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_e94cee41-d747-4bdc-8dd7-e04a7078166a_verboseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f9c5610e-a534-4896-9071-c964285cae2e_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options weighted average exercise price (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_fff97c92-845d-4352-8e51-52619b0d144f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_5d8a6ec5-eab5-41e6-8433-6c442749f88a_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_272131be-4039-44d1-8d88-00cde47954b5_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Goodwill, Beginning Balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_8fb67638-6f99-4bec-bad9-aef532bef6db_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Goodwill, Ending Balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_a71badc4-f9d2-4347-ac5c-8175b8242e16_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_7ab05b8e-e45f-449c-a091-890ce85111dd_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_75d22519-2649-4c47-9324-ec6b4669a355_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_8526d1f9-e712-485e-a51b-82af209ed586_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_da0b4d2f-e551-4021-9c9b-2ba68459f041_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice_47f49326-6d1a-4364-a21d-6281212234bc_terseLabel_en-US" xlink:label="lab_halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period of contract termination by written notice</link:label>
    <link:label id="lab_halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice_label_en-US" xlink:label="lab_halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Period Of Termination By Written Notice</link:label>
    <link:label id="lab_halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice_documentation_en-US" xlink:label="lab_halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Period Of Termination By Written Notice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice" xlink:href="halo-20240331.xsd#halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice" xlink:to="lab_halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_1c8ceada-dd29-4358-bb88-e10024798707_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0f651870-455b-4b7c-bc90-4b5c10e57154_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_7bee1710-e5ab-4e4f-b8d7-e7161f237033_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_73f0d541-477f-442a-8460-615b5f624e3d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_a5d0dd3c-609f-499b-a5ad-36519b7ebd7d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_6df44d01-7ae2-4c99-b467-d4b0e555a031_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and payroll taxes</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_c6733185-d4e5-42e0-bdbf-3d9fd3790d03_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_62477832-cad1-413d-9227-637b8f97af13_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net and other contract assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_VariableRateComponentTwoMember_6b12e659-8bcb-4a00-9b2b-0e5a8636f75b_terseLabel_en-US" xlink:label="lab_halo_VariableRateComponentTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate Component Two</link:label>
    <link:label id="lab_halo_VariableRateComponentTwoMember_label_en-US" xlink:label="lab_halo_VariableRateComponentTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate Component Two [Member]</link:label>
    <link:label id="lab_halo_VariableRateComponentTwoMember_documentation_en-US" xlink:label="lab_halo_VariableRateComponentTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Variable Rate Component Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentTwoMember" xlink:href="halo-20240331.xsd#halo_VariableRateComponentTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_VariableRateComponentTwoMember" xlink:to="lab_halo_VariableRateComponentTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_0fd1941f-89fa-47de-92c7-9be42c42e934_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_b2567539-a348-4d28-b4fb-4fed5b5c0aa5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized (loss) gain on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_RevenueRemainingPerformanceObligationsUnfulfilledProductPurchaseOrdersAmount_e001a90d-f5e9-491b-9a96-65673e812ff8_terseLabel_en-US" xlink:label="lab_halo_RevenueRemainingPerformanceObligationsUnfulfilledProductPurchaseOrdersAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue remaining performance obligations, related to unfulfilled product purchase orders</link:label>
    <link:label id="lab_halo_RevenueRemainingPerformanceObligationsUnfulfilledProductPurchaseOrdersAmount_label_en-US" xlink:label="lab_halo_RevenueRemainingPerformanceObligationsUnfulfilledProductPurchaseOrdersAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Remaining Performance Obligations, Unfulfilled Product Purchase Orders, Amount</link:label>
    <link:label id="lab_halo_RevenueRemainingPerformanceObligationsUnfulfilledProductPurchaseOrdersAmount_documentation_en-US" xlink:label="lab_halo_RevenueRemainingPerformanceObligationsUnfulfilledProductPurchaseOrdersAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Remaining Performance Obligations, Unfulfilled Product Purchase Orders, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RevenueRemainingPerformanceObligationsUnfulfilledProductPurchaseOrdersAmount" xlink:href="halo-20240331.xsd#halo_RevenueRemainingPerformanceObligationsUnfulfilledProductPurchaseOrdersAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_RevenueRemainingPerformanceObligationsUnfulfilledProductPurchaseOrdersAmount" xlink:to="lab_halo_RevenueRemainingPerformanceObligationsUnfulfilledProductPurchaseOrdersAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_47663c4d-df90-43c5-b2fc-4ed65bcb4bb9_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_f7c64188-569e-49eb-9327-db8f6cc64f7a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: Long-term portion</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_DebtInstrumentInterestPeriodFourMember_42f11d01-3d28-49e5-9d56-1a068eb47197_terseLabel_en-US" xlink:label="lab_halo_DebtInstrumentInterestPeriodFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year four</link:label>
    <link:label id="lab_halo_DebtInstrumentInterestPeriodFourMember_label_en-US" xlink:label="lab_halo_DebtInstrumentInterestPeriodFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest, Period Four [Member]</link:label>
    <link:label id="lab_halo_DebtInstrumentInterestPeriodFourMember_documentation_en-US" xlink:label="lab_halo_DebtInstrumentInterestPeriodFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest, Period Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentInterestPeriodFourMember" xlink:href="halo-20240331.xsd#halo_DebtInstrumentInterestPeriodFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_DebtInstrumentInterestPeriodFourMember" xlink:to="lab_halo_DebtInstrumentInterestPeriodFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_8a3182de-64de-4e25-8a2d-ab539dc2be02_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of contractual maturities of available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_f652c226-be5f-4847-9b56-60a2a3bc48bb_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_13b6072a-2296-4f5a-bfe5-50e5b6c792ec_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_321f4ab2-f05a-4bb7-9b3d-5846b0bf08b9_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment of debt issuance cost</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_821084f1-0782-431c-bac7-7523c1dc4b43_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_d47ab0dd-9be7-48d5-8db5-ef4409cccff3_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ff5e4e7-209c-49ae-9219-e3619f71f81b_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_6b105fb3-b188-4ba0-8ad6-6fed0f834779_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unamortized debt issuance cost</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAbstract_8a0e9df3-839c-442a-bfbe-c28e137ac1cb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeForwardMember_d784aa15-a31f-4407-9186-6ea84442f2e8_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeForwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency hedging contracts</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeForwardMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeForwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Exchange Forward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeForwardMember" xlink:to="lab_us-gaap_ForeignExchangeForwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_00e713e2-cc97-4a3e-a3b7-38ff591fee7c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded from calculation of diluted earnings per common share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_cb30759a-04d7-41c3-8da9-a84bf087e8eb_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_0e4acace-4a2b-4147-b760-768906e9d4f4_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_A2024CapitalReturnProgramMember_4e92ad11-6e33-4b31-a139-3c7ba3197c17_terseLabel_en-US" xlink:label="lab_halo_A2024CapitalReturnProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024 Capital Return Program</link:label>
    <link:label id="lab_halo_A2024CapitalReturnProgramMember_label_en-US" xlink:label="lab_halo_A2024CapitalReturnProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2024 Capital Return Program [Member]</link:label>
    <link:label id="lab_halo_A2024CapitalReturnProgramMember_documentation_en-US" xlink:label="lab_halo_A2024CapitalReturnProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2024 Capital Return Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A2024CapitalReturnProgramMember" xlink:href="halo-20240331.xsd#halo_A2024CapitalReturnProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_A2024CapitalReturnProgramMember" xlink:to="lab_halo_A2024CapitalReturnProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_b36f03aa-a5d4-4086-b191-3a769c91a848_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_739637a5-fc49-4f91-b9f4-84a036d82824_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_108a6080-4f20-4802-9910-e80748a68a9c_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_AccruedOutsourcedManufacturingExpenses_01650f91-88bb-4dbd-89ce-7d062a25145c_terseLabel_en-US" xlink:label="lab_halo_AccruedOutsourcedManufacturingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued outsourced manufacturing expenses</link:label>
    <link:label id="lab_halo_AccruedOutsourcedManufacturingExpenses_label_en-US" xlink:label="lab_halo_AccruedOutsourcedManufacturingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Outsourced Manufacturing Expenses</link:label>
    <link:label id="lab_halo_AccruedOutsourcedManufacturingExpenses_documentation_en-US" xlink:label="lab_halo_AccruedOutsourcedManufacturingExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Outsourced Manufacturing Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AccruedOutsourcedManufacturingExpenses" xlink:href="halo-20240331.xsd#halo_AccruedOutsourcedManufacturingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_AccruedOutsourcedManufacturingExpenses" xlink:to="lab_halo_AccruedOutsourcedManufacturingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f2c466ad-5a94-4065-987e-5465646b6204_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anti-dilutive shares excluded from per share calculation (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_475c3933-e357-4fcd-8b3b-1681a7c75b08_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_f12e5332-f9fe-43ac-9bc0-e6cc5b9d011b_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_50922c60-34f1-4ebe-bf75-8580b84fa737_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_c5cee0a6-ea97-4839-8937-6621ecabaaf1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_963c590c-529c-4d0a-bfbd-e8bc4a9ad3f0_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts accrued for purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_174ec5d6-065f-4055-99b5-c8c4fad8f257_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_f69dc443-a60a-4de2-9633-a92e16e4e71a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_313d7b67-d1ef-43ef-9a2e-cf4acbe96f71_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligation</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_da46d43e-fb6f-403c-b73b-6030ca776332_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remainder of 2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_RestrictedStockUnitsAndPerformanceSharesMember_794a9dac-2304-4522-91e7-7ad3e78e726f_terseLabel_en-US" xlink:label="lab_halo_RestrictedStockUnitsAndPerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSUs and PSUs</link:label>
    <link:label id="lab_halo_RestrictedStockUnitsAndPerformanceSharesMember_label_en-US" xlink:label="lab_halo_RestrictedStockUnitsAndPerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units And Performance Shares [Member]</link:label>
    <link:label id="lab_halo_RestrictedStockUnitsAndPerformanceSharesMember_documentation_en-US" xlink:label="lab_halo_RestrictedStockUnitsAndPerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Stock Units And Performance Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RestrictedStockUnitsAndPerformanceSharesMember" xlink:href="halo-20240331.xsd#halo_RestrictedStockUnitsAndPerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_RestrictedStockUnitsAndPerformanceSharesMember" xlink:to="lab_halo_RestrictedStockUnitsAndPerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_6a298a48-7d2c-4bd1-b140-4265f2c16724_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized from prior periods</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_409e1544-0015-4558-9e93-6edeaf5cccd5_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Income and Interest Expense Disclosure</link:label>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income and Interest Expense Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_c542836d-6f73-4530-aeac-175977ede9df_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_db3b43e3-cadb-4740-880d-deb0ec3518c5_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_242eeed4-6d3f-4c7a-8f9a-4c9405e11d5f_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_9ef61ad0-b3ed-4498-9c17-718f38365c3a_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Total unamortized debt discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_64e833f4-59c7-47b6-849d-b2ee2dd39607_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid manufacturing expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_0dabae31-f1eb-4193-a1e9-e635c579dc77_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, contract term</link:label>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_label_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTermOfContract" xlink:to="lab_us-gaap_DerivativeTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock_415e9a20-7600-4a2d-bcfe-23a33bca1ef6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Other Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_d5c73093-7256-48dd-a244-8bd9d965e16b_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangibles</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_a0211161-34a1-4d28-9412-7214526914b4_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_db699096-c05e-4c04-b699-c80afb595a12_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_29f0f2e6-a7a8-4a3b-a472-c43048c18623_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Carrying Value</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_9945328f-9c0e-4ecc-90b6-9be088438948_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_100faa8b-a728-4b90-9eca-03cbbdd79d7f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_129f4abd-3c10-4f3e-9625-8cdc854e0ed5_verboseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Adoption and Pending Adoption of Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_LicenseFeesAndEventBasedMember_b2e57f03-f90a-4495-85d1-3764cf704608_terseLabel_en-US" xlink:label="lab_halo_LicenseFeesAndEventBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Fees and Event-Based</link:label>
    <link:label id="lab_halo_LicenseFeesAndEventBasedMember_label_en-US" xlink:label="lab_halo_LicenseFeesAndEventBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Fees And Event-Based [Member]</link:label>
    <link:label id="lab_halo_LicenseFeesAndEventBasedMember_documentation_en-US" xlink:label="lab_halo_LicenseFeesAndEventBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Fees And Event-Based [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_LicenseFeesAndEventBasedMember" xlink:href="halo-20240331.xsd#halo_LicenseFeesAndEventBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_LicenseFeesAndEventBasedMember" xlink:to="lab_halo_LicenseFeesAndEventBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_12397501-46c1-4823-a356-566e1824d482_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average price paid per share (usd per share)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_ee7f81ff-23aa-45ae-bde2-eb90aa97d456_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_138abeed-b651-4ef9-9930-873961e3cb90_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8de91e95-8439-4dfa-8a5a-41aee895d712_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_81b97e54-35ec-40ab-a978-58a2826324bd_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_476b715f-a0b1-4223-8c52-931d3c0b069c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total fair value of outstanding notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_3ea3d6c3-543d-43b9-bf7c-91315eec04c2_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, price per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_04f3e3fd-cf61-4209-8283-07051a6720c2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_7a9c8751-1395-4512-ab5d-10b9eb0881cc_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average common shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_70f4ec03-2ce0-4ef9-93f3-53b7146e5bf6_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Denominator</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_5975c06d-c20f-4eb3-a5e1-458311ba6013_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_82085f25-e4a7-4a67-b1c7-53526f3f5c87_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitment fee percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ff3a9245-d4bc-4b7a-afc8-fde80ec1e905_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of assumptions used in Black-Scholes model</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_ddd7d436-a3af-49d4-a9ea-6e614a11279d_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_49633d73-cd9f-4e96-9680-f4317555f997_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total carrying amount</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_7fa2f504-3351-48b5-9368-9f70cb31cbf6_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2066f240-5c90-41ac-a248-b6fc660218ff_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_5af94022-e6c5-41cc-9b91-34d11d896b0c_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4da55154-01b0-4355-845f-72d8e38bb5b5_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_2b61e8d0-1515-4830-b1ed-9fe67ff3ac7d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_8b3aa0f3-c9f9-46d2-887e-db849803c974_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_164159fc-89e2-4eaf-8d56-685e1013f7d4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining Weighted-Average Recognition Period (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_a8f8bd3a-7c91-4d4d-a20e-3f068c139b19_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_1324876e-4a3f-4739-ab11-f477801f5251_verboseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_1257b7bf-d910-4dd3-a556-02ff050cdae5_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_7ed1db0b-f758-4229-a417-06012f7db715_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_75a2ad75-88b4-4134-a8c3-4487ac8f122e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_de1854cd-8100-4f3e-b20b-4befced09b65_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable_b1b4b001-3499-4c44-8463-d88c05340487_terseLabel_en-US" xlink:label="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements Valuation Inputs [Table]</link:label>
    <link:label id="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable_label_en-US" xlink:label="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements Valuation Inputs [Table]</link:label>
    <link:label id="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable_documentation_en-US" xlink:label="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements Valuation Inputs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable" xlink:href="halo-20240331.xsd#halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable" xlink:to="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_606f8b4a-b134-40b3-bc99-600bcd0fd380_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_165d6103-4ac5-4a6b-af1e-458d1b8381cd_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock repurchased</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_7d53ddd8-4ce3-4c2d-ba68-90028005b983_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities and Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_b9bcc1e1-8234-49c7-a876-3abe352956ff_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_614c36d6-c54c-44de-8c6f-809e69d4c102_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments, Financial Liabilities, Balance Sheet Groupings [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:to="lab_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5748592b-1207-4fef-9d23-74728a577da7_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d4210498-5f39-4ea0-9dea-2b048666bb5d_verboseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_82c2b1c1-7b9f-421d-bd09-9a6bcd657891_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_5878b485-c8c8-47c3-b0dd-77da1e22fb0a_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7f3dde8a-ee15-4ce0-a096-0bced9fbdbee_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_b7357ad9-3b97-44f2-88de-d6ef71eecab6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum employee subscription rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_f4425e40-3ac8-4fca-a076-ce2d244ef693_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_4101ddf9-1e80-4ebf-b5e5-6ed73f4c43e8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_DebtInstrumentInterestPeriodTwoMember_15e542f0-3a7d-48e6-a952-c2673dd509f2_terseLabel_en-US" xlink:label="lab_halo_DebtInstrumentInterestPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year two</link:label>
    <link:label id="lab_halo_DebtInstrumentInterestPeriodTwoMember_label_en-US" xlink:label="lab_halo_DebtInstrumentInterestPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest, Period two [Member]</link:label>
    <link:label id="lab_halo_DebtInstrumentInterestPeriodTwoMember_documentation_en-US" xlink:label="lab_halo_DebtInstrumentInterestPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest, Period two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentInterestPeriodTwoMember" xlink:href="halo-20240331.xsd#halo_DebtInstrumentInterestPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_DebtInstrumentInterestPeriodTwoMember" xlink:to="lab_halo_DebtInstrumentInterestPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_9df94872-c4fc-497e-918c-2b8b43a18b1f_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_ba90733c-f953-467f-9ac5-d839f6b576b5_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_ca5dbd47-605c-4fed-bf6b-a998b33b3475_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_13ef9691-d332-4a4c-b001-47528cd0190c_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_765f2b9b-4c2b-42d5-8d40-afb4140f8123_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_bd78d2cf-953c-4eee-8365-1e29df41bd62_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_ea3f3485-97ef-4a31-a621-c20fa03acae0_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_EventBasedDevelopmentAndRegulatoryMilestoneAndOtherFeesMember_9856a1e1-f141-4c35-82d9-2ffdf03ae39c_terseLabel_en-US" xlink:label="lab_halo_EventBasedDevelopmentAndRegulatoryMilestoneAndOtherFeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Event-based development and regulatory milestones and other fees</link:label>
    <link:label id="lab_halo_EventBasedDevelopmentAndRegulatoryMilestoneAndOtherFeesMember_label_en-US" xlink:label="lab_halo_EventBasedDevelopmentAndRegulatoryMilestoneAndOtherFeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Event -based Development And Regulatory Milestone And Other Fees [Member]</link:label>
    <link:label id="lab_halo_EventBasedDevelopmentAndRegulatoryMilestoneAndOtherFeesMember_documentation_en-US" xlink:label="lab_halo_EventBasedDevelopmentAndRegulatoryMilestoneAndOtherFeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Event -based Development And Regulatory Milestone And Other Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_EventBasedDevelopmentAndRegulatoryMilestoneAndOtherFeesMember" xlink:href="halo-20240331.xsd#halo_EventBasedDevelopmentAndRegulatoryMilestoneAndOtherFeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_EventBasedDevelopmentAndRegulatoryMilestoneAndOtherFeesMember" xlink:to="lab_halo_EventBasedDevelopmentAndRegulatoryMilestoneAndOtherFeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_6b832927-d576-4152-8afb-bda01f658cbb_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_PaymentForCappedCallTransactions_8dd91036-6ea4-40c8-9d9a-2e9b32c6eaa3_terseLabel_en-US" xlink:label="lab_halo_PaymentForCappedCallTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment for capped calls</link:label>
    <link:label id="lab_halo_PaymentForCappedCallTransactions_label_en-US" xlink:label="lab_halo_PaymentForCappedCallTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment for Capped Call Transactions</link:label>
    <link:label id="lab_halo_PaymentForCappedCallTransactions_documentation_en-US" xlink:label="lab_halo_PaymentForCappedCallTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment for Capped Call Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_PaymentForCappedCallTransactions" xlink:href="halo-20240331.xsd#halo_PaymentForCappedCallTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_PaymentForCappedCallTransactions" xlink:to="lab_halo_PaymentForCappedCallTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_2d93f31a-eb48-478a-b0cb-dab0a7b22765_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_1a9078aa-b852-48fb-96b0-54728d1b802f_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ATRS-1902 (IPR&amp;D)</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_AccountsReceivableAndContractWithCustomerAssetBeforeAllowanceForCreditLossCurrent_6a725bcf-dd16-4ef5-8221-6e4318dfd026_totalLabel_en-US" xlink:label="lab_halo_AccountsReceivableAndContractWithCustomerAssetBeforeAllowanceForCreditLossCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accounts receivable and contract assets</link:label>
    <link:label id="lab_halo_AccountsReceivableAndContractWithCustomerAssetBeforeAllowanceForCreditLossCurrent_label_en-US" xlink:label="lab_halo_AccountsReceivableAndContractWithCustomerAssetBeforeAllowanceForCreditLossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable And Contract With Customer Asset, Before Allowance For Credit Loss, Current</link:label>
    <link:label id="lab_halo_AccountsReceivableAndContractWithCustomerAssetBeforeAllowanceForCreditLossCurrent_documentation_en-US" xlink:label="lab_halo_AccountsReceivableAndContractWithCustomerAssetBeforeAllowanceForCreditLossCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Receivable And Contract With Customer Asset, Before Allowance For Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AccountsReceivableAndContractWithCustomerAssetBeforeAllowanceForCreditLossCurrent" xlink:href="halo-20240331.xsd#halo_AccountsReceivableAndContractWithCustomerAssetBeforeAllowanceForCreditLossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_AccountsReceivableAndContractWithCustomerAssetBeforeAllowanceForCreditLossCurrent" xlink:to="lab_halo_AccountsReceivableAndContractWithCustomerAssetBeforeAllowanceForCreditLossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_A100ConvertibleSeniorNotesDue2028Member_3ec7adce-55f2-4273-a73d-52d076dfb972_terseLabel_en-US" xlink:label="lab_halo_A100ConvertibleSeniorNotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.00% Convertible Senior Notes due 2028</link:label>
    <link:label id="lab_halo_A100ConvertibleSeniorNotesDue2028Member_ba735cb1-78c6-4211-b706-a01e502041e8_verboseLabel_en-US" xlink:label="lab_halo_A100ConvertibleSeniorNotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2028 Convertible Notes</link:label>
    <link:label id="lab_halo_A100ConvertibleSeniorNotesDue2028Member_label_en-US" xlink:label="lab_halo_A100ConvertibleSeniorNotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.00% Convertible Senior Notes due 2028 [Member]</link:label>
    <link:label id="lab_halo_A100ConvertibleSeniorNotesDue2028Member_documentation_en-US" xlink:label="lab_halo_A100ConvertibleSeniorNotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">1.00% Convertible Senior Notes due 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A100ConvertibleSeniorNotesDue2028Member" xlink:href="halo-20240331.xsd#halo_A100ConvertibleSeniorNotesDue2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_A100ConvertibleSeniorNotesDue2028Member" xlink:to="lab_halo_A100ConvertibleSeniorNotesDue2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_JanssenMember_29fef47e-e36a-4b2b-a903-b20345f5e5c6_terseLabel_en-US" xlink:label="lab_halo_JanssenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Janssen</link:label>
    <link:label id="lab_halo_JanssenMember_label_en-US" xlink:label="lab_halo_JanssenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Janssen [Member]</link:label>
    <link:label id="lab_halo_JanssenMember_documentation_en-US" xlink:label="lab_halo_JanssenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Janssen Collaboration [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_JanssenMember" xlink:href="halo-20240331.xsd#halo_JanssenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_JanssenMember" xlink:to="lab_halo_JanssenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_7c3d77c8-fa52-4468-9227-c49f827c33f7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock and performance stock units, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_HelenTorleyPriorPlanMember_label_en-US" xlink:label="lab_halo_HelenTorleyPriorPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Helen Torley Prior Plan [Member]</link:label>
    <link:label id="lab_halo_HelenTorleyPriorPlanMember_documentation_en-US" xlink:label="lab_halo_HelenTorleyPriorPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Helen Torley Prior Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_HelenTorleyPriorPlanMember" xlink:href="halo-20240331.xsd#halo_HelenTorleyPriorPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_HelenTorleyPriorPlanMember" xlink:to="lab_halo_HelenTorleyPriorPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_VariableRateComponentAxis_7753f9e1-3f03-407c-a331-290684bd06c2_terseLabel_en-US" xlink:label="lab_halo_VariableRateComponentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate Component [Axis]</link:label>
    <link:label id="lab_halo_VariableRateComponentAxis_label_en-US" xlink:label="lab_halo_VariableRateComponentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate Component [Axis]</link:label>
    <link:label id="lab_halo_VariableRateComponentAxis_documentation_en-US" xlink:label="lab_halo_VariableRateComponentAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Variable Rate Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentAxis" xlink:href="halo-20240331.xsd#halo_VariableRateComponentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_VariableRateComponentAxis" xlink:to="lab_halo_VariableRateComponentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_a6419a46-3e32-4517-a02d-13ba0f50d827_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Conversion of debt, principal</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_2867f1f7-ca10-4503-b70c-e796cc8e43a4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of accounts receivable</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_d20f8fa7-3652-4d0f-b8b8-e06f9202c988_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_c67ba21f-8f2e-4fe9-9867-92579479201b_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_6c90cb45-e5fe-4b9c-ba55-6a1d56b78b6c_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_213dd0d9-851a-4390-818d-4288523f07f4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issued for conversion of debt instrument (shares)</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_119aa5f1-a262-4c87-9bb4-c83e932aef62_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_RocheMember_dba897e3-c17e-445e-bded-1319c4cb080b_terseLabel_en-US" xlink:label="lab_halo_RocheMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Roche</link:label>
    <link:label id="lab_halo_RocheMember_label_en-US" xlink:label="lab_halo_RocheMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Roche [Member]</link:label>
    <link:label id="lab_halo_RocheMember_documentation_en-US" xlink:label="lab_halo_RocheMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Roche</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RocheMember" xlink:href="halo-20240331.xsd#halo_RocheMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_RocheMember" xlink:to="lab_halo_RocheMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_6fcf3225-2a4c-4507-a8f4-80dde10648a2_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_935aa071-7027-46eb-a716-5b541f09b2e7_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_2e1402b2-4be8-4447-9c5e-022bbab12d27_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_dd0869de-aa5f-4c24-b723-7cdbc624234b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_label_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTextBlock" xlink:to="lab_us-gaap_LongTermDebtTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_HelenTorleyMember_label_en-US" xlink:label="lab_halo_HelenTorleyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Helen Torley [Member]</link:label>
    <link:label id="lab_halo_HelenTorleyMember_documentation_en-US" xlink:label="lab_halo_HelenTorleyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Helen Torley</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_HelenTorleyMember" xlink:href="halo-20240331.xsd#halo_HelenTorleyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_HelenTorleyMember" xlink:to="lab_halo_HelenTorleyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_18bc40ae-0f6f-45d3-b246-2716d9650111_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_42f7cd61-93a7-4d76-9f4d-efe29e99207a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_5077f63a-89ec-4923-b5e5-7b97411b5511_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product sales, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_a60f9465-c869-4b0a-8e6e-2b6821c36149_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Product</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_22550e39-1b44-44e5-8211-001eaef26a99_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_9f5eaa0e-26dd-4ccc-8b51-ea460863d8b1_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_02fdc7a4-dc7a-4e63-9325-5cdadc28a828_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85a6c05b-e322-42e4-bc24-3a5a6c0e0639_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_e779104a-52a0-42d1-89ee-ecfe758ea612_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_OthercollaboratorsMember_b9bd5849-0082-4d16-ac65-e3dd7ec13dd7_terseLabel_en-US" xlink:label="lab_halo_OthercollaboratorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other collaborators</link:label>
    <link:label id="lab_halo_OthercollaboratorsMember_label_en-US" xlink:label="lab_halo_OthercollaboratorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other collaborators [Member]</link:label>
    <link:label id="lab_halo_OthercollaboratorsMember_documentation_en-US" xlink:label="lab_halo_OthercollaboratorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other collaborators [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_OthercollaboratorsMember" xlink:href="halo-20240331.xsd#halo_OthercollaboratorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_OthercollaboratorsMember" xlink:to="lab_halo_OthercollaboratorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_7e986798-c3fc-4d61-8985-f3153c7968eb_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5e2e1679-a8f6-44d6-bdbf-7dbe448e3065_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_10010c8b-4e0e-4221-b7ef-a3f087581d9d_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition and Cost of Sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_015404e4-1187-49d3-afcc-5f88a7238aeb_terseLabel_en-US" xlink:label="lab_halo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_halo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_label_en-US" xlink:label="lab_halo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:label id="lab_halo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_documentation_en-US" xlink:label="lab_halo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:href="halo-20240331.xsd#halo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:to="lab_halo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_30508612-4895-43a9-8a68-d2397df7b860_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Aggregate principal</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_afc830d9-e0f6-4e25-b2ab-85744d8a9ab5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_dfdfa931-8f3a-4958-a409-7636bfbe581d_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_df3a3c6d-03be-4f08-9c21-963463f7bc86_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableGrossCurrent_b1b8e149-7f0c-4053-9fec-1dacfc356b00_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableGrossCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, before Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableGrossCurrent" xlink:to="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_d64cb425-57f8-4563-a754-aea42fbd9301_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_53b0d20a-c4a2-4860-bb3d-ac04d69e9791_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_e304fffa-e050-477f-bf2c-2a8061a2e526_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7cc4c332-e95c-463d-b6b7-bb52cb469cb3_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_DebtInstrumentInterestPeriodOneMember_ed0fce70-8d2b-4ce1-b0ee-1720c3058185_terseLabel_en-US" xlink:label="lab_halo_DebtInstrumentInterestPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year one</link:label>
    <link:label id="lab_halo_DebtInstrumentInterestPeriodOneMember_label_en-US" xlink:label="lab_halo_DebtInstrumentInterestPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest, Period One [Member]</link:label>
    <link:label id="lab_halo_DebtInstrumentInterestPeriodOneMember_documentation_en-US" xlink:label="lab_halo_DebtInstrumentInterestPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest, Period One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentInterestPeriodOneMember" xlink:href="halo-20240331.xsd#halo_DebtInstrumentInterestPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_DebtInstrumentInterestPeriodOneMember" xlink:to="lab_halo_DebtInstrumentInterestPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_4f338f81-64ef-4182-bc58-635d2149840e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_83b65eaf-7bca-48dc-ba23-417ea2233540_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for amounts related to leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_2b53fe0e-538e-4a0e-b9d2-78ceab24b433_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of share-based compensation expense by type</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_ebaf9c94-80ef-4e5b-923f-5c3587f1a57e_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_e64b6800-436c-49fe-b739-004fd2d53fcf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt, convertible, conversion price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_8f52540e-baf0-4e6d-8bdd-64a0d5d56bbd_verboseLabel_en-US" xlink:label="lab_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_b127306e-cfbc-45be-91bc-f4c0f8b87215_totalLabel_en-US" xlink:label="lab_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment and Operating Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:label id="lab_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_documentation_en-US" xlink:label="lab_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment and Operating Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="halo-20240331.xsd#halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_bbe75521-d1b0-482f-bb52-9b57c925f244_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt, convertible, conversion ratio</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_aeb24205-3a05-48e2-a309-eaf84f93942d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_A025ConvertibleSeniorNotesDue2027Member_386ed02b-1829-46f4-be3c-173c9cf92e51_terseLabel_en-US" xlink:label="lab_halo_A025ConvertibleSeniorNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">0.25% Convertible Senior Notes due 2027</link:label>
    <link:label id="lab_halo_A025ConvertibleSeniorNotesDue2027Member_f396b33c-69ac-4127-9a39-64fab464c6af_verboseLabel_en-US" xlink:label="lab_halo_A025ConvertibleSeniorNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2027 Convertible Notes</link:label>
    <link:label id="lab_halo_A025ConvertibleSeniorNotesDue2027Member_label_en-US" xlink:label="lab_halo_A025ConvertibleSeniorNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">0.25% Convertible Senior Notes due 2027 [Member]</link:label>
    <link:label id="lab_halo_A025ConvertibleSeniorNotesDue2027Member_documentation_en-US" xlink:label="lab_halo_A025ConvertibleSeniorNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">0.25% Convertible Senior Notes due 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A025ConvertibleSeniorNotesDue2027Member" xlink:href="halo-20240331.xsd#halo_A025ConvertibleSeniorNotesDue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_A025ConvertibleSeniorNotesDue2027Member" xlink:to="lab_halo_A025ConvertibleSeniorNotesDue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_50caa35c-6090-4aea-b38d-1262ef40e683_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Equity, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_6264e36b-f272-4759-a6d2-f937349f2f5c_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Equity, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_d9e9569e-7767-4181-9cbf-9c0d8d5dc400_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible, threshold percentage of stock price trigger</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_73dfe774-f652-497e-b2ff-f62340619232_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_TakedaMember_25fc743e-d1a4-4f66-9956-81bf99b9a028_terseLabel_en-US" xlink:label="lab_halo_TakedaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Takeda</link:label>
    <link:label id="lab_halo_TakedaMember_label_en-US" xlink:label="lab_halo_TakedaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Takeda [Member]</link:label>
    <link:label id="lab_halo_TakedaMember_documentation_en-US" xlink:label="lab_halo_TakedaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Takeda</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_TakedaMember" xlink:href="halo-20240331.xsd#halo_TakedaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_TakedaMember" xlink:to="lab_halo_TakedaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_db4fed94-8396-46b7-a8da-709661b3b6e4_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_d005a5e0-7927-40e2-a4db-a2d02f99ed7e_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_8ea31732-3fc8-412e-9892-3a29fa935d69_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_a5d1fc3b-5dfb-4934-b52e-c570634608f2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of loss positions</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_a7427967-7b76-4645-9f29-c77312b75c47_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased and Retired During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_0291f430-91cc-4fc8-ad73-e1de7d1599b7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative liability, noncurrent</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_fe5667d0-d759-47ac-b746-fd5c97a549fd_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective income tax rate, percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_9826d94b-a5c1-48a3-a20c-ed47c3edb9f8_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_8ed722c5-d7bf-4d9c-873d-43acea9d6bbc_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_DebtInstrumentInterestPeriodThreeMember_d206c835-9f3f-44d6-9a1d-2b2b35ba8ce6_terseLabel_en-US" xlink:label="lab_halo_DebtInstrumentInterestPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year three</link:label>
    <link:label id="lab_halo_DebtInstrumentInterestPeriodThreeMember_label_en-US" xlink:label="lab_halo_DebtInstrumentInterestPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest, Period Three [Member]</link:label>
    <link:label id="lab_halo_DebtInstrumentInterestPeriodThreeMember_documentation_en-US" xlink:label="lab_halo_DebtInstrumentInterestPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest, Period Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentInterestPeriodThreeMember" xlink:href="halo-20240331.xsd#halo_DebtInstrumentInterestPeriodThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_DebtInstrumentInterestPeriodThreeMember" xlink:to="lab_halo_DebtInstrumentInterestPeriodThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_f4ceaf47-7a43-4cfa-949d-a474a30586ae_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5975c75e-3490-4621-a4c0-e564a040d449_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_92a241e3-73e7-4952-9450-b28f5232e944_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_554b7200-5416-41f9-ade3-45ee9a7d53fb_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive (Loss) Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2214ef0e-1125-4af4-8754-2452669fb907_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_b58c0525-9ae5-49ac-aaf4-d34d911abda6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_6ceaf570-670f-4786-9601-79bd80149a61_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair market value of gross unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent_022c30b9-a6cd-48dc-8bb6-f6016c27b5e7_verboseLabel_en-US" xlink:label="lab_halo_AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net and contract assets</link:label>
    <link:label id="lab_halo_AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent_e4e745b7-fe04-4b2a-b352-9aec51e78b0d_totalLabel_en-US" xlink:label="lab_halo_AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accounts receivable, net and contract assets</link:label>
    <link:label id="lab_halo_AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent_label_en-US" xlink:label="lab_halo_AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable And Contract With Customer Asset, After Allowance For Credit Loss, Current</link:label>
    <link:label id="lab_halo_AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent_documentation_en-US" xlink:label="lab_halo_AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Receivable And Contract With Customer Asset, After Allowance For Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent" xlink:href="halo-20240331.xsd#halo_AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent" xlink:to="lab_halo_AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_2993b059-1e7b-4d1e-a029-2d3754287647_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_0875635b-8960-4dd8-8ae5-bedb7827bcc9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_b0b35d74-0e23-474c-b37a-3619d02861ff_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays_f671d953-d46f-45cb-a883-f891cd3505a3_terseLabel_en-US" xlink:label="lab_halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible, threshold consecutive business days</link:label>
    <link:label id="lab_halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays_label_en-US" xlink:label="lab_halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Business Days</link:label>
    <link:label id="lab_halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays_documentation_en-US" xlink:label="lab_halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Business Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays" xlink:href="halo-20240331.xsd#halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays" xlink:to="lab_halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_9559767b-0b83-4309-86b7-6d208e6a47e6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_AutoInjectorTechnologyPlatformMember_d74d2106-ac2b-4947-976e-a44d4ea71e2d_terseLabel_en-US" xlink:label="lab_halo_AutoInjectorTechnologyPlatformMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auto Injector technology platform</link:label>
    <link:label id="lab_halo_AutoInjectorTechnologyPlatformMember_label_en-US" xlink:label="lab_halo_AutoInjectorTechnologyPlatformMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auto Injector Technology Platform [Member]</link:label>
    <link:label id="lab_halo_AutoInjectorTechnologyPlatformMember_documentation_en-US" xlink:label="lab_halo_AutoInjectorTechnologyPlatformMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Auto Injector Technology Platform</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AutoInjectorTechnologyPlatformMember" xlink:href="halo-20240331.xsd#halo_AutoInjectorTechnologyPlatformMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_AutoInjectorTechnologyPlatformMember" xlink:to="lab_halo_AutoInjectorTechnologyPlatformMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_42d7f5a5-8ff9-414e-a12c-bee9ff12cf27_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_b0fc3e98-c4b5-40bb-8ee8-743136fa16f5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock - $0.001 par value; 300,000 shares authorized; 127,186 and 126,770 shares issued and outstanding as of March&#160;31, 2024 and December&#160;31, 2023, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax_c1cd4b06-bcaf-48ec-a7b2-784920f009e6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_11eb9916-207b-41c4-8146-132840bdcad4_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due after one year but within five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_1fabd2c7-7ed2-41ca-98a9-00fad5658d29_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Excluding Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cff2aade-27d1-4872-a303-97f701e8ef9b_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_541540ee-29c9-4c0a-88bb-c09d315b26e5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use asset amortization</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_2aafaf96-af55-4364-aae7-fa0cef3d0368_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_4915779f-39c5-492b-88df-b169650eb7ea_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_2899a2d5-51ab-40ea-98ec-d6a14b680bd7_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_66091b53-353b-4ef4-a242-d9afcb7cfc29_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_e23d2dcf-5947-4840-b8e0-c2c207432911_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investment and other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_1bf41e96-852d-48bb-9d47-d7620b33546c_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration_3620cb6b-ca99-4cd4-b558-54731f53f689_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:to="lab_us-gaap_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_TermLoanFacilityMember_d7c9b72d-5214-43fa-9cba-a70d7ba656dd_terseLabel_en-US" xlink:label="lab_halo_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term Loan Facility</link:label>
    <link:label id="lab_halo_TermLoanFacilityMember_label_en-US" xlink:label="lab_halo_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loan Facility [Member]</link:label>
    <link:label id="lab_halo_TermLoanFacilityMember_documentation_en-US" xlink:label="lab_halo_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term Loan Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_TermLoanFacilityMember" xlink:href="halo-20240331.xsd#halo_TermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_TermLoanFacilityMember" xlink:to="lab_halo_TermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_6069557d-e244-4e95-bce9-bcb299e5e76e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_30ea2ef2-5756-479e-964e-668964aa96a4_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_1f5ab381-b62e-4e6c-b1d8-2d56398842a6_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital return program, authorized amount (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_b91603f6-11ee-46e7-ae55-df18ada20c78_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_e211199d-fa85-44b9-a5e1-4502788c2ede_terseLabel_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase period (in months)</link:label>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_label_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period</link:label>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_documentation_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:href="halo-20240331.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:to="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_ad99f075-343f-4b43-be44-9a4de349cb11_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_a25d66ef-34d2-4417-bdeb-9729b97be174_terseLabel_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Notes</link:label>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock" xlink:to="lab_us-gaap_DebtPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_9640ca24-5e15-4b47-8a0f-803652511894_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_d72868e0-952f-433a-9a71-7e4445f385d1_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Base Rate</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_AcceleratedShareRepurchaseAgreementMember_ff66e5b0-6d70-405d-9448-98f27a5123e0_terseLabel_en-US" xlink:label="lab_halo_AcceleratedShareRepurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASR</link:label>
    <link:label id="lab_halo_AcceleratedShareRepurchaseAgreementMember_label_en-US" xlink:label="lab_halo_AcceleratedShareRepurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accelerated Share Repurchase Agreement [Member]</link:label>
    <link:label id="lab_halo_AcceleratedShareRepurchaseAgreementMember_documentation_en-US" xlink:label="lab_halo_AcceleratedShareRepurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accelerated Share Repurchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AcceleratedShareRepurchaseAgreementMember" xlink:href="halo-20240331.xsd#halo_AcceleratedShareRepurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_AcceleratedShareRepurchaseAgreementMember" xlink:to="lab_halo_AcceleratedShareRepurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_0c56baba-05a9-4252-9f51-6614281787c1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_ab50e9cc-3d78-4009-955d-cb697b0a93a0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_b5ac46e7-2dd2-4836-8dcc-712e0c96568d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_1752787b-df8a-4b57-95c3-39a7750f336d_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable, net</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0f64a5e7-a8f9-43ac-8b8e-f7132962642c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_7ecdd35d-9647-4c04-acc3-f5ddd1f48cf3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_cf26913c-25ab-433b-9b5f-544ee7d5f8ce_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lenders fee</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fee Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFeeAmount" xlink:to="lab_us-gaap_DebtInstrumentFeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_1029b5c3-ddb2-45f9-9b7f-dcc0558d83d5_verboseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Organization and Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_8c066592-d3ea-4405-9aad-ac794a4d5f93_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_01ccef3b-29f4-4428-98e9-f73a73e7ce68_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_b343f89c-5498-422d-83aa-c27dc3ef5baa_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_baf58921-7a57-4a0c-b175-4f89171ee460_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate, stated percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_42599378-da87-4f61-851f-3d36b7c00088_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_9fffb9d5-46ef-4b5a-a52e-eb4baf6164f8_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_590ac107-4ba7-444b-82ec-547a36282b21_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Equity, beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_49b70205-3f42-41b0-8b68-a907b7d543d1_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Equity, ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_34f09dc5-b683-4748-a126-b511152c6e1b_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fee32da5-8abd-46f3-9f91-6b1ac1ce0733_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7d12f83d-e4d0-446a-a5a5-baa52f794809_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_CollaborativeAgreementsMember_0f101000-d5a5-4aa7-9c3b-54dee1f06912_terseLabel_en-US" xlink:label="lab_halo_CollaborativeAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues under collaborative agreements</link:label>
    <link:label id="lab_halo_CollaborativeAgreementsMember_b2408c9e-ff73-4a43-ae27-e2c78b45029b_verboseLabel_en-US" xlink:label="lab_halo_CollaborativeAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Agreements</link:label>
    <link:label id="lab_halo_CollaborativeAgreementsMember_label_en-US" xlink:label="lab_halo_CollaborativeAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreements [Member]</link:label>
    <link:label id="lab_halo_CollaborativeAgreementsMember_documentation_en-US" xlink:label="lab_halo_CollaborativeAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_CollaborativeAgreementsMember" xlink:href="halo-20240331.xsd#halo_CollaborativeAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_CollaborativeAgreementsMember" xlink:to="lab_halo_CollaborativeAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_126fd1fa-3280-4a76-a437-bfc974a22b2b_negatedLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized previously included in deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b3bed2b0-a1e3-4069-9671-f82ce10231a3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dad0a8f3-9f3c-47b5-9ff4-cc7c038f2355_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_443a8301-fe14-43d0-8d68-3c9a52aaf5e8_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_b90133ca-6817-4277-8fc4-5bbd6b6901d6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2efeacdb-01df-4a40-a95d-317ea08ca212_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_0aeb1e10-3bd4-4d74-86fc-a9b0f6a09896_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3578d77c-c42e-479a-bbff-38078c058a49_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for the conversion of the 2024 Convertible Notes (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_34af9685-9dec-43cd-b594-fd1d1151d75a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_a17b0f91-2425-4f4e-8034-c60a8abbbd75_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_bcc2f893-9c26-47ae-a67a-63427b36a080_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_bb95ba72-60e2-4e77-8aa1-32582a2c6599_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total intangibles, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_d52bbf3c-3570-4dd8-84b5-bdb8adef6d24_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_224ff593-cff1-44c1-a70c-326c2565cd72_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective interest rates</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_976763b1-db01-4e90-a37d-b8c4088c1f6a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_e22d00b7-f8bd-4595-835e-e1177870ce96_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities, available-for-sale</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Excluding Accrued Interest, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_b32aaf52-4187-49ba-aec1-8e55bc05dfd4_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_2eb6c494-5d9c-461f-9f01-f75bdccc6f4d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible, threshold trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_VariableRateComponentOneMember_9af2f455-d479-4789-8532-a0467ccbf4b3_terseLabel_en-US" xlink:label="lab_halo_VariableRateComponentOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate Component One</link:label>
    <link:label id="lab_halo_VariableRateComponentOneMember_label_en-US" xlink:label="lab_halo_VariableRateComponentOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate Component One [Member]</link:label>
    <link:label id="lab_halo_VariableRateComponentOneMember_documentation_en-US" xlink:label="lab_halo_VariableRateComponentOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Variable Rate Component One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentOneMember" xlink:href="halo-20240331.xsd#halo_VariableRateComponentOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_VariableRateComponentOneMember" xlink:to="lab_halo_VariableRateComponentOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_647f3052-baa0-4454-bad9-c9e7ce510d2d_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_01f20989-197d-440b-9813-11a02bc81ba5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramPeriodInForce1_eb986404-3233-4ec4-a584-4537d2fb6e7e_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital return program, purchase period</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramPeriodInForce1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Period in Force</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramPeriodInForce1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:to="lab_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_2ea26554-87a7-47d4-9d1f-4bccb930bd16_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_1daa442a-e2bc-4e02-b377-5f2077fbab98_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_24691f5f-ae9d-4253-a1de-c12f274aaf2a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_1d2b28ef-af90-4fe8-be62-0505833128af_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_80edee1c-8646-4d68-b555-7bd95e3caec1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_9642e2a2-2c0d-4634-8c60-b0f7ce60fa35_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalties</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsNoncurrent_7ae8e44d-2be0-47f7-b093-f2dfb97700dd_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative asset, noncurrent</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsNoncurrent" xlink:to="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_780cb95f-7ece-4ca8-aa58-c663c206cbfa_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_fb8b6b15-4e43-4bba-a9ba-e82018363734_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">ASR, payment to bank</link:label>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_label_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accelerated Share Repurchases, Settlement (Payment) or Receipt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt" xlink:to="lab_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_3db03157-cd43-4b02-a039-8105622361a5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_8464c408-1846-4080-a644-2a3eabb82bcb_verboseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_1880ddb3-05da-47f0-af7f-a724b54bb034_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_038a1325-1467-4aae-b7c9-3483b75f4c99_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_f37a88ce-2f2f-46d5-beba-3abac30078e4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_896dd84a-7751-469a-9eb5-ddd0a853870d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_b12327b4-364a-4fee-842d-fcc0e32bf617_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_c10b114a-c59d-4d85-8336-3c9f4aa0a8ad_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c2055c2b-1ef8-46e8-9eca-8067d859cd86_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Taxes paid related to net share settlement, net of proceeds from issuance of common stock under equity incentive plans</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_8bd50a4a-f3d0-4668-b1d1-a2627107a70c_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for tax withholding for restricted stock units vested, net</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_8547fd04-1c63-45b1-8240-a4c9e217f3d5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_a1fbfd8a-f625-4c34-84cc-2d221b307ebd_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_2c0ca542-1de1-4690-9ab9-913a03158153_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_dca2f1a3-c731-4018-adac-706d88086abc_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_87eea43b-f40d-4a57-b326-b66b21eae893_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of assets measured at fair value on a recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_54c89f76-45a7-48dc-8b2f-010ca95db371_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4ce87f54-5ac5-4b45-b1e8-646728b0d8d4_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_6e75ab2b-6590-4083-a58c-6583c6d70279_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetGrossCurrent_4a348651-ae3d-47bc-afd3-1ecaafc9fb38_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetGrossCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, before Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetGrossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetGrossCurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetGrossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_dcafa1a3-8239-4322-92bc-22625ee5a8e4_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_5c8ea404-99b0-4cc7-bd93-7aecafe4c034_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_b3ff0f7f-f710-4d93-a86a-672d1c491e98_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Amortization of premium on marketable securities, net</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_b049b949-ef13-49cd-98ff-5a3ddaaa45db_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_8fc486c4-1fcd-4b3a-b625-d829740a4709_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Right of use of assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_b91769c8-1926-44e2-9b63-2017acc8fa11_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_8167635c-745d-4603-9803-e887287a2235_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_814364b7-98a8-44ef-be2a-6f31571f2ee0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_a053bbb0-173a-4b03-b272-067660147465_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate_92af6c9e-2723-40f0-901b-546659422e2d_terseLabel_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum employee subscription rate</link:label>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Minimum Employee Subscription Rate</link:label>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate_documentation_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Minimum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" xlink:href="halo-20240331.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" xlink:to="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_1ed1f894-2165-4110-bb90-c65d6e65a435_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssued1_d68cddbf-82af-4d11-a09b-ce0e5e3f5e86_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued for conversion of 2024 Convertible Notes</link:label>
    <link:label id="lab_us-gaap_StockIssued1_label_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_c7a9bd5c-ec45-44cd-8fce-8ebb4c094a30_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_2e5ac392-e610-4c46-b557-43dbf8589dac_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certain Balance Sheet Items</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_0383b48d-4116-4ba1-bb9d-6e0aa20946b5_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_fdb8ae9d-4fe4-4437-977a-7a4202e68744_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Measurement period adjustment</link:label>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_label_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Purchase Accounting Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:to="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_76a59c13-bab4-4068-b20e-c2f8ae40cf91_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_c3946ad2-26c8-47cd-920e-89abbc531411_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b607b29f-b5b0-4dcb-9e1a-77a4067c48c1_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ArgenxMember_651247f6-8e33-444c-8d51-439e7d26c11a_terseLabel_en-US" xlink:label="lab_halo_ArgenxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Argenx</link:label>
    <link:label id="lab_halo_ArgenxMember_label_en-US" xlink:label="lab_halo_ArgenxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Argenx [Member]</link:label>
    <link:label id="lab_halo_ArgenxMember_documentation_en-US" xlink:label="lab_halo_ArgenxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Argenx [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ArgenxMember" xlink:href="halo-20240331.xsd#halo_ArgenxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ArgenxMember" xlink:to="lab_halo_ArgenxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest_f7f5c2a6-73fa-4834-b4e5-79f904ce7e24_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total coupon interest</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_0c5d5f06-1e17-4e71-9f4f-b0abe94035ad_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ec08ec74-ff40-4527-bc07-277e858c22cb_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_e784935b-479d-4135-894c-d0a41713e41f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_295b8daf-a1c2-4c38-a1fe-889e2019863c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_92110d4a-af71-4a24-87f8-1b59b8e37036_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_465ccbca-3244-4a09-880e-57fc21f5c91d_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_75e0de2d-7f02-4ee5-b4c8-762ba4d3795f_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from stock options exercised</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_17f56d24-50f5-488e-9ff1-1b61fb0dbf29_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_02956ce8-8693-497b-9493-864a61631df4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_206c8ce8-76f7-42dd-8b8c-812e8e6fb76c_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_b135b041-7695-4a62-a004-3dc0096fdf38_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_db3b588f-de89-4927-adba-9c8a906f1234_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_830d392f-9109-4ea0-9660-97a8df4ec2df_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total prepaid expenses and other assets, current</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_4b109f85-c862-40d7-abde-ef1b97df4460_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_AccountsReceivableAndContractWithCustomerAssetAllowanceForCreditLossCurrent_73b176a3-3108-4944-a418-c2f51e36be41_negatedLabel_en-US" xlink:label="lab_halo_AccountsReceivableAndContractWithCustomerAssetAllowanceForCreditLossCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Allowance for distribution fees and discounts</link:label>
    <link:label id="lab_halo_AccountsReceivableAndContractWithCustomerAssetAllowanceForCreditLossCurrent_label_en-US" xlink:label="lab_halo_AccountsReceivableAndContractWithCustomerAssetAllowanceForCreditLossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable And Contract With Customer Asset, Allowance for Credit Loss, Current</link:label>
    <link:label id="lab_halo_AccountsReceivableAndContractWithCustomerAssetAllowanceForCreditLossCurrent_documentation_en-US" xlink:label="lab_halo_AccountsReceivableAndContractWithCustomerAssetAllowanceForCreditLossCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Receivable And Contract With Customer Asset, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AccountsReceivableAndContractWithCustomerAssetAllowanceForCreditLossCurrent" xlink:href="halo-20240331.xsd#halo_AccountsReceivableAndContractWithCustomerAssetAllowanceForCreditLossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_AccountsReceivableAndContractWithCustomerAssetAllowanceForCreditLossCurrent" xlink:to="lab_halo_AccountsReceivableAndContractWithCustomerAssetAllowanceForCreditLossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_ba6b3406-52aa-4d60-80cd-72c0285ea2ac_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_ad5d9fec-63ac-44c3-92d6-c6257aaf4d9f_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerRefundLiability_86444cd9-1a21-44d7-8cce-0792c33888d0_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerRefundLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product returns and sales allowance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerRefundLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerRefundLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Refund Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerRefundLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerRefundLiability" xlink:to="lab_us-gaap_ContractWithCustomerRefundLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssets_b648bd68-b2d5-4cec-966f-3a75447c56d1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssets_label_en-US" xlink:label="lab_us-gaap_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssets" xlink:to="lab_us-gaap_OtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_53130ee7-3a2f-436f-92df-41002c257124_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period One</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_5c27b5d5-22ae-4523-8717-78dfd5c85334_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock and performance stock units, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_DeviceLicensingAndDevelopmentMember_078d626c-1050-49e0-b377-83b5813cff4b_terseLabel_en-US" xlink:label="lab_halo_DeviceLicensingAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Device licensing and development revenue</link:label>
    <link:label id="lab_halo_DeviceLicensingAndDevelopmentMember_label_en-US" xlink:label="lab_halo_DeviceLicensingAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Device Licensing and Development [Member]</link:label>
    <link:label id="lab_halo_DeviceLicensingAndDevelopmentMember_documentation_en-US" xlink:label="lab_halo_DeviceLicensingAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Device Licensing and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DeviceLicensingAndDevelopmentMember" xlink:href="halo-20240331.xsd#halo_DeviceLicensingAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_DeviceLicensingAndDevelopmentMember" xlink:to="lab_halo_DeviceLicensingAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_dc0efad6-1bf5-43a9-b9f6-3cf044cf3126_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_2c9fc194-98a7-4a4b-9e0d-fb578a7de645_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dilutive potential common stock outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ProprietaryProductsSalesMember_84feabb6-2a89-43e7-a5e1-d8f6202ff4a1_terseLabel_en-US" xlink:label="lab_halo_ProprietaryProductsSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proprietary product sales</link:label>
    <link:label id="lab_halo_ProprietaryProductsSalesMember_label_en-US" xlink:label="lab_halo_ProprietaryProductsSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proprietary Products Sales [Member]</link:label>
    <link:label id="lab_halo_ProprietaryProductsSalesMember_documentation_en-US" xlink:label="lab_halo_ProprietaryProductsSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proprietary Products Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ProprietaryProductsSalesMember" xlink:href="halo-20240331.xsd#halo_ProprietaryProductsSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ProprietaryProductsSalesMember" xlink:to="lab_halo_ProprietaryProductsSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_d02cea3b-fcc5-4d86-ad60-ae910b3321f7_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_b0099c6f-3e48-4038-8982-43c9ac2fea3e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of unrecognized estimated compensation cost by type</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_f91a49c2-25f9-464c-951a-16c1991eb95e_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_56de128d-9fba-4faa-9c8d-61160886cbe7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_XYOSTEDProprietaryProductMember_7bcdda3d-c679-4da1-81fc-78aa7682f9d2_terseLabel_en-US" xlink:label="lab_halo_XYOSTEDProprietaryProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">XYOSTED proprietary product</link:label>
    <link:label id="lab_halo_XYOSTEDProprietaryProductMember_label_en-US" xlink:label="lab_halo_XYOSTEDProprietaryProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">XYOSTED Proprietary Product [Member]</link:label>
    <link:label id="lab_halo_XYOSTEDProprietaryProductMember_documentation_en-US" xlink:label="lab_halo_XYOSTEDProprietaryProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">XYOSTED Proprietary Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_XYOSTEDProprietaryProductMember" xlink:href="halo-20240331.xsd#halo_XYOSTEDProprietaryProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_XYOSTEDProprietaryProductMember" xlink:to="lab_halo_XYOSTEDProprietaryProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_5ed1eee8-edd8-4923-83c5-d42f993d3aca_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_DebtInstrumentCapCallTransactionCapPricePerShare_9d525856-aac9-456d-81d7-cac9971b194f_terseLabel_en-US" xlink:label="lab_halo_DebtInstrumentCapCallTransactionCapPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cap call transaction, cap price per share (in usd per share)</link:label>
    <link:label id="lab_halo_DebtInstrumentCapCallTransactionCapPricePerShare_label_en-US" xlink:label="lab_halo_DebtInstrumentCapCallTransactionCapPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Cap Call Transaction, Cap Price Per Share</link:label>
    <link:label id="lab_halo_DebtInstrumentCapCallTransactionCapPricePerShare_documentation_en-US" xlink:label="lab_halo_DebtInstrumentCapCallTransactionCapPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Cap Call Transaction, Cap Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentCapCallTransactionCapPricePerShare" xlink:href="halo-20240331.xsd#halo_DebtInstrumentCapCallTransactionCapPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_DebtInstrumentCapCallTransactionCapPricePerShare" xlink:to="lab_halo_DebtInstrumentCapCallTransactionCapPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives_2b0b69a2-7c30-4f16-8fdb-57457f6f812d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Flow Hedges - Currency Risks</link:label>
    <link:label id="lab_us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives_label_en-US" xlink:label="lab_us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Methods of Accounting, Hedging Derivatives [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives" xlink:to="lab_us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_b23e232e-dc8e-4d6f-97c7-c088d579e753_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_RoyaltiesReceivedNumberOfProductsSold_07bb4b7c-3411-43c8-ab26-596db8210e88_terseLabel_en-US" xlink:label="lab_halo_RoyaltiesReceivedNumberOfProductsSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalties received, number of products sold</link:label>
    <link:label id="lab_halo_RoyaltiesReceivedNumberOfProductsSold_label_en-US" xlink:label="lab_halo_RoyaltiesReceivedNumberOfProductsSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalties Received, Number of Products Sold</link:label>
    <link:label id="lab_halo_RoyaltiesReceivedNumberOfProductsSold_documentation_en-US" xlink:label="lab_halo_RoyaltiesReceivedNumberOfProductsSold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalties Received, Number of Products Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RoyaltiesReceivedNumberOfProductsSold" xlink:href="halo-20240331.xsd#halo_RoyaltiesReceivedNumberOfProductsSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_RoyaltiesReceivedNumberOfProductsSold" xlink:to="lab_halo_RoyaltiesReceivedNumberOfProductsSold" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_549c6b34-8326-42ba-824a-c8f3a86f9e91_terseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dilutive potential common stock outstanding</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_68c14a5b-f949-4af5-8e52-41eb3c7f0e4d_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_c36f1dda-783f-4675-a43b-113278dce52b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Carrying Value</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_adb38fe9-56cc-4f84-92c7-ed4d2466f259_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_9007e248-7c98-4935-8110-d8e3e82c7b11_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income tax provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_ae1f89fc-c797-4e0e-a2bf-3bcf68b07733_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_3f06ca65-73b5-45ec-9f74-93f6d78752a8_terseLabel_en-US" xlink:label="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements Valuation Inputs [Line Items]</link:label>
    <link:label id="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_label_en-US" xlink:label="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements Valuation Inputs [Line Items]</link:label>
    <link:label id="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_documentation_en-US" xlink:label="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Line Items] for Schedule of Share-based Compensation Arrangements Valuation Inputs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems" xlink:href="halo-20240331.xsd#halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems" xlink:to="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_RSURSAandPRSUawardsMember_37b2e839-4aef-439c-ad42-461375c4287e_verboseLabel_en-US" xlink:label="lab_halo_RSURSAandPRSUawardsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">RSUs, PSUs and ESPP</link:label>
    <link:label id="lab_halo_RSURSAandPRSUawardsMember_label_en-US" xlink:label="lab_halo_RSURSAandPRSUawardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RSU, RSA, and PRSU awards [Member]</link:label>
    <link:label id="lab_halo_RSURSAandPRSUawardsMember_documentation_en-US" xlink:label="lab_halo_RSURSAandPRSUawardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Stock Unit, Restricted Stock Awards, and Performance Restricted Stock Unit awards [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RSURSAandPRSUawardsMember" xlink:href="halo-20240331.xsd#halo_RSURSAandPRSUawardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_RSURSAandPRSUawardsMember" xlink:to="lab_halo_RSURSAandPRSUawardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_77037b72-0441-44ac-9cd1-eec6890b22f0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_8dd592b0-31df-4f46-862e-ea4f533f231d_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_79e1b127-0353-42dc-8066-d881ae89fc50_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of disaggregation of revenues</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_f61f0e9d-0a5a-42f2-8d18-f0a18b57a6c3_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4dd5c305-c285-469a-9c98-f8e8da8f7c46_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_93da1e42-c50f-431d-877b-f3c352da54a9_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_86dddd9b-c294-430e-8411-7e1113a8e4db_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_c4beb82a-c13e-472b-af95-ec141f641ad3_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_5ddcb847-db00-4ae4-bfe4-0b211b179e25_verboseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_220de84b-3581-45d4-a941-11d3fcbd2b7a_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_d82a6e11-5882-4a53-8f2f-664bc367fe7e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_e57d8b51-05e7-43c6-aac0-d50ca4bea20f_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_a6e7907c-af8e-419d-948a-3899429b050b_verboseLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unit holders awards surrendered to pay for minimum withholding taxes (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_b17c415f-2495-4a1a-83d5-dbfb3d7d2972_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_0e606b62-9ebb-4fc8-9fa0-20709adb8c1b_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_2b8f2cf4-cfc0-4591-bcfa-f0dbe23d6563_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock (shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_581f484f-32d3-43a9-a1b8-c5c211a5a5db_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock repurchased (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_89c7c0c1-5b39-4366-8497-6984227c0a48_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_3360fd73-e0a2-40e4-8773-694a6a319a51_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_d5145869-bc9a-4327-b902-147e3ce76156_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_c64b64f4-7e88-41f0-87c5-49f4e6dfa264_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_170d0a9e-9083-4cb8-8795-58998742a80e_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt, excluding current maturities</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_SaleOfStockPremiumOverLastReportedSalePricePercentage_c6dbf123-e7c6-49c0-b200-cb2bae6dd9e9_terseLabel_en-US" xlink:label="lab_halo_SaleOfStockPremiumOverLastReportedSalePricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock premium over last reported sale price, percentage</link:label>
    <link:label id="lab_halo_SaleOfStockPremiumOverLastReportedSalePricePercentage_label_en-US" xlink:label="lab_halo_SaleOfStockPremiumOverLastReportedSalePricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock Premium Over Last Reported Sale Price, Percentage</link:label>
    <link:label id="lab_halo_SaleOfStockPremiumOverLastReportedSalePricePercentage_documentation_en-US" xlink:label="lab_halo_SaleOfStockPremiumOverLastReportedSalePricePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock Premium Over Last Reported Sale Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_SaleOfStockPremiumOverLastReportedSalePricePercentage" xlink:href="halo-20240331.xsd#halo_SaleOfStockPremiumOverLastReportedSalePricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_SaleOfStockPremiumOverLastReportedSalePricePercentage" xlink:to="lab_halo_SaleOfStockPremiumOverLastReportedSalePricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_AccruedLiabilitiesNoncurrent_c516f960-ace4-4f96-8c5c-110a724fea11_negatedTerseLabel_en-US" xlink:label="lab_halo_AccruedLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less long-term portion</link:label>
    <link:label id="lab_halo_AccruedLiabilitiesNoncurrent_label_en-US" xlink:label="lab_halo_AccruedLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Noncurrent</link:label>
    <link:label id="lab_halo_AccruedLiabilitiesNoncurrent_documentation_en-US" xlink:label="lab_halo_AccruedLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AccruedLiabilitiesNoncurrent" xlink:href="halo-20240331.xsd#halo_AccruedLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_AccruedLiabilitiesNoncurrent" xlink:to="lab_halo_AccruedLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_f937edbe-fc63-49c9-96be-21a81fd029c2_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019d7313-fb21-48ff-9f24-2f5d92ab30c5_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9c7757ef-4c1c-4528-886b-b1c899d19a90_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted average common shares outstanding for diluted earnings per share (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_881cf82b-5fc3-4565-8ed8-c7ca77b662d9_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration_2ca3d9fc-308b-4999-970c-48408a4ec2c2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:to="lab_us-gaap_DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_74b02439-56eb-4dee-8ead-6212f432d7fa_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of accounts receivable, deferred revenues from contracts with customers, and amounts under collaborative agreements included in transaction price</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_01226a5e-7c32-4c84-a3ab-5af9e22acb02_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Realized gain on marketable securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_fa3a933a-f7d3-4780-b5c6-d7cd53f745dd_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4efd737f-9444-46d2-b824-da4baf3b3187_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_3d3e29b8-971f-435d-bb75-7eba6241202b_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_bb87c7e9-fcb1-40e9-bc2f-bfa5667ab6d3_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_18c5905f-24b8-43e8-963f-572d745f5582_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Realized gain on derivative instruments, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_069bf060-1980-4699-99b1-752e52b500e0_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_584c1fef-8954-4a01-b5c9-63b7e64d9d90_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_9769a2e1-a379-43af-b8cf-a6fea196b278_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_A2021ESPPPlanMember_40a78abf-ec54-4256-8a29-5c3c270175c3_terseLabel_en-US" xlink:label="lab_halo_A2021ESPPPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021 ESPP Plan</link:label>
    <link:label id="lab_halo_A2021ESPPPlanMember_label_en-US" xlink:label="lab_halo_A2021ESPPPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2021 ESPP Plan [Member]</link:label>
    <link:label id="lab_halo_A2021ESPPPlanMember_documentation_en-US" xlink:label="lab_halo_A2021ESPPPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2021 ESPP Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A2021ESPPPlanMember" xlink:href="halo-20240331.xsd#halo_A2021ESPPPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_A2021ESPPPlanMember" xlink:to="lab_halo_A2021ESPPPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_VariableRateComponentDomain_c911cbe3-33ff-49c0-9a6d-41491d088ec2_terseLabel_en-US" xlink:label="lab_halo_VariableRateComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate Component [Domain]</link:label>
    <link:label id="lab_halo_VariableRateComponentDomain_label_en-US" xlink:label="lab_halo_VariableRateComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate Component [Domain]</link:label>
    <link:label id="lab_halo_VariableRateComponentDomain_documentation_en-US" xlink:label="lab_halo_VariableRateComponentDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Variable Rate Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentDomain" xlink:href="halo-20240331.xsd#halo_VariableRateComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_VariableRateComponentDomain" xlink:to="lab_halo_VariableRateComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_RestrictStockUnitsPerformanceSharesAndESPPMember_0f51fce9-fe89-46f4-8b45-173960133b5c_terseLabel_en-US" xlink:label="lab_halo_RestrictStockUnitsPerformanceSharesAndESPPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSUs, PSUs and ESPP</link:label>
    <link:label id="lab_halo_RestrictStockUnitsPerformanceSharesAndESPPMember_label_en-US" xlink:label="lab_halo_RestrictStockUnitsPerformanceSharesAndESPPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restrict Stock Units, Performance Shares and ESPP [Member]</link:label>
    <link:label id="lab_halo_RestrictStockUnitsPerformanceSharesAndESPPMember_documentation_en-US" xlink:label="lab_halo_RestrictStockUnitsPerformanceSharesAndESPPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restrict Stock Units, Performance Shares and ESPP</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RestrictStockUnitsPerformanceSharesAndESPPMember" xlink:href="halo-20240331.xsd#halo_RestrictStockUnitsPerformanceSharesAndESPPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_RestrictStockUnitsPerformanceSharesAndESPPMember" xlink:to="lab_halo_RestrictStockUnitsPerformanceSharesAndESPPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_BulkrHuPH20Member_d3eb2287-6f1c-4830-987c-8fe051e306c9_terseLabel_en-US" xlink:label="lab_halo_BulkrHuPH20Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bulk rHuPH20 sales</link:label>
    <link:label id="lab_halo_BulkrHuPH20Member_label_en-US" xlink:label="lab_halo_BulkrHuPH20Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bulk rHuPH20 [Member]</link:label>
    <link:label id="lab_halo_BulkrHuPH20Member_documentation_en-US" xlink:label="lab_halo_BulkrHuPH20Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">bulk rHuPH20 for use in collaboration products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BulkrHuPH20Member" xlink:href="halo-20240331.xsd#halo_BulkrHuPH20Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_BulkrHuPH20Member" xlink:to="lab_halo_BulkrHuPH20Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_c70c7e85-cc96-4cc9-9534-9b49c96ec57c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of 2028 Convertible Notes</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_dc112cac-c35f-4b36-88b3-96d69c1440c0_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_aec449a2-f62a-47bc-beb7-b0c39363d548_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other prepaid expenses</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_f268c44b-b22d-4d9a-8693-ed72ec521b56_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining amortization per period of debt discount (in years):</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Remaining Discount Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_0ca0fcdc-7393-4023-8493-5f77a167e264_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_c8537f72-02c3-43ae-b0c9-f1c08eff3c4e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, remaining performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_AnnualInterestPaymentPeriodDomain_cac53c77-b9dc-4849-ad15-4ee3ef2c4504_terseLabel_en-US" xlink:label="lab_halo_AnnualInterestPaymentPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual Interest Payment Period [Domain]</link:label>
    <link:label id="lab_halo_AnnualInterestPaymentPeriodDomain_label_en-US" xlink:label="lab_halo_AnnualInterestPaymentPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annual Interest Payment Period [Domain]</link:label>
    <link:label id="lab_halo_AnnualInterestPaymentPeriodDomain_documentation_en-US" xlink:label="lab_halo_AnnualInterestPaymentPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Annual Interest Payment Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AnnualInterestPaymentPeriodDomain" xlink:href="halo-20240331.xsd#halo_AnnualInterestPaymentPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_AnnualInterestPaymentPeriodDomain" xlink:to="lab_halo_AnnualInterestPaymentPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_7e8165de-55cc-40b2-96d8-8eb29252145c_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Flow Hedging</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e876f55c-cc48-4e60-8eda-fff248f63667_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e847fd16-2387-4911-8ba7-0942f9db7dd0_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_d38405ea-5e8e-4752-9b65-ab5c1c7a71dc_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_14f9cb2b-78cd-4f21-a32e-6da18f2fc224_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ESPP purchase price of common stock, percent of market price</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_A1.25ConvertibleSeniorNotesdue2024Member_8ef567fc-61f7-456d-9c02-340f2651aa6d_terseLabel_en-US" xlink:label="lab_halo_A1.25ConvertibleSeniorNotesdue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024 Convertible Notes</link:label>
    <link:label id="lab_halo_A1.25ConvertibleSeniorNotesdue2024Member_label_en-US" xlink:label="lab_halo_A1.25ConvertibleSeniorNotesdue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.25% Convertible Senior Notes due 2024 [Member]</link:label>
    <link:label id="lab_halo_A1.25ConvertibleSeniorNotesdue2024Member_documentation_en-US" xlink:label="lab_halo_A1.25ConvertibleSeniorNotesdue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">1.25% Convertible Senior Notes due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A1.25ConvertibleSeniorNotesdue2024Member" xlink:href="halo-20240331.xsd#halo_A1.25ConvertibleSeniorNotesdue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_A1.25ConvertibleSeniorNotesdue2024Member" xlink:to="lab_halo_A1.25ConvertibleSeniorNotesdue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_2167ac06-d8d4-4b7b-aa7a-be3ec30a8b7d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_980254fa-def6-433e-af43-5a34eed48110_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8affabd7-a2bc-4eb2-814b-6fcebe6e4e48_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_304a4528-ed9a-4de4-8d89-cc85ffa94c9c_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average common shares outstanding for basic earnings per share (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_cd23d76d-7b83-44c1-883d-ab2f82bfc453_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_8a36b540-2fa2-4632-b10c-780304a7aea7_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_8c1a3227-1c28-4db5-aad7-b2bee0d1dc18_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period Two</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AgencySecuritiesMember_d3de5814-e7cb-43c6-87b8-7b5015d879d5_terseLabel_en-US" xlink:label="lab_us-gaap_AgencySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agency bonds</link:label>
    <link:label id="lab_us-gaap_AgencySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AgencySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agency Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AgencySecuritiesMember" xlink:to="lab_us-gaap_AgencySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_736076a3-1167-4304-b42c-a9d77270f89d_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_9939d13c-2c8b-4f37-af52-7eb8d23b47a6_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3e5029d8-f300-4734-9196-dda5a6ec5f76_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_406ff6c0-3c3f-43be-a608-6f7b8f8aa82a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_440b402c-68d0-4ba7-b37c-dc99f96df6f8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for the conversion of the 2024 Convertible Notes</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_5339611c-d708-466b-ae3a-ba3a0e44bdae_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_7843450a-5589-4bb7-85c3-c54cb944ff5f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_f7cdd572-8648-4652-b5bd-bccb6c77cd8b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of available-for-sale marketable securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>halo-20240331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:17e6b7b2-f6c0-4a96-9180-046700296928,g:1765a142-e24e-49b0-883b-7a52af9d0516-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.halozyme.com/role/CoverPage" xlink:type="simple" xlink:href="halo-20240331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_510b196d-c118-4a17-a2c9-6b0395e85aff" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_2a37093e-4e30-4951-b12a-11baf0347911" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_510b196d-c118-4a17-a2c9-6b0395e85aff" xlink:to="loc_dei_DocumentType_2a37093e-4e30-4951-b12a-11baf0347911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_c3341843-d8e8-44fe-ab79-babf94af3ac7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_510b196d-c118-4a17-a2c9-6b0395e85aff" xlink:to="loc_dei_DocumentQuarterlyReport_c3341843-d8e8-44fe-ab79-babf94af3ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_d9a6defa-58ad-43be-8743-d668dc60e3d4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_510b196d-c118-4a17-a2c9-6b0395e85aff" xlink:to="loc_dei_DocumentPeriodEndDate_d9a6defa-58ad-43be-8743-d668dc60e3d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_afc17223-7669-4000-b4ae-ed127964f44f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_510b196d-c118-4a17-a2c9-6b0395e85aff" xlink:to="loc_dei_DocumentTransitionReport_afc17223-7669-4000-b4ae-ed127964f44f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_eb7f331a-7cb0-4dd6-982c-11c4094294bb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_510b196d-c118-4a17-a2c9-6b0395e85aff" xlink:to="loc_dei_EntityFileNumber_eb7f331a-7cb0-4dd6-982c-11c4094294bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_d434acc1-360d-48c4-879b-cb63283e93c4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_510b196d-c118-4a17-a2c9-6b0395e85aff" xlink:to="loc_dei_EntityRegistrantName_d434acc1-360d-48c4-879b-cb63283e93c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_61a8b89e-07b0-49de-a951-8461afe432ed" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_510b196d-c118-4a17-a2c9-6b0395e85aff" xlink:to="loc_dei_EntityIncorporationStateCountryCode_61a8b89e-07b0-49de-a951-8461afe432ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_43439929-3524-4c53-acaf-aa838caa7676" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_510b196d-c118-4a17-a2c9-6b0395e85aff" xlink:to="loc_dei_EntityTaxIdentificationNumber_43439929-3524-4c53-acaf-aa838caa7676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_01ac5596-602e-4edb-8ef2-9fc3445764f8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_510b196d-c118-4a17-a2c9-6b0395e85aff" xlink:to="loc_dei_EntityAddressAddressLine1_01ac5596-602e-4edb-8ef2-9fc3445764f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_cc16bdf2-763d-4bb8-bb2f-37bdb3de7656" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_510b196d-c118-4a17-a2c9-6b0395e85aff" xlink:to="loc_dei_EntityAddressCityOrTown_cc16bdf2-763d-4bb8-bb2f-37bdb3de7656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_ff7d0162-849b-401d-bc6a-95d7e41ae387" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_510b196d-c118-4a17-a2c9-6b0395e85aff" xlink:to="loc_dei_EntityAddressStateOrProvince_ff7d0162-849b-401d-bc6a-95d7e41ae387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_6e96436f-1896-44ea-b776-62a6f4ce39a7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_510b196d-c118-4a17-a2c9-6b0395e85aff" xlink:to="loc_dei_EntityAddressPostalZipCode_6e96436f-1896-44ea-b776-62a6f4ce39a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_f593a9a1-986a-4efb-8677-e2fd943694b3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_510b196d-c118-4a17-a2c9-6b0395e85aff" xlink:to="loc_dei_CityAreaCode_f593a9a1-986a-4efb-8677-e2fd943694b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_095a9c64-d2d3-4e1f-9fb7-62b6520a0947" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_510b196d-c118-4a17-a2c9-6b0395e85aff" xlink:to="loc_dei_LocalPhoneNumber_095a9c64-d2d3-4e1f-9fb7-62b6520a0947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_ed49394d-ccdb-47be-a6f8-c480bc1fa4b7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_510b196d-c118-4a17-a2c9-6b0395e85aff" xlink:to="loc_dei_Security12bTitle_ed49394d-ccdb-47be-a6f8-c480bc1fa4b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_d961143b-3194-42a4-82ff-3e44963448ab" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_510b196d-c118-4a17-a2c9-6b0395e85aff" xlink:to="loc_dei_TradingSymbol_d961143b-3194-42a4-82ff-3e44963448ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_e869347e-32b9-423b-a89e-c6007deb19f6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_510b196d-c118-4a17-a2c9-6b0395e85aff" xlink:to="loc_dei_SecurityExchangeName_e869347e-32b9-423b-a89e-c6007deb19f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_d0b4ae07-d273-4ec3-8b6a-1402f1602664" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_510b196d-c118-4a17-a2c9-6b0395e85aff" xlink:to="loc_dei_EntityCurrentReportingStatus_d0b4ae07-d273-4ec3-8b6a-1402f1602664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_c355f4ec-8ef2-4a36-b120-f720ed8a21dc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_510b196d-c118-4a17-a2c9-6b0395e85aff" xlink:to="loc_dei_EntityInteractiveDataCurrent_c355f4ec-8ef2-4a36-b120-f720ed8a21dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_35512240-e23e-48ce-ae92-e6d35cb75785" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_510b196d-c118-4a17-a2c9-6b0395e85aff" xlink:to="loc_dei_EntitySmallBusiness_35512240-e23e-48ce-ae92-e6d35cb75785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_5e92fb96-6742-49b7-aba7-55a25e084194" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_510b196d-c118-4a17-a2c9-6b0395e85aff" xlink:to="loc_dei_EntityEmergingGrowthCompany_5e92fb96-6742-49b7-aba7-55a25e084194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_f3187404-5621-4b5e-8914-bbc499bdfb6e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_510b196d-c118-4a17-a2c9-6b0395e85aff" xlink:to="loc_dei_EntityShellCompany_f3187404-5621-4b5e-8914-bbc499bdfb6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_f566fa7f-c386-4e34-b986-7bb8f816b61d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_510b196d-c118-4a17-a2c9-6b0395e85aff" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_f566fa7f-c386-4e34-b986-7bb8f816b61d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_5f50e0d7-4f68-4e82-9f52-0635861b81b3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_510b196d-c118-4a17-a2c9-6b0395e85aff" xlink:to="loc_dei_EntityCentralIndexKey_5f50e0d7-4f68-4e82-9f52-0635861b81b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_a31858c5-a402-4c7d-b85c-76cf574dcb14" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_510b196d-c118-4a17-a2c9-6b0395e85aff" xlink:to="loc_dei_AmendmentFlag_a31858c5-a402-4c7d-b85c-76cf574dcb14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_1f2cffc3-2b48-4f1b-b5ee-ac577f6c35c2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_510b196d-c118-4a17-a2c9-6b0395e85aff" xlink:to="loc_dei_DocumentFiscalYearFocus_1f2cffc3-2b48-4f1b-b5ee-ac577f6c35c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_64af2104-b40d-4993-918d-9e62cd8a55d4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_510b196d-c118-4a17-a2c9-6b0395e85aff" xlink:to="loc_dei_DocumentFiscalPeriodFocus_64af2104-b40d-4993-918d-9e62cd8a55d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_69c079df-fb5f-44fd-914f-2b7cf7542f4d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_510b196d-c118-4a17-a2c9-6b0395e85aff" xlink:to="loc_dei_CurrentFiscalYearEndDate_69c079df-fb5f-44fd-914f-2b7cf7542f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_756e7526-073e-483c-a89c-0c65be9d20c0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_510b196d-c118-4a17-a2c9-6b0395e85aff" xlink:to="loc_dei_EntityFilerCategory_756e7526-073e-483c-a89c-0c65be9d20c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="halo-20240331.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_dcfabde3-79be-43bc-8912-e32d2432fa42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_a76750c4-9fbc-4b12-9198-73518bdcd3fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_dcfabde3-79be-43bc-8912-e32d2432fa42" xlink:to="loc_us-gaap_AssetsAbstract_a76750c4-9fbc-4b12-9198-73518bdcd3fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_9efb5d08-3a5c-44b1-8190-596a1dcae034" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a76750c4-9fbc-4b12-9198-73518bdcd3fa" xlink:to="loc_us-gaap_AssetsCurrentAbstract_9efb5d08-3a5c-44b1-8190-596a1dcae034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ae28d05d-030a-4b01-ae15-8353434bf9a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9efb5d08-3a5c-44b1-8190-596a1dcae034" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ae28d05d-030a-4b01-ae15-8353434bf9a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_4379de37-6002-49aa-848e-08f629bf132a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9efb5d08-3a5c-44b1-8190-596a1dcae034" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_4379de37-6002-49aa-848e-08f629bf132a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent_74af3ce7-0e1b-4b5f-9b42-b95fe1aee48d" xlink:href="halo-20240331.xsd#halo_AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9efb5d08-3a5c-44b1-8190-596a1dcae034" xlink:to="loc_halo_AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent_74af3ce7-0e1b-4b5f-9b42-b95fe1aee48d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_20e25de8-e280-464a-b9bb-2a4b02212aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9efb5d08-3a5c-44b1-8190-596a1dcae034" xlink:to="loc_us-gaap_InventoryNet_20e25de8-e280-464a-b9bb-2a4b02212aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_695e5c5e-c61e-4a1f-a650-5b44dd41db5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9efb5d08-3a5c-44b1-8190-596a1dcae034" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_695e5c5e-c61e-4a1f-a650-5b44dd41db5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5eb2d718-1df9-45a2-98c6-127b50c836af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9efb5d08-3a5c-44b1-8190-596a1dcae034" xlink:to="loc_us-gaap_AssetsCurrent_5eb2d718-1df9-45a2-98c6-127b50c836af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_054fe7db-1663-4c21-ae7a-f9927c8ab271" xlink:href="halo-20240331.xsd#halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a76750c4-9fbc-4b12-9198-73518bdcd3fa" xlink:to="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_054fe7db-1663-4c21-ae7a-f9927c8ab271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_e7471480-4a95-4838-b85b-c27e689591e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a76750c4-9fbc-4b12-9198-73518bdcd3fa" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_e7471480-4a95-4838-b85b-c27e689591e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_5ca8247d-eea5-4c9f-9855-031f575decb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a76750c4-9fbc-4b12-9198-73518bdcd3fa" xlink:to="loc_us-gaap_Goodwill_5ca8247d-eea5-4c9f-9855-031f575decb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c6f6ccd6-f305-423a-8904-00e090d7c75d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a76750c4-9fbc-4b12-9198-73518bdcd3fa" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c6f6ccd6-f305-423a-8904-00e090d7c75d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_65166c72-41d3-40bd-9dc5-a5a72a022528" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a76750c4-9fbc-4b12-9198-73518bdcd3fa" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_65166c72-41d3-40bd-9dc5-a5a72a022528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_59afc161-56ec-4915-9147-29ccf3358a68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a76750c4-9fbc-4b12-9198-73518bdcd3fa" xlink:to="loc_us-gaap_Assets_59afc161-56ec-4915-9147-29ccf3358a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a41dcb2f-c685-41a8-a61f-276c143d79de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_dcfabde3-79be-43bc-8912-e32d2432fa42" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a41dcb2f-c685-41a8-a61f-276c143d79de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_9d6551bd-ea6d-40a5-b8be-70bd397030d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a41dcb2f-c685-41a8-a61f-276c143d79de" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_9d6551bd-ea6d-40a5-b8be-70bd397030d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_0730819b-1ba9-405d-8342-1aab50cc94c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9d6551bd-ea6d-40a5-b8be-70bd397030d7" xlink:to="loc_us-gaap_AccountsPayableCurrent_0730819b-1ba9-405d-8342-1aab50cc94c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c1ae60cb-4cdc-4d89-825f-ce802046862e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9d6551bd-ea6d-40a5-b8be-70bd397030d7" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c1ae60cb-4cdc-4d89-825f-ce802046862e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3b8176b6-c7c3-4bad-9da0-b3c294d67b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9d6551bd-ea6d-40a5-b8be-70bd397030d7" xlink:to="loc_us-gaap_LiabilitiesCurrent_3b8176b6-c7c3-4bad-9da0-b3c294d67b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_985d1540-5e8e-41d1-8cd9-55b1b92403ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a41dcb2f-c685-41a8-a61f-276c143d79de" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_985d1540-5e8e-41d1-8cd9-55b1b92403ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_a7fd0a55-2d75-44d0-b37f-f44583c1bfd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a41dcb2f-c685-41a8-a61f-276c143d79de" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_a7fd0a55-2d75-44d0-b37f-f44583c1bfd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8562bc55-7903-43c9-ad9f-c89f8da10d37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a41dcb2f-c685-41a8-a61f-276c143d79de" xlink:to="loc_us-gaap_Liabilities_8562bc55-7903-43c9-ad9f-c89f8da10d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_261f7ee8-2fe5-4812-b5a3-4348a441ea24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a41dcb2f-c685-41a8-a61f-276c143d79de" xlink:to="loc_us-gaap_CommitmentsAndContingencies_261f7ee8-2fe5-4812-b5a3-4348a441ea24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_800d2b83-07b3-4ac2-9781-80bc6331f7f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a41dcb2f-c685-41a8-a61f-276c143d79de" xlink:to="loc_us-gaap_StockholdersEquityAbstract_800d2b83-07b3-4ac2-9781-80bc6331f7f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_26e24201-84f1-41a1-95bf-3a7b93bbc8ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_800d2b83-07b3-4ac2-9781-80bc6331f7f9" xlink:to="loc_us-gaap_PreferredStockValue_26e24201-84f1-41a1-95bf-3a7b93bbc8ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_27224051-1889-4af3-ae22-f8c9e8775742" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_800d2b83-07b3-4ac2-9781-80bc6331f7f9" xlink:to="loc_us-gaap_CommonStockValue_27224051-1889-4af3-ae22-f8c9e8775742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_f1682e53-345d-48f7-9483-fdc2a767cbdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_800d2b83-07b3-4ac2-9781-80bc6331f7f9" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_f1682e53-345d-48f7-9483-fdc2a767cbdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0841b02e-e1bb-45b8-b574-1682de0f1527" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_800d2b83-07b3-4ac2-9781-80bc6331f7f9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0841b02e-e1bb-45b8-b574-1682de0f1527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c4e41ad9-1725-4eaa-ad36-426bed80fc88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_800d2b83-07b3-4ac2-9781-80bc6331f7f9" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c4e41ad9-1725-4eaa-ad36-426bed80fc88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3f16a429-cbbe-44ec-8b53-d775254ad3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_800d2b83-07b3-4ac2-9781-80bc6331f7f9" xlink:to="loc_us-gaap_StockholdersEquity_3f16a429-cbbe-44ec-8b53-d775254ad3c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_2febe3f1-9065-4efa-ac4c-754c650fb889" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a41dcb2f-c685-41a8-a61f-276c143d79de" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_2febe3f1-9065-4efa-ac4c-754c650fb889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="halo-20240331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_737a3e61-020a-4304-8167-16f9a42516c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0f5b269d-2ed0-4cf2-8776-83b86f372a78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_737a3e61-020a-4304-8167-16f9a42516c0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0f5b269d-2ed0-4cf2-8776-83b86f372a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2810bce5-4a83-44f2-890c-354cfff17c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_737a3e61-020a-4304-8167-16f9a42516c0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2810bce5-4a83-44f2-890c-354cfff17c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_fd5fb458-f97c-4442-8f1f-11b6c33b85f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_737a3e61-020a-4304-8167-16f9a42516c0" xlink:to="loc_us-gaap_PreferredStockSharesIssued_fd5fb458-f97c-4442-8f1f-11b6c33b85f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_e604395e-455d-4bd1-afe9-2dd25814753e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_737a3e61-020a-4304-8167-16f9a42516c0" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_e604395e-455d-4bd1-afe9-2dd25814753e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_0724c2e3-91ec-4be4-a79d-03a1f507f77f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_737a3e61-020a-4304-8167-16f9a42516c0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_0724c2e3-91ec-4be4-a79d-03a1f507f77f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_90738aae-8c1e-4162-aac1-383c33f9d133" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_737a3e61-020a-4304-8167-16f9a42516c0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_90738aae-8c1e-4162-aac1-383c33f9d133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_fc90051b-40ac-4e2e-899e-a7c76995cc3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_737a3e61-020a-4304-8167-16f9a42516c0" xlink:to="loc_us-gaap_CommonStockSharesIssued_fc90051b-40ac-4e2e-899e-a7c76995cc3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_cc50690c-4f45-4d86-9165-4b948f84ba25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_737a3e61-020a-4304-8167-16f9a42516c0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_cc50690c-4f45-4d86-9165-4b948f84ba25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="simple" xlink:href="halo-20240331.xsd#CondensedConsolidatedStatementsofIncomeUnaudited"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_85676e48-6234-4425-8f51-df81c3feab89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5f71299c-13f0-498c-9555-e66d549a8366" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_85676e48-6234-4425-8f51-df81c3feab89" xlink:to="loc_us-gaap_StatementTable_5f71299c-13f0-498c-9555-e66d549a8366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_609353ac-0d62-4584-9e9f-eeda87b91baf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5f71299c-13f0-498c-9555-e66d549a8366" xlink:to="loc_srt_ProductOrServiceAxis_609353ac-0d62-4584-9e9f-eeda87b91baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_00481f19-1654-4f20-b69f-f908ffa38d10" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_609353ac-0d62-4584-9e9f-eeda87b91baf" xlink:to="loc_srt_ProductsAndServicesDomain_00481f19-1654-4f20-b69f-f908ffa38d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_d5cf6dde-dcc5-45a5-aa41-b6400de292a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_00481f19-1654-4f20-b69f-f908ffa38d10" xlink:to="loc_us-gaap_RoyaltyMember_d5cf6dde-dcc5-45a5-aa41-b6400de292a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_d54c0369-fe47-44fe-80c1-650485de0144" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_00481f19-1654-4f20-b69f-f908ffa38d10" xlink:to="loc_us-gaap_ProductMember_d54c0369-fe47-44fe-80c1-650485de0144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_CollaborativeAgreementsMember_fdf0e258-112d-419f-8208-559c058c4f4d" xlink:href="halo-20240331.xsd#halo_CollaborativeAgreementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_00481f19-1654-4f20-b69f-f908ffa38d10" xlink:to="loc_halo_CollaborativeAgreementsMember_fdf0e258-112d-419f-8208-559c058c4f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b08ae9b3-0715-4c0e-8dc6-8c1d30356998" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5f71299c-13f0-498c-9555-e66d549a8366" xlink:to="loc_us-gaap_StatementLineItems_b08ae9b3-0715-4c0e-8dc6-8c1d30356998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_cad2960f-e8a6-4038-af2d-e73e9068f56f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b08ae9b3-0715-4c0e-8dc6-8c1d30356998" xlink:to="loc_us-gaap_RevenuesAbstract_cad2960f-e8a6-4038-af2d-e73e9068f56f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e2e8b421-2038-4912-8186-9c87a33f9507" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_cad2960f-e8a6-4038-af2d-e73e9068f56f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e2e8b421-2038-4912-8186-9c87a33f9507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_10e1e87f-a46e-4fed-874a-fba87d4953e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b08ae9b3-0715-4c0e-8dc6-8c1d30356998" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_10e1e87f-a46e-4fed-874a-fba87d4953e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_72749ba5-e9e6-4687-8743-92e2644af072" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_10e1e87f-a46e-4fed-874a-fba87d4953e7" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_72749ba5-e9e6-4687-8743-92e2644af072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_187597a4-c0e9-4045-bc6d-6becdef697e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_10e1e87f-a46e-4fed-874a-fba87d4953e7" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_187597a4-c0e9-4045-bc6d-6becdef697e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_2eccb5d6-c3af-45a7-b4e1-62563fc015c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_10e1e87f-a46e-4fed-874a-fba87d4953e7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_2eccb5d6-c3af-45a7-b4e1-62563fc015c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a4b7e0dc-bcda-444d-a319-cf2c18a18bd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_10e1e87f-a46e-4fed-874a-fba87d4953e7" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a4b7e0dc-bcda-444d-a319-cf2c18a18bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_0551a726-31d6-41e3-948b-c434df3e6e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_10e1e87f-a46e-4fed-874a-fba87d4953e7" xlink:to="loc_us-gaap_CostsAndExpenses_0551a726-31d6-41e3-948b-c434df3e6e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_40b2d3de-d6bd-4125-b67f-3fd1d656682d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b08ae9b3-0715-4c0e-8dc6-8c1d30356998" xlink:to="loc_us-gaap_OperatingIncomeLoss_40b2d3de-d6bd-4125-b67f-3fd1d656682d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_36dfbe06-61cb-415a-8cb3-e7ffdc2f906e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b08ae9b3-0715-4c0e-8dc6-8c1d30356998" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_36dfbe06-61cb-415a-8cb3-e7ffdc2f906e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_4b6d7e1c-e9f7-4fc0-8a1b-c0f620607614" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_36dfbe06-61cb-415a-8cb3-e7ffdc2f906e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_4b6d7e1c-e9f7-4fc0-8a1b-c0f620607614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_947c866f-d622-42f5-9a81-17d515af934c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_36dfbe06-61cb-415a-8cb3-e7ffdc2f906e" xlink:to="loc_us-gaap_InterestExpense_947c866f-d622-42f5-9a81-17d515af934c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0c1be247-260f-4e59-8ed5-85f93e82b016" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b08ae9b3-0715-4c0e-8dc6-8c1d30356998" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0c1be247-260f-4e59-8ed5-85f93e82b016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_be3a5464-50c2-4a6f-aa26-e4d2c3bdcf87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b08ae9b3-0715-4c0e-8dc6-8c1d30356998" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_be3a5464-50c2-4a6f-aa26-e4d2c3bdcf87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_558e16a9-9717-474d-9459-5c947559f6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b08ae9b3-0715-4c0e-8dc6-8c1d30356998" xlink:to="loc_us-gaap_NetIncomeLoss_558e16a9-9717-474d-9459-5c947559f6ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c306ac00-39c6-4326-a98c-44a3378ff557" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b08ae9b3-0715-4c0e-8dc6-8c1d30356998" xlink:to="loc_us-gaap_EarningsPerShareAbstract_c306ac00-39c6-4326-a98c-44a3378ff557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_a6773906-86ed-4316-aac7-18ac064368fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c306ac00-39c6-4326-a98c-44a3378ff557" xlink:to="loc_us-gaap_EarningsPerShareBasic_a6773906-86ed-4316-aac7-18ac064368fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_c76d9238-589d-459b-bf68-70054642f1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c306ac00-39c6-4326-a98c-44a3378ff557" xlink:to="loc_us-gaap_EarningsPerShareDiluted_c76d9238-589d-459b-bf68-70054642f1b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_265bb600-113f-4a5f-91a1-9d1cfe627425" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b08ae9b3-0715-4c0e-8dc6-8c1d30356998" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_265bb600-113f-4a5f-91a1-9d1cfe627425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ade74e9e-0202-4eb7-abb0-bb074b046350" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_265bb600-113f-4a5f-91a1-9d1cfe627425" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ade74e9e-0202-4eb7-abb0-bb074b046350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bb3dae29-a5c6-4f77-b963-dd70a7378d46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_265bb600-113f-4a5f-91a1-9d1cfe627425" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bb3dae29-a5c6-4f77-b963-dd70a7378d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="simple" xlink:href="halo-20240331.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7addfc25-d8a1-4c43-84e1-b46adc5e416a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_64f661d0-45a5-46a2-a0a0-db29fed174dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7addfc25-d8a1-4c43-84e1-b46adc5e416a" xlink:to="loc_us-gaap_NetIncomeLoss_64f661d0-45a5-46a2-a0a0-db29fed174dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_27adbc05-81a9-4411-8554-1a008ef94204" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7addfc25-d8a1-4c43-84e1-b46adc5e416a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_27adbc05-81a9-4411-8554-1a008ef94204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_fec5ca96-0ef2-4063-8177-f6c2b8190779" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_27adbc05-81a9-4411-8554-1a008ef94204" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_fec5ca96-0ef2-4063-8177-f6c2b8190779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_85767be7-040d-4e03-b9a4-34a7ae2c70c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_27adbc05-81a9-4411-8554-1a008ef94204" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_85767be7-040d-4e03-b9a4-34a7ae2c70c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_OtherComprehensiveIncomeLossCashFlowHedgeUnrealizedHoldingGainLossBeforeAdjustmentAfterTax_256e541f-fdc3-4131-b97d-66e8fff8fd8d" xlink:href="halo-20240331.xsd#halo_OtherComprehensiveIncomeLossCashFlowHedgeUnrealizedHoldingGainLossBeforeAdjustmentAfterTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_27adbc05-81a9-4411-8554-1a008ef94204" xlink:to="loc_halo_OtherComprehensiveIncomeLossCashFlowHedgeUnrealizedHoldingGainLossBeforeAdjustmentAfterTax_256e541f-fdc3-4131-b97d-66e8fff8fd8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_542e713e-2a0c-462a-a126-6e257712e517" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_27adbc05-81a9-4411-8554-1a008ef94204" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_542e713e-2a0c-462a-a126-6e257712e517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_d41d14b2-5d60-41af-8d3d-1ba8b7680efb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7addfc25-d8a1-4c43-84e1-b46adc5e416a" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_d41d14b2-5d60-41af-8d3d-1ba8b7680efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="halo-20240331.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_a08672a0-7834-4169-ae64-d4d21ebec1c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_12e25477-880f-4eb2-a887-9545717233ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a08672a0-7834-4169-ae64-d4d21ebec1c2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_12e25477-880f-4eb2-a887-9545717233ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f6950c10-c963-460c-809c-eed25204ebbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_12e25477-880f-4eb2-a887-9545717233ab" xlink:to="loc_us-gaap_NetIncomeLoss_f6950c10-c963-460c-809c-eed25204ebbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b66fbf2c-ecb7-4ea6-965c-751516964637" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_12e25477-880f-4eb2-a887-9545717233ab" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b66fbf2c-ecb7-4ea6-965c-751516964637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_6f7a9f5f-8630-4d3d-879a-2d70a7ef4005" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b66fbf2c-ecb7-4ea6-965c-751516964637" xlink:to="loc_us-gaap_ShareBasedCompensation_6f7a9f5f-8630-4d3d-879a-2d70a7ef4005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_650f0cfe-7c7b-4b3d-92ae-b76fa1282088" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b66fbf2c-ecb7-4ea6-965c-751516964637" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_650f0cfe-7c7b-4b3d-92ae-b76fa1282088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_cb296310-6c66-460a-abd5-93f68ae64b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b66fbf2c-ecb7-4ea6-965c-751516964637" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_cb296310-6c66-460a-abd5-93f68ae64b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_d6a164a9-8b7a-4fe9-a32a-5027e9046658" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b66fbf2c-ecb7-4ea6-965c-751516964637" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_d6a164a9-8b7a-4fe9-a32a-5027e9046658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_eb93b1e3-5ec2-4dde-9746-73c39683c7ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b66fbf2c-ecb7-4ea6-965c-751516964637" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_eb93b1e3-5ec2-4dde-9746-73c39683c7ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_dc9879db-5122-45b5-9949-b71b4ec771c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b66fbf2c-ecb7-4ea6-965c-751516964637" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_dc9879db-5122-45b5-9949-b71b4ec771c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DeferredRentPayments_815d9773-ca6e-4a74-b3f9-1410163eaa7d" xlink:href="halo-20240331.xsd#halo_DeferredRentPayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b66fbf2c-ecb7-4ea6-965c-751516964637" xlink:to="loc_halo_DeferredRentPayments_815d9773-ca6e-4a74-b3f9-1410163eaa7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_cd6f49d4-324b-43d4-997e-4c4e56ace3c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b66fbf2c-ecb7-4ea6-965c-751516964637" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_cd6f49d4-324b-43d4-997e-4c4e56ace3c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f82a4790-5eaa-492b-8c73-3d2230918011" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b66fbf2c-ecb7-4ea6-965c-751516964637" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f82a4790-5eaa-492b-8c73-3d2230918011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9399d9f0-5fe7-435d-8f9d-40a2e06e8438" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f82a4790-5eaa-492b-8c73-3d2230918011" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9399d9f0-5fe7-435d-8f9d-40a2e06e8438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_275979e7-65e8-458c-97fb-38749abc8003" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f82a4790-5eaa-492b-8c73-3d2230918011" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_275979e7-65e8-458c-97fb-38749abc8003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_795cc7a5-cd55-4ee4-9d57-df53684c3c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f82a4790-5eaa-492b-8c73-3d2230918011" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_795cc7a5-cd55-4ee4-9d57-df53684c3c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_326ef784-2c8e-4478-8b1f-bd846dbdd969" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f82a4790-5eaa-492b-8c73-3d2230918011" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_326ef784-2c8e-4478-8b1f-bd846dbdd969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a3de96af-7020-4c1a-9986-e4d9e4edb699" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_12e25477-880f-4eb2-a887-9545717233ab" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a3de96af-7020-4c1a-9986-e4d9e4edb699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_29f3ddea-1156-4264-9d5f-6e7c6a243546" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a08672a0-7834-4169-ae64-d4d21ebec1c2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_29f3ddea-1156-4264-9d5f-6e7c6a243546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4e08d02c-664c-4684-aa9e-8828f135ec51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_29f3ddea-1156-4264-9d5f-6e7c6a243546" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4e08d02c-664c-4684-aa9e-8828f135ec51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_003d7491-40f6-4661-9844-d498598faccf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_29f3ddea-1156-4264-9d5f-6e7c6a243546" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_003d7491-40f6-4661-9844-d498598faccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1ff9527c-8179-4cde-a270-bd131c4d789a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_29f3ddea-1156-4264-9d5f-6e7c6a243546" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1ff9527c-8179-4cde-a270-bd131c4d789a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6b0b0273-f4a4-4da7-9813-8c6873c80892" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_29f3ddea-1156-4264-9d5f-6e7c6a243546" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6b0b0273-f4a4-4da7-9813-8c6873c80892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e6cb532c-f315-4275-ab2e-7cbae721526c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a08672a0-7834-4169-ae64-d4d21ebec1c2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e6cb532c-f315-4275-ab2e-7cbae721526c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_85a451ef-bf06-47d7-82a8-6558013a2d67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e6cb532c-f315-4275-ab2e-7cbae721526c" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_85a451ef-bf06-47d7-82a8-6558013a2d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_cdb810a6-7e8e-44e5-8228-580bb6f83ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e6cb532c-f315-4275-ab2e-7cbae721526c" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_cdb810a6-7e8e-44e5-8228-580bb6f83ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_ab4b15de-37d9-4058-83e7-39c73b4f13b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e6cb532c-f315-4275-ab2e-7cbae721526c" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_ab4b15de-37d9-4058-83e7-39c73b4f13b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e55ff9b6-2fb7-4b7a-8e65-852fb097598d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e6cb532c-f315-4275-ab2e-7cbae721526c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e55ff9b6-2fb7-4b7a-8e65-852fb097598d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_be82b935-cf78-4eb3-ae2c-00a67549284b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a08672a0-7834-4169-ae64-d4d21ebec1c2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_be82b935-cf78-4eb3-ae2c-00a67549284b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_be3fc71f-3510-4ce5-9e58-82d34157899c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a08672a0-7834-4169-ae64-d4d21ebec1c2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_be3fc71f-3510-4ce5-9e58-82d34157899c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6992f0d3-fe81-43ea-a66a-3bebac69af74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a08672a0-7834-4169-ae64-d4d21ebec1c2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6992f0d3-fe81-43ea-a66a-3bebac69af74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3e0ed732-5d86-4dc5-9852-694d98aa4633" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a08672a0-7834-4169-ae64-d4d21ebec1c2" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3e0ed732-5d86-4dc5-9852-694d98aa4633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_ac4a97f3-9928-485d-9d94-b7a31a1083d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3e0ed732-5d86-4dc5-9852-694d98aa4633" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_ac4a97f3-9928-485d-9d94-b7a31a1083d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_42cc8edf-a5af-4f8f-aeee-c4af7b82c14e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3e0ed732-5d86-4dc5-9852-694d98aa4633" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_42cc8edf-a5af-4f8f-aeee-c4af7b82c14e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_eceb55a9-c5d1-4e4c-a57f-1a03353fc404" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3e0ed732-5d86-4dc5-9852-694d98aa4633" xlink:to="loc_us-gaap_StockIssued1_eceb55a9-c5d1-4e4c-a57f-1a03353fc404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" xlink:type="simple" xlink:href="halo-20240331.xsd#CondensedConsolidatedStatementsofStockholdersEquityUnaudited"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_3615f956-acf6-44c6-8f24-ce48e869bb39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2fa8c63d-e915-4843-98af-5ec01e55dd4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_3615f956-acf6-44c6-8f24-ce48e869bb39" xlink:to="loc_us-gaap_StatementTable_2fa8c63d-e915-4843-98af-5ec01e55dd4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ec188b13-71d6-4ebe-ba96-f3810f984f20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2fa8c63d-e915-4843-98af-5ec01e55dd4a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ec188b13-71d6-4ebe-ba96-f3810f984f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_944f9113-4963-4bc8-913f-fb0024821397" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ec188b13-71d6-4ebe-ba96-f3810f984f20" xlink:to="loc_us-gaap_EquityComponentDomain_944f9113-4963-4bc8-913f-fb0024821397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_692fde6f-0fd2-47ad-9bec-253d4d050d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_944f9113-4963-4bc8-913f-fb0024821397" xlink:to="loc_us-gaap_CommonStockMember_692fde6f-0fd2-47ad-9bec-253d4d050d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_c10536b6-49a6-4f89-8222-7f8dc57e930a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_944f9113-4963-4bc8-913f-fb0024821397" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_c10536b6-49a6-4f89-8222-7f8dc57e930a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_450cd986-4af6-467e-abba-d91e012d5ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_944f9113-4963-4bc8-913f-fb0024821397" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_450cd986-4af6-467e-abba-d91e012d5ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_a3f742db-c013-43d6-b25c-93b8043fd80e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_944f9113-4963-4bc8-913f-fb0024821397" xlink:to="loc_us-gaap_RetainedEarningsMember_a3f742db-c013-43d6-b25c-93b8043fd80e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b3bf8bae-6077-4e45-8002-ad478693ef93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2fa8c63d-e915-4843-98af-5ec01e55dd4a" xlink:to="loc_us-gaap_StatementLineItems_b3bf8bae-6077-4e45-8002-ad478693ef93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2efc2c4b-0f11-47b2-8f9d-c12586479250" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b3bf8bae-6077-4e45-8002-ad478693ef93" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2efc2c4b-0f11-47b2-8f9d-c12586479250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_20760742-6f78-4f63-b98a-4d02460703ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2efc2c4b-0f11-47b2-8f9d-c12586479250" xlink:to="loc_us-gaap_SharesOutstanding_20760742-6f78-4f63-b98a-4d02460703ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_45bf261b-56f7-481a-9551-5d569bd1211b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2efc2c4b-0f11-47b2-8f9d-c12586479250" xlink:to="loc_us-gaap_StockholdersEquity_45bf261b-56f7-481a-9551-5d569bd1211b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_cd998c59-e93f-49fc-bd56-4022f29f3b0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2efc2c4b-0f11-47b2-8f9d-c12586479250" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_cd998c59-e93f-49fc-bd56-4022f29f3b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0909d592-e990-4ea9-92a4-54832004996a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2efc2c4b-0f11-47b2-8f9d-c12586479250" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0909d592-e990-4ea9-92a4-54832004996a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_efcb581a-d471-430e-ab3b-80c579437d75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2efc2c4b-0f11-47b2-8f9d-c12586479250" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_efcb581a-d471-430e-ab3b-80c579437d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6f6f5cad-ad5b-4b0f-81a7-91b0ffcd6246" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2efc2c4b-0f11-47b2-8f9d-c12586479250" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6f6f5cad-ad5b-4b0f-81a7-91b0ffcd6246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_e556ab3d-e636-4637-84ef-69129a125c10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2efc2c4b-0f11-47b2-8f9d-c12586479250" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_e556ab3d-e636-4637-84ef-69129a125c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_09d9a018-fe96-45f6-9589-eb14bcbd64d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2efc2c4b-0f11-47b2-8f9d-c12586479250" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_09d9a018-fe96-45f6-9589-eb14bcbd64d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_fd13c0a1-e656-4a96-9873-63ed9e08ed80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2efc2c4b-0f11-47b2-8f9d-c12586479250" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_fd13c0a1-e656-4a96-9873-63ed9e08ed80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_91620269-39e1-48b8-8597-ba60d4bb0169" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2efc2c4b-0f11-47b2-8f9d-c12586479250" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_91620269-39e1-48b8-8597-ba60d4bb0169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_685550be-e1fe-4fe9-83f3-35d92daa73d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2efc2c4b-0f11-47b2-8f9d-c12586479250" xlink:to="loc_us-gaap_NetIncomeLoss_685550be-e1fe-4fe9-83f3-35d92daa73d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_76a24e51-1af3-41df-b2a5-07bd61433448" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2efc2c4b-0f11-47b2-8f9d-c12586479250" xlink:to="loc_us-gaap_SharesOutstanding_76a24e51-1af3-41df-b2a5-07bd61433448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_42c5e498-3a01-41e9-9e7f-53732b666792" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2efc2c4b-0f11-47b2-8f9d-c12586479250" xlink:to="loc_us-gaap_StockholdersEquity_42c5e498-3a01-41e9-9e7f-53732b666792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/OrganizationandBusiness" xlink:type="simple" xlink:href="halo-20240331.xsd#OrganizationandBusiness"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/OrganizationandBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_098d26a3-0879-4ba0-95fa-b622fab0cf4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_72859ce9-fd49-45b5-a671-2545a1f76cab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_098d26a3-0879-4ba0-95fa-b622fab0cf4d" xlink:to="loc_us-gaap_NatureOfOperations_72859ce9-fd49-45b5-a671-2545a1f76cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="halo-20240331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_41597d12-03eb-4d1d-8869-6f6194624d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_a5f0066e-83d1-467f-871e-8797b45732f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_41597d12-03eb-4d1d-8869-6f6194624d5f" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_a5f0066e-83d1-467f-871e-8797b45732f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/FairValueMeasurement" xlink:type="simple" xlink:href="halo-20240331.xsd#FairValueMeasurement"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/FairValueMeasurement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c58fae32-3120-4337-b848-a8a8463e9199" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_2612f421-5914-4683-9dc6-ae872d20381d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c58fae32-3120-4337-b848-a8a8463e9199" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_2612f421-5914-4683-9dc6-ae872d20381d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/Revenue" xlink:type="simple" xlink:href="halo-20240331.xsd#Revenue"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/Revenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4c2fe088-d296-4fd8-a871-ea56353860f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_6e3a348a-678c-4e6d-a117-71bbe24bd89c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4c2fe088-d296-4fd8-a871-ea56353860f7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_6e3a348a-678c-4e6d-a117-71bbe24bd89c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItems" xlink:type="simple" xlink:href="halo-20240331.xsd#CertainBalanceSheetItems"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItems" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_517043ef-63d4-48b0-a941-deea8e11b8cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_1b1b76d9-c125-413d-8c96-d7ede184083b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_517043ef-63d4-48b0-a941-deea8e11b8cb" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_1b1b76d9-c125-413d-8c96-d7ede184083b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="halo-20240331.xsd#GoodwillandIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/GoodwillandIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0819c886-43d8-47a6-999e-e9c18d4c206f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_d36a3b2f-7b19-447d-b252-71ab3f575810" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0819c886-43d8-47a6-999e-e9c18d4c206f" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_d36a3b2f-7b19-447d-b252-71ab3f575810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/LongTermDebtNet" xlink:type="simple" xlink:href="halo-20240331.xsd#LongTermDebtNet"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/LongTermDebtNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a7aedbf9-5b59-4834-944c-dd6f0fcf3e58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock_2291c0c2-4667-4fb3-9402-a1a9b4189e58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a7aedbf9-5b59-4834-944c-dd6f0fcf3e58" xlink:to="loc_us-gaap_LongTermDebtTextBlock_2291c0c2-4667-4fb3-9402-a1a9b4189e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SharebasedCompensation" xlink:type="simple" xlink:href="halo-20240331.xsd#SharebasedCompensation"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SharebasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_a898262b-cf26-4cbc-ab40-c29c4817b01e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ac6ad2ee-5110-4f8d-87c2-44ac9a49d286" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_a898262b-cf26-4cbc-ab40-c29c4817b01e" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ac6ad2ee-5110-4f8d-87c2-44ac9a49d286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/StockholdersEquity" xlink:type="simple" xlink:href="halo-20240331.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_b9eb02f4-8e2c-401a-a2f3-0444c2d000a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_381b814b-9f9e-4d71-bc3a-a820042ec94e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b9eb02f4-8e2c-401a-a2f3-0444c2d000a3" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_381b814b-9f9e-4d71-bc3a-a820042ec94e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/Earningspershare" xlink:type="simple" xlink:href="halo-20240331.xsd#Earningspershare"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/Earningspershare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_aefe3992-cf8f-4f14-8080-9db3e2d1e058" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_ab6bdad3-730a-4a9e-b32e-45c56561f962" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_aefe3992-cf8f-4f14-8080-9db3e2d1e058" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_ab6bdad3-730a-4a9e-b32e-45c56561f962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="halo-20240331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_52a06f9e-7095-40e3-bb96-d4e7cdce7e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0e49a9b7-9587-425b-8b49-94eaa32db12e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_52a06f9e-7095-40e3-bb96-d4e7cdce7e5c" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0e49a9b7-9587-425b-8b49-94eaa32db12e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="halo-20240331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7af659f6-cb96-42ba-bb3f-a38f18e83cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_3eba9e2a-1812-48f3-8988-ba6ba71be877" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7af659f6-cb96-42ba-bb3f-a38f18e83cc1" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_3eba9e2a-1812-48f3-8988-ba6ba71be877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_cb4e91e0-08f4-40ac-86df-e01a5d15d8af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7af659f6-cb96-42ba-bb3f-a38f18e83cc1" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_cb4e91e0-08f4-40ac-86df-e01a5d15d8af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_8c286fde-6f37-40d9-9954-1d6ef0d63f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7af659f6-cb96-42ba-bb3f-a38f18e83cc1" xlink:to="loc_us-gaap_UseOfEstimates_8c286fde-6f37-40d9-9954-1d6ef0d63f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_fdd84890-a913-4809-a122-d7f0c97cefc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7af659f6-cb96-42ba-bb3f-a38f18e83cc1" xlink:to="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_fdd84890-a913-4809-a122-d7f0c97cefc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_eac8ecb5-2e8d-4daa-84ef-4e125df51101" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7af659f6-cb96-42ba-bb3f-a38f18e83cc1" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_eac8ecb5-2e8d-4daa-84ef-4e125df51101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_e5970dd2-598e-4d3c-8853-c872b5d3e5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7af659f6-cb96-42ba-bb3f-a38f18e83cc1" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_e5970dd2-598e-4d3c-8853-c872b5d3e5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_8b1da6d3-9193-4a94-8fe6-2000ec2be70b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7af659f6-cb96-42ba-bb3f-a38f18e83cc1" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_8b1da6d3-9193-4a94-8fe6-2000ec2be70b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_047d0a8f-aed4-4aea-b4f1-423189e83350" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7af659f6-cb96-42ba-bb3f-a38f18e83cc1" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_047d0a8f-aed4-4aea-b4f1-423189e83350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_d80f4238-15d6-4aa8-9be4-feff0a9185d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7af659f6-cb96-42ba-bb3f-a38f18e83cc1" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_d80f4238-15d6-4aa8-9be4-feff0a9185d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_15d9c1bc-d743-456b-a526-96cd8b4b8b1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7af659f6-cb96-42ba-bb3f-a38f18e83cc1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_15d9c1bc-d743-456b-a526-96cd8b4b8b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentImpairment_1f5c61a6-c418-4fe7-b637-e11e02ee3163" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentImpairment"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7af659f6-cb96-42ba-bb3f-a38f18e83cc1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentImpairment_1f5c61a6-c418-4fe7-b637-e11e02ee3163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_852a13db-4400-4dcf-be3b-8aa206583d17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7af659f6-cb96-42ba-bb3f-a38f18e83cc1" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_852a13db-4400-4dcf-be3b-8aa206583d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock_44124583-bf45-4f18-84d3-df82c65a48d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7af659f6-cb96-42ba-bb3f-a38f18e83cc1" xlink:to="loc_us-gaap_DebtPolicyTextBlock_44124583-bf45-4f18-84d3-df82c65a48d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives_4254e4f0-1a77-4a9a-b072-50dc0bbdf11c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7af659f6-cb96-42ba-bb3f-a38f18e83cc1" xlink:to="loc_us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives_4254e4f0-1a77-4a9a-b072-50dc0bbdf11c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_4abfc072-f8ad-486b-b39c-0de7e4a7db54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7af659f6-cb96-42ba-bb3f-a38f18e83cc1" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_4abfc072-f8ad-486b-b39c-0de7e4a7db54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_bd7673ca-ab8a-4e65-a72e-bd45fff3cb58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7af659f6-cb96-42ba-bb3f-a38f18e83cc1" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_bd7673ca-ab8a-4e65-a72e-bd45fff3cb58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_7ce007eb-d23e-43c5-ae8f-8e04471a73bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7af659f6-cb96-42ba-bb3f-a38f18e83cc1" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_7ce007eb-d23e-43c5-ae8f-8e04471a73bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_0ef1f7a1-b415-41e1-baba-7412aceb8c01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7af659f6-cb96-42ba-bb3f-a38f18e83cc1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_0ef1f7a1-b415-41e1-baba-7412aceb8c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_d69e1586-196c-4697-970e-7df85eac9a19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7af659f6-cb96-42ba-bb3f-a38f18e83cc1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_d69e1586-196c-4697-970e-7df85eac9a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_41719692-8117-4498-a83e-c6cbcc72d10f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7af659f6-cb96-42ba-bb3f-a38f18e83cc1" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_41719692-8117-4498-a83e-c6cbcc72d10f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_d8165007-675f-4a9a-a3b9-cae9da462a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7af659f6-cb96-42ba-bb3f-a38f18e83cc1" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_d8165007-675f-4a9a-a3b9-cae9da462a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_60acd8d6-b38e-4ec5-9cbb-ebcce68b86d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7af659f6-cb96-42ba-bb3f-a38f18e83cc1" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_60acd8d6-b38e-4ec5-9cbb-ebcce68b86d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_20e37016-a03b-409b-a4e0-bf035ebb5150" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7af659f6-cb96-42ba-bb3f-a38f18e83cc1" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_20e37016-a03b-409b-a4e0-bf035ebb5150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/FairValueMeasurementTables" xlink:type="simple" xlink:href="halo-20240331.xsd#FairValueMeasurementTables"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/FairValueMeasurementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3b786aa8-32b5-4300-bdc5-76a04ac23087" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_07754620-1f2c-45b4-be37-67e7258ecb28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3b786aa8-32b5-4300-bdc5-76a04ac23087" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_07754620-1f2c-45b4-be37-67e7258ecb28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_86d17145-a86e-4337-9c5e-0d14fc491d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3b786aa8-32b5-4300-bdc5-76a04ac23087" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_86d17145-a86e-4337-9c5e-0d14fc491d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_a7919780-fd92-4660-89d9-5f1d65100c98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3b786aa8-32b5-4300-bdc5-76a04ac23087" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_a7919780-fd92-4660-89d9-5f1d65100c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/RevenueTables" xlink:type="simple" xlink:href="halo-20240331.xsd#RevenueTables"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/RevenueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7761a4dd-85a9-46f5-ad8a-f8e67c2babf9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_cd76c0f1-d88c-47a6-ba1a-1cf98567f103" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7761a4dd-85a9-46f5-ad8a-f8e67c2babf9" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_cd76c0f1-d88c-47a6-ba1a-1cf98567f103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_3c06fd6b-83b6-4281-ad97-7ee00493e684" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7761a4dd-85a9-46f5-ad8a-f8e67c2babf9" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_3c06fd6b-83b6-4281-ad97-7ee00493e684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsTables" xlink:type="simple" xlink:href="halo-20240331.xsd#CertainBalanceSheetItemsTables"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_ac447053-20fd-48d7-be2b-8f5165369d96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_b6dd88fc-e670-479b-ac4f-5ac316c06424" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_ac447053-20fd-48d7-be2b-8f5165369d96" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_b6dd88fc-e670-479b-ac4f-5ac316c06424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_0c443d29-0fdc-42ba-a022-e37b302c7da3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_ac447053-20fd-48d7-be2b-8f5165369d96" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_0c443d29-0fdc-42ba-a022-e37b302c7da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock_e3661172-7d79-460b-abc6-cfa5edbf3761" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_ac447053-20fd-48d7-be2b-8f5165369d96" xlink:to="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock_e3661172-7d79-460b-abc6-cfa5edbf3761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1fc11a03-73fb-4156-b1f1-47f0c015980b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_ac447053-20fd-48d7-be2b-8f5165369d96" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1fc11a03-73fb-4156-b1f1-47f0c015980b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_3a54fc6e-d572-4c1d-9010-7b87ddbd6da1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_ac447053-20fd-48d7-be2b-8f5165369d96" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_3a54fc6e-d572-4c1d-9010-7b87ddbd6da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="halo-20240331.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ebbd4eaa-b0f4-4972-b85b-bce2feab62fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_b03e258e-25c6-43ed-b8c2-bce14d8f2ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ebbd4eaa-b0f4-4972-b85b-bce2feab62fd" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_b03e258e-25c6-43ed-b8c2-bce14d8f2ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_a88b4ccc-6c32-42d5-b874-8181cf455d49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ebbd4eaa-b0f4-4972-b85b-bce2feab62fd" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_a88b4ccc-6c32-42d5-b874-8181cf455d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_4ff00980-1866-4889-b558-ad6b502d0eab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ebbd4eaa-b0f4-4972-b85b-bce2feab62fd" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_4ff00980-1866-4889-b558-ad6b502d0eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/LongTermDebtNetTables" xlink:type="simple" xlink:href="halo-20240331.xsd#LongTermDebtNetTables"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/LongTermDebtNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_07e01333-68d5-4736-8dac-feedba6c6bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_8c7dc0ed-b073-4c79-8cb4-1ed1139675e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_07e01333-68d5-4736-8dac-feedba6c6bd5" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_8c7dc0ed-b073-4c79-8cb4-1ed1139675e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_e0749109-7348-42b1-ba74-0c2987f2bd14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_07e01333-68d5-4736-8dac-feedba6c6bd5" xlink:to="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_e0749109-7348-42b1-ba74-0c2987f2bd14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SharebasedCompensationTables" xlink:type="simple" xlink:href="halo-20240331.xsd#SharebasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SharebasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_c1d4d5f5-39f5-4455-864e-5428a7701e11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_970640e0-9220-476f-be59-4a1f4348ecb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_c1d4d5f5-39f5-4455-864e-5428a7701e11" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_970640e0-9220-476f-be59-4a1f4348ecb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_28d80136-dd65-45ea-a617-bd58245bb946" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_c1d4d5f5-39f5-4455-864e-5428a7701e11" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_28d80136-dd65-45ea-a617-bd58245bb946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4d636dc0-8dd7-40d5-bfbf-a4716250ca3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_c1d4d5f5-39f5-4455-864e-5428a7701e11" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4d636dc0-8dd7-40d5-bfbf-a4716250ca3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_37a16921-2817-4df3-b52f-03f49fbcfe66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_c1d4d5f5-39f5-4455-864e-5428a7701e11" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_37a16921-2817-4df3-b52f-03f49fbcfe66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/EarningspershareTables" xlink:type="simple" xlink:href="halo-20240331.xsd#EarningspershareTables"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/EarningspershareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0a5cb5d1-a83b-4fa0-9d85-2aeffc65254c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_ba70838f-05a3-46fd-90e6-86258b00ddc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0a5cb5d1-a83b-4fa0-9d85-2aeffc65254c" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_ba70838f-05a3-46fd-90e6-86258b00ddc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_95ac79b3-2fb4-4557-a856-a54633c530b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0a5cb5d1-a83b-4fa0-9d85-2aeffc65254c" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_95ac79b3-2fb4-4557-a856-a54633c530b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/OrganizationandBusinessDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#OrganizationandBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/OrganizationandBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7296e090-0299-4c7f-9977-89b1a3255efe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9e1f248d-d8a6-4c2d-82a8-bb0923c29acc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7296e090-0299-4c7f-9977-89b1a3255efe" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9e1f248d-d8a6-4c2d-82a8-bb0923c29acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_74e2e288-7093-4274-a1c2-154a70d10e9c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9e1f248d-d8a6-4c2d-82a8-bb0923c29acc" xlink:to="loc_srt_CounterpartyNameAxis_74e2e288-7093-4274-a1c2-154a70d10e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_58098f10-5c67-43a7-aca5-68a4e2e000c9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_74e2e288-7093-4274-a1c2-154a70d10e9c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_58098f10-5c67-43a7-aca5-68a4e2e000c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_TakedaMember_b586679c-2861-4d58-99d6-cda264c314eb" xlink:href="halo-20240331.xsd#halo_TakedaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_58098f10-5c67-43a7-aca5-68a4e2e000c9" xlink:to="loc_halo_TakedaMember_b586679c-2861-4d58-99d6-cda264c314eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_JanssenMember_77c40d70-2cf7-4c24-ab3d-746c94e4e70c" xlink:href="halo-20240331.xsd#halo_JanssenMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_58098f10-5c67-43a7-aca5-68a4e2e000c9" xlink:to="loc_halo_JanssenMember_77c40d70-2cf7-4c24-ab3d-746c94e4e70c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ArgenxMember_ba08fc39-4693-43b9-b46a-a1bf1469ec43" xlink:href="halo-20240331.xsd#halo_ArgenxMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_58098f10-5c67-43a7-aca5-68a4e2e000c9" xlink:to="loc_halo_ArgenxMember_ba08fc39-4693-43b9-b46a-a1bf1469ec43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RocheMember_a007a761-55cf-48b4-9b56-59e1d8b1eea5" xlink:href="halo-20240331.xsd#halo_RocheMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_58098f10-5c67-43a7-aca5-68a4e2e000c9" xlink:to="loc_halo_RocheMember_a007a761-55cf-48b4-9b56-59e1d8b1eea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9d498a6-b13f-4b1e-96a0-c5ac39a40c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9e1f248d-d8a6-4c2d-82a8-bb0923c29acc" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9d498a6-b13f-4b1e-96a0-c5ac39a40c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RoyaltiesReceivedNumberOfProductsSold_3a628a9e-cb20-4294-aa7d-2ab1419b870e" xlink:href="halo-20240331.xsd#halo_RoyaltiesReceivedNumberOfProductsSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9d498a6-b13f-4b1e-96a0-c5ac39a40c6b" xlink:to="loc_halo_RoyaltiesReceivedNumberOfProductsSold_3a628a9e-cb20-4294-aa7d-2ab1419b870e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivablenetDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#SummaryofSignificantAccountingPoliciesAccountsReceivablenetDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivablenetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_fb12c162-04f0-49fe-b357-4c9c17a9b0b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_196ecf14-e9fb-47d8-aaa3-665d8d4bbc13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fb12c162-04f0-49fe-b357-4c9c17a9b0b8" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_196ecf14-e9fb-47d8-aaa3-665d8d4bbc13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#SummaryofSignificantAccountingPoliciesLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_cfdcb928-789d-460e-a994-99e124e64bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_11bdf2bb-f644-47ce-ab9b-5c7bd4b5cb85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cfdcb928-789d-460e-a994-99e124e64bcd" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_11bdf2bb-f644-47ce-ab9b-5c7bd4b5cb85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_63ad638a-d8f2-42c7-a874-31efa54edd6d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_11bdf2bb-f644-47ce-ab9b-5c7bd4b5cb85" xlink:to="loc_srt_RangeAxis_63ad638a-d8f2-42c7-a874-31efa54edd6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_509a0953-054c-428f-a303-dc492040d70e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_63ad638a-d8f2-42c7-a874-31efa54edd6d" xlink:to="loc_srt_RangeMember_509a0953-054c-428f-a303-dc492040d70e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_64a621d2-5219-4c64-8699-4b760c7c4f00" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_509a0953-054c-428f-a303-dc492040d70e" xlink:to="loc_srt_MinimumMember_64a621d2-5219-4c64-8699-4b760c7c4f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_326d6b3e-2713-447c-9cff-c945bc5d7b8b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_509a0953-054c-428f-a303-dc492040d70e" xlink:to="loc_srt_MaximumMember_326d6b3e-2713-447c-9cff-c945bc5d7b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_61b6f2e7-f7ee-43fc-8e3a-8fc248e9ec41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_11bdf2bb-f644-47ce-ab9b-5c7bd4b5cb85" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_61b6f2e7-f7ee-43fc-8e3a-8fc248e9ec41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_2e9198c0-ff72-4044-b66b-864ce09ace9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_61b6f2e7-f7ee-43fc-8e3a-8fc248e9ec41" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_2e9198c0-ff72-4044-b66b-864ce09ace9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentnetDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#SummaryofSignificantAccountingPoliciesPropertyandEquipmentnetDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentnetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ffc4369d-bf42-4043-a4a1-ace1c5035787" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8951f826-37c9-40c7-9ed2-c929a0894596" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ffc4369d-bf42-4043-a4a1-ace1c5035787" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8951f826-37c9-40c7-9ed2-c929a0894596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_efb4e5b6-c0b2-4a25-b74b-1b0ddfc1b870" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8951f826-37c9-40c7-9ed2-c929a0894596" xlink:to="loc_srt_RangeAxis_efb4e5b6-c0b2-4a25-b74b-1b0ddfc1b870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_849c4802-a107-4868-84a4-4473f1c8b8a1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_efb4e5b6-c0b2-4a25-b74b-1b0ddfc1b870" xlink:to="loc_srt_RangeMember_849c4802-a107-4868-84a4-4473f1c8b8a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_de9e92ef-b88e-4d27-931c-456b010f769d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_849c4802-a107-4868-84a4-4473f1c8b8a1" xlink:to="loc_srt_MinimumMember_de9e92ef-b88e-4d27-931c-456b010f769d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_236d43b9-82d9-4ded-bb4d-b1de08591c85" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_849c4802-a107-4868-84a4-4473f1c8b8a1" xlink:to="loc_srt_MaximumMember_236d43b9-82d9-4ded-bb4d-b1de08591c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_29e82a51-d84a-44c7-af88-b488187ec056" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8951f826-37c9-40c7-9ed2-c929a0894596" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_29e82a51-d84a-44c7-af88-b488187ec056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_9d648be8-a9e9-484a-afe7-5cce03160fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_29e82a51-d84a-44c7-af88-b488187ec056" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_9d648be8-a9e9-484a-afe7-5cce03160fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesCashFlowHedgesCurrencyRisksDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#SummaryofSignificantAccountingPoliciesCashFlowHedgesCurrencyRisksDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesCashFlowHedgesCurrencyRisksDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ed0084cd-4340-4366-bbcd-b011de7c6b66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_ef958998-f048-4925-97cc-07bf2aeee2c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ed0084cd-4340-4366-bbcd-b011de7c6b66" xlink:to="loc_us-gaap_DerivativeTermOfContract_ef958998-f048-4925-97cc-07bf2aeee2c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_95ad931d-99a1-4fb2-9f85-bdeeef80cc6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ed0084cd-4340-4366-bbcd-b011de7c6b66" xlink:to="loc_us-gaap_DerivativeTable_95ad931d-99a1-4fb2-9f85-bdeeef80cc6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7d048014-3564-4de5-87b5-4ce9d9a7371e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_95ad931d-99a1-4fb2-9f85-bdeeef80cc6e" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7d048014-3564-4de5-87b5-4ce9d9a7371e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_25cd261a-7cc0-44c7-8d3e-015be069ea89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7d048014-3564-4de5-87b5-4ce9d9a7371e" xlink:to="loc_us-gaap_HedgingRelationshipDomain_25cd261a-7cc0-44c7-8d3e-015be069ea89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_da65852f-871b-4930-8aa4-2a80dce0c17a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_25cd261a-7cc0-44c7-8d3e-015be069ea89" xlink:to="loc_us-gaap_CashFlowHedgingMember_da65852f-871b-4930-8aa4-2a80dce0c17a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_529ba929-28ee-48c0-8fc0-f477a523c44e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_95ad931d-99a1-4fb2-9f85-bdeeef80cc6e" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_529ba929-28ee-48c0-8fc0-f477a523c44e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_ef6bb067-8e50-4cd5-a6f4-831abf352881" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_529ba929-28ee-48c0-8fc0-f477a523c44e" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_ef6bb067-8e50-4cd5-a6f4-831abf352881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_293fe1bc-ff7b-41c9-a771-0a9b2fdab0cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_ef6bb067-8e50-4cd5-a6f4-831abf352881" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_293fe1bc-ff7b-41c9-a771-0a9b2fdab0cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_c38682c8-a432-435c-a07c-ed6ce13844aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_95ad931d-99a1-4fb2-9f85-bdeeef80cc6e" xlink:to="loc_us-gaap_DerivativeLineItems_c38682c8-a432-435c-a07c-ed6ce13844aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_3f0cd66a-1286-4409-99c3-b715aa334293" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_c38682c8-a432-435c-a07c-ed6ce13844aa" xlink:to="loc_us-gaap_DerivativeTermOfContract_3f0cd66a-1286-4409-99c3-b715aa334293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesRevenueandCostofProductSalesDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#SummaryofSignificantAccountingPoliciesRevenueandCostofProductSalesDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesRevenueandCostofProductSalesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3fea2501-3b8b-4dc5-bf0b-e4c2c741733f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice_cfe54675-1982-4a59-be44-22d8ac5c4ee4" xlink:href="halo-20240331.xsd#halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3fea2501-3b8b-4dc5-bf0b-e4c2c741733f" xlink:to="loc_halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice_cfe54675-1982-4a59-be44-22d8ac5c4ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#SummaryofSignificantAccountingPoliciesIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_48ea1406-330b-47ac-a3ce-de571b027633" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e845545f-aaeb-43ee-864f-fbba05eff041" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_48ea1406-330b-47ac-a3ce-de571b027633" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e845545f-aaeb-43ee-864f-fbba05eff041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1c9ff0c9-ead8-43e9-aaec-307797e6568d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_48ea1406-330b-47ac-a3ce-de571b027633" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1c9ff0c9-ead8-43e9-aaec-307797e6568d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#SummaryofSignificantAccountingPoliciesSegmentInformationDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_bf70c9d5-0ae8-4a21-ab4b-eb4a1a37a1f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_58a7c776-c923-49c5-b0d5-456bca605d85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bf70c9d5-0ae8-4a21-ab4b-eb4a1a37a1f4" xlink:to="loc_us-gaap_NumberOfOperatingSegments_58a7c776-c923-49c5-b0d5-456bca605d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a7d6dc0b-fda8-4bb3-b561-855a6fbbd37b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_012c148b-854e-4647-a5dd-f9fd61ce664e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a7d6dc0b-fda8-4bb3-b561-855a6fbbd37b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_012c148b-854e-4647-a5dd-f9fd61ce664e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_50c2fb3b-e9dc-45ab-b780-fe3e0c29c03c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_012c148b-854e-4647-a5dd-f9fd61ce664e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_50c2fb3b-e9dc-45ab-b780-fe3e0c29c03c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7fe8d086-9749-4d15-a3b4-bd568830b91a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_50c2fb3b-e9dc-45ab-b780-fe3e0c29c03c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7fe8d086-9749-4d15-a3b4-bd568830b91a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_b83a6029-bf67-4ac9-89be-204f82287088" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7fe8d086-9749-4d15-a3b4-bd568830b91a" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_b83a6029-bf67-4ac9-89be-204f82287088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_ae46744e-8a3f-446c-97e7-fa94627eede3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7fe8d086-9749-4d15-a3b4-bd568830b91a" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_ae46744e-8a3f-446c-97e7-fa94627eede3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_fda96b75-193d-4235-93bf-1cb94579f5f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7fe8d086-9749-4d15-a3b4-bd568830b91a" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_fda96b75-193d-4235-93bf-1cb94579f5f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember_6f67b146-3362-4493-b933-6e48d9a8eb00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7fe8d086-9749-4d15-a3b4-bd568830b91a" xlink:to="loc_us-gaap_AgencySecuritiesMember_6f67b146-3362-4493-b933-6e48d9a8eb00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_ba217f25-ce26-4d20-8081-7835444c3af5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7fe8d086-9749-4d15-a3b4-bd568830b91a" xlink:to="loc_us-gaap_CommercialPaperMember_ba217f25-ce26-4d20-8081-7835444c3af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f3848996-d383-4e8f-8527-7b155913afe2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_012c148b-854e-4647-a5dd-f9fd61ce664e" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f3848996-d383-4e8f-8527-7b155913afe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_a823979d-f63e-4e10-9d89-5091fd2ded13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f3848996-d383-4e8f-8527-7b155913afe2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_a823979d-f63e-4e10-9d89-5091fd2ded13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8db02277-92f1-4391-8d48-75ebb348c32a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f3848996-d383-4e8f-8527-7b155913afe2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8db02277-92f1-4391-8d48-75ebb348c32a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9c7a8c2a-706e-4c08-b175-bb62427347f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f3848996-d383-4e8f-8527-7b155913afe2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9c7a8c2a-706e-4c08-b175-bb62427347f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_584ac3f6-4757-4167-b195-66886b4e88cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f3848996-d383-4e8f-8527-7b155913afe2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_584ac3f6-4757-4167-b195-66886b4e88cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#FairValueMeasurementNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_cc434690-817e-4d38-be00-b958f405607f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6ab3ad5d-77b0-40fc-b8e5-05ca5940f981" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_cc434690-817e-4d38-be00-b958f405607f" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6ab3ad5d-77b0-40fc-b8e5-05ca5940f981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_285ae8f9-f3e3-4c84-9391-2c8ec23028f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6ab3ad5d-77b0-40fc-b8e5-05ca5940f981" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_285ae8f9-f3e3-4c84-9391-2c8ec23028f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_749264fe-750c-4972-92f9-a13ed70a3ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_285ae8f9-f3e3-4c84-9391-2c8ec23028f4" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_749264fe-750c-4972-92f9-a13ed70a3ca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_4c65d4a0-ed0b-4bb7-801a-172ad1b1a917" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_749264fe-750c-4972-92f9-a13ed70a3ca4" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_4c65d4a0-ed0b-4bb7-801a-172ad1b1a917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3844fa68-cd75-47a2-ab42-21ce3f511b10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_6ab3ad5d-77b0-40fc-b8e5-05ca5940f981" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3844fa68-cd75-47a2-ab42-21ce3f511b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_f537950d-54a0-452d-8b29-7b9b1c80603e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3844fa68-cd75-47a2-ab42-21ce3f511b10" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_f537950d-54a0-452d-8b29-7b9b1c80603e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_6b408b58-911d-417a-9c8f-b64831dc0fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3844fa68-cd75-47a2-ab42-21ce3f511b10" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_6b408b58-911d-417a-9c8f-b64831dc0fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7ee70a2f-836d-4cd9-8ce1-8783244538b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3844fa68-cd75-47a2-ab42-21ce3f511b10" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7ee70a2f-836d-4cd9-8ce1-8783244538b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_a554251a-21a2-4981-9b8e-00d476c97f67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3844fa68-cd75-47a2-ab42-21ce3f511b10" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_a554251a-21a2-4981-9b8e-00d476c97f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_5ebe47b9-1ce8-4d13-944a-9672ad86f6ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3844fa68-cd75-47a2-ab42-21ce3f511b10" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_5ebe47b9-1ce8-4d13-944a-9672ad86f6ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/FairValueMeasurementContractualMaturitiesofAvailableforsaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#FairValueMeasurementContractualMaturitiesofAvailableforsaleDebtSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/FairValueMeasurementContractualMaturitiesofAvailableforsaleDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3187cd3a-854c-4e1b-aa0b-e452286df3c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_e085bf15-3b60-42cc-91cf-d2c91ab2a13b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3187cd3a-854c-4e1b-aa0b-e452286df3c0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_e085bf15-3b60-42cc-91cf-d2c91ab2a13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_92a85083-adc9-4687-a053-8ff68bb0a0db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3187cd3a-854c-4e1b-aa0b-e452286df3c0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_92a85083-adc9-4687-a053-8ff68bb0a0db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_e20fd2e1-f855-4f43-b860-c5ad0e9850cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3187cd3a-854c-4e1b-aa0b-e452286df3c0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_e20fd2e1-f855-4f43-b860-c5ad0e9850cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2d35a8b2-25ee-4465-91c1-19f2fcf98f04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a5dce32f-0043-4bb2-b7ee-525e8144c593" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2d35a8b2-25ee-4465-91c1-19f2fcf98f04" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a5dce32f-0043-4bb2-b7ee-525e8144c593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1dba06c8-70da-4c07-9ae4-66cb40fc7f70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a5dce32f-0043-4bb2-b7ee-525e8144c593" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1dba06c8-70da-4c07-9ae4-66cb40fc7f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0758a658-5609-40f5-9bcd-6e55e6db10cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1dba06c8-70da-4c07-9ae4-66cb40fc7f70" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0758a658-5609-40f5-9bcd-6e55e6db10cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_a699431c-b40b-4d7a-9674-82123e43b35c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0758a658-5609-40f5-9bcd-6e55e6db10cb" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_a699431c-b40b-4d7a-9674-82123e43b35c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9cbd0ea2-a60e-4f7d-b534-3fa2c818868a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0758a658-5609-40f5-9bcd-6e55e6db10cb" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_9cbd0ea2-a60e-4f7d-b534-3fa2c818868a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_724ad22a-80cd-475c-9cd4-f5f7acd60a57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a5dce32f-0043-4bb2-b7ee-525e8144c593" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_724ad22a-80cd-475c-9cd4-f5f7acd60a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_06a7ccc9-9882-41ef-a246-ff0b052619fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_724ad22a-80cd-475c-9cd4-f5f7acd60a57" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_06a7ccc9-9882-41ef-a246-ff0b052619fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2f0c31d2-0610-4fa9-9e91-abea89f81d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_06a7ccc9-9882-41ef-a246-ff0b052619fc" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2f0c31d2-0610-4fa9-9e91-abea89f81d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_cad0e92f-4b82-44f7-b834-d2ed6f2d8bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_06a7ccc9-9882-41ef-a246-ff0b052619fc" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_cad0e92f-4b82-44f7-b834-d2ed6f2d8bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_9db2d5f0-ae42-45a1-bca8-d666c0696769" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a5dce32f-0043-4bb2-b7ee-525e8144c593" xlink:to="loc_us-gaap_FinancialInstrumentAxis_9db2d5f0-ae42-45a1-bca8-d666c0696769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7bba414b-89f6-4e45-813e-c884170799a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9db2d5f0-ae42-45a1-bca8-d666c0696769" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7bba414b-89f6-4e45-813e-c884170799a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_fd1c4747-12dc-4a6e-9916-bd482cb8c70f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7bba414b-89f6-4e45-813e-c884170799a9" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_fd1c4747-12dc-4a6e-9916-bd482cb8c70f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_19977649-7131-4cd5-b92c-4f887907dc79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7bba414b-89f6-4e45-813e-c884170799a9" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_19977649-7131-4cd5-b92c-4f887907dc79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_bdfdbff2-6402-42af-9c72-e1ab232603cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7bba414b-89f6-4e45-813e-c884170799a9" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_bdfdbff2-6402-42af-9c72-e1ab232603cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember_30adecf5-934d-471a-8dd1-e32dd190120a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7bba414b-89f6-4e45-813e-c884170799a9" xlink:to="loc_us-gaap_AgencySecuritiesMember_30adecf5-934d-471a-8dd1-e32dd190120a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_8fc971fe-49fd-4182-9f09-24d2163173cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7bba414b-89f6-4e45-813e-c884170799a9" xlink:to="loc_us-gaap_CommercialPaperMember_8fc971fe-49fd-4182-9f09-24d2163173cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_73f79759-d0eb-4590-8052-08e4ff4e6dba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a5dce32f-0043-4bb2-b7ee-525e8144c593" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_73f79759-d0eb-4590-8052-08e4ff4e6dba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_f4083177-db2f-4ce0-bbd1-3fbcb8c63fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_73f79759-d0eb-4590-8052-08e4ff4e6dba" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_f4083177-db2f-4ce0-bbd1-3fbcb8c63fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_f6e30ca6-539b-4e61-916b-b39d8fc09158" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_f4083177-db2f-4ce0-bbd1-3fbcb8c63fe3" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_f6e30ca6-539b-4e61-916b-b39d8fc09158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_802198c4-c783-4672-be76-a3771454a504" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a5dce32f-0043-4bb2-b7ee-525e8144c593" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_802198c4-c783-4672-be76-a3771454a504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_1a85e6d8-0af9-4bbb-86de-0246c4179af3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_802198c4-c783-4672-be76-a3771454a504" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_1a85e6d8-0af9-4bbb-86de-0246c4179af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d3fd0ad5-7e71-45fd-bb0e-15cffc4be7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_1a85e6d8-0af9-4bbb-86de-0246c4179af3" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d3fd0ad5-7e71-45fd-bb0e-15cffc4be7c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_5d5c2eba-2ec4-41a6-9557-1205be4da718" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_1a85e6d8-0af9-4bbb-86de-0246c4179af3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_5d5c2eba-2ec4-41a6-9557-1205be4da718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_3e1eeecf-a624-4dbd-9739-6bb5a61f3892" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_1a85e6d8-0af9-4bbb-86de-0246c4179af3" xlink:to="loc_us-gaap_DerivativeAssets_3e1eeecf-a624-4dbd-9739-6bb5a61f3892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_9461bf00-344f-4fde-a143-8aab0ae26af3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_1a85e6d8-0af9-4bbb-86de-0246c4179af3" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_9461bf00-344f-4fde-a143-8aab0ae26af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_b8a08fba-15b3-4412-9b11-53c1bbe9d553" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_802198c4-c783-4672-be76-a3771454a504" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_b8a08fba-15b3-4412-9b11-53c1bbe9d553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_7984e2d2-66d7-4e4f-ad2f-14fa9798874c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_b8a08fba-15b3-4412-9b11-53c1bbe9d553" xlink:to="loc_us-gaap_DerivativeLiabilities_7984e2d2-66d7-4e4f-ad2f-14fa9798874c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_223d91d8-c1f8-4ebd-82c5-73ff2a0fac50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_802198c4-c783-4672-be76-a3771454a504" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_223d91d8-c1f8-4ebd-82c5-73ff2a0fac50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_7480f5c0-731f-4789-b33e-7baaf19cf560" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_802198c4-c783-4672-be76-a3771454a504" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_7480f5c0-731f-4789-b33e-7baaf19cf560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_b6656b0d-cf6b-4f28-95bc-bcc417cad519" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_802198c4-c783-4672-be76-a3771454a504" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_b6656b0d-cf6b-4f28-95bc-bcc417cad519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_51b704ac-3d0d-4f14-a8f3-81aa3e3b3a48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_802198c4-c783-4672-be76-a3771454a504" xlink:to="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_51b704ac-3d0d-4f14-a8f3-81aa3e3b3a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration_50acceb6-3e8d-46e4-b4f1-703367036858" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_802198c4-c783-4672-be76-a3771454a504" xlink:to="loc_us-gaap_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration_50acceb6-3e8d-46e4-b4f1-703367036858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration_0d0f1f54-c64d-48b2-96dd-8747bb0b2d86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_802198c4-c783-4672-be76-a3771454a504" xlink:to="loc_us-gaap_DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration_0d0f1f54-c64d-48b2-96dd-8747bb0b2d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#RevenueDisaggregatedRevenuesDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_506d7a7a-ba59-4320-829e-43f7523c5e05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_537efb5f-25f3-450b-b09a-5837e6240701" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_506d7a7a-ba59-4320-829e-43f7523c5e05" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_537efb5f-25f3-450b-b09a-5837e6240701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_faf6085e-146e-4610-abbe-5cbda216cb40" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_537efb5f-25f3-450b-b09a-5837e6240701" xlink:to="loc_srt_ProductOrServiceAxis_faf6085e-146e-4610-abbe-5cbda216cb40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c8623c69-ef42-4589-a083-b9fe21e9e1b8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_faf6085e-146e-4610-abbe-5cbda216cb40" xlink:to="loc_srt_ProductsAndServicesDomain_c8623c69-ef42-4589-a083-b9fe21e9e1b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_d8bdd1b3-92fd-480d-93d2-df2730b9c9ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c8623c69-ef42-4589-a083-b9fe21e9e1b8" xlink:to="loc_us-gaap_RoyaltyMember_d8bdd1b3-92fd-480d-93d2-df2730b9c9ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_b22fafe3-179c-4bde-8991-adf286e6e637" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c8623c69-ef42-4589-a083-b9fe21e9e1b8" xlink:to="loc_us-gaap_ProductMember_b22fafe3-179c-4bde-8991-adf286e6e637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ProprietaryProductsSalesMember_e7c15b10-edbf-4e5c-93c3-f801f75bf30b" xlink:href="halo-20240331.xsd#halo_ProprietaryProductsSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_b22fafe3-179c-4bde-8991-adf286e6e637" xlink:to="loc_halo_ProprietaryProductsSalesMember_e7c15b10-edbf-4e5c-93c3-f801f75bf30b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BulkrHuPH20Member_6e8fb03d-6d91-47bc-a8e7-105a9865e5e6" xlink:href="halo-20240331.xsd#halo_BulkrHuPH20Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_b22fafe3-179c-4bde-8991-adf286e6e637" xlink:to="loc_halo_BulkrHuPH20Member_6e8fb03d-6d91-47bc-a8e7-105a9865e5e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DevicePartneredProductsMember_1d5ebeb2-d66e-42b9-b199-642fe7bd7f53" xlink:href="halo-20240331.xsd#halo_DevicePartneredProductsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_b22fafe3-179c-4bde-8991-adf286e6e637" xlink:to="loc_halo_DevicePartneredProductsMember_1d5ebeb2-d66e-42b9-b199-642fe7bd7f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_CollaborativeAgreementsMember_45271125-ebb5-47f8-996a-19d96bc85130" xlink:href="halo-20240331.xsd#halo_CollaborativeAgreementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c8623c69-ef42-4589-a083-b9fe21e9e1b8" xlink:to="loc_halo_CollaborativeAgreementsMember_45271125-ebb5-47f8-996a-19d96bc85130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_EventBasedDevelopmentAndRegulatoryMilestoneAndOtherFeesMember_ac97cce9-0d66-443c-bd5e-7dd572de13f9" xlink:href="halo-20240331.xsd#halo_EventBasedDevelopmentAndRegulatoryMilestoneAndOtherFeesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_CollaborativeAgreementsMember_45271125-ebb5-47f8-996a-19d96bc85130" xlink:to="loc_halo_EventBasedDevelopmentAndRegulatoryMilestoneAndOtherFeesMember_ac97cce9-0d66-443c-bd5e-7dd572de13f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DeviceLicensingAndDevelopmentMember_b112d057-c3b2-4c7f-b21d-a9916a5e899e" xlink:href="halo-20240331.xsd#halo_DeviceLicensingAndDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_CollaborativeAgreementsMember_45271125-ebb5-47f8-996a-19d96bc85130" xlink:to="loc_halo_DeviceLicensingAndDevelopmentMember_b112d057-c3b2-4c7f-b21d-a9916a5e899e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_8a7e5b94-6064-49d1-89b6-daa18fba2c38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_537efb5f-25f3-450b-b09a-5837e6240701" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_8a7e5b94-6064-49d1-89b6-daa18fba2c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e6982695-477e-4df7-93df-024e0b1c1bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8a7e5b94-6064-49d1-89b6-daa18fba2c38" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e6982695-477e-4df7-93df-024e0b1c1bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/RevenueNarrativeDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#RevenueNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/RevenueNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_20282cd9-4858-48fe-8657-c0ef20adb9a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_9c65fa08-bbe7-4fd0-ace8-17ab877386ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_20282cd9-4858-48fe-8657-c0ef20adb9a5" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_9c65fa08-bbe7-4fd0-ace8-17ab877386ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f0b1c023-9c2f-4030-8697-baaa7d4882cd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9c65fa08-bbe7-4fd0-ace8-17ab877386ff" xlink:to="loc_srt_ProductOrServiceAxis_f0b1c023-9c2f-4030-8697-baaa7d4882cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c78a3203-9ef5-4292-9008-efe117346709" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_f0b1c023-9c2f-4030-8697-baaa7d4882cd" xlink:to="loc_srt_ProductsAndServicesDomain_c78a3203-9ef5-4292-9008-efe117346709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_LicenseFeesAndEventBasedMember_89e66fcb-1e80-4c0a-99cc-ca93a775e442" xlink:href="halo-20240331.xsd#halo_LicenseFeesAndEventBasedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c78a3203-9ef5-4292-9008-efe117346709" xlink:to="loc_halo_LicenseFeesAndEventBasedMember_89e66fcb-1e80-4c0a-99cc-ca93a775e442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_4a38e358-3854-41e4-a44f-29c14f7cc7bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c78a3203-9ef5-4292-9008-efe117346709" xlink:to="loc_us-gaap_ProductMember_4a38e358-3854-41e4-a44f-29c14f7cc7bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_44a7d734-ed2a-49b9-be5a-c28fabbbe1b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9c65fa08-bbe7-4fd0-ace8-17ab877386ff" xlink:to="loc_us-gaap_TypeOfArrangementAxis_44a7d734-ed2a-49b9-be5a-c28fabbbe1b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3365078c-8566-4dde-accc-e163fd7f3dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_44a7d734-ed2a-49b9-be5a-c28fabbbe1b9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3365078c-8566-4dde-accc-e163fd7f3dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_OthercollaboratorsMember_f46a1d23-933e-4a1e-a385-d2bb99016ac8" xlink:href="halo-20240331.xsd#halo_OthercollaboratorsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3365078c-8566-4dde-accc-e163fd7f3dc0" xlink:to="loc_halo_OthercollaboratorsMember_f46a1d23-933e-4a1e-a385-d2bb99016ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_f31bc888-e004-4ca6-a5aa-7e266a5c1a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9c65fa08-bbe7-4fd0-ace8-17ab877386ff" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_f31bc888-e004-4ca6-a5aa-7e266a5c1a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_d97e5034-0be2-486c-81d7-a8043494d771" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9c65fa08-bbe7-4fd0-ace8-17ab877386ff" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_d97e5034-0be2-486c-81d7-a8043494d771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_f5a0c659-b6a0-46d5-9355-b3b49da267f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d97e5034-0be2-486c-81d7-a8043494d771" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_f5a0c659-b6a0-46d5-9355-b3b49da267f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_3aa3fa2d-5fc3-47bd-8f66-cb32207c099a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d97e5034-0be2-486c-81d7-a8043494d771" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_3aa3fa2d-5fc3-47bd-8f66-cb32207c099a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_edacba0b-65a5-462a-95e4-8e2bd545ddf9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d97e5034-0be2-486c-81d7-a8043494d771" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_edacba0b-65a5-462a-95e4-8e2bd545ddf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_c7610b5f-eb12-4e5a-83dc-eb8b952682b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d97e5034-0be2-486c-81d7-a8043494d771" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_c7610b5f-eb12-4e5a-83dc-eb8b952682b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RevenueRemainingPerformanceObligationsUnfulfilledProductPurchaseOrdersAmount_b2da247e-d98a-4c1a-aabd-500736000cfa" xlink:href="halo-20240331.xsd#halo_RevenueRemainingPerformanceObligationsUnfulfilledProductPurchaseOrdersAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d97e5034-0be2-486c-81d7-a8043494d771" xlink:to="loc_halo_RevenueRemainingPerformanceObligationsUnfulfilledProductPurchaseOrdersAmount_b2da247e-d98a-4c1a-aabd-500736000cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_cf831757-efa9-4c4f-809e-8a860a6943ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d97e5034-0be2-486c-81d7-a8043494d771" xlink:to="loc_us-gaap_ContractWithCustomerLiability_cf831757-efa9-4c4f-809e-8a860a6943ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_5045fed2-cef1-497e-9ac8-908367bc7130" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d97e5034-0be2-486c-81d7-a8043494d771" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_5045fed2-cef1-497e-9ac8-908367bc7130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetGrossCurrent_2673461b-6785-4096-a8b8-e85d72960d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetGrossCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d97e5034-0be2-486c-81d7-a8043494d771" xlink:to="loc_us-gaap_ContractWithCustomerAssetGrossCurrent_2673461b-6785-4096-a8b8-e85d72960d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/RevenueAccountsReceivableOtherContractAssetsandContractLiabilitiesDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#RevenueAccountsReceivableOtherContractAssetsandContractLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/RevenueAccountsReceivableOtherContractAssetsandContractLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f69c96e2-6a9c-419c-ad6c-b1f060f9fb73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_8c9d21f9-e224-4a19-a5de-0bd3a258926e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f69c96e2-6a9c-419c-ad6c-b1f060f9fb73" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_8c9d21f9-e224-4a19-a5de-0bd3a258926e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetGrossCurrent_6e3593b0-0071-4205-8f22-01101b4a62ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetGrossCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f69c96e2-6a9c-419c-ad6c-b1f060f9fb73" xlink:to="loc_us-gaap_ContractWithCustomerAssetGrossCurrent_6e3593b0-0071-4205-8f22-01101b4a62ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_4cd90acf-60c5-4523-86ce-f95f674ca193" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f69c96e2-6a9c-419c-ad6c-b1f060f9fb73" xlink:to="loc_us-gaap_ContractWithCustomerLiability_4cd90acf-60c5-4523-86ce-f95f674ca193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#CertainBalanceSheetItemsAccountsReceivablenetDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_bdf83438-bef8-4e2a-8dd4-79c3cb8b48ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_4ea6c496-c00e-4c6a-b53a-f70706803db6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_bdf83438-bef8-4e2a-8dd4-79c3cb8b48ae" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_4ea6c496-c00e-4c6a-b53a-f70706803db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_dba86945-d80d-41a2-aa82-ba599afd7564" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_4ea6c496-c00e-4c6a-b53a-f70706803db6" xlink:to="loc_srt_ProductOrServiceAxis_dba86945-d80d-41a2-aa82-ba599afd7564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5d452b7c-00dc-4bca-ba43-b416ddb43f6f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_dba86945-d80d-41a2-aa82-ba599afd7564" xlink:to="loc_srt_ProductsAndServicesDomain_5d452b7c-00dc-4bca-ba43-b416ddb43f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DevicePartneredProductsMember_dda89d7e-54d1-441e-8979-8c6b5781991e" xlink:href="halo-20240331.xsd#halo_DevicePartneredProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5d452b7c-00dc-4bca-ba43-b416ddb43f6f" xlink:to="loc_halo_DevicePartneredProductsMember_dda89d7e-54d1-441e-8979-8c6b5781991e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_CollaborativeAgreementsMember_93e5d4d7-e685-44ea-9f36-e348bf6f701d" xlink:href="halo-20240331.xsd#halo_CollaborativeAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5d452b7c-00dc-4bca-ba43-b416ddb43f6f" xlink:to="loc_halo_CollaborativeAgreementsMember_93e5d4d7-e685-44ea-9f36-e348bf6f701d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_a7729ec4-db0e-485b-b8e3-c960874a973d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5d452b7c-00dc-4bca-ba43-b416ddb43f6f" xlink:to="loc_us-gaap_RoyaltyMember_a7729ec4-db0e-485b-b8e3-c960874a973d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ProductSalesOtherMember_b9bf8899-fb2e-4f3a-9972-29fd8a32ef54" xlink:href="halo-20240331.xsd#halo_ProductSalesOtherMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5d452b7c-00dc-4bca-ba43-b416ddb43f6f" xlink:to="loc_halo_ProductSalesOtherMember_b9bf8899-fb2e-4f3a-9972-29fd8a32ef54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_b0b9c703-94b2-4244-b4d8-878301700dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_4ea6c496-c00e-4c6a-b53a-f70706803db6" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_b0b9c703-94b2-4244-b4d8-878301700dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_33d37ab3-4cb3-4f4b-aced-890e1ce43daa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_b0b9c703-94b2-4244-b4d8-878301700dbe" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_33d37ab3-4cb3-4f4b-aced-890e1ce43daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetGrossCurrent_28382da5-d91f-4514-a978-98b680094f29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetGrossCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_b0b9c703-94b2-4244-b4d8-878301700dbe" xlink:to="loc_us-gaap_ContractWithCustomerAssetGrossCurrent_28382da5-d91f-4514-a978-98b680094f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AccountsReceivableAndContractWithCustomerAssetBeforeAllowanceForCreditLossCurrent_559c0b34-4000-4f2b-af30-fcd242c2cc96" xlink:href="halo-20240331.xsd#halo_AccountsReceivableAndContractWithCustomerAssetBeforeAllowanceForCreditLossCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_b0b9c703-94b2-4244-b4d8-878301700dbe" xlink:to="loc_halo_AccountsReceivableAndContractWithCustomerAssetBeforeAllowanceForCreditLossCurrent_559c0b34-4000-4f2b-af30-fcd242c2cc96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AccountsReceivableAndContractWithCustomerAssetAllowanceForCreditLossCurrent_e5d127b1-cb54-457c-a7ef-69b031ed6939" xlink:href="halo-20240331.xsd#halo_AccountsReceivableAndContractWithCustomerAssetAllowanceForCreditLossCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_b0b9c703-94b2-4244-b4d8-878301700dbe" xlink:to="loc_halo_AccountsReceivableAndContractWithCustomerAssetAllowanceForCreditLossCurrent_e5d127b1-cb54-457c-a7ef-69b031ed6939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent_6b2ce132-9a61-4686-9d2a-284bbcda30ec" xlink:href="halo-20240331.xsd#halo_AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_b0b9c703-94b2-4244-b4d8-878301700dbe" xlink:to="loc_halo_AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent_6b2ce132-9a61-4686-9d2a-284bbcda30ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#CertainBalanceSheetItemsInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_647a6c15-eb59-4394-93d4-3d0424e7cfed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_e9d6dceb-ca4e-4e68-b221-f09bfc659f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_647a6c15-eb59-4394-93d4-3d0424e7cfed" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_e9d6dceb-ca4e-4e68-b221-f09bfc659f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_3ff797e9-c58f-4913-9073-ff9297bed5fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_647a6c15-eb59-4394-93d4-3d0424e7cfed" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_3ff797e9-c58f-4913-9073-ff9297bed5fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_a69cff30-c6e0-4d6a-ae26-999ce71f66f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_647a6c15-eb59-4394-93d4-3d0424e7cfed" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_a69cff30-c6e0-4d6a-ae26-999ce71f66f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_186d9b8d-470d-4e6c-a0f4-e39b15fec976" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_647a6c15-eb59-4394-93d4-3d0424e7cfed" xlink:to="loc_us-gaap_InventoryNet_186d9b8d-470d-4e6c-a0f4-e39b15fec976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_35d0c37d-8585-47b3-893d-6cf50d408559" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_d0f4fd39-3f3b-469e-be68-2d7a0a8039aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_35d0c37d-8585-47b3-893d-6cf50d408559" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_d0f4fd39-3f3b-469e-be68-2d7a0a8039aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_f9c0e783-5d98-4509-8234-c71743a68f77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_35d0c37d-8585-47b3-893d-6cf50d408559" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_f9c0e783-5d98-4509-8234-c71743a68f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_d35531dc-915d-4be9-8cc7-78cdc2f942a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_35d0c37d-8585-47b3-893d-6cf50d408559" xlink:to="loc_us-gaap_OtherAssets_d35531dc-915d-4be9-8cc7-78cdc2f942a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_11b2c42b-1aff-4376-b14c-0f9700f0b00f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_35d0c37d-8585-47b3-893d-6cf50d408559" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_11b2c42b-1aff-4376-b14c-0f9700f0b00f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_537c4979-b27e-4d87-911e-1b7c0be5d78c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_35d0c37d-8585-47b3-893d-6cf50d408559" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_537c4979-b27e-4d87-911e-1b7c0be5d78c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_63719292-9f4b-4d08-966e-3f546ff72575" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_35d0c37d-8585-47b3-893d-6cf50d408559" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_63719292-9f4b-4d08-966e-3f546ff72575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#CertainBalanceSheetItemsPropertyandEquipmentnetDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_381c36cb-20f1-45dd-b21f-025d266ace4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_df655e4a-22c7-4a14-8684-0e9e2006bde2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_381c36cb-20f1-45dd-b21f-025d266ace4a" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_df655e4a-22c7-4a14-8684-0e9e2006bde2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_66cae749-4480-40aa-8795-3f234c579881" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_df655e4a-22c7-4a14-8684-0e9e2006bde2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_66cae749-4480-40aa-8795-3f234c579881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_716b19a3-fae4-4051-bf9e-03a4b5af5123" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_66cae749-4480-40aa-8795-3f234c579881" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_716b19a3-fae4-4051-bf9e-03a4b5af5123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ResearchEquipmentMember_1ea5cd55-186b-4205-90e9-ef2bf46ef948" xlink:href="halo-20240331.xsd#halo_ResearchEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_716b19a3-fae4-4051-bf9e-03a4b5af5123" xlink:to="loc_halo_ResearchEquipmentMember_1ea5cd55-186b-4205-90e9-ef2bf46ef948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ManufacturingEquipmentMember_f9dd1ebd-eb52-4ae6-9a72-33da8754857c" xlink:href="halo-20240331.xsd#halo_ManufacturingEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_716b19a3-fae4-4051-bf9e-03a4b5af5123" xlink:to="loc_halo_ManufacturingEquipmentMember_f9dd1ebd-eb52-4ae6-9a72-33da8754857c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ComputerAndOfficeEquipmentMember_324afaec-e4cc-45c9-b2b1-9a18294343c6" xlink:href="halo-20240331.xsd#halo_ComputerAndOfficeEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_716b19a3-fae4-4051-bf9e-03a4b5af5123" xlink:to="loc_halo_ComputerAndOfficeEquipmentMember_324afaec-e4cc-45c9-b2b1-9a18294343c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_cb01ef5b-ef6e-4736-bee7-7cb830358607" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_716b19a3-fae4-4051-bf9e-03a4b5af5123" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_cb01ef5b-ef6e-4736-bee7-7cb830358607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5e207bbf-ebf4-411a-a416-9d48ca393e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_df655e4a-22c7-4a14-8684-0e9e2006bde2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5e207bbf-ebf4-411a-a416-9d48ca393e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_e9b65045-3365-490d-9f62-73964dc6851c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5e207bbf-ebf4-411a-a416-9d48ca393e9e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_e9b65045-3365-490d-9f62-73964dc6851c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b474b4ae-776e-4a80-ab07-eaf3833de9bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5e207bbf-ebf4-411a-a416-9d48ca393e9e" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b474b4ae-776e-4a80-ab07-eaf3833de9bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_692fc55e-aa75-46e7-8e5e-a61c6635fa2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5e207bbf-ebf4-411a-a416-9d48ca393e9e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_692fc55e-aa75-46e7-8e5e-a61c6635fa2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6a8f81b9-0818-40df-9184-657dd1a74d97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5e207bbf-ebf4-411a-a416-9d48ca393e9e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6a8f81b9-0818-40df-9184-657dd1a74d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_0d69a493-2571-44b6-b28b-de749b993917" xlink:href="halo-20240331.xsd#halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5e207bbf-ebf4-411a-a416-9d48ca393e9e" xlink:to="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_0d69a493-2571-44b6-b28b-de749b993917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_50ac4de7-8384-47ad-9abc-8b0d2f123d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5e207bbf-ebf4-411a-a416-9d48ca393e9e" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_50ac4de7-8384-47ad-9abc-8b0d2f123d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_26e151f8-bf60-4e66-b2b2-f11b483b60f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5e207bbf-ebf4-411a-a416-9d48ca393e9e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_26e151f8-bf60-4e66-b2b2-f11b483b60f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#CertainBalanceSheetItemsAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_89e2a243-868f-4822-a5e5-dcbdcbbbefb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_af9d0eda-01d2-44f5-96c4-b9c76070301c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_89e2a243-868f-4822-a5e5-dcbdcbbbefb4" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_af9d0eda-01d2-44f5-96c4-b9c76070301c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AccruedOutsourcedManufacturingExpenses_2f358a9f-af09-4fbf-a6d1-325c88ce20c0" xlink:href="halo-20240331.xsd#halo_AccruedOutsourcedManufacturingExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_89e2a243-868f-4822-a5e5-dcbdcbbbefb4" xlink:to="loc_halo_AccruedOutsourcedManufacturingExpenses_2f358a9f-af09-4fbf-a6d1-325c88ce20c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_2e81d78d-5eb2-4574-bd3a-31e4f1ccd026" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_89e2a243-868f-4822-a5e5-dcbdcbbbefb4" xlink:to="loc_us-gaap_TaxesPayableCurrent_2e81d78d-5eb2-4574-bd3a-31e4f1ccd026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiability_81c665f7-ca14-4ccf-94be-68e037085f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerRefundLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_89e2a243-868f-4822-a5e5-dcbdcbbbefb4" xlink:to="loc_us-gaap_ContractWithCustomerRefundLiability_81c665f7-ca14-4ccf-94be-68e037085f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_b8524ae5-8e4a-4f20-a5c2-f96e22f8f8d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_89e2a243-868f-4822-a5e5-dcbdcbbbefb4" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_b8524ae5-8e4a-4f20-a5c2-f96e22f8f8d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_84596aff-76da-4968-91a8-0e29bee163bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_89e2a243-868f-4822-a5e5-dcbdcbbbefb4" xlink:to="loc_us-gaap_OperatingLeaseLiability_84596aff-76da-4968-91a8-0e29bee163bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_00c9314e-3bbc-442a-82f0-496957e63a5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_89e2a243-868f-4822-a5e5-dcbdcbbbefb4" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_00c9314e-3bbc-442a-82f0-496957e63a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AccruedLiabilitiesNoncurrent_d0262031-cdaa-42aa-ba57-1d0dc00e24a3" xlink:href="halo-20240331.xsd#halo_AccruedLiabilitiesNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_89e2a243-868f-4822-a5e5-dcbdcbbbefb4" xlink:to="loc_halo_AccruedLiabilitiesNoncurrent_d0262031-cdaa-42aa-ba57-1d0dc00e24a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_59b191c4-bc52-4f96-a35e-b5dba70015d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_89e2a243-868f-4822-a5e5-dcbdcbbbefb4" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_59b191c4-bc52-4f96-a35e-b5dba70015d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_OperatingLeaseAccretionOfLiability_b9931f71-d2d9-44e9-a970-968112b5ff54" xlink:href="halo-20240331.xsd#halo_OperatingLeaseAccretionOfLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_89e2a243-868f-4822-a5e5-dcbdcbbbefb4" xlink:to="loc_halo_OperatingLeaseAccretionOfLiability_b9931f71-d2d9-44e9-a970-968112b5ff54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_f13e2c59-db4d-4651-b6e8-693744edf453" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_89e2a243-868f-4822-a5e5-dcbdcbbbefb4" xlink:to="loc_us-gaap_OperatingLeaseCost_f13e2c59-db4d-4651-b6e8-693744edf453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_0f0ab177-b097-47f5-a296-278bf576aa72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_89e2a243-868f-4822-a5e5-dcbdcbbbefb4" xlink:to="loc_us-gaap_OperatingLeasePayments_0f0ab177-b097-47f5-a296-278bf576aa72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsGoodwillRollforwardDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#GoodwillandIntangibleAssetsGoodwillRollforwardDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/GoodwillandIntangibleAssetsGoodwillRollforwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_573e9ea4-97f5-4246-9348-83d4f8ee423c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_6fc772f9-eef9-4f40-9db7-aadc24536dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_573e9ea4-97f5-4246-9348-83d4f8ee423c" xlink:to="loc_us-gaap_GoodwillRollForward_6fc772f9-eef9-4f40-9db7-aadc24536dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_2e2730ba-4971-40e7-a788-ce0997b4a458" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_6fc772f9-eef9-4f40-9db7-aadc24536dd0" xlink:to="loc_us-gaap_Goodwill_2e2730ba-4971-40e7-a788-ce0997b4a458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_c130a9ba-3153-4f4c-8b17-6b0133c3e69d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_6fc772f9-eef9-4f40-9db7-aadc24536dd0" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_c130a9ba-3153-4f4c-8b17-6b0133c3e69d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_40728c53-b6c8-4aa3-9575-23264de7a35e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_6fc772f9-eef9-4f40-9db7-aadc24536dd0" xlink:to="loc_us-gaap_Goodwill_40728c53-b6c8-4aa3-9575-23264de7a35e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#GoodwillandIntangibleAssetsAdditionalDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4248b699-e669-48bc-aeb5-8b97b1233725" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7585db2b-e0ce-4e97-ac83-99024b2692ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4248b699-e669-48bc-aeb5-8b97b1233725" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7585db2b-e0ce-4e97-ac83-99024b2692ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ae165932-e813-4b62-94ba-dc6ccd498eaa" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7585db2b-e0ce-4e97-ac83-99024b2692ae" xlink:to="loc_srt_RangeAxis_ae165932-e813-4b62-94ba-dc6ccd498eaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7af43159-8b8f-4be7-9814-a48ce6ddb33a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ae165932-e813-4b62-94ba-dc6ccd498eaa" xlink:to="loc_srt_RangeMember_7af43159-8b8f-4be7-9814-a48ce6ddb33a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_402b82ba-256f-4276-83c6-23da1aee5a73" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7af43159-8b8f-4be7-9814-a48ce6ddb33a" xlink:to="loc_srt_MinimumMember_402b82ba-256f-4276-83c6-23da1aee5a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ade37b12-ce70-489e-a760-7a9dc8d52895" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7af43159-8b8f-4be7-9814-a48ce6ddb33a" xlink:to="loc_srt_MaximumMember_ade37b12-ce70-489e-a760-7a9dc8d52895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_19817e88-a036-4170-b398-fecc79f292b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7585db2b-e0ce-4e97-ac83-99024b2692ae" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_19817e88-a036-4170-b398-fecc79f292b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_e045678a-1ad1-4626-9fd6-b29404c75154" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_19817e88-a036-4170-b398-fecc79f292b5" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_e045678a-1ad1-4626-9fd6-b29404c75154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#GoodwillandIntangibleAssetsIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3ab61a1a-d6be-4942-be52-bda5d974ad3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_97810f31-53ea-472d-9c24-40c3fa5361fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3ab61a1a-d6be-4942-be52-bda5d974ad3a" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_97810f31-53ea-472d-9c24-40c3fa5361fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c1f2008f-4709-45df-9d1d-06155bdf8cef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_97810f31-53ea-472d-9c24-40c3fa5361fb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c1f2008f-4709-45df-9d1d-06155bdf8cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_73876f1d-b77e-4b59-9656-3d5c037a679f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c1f2008f-4709-45df-9d1d-06155bdf8cef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_73876f1d-b77e-4b59-9656-3d5c037a679f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AutoInjectorTechnologyPlatformMember_decf1350-b861-4abc-9a75-4cee0c2fd4e0" xlink:href="halo-20240331.xsd#halo_AutoInjectorTechnologyPlatformMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_73876f1d-b77e-4b59-9656-3d5c037a679f" xlink:to="loc_halo_AutoInjectorTechnologyPlatformMember_decf1350-b861-4abc-9a75-4cee0c2fd4e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_XYOSTEDProprietaryProductMember_5c27f336-df46-44ab-a26c-c973109887ad" xlink:href="halo-20240331.xsd#halo_XYOSTEDProprietaryProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_73876f1d-b77e-4b59-9656-3d5c037a679f" xlink:to="loc_halo_XYOSTEDProprietaryProductMember_5c27f336-df46-44ab-a26c-c973109887ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_efb84010-1ca3-44d5-9938-146788138266" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_97810f31-53ea-472d-9c24-40c3fa5361fb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_efb84010-1ca3-44d5-9938-146788138266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_74d98acd-6a9f-4a66-87c1-bea58595721c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_efb84010-1ca3-44d5-9938-146788138266" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_74d98acd-6a9f-4a66-87c1-bea58595721c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_77112387-9cea-4463-802b-074506f71e65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_efb84010-1ca3-44d5-9938-146788138266" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_77112387-9cea-4463-802b-074506f71e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a059809b-f570-4d44-a553-3f2b674e5fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_efb84010-1ca3-44d5-9938-146788138266" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a059809b-f570-4d44-a553-3f2b674e5fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_bb48207f-74a8-4c74-9922-80c0d5137483" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_efb84010-1ca3-44d5-9938-146788138266" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_bb48207f-74a8-4c74-9922-80c0d5137483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_9da8ca6f-ca18-4987-8bd0-5b565521a97c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_efb84010-1ca3-44d5-9938-146788138266" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_9da8ca6f-ca18-4987-8bd0-5b565521a97c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_805b6163-de4d-4919-8fd9-717a3cb514ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_efb84010-1ca3-44d5-9938-146788138266" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_805b6163-de4d-4919-8fd9-717a3cb514ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#GoodwillandIntangibleAssetsFutureAmortizationDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_25313b1a-4d24-4970-9d2e-86c86f240af1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_a3949190-5d81-4e38-8ddb-a94ecb5048da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_25313b1a-4d24-4970-9d2e-86c86f240af1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_a3949190-5d81-4e38-8ddb-a94ecb5048da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_49669f4e-a7c1-4e7f-ba9a-7a7e4975d76c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_25313b1a-4d24-4970-9d2e-86c86f240af1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_49669f4e-a7c1-4e7f-ba9a-7a7e4975d76c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_f69db829-e1a4-4f33-bf66-8453fee61fbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_25313b1a-4d24-4970-9d2e-86c86f240af1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_f69db829-e1a4-4f33-bf66-8453fee61fbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_b0f26037-8f7f-472b-8c17-90acbc7dcabf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_25313b1a-4d24-4970-9d2e-86c86f240af1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_b0f26037-8f7f-472b-8c17-90acbc7dcabf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_6746c07c-a089-40fd-af5d-86bed08dde02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_25313b1a-4d24-4970-9d2e-86c86f240af1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_6746c07c-a089-40fd-af5d-86bed08dde02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_785fdd94-0c7b-40dc-84e8-78c1c4a88b57" xlink:href="halo-20240331.xsd#halo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_25313b1a-4d24-4970-9d2e-86c86f240af1" xlink:to="loc_halo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_785fdd94-0c7b-40dc-84e8-78c1c4a88b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8855b1c4-caf1-4cfa-9a9b-daa3f234bc0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_25313b1a-4d24-4970-9d2e-86c86f240af1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8855b1c4-caf1-4cfa-9a9b-daa3f234bc0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#LongTermDebtNetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f2ba059b-761d-4556-bf7f-35ef88ae65fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_45da4622-135a-4b64-a1c0-ce6afeef463d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f2ba059b-761d-4556-bf7f-35ef88ae65fa" xlink:to="loc_us-gaap_DebtInstrumentTable_45da4622-135a-4b64-a1c0-ce6afeef463d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c3e51902-4126-409d-964c-5cf3d4c64ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_45da4622-135a-4b64-a1c0-ce6afeef463d" xlink:to="loc_us-gaap_DebtInstrumentAxis_c3e51902-4126-409d-964c-5cf3d4c64ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f6999d24-1e87-4b17-a989-bc50d831ab0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_c3e51902-4126-409d-964c-5cf3d4c64ec8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f6999d24-1e87-4b17-a989-bc50d831ab0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A100ConvertibleSeniorNotesDue2028Member_ccebe56a-516e-464b-823a-11b6f468b1b9" xlink:href="halo-20240331.xsd#halo_A100ConvertibleSeniorNotesDue2028Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f6999d24-1e87-4b17-a989-bc50d831ab0c" xlink:to="loc_halo_A100ConvertibleSeniorNotesDue2028Member_ccebe56a-516e-464b-823a-11b6f468b1b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A025ConvertibleSeniorNotesDue2027Member_f2a5912b-ac3c-4d04-8bc3-7cf4127ba025" xlink:href="halo-20240331.xsd#halo_A025ConvertibleSeniorNotesDue2027Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f6999d24-1e87-4b17-a989-bc50d831ab0c" xlink:to="loc_halo_A025ConvertibleSeniorNotesDue2027Member_f2a5912b-ac3c-4d04-8bc3-7cf4127ba025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A1.25ConvertibleSeniorNotesdue2024Member_29e22fdb-efd9-406d-ab57-01bae822dd67" xlink:href="halo-20240331.xsd#halo_A1.25ConvertibleSeniorNotesdue2024Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f6999d24-1e87-4b17-a989-bc50d831ab0c" xlink:to="loc_halo_A1.25ConvertibleSeniorNotesdue2024Member_29e22fdb-efd9-406d-ab57-01bae822dd67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_CreditAgreementMember_e2e1e68d-d36b-4814-aa79-80f08d766f21" xlink:href="halo-20240331.xsd#halo_CreditAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f6999d24-1e87-4b17-a989-bc50d831ab0c" xlink:to="loc_halo_CreditAgreementMember_e2e1e68d-d36b-4814-aa79-80f08d766f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3fa85c72-9ae6-4d7c-92e3-9634f9c66524" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_45da4622-135a-4b64-a1c0-ce6afeef463d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3fa85c72-9ae6-4d7c-92e3-9634f9c66524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_42a5520e-78bf-49ca-8bd4-78bd3dc5b05d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3fa85c72-9ae6-4d7c-92e3-9634f9c66524" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_42a5520e-78bf-49ca-8bd4-78bd3dc5b05d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_d908d269-2589-42f2-84dd-d321efe9b08b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_42a5520e-78bf-49ca-8bd4-78bd3dc5b05d" xlink:to="loc_us-gaap_ConvertibleDebtMember_d908d269-2589-42f2-84dd-d321efe9b08b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_TermLoanFacilityMember_c74629f2-a516-41a1-861c-70b3c5052d2c" xlink:href="halo-20240331.xsd#halo_TermLoanFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_42a5520e-78bf-49ca-8bd4-78bd3dc5b05d" xlink:to="loc_halo_TermLoanFacilityMember_c74629f2-a516-41a1-861c-70b3c5052d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_66e2bf8e-0447-411c-ba84-e303ac95cafb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_45da4622-135a-4b64-a1c0-ce6afeef463d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_66e2bf8e-0447-411c-ba84-e303ac95cafb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_ff7d3253-1eea-4453-9656-509dc10a90ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_66e2bf8e-0447-411c-ba84-e303ac95cafb" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_ff7d3253-1eea-4453-9656-509dc10a90ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_f321165f-3044-4ae6-b744-ff5b51b7d9c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_ff7d3253-1eea-4453-9656-509dc10a90ec" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_f321165f-3044-4ae6-b744-ff5b51b7d9c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_f319a97f-e110-406e-bef7-e9a74cb437e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_ff7d3253-1eea-4453-9656-509dc10a90ec" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_f319a97f-e110-406e-bef7-e9a74cb437e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_026829a3-072f-421f-96c9-64f0d2a77df9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_45da4622-135a-4b64-a1c0-ce6afeef463d" xlink:to="loc_us-gaap_VariableRateAxis_026829a3-072f-421f-96c9-64f0d2a77df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_2e9933ba-85f2-44f2-b35f-b8107e4dbeba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_026829a3-072f-421f-96c9-64f0d2a77df9" xlink:to="loc_us-gaap_VariableRateDomain_2e9933ba-85f2-44f2-b35f-b8107e4dbeba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_53deceaf-87b1-4a7f-b632-65f96176e6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_2e9933ba-85f2-44f2-b35f-b8107e4dbeba" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_53deceaf-87b1-4a7f-b632-65f96176e6ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_0431c560-fdf5-4e55-acf1-5f9e99dd8466" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_2e9933ba-85f2-44f2-b35f-b8107e4dbeba" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_0431c560-fdf5-4e55-acf1-5f9e99dd8466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_be9a9293-a31c-422b-b39f-4d90cd241a69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_2e9933ba-85f2-44f2-b35f-b8107e4dbeba" xlink:to="loc_us-gaap_BaseRateMember_be9a9293-a31c-422b-b39f-4d90cd241a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cbc0a3b2-4161-4775-8b66-96f08b0fc5d4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_45da4622-135a-4b64-a1c0-ce6afeef463d" xlink:to="loc_srt_RangeAxis_cbc0a3b2-4161-4775-8b66-96f08b0fc5d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_32e889f7-df29-40aa-b3cb-14783b963db7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_cbc0a3b2-4161-4775-8b66-96f08b0fc5d4" xlink:to="loc_srt_RangeMember_32e889f7-df29-40aa-b3cb-14783b963db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8e5a200a-e6f0-4b15-94c0-20394925b077" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_32e889f7-df29-40aa-b3cb-14783b963db7" xlink:to="loc_srt_MinimumMember_8e5a200a-e6f0-4b15-94c0-20394925b077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e8a723b8-19de-4910-8059-b499d125ed83" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_32e889f7-df29-40aa-b3cb-14783b963db7" xlink:to="loc_srt_MaximumMember_e8a723b8-19de-4910-8059-b499d125ed83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_f31de8e1-f5ea-4f34-b8bd-55097afda20b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_45da4622-135a-4b64-a1c0-ce6afeef463d" xlink:to="loc_us-gaap_CreditFacilityAxis_f31de8e1-f5ea-4f34-b8bd-55097afda20b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_7189a399-05aa-4b1a-a6a3-4ee07559f390" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_f31de8e1-f5ea-4f34-b8bd-55097afda20b" xlink:to="loc_us-gaap_CreditFacilityDomain_7189a399-05aa-4b1a-a6a3-4ee07559f390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_9c0f6dec-64ea-41d1-88b7-a6020f7bb52c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_7189a399-05aa-4b1a-a6a3-4ee07559f390" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_9c0f6dec-64ea-41d1-88b7-a6020f7bb52c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AnnualInterestPaymentPeriodAxis_ac008b69-0199-4885-a029-e7b78099f1d8" xlink:href="halo-20240331.xsd#halo_AnnualInterestPaymentPeriodAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_45da4622-135a-4b64-a1c0-ce6afeef463d" xlink:to="loc_halo_AnnualInterestPaymentPeriodAxis_ac008b69-0199-4885-a029-e7b78099f1d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AnnualInterestPaymentPeriodDomain_c4779b36-a6df-4103-971a-1a5da327860c" xlink:href="halo-20240331.xsd#halo_AnnualInterestPaymentPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_AnnualInterestPaymentPeriodAxis_ac008b69-0199-4885-a029-e7b78099f1d8" xlink:to="loc_halo_AnnualInterestPaymentPeriodDomain_c4779b36-a6df-4103-971a-1a5da327860c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentInterestPeriodOneMember_2ae2b432-34fc-4189-8c16-179022383ee2" xlink:href="halo-20240331.xsd#halo_DebtInstrumentInterestPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_AnnualInterestPaymentPeriodDomain_c4779b36-a6df-4103-971a-1a5da327860c" xlink:to="loc_halo_DebtInstrumentInterestPeriodOneMember_2ae2b432-34fc-4189-8c16-179022383ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentInterestPeriodTwoMember_b098c8d2-bcc0-4184-978b-39da99a77532" xlink:href="halo-20240331.xsd#halo_DebtInstrumentInterestPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_AnnualInterestPaymentPeriodDomain_c4779b36-a6df-4103-971a-1a5da327860c" xlink:to="loc_halo_DebtInstrumentInterestPeriodTwoMember_b098c8d2-bcc0-4184-978b-39da99a77532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentInterestPeriodThreeMember_7c9d2a80-427e-41ef-adff-7ec91f1134cd" xlink:href="halo-20240331.xsd#halo_DebtInstrumentInterestPeriodThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_AnnualInterestPaymentPeriodDomain_c4779b36-a6df-4103-971a-1a5da327860c" xlink:to="loc_halo_DebtInstrumentInterestPeriodThreeMember_7c9d2a80-427e-41ef-adff-7ec91f1134cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentInterestPeriodFourMember_6a500dce-ad56-41bd-bf58-2399941a1084" xlink:href="halo-20240331.xsd#halo_DebtInstrumentInterestPeriodFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_AnnualInterestPaymentPeriodDomain_c4779b36-a6df-4103-971a-1a5da327860c" xlink:to="loc_halo_DebtInstrumentInterestPeriodFourMember_6a500dce-ad56-41bd-bf58-2399941a1084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentAxis_9738459b-e8b6-4704-bfa5-8329470d45f1" xlink:href="halo-20240331.xsd#halo_VariableRateComponentAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_45da4622-135a-4b64-a1c0-ce6afeef463d" xlink:to="loc_halo_VariableRateComponentAxis_9738459b-e8b6-4704-bfa5-8329470d45f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentDomain_68d4a88a-8670-44f0-b62f-6269d160f40f" xlink:href="halo-20240331.xsd#halo_VariableRateComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_VariableRateComponentAxis_9738459b-e8b6-4704-bfa5-8329470d45f1" xlink:to="loc_halo_VariableRateComponentDomain_68d4a88a-8670-44f0-b62f-6269d160f40f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentOneMember_f0070773-af50-4885-a62c-7bbbc5736281" xlink:href="halo-20240331.xsd#halo_VariableRateComponentOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_VariableRateComponentDomain_68d4a88a-8670-44f0-b62f-6269d160f40f" xlink:to="loc_halo_VariableRateComponentOneMember_f0070773-af50-4885-a62c-7bbbc5736281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentTwoMember_17e304f7-e30a-4fab-a441-1f98c6085669" xlink:href="halo-20240331.xsd#halo_VariableRateComponentTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_VariableRateComponentDomain_68d4a88a-8670-44f0-b62f-6269d160f40f" xlink:to="loc_halo_VariableRateComponentTwoMember_17e304f7-e30a-4fab-a441-1f98c6085669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ab381bde-8376-4b94-b8c0-6bbaeb548c07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_45da4622-135a-4b64-a1c0-ce6afeef463d" xlink:to="loc_us-gaap_DebtInstrumentLineItems_ab381bde-8376-4b94-b8c0-6bbaeb548c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_220b3e62-6039-4beb-817b-084c9f422834" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ab381bde-8376-4b94-b8c0-6bbaeb548c07" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_220b3e62-6039-4beb-817b-084c9f422834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_d2819480-0498-4143-bb9e-c2a34dc7b666" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ab381bde-8376-4b94-b8c0-6bbaeb548c07" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_d2819480-0498-4143-bb9e-c2a34dc7b666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_3b336fd1-5dfd-4071-b407-ccc22ec1b94c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ab381bde-8376-4b94-b8c0-6bbaeb548c07" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_3b336fd1-5dfd-4071-b407-ccc22ec1b94c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_daaf5217-8a7f-4c13-987d-2b54c11967c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ab381bde-8376-4b94-b8c0-6bbaeb548c07" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_daaf5217-8a7f-4c13-987d-2b54c11967c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_e0350011-2f00-40c1-9c44-1deef725c3da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ab381bde-8376-4b94-b8c0-6bbaeb548c07" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_e0350011-2f00-40c1-9c44-1deef725c3da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_27cce5bb-252f-4320-b952-373bfa000f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ab381bde-8376-4b94-b8c0-6bbaeb548c07" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_27cce5bb-252f-4320-b952-373bfa000f7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_3ef7de36-6ef4-4f59-8c91-f9ebaa2bc617" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ab381bde-8376-4b94-b8c0-6bbaeb548c07" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_3ef7de36-6ef4-4f59-8c91-f9ebaa2bc617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_2877a043-fa37-4149-9fa8-4b99b2af6963" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ab381bde-8376-4b94-b8c0-6bbaeb548c07" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_2877a043-fa37-4149-9fa8-4b99b2af6963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays_8c75dcaa-bcc6-4ad2-9f29-e2280819b1df" xlink:href="halo-20240331.xsd#halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ab381bde-8376-4b94-b8c0-6bbaeb548c07" xlink:to="loc_halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays_8c75dcaa-bcc6-4ad2-9f29-e2280819b1df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_bd7b06eb-c135-48a3-afa0-7ece7dfdde2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ab381bde-8376-4b94-b8c0-6bbaeb548c07" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_bd7b06eb-c135-48a3-afa0-7ece7dfdde2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_810df83e-458c-4522-a279-0b8262e94f27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ab381bde-8376-4b94-b8c0-6bbaeb548c07" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_810df83e-458c-4522-a279-0b8262e94f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentCapCallTransactionCapPricePerShare_d12c26fb-1f6b-4499-89fc-270377557989" xlink:href="halo-20240331.xsd#halo_DebtInstrumentCapCallTransactionCapPricePerShare"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ab381bde-8376-4b94-b8c0-6bbaeb548c07" xlink:to="loc_halo_DebtInstrumentCapCallTransactionCapPricePerShare_d12c26fb-1f6b-4499-89fc-270377557989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_SaleOfStockPremiumOverLastReportedSalePricePercentage_bc1e472b-a943-4bd9-be47-ecde2894c7df" xlink:href="halo-20240331.xsd#halo_SaleOfStockPremiumOverLastReportedSalePricePercentage"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ab381bde-8376-4b94-b8c0-6bbaeb548c07" xlink:to="loc_halo_SaleOfStockPremiumOverLastReportedSalePricePercentage_bc1e472b-a943-4bd9-be47-ecde2894c7df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_81930344-e700-4dbc-8d83-d2031e9efcbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ab381bde-8376-4b94-b8c0-6bbaeb548c07" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_81930344-e700-4dbc-8d83-d2031e9efcbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_PaymentForCappedCallTransactions_b8429052-e0c4-4712-b181-b472f65ea76a" xlink:href="halo-20240331.xsd#halo_PaymentForCappedCallTransactions"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ab381bde-8376-4b94-b8c0-6bbaeb548c07" xlink:to="loc_halo_PaymentForCappedCallTransactions_b8429052-e0c4-4712-b181-b472f65ea76a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_f3132a89-8a81-4ff1-acd0-e597dcf74ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ab381bde-8376-4b94-b8c0-6bbaeb548c07" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_f3132a89-8a81-4ff1-acd0-e597dcf74ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_4681ad3b-7233-4dbc-a9ad-9b67480958a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ab381bde-8376-4b94-b8c0-6bbaeb548c07" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_4681ad3b-7233-4dbc-a9ad-9b67480958a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ea10ded6-9321-4e11-b7d7-428f629e7438" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ab381bde-8376-4b94-b8c0-6bbaeb548c07" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ea10ded6-9321-4e11-b7d7-428f629e7438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_8dcebb7c-d921-4d29-90a2-c131141eaa87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ab381bde-8376-4b94-b8c0-6bbaeb548c07" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_8dcebb7c-d921-4d29-90a2-c131141eaa87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_310f79d0-2bf8-4583-8f11-c645cb2dd5c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ab381bde-8376-4b94-b8c0-6bbaeb548c07" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_310f79d0-2bf8-4583-8f11-c645cb2dd5c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_90494db3-859f-4d59-a20c-6e05dc916f98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ab381bde-8376-4b94-b8c0-6bbaeb548c07" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_90494db3-859f-4d59-a20c-6e05dc916f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_33e74ba7-e586-4eb4-9248-51626f91ed47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ab381bde-8376-4b94-b8c0-6bbaeb548c07" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_33e74ba7-e586-4eb4-9248-51626f91ed47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#LongTermDebtNetCarryingAmountofConvertibleNotesDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_c9becc8c-06ee-4c70-a47d-28f730085e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_5ed31473-ed53-4582-9d40-0dfe885aea54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c9becc8c-06ee-4c70-a47d-28f730085e0a" xlink:to="loc_us-gaap_DebtInstrumentTable_5ed31473-ed53-4582-9d40-0dfe885aea54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_6e645951-6d32-49e5-80d6-0da4810a65a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5ed31473-ed53-4582-9d40-0dfe885aea54" xlink:to="loc_us-gaap_DebtInstrumentAxis_6e645951-6d32-49e5-80d6-0da4810a65a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bfa5cd6f-a742-4acf-b7db-ef92b1f56328" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_6e645951-6d32-49e5-80d6-0da4810a65a8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bfa5cd6f-a742-4acf-b7db-ef92b1f56328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A025ConvertibleSeniorNotesDue2027Member_8d815816-6073-4742-8f04-caa13a5fcf0a" xlink:href="halo-20240331.xsd#halo_A025ConvertibleSeniorNotesDue2027Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bfa5cd6f-a742-4acf-b7db-ef92b1f56328" xlink:to="loc_halo_A025ConvertibleSeniorNotesDue2027Member_8d815816-6073-4742-8f04-caa13a5fcf0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A100ConvertibleSeniorNotesDue2028Member_e903e965-8334-49ca-a4cb-17c03d5352dd" xlink:href="halo-20240331.xsd#halo_A100ConvertibleSeniorNotesDue2028Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bfa5cd6f-a742-4acf-b7db-ef92b1f56328" xlink:to="loc_halo_A100ConvertibleSeniorNotesDue2028Member_e903e965-8334-49ca-a4cb-17c03d5352dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_78e85926-0adc-48be-bbc1-2e76f100848f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5ed31473-ed53-4582-9d40-0dfe885aea54" xlink:to="loc_us-gaap_DebtInstrumentLineItems_78e85926-0adc-48be-bbc1-2e76f100848f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_e7e71b2b-c158-4db1-9266-066cb062ccde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_78e85926-0adc-48be-bbc1-2e76f100848f" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_e7e71b2b-c158-4db1-9266-066cb062ccde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_658a6e6c-01a5-489d-bcc9-1096190e5a31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_78e85926-0adc-48be-bbc1-2e76f100848f" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_658a6e6c-01a5-489d-bcc9-1096190e5a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_9503df57-e1bc-452f-9075-7e4355e37f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_78e85926-0adc-48be-bbc1-2e76f100848f" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_9503df57-e1bc-452f-9075-7e4355e37f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_aef09b7f-be8e-44c5-bb75-d891be3c531e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_78e85926-0adc-48be-bbc1-2e76f100848f" xlink:to="loc_us-gaap_LongTermDebt_aef09b7f-be8e-44c5-bb75-d891be3c531e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_6ac51de8-d32f-42e0-b403-d721aaa563d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_78e85926-0adc-48be-bbc1-2e76f100848f" xlink:to="loc_us-gaap_DebtInstrumentFairValue_6ac51de8-d32f-42e0-b403-d721aaa563d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_55ac03eb-8fa9-4d09-9e15-7936b028ddee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_78e85926-0adc-48be-bbc1-2e76f100848f" xlink:to="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_55ac03eb-8fa9-4d09-9e15-7936b028ddee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#LongTermDebtNetComponentsofInterestExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b9ce718f-8a9c-428b-ae36-748361ac22c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_aa6b546b-aa20-4e28-9dd0-d871f403b21b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b9ce718f-8a9c-428b-ae36-748361ac22c8" xlink:to="loc_us-gaap_DebtInstrumentTable_aa6b546b-aa20-4e28-9dd0-d871f403b21b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_23125723-cf05-443d-8a1f-127232cc73fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_aa6b546b-aa20-4e28-9dd0-d871f403b21b" xlink:to="loc_us-gaap_DebtInstrumentAxis_23125723-cf05-443d-8a1f-127232cc73fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_23d5d4a0-7bb1-4129-a95e-f47b92e30337" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_23125723-cf05-443d-8a1f-127232cc73fa" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_23d5d4a0-7bb1-4129-a95e-f47b92e30337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A1.25ConvertibleSeniorNotesdue2024Member_42fad6b6-5db0-4da8-9e15-2680089543d8" xlink:href="halo-20240331.xsd#halo_A1.25ConvertibleSeniorNotesdue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_23d5d4a0-7bb1-4129-a95e-f47b92e30337" xlink:to="loc_halo_A1.25ConvertibleSeniorNotesdue2024Member_42fad6b6-5db0-4da8-9e15-2680089543d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A025ConvertibleSeniorNotesDue2027Member_61668a44-6119-46f9-9a2e-4732c55983e9" xlink:href="halo-20240331.xsd#halo_A025ConvertibleSeniorNotesDue2027Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_23d5d4a0-7bb1-4129-a95e-f47b92e30337" xlink:to="loc_halo_A025ConvertibleSeniorNotesDue2027Member_61668a44-6119-46f9-9a2e-4732c55983e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A100ConvertibleSeniorNotesDue2028Member_62ea4c7b-24a9-474b-8c3d-5af0e444dfb6" xlink:href="halo-20240331.xsd#halo_A100ConvertibleSeniorNotesDue2028Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_23d5d4a0-7bb1-4129-a95e-f47b92e30337" xlink:to="loc_halo_A100ConvertibleSeniorNotesDue2028Member_62ea4c7b-24a9-474b-8c3d-5af0e444dfb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1d714364-436b-4268-9ebd-b4a784a60da8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_aa6b546b-aa20-4e28-9dd0-d871f403b21b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1d714364-436b-4268-9ebd-b4a784a60da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e329fdd7-2737-464b-8a1d-9c7c4b43e62f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1d714364-436b-4268-9ebd-b4a784a60da8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e329fdd7-2737-464b-8a1d-9c7c4b43e62f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_a497abb1-ba0a-4661-80b1-71ebd34100d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e329fdd7-2737-464b-8a1d-9c7c4b43e62f" xlink:to="loc_us-gaap_ConvertibleDebtMember_a497abb1-ba0a-4661-80b1-71ebd34100d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_f2d25297-a6aa-4a8d-b580-94940595d364" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_aa6b546b-aa20-4e28-9dd0-d871f403b21b" xlink:to="loc_us-gaap_DebtInstrumentLineItems_f2d25297-a6aa-4a8d-b580-94940595d364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_d2a43b90-5fcf-4a24-9f39-404cb9777437" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f2d25297-a6aa-4a8d-b580-94940595d364" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_d2a43b90-5fcf-4a24-9f39-404cb9777437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_cbeaee1d-782d-4199-be2c-964ac487b7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f2d25297-a6aa-4a8d-b580-94940595d364" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_cbeaee1d-782d-4199-be2c-964ac487b7ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_8ff36f97-06b3-43b0-b182-2c600a955e42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f2d25297-a6aa-4a8d-b580-94940595d364" xlink:to="loc_us-gaap_InterestExpenseDebt_8ff36f97-06b3-43b0-b182-2c600a955e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_9a64b03e-fdcd-40f1-ad54-226947584a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f2d25297-a6aa-4a8d-b580-94940595d364" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_9a64b03e-fdcd-40f1-ad54-226947584a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#SharebasedCompensationSharebasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_c3e313cf-026b-4abc-a318-df5ecc8af527" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4405748f-7f1f-4e95-9570-7d8755168a46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_c3e313cf-026b-4abc-a318-df5ecc8af527" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4405748f-7f1f-4e95-9570-7d8755168a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_36e4fa9d-cdd4-45bb-a170-72959fd6b49d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4405748f-7f1f-4e95-9570-7d8755168a46" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_36e4fa9d-cdd4-45bb-a170-72959fd6b49d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_63943d7c-6ccf-491d-96ad-2551907feb56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_36e4fa9d-cdd4-45bb-a170-72959fd6b49d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_63943d7c-6ccf-491d-96ad-2551907feb56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2c773efc-d3c6-4b9f-985b-d374d8f2eced" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_63943d7c-6ccf-491d-96ad-2551907feb56" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2c773efc-d3c6-4b9f-985b-d374d8f2eced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_70b4af9e-83e1-48c9-a9b2-40d314d2c499" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_63943d7c-6ccf-491d-96ad-2551907feb56" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_70b4af9e-83e1-48c9-a9b2-40d314d2c499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bcf2171b-34bb-4ba3-94b9-99c9a949237b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4405748f-7f1f-4e95-9570-7d8755168a46" xlink:to="loc_us-gaap_AwardTypeAxis_bcf2171b-34bb-4ba3-94b9-99c9a949237b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a6eb39c7-e730-4b56-a5ff-5c42c82eda52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_bcf2171b-34bb-4ba3-94b9-99c9a949237b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a6eb39c7-e730-4b56-a5ff-5c42c82eda52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f7cdfd56-7086-4ea5-9e46-84c23ab41f71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a6eb39c7-e730-4b56-a5ff-5c42c82eda52" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f7cdfd56-7086-4ea5-9e46-84c23ab41f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RSURSAandPRSUawardsMember_cdcda707-0ed5-45b8-b19e-da2b15186489" xlink:href="halo-20240331.xsd#halo_RSURSAandPRSUawardsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a6eb39c7-e730-4b56-a5ff-5c42c82eda52" xlink:to="loc_halo_RSURSAandPRSUawardsMember_cdcda707-0ed5-45b8-b19e-da2b15186489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_840f61d6-92bb-4343-84d2-a9264072eb4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4405748f-7f1f-4e95-9570-7d8755168a46" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_840f61d6-92bb-4343-84d2-a9264072eb4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6f0f87e5-d59f-48f6-87b9-fe1dc5e4ddc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_840f61d6-92bb-4343-84d2-a9264072eb4e" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6f0f87e5-d59f-48f6-87b9-fe1dc5e4ddc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#SharebasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_4b7b0a5e-32f8-459f-964f-eabf45e19791" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dc373bc1-204a-4a79-b2a7-6affb52a0607" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_4b7b0a5e-32f8-459f-964f-eabf45e19791" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dc373bc1-204a-4a79-b2a7-6affb52a0607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f5eac0b9-9605-459f-ad20-f3248a1031dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dc373bc1-204a-4a79-b2a7-6affb52a0607" xlink:to="loc_us-gaap_AwardTypeAxis_f5eac0b9-9605-459f-ad20-f3248a1031dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df9363d4-4086-4e75-818e-4c565d65bd48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f5eac0b9-9605-459f-ad20-f3248a1031dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df9363d4-4086-4e75-818e-4c565d65bd48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_9088d327-f92e-4c41-9315-7b22393a8b79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df9363d4-4086-4e75-818e-4c565d65bd48" xlink:to="loc_us-gaap_EmployeeStockOptionMember_9088d327-f92e-4c41-9315-7b22393a8b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RSURSAandPRSUawardsMember_073f1b72-85d0-4f32-9c29-709fdebb6f60" xlink:href="halo-20240331.xsd#halo_RSURSAandPRSUawardsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df9363d4-4086-4e75-818e-4c565d65bd48" xlink:to="loc_halo_RSURSAandPRSUawardsMember_073f1b72-85d0-4f32-9c29-709fdebb6f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_4a539ea4-3598-44d5-aa91-787684d2a753" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df9363d4-4086-4e75-818e-4c565d65bd48" xlink:to="loc_us-gaap_EmployeeStockMember_4a539ea4-3598-44d5-aa91-787684d2a753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_094de255-ba7e-4328-b117-71ead6a8705b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dc373bc1-204a-4a79-b2a7-6affb52a0607" xlink:to="loc_us-gaap_PlanNameAxis_094de255-ba7e-4328-b117-71ead6a8705b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_3c814820-7247-405b-bc5f-96b132c10e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_094de255-ba7e-4328-b117-71ead6a8705b" xlink:to="loc_us-gaap_PlanNameDomain_3c814820-7247-405b-bc5f-96b132c10e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A2021ESPPPlanMember_8b35fd4e-5c2d-4cda-879b-86cb6a209fc0" xlink:href="halo-20240331.xsd#halo_A2021ESPPPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3c814820-7247-405b-bc5f-96b132c10e5d" xlink:to="loc_halo_A2021ESPPPlanMember_8b35fd4e-5c2d-4cda-879b-86cb6a209fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4adf41ad-c98a-4537-9261-7308962cd20b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dc373bc1-204a-4a79-b2a7-6affb52a0607" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4adf41ad-c98a-4537-9261-7308962cd20b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_248c739e-2381-4ce7-b7d9-719ac2590b98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4adf41ad-c98a-4537-9261-7308962cd20b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_248c739e-2381-4ce7-b7d9-719ac2590b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_0b9e6421-3e56-4f3f-855a-82f1c67aa26e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4adf41ad-c98a-4537-9261-7308962cd20b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_0b9e6421-3e56-4f3f-855a-82f1c67aa26e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate_2708f7a9-30fc-44b9-8832-1c348b6f61ba" xlink:href="halo-20240331.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4adf41ad-c98a-4537-9261-7308962cd20b" xlink:to="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate_2708f7a9-30fc-44b9-8832-1c348b6f61ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_f99d5042-6eea-4a23-9de3-6dedc6a4604a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4adf41ad-c98a-4537-9261-7308962cd20b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_f99d5042-6eea-4a23-9de3-6dedc6a4604a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_2bf1451f-8ed9-47cb-81f0-4fd29fa12216" xlink:href="halo-20240331.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4adf41ad-c98a-4537-9261-7308962cd20b" xlink:to="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_2bf1451f-8ed9-47cb-81f0-4fd29fa12216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7c3e53d5-a230-4e01-adfe-7268ad84ec2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4adf41ad-c98a-4537-9261-7308962cd20b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7c3e53d5-a230-4e01-adfe-7268ad84ec2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_6f9bc57f-bf88-44d3-967a-62342de9dacd" xlink:href="halo-20240331.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4adf41ad-c98a-4537-9261-7308962cd20b" xlink:to="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_6f9bc57f-bf88-44d3-967a-62342de9dacd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_e5ae9a8a-474c-4900-a7df-eb9993997886" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable_7ea82d73-f096-4693-b725-27c4d6af29cd" xlink:href="halo-20240331.xsd#halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_e5ae9a8a-474c-4900-a7df-eb9993997886" xlink:to="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable_7ea82d73-f096-4693-b725-27c4d6af29cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_762d085b-185f-4333-8bb6-4c48d4bd9a64" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable_7ea82d73-f096-4693-b725-27c4d6af29cd" xlink:to="loc_srt_RangeAxis_762d085b-185f-4333-8bb6-4c48d4bd9a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_831d9d6a-0546-44b7-9241-74e09e41006e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_762d085b-185f-4333-8bb6-4c48d4bd9a64" xlink:to="loc_srt_RangeMember_831d9d6a-0546-44b7-9241-74e09e41006e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_37b13c75-16bb-4c2f-9ed8-441c37139c28" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_831d9d6a-0546-44b7-9241-74e09e41006e" xlink:to="loc_srt_MinimumMember_37b13c75-16bb-4c2f-9ed8-441c37139c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1f4dc48d-19b3-4726-aed6-335dae35dd3d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_831d9d6a-0546-44b7-9241-74e09e41006e" xlink:to="loc_srt_MaximumMember_1f4dc48d-19b3-4726-aed6-335dae35dd3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_57bf4f03-7189-48c2-8b8b-11050eb0bae8" xlink:href="halo-20240331.xsd#halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable_7ea82d73-f096-4693-b725-27c4d6af29cd" xlink:to="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_57bf4f03-7189-48c2-8b8b-11050eb0bae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_1d06597f-7b5f-418d-957e-96664d58a7b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_57bf4f03-7189-48c2-8b8b-11050eb0bae8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_1d06597f-7b5f-418d-957e-96664d58a7b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9201183f-7ee6-4485-a92f-d937f94d2527" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_57bf4f03-7189-48c2-8b8b-11050eb0bae8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9201183f-7ee6-4485-a92f-d937f94d2527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_116c07e3-ee00-4b49-9137-574af1171bfe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_57bf4f03-7189-48c2-8b8b-11050eb0bae8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_116c07e3-ee00-4b49-9137-574af1171bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_7fb357a7-5646-4b09-b716-dd7154740a16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_57bf4f03-7189-48c2-8b8b-11050eb0bae8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_7fb357a7-5646-4b09-b716-dd7154740a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_74620584-2419-4aa6-a30a-9164db12bb20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_57bf4f03-7189-48c2-8b8b-11050eb0bae8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_74620584-2419-4aa6-a30a-9164db12bb20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_4ee87f25-67e0-4f7a-a99c-cde70718bd90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_79ca65d8-ab3d-4466-8a5b-d073b93cdf6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_4ee87f25-67e0-4f7a-a99c-cde70718bd90" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_79ca65d8-ab3d-4466-8a5b-d073b93cdf6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b3c81768-cceb-4d3f-a24a-2d4047e6a54e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_79ca65d8-ab3d-4466-8a5b-d073b93cdf6b" xlink:to="loc_us-gaap_AwardTypeAxis_b3c81768-cceb-4d3f-a24a-2d4047e6a54e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f1f358c-9436-4efd-a8f2-3c1b6360f21f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b3c81768-cceb-4d3f-a24a-2d4047e6a54e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f1f358c-9436-4efd-a8f2-3c1b6360f21f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7260ce0c-3374-42e0-bfc0-e2f5222d7f66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f1f358c-9436-4efd-a8f2-3c1b6360f21f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7260ce0c-3374-42e0-bfc0-e2f5222d7f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e6364348-5f4a-4d81-b197-9572f017a236" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f1f358c-9436-4efd-a8f2-3c1b6360f21f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e6364348-5f4a-4d81-b197-9572f017a236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_c32959b5-a62a-45e5-9f59-b92adbf405f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f1f358c-9436-4efd-a8f2-3c1b6360f21f" xlink:to="loc_us-gaap_PerformanceSharesMember_c32959b5-a62a-45e5-9f59-b92adbf405f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_a22edab9-f716-455a-9ab0-9f2569f63d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f1f358c-9436-4efd-a8f2-3c1b6360f21f" xlink:to="loc_us-gaap_EmployeeStockMember_a22edab9-f716-455a-9ab0-9f2569f63d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c033c7f-c608-4939-89b4-a4f5a076e31b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_79ca65d8-ab3d-4466-8a5b-d073b93cdf6b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c033c7f-c608-4939-89b4-a4f5a076e31b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_8eed62df-5bc8-4da3-886e-bb63fb1020dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c033c7f-c608-4939-89b4-a4f5a076e31b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_8eed62df-5bc8-4da3-886e-bb63fb1020dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_56a45ff7-31e0-4def-abf2-9217f0d1b292" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c033c7f-c608-4939-89b4-a4f5a076e31b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_56a45ff7-31e0-4def-abf2-9217f0d1b292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_35e44f22-b91b-4605-9adc-b8688d7f44cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_21ec367e-10c2-4dec-be17-59db4c982531" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_35e44f22-b91b-4605-9adc-b8688d7f44cd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_21ec367e-10c2-4dec-be17-59db4c982531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_118163b7-9dee-4e80-84f6-0c510700d791" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_21ec367e-10c2-4dec-be17-59db4c982531" xlink:to="loc_us-gaap_AwardTypeAxis_118163b7-9dee-4e80-84f6-0c510700d791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b6193fa8-af2a-4450-8589-faece9cc730c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_118163b7-9dee-4e80-84f6-0c510700d791" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b6193fa8-af2a-4450-8589-faece9cc730c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ce4b5334-9ac4-47ca-b626-06edb047267f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b6193fa8-af2a-4450-8589-faece9cc730c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ce4b5334-9ac4-47ca-b626-06edb047267f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RestrictedStockUnitsAndPerformanceSharesMember_952df324-d408-49e2-801a-f05dc34404e6" xlink:href="halo-20240331.xsd#halo_RestrictedStockUnitsAndPerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b6193fa8-af2a-4450-8589-faece9cc730c" xlink:to="loc_halo_RestrictedStockUnitsAndPerformanceSharesMember_952df324-d408-49e2-801a-f05dc34404e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_StockOptionsAndRestrictedStockUnitsMember_17663e9b-8826-4b5e-b7b1-0770dfb89245" xlink:href="halo-20240331.xsd#halo_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b6193fa8-af2a-4450-8589-faece9cc730c" xlink:to="loc_halo_StockOptionsAndRestrictedStockUnitsMember_17663e9b-8826-4b5e-b7b1-0770dfb89245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_cc608e1f-4b39-450f-8567-997f2f8a9ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_21ec367e-10c2-4dec-be17-59db4c982531" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_cc608e1f-4b39-450f-8567-997f2f8a9ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_49a15e20-1340-49e3-9a16-d6b7e044748c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_cc608e1f-4b39-450f-8567-997f2f8a9ae0" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_49a15e20-1340-49e3-9a16-d6b7e044748c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AcceleratedShareRepurchaseAgreementMember_5db8c8e5-110b-4663-b6ad-16c277d14f5f" xlink:href="halo-20240331.xsd#halo_AcceleratedShareRepurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_49a15e20-1340-49e3-9a16-d6b7e044748c" xlink:to="loc_halo_AcceleratedShareRepurchaseAgreementMember_5db8c8e5-110b-4663-b6ad-16c277d14f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A2024CapitalReturnProgramMember_dbe4ca9c-671b-40a1-be01-61462fdf09c5" xlink:href="halo-20240331.xsd#halo_A2024CapitalReturnProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_49a15e20-1340-49e3-9a16-d6b7e044748c" xlink:to="loc_halo_A2024CapitalReturnProgramMember_dbe4ca9c-671b-40a1-be01-61462fdf09c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4876fe32-0f06-4bce-9203-e2b6f1753cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_21ec367e-10c2-4dec-be17-59db4c982531" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4876fe32-0f06-4bce-9203-e2b6f1753cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_29ddf2ba-3f5c-4018-b01c-e43bc77c2f81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4876fe32-0f06-4bce-9203-e2b6f1753cc9" xlink:to="loc_us-gaap_StockholdersEquityAbstract_29ddf2ba-3f5c-4018-b01c-e43bc77c2f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c150f61f-1729-4671-a2ab-f5843e1e0a28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29ddf2ba-3f5c-4018-b01c-e43bc77c2f81" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c150f61f-1729-4671-a2ab-f5843e1e0a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_457a7e43-8125-4c94-a9d5-6c3d212a74ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29ddf2ba-3f5c-4018-b01c-e43bc77c2f81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_457a7e43-8125-4c94-a9d5-6c3d212a74ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_09478f9c-b3f6-4211-a24a-b47b87a9a159" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29ddf2ba-3f5c-4018-b01c-e43bc77c2f81" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_09478f9c-b3f6-4211-a24a-b47b87a9a159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_461602f3-be82-4eb8-a9ea-974889f9daf3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29ddf2ba-3f5c-4018-b01c-e43bc77c2f81" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_461602f3-be82-4eb8-a9ea-974889f9daf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_20b415f8-5c65-4c7a-b4c0-2ff46b7596fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29ddf2ba-3f5c-4018-b01c-e43bc77c2f81" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_20b415f8-5c65-4c7a-b4c0-2ff46b7596fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_0236a373-8a5f-4c8a-b20f-9de337882de6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29ddf2ba-3f5c-4018-b01c-e43bc77c2f81" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_0236a373-8a5f-4c8a-b20f-9de337882de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_138f4ea8-12e6-4d88-98e3-ef52fc95828a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29ddf2ba-3f5c-4018-b01c-e43bc77c2f81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_138f4ea8-12e6-4d88-98e3-ef52fc95828a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_6f9bbf87-4399-4e37-9d56-9cc6f6048315" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29ddf2ba-3f5c-4018-b01c-e43bc77c2f81" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_6f9bbf87-4399-4e37-9d56-9cc6f6048315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramPeriodInForce1_806e4002-04ab-4a48-8d3b-01da487dbcd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramPeriodInForce1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29ddf2ba-3f5c-4018-b01c-e43bc77c2f81" xlink:to="loc_us-gaap_StockRepurchaseProgramPeriodInForce1_806e4002-04ab-4a48-8d3b-01da487dbcd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_f234ad2f-bcc4-4b55-bf4c-b85c48278a81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29ddf2ba-3f5c-4018-b01c-e43bc77c2f81" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_f234ad2f-bcc4-4b55-bf4c-b85c48278a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_e4c0f50e-d64d-4c3d-88a1-305021845f18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29ddf2ba-3f5c-4018-b01c-e43bc77c2f81" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_e4c0f50e-d64d-4c3d-88a1-305021845f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_3edfb1e8-50d6-418d-96e1-467f7d10f99b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29ddf2ba-3f5c-4018-b01c-e43bc77c2f81" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_3edfb1e8-50d6-418d-96e1-467f7d10f99b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_1c0f740c-c28e-4094-92ea-08cada5e8cad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29ddf2ba-3f5c-4018-b01c-e43bc77c2f81" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_1c0f740c-c28e-4094-92ea-08cada5e8cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/EarningspershareComputationDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#EarningspershareComputationDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/EarningspershareComputationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_88c31b9c-711d-4d0c-ac07-4087af9cf1d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_bdb7bcf9-4c7b-4b37-81cf-e4fd4a0880ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_88c31b9c-711d-4d0c-ac07-4087af9cf1d6" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_bdb7bcf9-4c7b-4b37-81cf-e4fd4a0880ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_861b3ce6-1421-46b5-a7d4-1c26d1fa28b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_bdb7bcf9-4c7b-4b37-81cf-e4fd4a0880ab" xlink:to="loc_us-gaap_AwardTypeAxis_861b3ce6-1421-46b5-a7d4-1c26d1fa28b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7de5431c-ce1e-4982-a09a-5a74e3398bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_861b3ce6-1421-46b5-a7d4-1c26d1fa28b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7de5431c-ce1e-4982-a09a-5a74e3398bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d01deafc-7009-4ca7-9937-75a8825f48e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7de5431c-ce1e-4982-a09a-5a74e3398bfb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d01deafc-7009-4ca7-9937-75a8825f48e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RestrictStockUnitsPerformanceSharesAndESPPMember_99e75fbc-3b64-4378-9711-f4d8818d5c06" xlink:href="halo-20240331.xsd#halo_RestrictStockUnitsPerformanceSharesAndESPPMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7de5431c-ce1e-4982-a09a-5a74e3398bfb" xlink:to="loc_halo_RestrictStockUnitsPerformanceSharesAndESPPMember_99e75fbc-3b64-4378-9711-f4d8818d5c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8fcc95fb-4843-4446-af5e-5e9e059e4f46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_bdb7bcf9-4c7b-4b37-81cf-e4fd4a0880ab" xlink:to="loc_us-gaap_DebtInstrumentAxis_8fcc95fb-4843-4446-af5e-5e9e059e4f46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a3a0e209-cb33-40da-af40-8be89df1b0e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_8fcc95fb-4843-4446-af5e-5e9e059e4f46" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a3a0e209-cb33-40da-af40-8be89df1b0e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_ccdbd8f7-2605-4305-b720-0da246013b81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a3a0e209-cb33-40da-af40-8be89df1b0e6" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_ccdbd8f7-2605-4305-b720-0da246013b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems_bce6ad63-beb5-4bc7-846e-9c7c4dd77215" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_bdb7bcf9-4c7b-4b37-81cf-e4fd4a0880ab" xlink:to="loc_us-gaap_EarningsPerShareDilutedLineItems_bce6ad63-beb5-4bc7-846e-9c7c4dd77215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_38a34b7d-7605-4d07-adf1-749ec2b901a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_bce6ad63-beb5-4bc7-846e-9c7c4dd77215" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_38a34b7d-7605-4d07-adf1-749ec2b901a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_dfd95c4f-5ccb-40ad-b661-ba5e379bb048" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_38a34b7d-7605-4d07-adf1-749ec2b901a9" xlink:to="loc_us-gaap_NetIncomeLoss_dfd95c4f-5ccb-40ad-b661-ba5e379bb048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_91682c6d-2b80-445a-b252-90886cdadbea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_bce6ad63-beb5-4bc7-846e-9c7c4dd77215" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_91682c6d-2b80-445a-b252-90886cdadbea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_69af07bf-5672-42d5-b223-b97e416302ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_91682c6d-2b80-445a-b252-90886cdadbea" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_69af07bf-5672-42d5-b223-b97e416302ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_cf39fb35-fb93-4408-9c16-12e8478cbdd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_91682c6d-2b80-445a-b252-90886cdadbea" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_cf39fb35-fb93-4408-9c16-12e8478cbdd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_44864326-747b-45f9-819b-1a7b0314cd3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_cf39fb35-fb93-4408-9c16-12e8478cbdd0" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_44864326-747b-45f9-819b-1a7b0314cd3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_68bb64f6-5a2f-433f-8d4e-5d42a1c35303" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_cf39fb35-fb93-4408-9c16-12e8478cbdd0" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_68bb64f6-5a2f-433f-8d4e-5d42a1c35303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_d0def7ba-6459-4339-b0a8-21dda4a29705" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_bce6ad63-beb5-4bc7-846e-9c7c4dd77215" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_d0def7ba-6459-4339-b0a8-21dda4a29705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_6465efde-8e0d-48e6-83c5-97b1723b201f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_d0def7ba-6459-4339-b0a8-21dda4a29705" xlink:to="loc_us-gaap_EarningsPerShareBasic_6465efde-8e0d-48e6-83c5-97b1723b201f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_497218c7-b32a-40b3-aa67-95fa6f5c2f87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_d0def7ba-6459-4339-b0a8-21dda4a29705" xlink:to="loc_us-gaap_EarningsPerShareDiluted_497218c7-b32a-40b3-aa67-95fa6f5c2f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/EarningspershareAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="halo-20240331.xsd#EarningspershareAntidilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/EarningspershareAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3edab6af-8da7-4c66-af97-2e0cce74f6ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7a4883c5-e750-4aa1-be4e-0b6ea40d2fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3edab6af-8da7-4c66-af97-2e0cce74f6ce" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7a4883c5-e750-4aa1-be4e-0b6ea40d2fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RSURSAandPRSUawardsMember" xlink:href="halo-20240331.xsd#halo_RSURSAandPRSUawardsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_halo_RSURSAandPRSUawardsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_PerformanceSharesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RestrictedStockUnitsAndPerformanceSharesMember" xlink:href="halo-20240331.xsd#halo_RestrictedStockUnitsAndPerformanceSharesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_halo_RestrictedStockUnitsAndPerformanceSharesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_StockOptionsAndRestrictedStockUnitsMember" xlink:href="halo-20240331.xsd#halo_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_halo_StockOptionsAndRestrictedStockUnitsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RestrictStockUnitsPerformanceSharesAndESPPMember" xlink:href="halo-20240331.xsd#halo_RestrictStockUnitsPerformanceSharesAndESPPMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_halo_RestrictStockUnitsPerformanceSharesAndESPPMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_HelenTorleyPriorPlanMember" xlink:href="halo-20240331.xsd#halo_HelenTorleyPriorPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_halo_HelenTorleyPriorPlanMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_HelenTorleyMarch2024PlanMember" xlink:href="halo-20240331.xsd#halo_HelenTorleyMarch2024PlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_halo_HelenTorleyMarch2024PlanMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_HelenTorleyMember" xlink:href="halo-20240331.xsd#halo_HelenTorleyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_halo_HelenTorleyMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_NicoleLaBrosseMember" xlink:href="halo-20240331.xsd#halo_NicoleLaBrosseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_halo_NicoleLaBrosseMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>halo-20240331_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 halo-20240331_g1.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#Z17AI9@  34T *@    @ ! $[  (
M   0   (2H=I  0    !   (6IR=  $    @   0TNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $=E=&%S97<@
M665S96=A=   !9 #  (    4   0J) $  (    4   0O)*1  (    #,S8
M )*2  (    #,S8  .H<  <   @,   (G      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" "F 9D# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#Z1HHHH **
M** "BBB@ HHJ&[O+>PM7N;R5888QEG8\"C83:2NR:BO/K_XJVT4Q33=/>= ?
M]9+)LS]!@T_3?BG9SS+'J=E):@G'FQOYBCW(P#^6:Y_K-*]KG']?PW-R\QWU
M%1P3Q7,"36\BRQ2#<KH<AAZU)70=NX4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\[5]-D\;4Y2[O\O^'/D<^G>K"'9?G_PP %F 4$DG  [U]4Z;:_8=)M+3_GA
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MHD&EZU#=6B"..\5F9%& '4C./KD'ZYK*OAO9+G@SEQF 6'C[6D]CNO!GB?\
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M/J,UYM\3/$3W-Q'X<TTEW9E^T!.K,?NI_(_E78>*-=A\+>'6G7!EVB*VC/\
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MZ6V.3'("?Q7_ !KU.O+?C!_Q]Z5_N2?S6A :GQ$O'C^'MD@;FY>%7]P$+?S
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MEL<6#HO%8AU)[;O_ "-BBBBO8/J0HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH XG7? MSX@\61ZE>WL1LT**+
M?:<[%Y*Y]SG\Z[8#' X%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %>,?%EYM8\<Z;HUH-\BQ*BC/\ '(W^ 6O9Z\Q\,V']O_%W6]<E&Z#3
MI##$3T+@>6,?158_B#7H8"2IRE6?V5^+T1Y>91=6$*"^TU]RU9Z%I6G0Z1I%
MKI]L/W=M$L8..N!R?J3S7G_Q4U7?<VFE1MQ&/.E ]3POZ9_.O2W8(A=SA5&2
M3V%>%W+7/BWQA(;<$O>3X3/\*#@$_11^E>)C*C<;=9$YE/DHJC#KI\CH_AIX
M>^U7K:Q=)^ZMSM@!'WG[G\!^I]J]2JKIFGP:5IL%E:KB*% H]_4GW)YJU6M&
MFJ<.4[,+AUAZ2AUZ^H4445L=04444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 07UTECI]Q=R_<MXFE;Z*"3_*L/P)HS:-X3MUN!
MB[NB;FY..=[\X/T&!^%=!-#'<0/#.BR1R JZ,,A@>Q%/K13M3<%U_0R=.]13
M?1?G_P ,<SX^U3^S/"<ZHV);K]PGT/WO_'<_G65\-/#WV2P;5[I,37(VP@C[
ML?K^)_0>]1>);9_%7CRUT9"WV6QC\RY8=LX)_$C:!]37?1QI%&L<2A$10JJ!
M@ #H*X8Q]I6<WLM$<<(>VQ+JO:.B]>HZBBBNH]$**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IDL@BA>1@2$4L0/844
M4">Q@^#[$1Z6^J2X:ZU1OM,K#L&Y51[ '^==#116=/2",L.DJ4;=@HHHK0V"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>halo-20240331_g2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 halo-20240331_g2.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X0+Z17AI9@  34T *@    @ ! $[  (
M   0   !2H=I  0    !   !6IR=  $    @   "TNH<  <   $,    /@
M   <Z@    $
M
M
M
M
M
M1V5T87-E=R!997-E9V%T   %D ,  @   !0   *HD 0  @   !0   *\DI$
M @    ,P-0  DI(  @    ,P-0  ZAP !P   0P   &<     !SJ     0
M
M
M
M
M
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M_<_'_@!_J^_^?GX?\$^4**^K_*C_ .>:_P#?-'E1_P#/-?\ OFC^VO[GX_\
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MS\?^ '^K[_Y^?A_P3Y0HKZO\J/\ YYK_ -\T>5'_ ,\U_P"^:/[:_N?C_P
M/]7W_P _/P_X)\H45]7^5'_SS7_OFCRH_P#GFO\ WS1_;7]S\?\ @!_J^_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3*<A=OS'/4'H,8KKJUQ&L[_U^IEA;JG:W]?<@HHHKG.D**** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MMY518"RY 5"#OQGG)%:3FH-*UVS*G3E--WLEW.4\^;_GK)_WT://F_YZR?\
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M^^C1Y\W_ #UD_P"^C3**+(+L?Y\W_/63_OHT>?-_SUD_[Z-,HHL@NQ_GS?\
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MEW]CBW/IG]FE=QP%V[=WU]J9;>+5%G:1:KI%IJDMBNVUGG9U9%'(5@IPX!Z
MUG&G72]Z[7KK]YK*KAY-\MD_33ITL=)8_#NPDG\0:?<71%Q:O"MC<,VT$R#*
M!ATR>!7,^*=#BT.WT=5ADAN+BS\RY5VSB3>0?ITIK^+[^>SU:.Y"R3:I+'+)
M."5:,H<C:!_D8J/Q+XHN_%$UG-?QHLMK;B$NI/[SG.X^]53AB%43F[K_ ('^
M9G6J865)J"L^G_@3_)&+1117>>:%%%% !1110 4444 >S?!+_D ZG_U]#_T
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M%T:-M\<L3;7C;U!'MQ[U:HIIM.Z$TI*S*%CI$5E<-<//<7=P5V"6X?<57T
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M_P"#YLKFQU[\K_\  ?3RWT6N^A%9^)+<Z-'I>NZ8-2M[=V>W99S#)$6.6&X
MY4^F*6#Q/#;76K/::5#;0ZA9-9K#%(0(@0!NR<[CQSTS4G_"O?%?_0%N/S7_
M !H_X5[XK_Z MQ^:_P"-7S877WEKY_\ !(Y<8K>X]/[ORWL4M#U\Z3#=VEQ:
MI>V%ZH6XMG8KG!R&5A]UAV-7K7Q/IFGZI8W6G^'HHDLF:1 ]PSR2.1P6<CD
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M_P#0%N/S7_&C_A7OBO\ Z MQ^:_XT?6*/\Z^]!]5Q'\C^YG-T5TG_"O?%?\
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M4RA*/Q*PXSC+X7<CWR?\\C_WT*-\G_/(_P#?0J2BI+(]\G_/(_\ ?0HWR?\
M/(_]]"I** (]\G_/(_\ ?0HWR?\ /(_]]"I** (]\G_/(_\ ?0HWR?\ /(_]
M]"I** (]\G_/(_\ ?0HWR?\ /(_]]"I** (]\G_/(_\ ?0HWR?\ /(_]]"I*
M* (]\G_/(_\ ?0HWR?\ /(_]]"I** (]\G_/(_\ ?0HWR?\ /(_]]"I** (]
M\G_/(_\ ?0HWR?\ /(_]]"I** (]\G_/(_\ ?0HWR?\ /(_]]"I** (]\G_/
M(_\ ?0HWR?\ /(_]]"I** (]\G_/(_\ ?0HWR?\ /(_]]"I** (]\G_/(_\
M?0HWR?\ /(_]]"I** (]\G_/(_\ ?0HWR?\ /(_]]"I** (]\G_/(_\ ?0HW
MR?\ /(_]]"I** (]\G_/(_\ ?0HWR?\ /(_]]"I** (]\G_/(_\ ?0HWR?\
M/(_]]"I** (]\G_/(_\ ?0HWR?\ /(_]]"I** (]\G_/(_\ ?0HWR?\ /(_]
M]"I** (]\G_/(_\ ?0HWR?\ /(_]]"I** (]\G_/(_\ ?0HWR?\ /(_]]"I*
M* (]\G_/(_\ ?0HWR?\ /(_]]"I** (]\G_/(_\ ?0HWR?\ /(_]]"I** (]
M\G_/(_\ ?0HWR?\ /(_]]"I** (]\G_/(_\ ?0HWR?\ /(_]]"I** (]\G_/
M(_\ ?0HWR?\ /(_]]"I** (]\G_/(_\ ?0IJ3NY<"$_*VT_,/3_Z]35#!]^?
M_KI_04 .WR?\\C_WT*-\G_/(_P#?0J2B@"/?)_SR/_?0HWR?\\C_ -]"I**
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M['_US;^:T 2T444 %%%% $=Q_P >LO\ N'^5.C_U:_04VX_X]9?]P_RIT?\
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MMY8+]./]9T]JHZ)XEU6_L(H;"T%_/%$TUS+=7"Q'!ED5%7:F"Q"'LH&!D\T
M=E17,Z?XAN(?A[IFK7<;75[<P6ZB/*H9)I2JJ"1POS,,GH.:S[WQ=J6B:C?M
MKEI#$L5O;""**XW1/)+*Z!MY0,HX&<KP!D9H [:BN"O?&EQ=Z6'M'2WEAGDC
MF>T?S8Y%^RRR*4=T'=!U7@CN.NQI_B=WL;:&6 O?/)#$$:09D5X]_FDA0,;
MY.!C*D4 =+17#V7Q)AO(VF2UB:&2"6:!8[@M* B%QYJ[<)N"]06QP#6C#XKN
MTT_S-1TR.WNYK:.XM;>.Y\SS2[;0F[:,,&*@X!'S9&: .GHI!G:-W!QSBEH
M*A@^_/\ ]=/Z"IJA@^_/_P!=/Z"@":BBB@ HHHH AG_UD'_73_V4U-4,_P#K
M(/\ KI_[*:FH **** "BBB@"&T_X]5_'^=35#:?\>J_C_.IJ "BBB@ J)O\
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M5J^&;B::SO8KF5Y6MK^XA5W.24#DJ"?8$#\* -FBBB@ HHHH **** "BBB@
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M%(U;;NV#/RDE%.1W'&*YK3;_ %K7M4L[1=<DMK;[+<N;BU@C#76R<1QR#>K
M KR<#!ZC K2N-9,_PN;4=0+>9<66R1K<A#O?Y-P).%&6SDG '/:@"RW@W2+N
MR,<\EW=%IHY_M+W;F7?'G80X.0%)) '<FIQX4TW[#+;R">5Y95G:ZDG8S^8O
M"L'SD$ 8&.,?4US?PVUBSC6Y\/32VXUB%VGN8K(#[*H.T#R2."I&"0.02VX
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M[\__ %T_H*J,G%W1,HJ2LS$_X1:Z_P"AIUO_ +^0_P#QNC_A%KK_ *&G6_\
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M[GQ-K3A5)VM)%@^Q_=TJ^%[IE!_X2C6QD9P)(N/_ "'6]<?\>LO^X?Y4Z/\
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M@FW:-B?-E@<\JO7&:]%HH XRYT'4C'J4.GVEC/;ZM;);L\SE#;!5*8VA3O4
MY !'.?7-69O"=Q-J$L7VS;ITD!;(_P!8+HQ^5YGIC;\W^]S726G_ !ZK^/\
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M3G]*<GB^((H_L37>G_0.>M^X_P"/67_</\J='_JU^@HYH?R_B'+4_F_ P/\
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M37-U)<.5Z#<W 'T4*/PK1H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "H8/OS_]=/Z"IJA@^_/_ -=/Z"@":BBB@ HH
MHH AG_UD'_73_P!E-35#/_K(/^NG_LIJ:@ /3CFN+A\+:HBMK+WT_P#:KW9O
MFL0T7D[L;!%NV;L>5\OWL9YKM** /,-,TJ_N/ VFVRZ-#8PV*271O$D!+C:_
M"KC=O;=ALX'WN3Q4B>'-4UGP;IEA%HMMIHL]*DB5TF4K.9+<QB-0!D(2P9MV
M.5'!ZCTNB@#A[GP_>+'J-O8Z3;74&IVD=M%(TBHMH$!7!'78,[ALR<YX'!JW
M-X6OI;^6W6Z":>\)F$H/[P79C\O=CTQ\_7[U=/:?\>J_C_.IJ /.+3P7J\NG
MR6DQD@$&G&RB$\L)CE^9#M BC5O+(0@EN?F^[UK=TFPU"7QH-6N=$@TNW333
M:\3(\CMYBL!A>-H ..<]>!7544 <1HOA">VOM5N;^TMVDN;::")R0QVO<3R;
M?8$2(3_]:KLVBWTND>&+1U5KFP>WDN=SYQY:@.0>_/YUU51-_P ?L?\ US;^
M:T <4W@JZ/A71].MDBL[F$W(GGC(S'YL$R%@1R?G="?I[5;\*:#J-CJJW-\M
MQ#';V7V1$EE@(;Y@?E$4:_*-O!;GYCP,G/7T4 <?)HFJ"[N=/2T0V=SJT>HF
M]\X (BNDA39][=E,>F#G/:GZM:ZYJ5S!*FD0VUS')BVO8[L%K8"4[B_ W(Z!
M3L&>20>@:NMHH I137<UK>?;;1;79)(D6)1)YL8^Z_ &W/\ =[5;C_U:_04V
MX_X]9?\ </\ *G1_ZM?H* '4444 %%%% $*?\?DW^ZO]:FJ%/^/R;_=7^M34
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.'_KFO\ *@"6BBB@ HHHH A_Y?C_ -<_ZU-4/_+\?^N?]:FH **** "BBB@
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MF=>^WW,=K87%NI!U&S,,\;Y,H1UED8KCY /+8=3FNFH **** "BBB@ HHHH
M8T,3S)*\2-)'D(Y4$KGK@]LT^BB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "J][86>I6QM]1M(+N D$Q3QAU)'0X/%6** (8[.UACACAMH8T
MM_\ 4JL8 CXQ\H[<$CBIJ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !4-O]Z;_KH?Y"IJAM_O3?\
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MT188XH7BB@1<+&7<,Y'IDJO'08J:;2HI]:CU%FR5MI+9XBH*R*S*>?IM_4T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#=EQ76R_\?4'U;^5<Q=^%+Z2&7SM0DU"XN3;VSRNBQ[+>.7>20/O.1D9XZC
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M63RF;:WEJ_\ <,F-@;M@G.<#K0!K4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5#;_ 'IO^NA_D*FJ&W^]-_UT/\A0
M!-1110 4444 0W/^K3_KHO\ ,5-4-S_JT_ZZ+_,5-0 4444 %%%% $-M]Q_^
MNC?S-35#;?<?_KHW\S4U !1110 5#+_Q]0?5OY5-4,O_ !]0?5OY4 34444
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M_P#G[G_\ I__ (BMRX/[M?\ KHO\Q4M%Z?9_?_P M5_F7W?\$Y[_ (3OP_\
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MNFJ*U_X\X?\ KFO\J+T^S^__ ( 6J_S+[O\ @F'_ ,)WX?\ ^?N?_P  I_\
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M[.VTONQM#2,?NYZ#/J:GH.M:K:_9KG5K4P2G$H%G@IB0LC1G=E7"X&3D9 (
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M9%G8EB[AGD(S@R$@_/U&XX]*LZMH4.KRVDSW-U;36;,T4MM(%8;EVD'((/%
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M2U%:_P#'G#_US7^5 $M%%% !1110!#_R_'_KG_6IJA_Y?C_US_K4U !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%0O>6T=U';27$23R#*1,X#
M,/8=3TJ:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4 0_\OQ_ZY_UJ:JT<T4M^XBD1RB88*P.TY[U9H **** "BBB@ HHHH ****
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M<R6XCVQOC)0;G!=@.H7/IUXH P[BTNUGU'2!8W327NM0WL<ZQ$PB$/$[,7Z
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M!L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2>W%5-1\.7#:*-*L;J1[-H[:V$$A7$4:.-[[L;F8J,8)QP,8YKI** "BBB@
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MFA?!&Y& 93@\C@B@"Q1110!#_P OQ_ZY_P!:FJ'_ )?C_P!<_P"M34 %%%%
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MN"C*S2C?\FU#GCU(-=#H^J7$OCF_L;J_\_,1ECMX9$9+<#8"CK@,CY8D$G#
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M3\$&'3],N8)[V222XUB_6(3N"S$3R$@8 [*2?QKK* "BBB@ J&W^]-_UT/\
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M<DUE>$O!KZ%/:W;7JS[+8Q[1%MSF*W3.<G_GWS_P+VYN_P#"7?\ 4O:]_P"
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MWQ(V.!E0<4OEIO#[%W 8#8Y IU% #6BC<8=%8>A&:00Q *!&F%.5&T<&GT4
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M8^-=+N;-)K2*^N//EE\F..T<O(J-AW"XSM!(&[IDX&:MW/BW3+=8C$;B[$D
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MEA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !4-O\ >F_ZZ'^0J:H;?[TW_70_R% $U%%%
M !1110!#<_ZM/^NB_P Q4U0W/^K3_KHO\Q4U !1110 4444 0VWW'_ZZ-_,U
M-4-M]Q_^NC?S-34 %%%% !4,O_'U!]6_E4U0R_\ 'U!]6_E0!-1110 4444
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MDFQG"[&7<JMM+#(Y&>,CK5FYOK:SDMX[F41M<R^5"#_&^"V/R4_E0!/1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5#;_ 'IO^NA_
MD*FK G\(Z#J=]<W=_ID,T\DGS2-G)P /6JCRW]XF7-;W5_7XF_17/?\ "!>%
M_P#H#6_Z_P"-'_"!>%_^@-;_ *_XU=J?=_=_P2+U>R^__@'0T5SO_"!^%SG_
M (D]OQUZ_P"-+_P@7A?_ * UO^O^-%J?=_=_P0O5[+[_ /@&Y<_ZM/\ KHO\
MQ4M<S/X$\,*BD:-;\NH_B]?K4O\ P@7A?_H#6_Z_XT6I]W]W_!"]7LOO_P"
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M8Z)>7-_JD]QJ%Q+%=B:X?:(RLA "]$V[5PPPWJ3FN]HH X#3K"2W^!:6L:W
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M>,&, 9"LQ!;=@CCKUKT>B@#C%T/5HXY=*%FC6UU>PWC7OG ",*8V9"G4MF/
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M0TFWL99//"BVD2-D);/++AL_+D\$8KO:* ./A\)S6VE:C%%!#]IN-5BNTDR
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MNA)&1Q4EGXFU2:\T@W6CPPV.KL1#*MWNDB'E-(N]-H&2%_A)QSSZ@'3T444
M%%%% !4-O]Z;_KH?Y"IJQ;CQ/H>E7D]KJ6K6EK.'W&.64*P! P<&G&+D[)$R
ME&*O)V-JBL'_ (3GPM_T']/_ / A:/\ A.?"W_0?T_\ \"%J_95/Y7]Q'MJ7
M\R^\WJ*P?^$Y\+?]!_3_ /P(6C_A.?"W_0?T_P#\"%H]E4_E?W![:E_,OO-B
MY_U:?]=%_F*FKG)_&_AAD7;KVGG#J?\ 7KZU+_PG/A;_ *#^G_\ @0M'LJG\
MK^X/;4OYE]YO5B_\(EHYN)Y7MFD$RR*8I)G:-!)_K-B$X7=WP!4?_"<^%O\
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MY R@<+QT_P"6C?G46G>&M/TNZ6:U\_$2E8(I)W>.!3U"*3A1V]AP.*Y"PO\
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MW>@:???VA]IB9O[2@6WN<.1N1=V /3[[<CUI(]&C'B2YU>81O)););1@+RJ
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M&D,2@LW=C]%0,Q]EK8K!U/PT-:U^*[U*:46MI"5M8[:YDA<2/_K'8H0?NA5
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M&+72X[N8V=FNH7$UPYNHX@'*R2,P!?&3P1GZ4 4].\<1S6L=QJUD=/CFT_\
MM&(K,)B8AMSD*,AOG7 YSSCI5K_A);BU,<FLZ//I]K.VV*8RK(0QR5615^Z3
MT&,C)QGD9Q=$^'G]CZ+<:3 +2W@O+*'SI;=,/'=(J@LOR_,A(W8)&#GCYN-F
M2PUS5I+6#64L+>UMYTGD>VE=VN&C8,H"LH\L;@"1EO3/>@"CX=\;RZUKDUA<
MZ>MLH8K&Z3!\G!;!XZ84\CC(]P:W)->M(+W4(KEU@@T^*-Y[B1P%!?)V_7 !
M_P"!"GV.@Z9IMW)<V-G'#-("I9<_*I.2JCHHSS@8' K N]&O+W6-9$"(DJW=
MI?6S3J?*E*(!M) ]4/(R1E3CU -*V\8:1=37^RY1;:QABEEN&;"CS"X"X/(/
MR=#UW#%.'C+PZUNTXU>UV+*L+9?!61@2J$==QP<#J:QI/#>N7NJ7NK7*:9#<
MM):2VUO'([HQ@,F1(Y0')\SA@O&!P<<OMO#6KW'B1]7U1=/AW7T-P(;>1GVK
M'!)'RQ0;FRX.<#CCMR ;<OBG0X-0%C-J=O'<F18@C-C+G&$STW<CY>M1Z'XJ
MT[7O-6VDV21W4UL$?@N8FP2/;H?QK%F\,ZV+:+2K==,:PCU1;[[5*[^<4\_S
MBNS;C?DD;MW('09XL1>'=4T^:.\LS:7%Q%J%W<"&65D1XIV)QN"DAAQV(ZCW
MH U+KQ9H-E*([K5;:-R6^4OR-K%&)] &!!/0$5-#XATBX,PAU"!O)D2.3#=&
M=MJ_7+< C@FN?A\'7BVNI>=):M<7^G3P$C.$DEEED(Z9V R 9ZG&<5)>^$KR
M8QM:RVT9@L+:&-6SM,L,PE .!]P[<9ZC/2@#=U#Q#I.E,5U'4(+=@RIM=N2S
M E0!W)"G [XIMGXDT;4+J*VLM1@FFF3S(U1L[@.N/<=QU'I61'X>U"[\00:Q
MJ26D4J7:RF"*5I B+#)&,,57+$R$]!@4^U\+SV\%I'O@7R=6N+YRA(RLGG=.
M/O?O!G\>: +Q\6:&;PVD>I027675(0W,C*"65>S$;3G'3'-)H7BO2?$$,!L;
MJ,SS0+/Y&[+*" 2,]#@G!QG!K#3PSKI30["1-+6RT=WQ<*[^;,ODO&N$VX0_
M."WS'/.*GT/P]K,,/A^VU==.ABT-/EDLG<F=O*,0&TJ-BX8DC+9('2@#KZ**
M* "BBB@ HHHH **** ,[4M=LM+GCM[@S27$JEU@MH'FD*CJVU 2!GC)XJQ8:
MC::G9K=64RRPL2-V",$'!!!Y!!X(/(K'N#=:-XEO-0^P7%]:WT,2;K50TD+1
M[OE*D@E3NR".AW9ZBL=?"\FK:_:WVLZ8#;3WEQ=O:2L'6(&&.) X!PQ.PL1R
M 3[9H [DD 9)P*"0.IQ7GZZ+);?9QK.ARZII5N]Y%!9JBRB'-PQB;RR<%?*P
M%/\ "..,U+?Z01-$=2\.W.HVQTY8+2V$@G:SEW,6!9FX8@H!(#QL//3(!V<-
M];SW=S;129EM2HF7!&W<,CGOQ5C( SGCUKSPZ%JD;A]8L9-3MTDM6O84(?[5
MMMMA."1O"R8)!ZXS@U%/;QZ='IXUG3F_L>:]N'@TB3:VQ2JF/*$[2 0Y$>>-
MPP/EX /2**\QTJ"6UTH7>@6_V-[S5+FR@B:3.(9#]X$$CY"N\ '  8"O2+.T
MBL+&"TMEVPP1K&@] !@4 34444 %%%% !1110 4444 9%QKHM_%EKH[0_)<6
MS3&?=]U@P"IC'<;SG_9]ZK6_BVVE\07^FSQF%+:2"*&;);SWDWC& .,-&PS[
M5+J>@2WUY>W<%TL-Q+:Q16SF/=Y,D;NX<\\C<R\>B^]49_!SCR9;*[2.X@BM
M]CR1[@\L4C/N;!&0Q=\]_FS0!8UKQ;!I5Q)##"UR\,<S3*@;<K)$) H !W9#
M#ITJI:>/K)EB?48VMEN(K<V\21RR3/)*COLV!,CA#CKGVXRK>$KNZFEN[V]A
M^UW G\WRHB$&^%8E"@G. %!.>I)Z51N/"6JV6JZ3<Z7=1-+"T",\D.4016TT
M9+#=G#%P..1GO0!M'Q;9/<V*P?ZJ>:6&X:<-$UL8XC(=RL 1P!UQP<U=TOQ!
MI^KR&.S>4.$$JK- \1=#T==P&Y?<<5AS^"I=2DDFU:]C>6ZDE-T((BJ['MV@
M"IDDC .<G.3GIQB?PWX3?1M1-W<R6[ND/D1B%9.02"6)=VP3M' P/KQ@ OV6
MOK=>(M4TMXA$+#9ME+_ZS**[<8XV[U]?O"H= \56^M!UDC^S2^=.D:,2=Z1L
M/FSC )5E;'H>^,U%?>%I+M+LPWH@FNKWSY)%CR3$T:1O'UZE$QGL<''%5=6\
M*R20S16+LCWFI+.)(E ^SQF)8Y1SU!16'U8>E &E)XOT:/RR;B5D>)9F=;>1
MEBC;.UY"%PBG!(+8X&>E-'BNUBENX[Q)%>&]:UAB@C>:2;$:.6"*"> W/88Z
M\UEZUX#34-3N+BT>"*.\B2*<2K(2@5=H*!7"GY>,,",CODBK/_"+7EGJ3ZCI
M5Y ES]HE=$GB+1^5(D2E#@@Y!A4@CZ8YH LW'C;0K=8&-U++Y\#7*>1;22$1
M*=KLVU3M"G@YQ@U-;^+-&N8[B1+O9%;P_:&EEC9$:+_GHC$ .O'5<C\ZHV?A
M&2V>622]666>SG@E?RMN9)9#(S 9X4$X ].])-X.^T6-O;->;/(TQ+)72/HZ
M,C+)@G& 4'R]Z -'3?$^FZIJ3Z?;-<1WB0^>T%Q:R0MY><!OG4<9XK7KG]-T
M;5U\3'6-9OK27%F;5(+6W9 OSABQ+,2<XZ=JZ"@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "H;?[TW_70_P A4U8$^E:Q<WUS+9^(I;.%I/EA
M6TB<+P.[#)JHI-ZNQ,I-+17_ *\S?HKGO[#\0?\ 0VS_ /@!!_A1_8?B#_H;
M9_\ P @_PJ^2/\R_'_(CVDOY'^'^9T-%<]_8?B#_ *&V?_P @_PH_L/Q!_T-
ML_\ X 0?X4<D?YE^/^0>TE_(_P /\S;N?]6G_71?YBIJYF?1-?"+N\63GYU_
MY<8/7Z5+_8?B#_H;9_\ P @_PHY(_P R_'_(/:2_D?X?YG0T5SW]A^(/^AMG
M_P# "#_"C^P_$'_0VS_^ $'^%')'^9?C_D'M)?R/\/\ ,Z&BN>_L/Q!_T-L_
M_@!!_A1_8?B#_H;9_P#P @_PHY(_S+\?\@]I+^1_A_F;=M]Q_P#KHW\S4U<S
M!HFOE6V^+)Q\[9_T&#U^E2_V'X@_Z&V?_P  (/\ "CDC_,OQ_P @]I+^1_A_
MF=#17/?V'X@_Z&V?_P  (/\ "C^P_$'_ $-L_P#X 0?X4<D?YE^/^0>TE_(_
MP_S.AJ&7_CZ@^K?RK$_L/Q!_T-L__@!!_A44FB:^)X@?%DY)S@_88>./I1R1
M_F7X_P"0>TE_(_P_S.FHKGO[#\0?]#;/_P" $'^%']A^(/\ H;9__ "#_"CD
MC_,OQ_R#VDOY'^'^9T-%<]_8?B#_ *&V?_P @_PH_L/Q!_T-L_\ X 0?X4<D
M?YE^/^0>TE_(_P /\SH:BM?^/.'_ *YK_*L/^P_$'_0VS_\ @!!_A45OHFOF
MUB*^+)P"@P/L,/''THY(_P R_'_(/:2_D?X?YG345SW]A^(/^AMG_P# "#_"
MC^P_$'_0VS_^ $'^%')'^9?C_D'M)?R/\/\ ,Z&BN>_L/Q!_T-L__@!!_A1_
M8?B'_H;9_P#P @_PHY(_S+\?\@]I+^1_A_F7;S6]+T_5X[:^U"WMYI4 2.20
M*6YK4KP3QKX+\2R^,9OW%SJIN2I2Z2,888 ^;'"XZ=A7M^CVT]EH=C;7<GF3
MPVZ1R/G.Y@H!/YUM6HPIPC*,KW,,/B*E6I*,HV2+E%%%<AV!1110 4444 %%
M%% !7)VOBR[2^OEO-/EDLK?4_L1NT*@1[M@3Y<Y8;G )'3/L:ZRLIO#MH]I=
M6Y>;9=7@O'.X9#AE; XZ90?K0!6E\6V<%FEQ-#,N$F>X0 %H!%PV<=3NVJ .
MNZLO5?&.H6<,UO+H\VGW9M&NH))722,JLD:E3M/WOW@X_4UJ1>&+:6]UR:_C
M5UU4B-HT<X$00+^#$Y)Q[=^:KR>"(+JX:;4=8U2^?[*UJOG21@)&71C@*@&[
M,8^8Y)[]L %MO$]NNEPWI@EV2WLEF%R,AD=T+?3,9/XBJ-GXRN-0LK62RT&[
MDN+BV6\-L98PT<#?<8G.-S8.%!['.*M_\(G;?:BS7MXUKYTEPED63RHY7SN<
M?+NZLQ +$ G..F!O"D*0VBV&H7UA);6B6?G6[)OEB4<*VY2,CD@@ C)P1F@"
MD_CE)&E?3-*NKVU@LHK^:X#(@6)PQP QR7 0G;^M%OXKF>\N[6V@DU.Y>\=+
M:%%6(+"L43LS,21@&5>>"2P&.]:<'AC3[:TNK:V\R.&ZLTLR@;[D:*RC&1UP
MYY.:K#P=:0OYUE>WEI="8RK<Q,A9=T:1LF&4J5(C0D$'D ]A0!4T[Q;>W,;0
M_P!F33:A)=W*1VI*QF**)@I+MDC@LHR,YR,<4^Q\;K?W5C;KI5S!-=23HT<\
MD:-%Y4GEM_%ACGG"DG;S4UOX,M[.&+['JFHPW<<TTHO3(CRMYIS(K;E*E20#
MC;Q@8QBH[7P=8V\=K9#5;Z:.VN#=O#-*CM+(9#)N<E=P^8_PD<<'(H ;H_C[
M3=9U.&V@V+'=,RVLGVB-FD*@DYC!W)D*2,CH.<'BC4/%%[IWB#5;==-EO;2Q
MM(;EVB*J8U;S-_4_,<("%'IUYJ[IOA:VTR]CF@NKIH8-WD6S%!'%N]PH9L<@
M;F.*MS:);3SZE*[RAM1MUMYL$8"J' *\<'YSZ]J *Q\3VQTZ^O$BD>*SN4MS
MC'S[A&0P]OW@Z^AK-@\;RW,T"0Z#>$7DT\%FS2(!*\18-GGY%PC$$]<>I&;I
M\(VOGDI>WB6KR12S689/+F>,*%9OEW#[B9 (!V\CDYLV_AVTMCIYCDF/V"6:
M6+<PY,F[=GCD?.<=.U %./Q8;R&T73-,GN;R>-Y9+8R*GD*CE&W,3C.\$#&<
MX)Z53M/'4NI>2FG>'[Z662V:YDCD>./RE65HRK$M][*' 'YUH'PG!&(7L+^]
ML;B'S5$\+(69)'+LC!E*D;CD<9'KR<OT3PK9:"BK:SW4Q6W,!:XD#LP,CR$D
MXY.9#S]* *6M^+H?^$2GOO#UQ;SWS6J3PP-*HD17VX8J3Q@,#S6;9^*M:'B$
M:<+9]1<&Z1H@J1%&B%L1E\XQ^^;G R2.!BNC'AJP'AR+1@'$$=O';B48\PJ@
M &3CK\H[4MGX<L[+6Y=4BDF,\K3,RLPVYE\K=QC_ *8)CZG\ #!G\7SRQSWU
MF[+;Q0V4QMY8!N023R12*6#<GY#VXQP3FN@U^_GL;&#[&56>XNX;=&9<A0\@
M#''LNX_6L$^#KE;B[@A,0L9C:1@R2EI&CCGDFD) 4 $F3:!Z#)/:N@US3YM0
MM;86Q02V]W#<+YA(!"N"PR >=N['OB@#'/B"_&FF;,>_^WA8_<_Y9&X$?Y[3
MUJ;Q/J.J6%]9FTFCM+-P0]Q)#YD?FY&U)".41AD;QT.,GH#9_P"$8M_[2^T_
M:[K[/]I^U_8MR^5YW]_[N[K\V-V,\XIEYX56^CDBN-8U-H9A(EQ'YJ;9HW8M
MY9&W@ $J"N&V\9- %[7+Z33M&GGMP&N#B.!3T,CD*@_[Z(K*@GUG6[J]^Q:E
M'86]C,;5<6PD:>10-[-D\+DX"CG@G/( OR:(\FIP3O>RRV\=R;GR)<$(PCV*
MJ8 PHY;!SR>M1W/AP27UQ=6&IWVFM=8-PEJR;92!C=AU;:V !E<$X'I0!F3^
M)]5T[4[Z"ZTTWJV-E#<W#6I"K'D/OV[CEC\F0OMR>1ED'C&X;5YK&TLIM4EF
MGD^S",)"D42QQ,=S%CG_ %O!QGG&.,UMKX=M$AO(Q)<,+RU6TD+R;FV*K '<
M<DM\QR3FHM-\+6.EZB+VWDG:0!AAV!'S+&I[>D2_F: *T?BTWJ0+I.E7%Y</
M"9IH=ZQ^0H8I@L3@MN5@ .NTG(%)H_B675]0TN6.%X+/4M/DG6&90)(G1U&#
M@XZ/T]JD_P"$1@A$;:=J-]83*CQO- R%I$9V?:P92.&8X( (R>>31I'AD:/?
M6"02L]CIUBUM!YK[I'9G!9F.!T"+SWR?2@#H**** "BBB@ HHHH PKSQ78:=
MJM_97]Q:VK6MO'/'Y]RJ&;=OX /ILZ\]:;;^,=,>PLIKMVAEN;2*ZD1(WE6W
M61<@R.JX0=>6P#@U/+H*3ZIJ=W+Y3_;;:.! T>3&5W\Y]]X_*N;D^'<@CB2&
MYA;S+*"TN7=IEQY:;-RJC@-D=FS^.2* -^Y\9Z%::A/9W%XZ2V\BQ3-]GD,<
M;LH94+A=H8@C SDY ')J;_A*-*_L_P"UF:4+YWV?RC;R"8RXSL\K;OW8YQCI
MSTJC-X4:2VNH8[A%6;5+:^7*9VK$8?D]R?*Z^]+<^&[L:A-J-A=PK=_;_M<*
MRQDI@P+"R-@YY"D@CIQUYR ,E\=Z8TM@NGI<78N=1_L^7%M*IMY/++D,"F01
M\O!QU/\ =-7)->T/4IWTZ0K<[F9%66W8PRNF2R*[+L9A@\ DC!]#6?9^%=1%
MTMWJ5_;RW!U<:DXAA*J%%OY(C&23QUW'KZ4^V\+WT7V.REO+=M+L)VGMPL1$
MS'YMJL<XPN[J!EL#IDT /LO%VB_V5ILUR!:M):0W)CCA:1+-9%^7>ZKMC')
M+;> :MZIXNT71I)UU"Z>-;90UQ(EO))' #TWNJD+GL"1U%8]OX.U.QTAM,LM
M0M?L]W90VMV\D!+*4B$3-'SCE0.&Z'GGI6?K=AKD+:SHNDVC_9=4QY<S0F4
MM&L;'?D!1A>0W(ZC=D"@#M5UBQ>.-EGR)+@VRC8V3("05QC/8G/3'/2KM<]:
M:-(OC*XOF#K:QPIY:,!M:X9=KR#OG8J+^)]ZZ&@ HHHH **** "BBB@#G/&/
MB-M!L[6*TFM([Z\FVP_:Y0B;5&]R22/X1M'NRU)8^(/[3U_3TLI$DT^\TMKQ
M"!DD[T Y^C&M!]'M9M9.I7 ,TOD"!$D *1KNW':,=6.,G_9%9Q\)QQ:DE[I^
MIWMBZ"10D(B9=LCAV7#HV!N&>/4T 2^+==_L'0C+%-;0W=S(MM:M=.%C$K\
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MYP8UD5EPKM@;",XXXW#O0!N2>--#@M99[FYFMA$T:LD]K+')F0[4(1E#$,W
M(&">*5_&.BQPJ\MQ-&[7"VP@>TE6;S&!95\LKNY )!Q@XK"UWP[K]_-;:A+/
M:MJ$=S;1PBVA)CBC697=V#-ELXZ C '&36E%X:O[C78=9U2ZM_M23(3';QL$
M6-$E4*"3DDF5B3Z<8[T 6;CQ7HYD,(N7)20@.+>39(R'+JC[=KL #E5)/!XX
M-7+OQ!I=C&KW-VH5X1,A12^Y20JXP#DL6  ZL>@.#6+%X:OK<Z?9S7=N^EZ?
M=B> +$1,_)VJQSC W=0,G Z9-,G\"";2[FW>[\R3[3'+9EMRK%'&28XB58-@
M;FY!!Y'I0!L'Q3I*V(N6FE ,WD"'[-)YQDQG9Y6W?G'.,=.>G-06?BNVO='U
M?4H89'ATV62,JJL7?9&KD;<;E;+$;<9&*S;3P=>6 COK2XMDU..X:4*XDDB*
M% A0EF+G@9W9X/&,5H:;H-]#I&L0:C>037.J32REX8BB1;XU0+@DDXV]>] $
M=GXUT\Z59W&J%K6>XMUN)8TAF=;=&/#2,4&Q?]IPH.">@S6I8:YI^IWEY;6,
MS2R6+^7<'RG"H_\ =W$8)Q@X!/!'K6')X5U&"">WTV]MDBO[..UO&FA+,NQ/
M+WQX..5[-QD ^HK4T;0VT?3[VUCF#B>>26,X/R!@  ?4C'6@#,L/&"R^ ;GQ
M#]C;S8Q(PLQ)\S/D[$W8_B!4YQQN]JNZ)XHCUC4KRU^S^2MO'%(DA?(D#Q+(
MW&.-N]?KFJ6G>$FA:R1KI6M;>V\F:$1_ZV95,8DSV&UFX_W?2HH/!5S#H:V:
MZ@B7!E7S)DC/SP^4D4B8SU*KP>Q"GM0!;A\7_:/"NHZS':(GV.>6)8Y9B%=5
M;"N6"D@,I#=#UJY9^+-'O[X6EK<R.YF>W#FWD6,RH3NC$A7:6&UN,YX-5KSP
MNUQHVNV$-PD:ZI/YL9V<1?)&I&._*$_C3X?#<D6G6-M]H3-KJ4EZ2$^\&DD?
M;]?WG7VH JZYXW@T35[JRFM)2MM#;S/.RNL>)9A&?FV[?E!W=><$=C5I_%>D
M$K*9YD,<ODF%[:59B[+E0(BN]LC)& <@'T-,UGPQ)JNJ372W*(LD=JFQDS_J
M;CSC^8XJEXB\(OJVN+?I.@E!C:&-RZ#*)(IRR,&&1)U'3'>@#:N=?MD\,WNL
MV7^D):02RF-@8VW1J248$94Y&"",CTI\6K^;K%M8^3CS[)KK?N^[AE&W&/\
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M/(Y!S6E679:<UKXCU.[:0,+U8F50/N;5V_C6I0 4444 %%%% !1110 4444
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MLDL91#Y8N"?XL@?-]:D?P]X=DNY;G^SK%+F.02R3Q(J2(PPP)9<$>O7D>QH
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M$URTNHGO+5E1EM[EXI$+*-X)B8\X#'@CKSZULT %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5#
M;_>F_P"NA_D*FJ&W^]-_UT/\A0!-115/3=6LM7M6N=.N%GB25X69>S(Q5A^8
MZ]Q@C@T 7**0.I7<&!7U!XI-ZE0P9<'H<T 1W/\ JT_ZZ+_,5-4%PZE0 PRL
MB9&>G(J8L!G) P,G- "T4A=0FXL OKGBJ/\ ;=@--O;\SXMK%I%N'*D;#'G?
MQWQCMUH OT5#;7<=U;0S)N03*'19%*-CW4\BI0P)(!!(ZT 96JZFVCZ'<7D<
M0FD$PCC1FVJ7>0(N3V&6&3V&:YW4/$OB;3-:&DR6^E7,\HMS#,ADC7]Y(R-N
M0DD;=N1@_-[5O'4=(OH]8TVZ>.X%FI-] R%@J,"PR.^0#TJ+2O#/AX"+5+"S
MWO.D4JW$LDCR,J_-'EG)/&> >F: **^(=9DU3^PD6Q&IK,X>Z9'\GRUCC?<$
MW;MW[U5V[NS'/:HK36]4M?!NOZA<[)+VSN[E5"L9(TVG QT.T=<=NE:DMGX>
MUG5;^Q=5DOK:2.XN/+=XY(W9-JL'4@@[!C@].O6K^F:7IFC6+6>F6\5O;F1F
M:-3P78Y8G/<GD^M &)=64F@QV%]::O?7<TMU##,MQ<&1+L2.%)"'Y4(!+#8%
M'R^E95K?:G<^&?"Y&I/#=74<ZO<RMGYO)DVLV>N& /X5TL6@:%HA;48[41BU
M1G0EW=;=<?-Y:$D)QQA0..*@C\/Z!+<QW,5G&ZWT4F4D9BA209;;&QVKNZG
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M:D;O,B!(^0GY" <$@ ?PD5WE% '"ZAX2L?%%I#>:%LLK?S"P2:U=%9@[,)5
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MD]!ALU3L[74II]&DFU?5&_M.^NX;M?.8 0J)615 _P!7CRT&X88@GGFO0Z*
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MD6Y6*DD E6##..HR!QT-34 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MVBL[0];MO$&EKJ.GK+]ED9A%)(FWS5!P'7U4]0>XK1H **** "BBB@ HHHH
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M@ECW)/Z >IK*;PE/<M<7%_J\DU^QA^SW20+'Y/E,S(2O1LEVW= 0< "NFHH
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MEZ@[F&3N;CL0!D\5T5% '-^(/!T/B"_^U2WDD)\KRMJH#_RSG3/_ )')_P"
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M\,6<_,%Z ^F!VK6KS_\ MC4?^$,O[2XFOIM0MY(6$ACDM99DDD7(4N%(P2Z
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M(!U=%87A"[O+W2+B34F4W"WUS&P63>JA96 "GT&.*W: "BBB@ HK(\0^(8M
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MBJA^4Y5B>/3NEAXIU;4[>T6VT2!;RXM!>O#+?86*%CA 7$9R[8/ &!@_-TH
MZJBN6T_QJ+G25O;W3GM#):-<1P^:'9W5RC1<#&[=L''7?[55T[Q7>KJB6-W
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M_P"9?>=!16)_PFGAC_H8--_\"D_QH_X33PQ_T,&F_P#@4G^-'LJG\K#VU/\
MF7WFW16)_P )IX8_Z&#3?_ I/\:/^$T\,?\ 0P:;_P"!2?XT>RJ?RL/;4_YE
M]YMU%:_\></_ %S7^59/_":>&/\ H8--_P# I/\ &HK;QEX:6UB5M?TT$( 0
M;I../K1[*I_*P]M3_F7WG045B?\ ":>&/^A@TW_P*3_&C_A-/#'_ $,&F_\
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M=AXV7C7!_,-M^M:MIH[CQK>W[!TM$13%&RC#3LN))!_P!47ZEJZ"B@ HHHH
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M8[#N,N6"G)4\ =3T!]JYW0_%^N/X:DOQ;V\EEIEG;S3/<S,\]QNA61P"  "
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %0V_P!Z;_KH?Y"IJAM_O3?]=#_(4 34444
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M,BL+%;:WACMX3%;@+"I4-L X&,_2HKV^L;":VMIU_>7LGE11QQ%]Q SR .
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'13&\=H\"-'*NS<RL<;AGGD&M*=-U'9/^MC*K55-)M7_ *N=_17!1>(-1O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *BB_P!=/_O#_P!!%2U%%_KI_P#>'_H(H EHHHH
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MN+V<+6L<])X*TR73XK.6?4)$AF$\3M>R%XV"X&ULY P>@K2TC1K+1+5H+!&
MD<R222.7>1CU9F/)-7Z*'4G)6;"-*$7=+4I:?I5KI:7*VBLHNIWN)=S$Y=^I
M]OI5'3O".D:6\;6<+KLMC:E6D+"2,DG# _>Y)Z^M;=%'/+77<?LX::;&#9>#
M-'L+V&YABF?[.2UO#-<.\4!/=$)POX4T>"='_M![MUN)-]P;IH'N',)E_O>7
MG;G\*Z"BJ]K4WNR?8T[6Y48ESX1TB[UC^TIX9#*TBRO&)F$4CJ,*S)G!(XY/
MI2:AX1TO4KZ6[D%S!+.NV<VMR\(G'3#A2-W''-;E%+VLUU!TJ;^RC,'A[31=
MVMPL&&M;9K6)=QVB-L9&._05%HOA?3-!FDET^.0/(@CW2RM)L0'(1<GA03T%
M;%%+VD[6N/V<+WL%%%%0:!1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !447^NG_P!X?^@BI:BB_P!=/_O#^0H
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M8>]0V=A#8M<-#NW7,QGE9CDEB /R   ]@* +-%%% !1110 4444 <)J4U_\
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MH **** "BBB@ HHHH **** "BBB@ J*+_73_ .\/_014M11?ZZ?_ 'A_Z"*
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M4C:#ECD&O%X7U*]T98]3WBYN]5:ZF<%%:&%EPZ$ D89!LV@MC>.3C=7<T4
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MB7$;1D*2>%PV1Q\I)["GZ]HVO7NI6FJRVMBMVES;116\;/-'M1RY>1]JD<\
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MHHHK,T"BBB@ HHHH **** "L^UO-(_M"XM;.YLC=R.7GACD7S&8  EE!SD
M<^E:%</J9N['7_%MYHMLC:@FEVC0GR\G=NN,GH<GOC!SCH: .FM_#FBVL5Q'
M;:7:1)=#$RK"H$@]"/3GI2KI.CW%Y=7:V=I+<3*8+B4(I9A@ HQ^@ (^E<';
M:IJMW8W-O9:PQMWGLT%W;7HNWC9Y@K@2&)5!*?P\[>N!FHK:^BM?%-Q8:GKL
MVDZ=YUXY9'6$3.KQ!2\N.N">I!8^N* /0KO0-)OVMVO=-M9S; "'S(@=@'0#
MVXZ4ZZT32[V^BO;S3[>>YBQLEDC!9<'(Y]CR/2N-36)YK?3%\0ZQ<:;I\D4[
M)?9%NURRR8CWL1A28_GV\;B>G&*H:+JFNW^FB\M]5OKV2UTR>>!&B"?:9/M$
MR(SH%!)"J/E&,\<4 >G,RHI9R%51DDG  JCIMK;6]U?2P7(GFNIA/*=P)4%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3R* +%%0S7MK;NR3W,,3+&96#R!2$'5CGL/7I4JLKH'1@RL,@@Y!% "T444
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MB_;(TB564YXR'^8!L E1GKFJTOAG5;R226SMO[)2XN;B2*(2+FTWVC1!R%)
M8N0V%)]>N:[VB@#SZ\T:\.EW4UMH_P#8*6^D26T@C8.9V)4@ 1;B4 5OF(#?
M.<+UJE:#2?$.M3W6G:?;:9;6^CNDEW!+$_E.)$>,_NBR@+M+#)#<'*@=?3J0
M* ,   ^@H QO"T-P='74-2B6+4-1(N;A5S\A( 5!GG"J /S/<UM444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/_NFD@_X]X_]P?RI9/\ 5/\ [II(/^/>/_<'\J 'T444 %%%% $2_P#'X_\
MUS7^9J6HE_X_'_ZYK_,U+0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !447^NG_P!X?^@BI:BB_P!=/_O#_P!!% $M%%% !111
M0!#<?>A_ZZ#^1J:H;C[T/_70?R-34 %%%% !1110!#;?ZD_[[?S-35#;?ZD_
M[[?S-34 %%%% !4,G_'U#]&_I4U0R?\ 'U#]&_I0!-1110 4444 -D_U3_[I
MI(/^/>/_ '!_*ED_U3_[II(/^/>/_<'\J 'T444 %%%% $2_\?C_ /7-?YFI
M:B7_ (_'_P"N:_S-2T %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG2-,%905"X9<'C/^-6*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
$* /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>halo-20240331_g3.jpg
<TEXT>
begin 644 halo-20240331_g3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0*617AI9@  34T *@    @ ! $[  (
M   ,   !2H=I  0    !   !5IR=  $    8   "=NH<  <   $,    /@
M   <Z@    $
M
M
M
M
M
M0FQA:V4@3W)T:7H   'J'  '   !#    6@     '.H    !
M
M
M
M
M
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MNC_A>/\ U+W_ ).__:Z\ER/6C(]:/[-PG\GXO_,/[6QO\_X+_(]:_P"%X_\
M4O?^3O\ ]KH_X7C_ -2]_P"3O_VNO)<CUHR/6C^S<)_)^+_S#^UL;_/^"_R/
M6O\ A>/_ %+W_D[_ /:Z/^%X_P#4O?\ D[_]KKR7(]:,CUH_LW"?R?B_\P_M
M;&_S_@O\CUK_ (7C_P!2]_Y._P#VNC_A>/\ U+W_ ).__:Z\ER/6C(]:/[-P
MG\GXO_,/[6QO\_X+_(]:_P"%X_\ 4O?^3O\ ]KH_X7C_ -2]_P"3O_VNO)<C
MUHR/6C^S<)_)^+_S#^UL;_/^"_R/6O\ A>/_ %+W_D[_ /:Z/^%X_P#4O?\
MD[_]KKR7(]:,CUH_LW"?R?B_\P_M;&_S_@O\CUK_ (7C_P!2]_Y._P#VNC_A
M>/\ U+W_ ).__:Z\ER/6C(]:/[-PG\GXO_,/[6QO\_X+_(]:_P"%X_\ 4O?^
M3O\ ]KH_X7C_ -2]_P"3O_VNO)<CUHR/6C^S<)_)^+_S#^UL;_/^"_R/6O\
MA>/_ %+W_D[_ /:Z/^%X_P#4O?\ D[_]KKR7(]:,CUH_LW"?R?B_\P_M;&_S
M_@O\CUK_ (7C_P!2]_Y._P#VNC_A>/\ U+W_ ).__:Z\ER/6C(]:/[-PG\GX
MO_,/[6QO\_X+_(]:_P"%X_\ 4O?^3O\ ]KH_X7C_ -2]_P"3O_VNO)<CUHR/
M6C^S<)_)^+_S#^UL;_/^"_R/6O\ A>/_ %+W_D[_ /:Z/^%X_P#4O?\ D[_]
MKKR7(]:,CUH_LW"?R?B_\P_M;&_S_@O\CUK_ (7C_P!2]_Y._P#VNC_A>/\
MU+W_ ).__:Z\ER/6C(]:/[-PG\GXO_,/[6QO\_X+_(]:_P"%X_\ 4O?^3O\
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MHK+F;W-5&*V04444B@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P"QA;S#09EECWCS-LK28./]HG'%5]9O=-M;J]M[V\:*6\M%CVK [[%^<!N
M?[QX]JMZ3>66HW5W=6%P900B.IC9"A ..H'7-=4K^RZV_#IY'%#E5;I?\>OF
M:E%%%<IVA5>^LUOK4P/--""0=\$A1ACW%6*KWUDE_:F"62:-20=T,IC;CW'-
M5%V=R9*\6CG+*SDL_$20+=:K+(EPQ(FED>(P^6>23\I^8@>N:ZNN4LK!K/Q$
MD,<NJ.\=PS9FFD>$PF,\Y/RGYCC'7-=76U=W:]#GPRM%JUM0HHHKG.H****
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MC_P&B_\ B:/['Q'=?C_D']NX;M+[E_F?0M%?/7_"T?%__05'_@-%_P#$T?\
M"T?%_P#T%1_X#1?_ !-']CXCNOQ_R#^W<-VE]R_S/H6BOGK_ (6CXO\ ^@J/
M_ :+_P")H_X6CXO_ .@J/_ :+_XFC^Q\1W7X_P"0?V[ANTON7^9]"T5\]?\
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M?_T%1_X#1?\ Q-']CXCNOQ_R#^W<-VE]R_S/H6BOGK_A:/B__H*C_P !HO\
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M(ST&"0!U(KHIU74?W]==/(Y*U!4UN[Z=--?,SJ***W.8**** "BBB@ HHHH
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M[Q'TJN]CHEMXS3PB^CI)"76V>^WM]H,C 'S <[0,G[N.E<Y>>*]0OIM5EF6
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MX5)X5_YX7/\ X$-1_:V'[/[O^"']AXKNOO\ ^ >"9QTHST]NE>]_\*D\*_\
M/"Y_\"&H_P"%2>%?^>%S_P"!#4?VMA_/[O\ @A_8>*[K[_\ @'@F3G.>?6@D
MGJ<_6O>_^%2>%?\ GA<_^!#4?\*D\*_\\+G_ ,"&I?VMA^S^[_@A_8>*[K[_
M /@'@F:,G&,\>E>]_P#"I/"O_/"Y_P# AJ/^%2>%?^>%S_X$-1_:V'[/[O\
M@A_8>*[K[_\ @'@F:,G&,\5[W_PJ3PK_ ,\+G_P(:C_A4GA7_GA<_P#@0U/^
MUL/V?W?\$/[#Q7=??_P#P2C)/4FO>_\ A4GA7_GA<_\ @0U'_"I/"O\ SPN?
M_ AJ/[6P_G]W_!#^P\5W7W_\ \%R1T)_.DR:][_X5)X5_P">%S_X$-1_PJ3P
MK_SPN?\ P(:E_:V'[/[O^"']AXKNOO\ ^ >"$D]2:,D]Z][_ .%2>%?^>%S_
M .!#4?\ "I/"O_/"Y_\  AJ/[6P_9_=_P0_L/%=U]_\ P#P3)]:7<3U)_.O>
MO^%2>%?^>%S_ .!#4?\ "I/"O_/"Y_\  AJ/[6P_9_=_P0_L/%=U]_\ P#P2
MBO>_^%2>%?\ GA<_^!#4?\*D\*_\\+G_ ,"&I_VOA_/[O^"']AXKNOO_ . >
M"45[W_PJ3PK_ ,\+G_P(:C_A4GA7_GA<_P#@0U']KX?S^[_@A_8>*[K[_P#@
M'@E%>]_\*D\*_P#/"Y_\"&H_X5)X5_YX7/\ X$-1_:^'\_N_X(?V'BNZ^_\
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MPK_SPN?_  (:C_A4GA7_ )X7/_@0U']KX?S^[_@A_8>*[K[_ /@'@E%>]_\
M"I/"O_/"Y_\  AJ/^%2>%?\ GA<_^!#4?VOA_/[O^"']AXKNOO\ ^ >"45[W
M_P *D\*_\\+G_P "&H_X5)X5_P">%S_X$-1_:^'\_N_X(?V'BNZ^_P#X!X)1
M7O?_  J3PK_SPN?_  (:C_A4GA7_ )X7/_@0U']KX?S^[_@A_8>*[K[_ /@'
M@E%>]_\ "I/"O_/"Y_\  AJ/^%2>%?\ GA<_^!#4?VOA_/[O^"']AXKNOO\
M^ >"45[W_P *D\*_\\+G_P "&H_X5)X5_P">%S_X$-1_:^'\_N_X(?V'BNZ^
M_P#X!X)17O?_  J3PK_SPN?_  (:C_A4GA7_ )X7/_@0U']KX?S^[_@A_8>*
M[K[_ /@'@E%>]_\ "I/"O_/"Y_\  AJ/^%2>%?\ GA<_^!#4?VOA_/[O^"']
MAXKNOO\ ^ >"45[W_P *D\*_\\+G_P "&H_X5)X5_P">%S_X$-1_:^'\_N_X
M(?V'BNZ^_P#X!X)17O?_  J3PK_SPN?_  (:C_A4GA7_ )X7/_@0U']KX?S^
M[_@A_8>*[K[_ /@'@E%>]_\ "I/"O_/"Y_\  AJ/^%2>%?\ GA<_^!#4?VOA
M_/[O^"']AXKNOO\ ^ >"45[W_P *D\*_\\+G_P "&H_X5)X5_P">%S_X$-1_
M:^'\_N_X(?V'BNZ^_P#X!X)17O?_  J3PK_SPN?_  (:C_A4GA7_ )X7/_@0
MU']KX?S^[_@A_8>*[K[_ /@'@E%>]_\ "I/"O_/"Y_\  AJ/^%2>%?\ GA<_
M^!#4?VOA_/[O^"']AXKNOO\ ^ >"45[W_P *D\*_\\+G_P "&H_X5)X5_P">
M%S_X$-1_:^'\_N_X(?V'BNZ^_P#X!X)17O?_  J3PK_SPN?_  (:C_A4GA7_
M )X7/_@0U']KX?S^[_@A_8>*[K[_ /@'@E%>]_\ "I/"O_/"Y_\  AJ/^%2>
M%?\ GA<_^!#4?VOA_/[O^"']AXKNOO\ ^ =I#_Q[Q_[H_E3Z15"J%'0# I:^
M4/M$%%%% !1110 4444 ,D@BF'[V-7]-RYQ38[2")LQPHK?WL<_G4M%3RQO>
MP!1115 %(Z+(I610RGJ&&0:6B@"H-*L VX6</TV# _#I5H *H"@ #H!VI:*;
MDWNR8PC'X58****10$9&#R*IMI.GN^YK.'/?Y!@_4=ZN44[M -CC2% D2*BC
MHJC %.HHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !3)9DA4-*VT$X%/J*;_60_P"__0T ,^W6_P#ST_\ '31]
MNM_^>G_CIJQ13T%J5_MUO_ST_P#'31]NM_\ GI_XZ:L44:!J5S?VP&3+@>X-
M'VZW_P">G_CII]U_Q[M^'\ZEHT#4K_;K?_GI_P".FC[=;_\ /3_QTU8HHT#4
MK_;K?_GI_P".FC[=;_\ /3_QTU8I&^X?I1H&I +^V(!$N0>AP:/MUO\ \]/_
M !TU);_\>L7^X/Y5)1H&I7^W6_\ ST_\=-'VZW_YZ?\ CIJQ11H&I7^W6_\
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MHH *BF_UD/\ O_T-2U%-_K(?]_\ H: ):*** "BBB@"*Z_X]F_#^=2U%=?\
M'LWX?SJ6@ HHHH *1ON-]*6D;[C?2@!EO_QZQ?[@_E4E1V__ !ZQ?[@_E4E
M!1110 5%;_=?_KHW\ZEJ*W^Z_P#UT;^= $M%%% !1110!$/^/UO^N8_F:EJ(
M?\?K?]<Q_,U+0 4444 %1-_Q^)_N-_,5+43?\?B?[C?S% $M%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %13?ZR'_?_H:EJ*;_ %D/^_\ T- $
MM%%% !1110!%=?\ 'LWX?SJ6HKK_ (]F_#^=2T %%%% !2-]QOI2TC?<;Z4
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M $%K'_P)3_&HH-?T<*^=6L1\['_CY3U^M')+L'/'N:M%9_\ PD&C?]!:Q_\
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M?/93<-B>3<'WR<_.=R@\^F.G%;-% &/I_A?3]-NK::W-P?LD/DV\<D[,D0P
M2H/0D <_7U-;%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M13?ZR'_?_H:EJCJUZ-/@BN#;W%R!)CR[:(R.<@]A32;=D)M)79>HK _X2U/^
M@'KG_@ U)_PEJ?\ 0$US_P  &J_93[&?MJ?<Z"BL#_A+4_Z FN?^ #4?\):G
M_0$US_P :CV4^P>VI]S:NO\ CV;\/YU+7FOCWXBWFF:;!%I5A=V<]PQS+?6I
M0 #'W0>IY'TKH?A[XGN?%7AG[7?(JW,,IAD9!A7( .X#MP:TEAZD:?M'L9QQ
M5*=7V2W.IHHHKG.D*1ON'Z4M(WW&^E #+?\ X]8O]P?RJ2H[?_CUB_W!_*I*
M "BBB@ J*W^Z_P#UT;^=2U%;_=?_ *Z-_.@"6BBB@ H(#*0PR#P0>]%% ''Z
M=\-_#VF>)_[3MH)?,3]['$SYCC8D\@8_+)XKL*B'_'ZW_7,?S-2U<ZDYN\G<
MSA3A35H*P4445!H%1-_Q^)_N-_,5+43?\?B?[C?S% $M%%% !1110 4444 %
M%%% !4-U:6U];F"]MXKB%L9CF0.I_ \5-10!%]EM\$>1'@Q^4?D'*?W?IR>*
MAETK3Y[A)YK"VDFC4*DCPJ651T ..!5NB@"NFGV4=T+F.T@6< J)5B4, 3DC
M.,\GFFP:786V_P"S6-M#O<2/Y<*KN8<AC@<GWJU10!5_LK3PUPPL;;=<C$Y\
ME<R_[W'S?C2/I.G21V\<EA:LEKCR%:%2(L=-HQ\O0=*MT4 5;C3+"[N%GNK&
MVGF0;5DDA5F4>@)&:M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 57&GV:W[7RVD NV78UP(AYA7T+8SCCI5BB@");6
MW3RMD$:^2I6/" ;!Z#T'%5H-$TJU#"VTRSA#'+".W5<G(.>!ZJ#]0/2KU% %
M,:/IBV4EFNG6@M96W20"!=CGU*XP3Q4B:?91PB%+2!8A%Y(01*%$?]S&/N^W
M2K%% %$:)I0M(K4:99BWA?S(H?LZ[(VZ[E&, \]14ITVQ.H"_-G;F\"[1<>4
MOF8]-V,XJS10!4&E:<M\UZMA:BZ8@M.(5\PX]6QFK=%% !1110 4444 %%%%
M %2+2M/@698+"VC%PVZ8)"H\P^K8')^M2S6=K<)*MQ;0RK,H24/&&$BCH#GJ
M.3P?6IJ* *0T72UMOLZZ;9B#!'E"W7;@C!XQCIQ]*671],N+>"WGTZTEAM\>
M3&\"E8L=-H(P/PJY10!6N--L;R"2"[LK>>*5@\D<L2LKL, $@CD\#GV% TVQ
M%S#<"SMQ/ GEQ2^4NZ-?[JG&0/859HH K6VFV-G/--:65O!+<'=-)%$JM(?5
MB!SU/6FV>E:=I[L]A86MJS9W&&%4)SC/0>P_*K=% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5%-_K(?\ ?_H:EJ*;_60_[_\
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M;'3_ .SKN.W$]TD$F^#S,AL\CD8QBMJJ]Y8PWWD>?N_<3+,FTX^9>F?;F@#
M?Q;''XZ31#):^1M$+DR@2_:&7>H"Y^[L'7U8"DT#Q)<:L;NZNI;:UL=/GFMY
MY'PI=U<@=3\BA=O)^\3Q@#G5_P"$?L?[.DLR'(DF-P9=W[SS-^_=N]0V,?0"
MFVGAVQL;U;JU\R.3#B3#<3!F+8<=\%C@]1G'2@#&NO%-P/$2Q6DL,EB)88PR
MQ[XW609+-,#M0C/"GKQ_>X;HWB+4M22Z621(W:R-S$6MB@C;)&$R?WJ#CYQQ
MR/7 VKCPY9W-Z\TDDXAE=9)K17'DRNH 5F&,Y&U> 0#M&0:+'P[:V1.)[F<"
M$V\(FDW>1$<91>!QPO)R?E'- %";6;R33M#>.01RWENUQ.R*.BP%B #G'S%:
MHV?C'4#IR3?V4UU#%]EADG-PJR2R31QD$(%"X!D7=R,#D ]*V;G0OGTA+7_C
MWLD>W<.WS>4T17@]SD+^M/M_#5A;6)M(O-\HRPR\OSNB5%3](ES^- %!O$^H
M&[@L(-*ADOWN);>53=D11E(UDW;]F2"'4?=SD_C4*>-)18PWEQI?DQ74)EMU
M,^7.UT1@PVX7[^1@G('.*VX]#LX]4-^OF>?YKS<MQN9%0\?1!4#^%]-DL[>U
MD61HK>"2W0%_X7QGGU^48/:@"OJWB:;3]3:PM=.^U3;[=$S-L!,ID&3P<!?*
MR>O7VYK7/C,VHBMY+6%+]I98W1YV\I/+VY.\(20=ZX^7OSC%:4/ANUCD6:>>
MYNKA9DF,\S@LQ0$*#@ 8&YN .I)HF\.6LDK3P3W-K<F9YA/"X# N &'((*G:
MO!!Y -  OB&-O#"ZP;:8;@ (",,7+[ HSCJV,'T.:RKOQ)JD&L0:=>645DXD
M@D>6*?SDDC=G#*,JI!&WDX[\5M7NE!_#LFG6ZB;]WM7[5*YW'.<LX.[.>=PY
M!YK&TOPQ<2ZK)J6M/,T@$*Q*]P)6/EL[ DA54#Y\8 [9)YH +SQ3>IHSW360
MM$O+.::PF$HD8,L1D7>FW"DJ">"PXP:<_BJ^TZPBDU?3%C>:V$T.RXW%R-H9
M7^4!6^;/&X<'FKJ^$K#RFADENI8!#)!!#)+E;='&U@G&>G ))P.!@40>$K".
M!H;B:ZO(_LYM8EN9MWDQG&0I&#DX'S'+<#F@"EXD\17-E?&SM,PF(([RC#%U
M>*X. "" 080<_P"2VP\5WDL6^;3P;2":WMI;IYP'=Y4C(8(%Q@&49Y'MZ5?;
MPI92QM]KGNKJ5V#-/+(-[ (Z < # $C=!U.:GC\.6,5A)9KYOE23Q3ME^=T>
MS;^'[I?UH CU37FT[6+:R^S*5GB>3S9)=FXK_ G!#-CG&1QDC.#6;K?BJX@\
M.07-C R7%WIKWL9!#;"OE_+@C!SYF,\=*W+[2(=0O;:>YFG*6[!Q & C9AT8
MC&<C/8CWS6>W@W3I+*:TN);N:![<VL:/-_J(B02B$ $?=7DY/RCF@!)O$EQ8
M220:IIPCN6C62VC@G\P3;G6,)DJNU@SH#U'S9R<&IUU>_@O+6VU/38X6N9_*
M22&X\Q"/+=\C*@Y&S!! ZC!-"^&+)XIUO9KJ]>:,1>;<2Y>- =RA2H&,-@YZ
MY ))P*4^&X7B/G7U]+<>8LB73RCS(V4$#: -HX9@?EYR<YH S9_$MZVKV8AB
MBBLEN[J"Z,DAW,L2D[@-I],XR/2DN?%]_9P6]U=:*JVMU;S7$++=990D1D"N
MNW@L!V+ <\^NQ!X?LH!:_P"LD:W>23=(V3(T@(=F]2<GVJ@W@G3I#&)KF^DB
M@AE@MX7GRD*2(490,<_*< MDC'!H AF\826%I))JVG"VF,$4T,23[]WF/L"L
M=HVD,1G&1@\$T^U\6O=1^3%9+)?-<+!$B2-Y,A*E]WF,@. JMGY<\=\BM*\\
M/V5](7F\T/Y"P*R.5*!6#JP(Z,& (/M3#X>@DM#%/>7DTWG"9;IY1YD;@8!7
M VCC(P!@@G(.30!%8>(7NM673+FT\BZ7S1,%DW*A3RR-IP-P995.>,="*KZ3
MXK;5-2M;;[&ENMQ TH:2?YFP[*0@VX;&T$\@C>.#UJS_ ,(Q:B-##<W<5TLC
MR&\20>:[. &R2"I! 48Q@;1C&!4D'ARSM[FRDBDN!%8KB"W,F8U;:R[^F2V&
M;OSG.,T :U%%% !1110 5R@\=VT",MY:7+RH+B:7[-%N6*"*9XS(Q)']W) R
M>> :ZNN;B\(")+Y?MI/VNUGM_P#5?<\V623=UYQYF,=\>] "R^-M.AM7GDMK
MX?/"L48@R\XF8K$RC/1B".<$=P*=;^,["XEV&UO8=LK6\KRQ +%,H+>43GEL
M#((RO(YYI;GPL+C4(+K[65\I;1=OEYSY$C/US_%OQ[8[TZ3PPDH*O<Y5M3^W
MD>7U^7&SK^OZ4 +?^,-+TW3(;^Z,X@FLFOEV1%F\I=F>!SG]XO ]Z4>*K00R
M>;:WD-TDB1K9O$/.D9P2FT XY 8Y)&-K9Q@UGGP7<36*6EYJBRI;6?V*T9+;
M:R1[D)+_ #'<V(D&1M'7CFK^H>&WNM7?4[:]\B[4PM 6BWJC1B13N&1N#+*P
M(R".H- $)\8VJWD0D1K>!8;A[L3J1+;O$8OE*C.<B3/&<Y7&<U./%=FL%PUW
M;7EI/ (S]EFB_>R>8=L>T*2&W-\O7@]<52D\%?:YI;B_U!GN;A9O.DBBV#>_
ME;"@).T((%P#G/<U'J6@7_DS:G>W)OM200B%K.W$8B$;[LB-G.\DDEANY' P
M: +]GXNLKK5#ITMM>6EVLBQ/'<1!=K,C.HW D'*HV""1VZ\5J:=J$.J6*W=K
MN,+LP1F&-P5BN1['&0>XQ7#W&DZSJ^GZW=2&X6YOI+2*SE6W^SM"T;?ZT(Q8
MJJER?F.3ANQ%=Y:6L5C906ELNR&"-8XU]% P!^0H FHHHH **** "JVI736.
ME7=VBAF@@>0*>A*J3C]*LU7O[7[=IMS:;]GVB%XMV,[=P(SC\: ./T[X@*D*
MRZG-:WT4D,#K+I2,^R65MHA9=S9;.,8/U ZU:B\>V\*R)J%K<-+$)YYC;0DK
M!!',\9=R3U&SD#.>2 16Q)H2OI>FV:S;!82PR;@G^L\OVSQG%9\7@X11ZFOV
MXG^T+>>#_5?<\R:63/7G'FX_X#[T 65\76!MYI)(+N)T,?EPO%^\G$I(C**#
MSN*D<X(P<@8JL?'6GK<-:RV>HQWBW"VWV5K?+F1D9U P2""JD[@<>IZXFO\
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M#M'][<S,I)^]CGI5>XM5T77%35)[J]A@/VB1+29P',>Z0O(I<*6P59ASPB@
M[J[U=%TQ)K>5-/M1);+MA<1+F,>BG''6B71].N(C'<64$Z&8SD2H'_>?WN<\
M_P!..E %/693->:)#&["*XO [%3C<$C=P/\ OI5/X5R]IJNL:3X6MKG[8L_V
MBUNFCB://E-&K.C;NK<+SGUXQBNUO]/%[+92B0QO:7 F4@9S\K*5_$,:E6QM
M46)4MH56'/E@(,)D8./3()H YO7=:U*/4/LNE7$,8DCM-LC1[PIEG*$^_P H
MX^E1V^J:Q;W9-W>I<0P:HMAL$*J9E95(=B.C L!Q@8'3GCHK;1M,LH3%::?:
MP1F02%8X54;AR&X'48X]*G-E:G.;>(YE$Q^0<N,8;Z\#GVH X\Z[JJ6NC:C_
M &G;,FJ.^ZS\H?NP(9'"H>I*E0&SGG/3I3);W59/#DB:I?)-)>Z))?!HHA&+
M>1 IPI')'SCKS\OOBNJ&A:2+QKL:9:"X9BQE\A=Q)!!.<=2"?SI-2T:WU#3)
M+-52 /";<.D8RD1QN0>@(&/R]* *.GSN_BN;)8+<:;;S,F>%;<X_#(Q^5;U4
MX-.6'5KF^,A9IHXXE3&!&J;CCWR6)_*KE !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J
M*;_60_[_ /0U+44P_>0_[_\ 0T 2T444 %%%% $5U_Q[-^'\ZEJ*Z_X]F_#^
M=2T %%%% !2-]QOI2TC?<;Z4 ,M_^/6+_<'\JDJ.W_X]8O\ <'\JDH ****
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M,?S-2U$/^/UO^N8_F:EH **** "HF_X_$_W&_F*EJ)O^/Q/]QOYB@"6BBB@
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M<ZD_M+Q/_P!"[:?^#/\ ^UT>SEY?>O\ ,/:Q\_N?^1OT5@?VEXG_ .A=M/\
MP9__ &NC^TO$_P#T+MI_X,__ +71[.7E]Z_S#VL?/[G_ )&_2-]QOI6#_:7B
M?_H7;3_P9_\ VND;4O$VT_\ %.VG3_H)_P#VNCV<O+[U_F'M8^?W/_(W+?\
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MHHH **** "BBB@ HHHH *BF_UD/^_P#T-2U1U6R&H016[3W%N&DSYEM*8W&
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"E'HVFPZD^HQ6
M%LEZ^=UPL2ASGK\W7M5F""*VB\NWB2),EMJ* ,DDDX]R2?QJ2B@ HHHH ***
M* "BBB@ ID\RV]O),_"QH7;Z 9I]5M1M7O=+NK6.3RGGA>-9",[2RD9QWQF@
M#G6\;;?!=CK361%Q<O&DEIOYB)(\S)]%7<WO@>M;3ZY9);^;N;:;O[&/D/\
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M-2[NU@<@X\M"K,7]P-O/MFL4>!$1DV_V=-O@ABFDNK!99 8T"90DX&54<$$
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MV%S+:22+.7(EC#$D#:,I\AYR#G^&GVOB+4)=0TJ.YTE(;75-YAE6YW-&!&7
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MOOE?*Y/0[ZV(?#FF6^H+=QPR!T=I(XS.YBC=LY98R=JDY/('\1]35VSLH+"
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9G5KBWF:7S?.MYV1P=BH0".Q5%&/:@#GK[Q;JLSV[V5C):1M:WIF65T+1RQ
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M=]W=/(04.5 R>!G/'?/-5D\$:2ERDK->2+"'6"&2Z<QP!T9&"+G &UB/;C%
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M2RVR/';K/=/(D"-C*JI. /E'Y4 ;M%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !574)DM[3S9 Y5'0G8A<_>'0 $G\*M5#<_ZM/\
MKHG_ *$* */_  D-C_SSO_\ P77'_P 11_PD-C_SSO\ _P %UQ_\16I15WAV
M_'_@$6GW7W?\$R_^$AL?^>=__P""ZX_^(H_X2&Q_YYW_ /X+KC_XBM2BB\.W
MX_\  "T^Z^[_ ()CW/B"R:UE 2_!*'_F'7'I_N5)_P )#8_\\[__ ,%UQ_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "H;G_5I_UT3_ -"%35#<_P"K3_KHG_H0H FHHHH
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M3^Z3.2S";&">#SD]*6\\6ZWIFFS75S;Z;<O/ILM_9I;2-A=@4A'8YW [Q\X
MZ'CD4 =O17%7?B&^M-2BLM;AAFNK:>&8M8O*B^7)'.0,;OF8&!A@\'(X!K7T
M._UF[D@FU-]*-K>0F:%+5V\Q.A R<B08;E@%QQP<\ &]17&#6_$$NO3:9I?V
M-R]U='SKP,5A2)8-JA5P6R93WX_2L>?6=0U35%U:.X:&T:WTMXX8GD#+YMX
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M *Z)_P"A"@":BBB@ HHHH BNN+.;M\A_E4HZ5%=?\><W_7-OY5*.E !1110
M4C_<;Z4M(_\ JV^E #+?_CVC_P!T5)4=O_Q[1_[HJ2@ HHHH *BA.9)L_P!_
M^@J6H8/]9-_O_P!!0!-1110 4C*&4JPR",$>M+10!P6E_"O1],\6#4HYYI$A
M830VS ;4;/'/?':N]J$?\?K?]<Q_,U-6E2K.H[S=S*G1ITE:"L%%%%9FH5"W
M_'['_P!<V_FM35"W_'Y'_N-_-: )J*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,'Q
M1XC?P_':^5#9NUPSC=>WOV6-0J[OO;6Y/88_&IK?Q/82:5+?3EX%@L$U"=&0
MDQQ,'(/ Y_U;\#T]Q2>(="FUDV<EM<P6\MJ[,/M%J+A&RN#E2P_/-94O@9_[
M/6RL]6>"":R%C?9@5C<1 L?E.0(S^\D ." &Z<4 .7Q5;OJER-5MX%M[&24P
MR",N^]65%VCD[CYA&!SSBM:R\3:;?-$D;S132S_9Q!/ \4BOY;2 ,K %<HC$
M$\&L^?P7'+=7%RE])%-),T\3",'RI-ZNIP>H!3IW!-#>%+N13>2:OG61<).E
MX+8"-2J-&%\K=]W9(X^]G+9SP!0!>C\4Z7-?Q6<,LLDLDLL7R0.51HY#&VXX
MPHWC:">">E9NO>,GT76I+,6ME)%##'-(9;_RIG#LPQ%%L.\C;TW#).*=#X.D
MAN=,F.I[FM)I+B9OLRAY9)&+.58'**2QRO((P/>M==%MO[<GU25(Y99(XXUW
MQ@F/86.0>O.[]* (4\3Z:^J&P5I]XD\HR_9W\D2?\\_,QMW=L9SGBLRU\=^'
M3&!8K=%92\D2PZ=-_I!W?O"@"?.0Q)8C.#DFHA\/;%/$W]J)]CV&Z^V%6L$:
M;S-V[B4]!NY^[D=F'&-*Q\,1V*Z2%NG?^S;:2W7* >8'"\GT^[0 R?QMHL$P
M027,P\E)W>"TED2*)QE7=E4A1C)R?0^E-@\869UVZTVXW@QSI$DL4+O&-ZJ4
MWN!M4L6P,GGBL^W\*ZO;W=W!9:N]G:/!! 7-NDAE55(9DR?D;G&3N'3CUU?^
M$6MUL+BT@F:**:>&50!G8(]@"^_"#GWH J?\)9I&GQ?:KY_/NFA,EQ-8V$K>
M7"K, SX#%5&&^\<<,14\_BS0//M992\N$25;E;1W2V61?E+N%Q'N4]R.#SQ6
M!JVB:UI+RP>'8[R07=MY,LT,<#!CN<C.]U,9&_[P#@C^'CG3A\&72:8M@NJF
M&TN;:*'4;<0AS,4B6)MCD_)N5 IX/'(P>: +Q\56EIF.[E>ZF::55CL;.61E
M1&P2R@,0!D MP">E-M/$_G^ /^$C>-#_ *,\X5,[3C..O/.!36\+W5M=/=Z-
MJWV.YF+B5I+<2JZ%RX&W(P5+-@YQ\QR#Q@G\.2VWP\FT&UN'NYUM'C2:7 :1
M^2">V<_A0!7M_&$W_"4_V+<VMH669;=FAO,S>9Y*REO)*Y$?.-VX_2L^P\<O
M)8W)M=.TV,BTGO8DL[WSR"F"PE4(NQFSZGG.??1/A&2YUY]3ENXXX)[B.\:W
M^RKYR.L:J%\X-]WY!D >HS@U9GT!=/\ !=YINF0+)<RVCP!TC5&D+ @$]!QG
M- &]!*)[>.5>DB!A^(S3ZCMHO(M8H?\ GF@7\ABI* "BBB@ HHHH **** "B
MBB@ HHHH *AN?]6G_71/_0A4U5[V-9;<1R*'1G4,I&01D=: +%%9?_",:'_T
M"K3_ +]"C_A&-$_Z!5I_WZ%7:'?\/^"1>?9??_P#4HK+_P"$8T3_ *!5I_WZ
M%'_",:)_T"K3_OT*+0[_ (?\$+S[+[_^ 7[K_CSF_P!P_P JE'2L:Y\-:(+6
M4KI5H"$)'[H>E2#PSHG_ $"K3_OT*+0[_A_P0O/LOO\ ^ :M%9?_  C&B?\
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M:@ HHHH *A;_ (_8_P#KFW\UJ:H6_P"/V/\ ZYM_-: )J*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** .6\;WFJ6W]D+HDSI.+QIY8DQ^_BCB=FC.>S':*R)?$VIW.O
MRZKHTWVG3&T^7[):XRMPT3QL[C&#N(:1!SC*@]S74ZYK.GZ*]K/J%I<S.S^7
M"]O9/.49L#&5!VYR![U7L;_1+VW>UL&M]/N+<3Q0QE(TDA"L49U3LN03T[<T
M 9R>*KW5S"=#FL([6_N6BL;RXC:1&1$R[8#KO+$$* 5X5CSC%5I/%NIG[*DP
MT\P%Y+>ZEC5F25PYC4J0V8U8CC(?+?)D??K>_LWP]9^&[71[Y+&738X5"17F
MQD=5Q\V&X/)!SZFI!;^'9;VTMT@TR2[LX<VD(6,R0QD8^0=54CCC Q0!Q5C=
MW::VTEP]J]D;?2VAMMLBB L9>=QD/3!Y(YXSTYZ[PKK%[JNE2R:J(!>0OMEC
MMT*A#M# 8+-G@\,#A@0<#. LNHZ)9Z?'>7L%K:2R0^8EN[1>:XC!(5<$AB,G
M&"0,^]']HZ-X=TBS>ST][>"]?,-M8619F9E+D[(P>< DF@#E[#4[Z*UT<B\E
M N;;3KF;Y\AGFN"93SV.2/IQ5*V\0:[-X(ETI[Z1=;O(6NK:[XWI;LK2%O\
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MO^"9?_"1Z=_>N?\ P#F_^)H_X2/3O[US_P" <W_Q-:E%%X=OQ_X 6GW7W?\
M!,O_ (2/3O[US_X!S?\ Q--;Q'IQ0_-<]/\ GSF_^)K6I'_U;?2B\.WX_P#
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M?^XW\Q4U0M_Q^Q_]<V_FM $U%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)+%=QE=S$C.<XXP?R-9\_A[5]0DN=0N8-,M[TO T5I'*\D,OE,6'FN44DG.
M=AVX!^;I3;?PUJMQJ%S?W\6FVLMQ?6MRT5K([@+%D'+E%W,1CG:/3MD@&QI_
MBO1[^.3-_:P3PAVFMY;A!)$BN5WLN<A3QR?45JBXA:X-NLT9F5!(8PPW!22
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M_0&T_P#\!4_PHM#O_7WA>?9??_P#1WK_ 'A^=&]?[P_.L[_A'-#_ .@-I_\
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MK?\ 7,?S-35"/^/UO^N8_F:FH **** "H6_X_8_^N;?S6IJA;_C\C_W&_F*
M)J*** "BBB@ HHHH **** "BB@G'6@ HJ*YNK>SMI+B[GC@@B4O)+*X544#)
M))X  [TRTU"RO_,^PWD%SY3;)/)E5]C8!P<'@X(/XT 6** 0>AHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MJ&Y^XG_71/YBIJAN?N)_UT3_ -"% $U%%% !1110!%=?\><W^X?Y5*.E177_
M !YS?[A_E4HZ4 %%%% !2/\ <;Z4M(_W&^E #+?_ (]H_P#=%25';_\ 'M'_
M +HJ2@ HHHH *A@_UDW^_P#T%35#!_K)O]_^@H FHHHH **** (1_P ?K?\
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MEQ6&^+8'DG,ZJPSGE4/WE&,$@Y!/0UKT""BBB@ HHHH **** "BBB@ HHHH
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M*1HY4R$;,J@XRQP!GK6I%XOT6:UN+A+B41VX0G=;2*9 YPAC!7,@8\*4SN/
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MOEMVU>4V\OE1F-G);RF,0.X! 3P-PR,]77KSWM]HD\?B"/5(8C> R1VT>RX
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M Q^- '?4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%(_^K;Z4M(_^K;Z4 ,M_^/:/_=%25';_ /'M'_NBI* "BBB@ J&#_63?[_\
M05-4,'^LF_W_ .@H FHHHH **** (1_Q^M_US'\S4U0C_C];_KF/YFIJ "BB
MB@ J)O\ C\CZ_<;^8J6H6_X_8_\ KFW\UH FHHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ J&Y_U:?]=$_]"%35#<_ZM/\ KHG_ *$* )J*** "
MBBB@"*Z_X\YO]QOY5*.E177_ !YS?]<V_E4HZ4 %%%% !2/_ *MOI2TC_P"K
M;Z4 ,M_^/:/_ '14E1V__'M'_NBI* "BBB@ J&#_ %DW^_\ T%35#!_K)O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@R<]:?'%'"NV%%C7KA1@4ZBG=BL@HHHI#"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ J&Y^XG_71/_0A4U0W/W$_ZZ)_Z$*
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M8$GMI4FBD4,DD;!E8>H(ZT 2445$]S!'<16\DT:S3!C'&S ,X7&<#OC(S]:
M):**A2[MY+R6TCGB:XA57DA#@NBMG:2.H!P<?0T 345#!=VUTTRVUQ%,T$AB
ME$;AO+? .UL=#@@X]ZFH **** "BBJKZII\=\ED][;K=.VQ8#*H=FV[L!<YS
MMY^G- %JBF3SQ6T#S7,J111C<[NP"J/4D]*:UU L\4+31B68%HD+#+@8R0.^
M,C\Z ):*AN[NWL+26ZO9X[>WB7=)+*X54'J2>!3XI8YX4F@=9(Y%#(ZG(8'D
M$'TH ?1144UU;V[Q)<3QQ-,Q6,.P!<X)P/4X!/X4 2T5#:7EM?V<5W8W$5S;
MS*&CFB<,CCU!'!%34 %%%% !1110 4444 %%%% !4-S_ *M/^NB?^A"IJAN?
M]6G_ %T3_P!"% $U%%% !1110!%=?\><W^X?Y5*.E177_'G-_N'^52CI0 44
M44 %(_W&^E+2/_JV^E #+?\ X]H_]T5)4=O_ ,>T?^Z*DH **** "H8/]9-_
MO_T%35#!_K)O]_\ H* )J*** "BBB@"$?\?K_P#7,?S-35"/^/UO^N8_F:FH
M **** "H6_X_(_\ <;^8J:H6_P"/V/\ ZYM_-: )J*** "BBB@ HHHH ****
M "F3N(K>20AV"H6(098X'8>M/HH \TM]:_LOP]=GP],)\30K-?K<;U1&W9=O
M,.V.48PP/ )4D=JEAUW4;JWL[_*WLUJ]V+:4,DOG 0 Y/E?*Q!)'R=<=CFO1
M=HP1@8/7B@  < "@#S35-5EO[+5-.L_%@U:W;2)9WEBAA+12!D&W<J[<$$_*
M1N&<D\C&GJ&MWMC<2P_VXL%U:)$MII\D,9;4<JN6(QN.XDK^[P%QDUW 4#H
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M?5S[5I6NB:58B<6.F6=L+CB80VZ)YO\ O8'/4]:NHBQQJD:A$4 *JC  ] *
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M+4_^@%-_X$1?_%5HV_\ Q[1_[HJ2CF7;\_\ ,.5_S/\ #_(RO[2U/_H!3?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M0W/W$_ZZ)_Z$*FJ*Y1WAQ$%+AE8!C@'!!H EHJIYFH?\^]O_ -_C_P#$T>9J
M'_/O;_\ ?X__ !- %NBJGF:A_P ^]O\ ]_C_ /$T>9J'_/O;_P#?X_\ Q- $
MUU_QYS?[A_E4HZ51E.H20N@@MQN4C_7'_P")I_F:A_S[V_\ W^/_ ,30!;HJ
MIYFH?\^]O_W^/_Q-'F:A_P ^]O\ ]_C_ /$T 6Z1_P#5M]*J^9J'_/O;_P#?
MX_\ Q-(7U J1]GM^1_SV/_Q- %BW_P"/:/\ W14E4HSJ"1*OV>W.T8_UQ_\
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' **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704503644368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Apr. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-32335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">HALOZYME THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">88-0488686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">12390 El Camino Real<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">794-8889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HALO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,274,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001159036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704422391184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 164,627<span></span>
</td>
<td class="nump">$ 118,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, available-for-sale</a></td>
<td class="nump">298,824<span></span>
</td>
<td class="nump">217,630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent', window );">Accounts receivable, net and contract assets</a></td>
<td class="nump">195,902<span></span>
</td>
<td class="nump">234,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">168,541<span></span>
</td>
<td class="nump">127,601<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">45,690<span></span>
</td>
<td class="nump">48,613<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">873,584<span></span>
</td>
<td class="nump">746,424<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">78,071<span></span>
</td>
<td class="nump">74,944<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Prepaid expenses and other assets</a></td>
<td class="nump">17,319<span></span>
</td>
<td class="nump">17,816<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">416,821<span></span>
</td>
<td class="nump">416,821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">455,116<span></span>
</td>
<td class="nump">472,879<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="nump">616<span></span>
</td>
<td class="nump">4,386<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,841,527<span></span>
</td>
<td class="nump">1,733,270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">13,325<span></span>
</td>
<td class="nump">11,816<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">118,314<span></span>
</td>
<td class="nump">100,678<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">131,639<span></span>
</td>
<td class="nump">112,494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net</a></td>
<td class="nump">1,500,879<span></span>
</td>
<td class="nump">1,499,248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">31,201<span></span>
</td>
<td class="nump">37,720<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,663,719<span></span>
</td>
<td class="nump">1,649,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock - $0.001 par value; 20,000 shares authorized; no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock - $0.001 par value; 300,000 shares authorized; 127,186 and 126,770 shares issued and outstanding as of March&#160;31, 2024 and December&#160;31, 2023, respectively</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">11,794<span></span>
</td>
<td class="nump">2,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1,486)<span></span>
</td>
<td class="num">(9,278)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">167,373<span></span>
</td>
<td class="nump">90,550<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">177,808<span></span>
</td>
<td class="nump">83,808<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 1,841,527<span></span>
</td>
<td class="nump">$ 1,733,270<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable And Contract With Customer Asset, After Allowance For Credit Loss, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property, Plant, and Equipment and Operating Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704503661328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">127,186,000<span></span>
</td>
<td class="nump">126,770,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">127,186,000<span></span>
</td>
<td class="nump">126,770,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704419004704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Income (Unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 195,879<span></span>
</td>
<td class="nump">$ 162,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">28,329<span></span>
</td>
<td class="nump">35,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangibles</a></td>
<td class="nump">17,763<span></span>
</td>
<td class="nump">17,835<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">19,111<span></span>
</td>
<td class="nump">17,979<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">35,134<span></span>
</td>
<td class="nump">37,357<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">100,337<span></span>
</td>
<td class="nump">108,341<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">95,542<span></span>
</td>
<td class="nump">53,802<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Investment and other income, net</a></td>
<td class="nump">4,993<span></span>
</td>
<td class="nump">2,979<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(4,507)<span></span>
</td>
<td class="num">(4,543)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net income before income taxes</a></td>
<td class="nump">96,028<span></span>
</td>
<td class="nump">52,238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">19,205<span></span>
</td>
<td class="nump">12,623<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 76,823<span></span>
</td>
<td class="nump">$ 39,615<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (USD per share)</a></td>
<td class="nump">$ 0.61<span></span>
</td>
<td class="nump">$ 0.29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (USD per share)</a></td>
<td class="nump">$ 0.60<span></span>
</td>
<td class="nump">$ 0.29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted average common shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (shares)</a></td>
<td class="nump">126,941<span></span>
</td>
<td class="nump">135,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (shares)</a></td>
<td class="nump">128,887<span></span>
</td>
<td class="nump">137,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 120,593<span></span>
</td>
<td class="nump">$ 99,640<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">58,583<span></span>
</td>
<td class="nump">60,794<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=halo_CollaborativeAgreementsMember', window );">Revenues under collaborative agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 16,703<span></span>
</td>
<td class="nump">$ 1,709<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=halo_CollaborativeAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=halo_CollaborativeAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704420230928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 76,823<span></span>
</td>
<td class="nump">$ 39,615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on marketable securities</a></td>
<td class="num">(313)<span></span>
</td>
<td class="nump">924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_OtherComprehensiveIncomeLossCashFlowHedgeUnrealizedHoldingGainLossBeforeAdjustmentAfterTax', window );">Unrealized gain on derivative instruments, net</a></td>
<td class="nump">8,615<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Realized gain on derivative instruments, net</a></td>
<td class="num">(518)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">$ 84,615<span></span>
</td>
<td class="nump">$ 40,561<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_OtherComprehensiveIncomeLossCashFlowHedgeUnrealizedHoldingGainLossBeforeAdjustmentAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Cash Flow Hedge, Unrealized Holding Gain (Loss), Before Adjustment, after Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_OtherComprehensiveIncomeLossCashFlowHedgeUnrealizedHoldingGainLossBeforeAdjustmentAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481839/830-10-45-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482014/830-20-35-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704503811376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 76,823<span></span>
</td>
<td class="nump">$ 39,615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">9,874<span></span>
</td>
<td class="nump">7,966<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,443<span></span>
</td>
<td class="nump">2,622<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangibles</a></td>
<td class="nump">17,763<span></span>
</td>
<td class="nump">17,835<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">1,830<span></span>
</td>
<td class="nump">1,835<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premium on marketable securities, net</a></td>
<td class="num">(2,365)<span></span>
</td>
<td class="num">(917)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Realized gain on marketable securities</a></td>
<td class="num">(7)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_DeferredRentPayments', window );">Lease payments deferred</a></td>
<td class="nump">220<span></span>
</td>
<td class="nump">320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred income taxes</a></td>
<td class="nump">1,291<span></span>
</td>
<td class="nump">3,874<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net and other contract assets</a></td>
<td class="nump">38,308<span></span>
</td>
<td class="nump">36,189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories, net</a></td>
<td class="num">(40,233)<span></span>
</td>
<td class="num">(7,250)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">4,795<span></span>
</td>
<td class="nump">8,881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">18,685<span></span>
</td>
<td class="num">(24,006)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">129,427<span></span>
</td>
<td class="nump">86,964<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(198,763)<span></span>
</td>
<td class="num">(109,919)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="nump">119,627<span></span>
</td>
<td class="nump">61,134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(3,545)<span></span>
</td>
<td class="num">(11,377)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(82,681)<span></span>
</td>
<td class="num">(60,162)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayment of 2024 Convertible Notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(13,483)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(150,083)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement, net of proceeds from issuance of common stock under equity incentive plans</a></td>
<td class="num">(489)<span></span>
</td>
<td class="num">(1,048)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(489)<span></span>
</td>
<td class="num">(164,614)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">46,257<span></span>
</td>
<td class="num">(137,812)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">118,370<span></span>
</td>
<td class="nump">234,695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">164,627<span></span>
</td>
<td class="nump">96,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Amounts accrued for purchases of property and equipment</a></td>
<td class="nump">1,515<span></span>
</td>
<td class="nump">390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligation</a></td>
<td class="nump">1,242<span></span>
</td>
<td class="nump">406<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Common stock issued for conversion of 2024 Convertible Notes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_DeferredRentPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Rent Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_DeferredRentPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704420358624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive (Loss) Income</div></th>
<th class="th"><div>Retained Earnings</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity, beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 169,798<span></span>
</td>
<td class="nump">$ 135<span></span>
</td>
<td class="nump">$ 27,368<span></span>
</td>
<td class="num">$ (922)<span></span>
</td>
<td class="nump">$ 143,217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">7,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock for the conversion of the 2024 Convertible Notes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock for the conversion of the 2024 Convertible Notes</a></td>
<td class="num">(126)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(126)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock and performance stock units, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock and performance stock units, net</a></td>
<td class="num">(1,048)<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1,049)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchase of common stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,165)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Repurchase of common stock</a></td>
<td class="num">(151,301)<span></span>
</td>
<td class="num">$ (4)<span></span>
</td>
<td class="num">(34,159)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(117,138)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">39,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,615<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity, ending balance at Mar. 31, 2023</a></td>
<td class="nump">65,850<span></span>
</td>
<td class="nump">$ 132<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">65,694<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity, beginning balance at Dec. 31, 2023</a></td>
<td class="nump">83,808<span></span>
</td>
<td class="nump">$ 127<span></span>
</td>
<td class="nump">2,409<span></span>
</td>
<td class="num">(9,278)<span></span>
</td>
<td class="nump">90,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">9,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock and performance stock units, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock and performance stock units, net</a></td>
<td class="num">(489)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(489)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">7,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">76,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,823<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, ending balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity, ending balance at Mar. 31, 2024</a></td>
<td class="nump">$ 177,808<span></span>
</td>
<td class="nump">$ 127<span></span>
</td>
<td class="nump">$ 11,794<span></span>
</td>
<td class="num">$ (1,486)<span></span>
</td>
<td class="nump">$ 167,373<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704416571008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization and Business</a></td>
<td class="text">Organization and Business <div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the innovators of ENHANZE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> drug delivery technology (&#8220;ENHANZE&#8221;) with our proprietary enzyme, rHuPH20, our commercially validated solution is used to facilitate the subcutaneous (&#8220;SC&#8221;) delivery of injected drugs and fluids with the goal of reducing the treatment burden for patients. We license our technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with our partners&#8217; proprietary compounds. We also develop, manufacture and commercialize, for ourselves or with our partners, drug-device combination products using our advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ENHANZE partners&#8217; approved products and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. rHuPH20 works by breaking down hyaluronan (&#8220;HA&#8221;), a naturally occurring carbohydrate that is a major component of the extracellular matrix of the SC space. This temporarily reduces the barrier to bulk fluid flow allowing for improved and more rapid SC delivery of high dose, high volume injectable biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids. We refer to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as ENHANZE. We license our ENHANZE technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the SC route of administration. In the development of proprietary intravenous (&#8220;IV&#8221;) drugs combined with our ENHANZE technology, data has been generated supporting the potential for ENHANZE to reduce patient treatment burden, as a result of shorter duration of SC administration with ENHANZE compared to IV administration. ENHANZE may enable fixed-dose SC dosing compared to weight-based dosing typically required for IV administration, extend the dosing interval for drugs that are already administered subcutaneously and potentially allow for lower rates of infusion-related reactions.&#160;ENHANZE may enable more flexible treatment options such as home administration by a healthcare professional or potentially the patient or caregiver. Lastly, certain proprietary drugs co-formulated with ENHANZE have been granted additional exclusivity, extending the patent life of the product beyond the patent expiry of the proprietary IV drug.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have ENHANZE collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (&#8220;Roche&#8221;), Takeda Pharmaceuticals International AG and Baxalta US Inc. (&#8220;Takeda&#8221;), Pfizer Inc. (&#8220;Pfizer&#8221;), Janssen Biotech, Inc. (&#8220;Janssen&#8221;), AbbVie, Inc. (&#8220;AbbVie&#8221;), Eli Lilly and Company (&#8220;Lilly&#8221;), Bristol-Myers Squibb Company (&#8220;BMS&#8221;), argenx BVBA (&#8220;argenx&#8221;), ViiV Healthcare (the global specialist HIV Company majority owned by GlaxoSmithKline) (&#8220;ViiV&#8221;), Chugai Pharmaceutical Co., Ltd. (&#8220;Chugai&#8221;) and Acumen Pharmaceuticals, Inc. (&#8220;Acumen&#8221;). In addition to receiving upfront licensing fees from our ENHANZE collaborations, we are entitled to receive event and sales-based milestone payments, revenues from the sale of bulk rHuPH20 and royalties from commercial sales of approved partner products co-formulated with ENHANZE. We currently earn royalties from sales of seven commercial products including sales of one commercial product from each of the Takeda, Janssen and argenx collaborations and four commercial products products from the Roche collaboration. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have commercialized auto-injector products with several pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (&#8220;Teva&#8221;) and Otter Pharmaceuticals, LLC (&#8220;Otter&#8221;). We have development programs including auto-injectors with Idorsia Pharmaceuticals Ltd. (&#8220;Idorsia&#8221;).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial portfolio of proprietary products includes Hylenex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, utilizing rHuPH20, and XYOSTED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> utilizing our auto-injector technology.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except where specifically noted or the context otherwise requires, references to &#8220;Halozyme,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; and &#8220;us&#8221; in these notes to our condensed consolidated financial statements refer to Halozyme Therapeutics, Inc. and each of its directly and indirectly wholly owned subsidiaries as disclosed in Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704417718880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim unaudited condensed consolidated financial statements have been prepared for purposes of and in accordance with United States generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and with the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) related to a quarterly report on Form 10-Q. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for a complete set of financial statements. These condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December&#160;31, 2023, filed with the SEC on February&#160;20, 2024. The unaudited financial information for the interim periods presented herein reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operations for the periods presented, with such adjustments consisting only of normal recurring adjustments. Operating results for interim periods are not necessarily indicative of the operating results for an entire fiscal year.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements include the accounts of Halozyme Therapeutics, Inc. and our wholly owned subsidiaries, Halozyme, Inc. and Antares Pharma, Inc., and Antares Pharma, Inc.&#8217;s wholly owned Swiss subsidiaries, Antares Pharma IPL AG and Antares Pharma AG. All intercompany accounts and transactions have been eliminated.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that we believe to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from our estimates.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents and Marketable Securities </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of highly liquid investments, readily convertible to cash, which mature within 90 days or less from the date of purchase. As of March&#160;31, 2024, our cash and cash equivalents consisted of money market funds, bank certificate of deposits, U.S. treasury securities and demand deposits at commercial banks.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities are investments with original maturities of more than 90 days from the date of purchase that are specifically identified to fund current operations. Marketable securities are considered available-for-sale. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date which reflects management&#8217;s intention to use the proceeds from the sale of these investments to fund our operations, as necessary. Such available-for-sale investments are carried at fair value with unrealized gains and losses recorded in other comprehensive income and included as a separate component of stockholders&#8217; equity. The cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in investment and other income, net in our condensed consolidated statements of income. We use the specific identification method for calculating realized gains and losses on marketable securities sold. None of the realized gains and losses and declines in value that were judged to be as a result of credit loss on marketable securities, if any, are included in investment and other income, net in our condensed consolidated statements of income.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authoritative guidance for fair value measurements establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments include cash equivalents, available-for-sale marketable securities, accounts receivable, prepaid expenses and other assets, accounts payable, accrued expenses and long-term debt. Fair value estimates of these instruments are made at a specific point in time based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore, cannot be determined with precision. The carrying amount of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale marketable securities consist of asset-backed securities, corporate debt securities, U.S. Treasury securities, agency bonds and commercial paper, and are measured at fair value using Level 1 and Level 2 inputs. Level 2 financial instruments are valued using market prices on less active markets and proprietary pricing valuation models with observable inputs, including interest rates, yield curves, maturity dates, issue dates, settlement dates, reported trades, broker-dealer quotes, issue spreads, benchmark securities or other market related data. We obtain the fair value of Level 2 investments from our investment manager, who obtains these fair values from a third-party pricing source. We validate the fair values of Level 2 financial instruments provided by our investment manager by comparing these fair values to a third-party pricing source.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable, net</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable is recorded at the invoiced amount and is non-interest bearing. Accounts receivable is recorded net of estimated prompt pay discounts, distribution fees and chargebacks. We believe the risk of accounts being uncollectible is minimal; therefore, no significant allowances for doubtful accounts were established as of March&#160;31, 2024 and December&#160;31, 2023.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Inventories are reviewed periodically for potential excess, dated or obsolete status. We evaluate the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the price we expect to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into operating leases primarily for real estate and automobiles. These leases have contractual terms which range from 3 years to 12 years. We determine if an arrangement contains a lease at inception. Right of use (&#8220;ROU&#8221;) assets and liabilities resulting from operating leases are included in property and equipment, accrued expenses and other long-term liabilities on our condensed consolidated balance sheets. Operating lease ROU assets and liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the discount rate to calculate the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. Our leases often include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that we will exercise that option. Short-term leases with an initial term of 12 months or less are not recorded on our condensed consolidated balance sheet. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have lease agreements with lease and non-lease components, which are generally accounted for separately. For certain leases, such as automobiles, we account for the lease and non-lease components as a single lease component.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, including ROU assets are recorded at cost, less accumulated depreciation and amortization. Equipment is depreciated using the straight-line method over its estimated useful life ranging from three years to ten years and leasehold improvements are amortized using the straight-line method over the estimated useful life of the asset or the lease term, whichever is shorter. </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for long-lived assets in accordance with authoritative guidance for impairment or disposal of long-lived assets. Long-lived assets are reviewed for events or changes in circumstances, which indicate that their carrying value may not be recoverable. </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income is defined as the change in equity during the period from transactions and other events and circumstances from non-owner sources.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Notes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Convertible Notes, the 2027 Convertible Notes and the 2028 Convertible Notes (collectively, the &#8220;Convertible Notes&#8221;) are accounted for in accordance with authoritative guidance for debt and derivatives. We evaluate all the embedded conversion options contained in the Convertible Notes to determine if there are embedded features that require bifurcation as a derivative as required by U.S. GAAP. Based on our analysis, we account for each of our Convertible Notes as single units of accounting, a liability, because we concluded that the conversion features do not require bifurcation as a derivative under embedded derivative authoritative guidance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flow Hedges - Currency Risks</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the second quarter of 2023, we entered into a cash flow hedging program to mitigate foreign currency exchange risk associated with forecasted royalty revenue denominated in Swiss francs. Under the program, we can hedge these forecasted royalties up to a maximum of four years into the future. We hedge these cash flow exposures to reduce the risk of our earnings and cash flows being adversely affected by fluctuations in exchange rates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the hedge accounting treatment, all hedging relationships are formally documented at the inception of the hedge and are highly effective in offsetting changes to future cash flows on hedged transactions. Both at inception of the hedge and on an ongoing basis, we assess whether the foreign currency forward contracts are highly effective in offsetting changes in cash flows of hedged items on a prospective and retrospective basis. If we determine a (i) foreign currency forward contract is not highly effective as a cash flow hedge, (ii) foreign currency forward contract has ceased to be a highly effective hedge or (iii) forecasted transaction is no longer probable of occurring, we would discontinue hedge accounting treatment prospectively. We measure effectiveness based on the change in fair value of the forward currency forward contract and the fair value of the hypothetical foreign currency forward contract with terms that match the critical terms of the risk being hedged. No portion of our foreign currency forward contracts were excluded from the assessment of hedge effectiveness. As of March&#160;31, 2024, all hedges were determined to be highly effective. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets or liabilities associated with our hedging contracts are recorded at fair market value in prepaid expense and other current assets, accrued expenses, or other long-term liabilities, respectively, in our condensed consolidated balance sheets. Gains and losses related to changes in the fair market value of these hedging contracts are recorded as a component of accumulated other comprehensive income (loss) (&#8220;AOCI&#8221;) within stockholder&#8217;s equity in our condensed consolidated balance sheets and reclassified to royalty revenue in our condensed consolidated statements of income in the same period as the recognition of the underlying hedged transaction. In the event the underlying forecasted transaction does not occur, or it becomes probable that it will not occur, within the defined hedge period, we reclassify the gains or losses on the related cash flow hedge from AOCI to royalties revenue in our condensed consolidated statements of income. Settlements from the cash flow hedge are included in operating activities on the condensed consolidated statements of cash flows. Since the fair market value of these hedging contracts is derived from current market rates, the hedging contracts are classified as derivative financial instruments. We do not use derivatives for speculative or trading purposes. As of March&#160;31, 2024, amounts expected to be recognized as a net gain out of AOCI into our condensed consolidated statements of income during the next 12 months are not material.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the acquisition method of accounting, we allocate the fair value of the total consideration transferred to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the date of acquisition. These valuations require us to make estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill. Costs incurred to complete a business combination, such as legal and other professional fees, are expensed as incurred.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the initial accounting for a business combination is incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date. We record these adjustments to the provisional amounts with a corresponding offset to goodwill. Any adjustments identified after the measurement period are recorded in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill, Intangible Assets and Other Long-Lived Asset</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets acquired, including intangible assets and in-process research and development (&#8220;IPR&amp;D&#8221;), and liabilities assumed are measured at fair value as of the acquisition date. Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of the net assets acquired. Intangible assets acquired in a business combination that are used for IPR&amp;D activities are considered indefinite lived until the completion or abandonment of the associated research and development efforts. Upon reaching the end of the relevant research and development project (i.e., upon commercialization), the IPR&amp;D </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">asset is amortized over its estimated useful life. If the relevant research and development project is abandoned, the IPR&amp;D asset is expensed in the period of abandonment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and IPR&amp;D are not amortized; however, they are reviewed for impairment at least annually during the second quarter, or more frequently if an event occurs indicating the potential for impairment. Goodwill and IPR&amp;D are considered to be impaired if the carrying value of the reporting unit or IPR&amp;D asset exceeds its respective fair value.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform our goodwill impairment analysis at the reporting unit level, which aligns with our reporting and operating segment structure and availability of discrete financial information. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair values of our reporting unit is less than the carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and our overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amounts, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair value of the reporting unit with the carrying value, including goodwill. If the carrying amount of the reporting unit exceeds the fair value, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative goodwill impairment test.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our identifiable intangible assets with finite useful lives are typically comprised of acquired device technologies and product rights. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#8217; respective estimated useful lives.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform regular reviews to determine if any event has occurred that may indicate intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to the net book value, significant changes in the ability of a particular asset to generate positive cash flows for our strategic business objectives, and the pattern of utilization of a particular asset.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate revenues from payments received (i) as royalties from licensing our ENHANZE technology and other royalty arrangements, (ii) under collaborative agreements and (iii) from sales of our proprietary and partnered products. We recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, we perform the following five steps: (i) identify the promised goods or services in the contract; (ii) identify the performance obligations in the contract, including whether they are distinct in the context of the contract; (iii) determine the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ENHANZE and Device Royalties</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our ENHANZE collaboration and license agreements, our partners will pay us royalties at an on average mid-single digit percent rate of their sales if products under the collaboration are commercialized. All amounts owed to us are noncancelable after the underlying triggering event occurs, and nonrefundable once paid. Unless terminated earlier in accordance with its terms, collaborations generally continue in effect until the last to expire royalty payment term, as determined on a product by product and country by country basis, with each royalty term starting on the first commercial sale of that product and ending the later of: (i) a specified period or term set forth in the agreement or (ii) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration. In general, when there are no valid claims of a specified patent developed under the collaboration covering the product in a given country, the royalty rate is reduced for those sales in that country upon the expiration of our patents covering rHuPH20. Janssen&#8217;s patents covering DARZALEX SC do not impact the timing for this royalty reduction. Partners may terminate the agreement prior to expiration for any reason in its entirety or on a target-by-target basis generally upon 90 days prior written notice to us.&#160;Upon any such termination, the license granted to partners (in total or with respect to the terminated target, as applicable) will terminate provided; however, that in the event of expiration of the agreement (as opposed to a termination), the on-going licenses granted may become perpetual, non-exclusive and fully paid. Sales-based milestones and royalties are recognized in the period the underlying sales or milestones occur. We do not receive final royalty reports from our ENHANZE partners until after we complete our financial statements for a prior quarter. Therefore, we recognize revenue based on estimates of the royalty earned, which are based on internal estimates and available preliminary reports provided by our partners. We will record adjustments in the following quarter, if necessary, when final royalty reports are received. To date, we have not recorded any material adjustments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also earn royalties in connection with several of our licenses granted under license and development arrangements with our device partners. These royalties are based upon a percentage of commercial sales of partnered products with rates ranging from mid-single digits to low double digits and are tiered based on levels of net sales. These sales-based royalties, for which the license was deemed the predominant element to which the royalties relate, are estimated and recognized in the period in which the partners&#8217; commercial sales occur. The royalties are generally reported and payable to us within 45 to 60 days after the end of the period in which the commercial sales are made. We base our estimates of royalties earned on actual sales information from our partners when available or estimated, prescription sales from external sources and estimated net selling price. We will record adjustments in the following quarter, if necessary, when final royalty reports are received. To date, we have not recorded any material adjustments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue under ENHANZE and Device Collaborative Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ENHANZE Collaboration and License Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under these agreements, we grant the collaboration partner a worldwide license to develop and commercialize products using our ENHANZE technology to combine our patented rHuPH20 enzyme with their proprietary biologics directed at up to a specified number of targets. Targets are usually licensed on an exclusive, global basis. Targets selected subsequent to inception of the arrangement generally require payment of an additional license fee. The collaboration partner is responsible for all development, manufacturing, clinical, regulatory, sales and marketing costs for any products developed under the agreement. We are responsible for supply of bulk rHuPH20 based on the collaboration partner&#8217;s purchase orders, and may also be separately engaged to perform research and development services. While these collaboration agreements are similar in that they originate from the same framework, each one is the result of an arms-length negotiation and thus may vary from one to the other.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally collect an upfront license payment from collaboration partners, and are also entitled to receive event-based payments subject to collaboration partners&#8217; achievement of specified development, regulatory and sales-based milestones. In several agreements, collaboration partners pay us annual fees to maintain their exclusive license rights if they are unable to advance product development to specified stages. We earn separate fees for bulk rHuPH20 supplies and research and development services. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although these agreements are in form identified as collaborative agreements, we concluded for accounting purposes they represent contracts with customers and are not subject to accounting literature on collaborative arrangements. This is because we grant to partners licenses to our intellectual property and provide supply of bulk rHuPH20 and research and development services which are all outputs of our ongoing activities, in exchange for respective consideration. Under these collaborative agreements, our partners lead development of assets, and we do not share in significant financial risks of their development or commercialization activities. Accordingly, we concluded our collaborative agreements are appropriately accounted for pursuant to U.S. GAAP. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under all of our ENHANZE collaborative agreements, we have identified licenses to use functional intellectual property as the only performance obligation. The intellectual property underlying the license is our proprietary ENHANZE technology which represents application of rHuPH20 to facilitate delivery of drugs. Each of the licenses grants the partners rights to use our intellectual property as it exists and is identified on the effective date of the license, because there is no ongoing development of the ENHANZE technology required. Therefore, we recognize revenue from licenses at the point when the license becomes effective and the partner has received access to our intellectual property, usually at the inception of the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When partners can select additional targets to add to the licenses granted, we consider these rights to be options. We evaluate whether such options contain material rights, i.e. have exercise prices that are discounted compared to what we would charge for a similar license to a new partner. The exercise price of these options includes a combination of the target selection fees, event-based milestone payments and royalties. When these amounts in aggregate are not offered at a discount that exceeds discounts available to other customers, we conclude the option does not contain a material right, and we consider grants of additional licensing rights upon option exercises to be separate contracts (target selection contracts).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, we provide indemnification and protection of licensed intellectual property for our customers. These provisions are part of assurance that the licenses meet the agreements&#8217; representations and are not obligations to provide goods or services.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also fulfill purchase orders for supply of bulk rHuPH20 and perform research and development services pursuant to project authorization forms for our partners, which represent separate contracts. In addition to our licenses, we price our supply of bulk rHuPH20 and research and development services at our regular selling prices, called standalone selling prices (&#8220;SSP&#8221;). Therefore, our partners do not have material rights to order these items at prices not reflective of SSP. Refer to the discussion below regarding recognition of revenue for these separate contracts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction price for a contract represents the amount to which we are entitled in exchange for providing goods and services to the customer. Transaction price does not include amounts subject to uncertainties unless it is probable that there will be no significant reversal of revenue when the uncertainty is resolved. Apart from the upfront license payment (or target selection fees in the target selection contracts), all other fees we may earn under our collaborative agreements are subject to significant uncertainties of product development. Achievement of many of the event-based development and regulatory milestones may not be probable until such milestones are actually achieved. This generally relates to milestones such as obtaining marketing authorization approvals. With respect to other development milestones, e.g., dosing of a first patient in a clinical trial, achievement could be considered probable prior to its actual occurrence, based on the progress towards commencement of the trial. In order to evaluate progress towards commencement of a trial, we assess the status of activities leading up to our partner&#8217;s initiation of a trial such as feedback received from the applicable regulatory authorities, completion of Investigational New Drug (&#8220;IND&#8221;) or equivalent filings, readiness and availability of drug, readiness of study sites and our partner&#8217;s commitment of resources to the program. We do not include any amounts subject to uncertainties in the transaction price until it is probable that the amount will not result in a significant reversal of revenue in the future. At the end of each reporting period, we re-evaluate the probability of achievement of such milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When target exchange rights are held by partners, and the amounts attributed to these rights are not refundable, they are included in the transaction price. However, they are recorded as deferred revenues because we have a potential performance obligation to provide a new target upon an exchange right being exercised. These amounts are recognized in revenue when the right of exchange expires or is exercised.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because our agreements have one type of performance obligation (licenses) which are typically all transferred at the same time at agreement inception, allocation of transaction price often is not required. However, allocation is required when licenses for some of the individual targets are subject to rights of exchange, because revenue associated with these targets cannot be recognized. When allocation is needed, we perform an allocation of the upfront amount based on relative SSP of licenses for individual targets. We determine license SSP using an income-based valuation approach utilizing risk-adjusted discounted cash flow projections of the estimated return a licensor would receive. When amounts subject to uncertainties, such as milestones and royalties, are included in the transaction price, we attribute them to the specific individual target licenses which generate such milestone or royalty amounts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also estimate SSP of bulk rHuPH20 and research and development services, to determine that our partners do not have material rights to order them at discounted prices. For supplies of bulk rHuPH20, because we effectively act as a contract manufacturer to our partners, we estimate and charge SSP based on the typical contract manufacturer margins consistent with all of our partners. We determine SSP of research and development services based on a fully-burdened labor rate. Our rates are comparable to those we observe in other collaborative agreements. We also have a history of charging similar rates to all of our partners. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront amounts allocated to licenses to individual targets are recognized as revenue when the license is transferred to the partner, as discussed above, if the license is not subject to exchange rights, or when the exchange right expires or is exercised. Development milestones and other fees are recognized in revenue when they are included in the transaction price, because by that time, we have already transferred the related license to the partner. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In contracts to provide research and development services, such services represent the only performance obligation. The fees are charged based on hours worked by our employees and the fixed contractual rate per hour, plus third-party pass-through costs, on a monthly basis. We recognize revenues as the related services are performed based on the amounts billed, as the partner consumes the benefit of research and development work simultaneously as we perform these services, and the amounts billed reflect the value of these services to the customer. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Device License, Development and Supply Arrangements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have several license, development and supply arrangements with pharmaceutical partners, under which we grant a license to our device technology and provide research and development services that often involve multiple performance obligations and highly-customized deliverables. For such arrangements, we identify each of the promised goods and services within the contract and the distinct performance obligations at inception of the contract and allocate consideration to each performance obligation based on relative SSP, which is generally determined based on the expected cost plus mark-up. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the contract includes an enforceable right to payment for performance completed to date and performance obligations are satisfied over time, we recognize revenue over the development period using either the input or output method depending on which is most appropriate given the nature of the distinct deliverable. For other contracts that do not contain an enforceable right to payment for performance completed to date, revenue is recognized when control of the product is transferred to the customer. Factors that may indicate transfer of control has occurred include the transfer of legal title, transfer of physical possession, the customer has obtained the significant risks and rewards of ownership of the assets, and we have a present right to payment. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our payment terms for development contracts may include an upfront payment equal to a percentage of the total contract value with the remaining portion to be billed upon completion and transfer of the individual deliverables or satisfaction of the individual performance obligations. We record a contract liability for cash received in advance of performance, which is presented within deferred revenue and deferred revenue, long-term in our condensed consolidated balance sheets and recognized as revenue in our condensed consolidated statements of income when the associated performance obligations have been satisfied. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License fees and milestones received in exchange for the grant of a license to our functional intellectual property, such as patented technology and know-how in connection with a partnered development arrangement, are generally recognized at inception of the arrangement, or over the development period depending on the facts and circumstances, as the license is generally not distinct from the non-licensed goods or services to be provided under the contract. Milestone payments that are contingent upon the occurrence of future events are evaluated and recorded at the most likely amount, and to the extent that it is probable that a significant reversal of revenue will not occur when the associated uncertainty is resolved.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 4,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion on our collaborative arrangements.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales, Net</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Proprietary Product Sales</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial portfolio of proprietary products includes XYOSTED and Hylenex recombinant which we sell primarily to wholesale pharmaceutical distributors and specialty pharmacies, who sell the products to hospitals, retail chain drug stores and other end-user customers. Sales to wholesalers are made pursuant to purchase orders subject to the terms of a master agreement, and delivery of individual packages of products represents performance obligations under each purchase order. We use contract manufacturers to produce our proprietary products and third-party logistics (&#8220;3PL&#8221;) vendors to process and fulfill orders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We concluded we are the principal in the sales to wholesalers because we control access to services rendered by both vendors and direct their activities. We have no significant obligations to wholesalers to generate pull-through sales.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized when control has transferred to the customer, which is typically upon delivery, at the net selling price, which reflects the variable consideration for which reserves and sales allowances are established for estimated returns, wholesale distribution fees, prompt payment discounts, government rebates and chargebacks, plan rebate arrangements and patient discount and support programs. We recognize revenue from product sales and related cost of sales upon product delivery to the wholesaler location. At that time, the wholesalers take control of the product as they take title, bear the risk of loss of ownership, and have an enforceable obligation to pay us. They also have the ability to direct sales of product to their customers on terms and at prices they negotiate. Although wholesalers have product return rights, we do not believe they have a significant incentive to return the product to us.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of certain reserves and sales allowances requires us to make a number of judgements and estimates to reflect our best estimate of the transaction price and the amount of consideration to which we believe we would be ultimately entitled to receive. The expected value is determined based on unit sales data, contractual terms with customers and third-party payers, historical and estimated future percentage of rebates incurred on sales, historical and future insurance plan billings, any new or anticipated changes in programs or regulations that would impact the amount of the actual rebates, customer purchasing patterns, product expiration dates and levels of inventory in the distribution channel. The estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, rebates and customer co-pay support programs are included in accrued expenses and accounts receivable, net in our condensed consolidated balance sheets upon recognition of revenue from product sales. We monitor actual product returns, chargebacks, discounts and fees subsequent to the sale. If these amounts differ from our estimates, we make adjustments to these allowances, which are applied to increase or reduce product sales revenue and earnings in the period of adjustment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling prices initially billed to wholesalers are subject to discounts for prompt payment and subsequent chargebacks when wholesalers sell our products at negotiated discounted prices to members of certain group purchasing organizations (&#8220;GPOs&#8221;), Pharmacy Benefit Managers (&#8220;PBMs&#8221;) and government programs. We also pay quarterly distribution fees to certain wholesalers for inventory reporting and chargeback processing, and to PBMs and GPOs as administrative fees for services and for access to their members. We concluded the benefits received in exchange for these fees are not distinct from our sales of our products, and accordingly we apply these amounts to reduce revenues. Wholesalers also have rights to return unsold product nearing or past the expiration date. Because of the shelf life of our products and our lengthy return period, there may be a significant period of time between when the product is shipped and when we issue credits on returned product. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the transaction price when we receive each purchase order taking into account the expected reductions of the selling price initially billed to the wholesaler arising from all of the above factors. We have compiled historical experience and data to estimate future returns and chargebacks of our products and the impact of the other discounts and fees we pay. When estimating these adjustments to the transaction price, we reduce it sufficiently to be able to assert that it is probable that there will be no significant reversal of revenue when the ultimate adjustment amounts are known.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each purchase order contains only one type of product, and is usually shipped to the wholesaler in a single shipment. Therefore, allocation of the transaction price to individual packages is not required.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the orders placed by wholesalers, we incur costs such as commissions to our sales representatives. However, as revenue from product sales is recognized upon delivery to the wholesaler, which occurs shortly after we receive a purchase order, we do not capitalize these commissions and other costs, based on application of the practical expedient allowed within the applicable guidance. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Partnered Product Sales</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bulk rHuPH20</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell bulk rHuPH20 to partners for use in research and development and, subsequent to receiving marketing approval, we sell it for use in collaboration commercial products. Sales are made pursuant to purchase orders subject to the terms of the collaborative agreement or a supply agreement, and delivery of units of bulk rHuPH20 represent performance obligations under each purchase order. We provide a standard warranty that the product conforms to specifications. We use contract manufacturers to produce bulk rHuPH20 and have concluded we are the principal in the sales to partners. The transaction price for each purchase order of bulk rHuPH20 is fixed based on the cost of production plus a contractual markup, and is not subject to adjustments. Allocation of the transaction price to individual quantities of the product is usually not required because each order contains only one type of product.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue from the sale of bulk rHuPH20 as product sales and related cost of sales upon transfer of title to our partners. At that time, the partners take control of the product, bear the risk of loss of ownership, and have an enforceable obligation to pay us. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Devices</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to several license, development, supply and distribution arrangements with pharmaceutical partners, under which we produce and are the exclusive supplier of certain products, devices and/or components. Revenue is recognized when or as control of the goods transfers to the customer as discussed below.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the exclusive supplier of OTREXUP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to Otter. Because this product is custom manufactured with no alternative use and we have a contractual right to payment for performance completed to date, control is continuously transferred to the customer as the product is produced pursuant to firm purchase orders. Revenue is recognized over time using the output method based on the contractual selling price and number of units produced. The amount of revenue recognized in excess of the amount shipped/billed to the customer, if any, is recorded as contract assets in our condensed consolidated balance sheets due to the short-term nature in which the amount is ultimately expected to be billed and collected from the customer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other device partnered product sales are recognized at the point in time in which control is transferred to the customer, which is typically upon shipment. Sales terms and pricing are governed by the respective supply and distribution agreements, and there is generally no right of return. Revenue is recognized at the transaction price, which includes the contractual per unit selling price and estimated variable consideration, such as volume-based pricing arrangements or profit-sharing arrangements, if any. We recognize revenue, including the estimated variable consideration we expect to receive for contract margin on future commercial sales, upon shipment of the goods to our partner. The estimated variable consideration is recognized at an amount we believe is not subject to significant reversal of revenue based on historical experience and is adjusted at each reporting period if the most likely amount of expected consideration changes or becomes fixed.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales consists primarily of raw materials, third-party manufacturing costs, fill and finish costs, freight costs, internal costs and manufacturing overhead associated with the production of proprietary and partnered products. Cost of sales also consists of the write-down of excess, dated and obsolete inventories and the write-off of inventories that do not meet certain product specifications, if any.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include salaries and benefits, allocation of facilities and other overhead expenses, research related manufacturing services, contract services, and other outside expenses related to manufacturing, preclinical and regulatory activities and our partner development platforms. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to our research and development efforts and have no alternative future uses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as expense as the related goods are delivered or the related services are performed or such time when we do not expect the goods to be delivered or services to be performed.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record compensation expense associated with stock options, restricted stock units (&#8220;RSUs&#8221;), performance stock units (&#8220;PSUs&#8221;) and shares issued under our employee stock purchase plan (&#8220;ESPP&#8221;) in accordance with the authoritative guidance for share-based compensation. The cost of employee services received in exchange for an award of an equity instrument is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense on a straight-line basis over the requisite service period of the award. Share-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed. Forfeitures are recognized as a reduction of share-based compensation expense as they occur.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide for income taxes using the liability method. Under this method, deferred income tax assets and liabilities are determined based on the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases at each reporting period. We measure deferred tax assets and liabilities using enacted tax rates for the year in which the differences are expected to reverse. Significant judgment is required by management to determine our provision for income taxes, our deferred tax assets and liabilities, and any associated valuation allowances recorded against our net deferred tax assets, which are based on complex and evolving tax regulations. Deferred tax assets (&#8220;DTA&#8221;) and other tax benefits are recorded when they are more likely than not to be realized. On a quarterly basis, we assess the need for valuation allowance on our DTAs, weighing all positive and negative evidence, to assess if it is more-likely-than-not that some or all of our DTAs will be realized. We recorded a provision for income taxes of $19.2 million using an effective tax rate of 20% for the three months ended March&#160;31, 2024. The difference between our effective tax rate and the U.S. federal statutory rate of 21% is primarily due to state income taxes, research and development credit generations, tax benefits on the Foreign Derived Intangible Income Deduction (&#8220;FDII&#8221;) (net of reserves), tax detriments on 162(m) and other share-based compensation.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate our business in one operating segment, which includes all activities related to the research, development and commercialization of our proprietary enzymes and devices. This segment also includes revenues and expenses related to (i)&#160;research and development and manufacturing activities conducted under our collaborative agreements with third parties, and (ii)&#160;product sales of proprietary and partnered products. The chief operating decision-maker (&#8220;CODM&#8221;), our Chief Executive Officer (&#8220;CEO&#8221;), reviews the operating results on an aggregate basis and manages the operations as a single operating segment.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adoption and Pending Adoption of Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a brief description of recently issued accounting standards, those adopted in the current period and those not yet adopted:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"><tr><td style="width:1.0%"></td><td style="width:17.852%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.631%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.154%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.688%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.878%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.787%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Standard</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Adoption Method</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Effect on the Financial<br/>Statements or Other Significant Matters</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The new standard is intended to improve annual and interim reportable segment disclosure requirements regardless of number of reporting units, primarily through enhanced disclosures of significant expenses. The amendment requires public entities to disclose significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit and loss.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Annual periods beginning after December 15, 2023 (our 2024 Form 10-K), and interim periods within fiscal years beginning after December 15, 2024 (our Q1 2025 Form 10-Q) - Early adoption is permitted, including adoption in an interim period<br/></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Retrospective</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are currently evaluating the impact of the standard on our consolidated financial statements and related disclosures.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The new guidance includes amendments that further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Annual periods beginning after December 15, 2024 (our 2025 Form 10-K) - Early adoption is permitted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prospective or Retrospective</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are currently evaluating the impact of the standard on our consolidated financial statements and related disclosures.</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704507555776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurement</a></td>
<td class="text">Fair Value Measurement<div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale marketable securities consisted of the following (in thousands):</span></div><div style="margin-top:11pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:52.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.779%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,384&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,379&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities, available-for-sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298,983&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(197)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298,824&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:52.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.779%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,512&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,504&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities, available-for-sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,475&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,630&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, 33 available-for-sale marketable securities with a fair market value of $215.5 million were in a gross unrealized loss position of $0.2&#160;million. Based on our review of these marketable securities, we believe none of the unrealized loss is as a result of a credit loss as of&#160;March&#160;31, 2024 because we do not intend to sell these securities and it is not more-likely-than-not that we will be required to sell these securities before the recovery of their amortized cost basis.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of our contractual maturities of available-for-sale debt securities were as follows (in thousands):</span></div><div style="margin-top:11pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:67.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.063%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,059&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,633&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year but within five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total estimated fair value of contractual maturities, available-for-sale</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298,824&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,630&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes, by major security type, our cash equivalents and available-for-sale marketable securities measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"></td><td style="width:29.421%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.329%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.329%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.967%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.329%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.329%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.337%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Estimated Fair Value</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Estimated Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale marketable <br/>&#160;&#160;&#160;securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,504&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,504&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency hedging contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,574&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,574&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298,711&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,963&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,674&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,429&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,343&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241,772&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency hedging contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Based on observable market transactions of spot currency rates, forward currency rates or equivalently-termed instruments. Carrying amounts of the financial assets and liabilities are equal to the fair value. As of March&#160;31, 2024, the derivative assets and liabilities recorded within prepaid expenses and other current assets, prepaid expense and other assets and other long-term liabilities in our condensed consolidated balance sheets were $<span style="-sec-ix-hidden:f-420">1.3 million</span>, $<span style="-sec-ix-hidden:f-422">0.3 million</span> and $<span style="-sec-ix-hidden:f-424">0.5 million</span>, respectively.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had no available for sale securities that were classified within Level 3 as of March&#160;31, 2024 and December&#160;31, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704417741680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text">Revenue<div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our disaggregated revenues were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"><tr><td style="width:1.0%"></td><td style="width:78.869%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.144%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.147%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,593&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,640&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proprietary product sales</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,961&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bulk rHuPH20 sales</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,069&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Device partnered product sales</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,818&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,583&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,794&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues under collaborative agreements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Event-based development and regulatory milestones and other fees</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Device licensing and development revenue</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues under collaborative agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,703&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,709&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,879&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,143&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024, we recognized revenue related to licenses granted to partners in prior periods in the amount of $134.6 million. This amount represents royalties earned in the current period in addition to $14.0&#160;million of variable consideration in the contracts where uncertainties were resolved and the development milestones are expected to be achieved or were achieved. We also recognized revenue of $0.1&#160;million during the three months ended March&#160;31, 2024 that had been included in accrued expense and other long-term liabilities in our condensed consolidated balance sheets as of December&#160;31, 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, other contract assets and deferred revenues (contract liabilities) from contracts with customers, including partners, consisted of the following (in thousands): </span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:75.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.859%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233,254&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other contract assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,595&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,048&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, the amounts included in the transaction price of our contracts with customers, including collaboration partners, and allocated to goods and services not yet provided were $77.3 million, of which $72.7 million relates to unfulfilled product purchase orders and $4.6&#160;million has been collected and is reported as accrued expense and other long-term liabilities in our condensed consolidated balance sheets. The unfulfilled product purchase orders are estimated to be delivered by the end of 2024. Of the total deferred revenues of $4.6&#160;million, $1.2 million is expected to be used by our customers within the next 12 months. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized contract assets of $10.6 million as of March&#160;31, 2024, which related to development milestones deemed probable of receipt for intellectual property licenses granted to partners in prior periods and for goods or services when control has transferred to the customer, and corresponding revenue is recognized on an over time basis but is not yet billable to the customer in accordance with the terms of the contract.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704416562448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain Balance Sheet Items<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Certain Balance Sheet Items</a></td>
<td class="text">Certain Balance Sheet Items<div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net and contract assets consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:68.485%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from product sales to partners</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,045&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,588&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from revenues under collaborative agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from royalty payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from other product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,060&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts receivable and contract assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202,111&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240,957&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for distribution fees and discounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,209)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,747)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts receivable, net and contract assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,902&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,210&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:68.485%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,112&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,646&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,611&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,818&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,930&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,541&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,601&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:68.485%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid manufacturing expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,211&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,850&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,902&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,951&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,677&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,009&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,429&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Long-term portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,319)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,816)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other assets, current</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,690&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,613&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid manufacturing expenses include raw materials, slot reservation fees and other amounts paid to contract manufacturing organizations.&#160;Such amounts are reclassified to work-in-process inventory as materials are used or the contract manufacturing organization services are complete.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:68.485%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,690&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,588&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer and office equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,888&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,066&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,769&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,180)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,661)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,886&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use of assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,071&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,944&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">                            </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense was approximately $2.4 million and $2.6 million, inclusive of ROU asset amortization of $1.4 million and $1.4 million for the three months ended March&#160;31, 2024 and 2023, respectively. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:68.485%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and payroll taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,442&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,361&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued outsourced manufacturing expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,074&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product returns and sales allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,515&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,398&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less long-term portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,201)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,720)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses, current</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,314&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,678&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expense associated with the accretion of the lease liabilities was approximately $0.6 million and $0.7 million for the three months ended March&#160;31, 2024 and 2023, respectively. Total lease expense for the three months ended March&#160;31, 2024 and 2023 was $2.0 million and $2.1 million, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts related to leases for the three months ended March&#160;31, 2024 and 2023 was $1.8 million and $1.7 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704416629472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">Goodwill and Intangible Assets<div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the activity impacting goodwill is presented below (in thousands):</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"><tr><td style="width:1.0%"></td><td style="width:84.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustment</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416,821&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our acquired intangible assets are amortized using the straight-line method over their estimated useful lives of <span style="-sec-ix-hidden:f-557">seven</span> to ten years. The following table shows the cost, accumulated amortization and weighted average useful life in years for our acquired intangible assets as of March&#160;31, 2024 (in thousands).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"><tr><td style="width:1.0%"></td><td style="width:47.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.993%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.993%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Useful Life </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auto Injector technology platform</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,521&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,479&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XYOSTED proprietary product</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived intangibles, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538,200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,784&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406,416&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ATRS-1902 (IPR&amp;D)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,700&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangibles, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455,116&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated future annual amortization of finite-lived intangible assets is shown in the following table (in thousands). Actual amortization expense to be reported in future periods could differ from these estimates as a result of acquisitions, divestitures, and asset impairments, among other factors.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"></td><td style="width:82.561%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.010%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,286&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,934&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406,416&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704417437216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt, Net<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Long-Term Debt, Net</a></td>
<td class="text">Long-Term Debt, Net<div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">1.00% Convertible Notes due 2028</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, we completed the sale of $720.0&#160;million in aggregate principal amount of 1.00% Convertible Senior Notes due 2028 (the &#8220;2028 Convertible Notes&#8221;). The net proceeds in connection with the issuance of the 2028 Convertible Notes, after deducting the initial purchasers&#8217; fee of $18.0&#160;million, was approximately $702.0&#160;million. We also incurred additional debt issuance costs totaling $1.0&#160;million. Debt issuance costs and the initial purchasers&#8217; fee are presented as a debt discount.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2028 Convertible Notes pay interest semi-annually in arrears on February 15th and August 15th of each year at an annual rate of 1.00%. The 2028 Convertible Notes are general unsecured obligations and rank senior in right of payment to all indebtedness that is expressly subordinated in right of payment to the 2028 Convertible Notes, rank equally in right of payment with all existing and future liabilities that are not so subordinated, are effectively junior to any secured indebtedness to the extent of the value of the assets securing such indebtedness, and are structurally subordinated to all indebtedness and other liabilities (including trade payables) of our current or future subsidiaries. The 2028 Convertible Notes have a maturity date of August 15, 2028.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their 2028 Convertible Notes at their option only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on December 31, 2022, if the last reported sale price per share of common stock exceeds 130% of the conversion price for each of at least 20 trading days during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the five consecutive business days immediately after any five consecutive trading day period (such five consecutive trading day period, the &#8220;measurement period&#8221;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of our common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on our common stock, as described in the offering memorandum for the 2028 Convertible Notes; (4) if we call such notes for redemption; and (5) at any time from, and including, February 15, 2028 until the close of business on the second scheduled trading day immediately before the maturity date. As of March&#160;31, 2024, the 2028 Convertible Notes were not convertible.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, we will pay cash for the settlement of principal, and for the premium, if applicable, we will pay cash, deliver shares of common stock or a combination of cash and shares of common stock, at our election. The initial conversion rate for the 2028 Convertible Notes is 17.8517 shares of common stock per $1,000 in principal amount of 2028 Convertible Notes, equivalent to a conversion price of approximately $56.02 per share of our common stock. The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued or unpaid interest.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, we were in compliance with all covenants and there was no material adverse change in our business, operations or financial condition. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capped Call Transactions</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the offering of the 2028 Convertible Notes, we entered into capped call transactions with certain counterparties (the &#8220;Capped Call Transactions&#8221;). The Capped Call Transactions are expected generally to reduce potential dilution to holders of our common stock upon conversion of the 2028 Convertible Notes or at our election (subject to certain conditions) offset any cash payments we are required to make in excess of the principal amount of such converted 2028 Convertible Notes. The cap price of the Capped Call Transactions is initially $75.4075 per share of common stock, representing a premium of 75% above the last reported sale price of $43.09 per share of common stock on August 15, 2022, and is subject to certain adjustments under the terms of the Capped Call Transactions. As of March&#160;31, 2024, no capped calls had been exercised.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to their terms, the capped calls qualify for classification within stockholders&#8217; equity in our condensed consolidated balance sheets, and their fair value is not remeasured and adjusted as long as they continue to qualify for stockholders&#8217; equity classification. We paid approximately $69.1&#160;million for the Capped Calls, including applicable transaction costs, which was recorded as a reduction to additional paid-in capital in our condensed consolidated balance sheets. The Capped Call Transactions are separate transactions entered into by us with the capped call Counterparties, are not part of the terms of the Convertible Notes, and do not affect any holder&#8217;s rights under the Convertible Notes. Holders of the Convertible Notes do not have any rights with respect to the Capped Call Transactions.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">0.25% Convertible Notes due 2027</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, we completed the sale of $805.0&#160;million in aggregate principal amount of 0.25% Convertible Senior Notes due 2027 (the &#8220;2027 Convertible Notes&#8221;). The net proceeds in connection with the issuance of the 2027 Convertible Notes, after deducting the initial purchasers&#8217; fee of $20.1&#160;million, was approximately $784.9&#160;million. We also incurred additional debt issuance costs totaling $0.4&#160;million. Debt issuance costs and the initial purchasers&#8217; fee are presented as a debt discount.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2027 Convertible Notes pay interest semi-annually in arrears on March 1st and September 1st of each year at an annual rate of 0.25%. The 2027 Convertible Notes are general unsecured obligations and rank senior in right of payment to all indebtedness that is expressly subordinated in right of payment to the 2027 Convertible Notes, rank equally in right of payment with all existing and future liabilities that are not so subordinated, are effectively junior to any secured indebtedness to the extent of the value of the assets securing such indebtedness and are structurally subordinated to all indebtedness and other liabilities (including trade payables) of our current or future subsidiaries. The 2027 Convertible Notes have a maturity date of March 1, 2027.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their 2027 Convertible Notes at their option only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on June 30, 2021, if the last reported sale price per share of common stock exceeds 130% of the conversion price for each of at least 20 trading days during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the five consecutive business days immediately after any five consecutive trading day period (such five consecutive trading day period, the &#8220;measurement period&#8221;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of our common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on our common stock, as described in the offering memorandum for the 2027 Convertible Notes; (4) if we call such notes for redemption; and (5) at any time from, and including, September 1, 2026 until the close of business on the scheduled trading day immediately before the maturity date. As of March&#160;31, 2024, the 2027 Convertible Notes were not convertible.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, we will pay cash for the settlement of principal and for the premium, if applicable, we will pay cash, deliver shares of common stock or a combination of cash and shares of common stock, at our election. The initial conversion rate for the 2027 Convertible Notes is 12.9576 shares of common stock per $1,000 in principal amount of 2027 Convertible Notes, equivalent to a conversion price of approximately $77.17 per share of our common stock. The conversion rate is subject to adjustment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, we were in compliance with all covenants and there was no material adverse change in our business, operations or financial condition. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">1.25% Convertible Notes due 2024</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we completed the sale of $460.0 million in aggregate principal amount of 1.25% Convertible Senior Notes due 2024 (the &#8220;2024 Convertible Notes&#8221;). The net proceeds in connection with the issuance of the 2024 Convertible Notes, after deducting the initial purchasers&#8217; fee of $12.7&#160;million, was approximately $447.3 million. We also incurred debt issuance cost totaling $0.3&#160;million. Debt issuance costs and the initial purchasers&#8217; fee were presented as a debt discount.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we notified the note holders of our irrevocable election to settle the principal of the 2024 Convertible Notes in cash and for the premium, to deliver shares of common stock. The conversion rate for the 2024 Convertible Notes was 41.9208 shares of common stock per $1,000 in principal amount of 2024 Convertible Notes, equivalent to a conversion price of approximately $23.85 per share of our common stock. The conversion rate was subject to adjustment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, we issued a notice for the redemption of 2024 Convertible Notes. Holders of the notes could convert their notes at any time prior to the close of the business day prior to the redemption date. In March 2023, holders of the notes elected to convert the 2024 Convertible Notes in full. In connection with the conversion, we paid approximately $13.5 million in cash which included principal and accrued interest, and issued 288,886 shares of our common stock representing the intrinsic value based on the contractual conversion rate.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Carrying Amounts of our Convertible Notes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount and fair value of our Convertible Notes were as follows (in thousands). </span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"><tr><td style="width:1.0%"></td><td style="width:69.570%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.580%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.474%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total principal amount</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,525,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,525,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,094)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,950)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,027)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,802)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total unamortized debt discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,121)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,752)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794,906&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705,198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carrying amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500,879&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,499,248&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value based on trading levels (Level 2):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695,826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702,403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670,522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of outstanding notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,416,647&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,366,348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization per period of debt discount (in years):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of interest expense and the effective interest rates for each of our Convertible Notes (in thousands).</span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.011%"><tr><td style="width:1.0%"></td><td style="width:77.305%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.464%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.368%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.464%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.699%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Coupon interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,800</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,800</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total coupon interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,303</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,339</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">856</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortization of debt discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,631</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,638</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,359</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,353</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,575</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,564</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,934</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,977</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective interest rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revolving Credit and Term Loan Facilities (May 2022)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, we entered into a credit agreement, which was subsequently amended in August 2022 (the &#8220;Amendment&#8221;), with Bank of America, N.A., as Administrative Agent, Swing Line Lender and an L/C Issuer, and the other lenders and L/C Issuers party thereto (the &#8220;2022 Credit Agreement), evidencing a credit facility (the &#8220;2022 Facility&#8221;) that provides for (i) a $575&#160;million revolving credit facility (the &#8220;Revolving Credit Facility&#8221;) and (ii) a $250&#160;million term loan facility (the &#8220;Term Facility&#8221;). Concurrently, with the entry into the Amendment, we repaid the entire outstanding Term Loan Facility and repaid all outstanding loans under the Revolving Credit Facility under the 2022 Credit Agreement. The 2022 Facility will mature on November 30, 2026 unless either the Revolving Credit Facility or the Term Facility is extended prior to such date in accordance with the 2022 Credit Agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Facility requires quarterly scheduled repayments of the term loans in each of the first, second, third and fourth years following the closing in annual amounts equal to 2.50%, 5.00%, 7.50% and 10.00% of the initial principal amount of the term loans, respectively. The term loans are also subject to mandatory prepayments from the proceeds of certain asset sales, subject to our right to reinvest the proceeds thereof.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2022 Facility bear interest, at our option, at a rate equal to an applicable margin plus: (a) the applicable Term Secured Overnight Financing Rate (&#8220;SOFR&#8221;) (which includes a SOFR adjustment of 0.10%), or (b) a base rate determined by reference to the highest of (1) the federal funds effective rate plus 0.50%, (2) the Bank of America prime rate, (3) the Term SOFR rate for an interest period of one month plus 1.10%, and (4) 1.00%. The margin for the 2022 Facility ranges, based on our consolidated total net leverage ratio, from 0.25% to 1.25% in the case of base rate loans and from 1.25% to 2.25% in the case of Term SOFR rate loans. In addition to paying interest on the outstanding principal under the Facility, we will pay (i) a commitment fee in respect of the unutilized commitments thereunder and (ii) customary letter of credit fees and agency fees. The commitment fees range from 0.15% to 0.35% per annum based on our consolidated net leverage ratio.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, the Revolving Credit Facility was undrawn. We incurred a total of $3.6&#160;million in third-party costs related to the 2022 Credit Agreement which are recorded as debt issuance cost within prepaid expenses and other assets in our condensed consolidated balance sheets. As of March&#160;31, 2024, the unamortized debt issuance cost related to the revolving credit facility was $2.1 million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704420153792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-Based Payment Arrangement, Noncash Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Compensation</a></td>
<td class="text">Share-based Compensation<div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarized share-based compensation expense included in our condensed consolidated statements of income related to share-based awards (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:79.143%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.018%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.021%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,345&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,101&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,529&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,865&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,874&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,966&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense by type of share-based award was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"></td><td style="width:79.351%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.922%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.925%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,299&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,455&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs, PSUs and ESPP</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,575&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,511&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,874&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,966&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We granted stock options to purchase approximately 0.5 million and 1.2 million shares of common stock during the three months ended March&#160;31, 2024 and 2023, respectively. The exercise price of stock options granted is equal to the closing price of the common stock on the date of grant. The fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option pricing model (&#8220;Black-Scholes Model&#8221;). Expected volatility is based on historical volatility of our common stock. The expected term of options granted is based on analyses of historical employee termination rates and option exercises. The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The dividend yield assumption is based on the expectation of no future dividend payments. The assumptions used in the Black-Scholes Model were as follows:</span></div><div style="margin-top:5pt;text-align:center;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:67.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.804%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.02 - 40.08%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.68 - 39.98%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.80 - 4.28%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.48 - 4.27%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, our Board of Directors approved our 2021 ESPP and our stockholders approved the plan in May 2021. The ESPP enables eligible employees to purchase shares of our common stock at the end of each offering period at a price equal to 85% of the fair market value of the shares on the first business day or the last business day of the offering period, whichever is lower. Share purchases are funded through payroll deduction of at least 1% and up to 15% of an employee&#8217;s compensation for each payroll period, and no employee may purchase shares under the ESPP that exceeds $25,000 worth of our common stock for a calendar year. As of March&#160;31, 2024, 2,604,222 shares were available for future purchase. The offering period is generally for a six-month period and the first offering period commenced on June 16, 2021. Offering periods shall commence on or about the sixteenth day of June and December of each year and end on or about the fifteenth day of the next December and June, respectively, occurring thereafter. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total unrecognized estimated compensation cost by type of award and the weighted-average remaining requisite service period over which such expense is expected to be recognized was as follows (in thousands, unless otherwise noted):</span></div><div style="margin-top:5pt;text-align:center;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.643%"><tr><td style="width:1.0%"></td><td style="width:66.158%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.030%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrecognized<br/>Expense</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Recognition Period</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,038&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.70</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.05</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.30</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.21</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704419562288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity <div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024 and 2023, we issued an aggregate of 154,556 and 143,931 shares of common stock, respectively, in connection with the exercises of stock options at a weighted average exercise price of $17.47 and $16.87 per share, respectively, for net proceeds of approximately $2.7 million and $2.4 million, respectively. For the three months ended March&#160;31, 2024 and 2023, we issued 262,195 and 239,919 shares of common stock, respectively, upon vesting of certain RSUs and PSUs for which the RSU and PSU holders surrendered 88,825 and 70,733 RSUs and PSUs, respectively, to pay for minimum withholding taxes totaling approximately $6.0 million and $6.5 million, respectively. Stock options and unvested restricted units totaling approximately 8.7 million and 7.8 million shares of our common stock were outstanding as of March&#160;31, 2024 and December&#160;31, 2023, respectively. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchases</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Board of Directors authorized a second capital return program to repurchase up to $750.0&#160;million of outstanding stock over a three-year period. During 2021, we repurchased 3.9&#160;million shares of common stock for $150.0&#160;million at an average price of $38.51. During 2022, we repurchased 4.5&#160;million shares of common stock for $200.0&#160;million at an average price of $44.44. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accelerated the initiation of our planned 2024 share repurchases and in November 2023, we entered into an Accelerated Share Repurchase (&#8220;ASR&#8221;) agreement with Bank of America, N.A. to accelerate the remaining $250.0&#160;million of share repurchases under the approved capital return program. Pursuant to the agreement, at the inception of the ASR, we paid $250.0&#160;million to Bank of America, N.A. and took initial delivery of 5.5&#160;million shares. All shares repurchased under our capital return programs have been retired and have resumed their status of authorized and unissued shares. We continued to execute share repurchases during the three months ended March 31, 2024 under our ASR agreement with Bank of America, N.A.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, excluding the shares we received under the ASR, we have repurchased a total of 12.6&#160;million shares for $500.0&#160;million at an average price per share of $39.81 under our $750&#160;million 3-year share repurchase plan.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2024, our Board of Directors authorized a new capital return program to repurchase up to $750.0&#160;million of our outstanding common stock.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704417437216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per share</a></td>
<td class="text">Earnings per share<div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is computed by dividing net income for the period by the weighted average number of common shares outstanding during the period, without consideration for common stock equivalents. Outstanding stock options, unvested RSUs, unvested PSUs, common shares expected to be issued under our ESPP and the Convertible Notes are considered common stock equivalents and are only included in the calculation of diluted earnings per common share when net income is reported and their effect is dilutive. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive common shares issuable upon vesting of stock options, RSUs and PSUs are determined using the average share price for each period under the treasury stock method. Potentially dilutive common shares issuable upon conversion of the Convertible Notes are determined using the if-converted method. Since we have committed to settle the principal amount of the Convertible Notes in cash upon conversion only, the number of shares for the conversion spread will be included as a dilutive common stock equivalent. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the numerators and the denominators of the basic and diluted earnings per share computations is as follows (in thousands, except per share amounts):</span></div><div style="margin-top:11pt;text-align:center;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:77.307%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.547%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.316%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,823&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,615&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding for basic earnings per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,027&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive potential common stock outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs, PSUs and ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding for diluted earnings per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,887&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares which have been excluded from the calculation of diluted earnings per common share because their effect was anti-dilutive include the following (shares in millions):</span></div><div style="margin-top:11pt;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:77.640%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.821%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span>    The anti-dilutive securities include outstanding stock options, unvested RSUs, unvested PSUs, common shares expected to be issued under our ESPP and Convertible Notes<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704416637936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of our business. Any of these claims could subject us to costly legal expenses and, while we generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage or our policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on our condensed consolidated statements of income and balance sheets. Additionally, any such claims, whether or not successful, could damage our reputation and business. We currently are not a party to any legal proceedings, the adverse outcome of which, in our opinion, individually or in the aggregate, would have a material adverse effect on our condensed consolidated statements of income or balance sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704418353136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="nump">$ 76,823<span></span>
</td>
<td class="nump">$ 39,615<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704507720704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fiscal quarter ended ended March&#160;31, 2024, the following officers adopted or terminated any Rule 10b5-1 trading arrangement (as such terms are defined pursuant to Item 408(a) of Regulation S-K) as noted in the table below.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"><tr><td style="width:1.0%"></td><td style="width:19.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.947%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.202%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.319%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.196%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Arrangement</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name and Title</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Action</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rule 10b5-1*</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-Rule 10b5-1**</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Shares To Be Sold</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration Date</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Helen Torley</span></div><div><span><br/></span></div></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination</span></div></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/30/2024</span></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></div></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,000&#160;</span></td><td rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Terminated</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Helen Torley</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adoption</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/22/2024</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="2" rowspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,000&#160;</span></td><td rowspan="2" style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The earlier of 02/13/2025 or date all shares are sold</span></div></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nicole LaBrosse</span></div></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adoption</span></div></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/22/2024</span></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></div></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,000&#160;</span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></div></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The earlier of 06/25/2025 or date all shares are sold</span></div></td></tr><tr style="height:35pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer</span></div></td></tr></table></div><div style="margin-top:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Non-Rule 10b5-1 trading arrangement&#8221; as defined in Item 408(c) of Regulation S-K under the Exchange Act.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The duration of the trading arrangement was until May 30, 2024, or earlier if all transaction under the trading arrangement had been completed. At the time of termination, no shares had been sold under the trading arrangement.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Represents a sale of common shares acquired upon exercise of stock options with ten-year term expiring in 2025.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=halo_HelenTorleyMember', window );">Helen Torley [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrTerminationDate', window );">Termination Date</a></td>
<td class="text">1/30/2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">328 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=halo_NicoleLaBrosseMember', window );">Nicole LaBrosse [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Nicole LaBrosse<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Senior Vice President and Chief Financial Officer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">3/22/2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">460 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrAxis=halo_HelenTorleyPriorPlanMember', window );">Helen Torley Prior Plan [Member] | Helen Torley [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Helen Torley<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">President and Chief Executive Officer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrAxis=halo_HelenTorleyMarch2024PlanMember', window );">Helen Torley March 2024 Plan [Member] | Helen Torley [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Helen Torley<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">President and Chief Executive Officer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">3/22/2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">110<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrTerminationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrTerminationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=halo_HelenTorleyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=halo_HelenTorleyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=halo_NicoleLaBrosseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=halo_NicoleLaBrosseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrAxis=halo_HelenTorleyPriorPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrAxis=halo_HelenTorleyPriorPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrAxis=halo_HelenTorleyMarch2024PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrAxis=halo_HelenTorleyMarch2024PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704418872048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim unaudited condensed consolidated financial statements have been prepared for purposes of and in accordance with United States generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and with the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) related to a quarterly report on Form 10-Q. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for a complete set of financial statements. These condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December&#160;31, 2023, filed with the SEC on February&#160;20, 2024. The unaudited financial information for the interim periods presented herein reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operations for the periods presented, with such adjustments consisting only of normal recurring adjustments. Operating results for interim periods are not necessarily indicative of the operating results for an entire fiscal year.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements include the accounts of Halozyme Therapeutics, Inc. and our wholly owned subsidiaries, Halozyme, Inc. and Antares Pharma, Inc., and Antares Pharma, Inc.&#8217;s wholly owned Swiss subsidiaries, Antares Pharma IPL AG and Antares Pharma AG. All intercompany accounts and transactions have been eliminated.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div>The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that we believe to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from our estimates<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy', window );">Cash Equivalents</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of highly liquid investments, readily convertible to cash, which mature within 90 days or less from the date of purchase. As of March&#160;31, 2024, our cash and cash equivalents consisted of money market funds, bank certificate of deposits, U.S. treasury securities and demand deposits at commercial banks.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities are investments with original maturities of more than 90 days from the date of purchase that are specifically identified to fund current operations. Marketable securities are considered available-for-sale. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date which reflects management&#8217;s intention to use the proceeds from the sale of these investments to fund our operations, as necessary. Such available-for-sale investments are carried at fair value with unrealized gains and losses recorded in other comprehensive income and included as a separate component of stockholders&#8217; equity. The cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in investment and other income, net in our condensed consolidated statements of income. We use the specific identification method for calculating realized gains and losses on marketable securities sold. None of the realized gains and losses and declines in value that were judged to be as a result of credit loss on marketable securities, if any, are included in investment and other income, net in our condensed consolidated statements of income.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authoritative guidance for fair value measurements establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments include cash equivalents, available-for-sale marketable securities, accounts receivable, prepaid expenses and other assets, accounts payable, accrued expenses and long-term debt. Fair value estimates of these instruments are made at a specific point in time based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore, cannot be determined with precision. The carrying amount of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale marketable securities consist of asset-backed securities, corporate debt securities, U.S. Treasury securities, agency bonds and commercial paper, and are measured at fair value using Level 1 and Level 2 inputs. Level 2 financial instruments are valued using market prices on less active markets and proprietary pricing valuation models with observable inputs, including interest rates, yield curves, maturity dates, issue dates, settlement dates, reported trades, broker-dealer quotes, issue spreads, benchmark securities or other market related data. We obtain the fair value of Level 2 investments from our investment manager, who obtains these fair values from a third-party pricing source. We validate the fair values of Level 2 financial instruments provided by our investment manager by comparing these fair values to a third-party pricing source.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable, net</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable, net</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable is recorded at the invoiced amount and is non-interest bearing. Accounts receivable is recorded net of estimated prompt pay discounts, distribution fees and chargebacks. We believe the risk of accounts being uncollectible is minimal; therefore, no significant allowances for doubtful accounts were established as of March&#160;31, 2024 and December&#160;31, 2023.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Inventories are reviewed periodically for potential excess, dated or obsolete status. We evaluate the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the price we expect to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into operating leases primarily for real estate and automobiles. These leases have contractual terms which range from 3 years to 12 years. We determine if an arrangement contains a lease at inception. Right of use (&#8220;ROU&#8221;) assets and liabilities resulting from operating leases are included in property and equipment, accrued expenses and other long-term liabilities on our condensed consolidated balance sheets. Operating lease ROU assets and liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the discount rate to calculate the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. Our leases often include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that we will exercise that option. Short-term leases with an initial term of 12 months or less are not recorded on our condensed consolidated balance sheet. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have lease agreements with lease and non-lease components, which are generally accounted for separately. For certain leases, such as automobiles, we account for the lease and non-lease components as a single lease component.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div>Property and equipment, including ROU assets are recorded at cost, less accumulated depreciation and amortization. Equipment is depreciated using the straight-line method over its estimated useful life ranging from three years to ten years and leasehold improvements are amortized using the straight-line method over the estimated useful life of the asset or the lease term, whichever is shorter.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentImpairment', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div>We account for long-lived assets in accordance with authoritative guidance for impairment or disposal of long-lived assets. Long-lived assets are reviewed for events or changes in circumstances, which indicate that their carrying value may not be recoverable.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income is defined as the change in equity during the period from transactions and other events and circumstances from non-owner sources.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Convertible Notes</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Notes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Convertible Notes, the 2027 Convertible Notes and the 2028 Convertible Notes (collectively, the &#8220;Convertible Notes&#8221;) are accounted for in accordance with authoritative guidance for debt and derivatives. We evaluate all the embedded conversion options contained in the Convertible Notes to determine if there are embedded features that require bifurcation as a derivative as required by U.S. GAAP. Based on our analysis, we account for each of our Convertible Notes as single units of accounting, a liability, because we concluded that the conversion features do not require bifurcation as a derivative under embedded derivative authoritative guidance.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives', window );">Cash Flow Hedges - Currency Risks</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flow Hedges - Currency Risks</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the second quarter of 2023, we entered into a cash flow hedging program to mitigate foreign currency exchange risk associated with forecasted royalty revenue denominated in Swiss francs. Under the program, we can hedge these forecasted royalties up to a maximum of four years into the future. We hedge these cash flow exposures to reduce the risk of our earnings and cash flows being adversely affected by fluctuations in exchange rates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the hedge accounting treatment, all hedging relationships are formally documented at the inception of the hedge and are highly effective in offsetting changes to future cash flows on hedged transactions. Both at inception of the hedge and on an ongoing basis, we assess whether the foreign currency forward contracts are highly effective in offsetting changes in cash flows of hedged items on a prospective and retrospective basis. If we determine a (i) foreign currency forward contract is not highly effective as a cash flow hedge, (ii) foreign currency forward contract has ceased to be a highly effective hedge or (iii) forecasted transaction is no longer probable of occurring, we would discontinue hedge accounting treatment prospectively. We measure effectiveness based on the change in fair value of the forward currency forward contract and the fair value of the hypothetical foreign currency forward contract with terms that match the critical terms of the risk being hedged. No portion of our foreign currency forward contracts were excluded from the assessment of hedge effectiveness. As of March&#160;31, 2024, all hedges were determined to be highly effective. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets or liabilities associated with our hedging contracts are recorded at fair market value in prepaid expense and other current assets, accrued expenses, or other long-term liabilities, respectively, in our condensed consolidated balance sheets. Gains and losses related to changes in the fair market value of these hedging contracts are recorded as a component of accumulated other comprehensive income (loss) (&#8220;AOCI&#8221;) within stockholder&#8217;s equity in our condensed consolidated balance sheets and reclassified to royalty revenue in our condensed consolidated statements of income in the same period as the recognition of the underlying hedged transaction. In the event the underlying forecasted transaction does not occur, or it becomes probable that it will not occur, within the defined hedge period, we reclassify the gains or losses on the related cash flow hedge from AOCI to royalties revenue in our condensed consolidated statements of income. Settlements from the cash flow hedge are included in operating activities on the condensed consolidated statements of cash flows. Since the fair market value of these hedging contracts is derived from current market rates, the hedging contracts are classified as derivative financial instruments. We do not use derivatives for speculative or trading purposes. As of March&#160;31, 2024, amounts expected to be recognized as a net gain out of AOCI into our condensed consolidated statements of income during the next 12 months are not material.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the acquisition method of accounting, we allocate the fair value of the total consideration transferred to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the date of acquisition. These valuations require us to make estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill. Costs incurred to complete a business combination, such as legal and other professional fees, are expensed as incurred.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the initial accounting for a business combination is incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date. We record these adjustments to the provisional amounts with a corresponding offset to goodwill. Any adjustments identified after the measurement period are recorded in our condensed consolidated statements of income.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets acquired, including intangible assets and in-process research and development (&#8220;IPR&amp;D&#8221;), and liabilities assumed are measured at fair value as of the acquisition date. Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of the net assets acquired. Intangible assets acquired in a business combination that are used for IPR&amp;D activities are considered indefinite lived until the completion or abandonment of the associated research and development efforts. Upon reaching the end of the relevant research and development project (i.e., upon commercialization), the IPR&amp;D </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">asset is amortized over its estimated useful life. If the relevant research and development project is abandoned, the IPR&amp;D asset is expensed in the period of abandonment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and IPR&amp;D are not amortized; however, they are reviewed for impairment at least annually during the second quarter, or more frequently if an event occurs indicating the potential for impairment. Goodwill and IPR&amp;D are considered to be impaired if the carrying value of the reporting unit or IPR&amp;D asset exceeds its respective fair value.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform our goodwill impairment analysis at the reporting unit level, which aligns with our reporting and operating segment structure and availability of discrete financial information. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair values of our reporting unit is less than the carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and our overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amounts, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair value of the reporting unit with the carrying value, including goodwill. If the carrying amount of the reporting unit exceeds the fair value, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative goodwill impairment test.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our identifiable intangible assets with finite useful lives are typically comprised of acquired device technologies and product rights. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#8217; respective estimated useful lives.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock', window );">Intangible Assets and Other Long-Lived Assets</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform regular reviews to determine if any event has occurred that may indicate intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to the net book value, significant changes in the ability of a particular asset to generate positive cash flows for our strategic business objectives, and the pattern of utilization of a particular asset.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition and Cost of Sales</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate revenues from payments received (i) as royalties from licensing our ENHANZE technology and other royalty arrangements, (ii) under collaborative agreements and (iii) from sales of our proprietary and partnered products. We recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, we perform the following five steps: (i) identify the promised goods or services in the contract; (ii) identify the performance obligations in the contract, including whether they are distinct in the context of the contract; (iii) determine the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ENHANZE and Device Royalties</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our ENHANZE collaboration and license agreements, our partners will pay us royalties at an on average mid-single digit percent rate of their sales if products under the collaboration are commercialized. All amounts owed to us are noncancelable after the underlying triggering event occurs, and nonrefundable once paid. Unless terminated earlier in accordance with its terms, collaborations generally continue in effect until the last to expire royalty payment term, as determined on a product by product and country by country basis, with each royalty term starting on the first commercial sale of that product and ending the later of: (i) a specified period or term set forth in the agreement or (ii) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration. In general, when there are no valid claims of a specified patent developed under the collaboration covering the product in a given country, the royalty rate is reduced for those sales in that country upon the expiration of our patents covering rHuPH20. Janssen&#8217;s patents covering DARZALEX SC do not impact the timing for this royalty reduction. Partners may terminate the agreement prior to expiration for any reason in its entirety or on a target-by-target basis generally upon 90 days prior written notice to us.&#160;Upon any such termination, the license granted to partners (in total or with respect to the terminated target, as applicable) will terminate provided; however, that in the event of expiration of the agreement (as opposed to a termination), the on-going licenses granted may become perpetual, non-exclusive and fully paid. Sales-based milestones and royalties are recognized in the period the underlying sales or milestones occur. We do not receive final royalty reports from our ENHANZE partners until after we complete our financial statements for a prior quarter. Therefore, we recognize revenue based on estimates of the royalty earned, which are based on internal estimates and available preliminary reports provided by our partners. We will record adjustments in the following quarter, if necessary, when final royalty reports are received. To date, we have not recorded any material adjustments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also earn royalties in connection with several of our licenses granted under license and development arrangements with our device partners. These royalties are based upon a percentage of commercial sales of partnered products with rates ranging from mid-single digits to low double digits and are tiered based on levels of net sales. These sales-based royalties, for which the license was deemed the predominant element to which the royalties relate, are estimated and recognized in the period in which the partners&#8217; commercial sales occur. The royalties are generally reported and payable to us within 45 to 60 days after the end of the period in which the commercial sales are made. We base our estimates of royalties earned on actual sales information from our partners when available or estimated, prescription sales from external sources and estimated net selling price. We will record adjustments in the following quarter, if necessary, when final royalty reports are received. To date, we have not recorded any material adjustments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue under ENHANZE and Device Collaborative Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ENHANZE Collaboration and License Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under these agreements, we grant the collaboration partner a worldwide license to develop and commercialize products using our ENHANZE technology to combine our patented rHuPH20 enzyme with their proprietary biologics directed at up to a specified number of targets. Targets are usually licensed on an exclusive, global basis. Targets selected subsequent to inception of the arrangement generally require payment of an additional license fee. The collaboration partner is responsible for all development, manufacturing, clinical, regulatory, sales and marketing costs for any products developed under the agreement. We are responsible for supply of bulk rHuPH20 based on the collaboration partner&#8217;s purchase orders, and may also be separately engaged to perform research and development services. While these collaboration agreements are similar in that they originate from the same framework, each one is the result of an arms-length negotiation and thus may vary from one to the other.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally collect an upfront license payment from collaboration partners, and are also entitled to receive event-based payments subject to collaboration partners&#8217; achievement of specified development, regulatory and sales-based milestones. In several agreements, collaboration partners pay us annual fees to maintain their exclusive license rights if they are unable to advance product development to specified stages. We earn separate fees for bulk rHuPH20 supplies and research and development services. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although these agreements are in form identified as collaborative agreements, we concluded for accounting purposes they represent contracts with customers and are not subject to accounting literature on collaborative arrangements. This is because we grant to partners licenses to our intellectual property and provide supply of bulk rHuPH20 and research and development services which are all outputs of our ongoing activities, in exchange for respective consideration. Under these collaborative agreements, our partners lead development of assets, and we do not share in significant financial risks of their development or commercialization activities. Accordingly, we concluded our collaborative agreements are appropriately accounted for pursuant to U.S. GAAP. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under all of our ENHANZE collaborative agreements, we have identified licenses to use functional intellectual property as the only performance obligation. The intellectual property underlying the license is our proprietary ENHANZE technology which represents application of rHuPH20 to facilitate delivery of drugs. Each of the licenses grants the partners rights to use our intellectual property as it exists and is identified on the effective date of the license, because there is no ongoing development of the ENHANZE technology required. Therefore, we recognize revenue from licenses at the point when the license becomes effective and the partner has received access to our intellectual property, usually at the inception of the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When partners can select additional targets to add to the licenses granted, we consider these rights to be options. We evaluate whether such options contain material rights, i.e. have exercise prices that are discounted compared to what we would charge for a similar license to a new partner. The exercise price of these options includes a combination of the target selection fees, event-based milestone payments and royalties. When these amounts in aggregate are not offered at a discount that exceeds discounts available to other customers, we conclude the option does not contain a material right, and we consider grants of additional licensing rights upon option exercises to be separate contracts (target selection contracts).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, we provide indemnification and protection of licensed intellectual property for our customers. These provisions are part of assurance that the licenses meet the agreements&#8217; representations and are not obligations to provide goods or services.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also fulfill purchase orders for supply of bulk rHuPH20 and perform research and development services pursuant to project authorization forms for our partners, which represent separate contracts. In addition to our licenses, we price our supply of bulk rHuPH20 and research and development services at our regular selling prices, called standalone selling prices (&#8220;SSP&#8221;). Therefore, our partners do not have material rights to order these items at prices not reflective of SSP. Refer to the discussion below regarding recognition of revenue for these separate contracts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction price for a contract represents the amount to which we are entitled in exchange for providing goods and services to the customer. Transaction price does not include amounts subject to uncertainties unless it is probable that there will be no significant reversal of revenue when the uncertainty is resolved. Apart from the upfront license payment (or target selection fees in the target selection contracts), all other fees we may earn under our collaborative agreements are subject to significant uncertainties of product development. Achievement of many of the event-based development and regulatory milestones may not be probable until such milestones are actually achieved. This generally relates to milestones such as obtaining marketing authorization approvals. With respect to other development milestones, e.g., dosing of a first patient in a clinical trial, achievement could be considered probable prior to its actual occurrence, based on the progress towards commencement of the trial. In order to evaluate progress towards commencement of a trial, we assess the status of activities leading up to our partner&#8217;s initiation of a trial such as feedback received from the applicable regulatory authorities, completion of Investigational New Drug (&#8220;IND&#8221;) or equivalent filings, readiness and availability of drug, readiness of study sites and our partner&#8217;s commitment of resources to the program. We do not include any amounts subject to uncertainties in the transaction price until it is probable that the amount will not result in a significant reversal of revenue in the future. At the end of each reporting period, we re-evaluate the probability of achievement of such milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When target exchange rights are held by partners, and the amounts attributed to these rights are not refundable, they are included in the transaction price. However, they are recorded as deferred revenues because we have a potential performance obligation to provide a new target upon an exchange right being exercised. These amounts are recognized in revenue when the right of exchange expires or is exercised.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because our agreements have one type of performance obligation (licenses) which are typically all transferred at the same time at agreement inception, allocation of transaction price often is not required. However, allocation is required when licenses for some of the individual targets are subject to rights of exchange, because revenue associated with these targets cannot be recognized. When allocation is needed, we perform an allocation of the upfront amount based on relative SSP of licenses for individual targets. We determine license SSP using an income-based valuation approach utilizing risk-adjusted discounted cash flow projections of the estimated return a licensor would receive. When amounts subject to uncertainties, such as milestones and royalties, are included in the transaction price, we attribute them to the specific individual target licenses which generate such milestone or royalty amounts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also estimate SSP of bulk rHuPH20 and research and development services, to determine that our partners do not have material rights to order them at discounted prices. For supplies of bulk rHuPH20, because we effectively act as a contract manufacturer to our partners, we estimate and charge SSP based on the typical contract manufacturer margins consistent with all of our partners. We determine SSP of research and development services based on a fully-burdened labor rate. Our rates are comparable to those we observe in other collaborative agreements. We also have a history of charging similar rates to all of our partners. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront amounts allocated to licenses to individual targets are recognized as revenue when the license is transferred to the partner, as discussed above, if the license is not subject to exchange rights, or when the exchange right expires or is exercised. Development milestones and other fees are recognized in revenue when they are included in the transaction price, because by that time, we have already transferred the related license to the partner. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In contracts to provide research and development services, such services represent the only performance obligation. The fees are charged based on hours worked by our employees and the fixed contractual rate per hour, plus third-party pass-through costs, on a monthly basis. We recognize revenues as the related services are performed based on the amounts billed, as the partner consumes the benefit of research and development work simultaneously as we perform these services, and the amounts billed reflect the value of these services to the customer. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Device License, Development and Supply Arrangements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have several license, development and supply arrangements with pharmaceutical partners, under which we grant a license to our device technology and provide research and development services that often involve multiple performance obligations and highly-customized deliverables. For such arrangements, we identify each of the promised goods and services within the contract and the distinct performance obligations at inception of the contract and allocate consideration to each performance obligation based on relative SSP, which is generally determined based on the expected cost plus mark-up. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the contract includes an enforceable right to payment for performance completed to date and performance obligations are satisfied over time, we recognize revenue over the development period using either the input or output method depending on which is most appropriate given the nature of the distinct deliverable. For other contracts that do not contain an enforceable right to payment for performance completed to date, revenue is recognized when control of the product is transferred to the customer. Factors that may indicate transfer of control has occurred include the transfer of legal title, transfer of physical possession, the customer has obtained the significant risks and rewards of ownership of the assets, and we have a present right to payment. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our payment terms for development contracts may include an upfront payment equal to a percentage of the total contract value with the remaining portion to be billed upon completion and transfer of the individual deliverables or satisfaction of the individual performance obligations. We record a contract liability for cash received in advance of performance, which is presented within deferred revenue and deferred revenue, long-term in our condensed consolidated balance sheets and recognized as revenue in our condensed consolidated statements of income when the associated performance obligations have been satisfied. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License fees and milestones received in exchange for the grant of a license to our functional intellectual property, such as patented technology and know-how in connection with a partnered development arrangement, are generally recognized at inception of the arrangement, or over the development period depending on the facts and circumstances, as the license is generally not distinct from the non-licensed goods or services to be provided under the contract. Milestone payments that are contingent upon the occurrence of future events are evaluated and recorded at the most likely amount, and to the extent that it is probable that a significant reversal of revenue will not occur when the associated uncertainty is resolved.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 4,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion on our collaborative arrangements.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales, Net</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Proprietary Product Sales</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial portfolio of proprietary products includes XYOSTED and Hylenex recombinant which we sell primarily to wholesale pharmaceutical distributors and specialty pharmacies, who sell the products to hospitals, retail chain drug stores and other end-user customers. Sales to wholesalers are made pursuant to purchase orders subject to the terms of a master agreement, and delivery of individual packages of products represents performance obligations under each purchase order. We use contract manufacturers to produce our proprietary products and third-party logistics (&#8220;3PL&#8221;) vendors to process and fulfill orders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We concluded we are the principal in the sales to wholesalers because we control access to services rendered by both vendors and direct their activities. We have no significant obligations to wholesalers to generate pull-through sales.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized when control has transferred to the customer, which is typically upon delivery, at the net selling price, which reflects the variable consideration for which reserves and sales allowances are established for estimated returns, wholesale distribution fees, prompt payment discounts, government rebates and chargebacks, plan rebate arrangements and patient discount and support programs. We recognize revenue from product sales and related cost of sales upon product delivery to the wholesaler location. At that time, the wholesalers take control of the product as they take title, bear the risk of loss of ownership, and have an enforceable obligation to pay us. They also have the ability to direct sales of product to their customers on terms and at prices they negotiate. Although wholesalers have product return rights, we do not believe they have a significant incentive to return the product to us.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of certain reserves and sales allowances requires us to make a number of judgements and estimates to reflect our best estimate of the transaction price and the amount of consideration to which we believe we would be ultimately entitled to receive. The expected value is determined based on unit sales data, contractual terms with customers and third-party payers, historical and estimated future percentage of rebates incurred on sales, historical and future insurance plan billings, any new or anticipated changes in programs or regulations that would impact the amount of the actual rebates, customer purchasing patterns, product expiration dates and levels of inventory in the distribution channel. The estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, rebates and customer co-pay support programs are included in accrued expenses and accounts receivable, net in our condensed consolidated balance sheets upon recognition of revenue from product sales. We monitor actual product returns, chargebacks, discounts and fees subsequent to the sale. If these amounts differ from our estimates, we make adjustments to these allowances, which are applied to increase or reduce product sales revenue and earnings in the period of adjustment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling prices initially billed to wholesalers are subject to discounts for prompt payment and subsequent chargebacks when wholesalers sell our products at negotiated discounted prices to members of certain group purchasing organizations (&#8220;GPOs&#8221;), Pharmacy Benefit Managers (&#8220;PBMs&#8221;) and government programs. We also pay quarterly distribution fees to certain wholesalers for inventory reporting and chargeback processing, and to PBMs and GPOs as administrative fees for services and for access to their members. We concluded the benefits received in exchange for these fees are not distinct from our sales of our products, and accordingly we apply these amounts to reduce revenues. Wholesalers also have rights to return unsold product nearing or past the expiration date. Because of the shelf life of our products and our lengthy return period, there may be a significant period of time between when the product is shipped and when we issue credits on returned product. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the transaction price when we receive each purchase order taking into account the expected reductions of the selling price initially billed to the wholesaler arising from all of the above factors. We have compiled historical experience and data to estimate future returns and chargebacks of our products and the impact of the other discounts and fees we pay. When estimating these adjustments to the transaction price, we reduce it sufficiently to be able to assert that it is probable that there will be no significant reversal of revenue when the ultimate adjustment amounts are known.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each purchase order contains only one type of product, and is usually shipped to the wholesaler in a single shipment. Therefore, allocation of the transaction price to individual packages is not required.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the orders placed by wholesalers, we incur costs such as commissions to our sales representatives. However, as revenue from product sales is recognized upon delivery to the wholesaler, which occurs shortly after we receive a purchase order, we do not capitalize these commissions and other costs, based on application of the practical expedient allowed within the applicable guidance. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Partnered Product Sales</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bulk rHuPH20</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell bulk rHuPH20 to partners for use in research and development and, subsequent to receiving marketing approval, we sell it for use in collaboration commercial products. Sales are made pursuant to purchase orders subject to the terms of the collaborative agreement or a supply agreement, and delivery of units of bulk rHuPH20 represent performance obligations under each purchase order. We provide a standard warranty that the product conforms to specifications. We use contract manufacturers to produce bulk rHuPH20 and have concluded we are the principal in the sales to partners. The transaction price for each purchase order of bulk rHuPH20 is fixed based on the cost of production plus a contractual markup, and is not subject to adjustments. Allocation of the transaction price to individual quantities of the product is usually not required because each order contains only one type of product.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue from the sale of bulk rHuPH20 as product sales and related cost of sales upon transfer of title to our partners. At that time, the partners take control of the product, bear the risk of loss of ownership, and have an enforceable obligation to pay us. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Devices</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to several license, development, supply and distribution arrangements with pharmaceutical partners, under which we produce and are the exclusive supplier of certain products, devices and/or components. Revenue is recognized when or as control of the goods transfers to the customer as discussed below.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the exclusive supplier of OTREXUP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to Otter. Because this product is custom manufactured with no alternative use and we have a contractual right to payment for performance completed to date, control is continuously transferred to the customer as the product is produced pursuant to firm purchase orders. Revenue is recognized over time using the output method based on the contractual selling price and number of units produced. The amount of revenue recognized in excess of the amount shipped/billed to the customer, if any, is recorded as contract assets in our condensed consolidated balance sheets due to the short-term nature in which the amount is ultimately expected to be billed and collected from the customer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other device partnered product sales are recognized at the point in time in which control is transferred to the customer, which is typically upon shipment. Sales terms and pricing are governed by the respective supply and distribution agreements, and there is generally no right of return. Revenue is recognized at the transaction price, which includes the contractual per unit selling price and estimated variable consideration, such as volume-based pricing arrangements or profit-sharing arrangements, if any. We recognize revenue, including the estimated variable consideration we expect to receive for contract margin on future commercial sales, upon shipment of the goods to our partner. The estimated variable consideration is recognized at an amount we believe is not subject to significant reversal of revenue based on historical experience and is adjusted at each reporting period if the most likely amount of expected consideration changes or becomes fixed.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales consists primarily of raw materials, third-party manufacturing costs, fill and finish costs, freight costs, internal costs and manufacturing overhead associated with the production of proprietary and partnered products. Cost of sales also consists of the write-down of excess, dated and obsolete inventories and the write-off of inventories that do not meet certain product specifications, if any.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include salaries and benefits, allocation of facilities and other overhead expenses, research related manufacturing services, contract services, and other outside expenses related to manufacturing, preclinical and regulatory activities and our partner development platforms. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to our research and development efforts and have no alternative future uses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as expense as the related goods are delivered or the related services are performed or such time when we do not expect the goods to be delivered or services to be performed.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record compensation expense associated with stock options, restricted stock units (&#8220;RSUs&#8221;), performance stock units (&#8220;PSUs&#8221;) and shares issued under our employee stock purchase plan (&#8220;ESPP&#8221;) in accordance with the authoritative guidance for share-based compensation. The cost of employee services received in exchange for an award of an equity instrument is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense on a straight-line basis over the requisite service period of the award. Share-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed. Forfeitures are recognized as a reduction of share-based compensation expense as they occur.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide for income taxes using the liability method. Under this method, deferred income tax assets and liabilities are determined based on the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases at each reporting period. We measure deferred tax assets and liabilities using enacted tax rates for the year in which the differences are expected to reverse. Significant judgment is required by management to determine our provision for income taxes, our deferred tax assets and liabilities, and any associated valuation allowances recorded against our net deferred tax assets, which are based on complex and evolving tax regulations. Deferred tax assets (&#8220;DTA&#8221;) and other tax benefits are recorded when they are more likely than not to be realized. On a quarterly basis, we assess the need for valuation allowance on our DTAs, weighing all positive and negative evidence, to assess if it is more-likely-than-not that some or all of our DTAs will be realized. We recorded a provision for income taxes of $19.2 million using an effective tax rate of 20% for the three months ended March&#160;31, 2024. The difference between our effective tax rate and the U.S. federal statutory rate of 21% is primarily due to state income taxes, research and development credit generations, tax benefits on the Foreign Derived Intangible Income Deduction (&#8220;FDII&#8221;) (net of reserves), tax detriments on 162(m) and other share-based compensation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate our business in one operating segment, which includes all activities related to the research, development and commercialization of our proprietary enzymes and devices. This segment also includes revenues and expenses related to (i)&#160;research and development and manufacturing activities conducted under our collaborative agreements with third parties, and (ii)&#160;product sales of proprietary and partnered products. The chief operating decision-maker (&#8220;CODM&#8221;), our Chief Executive Officer (&#8220;CEO&#8221;), reviews the operating results on an aggregate basis and manages the operations as a single operating segment.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Adoption and Pending Adoption of Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:3pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adoption and Pending Adoption of Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a brief description of recently issued accounting standards, those adopted in the current period and those not yet adopted:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"><tr><td style="width:1.0%"></td><td style="width:17.852%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.631%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.154%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.688%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.878%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.787%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Standard</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Adoption Method</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Effect on the Financial<br/>Statements or Other Significant Matters</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The new standard is intended to improve annual and interim reportable segment disclosure requirements regardless of number of reporting units, primarily through enhanced disclosures of significant expenses. The amendment requires public entities to disclose significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit and loss.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Annual periods beginning after December 15, 2023 (our 2024 Form 10-K), and interim periods within fiscal years beginning after December 15, 2024 (our Q1 2025 Form 10-Q) - Early adoption is permitted, including adoption in an interim period<br/></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Retrospective</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are currently evaluating the impact of the standard on our consolidated financial statements and related disclosures.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The new guidance includes amendments that further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Annual periods beginning after December 15, 2024 (our 2025 Form 10-K) - Early adoption is permitted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prospective or Retrospective</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are currently evaluating the impact of the standard on our consolidated financial statements and related disclosures.</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479515/805-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for derivatives used in hedging relationships, which may include how gains or losses are recognized and presented in the financial statements, and amortization policies for deferred amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 25<br> -Name Accounting Standards Codification<br> -Section 40<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480270/815-25-40-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4EEEE<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4EEEE<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for assessing and recognizing impairments of its property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-11B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704422477168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of available-for-sale marketable securities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale marketable securities consisted of the following (in thousands):</span></div><div style="margin-top:11pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:52.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.779%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,384&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,379&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities, available-for-sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298,983&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(197)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298,824&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:52.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.779%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,512&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,504&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities, available-for-sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,475&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,630&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of contractual maturities of available-for-sale debt securities</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of our contractual maturities of available-for-sale debt securities were as follows (in thousands):</span></div><div style="margin-top:11pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:67.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.063%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,059&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,633&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year but within five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total estimated fair value of contractual maturities, available-for-sale</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298,824&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,630&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of assets measured at fair value on a recurring basis</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes, by major security type, our cash equivalents and available-for-sale marketable securities measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"></td><td style="width:29.421%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.329%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.329%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.967%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.329%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.329%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.337%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Estimated Fair Value</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Estimated Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale marketable <br/>&#160;&#160;&#160;securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,504&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,504&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency hedging contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,574&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,574&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298,711&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,963&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,674&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,429&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,343&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241,772&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency hedging contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Based on observable market transactions of spot currency rates, forward currency rates or equivalently-termed instruments. Carrying amounts of the financial assets and liabilities are equal to the fair value. As of March&#160;31, 2024, the derivative assets and liabilities recorded within prepaid expenses and other current assets, prepaid expense and other assets and other long-term liabilities in our condensed consolidated balance sheets were $<span style="-sec-ix-hidden:f-420">1.3 million</span>, $<span style="-sec-ix-hidden:f-422">0.3 million</span> and $<span style="-sec-ix-hidden:f-424">0.5 million</span>, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704507519536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of disaggregation of revenues</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our disaggregated revenues were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"><tr><td style="width:1.0%"></td><td style="width:78.869%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.144%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.147%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,593&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,640&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proprietary product sales</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,961&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bulk rHuPH20 sales</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,069&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Device partnered product sales</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,818&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,583&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,794&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues under collaborative agreements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Event-based development and regulatory milestones and other fees</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Device licensing and development revenue</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues under collaborative agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,703&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,709&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,879&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,143&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of accounts receivable, deferred revenues from contracts with customers, and amounts under collaborative agreements included in transaction price</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, other contract assets and deferred revenues (contract liabilities) from contracts with customers, including partners, consisted of the following (in thousands): </span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:75.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.859%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233,254&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other contract assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,595&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,048&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704418573648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain Balance Sheet Items (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of accounts receivable</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net and contract assets consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:68.485%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from product sales to partners</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,045&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,588&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from revenues under collaborative agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from royalty payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from other product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,060&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts receivable and contract assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202,111&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240,957&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for distribution fees and discounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,209)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,747)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts receivable, net and contract assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,902&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,210&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventories</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:68.485%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,112&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,646&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,611&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,818&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,930&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,541&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,601&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock', window );">Schedule of prepaid expenses and other assets</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:68.485%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid manufacturing expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,211&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,850&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,902&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,951&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,677&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,009&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,429&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Long-term portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,319)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,816)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other assets, current</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,690&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,613&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment, net</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:68.485%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,690&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,588&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer and office equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,888&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,066&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,769&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,180)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,661)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,886&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use of assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,071&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,944&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:68.485%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and payroll taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,442&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,361&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued outsourced manufacturing expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,074&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product returns and sales allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,515&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,398&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less long-term portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,201)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,720)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses, current</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,314&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,678&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704419658016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the activity impacting goodwill is presented below (in thousands):</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"><tr><td style="width:1.0%"></td><td style="width:84.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustment</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416,821&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets</a></td>
<td class="text">The following table shows the cost, accumulated amortization and weighted average useful life in years for our acquired intangible assets as of March&#160;31, 2024 (in thousands).<div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"><tr><td style="width:1.0%"></td><td style="width:47.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.993%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.993%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Useful Life </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auto Injector technology platform</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,521&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,479&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XYOSTED proprietary product</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived intangibles, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538,200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,784&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406,416&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ATRS-1902 (IPR&amp;D)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,700&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangibles, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455,116&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated future annual amortization of finite-lived intangible assets is shown in the following table (in thousands). Actual amortization expense to be reported in future periods could differ from these estimates as a result of acquisitions, divestitures, and asset impairments, among other factors.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"></td><td style="width:82.561%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.010%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,286&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,934&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406,416&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704422307744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Carrying Amounts of our Convertible Notes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount and fair value of our Convertible Notes were as follows (in thousands). </span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"><tr><td style="width:1.0%"></td><td style="width:69.570%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.580%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.474%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total principal amount</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,525,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,525,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,094)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,950)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,027)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,802)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total unamortized debt discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,121)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,752)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794,906&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705,198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carrying amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500,879&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,499,248&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value based on trading levels (Level 2):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695,826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702,403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670,522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of outstanding notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,416,647&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,366,348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization per period of debt discount (in years):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Interest Income and Interest Expense Disclosure</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of interest expense and the effective interest rates for each of our Convertible Notes (in thousands).</span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.011%"><tr><td style="width:1.0%"></td><td style="width:77.305%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.464%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.368%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.464%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.699%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Coupon interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,800</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,800</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total coupon interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,303</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,339</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">856</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortization of debt discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,631</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,638</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,359</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,353</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,575</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,564</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,934</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,977</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective interest rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704419601472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-Based Payment Arrangement, Noncash Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of share-based compensation expense</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarized share-based compensation expense included in our condensed consolidated statements of income related to share-based awards (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:79.143%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.018%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.021%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,345&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,101&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,529&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,865&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,874&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,966&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of share-based compensation expense by type</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense by type of share-based award was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"></td><td style="width:79.351%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.922%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.925%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,299&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,455&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs, PSUs and ESPP</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,575&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,511&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,874&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,966&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used in Black-Scholes model</a></td>
<td class="text">The assumptions used in the Black-Scholes Model were as follows:<div style="margin-top:5pt;text-align:center;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:67.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.804%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.02 - 40.08%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.68 - 39.98%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.80 - 4.28%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.48 - 4.27%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock', window );">Schedule of unrecognized estimated compensation cost by type</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total unrecognized estimated compensation cost by type of award and the weighted-average remaining requisite service period over which such expense is expected to be recognized was as follows (in thousands, unless otherwise noted):</span></div><div style="margin-top:5pt;text-align:center;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.643%"><tr><td style="width:1.0%"></td><td style="width:66.158%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.030%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrecognized<br/>Expense</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Recognition Period</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,038&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.70</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.05</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.30</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.21</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (i)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704417493280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of reconciliation of numerators and denominators of basic and diluted computations</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the numerators and the denominators of the basic and diluted earnings per share computations is as follows (in thousands, except per share amounts):</span><div style="margin-top:11pt;text-align:center;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:77.307%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.547%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.316%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,823&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,615&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding for basic earnings per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,027&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive potential common stock outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs, PSUs and ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding for diluted earnings per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,887&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Antidilutive securities excluded from calculation of diluted earnings per common share</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares which have been excluded from the calculation of diluted earnings per common share because their effect was anti-dilutive include the following (shares in millions):</span></div><div style="margin-top:11pt;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:77.640%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.821%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span>    The anti-dilutive securities include outstanding stock options, unvested RSUs, unvested PSUs, common shares expected to be issued under our ESPP and Convertible Notes<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704507766064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Business (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>product</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_RoyaltiesReceivedNumberOfProductsSold', window );">Royalties received, number of products sold</a></td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=halo_TakedaMember', window );">Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_RoyaltiesReceivedNumberOfProductsSold', window );">Royalties received, number of products sold</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=halo_JanssenMember', window );">Janssen</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_RoyaltiesReceivedNumberOfProductsSold', window );">Royalties received, number of products sold</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=halo_ArgenxMember', window );">Argenx</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_RoyaltiesReceivedNumberOfProductsSold', window );">Royalties received, number of products sold</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=halo_RocheMember', window );">Roche</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_RoyaltiesReceivedNumberOfProductsSold', window );">Royalties received, number of products sold</a></td>
<td class="nump">4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_RoyaltiesReceivedNumberOfProductsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties Received, Number of Products Sold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_RoyaltiesReceivedNumberOfProductsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=halo_TakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=halo_TakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=halo_JanssenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=halo_JanssenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=halo_ArgenxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=halo_ArgenxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=halo_RocheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=halo_RocheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704419987072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies -Accounts Receivable, net (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Accounts receivable, allowance for doubtful accounts</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704420140208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Leases (Details)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of leases</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of leases</a></td>
<td class="text">12 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704420343200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies -Property and Equipment, net (Details)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704419959456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Cash Flow Hedges - Currency Risks (Details) - Cash Flow Hedging - Currency hedging contracts<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeTermOfContract', window );">Derivative, contract term</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeTermOfContract', window );">Derivative, contract term</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704583616752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Revenue and Cost of Product Sales (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice', window );">Period of contract termination by written notice</a></td>
<td class="text">90 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Period Of Termination By Written Notice</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704419681872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="nump">$ 19,205<span></span>
</td>
<td class="nump">$ 12,623<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate, percent</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704583624656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Segment Information (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704419671584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Components of Available-for-sale Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">$ 298,983<span></span>
</td>
<td class="nump">$ 217,475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(197)<span></span>
</td>
<td class="num">(46)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value</a></td>
<td class="nump">298,824<span></span>
</td>
<td class="nump">217,630<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">2,384<span></span>
</td>
<td class="nump">3,512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value</a></td>
<td class="nump">2,379<span></span>
</td>
<td class="nump">3,504<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">43,118<span></span>
</td>
<td class="nump">6,022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(64)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value</a></td>
<td class="nump">43,056<span></span>
</td>
<td class="nump">6,013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">239,347<span></span>
</td>
<td class="nump">175,996<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(106)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value</a></td>
<td class="nump">239,277<span></span>
</td>
<td class="nump">176,184<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AgencySecuritiesMember', window );">Agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">9,180<span></span>
</td>
<td class="nump">16,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value</a></td>
<td class="nump">9,158<span></span>
</td>
<td class="nump">16,103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">4,954<span></span>
</td>
<td class="nump">15,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value</a></td>
<td class="nump">$ 4,954<span></span>
</td>
<td class="nump">$ 15,826<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AgencySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AgencySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704420305424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>security</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of loss positions | security</a></td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair market value of gross unrealized loss position</a></td>
<td class="nump">$ 215,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized loss position of debt securities</a></td>
<td class="nump">197,000<span></span>
</td>
<td class="nump">$ 46,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest', window );">Credit loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale marketable securities</a></td>
<td class="nump">298,824,000<span></span>
</td>
<td class="nump">217,630,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704529020640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Contractual Maturities of Available-for-sale Debt Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due within one year</a></td>
<td class="nump">$ 235,059<span></span>
</td>
<td class="nump">$ 197,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year but within five years</a></td>
<td class="nump">63,765<span></span>
</td>
<td class="nump">19,997<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total estimated fair value of contractual maturities, available-for-sale</a></td>
<td class="nump">$ 298,824<span></span>
</td>
<td class="nump">$ 217,630<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704420562736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Assets Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale marketable securities</a></td>
<td class="nump">$ 298,824<span></span>
</td>
<td class="nump">$ 217,630<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">350,674<span></span>
</td>
<td class="nump">241,772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Derivative asset, current</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Derivative asset, noncurrent</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liability, noncurrent</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Total prepaid expenses and other assets, current<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Total accrued expenses, current<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other long-term liabilities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember', window );">Currency hedging contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative instruments</a></td>
<td class="nump">$ 1,574<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative instruments</a></td>
<td class="nump">478<span></span>
</td>
<td class="nump">9,480<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale marketable securities</a></td>
<td class="nump">2,379<span></span>
</td>
<td class="nump">3,504<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale marketable securities</a></td>
<td class="nump">43,056<span></span>
</td>
<td class="nump">6,013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale marketable securities</a></td>
<td class="nump">239,277<span></span>
</td>
<td class="nump">176,184<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AgencySecuritiesMember', window );">Agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale marketable securities</a></td>
<td class="nump">9,158<span></span>
</td>
<td class="nump">16,103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale marketable securities</a></td>
<td class="nump">4,954<span></span>
</td>
<td class="nump">15,826<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">20,276<span></span>
</td>
<td class="nump">22,142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">298,711<span></span>
</td>
<td class="nump">216,429<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Currency hedging contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale marketable securities</a></td>
<td class="nump">239,277<span></span>
</td>
<td class="nump">176,184<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale marketable securities</a></td>
<td class="nump">9,158<span></span>
</td>
<td class="nump">16,103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">20,276<span></span>
</td>
<td class="nump">22,142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">51,963<span></span>
</td>
<td class="nump">25,343<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Currency hedging contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative instruments</a></td>
<td class="nump">1,574<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative instruments</a></td>
<td class="nump">478<span></span>
</td>
<td class="nump">9,480<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale marketable securities</a></td>
<td class="nump">2,379<span></span>
</td>
<td class="nump">3,504<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale marketable securities</a></td>
<td class="nump">43,056<span></span>
</td>
<td class="nump">6,013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale marketable securities</a></td>
<td class="nump">4,954<span></span>
</td>
<td class="nump">15,826<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes derivative asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-10<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-10<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes derivative liability classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes derivative liability classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AgencySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AgencySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704411719200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Disaggregated Revenues (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 195,879<span></span>
</td>
<td class="nump">$ 162,143<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">120,593<span></span>
</td>
<td class="nump">99,640<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">58,583<span></span>
</td>
<td class="nump">60,794<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=halo_ProprietaryProductsSalesMember', window );">Proprietary product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">35,254<span></span>
</td>
<td class="nump">27,961<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=halo_BulkrHuPH20Member', window );">Bulk rHuPH20 sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">10,511<span></span>
</td>
<td class="nump">22,069<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=halo_DevicePartneredProductsMember', window );">Device partnered product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">12,818<span></span>
</td>
<td class="nump">10,764<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=halo_CollaborativeAgreementsMember', window );">Collaborative Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">16,703<span></span>
</td>
<td class="nump">1,709<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=halo_EventBasedDevelopmentAndRegulatoryMilestoneAndOtherFeesMember', window );">Event-based development and regulatory milestones and other fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">14,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=halo_DeviceLicensingAndDevelopmentMember', window );">Device licensing and development revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 2,703<span></span>
</td>
<td class="nump">$ 1,709<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=halo_ProprietaryProductsSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=halo_ProprietaryProductsSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=halo_BulkrHuPH20Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=halo_BulkrHuPH20Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=halo_DevicePartneredProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=halo_DevicePartneredProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=halo_CollaborativeAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=halo_CollaborativeAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=halo_EventBasedDevelopmentAndRegulatoryMilestoneAndOtherFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=halo_EventBasedDevelopmentAndRegulatoryMilestoneAndOtherFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=halo_DeviceLicensingAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=halo_DeviceLicensingAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704418665008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized', window );">Revenue recognized variable consideration and other uncertainties satisfied</a></td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized previously included in deferred revenue</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenues</a></td>
<td class="nump">4,595<span></span>
</td>
<td class="nump">$ 4,048<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetGrossCurrent', window );">Contract assets</a></td>
<td class="nump">10,589<span></span>
</td>
<td class="nump">$ 956<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-04-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-04-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Deferred revenue, remaining performance obligation, expected timing</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=halo_OthercollaboratorsMember', window );">Other collaborators</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="nump">$ 77,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=halo_LicenseFeesAndEventBasedMember', window );">License Fees and Event-Based</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Revenue recognized from prior periods</a></td>
<td class="nump">134,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_RevenueRemainingPerformanceObligationsUnfulfilledProductPurchaseOrdersAmount', window );">Revenue remaining performance obligations, related to unfulfilled product purchase orders</a></td>
<td class="nump">$ 72,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_RevenueRemainingPerformanceObligationsUnfulfilledProductPurchaseOrdersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Remaining Performance Obligations, Unfulfilled Product Purchase Orders, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_RevenueRemainingPerformanceObligationsUnfulfilledProductPurchaseOrdersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-04-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-04-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=halo_OthercollaboratorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=halo_OthercollaboratorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=halo_LicenseFeesAndEventBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=halo_LicenseFeesAndEventBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704419891360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue - Accounts Receivable, Other Contract Assets and Contract Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 185,313<span></span>
</td>
<td class="nump">$ 233,254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetGrossCurrent', window );">Contract assets</a></td>
<td class="nump">10,589<span></span>
</td>
<td class="nump">956<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenues</a></td>
<td class="nump">$ 4,595<span></span>
</td>
<td class="nump">$ 4,048<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704418853216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Certain Balance Sheet Items - Accounts Receivable, net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetGrossCurrent', window );">Contract assets</a></td>
<td class="nump">$ 10,589<span></span>
</td>
<td class="nump">$ 956<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_AccountsReceivableAndContractWithCustomerAssetBeforeAllowanceForCreditLossCurrent', window );">Total accounts receivable and contract assets</a></td>
<td class="nump">202,111<span></span>
</td>
<td class="nump">240,957<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_AccountsReceivableAndContractWithCustomerAssetAllowanceForCreditLossCurrent', window );">Allowance for distribution fees and discounts</a></td>
<td class="num">(6,209)<span></span>
</td>
<td class="num">(6,747)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent', window );">Total accounts receivable, net and contract assets</a></td>
<td class="nump">195,902<span></span>
</td>
<td class="nump">234,210<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=halo_DevicePartneredProductsMember', window );">Device partnered product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Accounts receivable</a></td>
<td class="nump">27,045<span></span>
</td>
<td class="nump">58,588<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=halo_CollaborativeAgreementsMember', window );">Revenues under collaborative agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Accounts receivable</a></td>
<td class="nump">2,078<span></span>
</td>
<td class="nump">16,183<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Accounts receivable</a></td>
<td class="nump">115,413<span></span>
</td>
<td class="nump">118,170<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=halo_ProductSalesOtherMember', window );">Other product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 46,986<span></span>
</td>
<td class="nump">$ 47,060<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable And Contract With Customer Asset, After Allowance For Credit Loss, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AccountsReceivableAndContractWithCustomerAssetAllowanceForCreditLossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable And Contract With Customer Asset, Allowance for Credit Loss, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_AccountsReceivableAndContractWithCustomerAssetAllowanceForCreditLossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AccountsReceivableAndContractWithCustomerAssetBeforeAllowanceForCreditLossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable And Contract With Customer Asset, Before Allowance For Credit Loss, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_AccountsReceivableAndContractWithCustomerAssetBeforeAllowanceForCreditLossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=halo_DevicePartneredProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=halo_DevicePartneredProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=halo_CollaborativeAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=halo_CollaborativeAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=halo_ProductSalesOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=halo_ProductSalesOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704417976896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Certain Balance Sheet Items - Inventories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 29,112<span></span>
</td>
<td class="nump">$ 23,646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">43,611<span></span>
</td>
<td class="nump">34,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">95,818<span></span>
</td>
<td class="nump">69,930<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories, net</a></td>
<td class="nump">$ 168,541<span></span>
</td>
<td class="nump">$ 127,601<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704415668160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Certain Balance Sheet Items - Prepaid Expenses and Other Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid manufacturing expenses</a></td>
<td class="nump">$ 36,211<span></span>
</td>
<td class="nump">$ 36,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses</a></td>
<td class="nump">13,847<span></span>
</td>
<td class="nump">12,902<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="nump">12,951<span></span>
</td>
<td class="nump">16,677<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Total prepaid expenses and other assets</a></td>
<td class="nump">63,009<span></span>
</td>
<td class="nump">66,429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Less: Long-term portion</a></td>
<td class="num">(17,319)<span></span>
</td>
<td class="num">(17,816)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other assets, current</a></td>
<td class="nump">$ 45,690<span></span>
</td>
<td class="nump">$ 48,613<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704503744208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain Balance Sheet Items - Property and Equipment, net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 63,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(21,180)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,661)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Subtotal</a></td>
<td class="nump">41,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use of assets</a></td>
<td class="nump">36,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,836<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">78,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,944<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,443<span></span>
</td>
<td class="nump">$ 2,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Right-of-use asset amortization</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=halo_ResearchEquipmentMember', window );">Research equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">8,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,588<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=halo_ManufacturingEquipmentMember', window );">Manufacturing equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">36,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,472<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=halo_ComputerAndOfficeEquipmentMember', window );">Computer and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">10,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,722<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 7,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,987<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property, Plant, and Equipment and Operating Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=halo_ResearchEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=halo_ResearchEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=halo_ManufacturingEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=halo_ManufacturingEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=halo_ComputerAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=halo_ComputerAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704418894720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain Balance Sheet Items - Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent', window );">Accrued compensation and payroll taxes</a></td>
<td class="nump">$ 10,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_AccruedOutsourcedManufacturingExpenses', window );">Accrued outsourced manufacturing expenses</a></td>
<td class="nump">27,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,361<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income taxes payable</a></td>
<td class="nump">19,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerRefundLiability', window );">Product returns and sales allowance</a></td>
<td class="nump">39,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,932<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent', window );">Other accrued expenses</a></td>
<td class="nump">20,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,584<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="nump">31,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,197<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total accrued expenses</a></td>
<td class="nump">149,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_AccruedLiabilitiesNoncurrent', window );">Less long-term portion</a></td>
<td class="num">(31,201)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37,720)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses, current</a></td>
<td class="nump">118,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,678<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_OperatingLeaseAccretionOfLiability', window );">Expense associated with accretion of lease liabilities</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Total operating lease cost</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts related to leases</a></td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AccruedLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_AccruedLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AccruedOutsourcedManufacturingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Outsourced Manufacturing Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_AccruedOutsourcedManufacturingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_OperatingLeaseAccretionOfLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Accretion Of Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_OperatingLeaseAccretionOfLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerRefundLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerRefundLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704513292752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Goodwill Rollforward (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, Beginning Balance</a></td>
<td class="nump">$ 416,821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Measurement period adjustment</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, Ending Balance</a></td>
<td class="nump">$ 416,821<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 16<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479405/805-10-25-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704419574576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Additional (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average useful life (in years)</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average useful life (in years)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704418604576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="nump">$ 538,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">131,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Value</a></td>
<td class="nump">406,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">ATRS-1902 (IPR&amp;D)</a></td>
<td class="nump">48,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total intangibles, net</a></td>
<td class="nump">$ 455,116<span></span>
</td>
<td class="nump">$ 472,879<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=halo_AutoInjectorTechnologyPlatformMember', window );">Auto Injector technology platform</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted Average Useful Life (in years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="nump">$ 402,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">106,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Value</a></td>
<td class="nump">$ 295,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=halo_XYOSTEDProprietaryProductMember', window );">XYOSTED proprietary product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted Average Useful Life (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="nump">$ 136,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">25,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Value</a></td>
<td class="nump">$ 110,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=halo_AutoInjectorTechnologyPlatformMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=halo_AutoInjectorTechnologyPlatformMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=halo_XYOSTEDProprietaryProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=halo_XYOSTEDProprietaryProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704420168416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Future Amortization (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Remainder of 2024</a></td>
<td class="nump">$ 53,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2025</a></td>
<td class="nump">71,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2026</a></td>
<td class="nump">71,049<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2027</a></td>
<td class="nump">71,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2028</a></td>
<td class="nump">71,049<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour', window );">Thereafter</a></td>
<td class="nump">68,934<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 406,416<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Amortization, After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704407744544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt, Net - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>USD ($) </div>
<div>trading_day </div>
<div>businessDay </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>trading_day </div>
<div>businessDay </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 15, 2022 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,525,000,000<span></span>
</td>
<td class="nump">$ 1,525,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of debt, principal</a></td>
<td class="nump">$ 13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Stock issued for conversion of debt instrument (shares) | shares</a></td>
<td class="nump">288,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A100ConvertibleSeniorNotesDue2028Member', window );">1.00% Convertible Senior Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">720,000,000<span></span>
</td>
<td class="nump">720,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_DebtInstrumentCapCallTransactionCapPricePerShare', window );">Cap call transaction, cap price per share (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.4075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_SaleOfStockPremiumOverLastReportedSalePricePercentage', window );">Sale of stock premium over last reported sale price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43.09<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_PaymentForCappedCallTransactions', window );">Payment for capped calls</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A100ConvertibleSeniorNotesDue2028Member', window );">1.00% Convertible Senior Notes due 2028 | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 720,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Lenders fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of 2028 Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">702,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of debt issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt, convertible, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.8517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt, convertible, conversion price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A100ConvertibleSeniorNotesDue2028Member', window );">1.00% Convertible Senior Notes due 2028 | Convertible Debt | Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Convertible, threshold percentage of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Convertible, threshold trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Convertible, threshold consecutive trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A100ConvertibleSeniorNotesDue2028Member', window );">1.00% Convertible Senior Notes due 2028 | Convertible Debt | Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Convertible, threshold percentage of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Convertible, threshold consecutive trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays', window );">Convertible, threshold consecutive business days | businessDay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A025ConvertibleSeniorNotesDue2027Member', window );">0.25% Convertible Senior Notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">805,000,000<span></span>
</td>
<td class="nump">$ 805,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of 2028 Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 784,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A025ConvertibleSeniorNotesDue2027Member', window );">0.25% Convertible Senior Notes due 2027 | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 805,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Lenders fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of debt issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt, convertible, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.9576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt, convertible, conversion price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A025ConvertibleSeniorNotesDue2027Member', window );">0.25% Convertible Senior Notes due 2027 | Convertible Debt | Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Convertible, threshold percentage of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Convertible, threshold trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Convertible, threshold consecutive trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A025ConvertibleSeniorNotesDue2027Member', window );">0.25% Convertible Senior Notes due 2027 | Convertible Debt | Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Convertible, threshold percentage of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Convertible, threshold consecutive trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays', window );">Convertible, threshold consecutive business days | businessDay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A1.25ConvertibleSeniorNotesdue2024Member', window );">2024 Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of 2028 Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 447,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A1.25ConvertibleSeniorNotesdue2024Member', window );">2024 Convertible Notes | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 460,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Lenders fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of debt issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt, convertible, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.9208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt, convertible, conversion price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember', window );">Credit Agreement | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 575,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember', window );">Credit Agreement | Minimum | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember', window );">Credit Agreement | Maximum | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember', window );">Credit Agreement | SOFR | Revolving Credit Facility | Variable Rate Component One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember', window );">Credit Agreement | SOFR | Minimum | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember', window );">Credit Agreement | SOFR | Minimum | Revolving Credit Facility | Variable Rate Component Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember', window );">Credit Agreement | SOFR | Maximum | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember', window );">Credit Agreement | SOFR | Maximum | Revolving Credit Facility | Variable Rate Component Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember', window );">Credit Agreement | Fed Funds Rate | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember', window );">Credit Agreement | Base Rate | Minimum | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember', window );">Credit Agreement | Base Rate | Maximum | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember', window );">Credit Agreement | Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember', window );">Credit Agreement | Term Loan Facility | Year one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember', window );">Credit Agreement | Term Loan Facility | Year two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember', window );">Credit Agreement | Term Loan Facility | Year three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember', window );">Credit Agreement | Term Loan Facility | Year four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_DebtInstrumentCapCallTransactionCapPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Cap Call Transaction, Cap Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_DebtInstrumentCapCallTransactionCapPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Threshold Consecutive Business Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_PaymentForCappedCallTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment for Capped Call Transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_PaymentForCappedCallTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_SaleOfStockPremiumOverLastReportedSalePricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock Premium Over Last Reported Sale Price, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_SaleOfStockPremiumOverLastReportedSalePricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=halo_A100ConvertibleSeniorNotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=halo_A100ConvertibleSeniorNotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=halo_A025ConvertibleSeniorNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=halo_A025ConvertibleSeniorNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=halo_A1.25ConvertibleSeniorNotesdue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=halo_A1.25ConvertibleSeniorNotesdue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_VariableRateComponentAxis=halo_VariableRateComponentOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_VariableRateComponentAxis=halo_VariableRateComponentOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_VariableRateComponentAxis=halo_VariableRateComponentTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_VariableRateComponentAxis=halo_VariableRateComponentTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=halo_TermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=halo_TermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AnnualInterestPaymentPeriodAxis=halo_DebtInstrumentInterestPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_AnnualInterestPaymentPeriodAxis=halo_DebtInstrumentInterestPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AnnualInterestPaymentPeriodAxis=halo_DebtInstrumentInterestPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_AnnualInterestPaymentPeriodAxis=halo_DebtInstrumentInterestPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AnnualInterestPaymentPeriodAxis=halo_DebtInstrumentInterestPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_AnnualInterestPaymentPeriodAxis=halo_DebtInstrumentInterestPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AnnualInterestPaymentPeriodAxis=halo_DebtInstrumentInterestPeriodFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_AnnualInterestPaymentPeriodAxis=halo_DebtInstrumentInterestPeriodFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704420358336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Debt, Net - Carrying Amount of Convertible Notes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Total principal amount</a></td>
<td class="nump">$ 1,525,000<span></span>
</td>
<td class="nump">$ 1,525,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Total unamortized debt discount</a></td>
<td class="num">(24,121)<span></span>
</td>
<td class="num">(25,752)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, excluding current maturities</a></td>
<td class="nump">1,500,879<span></span>
</td>
<td class="nump">1,499,248<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total carrying amount</a></td>
<td class="nump">1,500,879<span></span>
</td>
<td class="nump">1,499,248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Total fair value of outstanding notes</a></td>
<td class="nump">1,416,647<span></span>
</td>
<td class="nump">1,366,348<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A025ConvertibleSeniorNotesDue2027Member', window );">2027 Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Total principal amount</a></td>
<td class="nump">805,000<span></span>
</td>
<td class="nump">805,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Total unamortized debt discount</a></td>
<td class="num">(10,094)<span></span>
</td>
<td class="num">(10,950)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, excluding current maturities</a></td>
<td class="nump">794,906<span></span>
</td>
<td class="nump">794,050<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Total fair value of outstanding notes</a></td>
<td class="nump">$ 714,244<span></span>
</td>
<td class="nump">$ 695,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1', window );">Remaining amortization per period of debt discount (in years):</a></td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A100ConvertibleSeniorNotesDue2028Member', window );">2028 Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Total principal amount</a></td>
<td class="nump">$ 720,000<span></span>
</td>
<td class="nump">$ 720,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Total unamortized debt discount</a></td>
<td class="num">(14,027)<span></span>
</td>
<td class="num">(14,802)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, excluding current maturities</a></td>
<td class="nump">705,973<span></span>
</td>
<td class="nump">705,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Total fair value of outstanding notes</a></td>
<td class="nump">$ 702,403<span></span>
</td>
<td class="nump">$ 670,522<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1', window );">Remaining amortization per period of debt discount (in years):</a></td>
<td class="text">4 years 4 months 24 days<span></span>
</td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=halo_A025ConvertibleSeniorNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=halo_A025ConvertibleSeniorNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=halo_A100ConvertibleSeniorNotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=halo_A100ConvertibleSeniorNotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704418719840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt, Net - Components of Interest Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Total amortization of debt discount</a></td>
<td class="nump">$ 1,830<span></span>
</td>
<td class="nump">$ 1,835<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentInterest', window );">Total coupon interest</a></td>
<td class="nump">2,303<span></span>
</td>
<td class="nump">2,339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Total amortization of debt discount</a></td>
<td class="nump">1,631<span></span>
</td>
<td class="nump">1,638<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest expense</a></td>
<td class="nump">3,934<span></span>
</td>
<td class="nump">3,977<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A1.25ConvertibleSeniorNotesdue2024Member', window );">2024 Convertible Notes | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentInterest', window );">Total coupon interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Total amortization of debt discount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A025ConvertibleSeniorNotesDue2027Member', window );">2027 Convertible Notes | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentInterest', window );">Total coupon interest</a></td>
<td class="nump">503<span></span>
</td>
<td class="nump">503<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Total amortization of debt discount</a></td>
<td class="nump">856<span></span>
</td>
<td class="nump">850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest expense</a></td>
<td class="nump">$ 1,359<span></span>
</td>
<td class="nump">$ 1,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rates</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A100ConvertibleSeniorNotesDue2028Member', window );">2028 Convertible Notes | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentInterest', window );">Total coupon interest</a></td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Total amortization of debt discount</a></td>
<td class="nump">775<span></span>
</td>
<td class="nump">764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest expense</a></td>
<td class="nump">$ 2,575<span></span>
</td>
<td class="nump">$ 2,564<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rates</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=halo_A1.25ConvertibleSeniorNotesdue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=halo_A1.25ConvertibleSeniorNotesdue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=halo_A025ConvertibleSeniorNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=halo_A025ConvertibleSeniorNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=halo_A100ConvertibleSeniorNotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=halo_A100ConvertibleSeniorNotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704422103360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation - Share-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 9,874<span></span>
</td>
<td class="nump">$ 7,966<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">4,299<span></span>
</td>
<td class="nump">3,455<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=halo_RSURSAandPRSUawardsMember', window );">RSUs, PSUs and ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">5,575<span></span>
</td>
<td class="nump">4,511<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">3,345<span></span>
</td>
<td class="nump">3,101<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 6,529<span></span>
</td>
<td class="nump">$ 4,865<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=halo_RSURSAandPRSUawardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=halo_RSURSAandPRSUawardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704419417024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=halo_A2021ESPPPlanMember', window );">2021 ESPP Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,604,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP | 2021 ESPP Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">ESPP purchase price of common stock, percent of market price</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate', window );">Minimum employee subscription rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum employee subscription rate</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount', window );">Maximum contribution amount</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod', window );">Purchase period (in months)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Minimum Employee Subscription Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=halo_A2021ESPPPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=halo_A2021ESPPPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704511340832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation - Assumptions Used in the Black-Scholes Model (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems', window );"><strong>Schedule of Share-based Compensation Arrangements Valuation Inputs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Average expected term (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">3.80%<span></span>
</td>
<td class="nump">3.48%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.28%<span></span>
</td>
<td class="nump">4.27%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems', window );"><strong>Schedule of Share-based Compensation Arrangements Valuation Inputs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">40.02%<span></span>
</td>
<td class="nump">39.68%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems', window );"><strong>Schedule of Share-based Compensation Arrangements Valuation Inputs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">40.08%<span></span>
</td>
<td class="nump">39.98%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Schedule of Share-based Compensation Arrangements Valuation Inputs [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704507581984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation - Unrecognized Estimated Compensation Cost (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized Expense</a></td>
<td class="nump">$ 42,038<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Remaining Weighted-Average Recognition Period (in years)</a></td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized Expense</a></td>
<td class="nump">$ 56,513<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Remaining Weighted-Average Recognition Period (in years)</a></td>
<td class="text">3 years 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized Expense</a></td>
<td class="nump">$ 11,543<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Remaining Weighted-Average Recognition Period (in years)</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized Expense</a></td>
<td class="nump">$ 118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Remaining Weighted-Average Recognition Period (in years)</a></td>
<td class="text">2 months 15 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704407688560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">28 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Feb. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit) (textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments for tax withholding for restricted stock units vested, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 489<span></span>
</td>
<td class="nump">$ 1,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Capital return program, authorized amount (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramPeriodInForce1', window );">Capital return program, purchase period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Stock repurchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
<td class="nump">12,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Stock repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Weighted-average price paid per share (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44.44<span></span>
</td>
<td class="nump">$ 38.51<span></span>
</td>
<td class="nump">$ 39.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=halo_AcceleratedShareRepurchaseAgreementMember', window );">ASR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit) (textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Stock repurchased (in shares)</a></td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Stock repurchased</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt', window );">ASR, payment to bank</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=halo_A2024CapitalReturnProgramMember', window );">2024 Capital Return Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit) (textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Capital return program, authorized amount (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit) (textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares of common stock issued as a result of stock option exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,556<span></span>
</td>
<td class="nump">143,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Stock options weighted average exercise price (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.47<span></span>
</td>
<td class="nump">$ 16.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Net proceeds from stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=halo_RestrictedStockUnitsAndPerformanceSharesMember', window );">RSUs and PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit) (textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Stock issued during period, shares, restricted stock award, net of forfeitures (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">262,195<span></span>
</td>
<td class="nump">239,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Unit holders awards surrendered to pay for minimum withholding taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,825<span></span>
</td>
<td class="nump">70,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments for tax withholding for restricted stock units vested, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=halo_StockOptionsAndRestrictedStockUnitsMember', window );">Stock options and restricted units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit) (textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding stock options and restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,800,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash receipt from (payment to) bank; or stock received from (issuance to) bank in the settlement of the accelerated share repurchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481138/505-30-25-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramPeriodInForce1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period which shares may be purchased under a stock repurchase plan authorized by an entity's Board of Directors, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramPeriodInForce1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=halo_AcceleratedShareRepurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=halo_AcceleratedShareRepurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=halo_A2024CapitalReturnProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=halo_A2024CapitalReturnProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=halo_RestrictedStockUnitsAndPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=halo_RestrictedStockUnitsAndPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=halo_StockOptionsAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=halo_StockOptionsAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704418114784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share - Computation (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Numerator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 76,823<span></span>
</td>
<td class="nump">$ 39,615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding for basic earnings per share (shares)</a></td>
<td class="nump">126,941<span></span>
</td>
<td class="nump">135,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Dilutive potential common stock outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding for diluted earnings per share (shares)</a></td>
<td class="nump">128,887<span></span>
</td>
<td class="nump">137,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (USD per share)</a></td>
<td class="nump">$ 0.61<span></span>
</td>
<td class="nump">$ 0.29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (USD per share)</a></td>
<td class="nump">$ 0.60<span></span>
</td>
<td class="nump">$ 0.29<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Dilutive potential common stock outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive potential common stock outstanding (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">232<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Dilutive potential common stock outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive potential common stock outstanding (shares)</a></td>
<td class="nump">1,607<span></span>
</td>
<td class="nump">2,173<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=halo_RestrictStockUnitsPerformanceSharesAndESPPMember', window );">RSUs, PSUs and ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Dilutive potential common stock outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive potential common stock outstanding (shares)</a></td>
<td class="nump">339<span></span>
</td>
<td class="nump">468<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480454/718-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=halo_RestrictStockUnitsPerformanceSharesAndESPPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=halo_RestrictStockUnitsPerformanceSharesAndESPPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139704417507504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share - Antidilutive Securities (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from per share calculation (in shares)</a></td>
<td class="nump">28.2<span></span>
</td>
<td class="nump">26.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>76
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M"  W@:=87VLUBM4%  #-'@  &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;+69:W/B-A2&_XJ&=CKM3 B6# EL$V:(0S9,DRP;LNWL=OI!V (\:UM4EB'Y
M]STR8">I?& \RY?$M_.B1T>75]+%6JKOZ4((39[C*$DO&PNMEQ]:K=1?B)BG
MIW(I$G@SDRKF&F[5O)4NE>!!'A1'+>8X9ZV8ATFC?Y$_&ZO^A<QT%"9BK$B:
MQ3%7+U<BDNO+!FWL'CR&\X4V#UK]BR6?BXG07Y9C!7>M0B4(8Y&DH4R($K/+
MQH!^\%QF O(O_@S%.GUU30S*5,KOYF847#8<4R(1"5\;"0[_5L(34624H!S_
M;D4;Q6^:P-?7._6;'!Y@ICP5GHS^"@.]N&QT&R00,YY%^E&N;\46J&/T?!FE
M^5^RWGS;;C>(GZ5:QMM@*$$<)IO__'E;$:\"7%H1P+8![%T K?H%=QO@YJ";
MDN58UUSS_H62:Z+,UZ!F+O*ZR:.!)DQ,&B=:P=L0XG3?DRNAR!@R1IHD77 E
MTHN6!F'SNN5O1:XV(JQ"Q"7W,M&+E R30 1OXUM0H*)4;%>J*X8*WG-U2EQZ
M0IC#VI;R>'CX8&G"'5OXF^*X126YN9Z+5M+?@VFJ%;2[?VPUM%%HVQ5,9_R0
M+KDO+AO0VU*A5J+1_^4G>N;\;L/[06)O8-L%;!M3[U]+/X-^JLG3RU+82/%P
MZC0_VY#0J)I(G0*I<QC2YXPK+53T0A[%4BIMP\.EM,ILE>*A437QS@J\L\/P
MQD*%,C"]D,!@8$T>KE3TN\J.A\;7Y#PO.,\/;)F*PSR23P/5><2U9CQ*K8E$
MPVH"=@O +EJH8:)#_4)NPDB0ARR>"F4#PS4<AS9=YKH=&QP:6A.N5\#U#H%[
M%//0#*.0Q@<>6]LHKG,[N/OT[>O]D#S=#A\'X^&7IY$W.2&C!^_4AHR*U42F
M3CF[.H= CQ)?*FBHW+39$S+1T#N)5,236:+5"_P/K#6Q1_UZ:"/&@^HBOS(4
M]!#D)_Y,1@'TUG 6^CDWTJ3W2':[3:?=[9YUSZR\:'!=7E;RLD-X!T$ ZNG)
M[H+<P7?D4V+/*RY)F=MSR# B'@?+)Z'/\,A*CLK4)2]=$45]R/_(/7,'K?I)
MKA,K-2XWX0FY#L5<6E&/88EHZ8DH[FK>HQ8]>*SD*DQ\>Y9Q36]@!3V&4:*E
M4Z*XOWD/.I:IYA'Y%BZK!RE<L<>HZUA)C^&9:&F:*.YU\M8Z@*5O-1@NT.UT
MK5C'L$BT]$@4-S9WTH=\C1<RP3S$'I'S7KO9[79[5KYC."1:6B2*^YNG4(,[
MDC-"V:_3W\A$^)F"3%HA<25/QC',2A,M_>\GY&?G%*P367)%5CRRFWQ<L"YZ
M:: H[GS ]@9A,B>3EW@J;1/"U1X!8YVL7,<P2:PT20RW,;L<DN&SO^#)7%0Z
MPSU"#X/)]<"Z^L0#ZQ*6GH@=Y(F\3"FS?MDL6O)4PCR267=<]BA^M>[3>'A4
M7<[2"[&#O- H@47V9H/.+$3Y#MS*B2M6<1[#^;#2^;"#G,\DYE%$KK(47J?V
M+.(ZE:M0/*XN7VEWV$%V9Q@+-3?-]",HZ 5,E/&2)]:Q=H]@->@Q[ XK[0X[
MR.Y,%@(2B>'A,M5XQ_ XK/0X#+<HNW'GS4PWR7=YR:=,@[5+S(QB)?Y!-F9;
M#QNU3JYFCA96L,@Y9^=MQP%ON+)!EHZ'X69E!PD#C +K,TH"\4S^$/8\XE)0
M&DH[/<>U+C3QX+K)+)T/P_W*(!9)D.]_W43<GC-<H+J5'L/7L-+7,-R6%/MZ
M-V%JS.M7 2;L!A[:AU1<K/+$X!@>QRT]CKMGJ^8=XW:KMI)RC]QG:CTV.(;+
M<4N7X^*>9&=O7J<1VXO>(]=L4M9T[:#'L#EN:7/<@VR.V:=5Q .ZN536X6:/
MSAU78'8'OB] "&2"C:25^(<:GM:K T,SQ^?GJ"GQS7;DYNRP>%J<U0[R$\I6
M^?GFH/>>&XN0DDC,(-0Y/8<Q7FW.3C<W6B[SX\>IU%K&^>5"\$ H\P&\GTFI
M=S?F!XH3[/Y_4$L#!!0    ( #>!IUA 8!ZH*P8   $9   8    >&PO=V]R
M:W-H965T<R]S:&5E=#(N>&ULK5EM3]PX$/XKUK:J6@E8VWDOL%(+NKM*]X)*
M>_?9)(:-2.*M[2QPO_[&V9!L$L=;>OT">9F9/#,>SS/C/7L0\EZM.=?HL2PJ
M=;Y8:[UYOURJ=,U+ID[$AE?PYE;(DFFXE7=+M9&<98U262PIQN&R9'FU6)TU
MSZ[DZDS4NL@K?B61JLN2R:>/O! /YPNR>'[P.;];:_-@N3K;L#M^S?77S96$
MNV5G)<M+7JE<5$CRV_/%!_+^PL-&H9'X.^</:N\:&5=NA+@W-Y^R\P4VB'C!
M4VU,,/BWY1>\*(PEP/&M-;KHOFD4]Z^?K?_2. _.W##%+T3Q3Y[I]?DB7J",
MW[*ZT)_%PV^\=2@P]E)1J.8O>FAE\0*EM=*B;)4!09E7N__LL0W$G@+Q9Q1H
MJT"_5\%K%;S&T1VRQJU+IMGJ3(H')(TT6#,736P:;? FK\PR7FL);W/0TZL+
M466P*#Q#<*5$D6=,P\U'5K JY>C:&%;H[=>*U5D.;]ZA8_3U^A*]??T.O49Y
MA;ZL1:U8E:FSI08\QNHR;;_]<?=M.O/M/Y@\01XY0A13WZ)^X5:_Y&FG[@W5
MEQ"%+A2T"P5M['ESH:BEY)5&3"GPV>;.3M^WZYL-]UYM6,K/%["C%)=;OEB]
M>45"?&IS[B<9&[CJ=:YZ+NNK"Z;6"!8-I>:"?ZOS+2O =ZO7.U-A8\I4A>V*
MA'Y(H[/E=M\?BQB)O0AW8@.D?H?4=R*%'+GGFMT4'"F>UC+7.5='B&U97IBG
MQU#)CA6 MR'?F0[V(-$DCDVN#9!;Q$@4>C/(@PYYX$3^(4U%#2&%8I=RB"^
M/4(5%.8F[J+2$DJ8(]F""2J2! FF(_!3,>KYE,R #SOPH1/\IVH+Z2!D$VP
M;0,83@&&<>"3$4"+&(U"3.P HPY@Y 1X)?F&Y1GBCQM3OE035:'77$+5/+2/
MHPDD/P@3/ )ND8I#XMEQQQWNV(G[B]"L^ Z(\>3C<>0%\3AUIV*1'_I[&3X
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M-$_T@]A\ALI0W_"%(E'%/]F4L?[((F&NM$@K,"I(&2^O]+E*Q!; [>T!>!7
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MR7GUC=;X%=&*_.;/B!.A=?NA74Q0^V+"^KETTJ7"5&C=0-NE K4O%7Z=D35
M]V-HX/0STF06./U5W?SDX"#C^:8\3U&09WNAJV_KS=WFS.:Z/*GHW;_!EZOJ
MY*6%J0Z"OK!\DPB%4OX$D,Y% ),DK\Y6JH:6N_)XXE%J+;/R<LL9I'MA ,^?
MI-3'1O&"YH1K^3]02P,$%     @ -X&G6)+MSJ5' P  2 H  !@   !X;"]W
M;W)K<VAE971S+W-H965T-2YX;6RM5FUOTS 0_BM60&B3QO+6U]%&V@J(?1A,
M*X,/B ]N<FW,$KO83KOQZSD[:6B;M)K$OB1^N7O\W)U]=Z.UD \J!=#D,<^X
M&CNIULL+UU5Q"CE5YV()''?F0N94XU0N7+640!.KE&=NX'D]-Z>,.]'(KMW*
M:"0*G3$.MY*H(L^I?+J"3*S'CN]L%N[8(M5FP8U&2[J *>C[Y:W$F5NC)"P'
MKIC@1,)\[%SZ%Q/?,PI6XAN#M=H:$V/*3(@',[E.QHYG&$$&L380%'\KF$"6
M&23D\;L"=>HSC>+V>(/^T1J/QLRH@HG(OK-$IV-GX) $YK3(])U8?X+*H*[!
MBT6F[)>L*UG/(7&AM,@K9620,U[^Z6/EB"T%Q&E7""J%8%^A<T AK!1":VC)
MS)KUGFH:C:18$VFD$<T,K&^L-EK#N GC5$O<9:BGHXG@"08%$H(C)3*64(V3
MJ<8?1DLK(N:XE>,=24WP5D"N>2QR("?WG!8)0^E3\I;<3]^3D]>GY#5AG'Q-
M1:$H3]3(U<C1G.3&%9^KDD]P@$](;@37J2(?D%>RJ^^B;;6!P<; J^ HX V5
MYR3TSTC@!9T6/I/GJX='Z(2UOT.+%Q[ JQU[T*\_+F=*2[S>/]N\5Z)WVM'-
MF[]02QK#V$%@!7(%3O3FE=_SWK69_D)@.X[HU([H'$.//F.*8M;B-C-+W9[5
M-9EH%?5[ Q. U3;_IE0X[/G=6FJ'6+<FUCT:H2\Z!4GBG= <)MI]R7B\$-B.
MV;W:[-[1>-QSK (9^X./_R032IV2!18!@ID6T_L#:#K+@"B("\DT@]:771[0
MW0K'V]#?CUE3:&C>95O$^C7U_E'JF,\Q6W-,EU("CY\(/A^N,EK6B>079E'S
MXMHH]QML!GM\FQ)!T$YW4-,=/-?3&Q<G(-F*ZO*JX>LO;.H](QQ:60^:K+>O
M?4F\*>2U\Q[6O(='>=_])^MA\WIT_7UW-X4.L/:]?Q7..\I[\LRG7,%LIY-!
MI^G7%K&.U^WY>S3=K9J<@US85D5A7BFX+JM7O5JW0Y>V"=A;OS)MDJWU_V#*
M'@MKTP(=3S*8(Z1WWD>WR;)M*2=:+&WEGPF-?80=IMCJ@30"N#\70F\FYH"Z
M>8S^ E!+ P04    "  W@:=81*4-CDX'  #G'@  &    'AL+W=O<FMS:&5E
M=',O<VAE970V+GAM;+5986_;.!+]*X1OL6B!NA9)699ZB8'4O>(6N/:"9GO[
MF9;HF%M)])*TD^ZOOR&E6+9$L<YM#@AB21Z.W\QPYLU05P]2?=-;S@UZK,I:
M7T^VQNS>S68ZW_**Z;=RQVOX9B-5Q0S<JON9WBG."K>H*F<DBI)9Q40]65ZY
M9[=J>27WIA0UOU5([ZN*J>_O>2D?KB=X\O3@B[C?&OM@MKS:L7M^Q\W7W:V"
MN]E12R$J7FLA:Z3XYGIR@]^M:&(7.(G_"/Z@3ZZ1-64MY3=[\TMQ/8DL(E[R
MW%@5##X.?,7+TFH"''^T2B?'W[0+3Z^?M']TQH,Q:Z;Y2I:_B<)LKR?I!!5\
MP_:E^2(?_LE;@^967RY+[?ZCAU8VFJ!\KXVLVL6 H!)U\\D>6T><+  ]_@6D
M74#Z"^*1!;1=0)VA#3)GU@=FV/)*R0>DK#1HLQ?.-VXU6"-J&\8[H^!; >O,
M<B7K H+""P176I:B8 9N[@Q\0+2,1G*#5DQOT4>(N$:OOM9L7PB0>8VFZ.O=
M!_3JI]?H)R1J].M6[C6K"WTU,X#,ZI_E+8KW#0HR@H*B3[(V6XW^ 6B*\_4S
ML.AH%GDRZST)*OS$U%M$\1M$(A)[\*PN7TX#<.C1R]3IHR/Z_KWCBAE1WS?;
M5AC!O5YJM,1^+3:CW^D=R_GU!%)6<W7@D^7/?\-)]'>?B2^D[,S@^&AP'-*^
M_ P%2-2YK+C/S&9MXM;:.G-8+I+4.OIPBG\H1;,$SX]29\#F1V#S8"1NBM\A
MJ9J=;204HES6N2@YJH^([7-[E]M=OU/R(&!/HO5W)"^,XOPEH_A"RLZ<E1R=
ME02C>+=EBD]ME2P0> :H0S-;?'U&-YKF)]'*TD7<"^E0:)$EB3^BBR/(11#D
M!PZ6YX(UK% 7B%52&?'G*-+%  2)X_[F\P@EA/B1ID>D:1#IS0DP6U9%;5A]
M+]:E?QNE PAXL4CZ0'U2*1W)DNR(-'L6TH*O#2J$SN6^-CZLV1!%2J,>5*_0
M"%(<=006/0LK[(9*["L$=]"8?..&@8.1YOE>N8Q]8Y/;2U'1 -^4T&3>L\(G
MEN'%B!DG/(R#9GSAK!1_0J+=0^\U"MZ+&P\!+?J@AS+1"&+2(29!Q/_B4!C0
MCGUOJBGT3ERI/GNW$,DPG4A_>WB$*!E#V3$O#O(<E(<&UK&XL\<1-]+A]B09
M[H,<2M'3.G>.LJ-+' =I:;6%2L"U;:-.6$9K#HZU-:T4;"W*\2T09./G4LY+
M:3OW1<?0.,AIRYO<E1EMR9F+@\T E[/.$=)LN0(RJHT"$FY=Y'7)W!,H&J7]
M>'K$$IQF(P'MF!.'J?.7^@!9(56PX SI<!I#P]DO\3ZY!9F/I49'G#C,G+>*
M[Y@H$'^TS,[UB8,#?ATR8[S(!D5R*)6F*1Y!W!$H_@&#/FT-J#JN,CJ^SW.U
MYYT97M0>FDR3= ![*#8E,4S$(\ [/L5A0OW\5_I)["%.DL5D4.2'<FF2)2/%
MB70,2Z)@<;)[65^ DP2)^KE5Z*6TG1O=\3$)\_'M7N5;9K,">HJ+N9AXN!A#
M(SQHV[R"49;AD<I#.EHF85J^53+GO-!HHV2%-"O;Q*Z8:8$_SZ(A*V.<)8/-
MYY%+,*9CFZ_C;Q+F[[,X0/9 SICOSB#^QU[L;._AA3WDZ2F=Q_V$]XD!ZL5(
M.T<Z0B<_'H!=PN^UZSW@[\(DBH>(4I*D_4;$)Y=$.!F944A'OR0\(7\4-8.1
M^,= 7W3,?2EMYT9W=$W"=/V%MWVLW67VS,@>AQU@J]GI#'V69L0'0V;N=[4>
MD2FD14I'XM2Q-PFS-T!N4\-BAMZV@J%!&YE_\R(=$O( Z5!DBN=1- JUHVT2
MINU?;<^-7*^A>.D.&-LS%FU/&* "&5.ZX\:FT6LR_:2*":WWL"D'EJ)]74"W
M8BL!% 7H\$&%.,!04K+:'S /P<<GW5[K"8\4CN)TQ ]=%T N[ *>BL+FTEP;
M,KL/MD<*)W&"1XHP[3H &IZQV^,\Y2:^5P5OKEY;$ZP];QJK;!@.P#=U.[1
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MO7N3JI$;KYO7;,>GQ[>U-^X=9>_Y>_QNU;QS[=0TKX _,0754D.(-J R>KL
MUZKFK6IS8^3.O9A<2V-DY2ZWG &A6P'X?B/!"^V-_8'CN^WE?P%02P,$%
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MT#/&]OS8>"G0T9XT0\_EX&8IZW.S-EMER WD0KW,"N\V2QNY,+))>TXL"UT
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MD\#NKBY;B&K^1/SBJ(_AZZDR:Y&A*H5,K,YFFH[W.$0]*JWZ9;@W5H)!&[V
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M^P>B!>V7L3]@R&+=C[0O_G%'6L<->( ^W_3DW^@OF  <R\M[]=]02P,$%
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M?02NZ!/)>:UW%QD7Y=?UI\;%F>U.(K.\C(CGJ>,<#(/YDFV^5+!?%HB'1KB
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M5X+C?.X_P/N%UF[[X!7L_D5Q_3]02P,$%     @ -X&G6 O$-T=(!   6 D
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M$5MG8*-[#).4G 5HH$40U!TH,^0I$-Y*G2XK&QK(0 \P\R@6)LK$&&6]/"\
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MXB[N7G/!4?2T /-KA4"V'Z2@_W?*S?\ 4$L#!!0    ( #>!IUA,@V0G:@4
M !X.   9    >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;*57VV[;.!#]%<(-
MNKN 5K8D7YO$@-.T:!]:! FZ?5CL RU-+"(2J9)4G.S7[PPIR;+CI%D4R(6W
MF3ESYB+R;*OTG<D!+'LH"VG.![FUU;OAT*0YE-R$J@*).[=*E]SB5&^&IM+
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M*L;!>0 Y+EDMZ$YM/F.K9^#X,B6,_\*F\1T, LAJ0ZILP3:#DLMF98]M'78
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ML5#ZFYD!6/:49X6Y[,RLG;\- I/,(!>FJ^90X)V)TKFP>*FG@9EK$*DSRK.
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MH)'$&^(C0>9Z/+-DAO#!(@4S[.0#H-<D@G(3.#/(OZ=U:%P<9FAF'47S=Q+
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M'+C]5(IC@8]FI!T4<_S=<3PL1OPHRVY17+'9[_YZ5+8P S0(/O[,D)_=4KB
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M!!_QB%I&ZV3WC*J^.0V1N(SP_LO3F/R)G4L$H0-P/W3,'>,[7:/H81;14U
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M&[N*N="L(R"Y*#$8Z*R/>T@+$D[&SC'Z=*_TBU&'SZ<#EVWQAAA$N+R/T,(
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MI8:IDXB2JVI)SHX5XE)=.9UE#"J=#?M8\6]]=.-=(^ "PWQ6@:,6), )@B
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M4KDEP0HXTRR*]4DR $WBI\R*EI$=#5O26?\0002PB=K$YM71A</P;XDC.>,
MIP,^;BWV%)HOE$E2 HCA($)_['C,[BO%AMD44'"AA6Y&*N*6 E^"!Y)O2IW?
M_-4>\]@>X7$TPH8U\ EZ.QQ>0?;1^N,.3O.)\%;_Z>#X2K$M-N$$[D<7H4@%
MX8A+)+/3<7(^0>PQ21=:&JC5;\K44VX0E"IUD,&G6&']$NLTINBSV;:*<Q&8
M"53O]3302SO- 0VP+E<<:' "FW.I:*I*VP2-*A,6N.LTEA#%GB\6HGN=(T"P
M.V&]C"(+26!@2C>U'>1FA&X+:H0NC)7>4'K(\]'>>=_+NNW&U@AQ23'*)@B'
MB#)*:U%9?.%VZ,DLR&\G.R=F._H4"&Z7)FN[-7@R#6P^]["SWR0*F6#1?$TX
MJB84XN+NS2;CX>?%R+YC,HTJ#:2V8&&Q3S&X9?QQI[P8>[5>LM=)LYU/BCIR
MR'T6?)5QJ:0@'8X')>W^[(1J$5[S:9'(B"KFVJL6MIB"-_W!1))Q-IPV+C6+
MO1)6+LMVOZCF!( H>N&C(H])@ZP9$6(7DX]DW9A\<$H9,31J<,(1)5DW#8M0
M@SQQJI''AKT)QW'#!-\[Z.JCI9ZT^B]CNS9G5*@<]N+0 K ,$+F?9#\5<%-Z
M3T&CW<<%XY(4+X8XQN#,N1"<B8(3\;=_1["-X4R=ML?AR A%L(]#E19V>BF(
M[5R'3P<NZ6FQ5FO;X)J="%JV]6Y4-,R+8 [#8V[^P-?'GHY[4_/A,:4YHZ@[
M.(%_I3A+*H:TSD+'9_SFEW>O_O[KV^S/?[KXXMG7..:;GGH9/K=. F7G^9T_
MYT6* ./Q/I**FHV13!VDSUY$3"1 P$^ JB@YRDYRH0/CZTXD!@S/%^<OFUDD
MJF-=MKNQ_CBV088J$HP0F3D))F@DO^*J4X.>&AQ;,)15BLY.[G.VJ-FHW_@?
MYCY*B96+L8E!^#CU$F*JA*^E6.BJM#0F0LKXSH*/BB85@Z%6R5YB5(5 G9*^
M>3))%)PNW)K>LBHSYQYIE?0,BW?@&M*(K_1(VS1&Q\WUY9O>A\AM*E"3E3LW
M0\=BGY1NBF:V)$LMQ(];3B80 ALH^,'V,$-UK(O-4>'E.K"(3]5., FQ4(C=
MLV,<+#28\YUX79K''O,O(G<YMCUAY!A2G<^=1<S(35,-5G82R>*$,X?"UF5_
MAHUVQG]6#I[7E^,&\W?-*[T8P-K'NE;^4F> YUEO'!GU?ERDFS^2UXE^'<>?
MCTQJLE_QQ@.7O)@:.G>YJ!' ?=3CQPO2M-('6VG,%2HJ?'\*(.%:*L.%^C5I
M[@#[=4DW&#+WSM.K->PG/KY2W-$YE 2N)[^UZA:Z#RMF3I+6?>IAK?7&.KQ0
MIS-H^;H-=&+D1^NPR^XH]\KSH^&YW6*7J)FB,&^@C@ BG'.=WHN1KI1B;[9<
MX2'L3AW."C"AI$H-Y/TB*PS2TRQ!)@>Z0(@#G]KX++[<K-<^/5(J9%I<5>K-
M,;);1@Z%G;A3%ZQ<Q@M6+N^X",4YD1ZA_DJR'+.7J_R38V;OCKFNEEM1&";L
M1FYDU*CM.%@BO:'T,7;GC3UTS$7TF-4F3QDJE@&8M$DK V3@H<>#%.>JHU%6
M-6E5N6^#U=B/F@[X*T/3*NP4* >/DV=Y?@^B^>H0E'1V,V)\PJ4C;V-K'_I[
M4:(\U>6HJ+SKYM'H18Q,3A'/0Z<M85KS+)16[\,88RN.4?@05L-<>GL^WN&J
MM:ZTCZ&,YS50>G^%W=^'ZF4&'TB94XDWTI6OE*82D Z#WB3X>FQ:Z:6PBG@%
M:X1T[WS%<6YWF8X+:*22H;7^9SPE_\B1&ALMG2#K2J/C(G!4VWH-N1Q]8HR9
MU(%/2J"G40(]/2DMKK%]W]ESTH4OP,^ M=/!GA4\GS:4 SJO_*\CI5,%PK=V
M-7K[.^PPV'[<*Y?^PMZ!IM/>7?_JTF_>;9I[^JU[FI.*..F.4Q^%ZYBB%5QZ
MAYCZ0X0-T-%>7;^UKC]SEZV0D2\-*.1R1 E(<@:-",9VB*=,>D-AG$D$JQW)
MFJ%EA-A]2LS6U+ "H:38]F#@,O0NN2DZ0I_9JTQ+6DY<@$E?L0C3_ %J[KP1
MD4)$V I#E^836/H5.+!'R&1?2I:NN.K$?Y9K4^?""XS!F#:2.#J  [D8BGG)
MM2I2Z0,J:B6U]Z>'HK3FL>&DA)/MDAZOF)A?_6@#I.G%'J]AY)B ^^OQ = ^
M1NGX?=.N@ZBBJ7#,8V:.5G?7SB@0C;O3GQ)8SZ+ >G;'C99$VU_R#T>LH_N_
M[N/,G#"GO_7TMQC0B"49'-.(#57I..&O%K&B(@[B[TQ,[FUOPRQ2BG$Z>EUK
M9^E;_/W,O1N3NW#9*J8L^>;HM]D<+I-VL3A7G$5WU,EAS M+CKC4$VN4DK$Z
MYU &/,C5V5IP<0C<_CH&0_S*"3/JXB#"GB *G$^'B#D5:C'83$Y/OK'+&&*A
MN^1BN5_?9+\74G]YY](6=L2<WG(=(SSD3R-*&PQV,WX/P4DS7YF]Y83C?A\X
MIH#5G,212,N(,</(\'3.JJ!>_G*5:#LVH6F_%8*1M(5)B[SG+V]NN,.'WGCV
M!L5\1*CHY5U)*RAL^$$4GZ&3EBK 5.D]T!;$OU45[\RDZ"!VO.3&X5ASBA&:
MWBYA!9\L7N]]QE,^PRF?V7W3W TE:?"+GS0C,Z[H-T>0_ 3+X##_X^(OYY=8
M9E3A$]9.)+9V5=;'AR^?_(<=@'X+5C.7<N/E3?BMG\B.?7JQ@ <OGPG:U$Z%
MB0.R3J;CJZ-+'8W7H:"L /7@8@B0SN'B/SCRJQ$$"5>26!F=B*.VM< #!<G.
M9EK"5"+-0)G ?M; HBW9*^XV8I'#+TV=*,M^__+U:^/9AWA<I,8<L;6/^#MP
MJ&'^'!^KLXO/+Q_N/'\?M:M.*:#/H@+Z[+29*_?<OXX7E,SJH8\>!1F/G486
M5G89+ 7<@G,H.WYY$J-$WG9^C_.,);1*VSDM9Y^VX6ZF-YKR=1J=,H-<!(HZ
M4*;#41N;3&Q%4!>SWCI>O7<JBSZ*#[B%H1$UK.)=1B=;'(HE7K8<>#(13I?W
MI?'Q>\:JR#H'BW'MMJ0(*Y(29^A7M\;-+]Z\_"EZ)SC/%_3B*W:Q8:9O$)3C
MWWCU)KY@=VEO_?9SY[5.KAJ)W8#9O!;*$33%O4=HBRZB8";<=/)T?!Y/Q^<G
M^?JJD%Z^.(VW4EYHOP0"OPMTZ>95[-O_MFWJ9I"&@O,VW;_YF]SAPV[RZ:7+
M(EF&2+)EBWM6N%N%2":M&$HEOJ.[B4 A"Q2.;0BM!9,)UBV%"Q4-K\>B&Y]#
M;74(O3[_57:MX(>7[N.O3/J_Q&VWE?[$*3?^L\E@LQQ?U]G/X'M1D@TTS-/%
MZ.^.//K9+GO>X-=-.%]=/X\.+Z][]K5?]]2?0-^[NO[57L-/GSWY8I&I"'QG
MQN;#7YI]N<HNOWSRZ*OL]0YW(!C$C1^CK=$W7Y;=JFK0*)53B3!]PXM@S_BZ
M9]V*( 8>+Y.+.\AWQ2!WN1-SEX9665;8T&I<\D2XI6XEJ<:8LHP6,P4<%KZ2
M44J\0KU%@Z=P8W-+2&?4JIS4G"?,7HJ;I'QD/RPK(%%0$(8 IRNZ_](-I.LP
MP6NUL]+JN#K$\EM1$"BLA"Z*>6%4E?,),&PK?@!.7;["*2HVE9L. X%,9&9P
M=&4V94T%^ P=>PEGARAW\1E9.T^SAR@;T>Y!HV&773PY^\]'BV23="R9TQI6
M#5] 1^+N\9_Q^'^[P!\^LT_\[5%VEKTB6N1ZB$JJG=SA19B%#U_&!TCJIK,"
MYNS;QAPJB;?*,<>DKAB^XE&F"%!C6"O:=<GEV0L7/;"E\&?@=1V7[HXXG%H[
MK=>_R@G\RR)+G&$Y?%\\FSM\\<GY0V=QK6B+*.\*ZVF1LIP"[R>[)<R=&Z6/
M=>7EA+#J/17'><]V>XW9"$FSP>\V,0^4&.]X,R>ZB[^#==$5I=S*^I%\^\SX
M]C/'MZ>9"G6/<0IX _]OL,Z<\G],B ;0,?EWWX!]N DO0E6A]07B_ML'%P_<
M;[%&#8R#BZ^N+A\\AC?CX]]]LP=3Y"?I3U>%-;SZY/P+L(XI0Z\_],T>A\3B
MV[[9T3\Q?11:? #^OFZ:7G_ #V!S*9K>=_\74$L#!!0    ( #>!IUC^STPH
M*@8  *\1   9    >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;+U8;6_;-A#^
M*X0W%#&@V'J7G28&G*3M!K1 T:3=AV$?:(FVN4JB2U)QO5^_.Y*2[<1VT@[8
M%XD\\8[W^ARIR[607]62,4V^5V6MKGI+K5<7PZ'*EZRB:B!6K(8O<R$KJF$J
M%T.UDHP6AJDJAZ'OI\.*\KHWN32TCW)R*1I=\II]E$0U547EYIJ58GW5"WHM
MX1-?+#42AI/+%5VP.Z8_KSY*F T[*06O6*VXJ(ED\ZO>-+BX3G&]6?"%L[7:
M&1.T9";$5YS\7ESU?%2(E2S7*('"ZX'=L+)$0:#&-R>SUVV)C+OC5OI;8SO8
M,J.*W8CR#U[HY55OU",%F].FU)_$^C?F[$E07BY*99YD;==F48_DC=*B<LR@
M0<5K^Z;?G1]V&$;^$8;0,81&;[N1T?*6:CJYE&)-)*X&:3@PIAIN4([7&)0[
M+>$K!SX]>4NY)%]HV3#R@5'52 8>U^3LGLY*IOJ70PV;X-)A[@1>6X'A$8$1
M^2!JO53D35VP8I]_",IU&H:MAM?A28$?J!R0*/!(Z(?Q"7E19W%DY$7/6WS+
M55X*-%J1/Z<SI24DR5^';+8BX\,BL7 NU(KF[*H'E:&8?&"]R:M?@M1_?4+A
MN%,X/B5]<@>%6#0E(V).Z /E)8;F'.KQ7%&@0BU]91II1+&\D5QSI@[9<'*7
MPS9,7[@=R064J=*L0"7UDI&Y**'>>;T@9[P&BF@4K0O5OR 0SWS9!91,*R$U
M_P<X;X32Y)T42I'/-0!,::CO %C44_)[F,.^;Y3F4)I V GK%#[I\QG-OP)]
M1\E?2>A%HQC>KWX9A4'X&D9G2=_2LS$H(%="@C0HZYG>Y8PC+PA&)"1G:=S'
MF9^DY//@;D"T-%6SV5T=1F,OBC,2I>0L\-.^(8191J8+5N<;,A/@"3+V@I'?
M:7(6AGTD)2-0HZJ8S#DMR8JNF"2Q-T[B;F7[MM1[H6'=P:!XA[(%;!V/O/$H
M@E$T0@<$XZSOR".(QRW+636#75V$HO\W0I&7!.%^A$9]2_?C$Q%*/3\,28 .
M[^,DB([')\@2;SQ.P3H?UH/?@RR%8,3[\0F %HRW 0H@D$CSHZ<1"A+P7?HD
M1([\$S$*,B_.$ASY ?H@3ON.G$8^.0$J20<JR8M!!8K7(%]CM-2MFP[#S2/'
M'P*:DSL?!II[@ S69<H<,^7!9 HH(1KYGU0D:R89H<IADGH.D9Y6P"THLN9Z
M"7RB9F3#J,1H1 G@P!A&4$(0%[N.SC6P=LMFC6Y9YW#\,$3(ULC+T@3X( \S
MEQ_'S#]L^HGBQBI^4:ZD7:ZD+V] 6+F*5/:L4!"J]]2%8Q8<U<#S$J$?CDO\
M8(:<WN]^KW^XDC&'1@ 6L'RV 4?\+60;XPW1FQ7S;*)0M23L6\-!(3C(* (Q
M?G'7_!&SK&!(K!QBMA#28%ZCC,:H_Y9[R9G$#-O\>.*]9P^L!%2S[]!ERD%(
M_8&E4QO#F\>N@H,;VSC/D'F#((@ !*TKW4/DCA2&7A#OH[4C'<7>R/=\?]OV
MW#3<(]K9Z;/'L0ZRE8$=W3Z[S4P/>:Z3=/W5=GGW:JFVM3S38-I^WRGCYFV?
MZ?K#H;YC#P'M$CMS?:?C.]*&]H\&^\<&UXO<ZY9)"#M>B @T;RV;RF3 #62X
M404*?H&IW((/@&;0W\KRDBQVS\<]KWW;_'-P88$I"["7)8$W3LWQ(_&]-+-8
ME7IQB$@:)G!RPH]A''A9%I+WG,YX:=WZ<TKO9F><C;KGECKV8CB)M6_DN89[
M7H%E+V;8H$S&N;H R;6BYDII^H]:"4WR5@7,*$ HR-@UE<4C.@'(VM9;N3F'
M3E'!/CO&#* JI=R@%;02#9K7'JAY36L3:^=3Q)]RQSN(12 =%FCQ"((&4"XH
M9Q]O/+.JV#KUB&  /B'A+M?V,>C:*\H+PKZOX'+.+(, 6=+9JYTD[_'2G94[
M>UE"*>J%<<C>WMAQ;?LO4$!A+AJBY(7!M!DMP2> X'C]=7T>NO$@@IMR6>*E
MW]\;)^WX4%,<[ERBH:P6YE<!WFP@"O8^W5&[OQ%3>PG?+K>_,L#/"SP3EVP.
MK/X@@Q.1M+\'[$2+E;F2SX2&"[X9+AF%4. "^#X70K<3W*#[1S/Y%U!+ P04
M    "  W@:=88^OER^8#  !H"0  &0   'AL+W=O<FMS:&5E=',O<VAE970R
M,RYX;6R-5MMNVS@0_96!NB@20(WNMI7:!G+9(OM0-$BRNP^+?:"EL46$$K4D
M9;=_OT-*5IW =?(B4>3,X3G#F:'F.ZF>=85HX'LM&KWP*F/:RR#0184UTQ>R
MQ896UE+5S-"GV@2Z5<A*YU2+( [#25 SWGC+N9N[5\NY[(S@#=XKT%U=,_7C
M&H7<+;S(VT\\\$UE[$2PG+=L@X]H_FSO%7T%(TK):VPTEPTH7"^\J^CR.K/V
MSN OCCM], :K9"7EL_WXHUQXH26$ @MC$1B]MGB#0E@@HO'?@.F-6UK'P_$>
M_8O33EI63..-%'_STE0+;^9!B6O6"?,@=W<XZ'$$"RFT>\)NL T]*#IM9#TX
M$X.:-_V;?1_B\!Z'>'"('>]^(\?REAFVG"NY V6M"<T.G%3G3>1X8P_ET2A:
MY>1GE@^XQ:9#.'MB*X'Z?!X80K5K03$@7/<(\2\0$O@J&U-I^+TIL7SI'Q";
MD5*\IW0=GP3\RM0%))$/<1BG)_"246+B\)(W)*Z5K.&&N"I*!0JSJ>#&!1@5
M_'.UTF[^WV,!Z/'3X_BV;"YURPI<>%07&M46O>7'#]$D_'R"?3JR3T^A+Q^I
M#,M.(,@UE%RSS4;AAKF,IAG5:]/'6)_$/<[Z6Z<.-\%RW !VJ!"8AK445,@:
MSG@#II*=9DVISR_AJ5*(+U(!Z""+:CQ)^TC@0?Y@PG "_ VB./2S/*%1GON3
M-(1[)<N.SD8S2D4?&NI)--4JCH8:!K2'RY!D?IP1ZM3/)Q%<=^(9U%UW?Q>'
M@T%$Z%$$<>R'DQQN<<L+A)8ITY"4\A5:%/NS:&9]II,4GJ1AXJ5%3R>;^=DL
M@0F9Y2D\[(/3D5X%5(N"K:1BMM$ HQ@BM2]#X2 S\\DVCY(ZQI8Z86L7@$)'
M =YT@AE)^FI.^QC9$*!=D:8BT#5:=JD?AB%\_#"+H_CS7HN@!W7'9N/,#X&'
M4X/8GX8)1/3,!TWJG92CR:]=Z>3RS)]-<SN:Q'Z4)G BT[,QT[-W9SHK"ME9
M'@H+Y%O;FWS;;%&IPZ1T)5T,):W[FBZ&FJ83LV%A=0_TAE[>%**S26O36K%&
ML_[6H.0K\%AUG=1RO+JNCHGJ3WFO@2I,H]'#@;Z6>S::"<Y67'!;2.=O1:&7
M9M-D2'Z:(VO-M2UP"C8Q&,K:&KTN[%=5?$O<ZQ51'F82."K+%@MEQRSSD\A6
M>)PDKER_'95K2W660YY-"/^UZI2:1$;/,)T=3;/@X/8CQ1MWQVMPI/J+<)P=
M?R.N^MOSIWG_#T):-[S1('!-KN'%E$Y9]?=Z_V%DZ^[2E3047C>LZ%<(E36@
M];649O]A-QA_KI;_ U!+ P04    "  W@:=8>WC25L8%  "R#P  &0   'AL
M+W=O<FMS:&5E=',O<VAE970R-"YX;6RM5VUOVS80_BL'+Q@20*U%O5!2E@1(
MTA4+T*)!TJT?AGV@)=H6*HD>2>5EOWX/*4=YJ>VV0+Y8),U[[GCWW/%X=*OT
M5[.4TM)=VW3F>+*T=G4XG9IR*5MAWJJ5[/#/7.E66$SU8FI66HK*"[7-- I#
M/FU%W4U.COS:I3XY4KUMZDY>:C)]VPI]?R8;=7L\89.'A:MZL;1N87IRM!(+
M>2WMGZM+C=ET1*GJ5G:F5AUI.3^>G++#L]SM]QO^JN6M>3(F=Y*94E_=Y*(Z
MGH3.(-G(TCH$@<^-/)=-XX!@QK]KS,FHT@D^'3^@O_=GQUEFPLASU7RI*[L\
MGN03JN1<](V]4K=_R/5Y4H=7JL;X7[H=]B9\0F5OK&K7PK"@K;OA*^[6?G@B
MD(=;!**U0.3M'A1Y*]\)*TZ.M+HE[78#S0W\4;TTC*L[%Y1KJ_%O#3E[<BZU
M1>CH3#2B*R5=>R9<6-D:VO\L9HTT!T=3"TUN_[1<HYX-J-$6U)@^JLXN#?W>
M5;)Z+C^%A:.9T8.99]%.P(]"OZ68!12%4;(#+QZ/'7N\> O>\^->R4986=&[
MVI2-,KV6AOX^G1FK09I_-AU_0$\VH[M$.C0K4<KC"3+%2'TC)R>__L)X^-L.
MVY/1]F07^LDU$K/J&TEJ#E*7JN^L07Z4LKYQ\=ID[D[ S>:>?HL<4 =GB:ZB
M$M%UOB%AC,0>S$UMG MADUU*FJL&Z5YW"]H'N>Q2]09RYN"0$,ERZ4/Y#L#M
M3&H_V:".YEJUM-*JZJ')"%"1K**5T+:3VM >15D0)BD&:1ZD>;X=1,L;V?60
M[\%'#7.;1LR4%JXBD%AH*5%G(!<%8983XP'+XQUHZEXT]AZ6W ]BC*5!PF)\
M\X!EX79)!=_H%T=*>%#DG!*<A8=T_L*S+,3)"BI23I^5%<VFB&\,"1(E8(Q1
ME(1!D69TZ@+B.8]*3A6BI>M9[ROC7,(,AX'5-?@^#Z*P.'#?+,D.MNO>SHD]
M8D4:%&'D A4G0<1"VL'^=&1_^L/LKSN$U2I=2[.)]3N!-K/^XA$Q> 567XE;
M%&LK=2T:3]@",1D<$O"$TQ?<6&_J[@T844H#+F 9,8.WPBBE]W57H[)7M%"J
M,N! D+.<>!$4<;B.2/W47A<)>)TC&1+F1L@/'K)=7N>CU_D/>QW>6HFZ(GF'
MSL"LJ3,P>PC]IECLA-\<B\OOZ7F% #WH:$77ST'>7COA4>,>Q4@$QH9!GH;T
M:9W!+TQC<9 G&3SN"?_IJ9%N+66NJ/ L6X?MNRXD'@=A6!#G01(5] 'D.*0/
MJEN\ 9E0%)7VF;O/LB!F+D\QR!D_^%%\D+O7&M3!R9(TX$7H!CG8%^^B2S;2
M)?L)NJ"#U"B7S@;Y;U^O7-'T;-U$E)W VXBR5<-KY##4^']&9+@J7[MLN'<^
M/F?/N ^<B7E"<10D6832WJYZZT+@@C&?UZC%CWM1Z'- %4$618@W&LVE:BJJ
M6_CO9GT]90&+$G+W14;7_<SZ6#NF<$YI%F2\<%=/W_9#.U-)^*BLQ=#^0JEH
M'6_^&Q;V(X9K+G3<*0+.V<$C9,)@"Z<8MUF8DV_4G?MZ,_0< T-C=TNF/B]B
M3KMBL$=9CHO595&6!$62[*)8/E(L_YDN2/?RD>Z;>+43;6L+] SV==H<#UF"
M"\!\# UZ"0TPLN+.UQW0(4G<3>$RG+-1$.\JHWI=RJTU"T4_0;> LN/D+CJH
MDFM8*/'] @(>9@D5/'9Q\[V(EL#IAD(Q]"5B;!ABW#BX4,"*(AZ+VTO?1.!O
M7% <(R.2@<#4U&)6-S58@;-GT(9,8$7VV$T\AV!)$:0L13'-@[C(?=6CYMNB
M![ H!%_W8W ^"@^VX#VM<:XSBUGB'1NB$.<;*3A]\HYJI5[XUZ(+.YJ>X4DU
MKHX/TM/A'?:X?7C-(OZ+&OYLY!RBX=L,S8@>7HC#Q*J5?Y7-E,4;SP^7>%1+
M[3;@_[E2]F'B%(S/])/_ 5!+ P04    "  W@:=8<"57G(D$  #:"@  &0
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M\(G:':#WN5*VV3@'FW%V^@]02P,$%     @ -X&G6 WTN.2+!   )@P  !D
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MN,*'/ @M@.L+CHR[B5;0_S68_0]02P,$%     @ -X&G6)<G8#6'!   %@P
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M:'!':03H^T;011X/QD'[K\#L+U!+ P04    "  W@:=8M)" W+<#   Q"0
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M;B[H9F!5Y2_%C;)TQ?K/@OYI4+L%-+]5U!+MP 7H_I(6WP!02P,$%     @
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M$XT^/F"DVU9M#:OJ4.T[95WOA.7>33?0WL&=%TK9D^$;J)^7V5]02P,$%
M  @ -X&G6&7 YBD^ @  JP8  !D   !X;"]W;W)K<VAE971S+W-H965T,S$N
M>&ULM97;CMHP$(9?Q7*EJI4H.4&H:(BT+*JZ$I70TL-%U0L3)L1:'U+;6=BW
M7]N!B$J0BU;<$-OQ_\\W'C/)]E(]Z0K H -G0L]P94P]#0)=5,")'LH:A'U3
M2L6)L5.U"W2M@&R]B+,@#L,TX(0*G&=^;:7R3#:&40$KA73#.5$O<V!R/\,1
M/BT\TEUEW$*09S79P1K,]WJE["SH7+:4@]!4"J2@G.&[:#J?N/U^PP\*>WTV
M1BZ3C91/;O*PG>'0 0&#PC@'8A_/< ^,.2.+\>?HB;N03G@^/KE_]KG;7#9$
MP[UD/^G65#/\$:,ME*1AYE'NO\ QG['S*R33_A?MV[UIC%'1:"/Y46P).!7M
MDQR.YW FB$97!/%1$'ON-I"G7!!#\DS)/5)NMW5S Y^J5ULX*EQ1UD;9M]3J
M3+YNBX%DB=9T)VA)"R(,NBL*V0A#Q0ZM)*,%!8T^H"78_#5ZMP!#*-/OL\!8
M!&<4%,=P\S9<?"7<5Z*&*(D&* [CT=_RP))W^'&''WN_T34_*BAO^"607J&[
MZU-=DP)FV%YF#>H9</[V392&GWJPD@XK\>[)%:PE: TP: ]L@!:@"T5K?PU_
M+>U>]&" Z]^7L),;8(\Z[%'O:7X#Q=U-8+[.E^CZ]0EZ :)T#\FX(QGWUY4<
MKM6U5_B/!Y1V6.FMZIK> 'O284_^LZ[]^BB^7MC@K/>X-F[_X3LJM(U56J]P
M.+'U4FUK;"=&UKX=;:2QS<T/*_LU >4VV/>EE.8T<1VN^S[EKU!+ P04
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M2XO#+25KRO, ]?N&,?EZDG_CJ[[ISOX'4$L#!!0    ( #>!IU@^;B[\+ ,
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M:]IQUS:#C@L$ !1L'!2:>F/_8\,V('#9H5FB4I,G 9C#'GL-BTW*&51J<IC
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MW_7^J@/=D+,]"MH%!6V;]R*5!(1\GK+_("(K*AB=QD!"CH4?@<C9P10B7"U
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MON*W7YH'(%A BJ8Y3PCE-9-5^76SX(+)'?E;EVSK[NG=U2D=\@HG,#;D,>3
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MU0#Y^X92\711)>C.Q5;_ U!+ P04    "  W@:=8\!M^P7X$  # $0  &0
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MHZ[3G<O# <\&;HH:AJYS KB[!^[^1,4_HFZ6$G)M9,#M%X&./=I=RH<CG\V
M:Q -3A">*OU>&])!D31KA#EA2HDXK93A+M6;BA.H-(U8$7ZT"J0GYH37(R9P
MG"XK7@]'V!VT&$[Y)W4=W0L[.JSLZJ; C;%$48<RID8?"V7N!]^PU/=Q&T;1
M/O W$GW'P/=ZC@X+NCE3&]0P:4)6 C]SF2ARK?!;7V\8M*B9,!=_U._/<9\%
MPRA#^=](]=4LV =;VPSDNCHB4%A.!%?O"-NG[3'$=;7Y[CR_H5?S^C!A[Z8^
MV\#]WCI%-<1AA2Z=RQ !R/JXH+[18EMMH)="XW:\NMP 2T"6 _#]2@C]<E,&
M: ]M9O\#4$L#!!0    ( #>!IUCX) EP<0(  ,\%   9    >&PO=V]R:W-H
M965T<R]S:&5E=#0Y+GAM;(U4WT_;,!#^5TX9FD!B)$W;P+HT$H7!>$!"[=@>
MICVXR37Q<.S,=AKVW\\_VJR32N$E]MGW???=Q7=I)^23JA U/->,JVE0:=U,
MPE#E%=9$G8D&N;E9"5D3;4Q9AJJ12 H'JED81U$2UH3R($O=V8/,4M%J1CD^
M2%!M71/Y9X9,=--@$&P/YK2LM#T(L[0A)2Y0/S8/TEAASU+0&KFB@H/$U32X
M'$QFB?5W#M\H=FIG#S:3I1!/UK@KID%D!2'#7%L&8I8U7B%CELC(^+WA#/J0
M%KB[W[+?N-Q-+DNB\$JP[[30U32X"*# %6F9GHON"V[R&5N^7##EOM!YW_./
M >2MTJ+>@(V"FG*_DN=-'78 <?P"(-X 8J?;!W(JKXDF62I%!])Z&S:[<:DZ
MM!%'N?TI"RW-+34XG=T*4724,2"\@#NN"2_IDB%<*H5:P0?H'>:"V4?0$5G
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M1/\+I>&"1!% 20AN$H&2*7F.,!APC@4'%PW/SD98(!+Q<_GV:3P"9^_.P3M
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MW<F1 [K5 =V] P:C(P?TJ@-Z^R/$1P[H5P?TSQUA4!TPV!]A<.2 877 </^
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M1C6):@K5-*H95+.4YB?!M='=<!M]) GE>?HFFS[M-BAKF0JTMZZT>BIZ!ZE
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M@-V-?(#VX:B6H)I -8EJ"M4TJAE4LY3FQ6/HFO-AN#F_9"N#,-DV(JB6H)I
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M/Y8QO(H^KXMBO=Q]^)"ELRS??D'YYW?K=?'RF^T 7]?Y;[N'??O_4$L#!!0
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M(EA*#4'5OSW,(8HTDN+Q=PYJ%>_4B=7K9_1?4_%*S((*F+/HCS"0FZDULE
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M_ I?SK-CV1(F.R6^HWP=)@)%L%*0SL5059%G!Z_9C63;].QRP:1D<7JY 1H
MUP'J\Q534S&_T2\HCK]G_P-02P,$%     @ -X&G6)"_AIFP P  <1$  !D
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M?F1)BT32-/D/HA&YRM@.K?_^ R')9PF9^*=+W_)\K_M\]5:X% 4-86[@8R^
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MN/*2@@.12]*9[9E2-%L!K@^CR3?*BVKZ/LL+G/CQ+W*2>P-"_VQ+<"5@T"[
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MRVO\T*KJA% -C,S+)OM%&FS9R\L43U6@; #>7TII=@/[@.:<%OT/4$L#!!0
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MZ5_<8VXZ1I1V@7F_$$+O!S9 TX-._@902P,$%     @ -X&G6#ZU%U75"
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M)"-6GBZ5-X+FQ0'-&Q6"9L7E'J,8,V4@GV^IC%9UHUY0G_%%_P%02P,$%
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M2]^S<N,BI4/_X>S]ST6AKM]Y]GKRX>2D\W!^O1L_,\"Y'SA%KPX0O>AT<&$
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M_+C5,&_ P/) IN>M-;[;>(7LKP-L3_=5"#93O!*QF>)K#8A[W8"1).[=QO(
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MTZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0
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M^OC+\NOD[+U<<$ZW%>7Y+U!+ P04    "  W@:=8_R>G=>,!  !L)   $P
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M(9\-?S*:O0%02P$"% ,4    "  W@:=8!T%-8H$   "Q    $
M    @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( #>!IU@;U6FF
M[P   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+
M 0(4 Q0    ( #>!IUB97)PC$ 8  )PG   3              "  <T!  !X
M;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ -X&G6%]K-8K5!0  S1X
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M965T-2YX;6Q02P$"% ,4    "  W@:=81*4-CDX'  #G'@  &
M    @($0(0  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @
M-X&G6'G'56BX!@  <BT  !@              ("!E"@  'AL+W=O<FMS:&5E
M=',O<VAE970W+GAM;%!+ 0(4 Q0    ( #>!IUBQ\8)[PPD   08   8
M          " @8(O  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M    "  W@:=8E,=2.,8I  "#A0  &               @(%[.0  >&PO=V]R
M:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ -X&G6*F/KQ+3!@  ;A(
M !D              ("!=V,  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q0
M2P$"% ,4    "  W@:=8Y'5UF0\&  "Z#@  &0              @(&!:@
M>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( #>!IUANY[/U
M<08  *X0   9              " @<=P  !X;"]W;W)K<VAE971S+W-H965T
M,3(N>&UL4$L! A0#%     @ -X&G6 O$-T=(!   6 D  !D
M ("!;W<  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    "  W
M@:=8O_.JSO<0  "8/0  &0              @('N>P  >&PO=V]R:W-H965T
M<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( #>!IUC393_!(0<  %H1   9
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M970Q.2YX;6Q02P$"% ,4    "  W@:=8+_P$BE4&  "M&@  &0
M    @(&DI0  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    (
M #>!IUC(OGPIG3P  !K1   9              " @3"L  !X;"]W;W)K<VAE
M971S+W-H965T,C$N>&UL4$L! A0#%     @ -X&G6/[/3"@J!@  KQ$  !D
M             ("!!.D  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"
M% ,4    "  W@:=88^OER^8#  !H"0  &0              @(%E[P  >&PO
M=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( #>!IUA[>-)6Q@4
M +(/   9              " @8+S  !X;"]W;W)K<VAE971S+W-H965T,C0N
M>&UL4$L! A0#%     @ -X&G6' E5YR)!   V@H  !D              ("!
M?_D  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    "  W@:=8
M#?2XY(L$   F#   &0              @($__@  >&PO=V]R:W-H965T<R]S
M:&5E=#(V+GAM;%!+ 0(4 Q0    ( #>!IUB7)V UAP0  !8,   9
M      " @0$# 0!X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%
M  @ -X&G6+20@-RW P  ,0D  !D              ("!OP<! 'AL+W=O<FMS
M:&5E=',O<VAE970R."YX;6Q02P$"% ,4    "  W@:=8_BKEROL"   -#0
M&0              @(&M"P$ >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+
M 0(4 Q0    ( #>!IUA8Q,H2.@(  #L%   9              " @=\. 0!X
M;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ -X&G6&7 YBD^
M @  JP8  !D              ("!4!$! 'AL+W=O<FMS:&5E=',O<VAE970S
M,2YX;6Q02P$"% ,4    "  W@:=8@P#9:4T"  #O!@  &0
M@('%$P$ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( #>!
MIUC7 6(^9P(  %$&   9              " @4D6 0!X;"]W;W)K<VAE971S
M+W-H965T,S,N>&UL4$L! A0#%     @ -X&G6 $NS7I# @  ^P0  !D
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M=#,X+GAM;%!+ 0(4 Q0    ( #>!IUC+JF['N (  -<&   9
M  " @6,I 0!X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @
M-X&G6*DV>5:V"0  .50  !D              ("!4BP! 'AL+W=O<FMS:&5E
M=',O<VAE970T,"YX;6Q02P$"% ,4    "  W@:=8H<R/]ZX$  #)&@  &0
M            @($_-@$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4
M Q0    ( #>!IU@RV*@*C@0  !T5   9              " @20[ 0!X;"]W
M;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ -X&G6!T:)="- @
MBP8  !D              ("!Z3\! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX
M;6Q02P$"% ,4    "  W@:=828X@#?\#  !?$@  &0              @(&M
M0@$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( #>!IU@1
M+%_#JP(    '   9              " @>-& 0!X;"]W;W)K<VAE971S+W-H
M965T-#4N>&UL4$L! A0#%     @ -X&G6/_XZU7U @  H@@  !D
M     ("!Q4D! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #>!IUB0)'XI/@0  ,03   9              "
M@>Q; 0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ -X&G
M6%['<DJ" @  Y@8  !D              ("!86 ! 'AL+W=O<FMS:&5E=',O
M<VAE970U,BYX;6Q02P$"% ,4    "  W@:=8_?-!V5P5  #]9 $ &0
M        @($:8P$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0
M   ( #>!IU@2U<:U:P0  ,(3   9              " @:UX 0!X;"]W;W)K
M<VAE971S+W-H965T-30N>&UL4$L! A0#%     @ -X&G6%J^JK!B!   "A<
M !D              ("!3WT! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q0
M2P$"% ,4    "  W@:=8D+^&F; #  !Q$0  &0              @('H@0$
M>&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( #>!IUBE04 O
M#P0  ,D3   9              " @<^% 0!X;"]W;W)K<VAE971S+W-H965T
M-3<N>&UL4$L! A0#%     @ -X&G6/QL2_UY P  LPT  !D
M ("!%8H! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"% ,4    "  W
M@:=8%:R)EFH#  "/#@  &0              @('%C0$ >&PO=V]R:W-H965T
M<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( #>!IU@^M1=5U0@   1<   9
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M 0!X;"]S='EL97,N>&UL4$L! A0#%     @ -X&G6)>*NQS     $P(   L
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64$L%!@    !& $8 (1,  #FO 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>229</ContextCount>
  <ElementCount>316</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>76</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Statements of Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Organization and Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/OrganizationandBusiness</Role>
      <ShortName>Organization and Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Fair Value Measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/FairValueMeasurement</Role>
      <ShortName>Fair Value Measurement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Certain Balance Sheet Items</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CertainBalanceSheetItems</Role>
      <ShortName>Certain Balance Sheet Items</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/GoodwillandIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Long-Term Debt, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/LongTermDebtNet</Role>
      <ShortName>Long-Term Debt, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Share-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SharebasedCompensation</Role>
      <ShortName>Share-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Earnings per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/Earningspershare</Role>
      <ShortName>Earnings per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Fair Value Measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/FairValueMeasurementTables</Role>
      <ShortName>Fair Value Measurement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/FairValueMeasurement</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/RevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/Revenue</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Certain Balance Sheet Items (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CertainBalanceSheetItemsTables</Role>
      <ShortName>Certain Balance Sheet Items (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/CertainBalanceSheetItems</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/GoodwillandIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/GoodwillandIntangibleAssets</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Long-Term Debt, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/LongTermDebtNetTables</Role>
      <ShortName>Long-Term Debt, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/LongTermDebtNet</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Share-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SharebasedCompensationTables</Role>
      <ShortName>Share-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/SharebasedCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Earnings per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/EarningspershareTables</Role>
      <ShortName>Earnings per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/Earningspershare</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Organization and Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/OrganizationandBusinessDetails</Role>
      <ShortName>Organization and Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/OrganizationandBusiness</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Summary of Significant Accounting Policies -Accounts Receivable, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivablenetDetails</Role>
      <ShortName>Summary of Significant Accounting Policies -Accounts Receivable, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Summary of Significant Accounting Policies - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Summary of Significant Accounting Policies -Property and Equipment, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentnetDetails</Role>
      <ShortName>Summary of Significant Accounting Policies -Property and Equipment, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Summary of Significant Accounting Policies - Cash Flow Hedges - Currency Risks (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesCashFlowHedgesCurrencyRisksDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Cash Flow Hedges - Currency Risks (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Summary of Significant Accounting Policies - Revenue and Cost of Product Sales (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesRevenueandCostofProductSalesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Revenue and Cost of Product Sales (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Summary of Significant Accounting Policies - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Summary of Significant Accounting Policies - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Fair Value Measurement - Components of Available-for-sale Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails</Role>
      <ShortName>Fair Value Measurement - Components of Available-for-sale Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Fair Value Measurement - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails</Role>
      <ShortName>Fair Value Measurement - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Fair Value Measurement - Contractual Maturities of Available-for-sale Debt Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/FairValueMeasurementContractualMaturitiesofAvailableforsaleDebtSecuritiesDetails</Role>
      <ShortName>Fair Value Measurement - Contractual Maturities of Available-for-sale Debt Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Fair Value Measurement - Assets Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurement - Assets Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Revenue - Disaggregated Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails</Role>
      <ShortName>Revenue - Disaggregated Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Revenue - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/RevenueNarrativeDetails</Role>
      <ShortName>Revenue - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Revenue - Accounts Receivable, Other Contract Assets and Contract Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/RevenueAccountsReceivableOtherContractAssetsandContractLiabilitiesDetails</Role>
      <ShortName>Revenue - Accounts Receivable, Other Contract Assets and Contract Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Certain Balance Sheet Items - Accounts Receivable, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails</Role>
      <ShortName>Certain Balance Sheet Items - Accounts Receivable, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Certain Balance Sheet Items - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails</Role>
      <ShortName>Certain Balance Sheet Items - Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Certain Balance Sheet Items - Prepaid Expenses and Other Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails</Role>
      <ShortName>Certain Balance Sheet Items - Prepaid Expenses and Other Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Certain Balance Sheet Items - Property and Equipment, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails</Role>
      <ShortName>Certain Balance Sheet Items - Property and Equipment, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Certain Balance Sheet Items - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails</Role>
      <ShortName>Certain Balance Sheet Items - Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - Goodwill and Intangible Assets - Goodwill Rollforward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/GoodwillandIntangibleAssetsGoodwillRollforwardDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Goodwill Rollforward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - Goodwill and Intangible Assets - Additional (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Additional (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - Goodwill and Intangible Assets - Future Amortization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Future Amortization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - Long-Term Debt, Net - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails</Role>
      <ShortName>Long-Term Debt, Net - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - Long-Term Debt, Net - Carrying Amount of Convertible Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails</Role>
      <ShortName>Long-Term Debt, Net - Carrying Amount of Convertible Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954505 - Disclosure - Long-Term Debt, Net - Components of Interest Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails</Role>
      <ShortName>Long-Term Debt, Net - Components of Interest Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954506 - Disclosure - Share-based Compensation - Share-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails</Role>
      <ShortName>Share-based Compensation - Share-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9954507 - Disclosure - Share-based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails</Role>
      <ShortName>Share-based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9954508 - Disclosure - Share-based Compensation - Assumptions Used in the Black-Scholes Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails</Role>
      <ShortName>Share-based Compensation - Assumptions Used in the Black-Scholes Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9954509 - Disclosure - Share-based Compensation - Unrecognized Estimated Compensation Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails</Role>
      <ShortName>Share-based Compensation - Unrecognized Estimated Compensation Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9954510 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9954511 - Disclosure - Earnings per share - Computation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/EarningspershareComputationDetails</Role>
      <ShortName>Earnings per share - Computation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="halo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9954512 - Disclosure - Earnings per share - Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/EarningspershareAntidilutiveSecuritiesDetails</Role>
      <ShortName>Earnings per share - Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 3 fact(s) appearing in ix:hidden were eligible for transformation: ecd:TrdArrDuration, us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife -  halo-20240331.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="halo-20240331.htm">halo-20240331.htm</File>
    <File>halo-20240331.xsd</File>
    <File>halo-20240331_cal.xml</File>
    <File>halo-20240331_def.xml</File>
    <File>halo-20240331_lab.xml</File>
    <File>halo-20240331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>halo-20240331_g1.jpg</File>
    <File>halo-20240331_g2.jpg</File>
    <File>halo-20240331_g3.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="735">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="20">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>83
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "halo-20240331.htm": {
   "nsprefix": "halo",
   "nsuri": "http://www.halozyme.com/20240331",
   "dts": {
    "inline": {
     "local": [
      "halo-20240331.htm"
     ]
    },
    "schema": {
     "local": [
      "halo-20240331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "halo-20240331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "halo-20240331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "halo-20240331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "halo-20240331_pre.xml"
     ]
    }
   },
   "keyStandard": 296,
   "keyCustom": 20,
   "axisStandard": 24,
   "axisCustom": 2,
   "memberStandard": 35,
   "memberCustom": 40,
   "hidden": {
    "total": 11,
    "http://fasb.org/us-gaap/2023": 4,
    "http://xbrl.sec.gov/dei/2023": 5,
    "http://xbrl.sec.gov/ecd/2023": 2
   },
   "contextCount": 229,
   "entityCount": 1,
   "segmentCount": 76,
   "elementCount": 585,
   "unitCount": 9,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 735,
    "http://xbrl.sec.gov/dei/2023": 29,
    "http://xbrl.sec.gov/ecd/2023": 20
   },
   "report": {
    "R1": {
     "role": "http://www.halozyme.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
     "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
     "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
     "longName": "0000004 - Statement - Condensed Consolidated Statements of Income (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Income (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
     "longName": "0000005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
     "longName": "0000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited",
     "longName": "0000007 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.halozyme.com/role/OrganizationandBusiness",
     "longName": "0000008 - Disclosure - Organization and Business",
     "shortName": "Organization and Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.halozyme.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "0000009 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.halozyme.com/role/FairValueMeasurement",
     "longName": "0000010 - Disclosure - Fair Value Measurement",
     "shortName": "Fair Value Measurement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.halozyme.com/role/Revenue",
     "longName": "0000011 - Disclosure - Revenue",
     "shortName": "Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.halozyme.com/role/CertainBalanceSheetItems",
     "longName": "0000012 - Disclosure - Certain Balance Sheet Items",
     "shortName": "Certain Balance Sheet Items",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.halozyme.com/role/GoodwillandIntangibleAssets",
     "longName": "0000013 - Disclosure - Goodwill and Intangible Assets",
     "shortName": "Goodwill and Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.halozyme.com/role/LongTermDebtNet",
     "longName": "0000014 - Disclosure - Long-Term Debt, Net",
     "shortName": "Long-Term Debt, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.halozyme.com/role/SharebasedCompensation",
     "longName": "0000015 - Disclosure - Share-based Compensation",
     "shortName": "Share-based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.halozyme.com/role/StockholdersEquity",
     "longName": "0000016 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.halozyme.com/role/Earningspershare",
     "longName": "0000017 - Disclosure - Earnings per share",
     "shortName": "Earnings per share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.halozyme.com/role/CommitmentsandContingencies",
     "longName": "0000018 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R20": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.halozyme.com/role/FairValueMeasurementTables",
     "longName": "9954472 - Disclosure - Fair Value Measurement (Tables)",
     "shortName": "Fair Value Measurement (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.halozyme.com/role/RevenueTables",
     "longName": "9954473 - Disclosure - Revenue (Tables)",
     "shortName": "Revenue (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.halozyme.com/role/CertainBalanceSheetItemsTables",
     "longName": "9954474 - Disclosure - Certain Balance Sheet Items (Tables)",
     "shortName": "Certain Balance Sheet Items (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.halozyme.com/role/GoodwillandIntangibleAssetsTables",
     "longName": "9954475 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.halozyme.com/role/LongTermDebtNetTables",
     "longName": "9954476 - Disclosure - Long-Term Debt, Net (Tables)",
     "shortName": "Long-Term Debt, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.halozyme.com/role/SharebasedCompensationTables",
     "longName": "9954477 - Disclosure - Share-based Compensation (Tables)",
     "shortName": "Share-based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.halozyme.com/role/EarningspershareTables",
     "longName": "9954478 - Disclosure - Earnings per share (Tables)",
     "shortName": "Earnings per share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.halozyme.com/role/OrganizationandBusinessDetails",
     "longName": "9954479 - Disclosure - Organization and Business (Details)",
     "shortName": "Organization and Business (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "halo:RoyaltiesReceivedNumberOfProductsSold",
      "unitRef": "product",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "halo:RoyaltiesReceivedNumberOfProductsSold",
      "unitRef": "product",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivablenetDetails",
     "longName": "9954480 - Disclosure - Summary of Significant Accounting Policies -Accounts Receivable, net (Details)",
     "shortName": "Summary of Significant Accounting Policies -Accounts Receivable, net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:AllowanceForDoubtfulAccountsReceivable",
       "span",
       "div",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:AllowanceForDoubtfulAccountsReceivable",
       "span",
       "div",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails",
     "longName": "9954481 - Disclosure - Summary of Significant Accounting Policies - Leases (Details)",
     "shortName": "Summary of Significant Accounting Policies - Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-42",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:LesseeLeasesPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-42",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:LesseeLeasesPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentnetDetails",
     "longName": "9954482 - Disclosure - Summary of Significant Accounting Policies -Property and Equipment, net (Details)",
     "shortName": "Summary of Significant Accounting Policies -Property and Equipment, net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-42",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-42",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesCashFlowHedgesCurrencyRisksDetails",
     "longName": "9954483 - Disclosure - Summary of Significant Accounting Policies - Cash Flow Hedges - Currency Risks (Details)",
     "shortName": "Summary of Significant Accounting Policies - Cash Flow Hedges - Currency Risks (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-44",
      "name": "us-gaap:DerivativeTermOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:DerivativesMethodsOfAccountingHedgingDerivatives",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R34": {
     "role": "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesRevenueandCostofProductSalesDetails",
     "longName": "9954484 - Disclosure - Summary of Significant Accounting Policies - Revenue and Cost of Product Sales (Details)",
     "shortName": "Summary of Significant Accounting Policies - Revenue and Cost of Product Sales (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "halo:RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "halo:RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails",
     "longName": "9954485 - Disclosure - Summary of Significant Accounting Policies - Income Taxes (Details)",
     "shortName": "Summary of Significant Accounting Policies - Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "us-gaap:IncomeTaxPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails",
     "longName": "9954486 - Disclosure - Summary of Significant Accounting Policies - Segment Information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Segment Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails",
     "longName": "9954487 - Disclosure - Fair Value Measurement - Components of Available-for-sale Marketable Securities (Details)",
     "shortName": "Fair Value Measurement - Components of Available-for-sale Marketable Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails",
     "longName": "9954488 - Disclosure - Fair Value Measurement - Narrative (Details)",
     "shortName": "Fair Value Measurement - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "unitRef": "security",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "unitRef": "security",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.halozyme.com/role/FairValueMeasurementContractualMaturitiesofAvailableforsaleDebtSecuritiesDetails",
     "longName": "9954489 - Disclosure - Fair Value Measurement - Contractual Maturities of Available-for-sale Debt Securities (Details)",
     "shortName": "Fair Value Measurement - Contractual Maturities of Available-for-sale Debt Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails",
     "longName": "9954490 - Disclosure - Fair Value Measurement - Assets Measured at Fair Value on a Recurring Basis (Details)",
     "shortName": "Fair Value Measurement - Assets Measured at Fair Value on a Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails",
     "longName": "9954491 - Disclosure - Revenue - Disaggregated Revenues (Details)",
     "shortName": "Revenue - Disaggregated Revenues (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-99",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.halozyme.com/role/RevenueNarrativeDetails",
     "longName": "9954492 - Disclosure - Revenue - Narrative (Details)",
     "shortName": "Revenue - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.halozyme.com/role/RevenueAccountsReceivableOtherContractAssetsandContractLiabilitiesDetails",
     "longName": "9954493 - Disclosure - Revenue - Accounts Receivable, Other Contract Assets and Contract Liabilities (Details)",
     "shortName": "Revenue - Accounts Receivable, Other Contract Assets and Contract Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails",
     "longName": "9954494 - Disclosure - Certain Balance Sheet Items - Accounts Receivable, net (Details)",
     "shortName": "Certain Balance Sheet Items - Accounts Receivable, net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:ContractWithCustomerAssetGrossCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "halo:AccountsReceivableAndContractWithCustomerAssetBeforeAllowanceForCreditLossCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails",
     "longName": "9954495 - Disclosure - Certain Balance Sheet Items - Inventories (Details)",
     "shortName": "Certain Balance Sheet Items - Inventories (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails",
     "longName": "9954496 - Disclosure - Certain Balance Sheet Items - Prepaid Expenses and Other Assets (Details)",
     "shortName": "Certain Balance Sheet Items - Prepaid Expenses and Other Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails",
     "longName": "9954497 - Disclosure - Certain Balance Sheet Items - Property and Equipment, net (Details)",
     "shortName": "Certain Balance Sheet Items - Property and Equipment, net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails",
     "longName": "9954498 - Disclosure - Certain Balance Sheet Items - Accrued Expenses (Details)",
     "shortName": "Certain Balance Sheet Items - Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.halozyme.com/role/GoodwillandIntangibleAssetsGoodwillRollforwardDetails",
     "longName": "9954499 - Disclosure - Goodwill and Intangible Assets - Goodwill Rollforward (Details)",
     "shortName": "Goodwill and Intangible Assets - Goodwill Rollforward (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillPurchaseAccountingAdjustments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalDetails",
     "longName": "9954500 - Disclosure - Goodwill and Intangible Assets - Additional (Details)",
     "shortName": "Goodwill and Intangible Assets - Additional (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-130",
      "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-130",
      "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails",
     "longName": "9954501 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details)",
     "shortName": "Goodwill and Intangible Assets - Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails",
     "longName": "9954502 - Disclosure - Goodwill and Intangible Assets - Future Amortization (Details)",
     "shortName": "Goodwill and Intangible Assets - Future Amortization (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails",
     "longName": "9954503 - Disclosure - Long-Term Debt, Net - Narrative (Details)",
     "shortName": "Long-Term Debt, Net - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-152",
      "name": "us-gaap:DebtConversionConvertedInstrumentAmount1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails",
     "longName": "9954504 - Disclosure - Long-Term Debt, Net - Carrying Amount of Convertible Notes (Details)",
     "shortName": "Long-Term Debt, Net - Carrying Amount of Convertible Notes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails",
     "longName": "9954505 - Disclosure - Long-Term Debt, Net - Components of Interest Expense (Details)",
     "shortName": "Long-Term Debt, Net - Components of Interest Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AmortizationOfDebtDiscountPremium",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-163",
      "name": "us-gaap:DebtInstrumentPeriodicPaymentInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails",
     "longName": "9954506 - Disclosure - Share-based Compensation - Share-based Compensation Expense (Details)",
     "shortName": "Share-based Compensation - Share-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails",
     "longName": "9954507 - Disclosure - Share-based Compensation - Narrative (Details)",
     "shortName": "Share-based Compensation - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails",
     "longName": "9954508 - Disclosure - Share-based Compensation - Assumptions Used in the Black-Scholes Model (Details)",
     "shortName": "Share-based Compensation - Assumptions Used in the Black-Scholes Model (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails",
     "longName": "9954509 - Disclosure - Share-based Compensation - Unrecognized Estimated Compensation Cost (Details)",
     "shortName": "Share-based Compensation - Unrecognized Estimated Compensation Cost (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-200",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-200",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails",
     "longName": "9954510 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-212",
      "name": "us-gaap:StockRepurchaseProgramPeriodInForce1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.halozyme.com/role/EarningspershareComputationDetails",
     "longName": "9954511 - Disclosure - Earnings per share - Computation (Details)",
     "shortName": "Earnings per share - Computation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-221",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.halozyme.com/role/EarningspershareAntidilutiveSecuritiesDetails",
     "longName": "9954512 - Disclosure - Earnings per share - Antidilutive Securities (Details)",
     "shortName": "Earnings per share - Antidilutive Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "halo-20240331.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "halo_A025ConvertibleSeniorNotesDue2027Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "A025ConvertibleSeniorNotesDue2027Member",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails",
      "http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "0.25% Convertible Senior Notes due 2027",
        "verboseLabel": "2027 Convertible Notes",
        "label": "0.25% Convertible Senior Notes due 2027 [Member]",
        "documentation": "0.25% Convertible Senior Notes due 2027"
       }
      }
     },
     "auth_ref": []
    },
    "halo_A1.25ConvertibleSeniorNotesdue2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "A1.25ConvertibleSeniorNotesdue2024Member",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 Convertible Notes",
        "label": "1.25% Convertible Senior Notes due 2024 [Member]",
        "documentation": "1.25% Convertible Senior Notes due 2024 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "halo_A100ConvertibleSeniorNotesDue2028Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "A100ConvertibleSeniorNotesDue2028Member",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails",
      "http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1.00% Convertible Senior Notes due 2028",
        "verboseLabel": "2028 Convertible Notes",
        "label": "1.00% Convertible Senior Notes due 2028 [Member]",
        "documentation": "1.00% Convertible Senior Notes due 2028"
       }
      }
     },
     "auth_ref": []
    },
    "halo_A2021ESPPPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "A2021ESPPPlanMember",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 ESPP Plan",
        "label": "2021 ESPP Plan [Member]",
        "documentation": "2021 ESPP Plan"
       }
      }
     },
     "auth_ref": []
    },
    "halo_A2024CapitalReturnProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "A2024CapitalReturnProgramMember",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 Capital Return Program",
        "label": "2024 Capital Return Program [Member]",
        "documentation": "2024 Capital Return Program"
       }
      }
     },
     "auth_ref": []
    },
    "halo_AcceleratedShareRepurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "AcceleratedShareRepurchaseAgreementMember",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASR",
        "label": "Accelerated Share Repurchase Agreement [Member]",
        "documentation": "Accelerated Share Repurchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AcceleratedShareRepurchasesSettlementPaymentOrReceipt",
     "crdr": "debit",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "ASR, payment to bank",
        "label": "Accelerated Share Repurchases, Settlement (Payment) or Receipt",
        "documentation": "Amount of cash receipt from (payment to) bank; or stock received from (issuance to) bank in the settlement of the accelerated share repurchase agreement."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r736"
     ]
    },
    "halo_AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails",
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts receivable, net and contract assets",
        "totalLabel": "Total accounts receivable, net and contract assets",
        "label": "Accounts Receivable And Contract With Customer Asset, After Allowance For Credit Loss, Current",
        "documentation": "Accounts Receivable And Contract With Customer Asset, After Allowance For Credit Loss, Current"
       }
      }
     },
     "auth_ref": []
    },
    "halo_AccountsReceivableAndContractWithCustomerAssetAllowanceForCreditLossCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "AccountsReceivableAndContractWithCustomerAssetAllowanceForCreditLossCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails": {
       "parentTag": "halo_AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Allowance for distribution fees and discounts",
        "label": "Accounts Receivable And Contract With Customer Asset, Allowance for Credit Loss, Current",
        "documentation": "Accounts Receivable And Contract With Customer Asset, Allowance for Credit Loss, Current"
       }
      }
     },
     "auth_ref": []
    },
    "halo_AccountsReceivableAndContractWithCustomerAssetBeforeAllowanceForCreditLossCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "AccountsReceivableAndContractWithCustomerAssetBeforeAllowanceForCreditLossCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails": {
       "parentTag": "halo_AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total accounts receivable and contract assets",
        "label": "Accounts Receivable And Contract With Customer Asset, Before Allowance For Credit Loss, Current",
        "documentation": "Accounts Receivable And Contract With Customer Asset, Before Allowance For Credit Loss, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableGrossCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableGrossCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails": {
       "parentTag": "halo_AccountsReceivableAndContractWithCustomerAssetBeforeAllowanceForCreditLossCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, before Allowance for Credit Loss, Current",
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r275",
      "r276",
      "r698"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.halozyme.com/role/RevenueAccountsReceivableOtherContractAssetsandContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, net",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r276"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amortization of premium on marketable securities, net",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total accrued expenses",
        "label": "Accrued Liabilities and Other Liabilities",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails_1": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails",
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses",
        "terseLabel": "Total accrued expenses, current",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "halo_AccruedLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "AccruedLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails_1": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less long-term portion",
        "label": "Accrued Liabilities, Noncurrent",
        "documentation": "Accrued Liabilities, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "halo_AccruedOutsourcedManufacturingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "AccruedOutsourcedManufacturingExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued outsourced manufacturing expenses",
        "label": "Accrued Outsourced Manufacturing Expenses",
        "documentation": "Accrued Outsourced Manufacturing Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accumulated depreciation and amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r182",
      "r586"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37",
      "r113",
      "r189",
      "r582",
      "r606",
      "r607"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive (Loss) Income",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r12",
      "r37",
      "r498",
      "r501",
      "r532",
      "r602",
      "r603",
      "r837",
      "r838",
      "r839",
      "r843",
      "r844",
      "r845"
     ]
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalDetails",
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average useful life (in years)",
        "terseLabel": "Weighted Average Useful Life (in years)",
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r468",
      "r469",
      "r611",
      "r843",
      "r844",
      "r845",
      "r924",
      "r945"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r73",
      "r429"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Adjustments to reconcile net income to net cash provided by operating activities",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AgencySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AgencySecuritiesMember",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agency bonds",
        "label": "Agency Securities [Member]",
        "documentation": "Securities issued by government sponsored entities."
       }
      }
     },
     "auth_ref": [
      "r848",
      "r860"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r757",
      "r768",
      "r778",
      "r803"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r760",
      "r771",
      "r781",
      "r806"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r764",
      "r772",
      "r782",
      "r799",
      "r807",
      "r811",
      "r819"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r474"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivablenetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, allowance for doubtful accounts",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "documentation": "Amount of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r279",
      "r317",
      "r320",
      "r321",
      "r939"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Amortization of debt discount",
        "terseLabel": "Total amortization of debt discount",
        "label": "Amortization of Debt Discount (Premium)",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r92",
      "r119",
      "r373"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of intangibles",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r58",
      "r62"
     ]
    },
    "halo_AnnualInterestPaymentPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "AnnualInterestPaymentPeriodAxis",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual Interest Payment Period [Axis]",
        "label": "Annual Interest Payment Period [Axis]",
        "documentation": "Annual Interest Payment Period"
       }
      }
     },
     "auth_ref": []
    },
    "halo_AnnualInterestPaymentPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "AnnualInterestPaymentPeriodDomain",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual Interest Payment Period [Domain]",
        "label": "Annual Interest Payment Period [Domain]",
        "documentation": "Annual Interest Payment Period [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.halozyme.com/role/EarningspershareAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Anti-dilutive shares excluded from per share calculation (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "halo_ArgenxMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "ArgenxMember",
     "presentation": [
      "http://www.halozyme.com/role/OrganizationandBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Argenx",
        "label": "Argenx [Member]",
        "documentation": "Argenx [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetBackedSecuritiesMember",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset-backed securities",
        "label": "Asset-Backed Securities [Member]",
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans."
       }
      }
     },
     "auth_ref": [
      "r730",
      "r855",
      "r861",
      "r862"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r186",
      "r218",
      "r252",
      "r266",
      "r270",
      "r314",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r491",
      "r493",
      "r511",
      "r578",
      "r643",
      "r736",
      "r748",
      "r885",
      "r886",
      "r927"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r194",
      "r218",
      "r314",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r491",
      "r493",
      "r511",
      "r736",
      "r885",
      "r886",
      "r927"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current assets",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "halo_AutoInjectorTechnologyPlatformMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "AutoInjectorTechnologyPlatformMember",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auto Injector technology platform",
        "label": "Auto Injector Technology Platform [Member]",
        "documentation": "Auto Injector Technology Platform"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails",
      "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gross Unrealized Losses",
        "terseLabel": "Unrealized loss position of debt securities",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r287"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/FairValueMeasurementContractualMaturitiesofAvailableforsaleDebtSecuritiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementContractualMaturitiesofAvailableforsaleDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due after one year but within five years",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r575"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/FairValueMeasurementContractualMaturitiesofAvailableforsaleDebtSecuritiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementContractualMaturitiesofAvailableforsaleDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due within one year",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r574"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.halozyme.com/role/EarningspershareComputationDetails",
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails",
      "http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails",
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r433",
      "r434",
      "r435",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Related Disclosures [Abstract]",
        "label": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BaseRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BaseRateMember",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Base Rate",
        "label": "Base Rate [Member]",
        "documentation": "Minimum rate investor will accept."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "halo_BulkrHuPH20Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "BulkrHuPH20Member",
     "presentation": [
      "http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bulk rHuPH20 sales",
        "label": "bulk rHuPH20 [Member]",
        "documentation": "bulk rHuPH20 for use in collaboration products"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationsPolicy",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combinations",
        "label": "Business Combinations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts accrued for purchases of property and equipment",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r49"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r180",
      "r696"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Axis]",
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Equivalents",
        "label": "Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r122",
      "r215"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r122"
     ]
    },
    "us-gaap_CashFlowHedgingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowHedgingMember",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesCashFlowHedgesCurrencyRisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Flow Hedging",
        "label": "Cash Flow Hedging [Member]",
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "halo_CollaborativeAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "CollaborativeAgreementsMember",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails",
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues under collaborative agreements",
        "verboseLabel": "Collaborative Agreements",
        "label": "Collaborative Agreements [Member]",
        "documentation": "Collaborative Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.halozyme.com/role/OrganizationandBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial paper",
        "label": "Commercial Paper [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r743",
      "r744",
      "r745",
      "r746"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 11)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r97",
      "r579",
      "r630"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.halozyme.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r343",
      "r344",
      "r691",
      "r882"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r739",
      "r740",
      "r741",
      "r743",
      "r744",
      "r745",
      "r746",
      "r843",
      "r844",
      "r924",
      "r942",
      "r945"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, par value (usd per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r631"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, shares outstanding (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r104",
      "r631",
      "r649",
      "r945",
      "r946"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock - $0.001 par value; 300,000 shares authorized; 127,186 and 126,770 shares issued and outstanding as of March\u00a031, 2024 and December\u00a031, 2023, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r581",
      "r736"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive income",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r201",
      "r203",
      "r210",
      "r571",
      "r592"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Income",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "halo_ComputerAndOfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "ComputerAndOfficeEquipmentMember",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer and office equipment",
        "label": "Computer and Office Equipment [Member]",
        "documentation": "Computer and office equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r706"
     ]
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "presentation": [
      "http://www.halozyme.com/role/RevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of accounts receivable, deferred revenues from contracts with customers, and amounts under collaborative agreements included in transaction price",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability."
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "us-gaap_ContractWithCustomerAssetGrossCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerAssetGrossCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails": {
       "parentTag": "halo_AccountsReceivableAndContractWithCustomerAssetBeforeAllowanceForCreditLossCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails",
      "http://www.halozyme.com/role/RevenueAccountsReceivableOtherContractAssetsandContractLiabilitiesDetails",
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract assets",
        "label": "Contract with Customer, Asset, before Allowance for Credit Loss, Current",
        "documentation": "Amount, before allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current."
       }
      }
     },
     "auth_ref": [
      "r889",
      "r890"
     ]
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.halozyme.com/role/RevenueAccountsReceivableOtherContractAssetsandContractLiabilitiesDetails",
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenues",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r395",
      "r396",
      "r416"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognized variable consideration and other uncertainties satisfied",
        "label": "Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized",
        "documentation": "Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied."
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Revenue recognized previously included in deferred revenue",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "crdr": "credit",
     "presentation": [
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognized from prior periods",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "us-gaap_ContractWithCustomerRefundLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerRefundLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product returns and sales allowance",
        "label": "Contract with Customer, Refund Liability",
        "documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer."
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "us-gaap_ConvertibleDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtMember",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Debt",
        "label": "Convertible Debt [Member]",
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r358",
      "r359",
      "r364",
      "r365",
      "r366",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720"
     ]
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtSecuritiesMember",
     "presentation": [
      "http://www.halozyme.com/role/EarningspershareComputationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Notes",
        "label": "Convertible Debt Securities [Member]",
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate debt securities",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r730",
      "r732",
      "r941"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cost of sales",
        "label": "Cost of Goods and Services Sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r566"
     ]
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Costs and Expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpensesAbstract",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating expenses",
        "label": "Costs and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.halozyme.com/role/OrganizationandBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r219",
      "r220",
      "r361",
      "r382",
      "r533",
      "r703",
      "r705"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "halo_CreditAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "CreditAgreementMember",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Agreement",
        "label": "Credit Agreement [Member]",
        "documentation": "Credit Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Axis]",
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Domain]",
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Conversion of debt, principal",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r49"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock issued for conversion of debt instrument (shares)",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r49"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure [Abstract]",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.halozyme.com/role/EarningspershareComputationDetails",
      "http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails",
      "http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r101",
      "r102",
      "r150",
      "r151",
      "r221",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r523",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r841"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis spread on variable rate",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "halo_DebtInstrumentCapCallTransactionCapPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "DebtInstrumentCapCallTransactionCapPricePerShare",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cap call transaction, cap price per share (in usd per share)",
        "label": "Debt Instrument, Cap Call Transaction, Cap Price Per Share",
        "documentation": "Debt Instrument, Cap Call Transaction, Cap Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt, convertible, conversion price (in usd per share)",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r360"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt, convertible, conversion ratio",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r66",
      "r141",
      "r142",
      "r360"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining amortization per period of debt discount (in years):",
        "label": "Debt Instrument, Convertible, Remaining Discount Amortization Period",
        "documentation": "Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveBusinessDays",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible, threshold consecutive business days",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Business Days",
        "documentation": "Debt Instrument, Convertible, Threshold Consecutive Business Days"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible, threshold consecutive trading days",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible, threshold percentage of stock price trigger",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible, threshold trading days",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Aggregate principal",
        "terseLabel": "Total principal amount",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r95",
      "r358",
      "r523",
      "r717",
      "r718"
     ]
    },
    "us-gaap_DebtInstrumentFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total fair value of outstanding notes",
        "label": "Debt Instrument, Fair Value Disclosure",
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r510",
      "r717",
      "r718"
     ]
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lenders fee",
        "label": "Debt Instrument, Fee Amount",
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "halo_DebtInstrumentInterestPeriodFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "DebtInstrumentInterestPeriodFourMember",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year four",
        "label": "Debt Instrument, Interest, Period Four [Member]",
        "documentation": "Debt Instrument, Interest, Period Four"
       }
      }
     },
     "auth_ref": []
    },
    "halo_DebtInstrumentInterestPeriodOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "DebtInstrumentInterestPeriodOneMember",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year one",
        "label": "Debt Instrument, Interest, Period One [Member]",
        "documentation": "Debt Instrument, Interest, Period One"
       }
      }
     },
     "auth_ref": []
    },
    "halo_DebtInstrumentInterestPeriodThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "DebtInstrumentInterestPeriodThreeMember",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year three",
        "label": "Debt Instrument, Interest, Period Three [Member]",
        "documentation": "Debt Instrument, Interest, Period Three"
       }
      }
     },
     "auth_ref": []
    },
    "halo_DebtInstrumentInterestPeriodTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "DebtInstrumentInterestPeriodTwoMember",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year two",
        "label": "Debt Instrument, Interest, Period two [Member]",
        "documentation": "Debt Instrument, Interest, Period two"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective interest rates",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r93",
      "r377",
      "r523"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate, stated percentage",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r359"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails",
      "http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r523",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r841"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.halozyme.com/role/EarningspershareComputationDetails",
      "http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails",
      "http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r221",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r523",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r841"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPaymentInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentPeriodicPaymentInterest",
     "crdr": "debit",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total coupon interest",
        "label": "Debt Instrument, Periodic Payment, Interest",
        "documentation": "Amount of the required periodic payments applied to interest."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period One",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period Two",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails",
      "http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r66",
      "r67",
      "r92",
      "r93",
      "r95",
      "r99",
      "r140",
      "r142",
      "r221",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r523",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r841"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Total unamortized debt discount",
        "label": "Debt Instrument, Unamortized Discount",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r95",
      "r888"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unamortized debt issuance cost",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r364",
      "r375",
      "r717",
      "r718"
     ]
    },
    "us-gaap_DebtPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtPolicyTextBlock",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Notes",
        "label": "Debt, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit loss",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Excluding Accrued Interest",
        "documentation": "Amount excluding accrued interest, of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss",
        "documentation": "Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.halozyme.com/role/FairValueMeasurementContractualMaturitiesofAvailableforsaleDebtSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails",
      "http://www.halozyme.com/role/FairValueMeasurementContractualMaturitiesofAvailableforsaleDebtSecuritiesDetails",
      "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Fair Value",
        "verboseLabel": "Available-for-sale marketable securities",
        "totalLabel": "Total estimated fair value of contractual maturities, available-for-sale",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest",
        "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities, available-for-sale",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest, Current",
        "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Realized gain on marketable securities",
        "label": "Debt Securities, Available-for-Sale, Realized Gain (Loss)",
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Available-for-sale Securities [Table]",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of available-for-sale marketable securities",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r863"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "crdr": "debit",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair market value of gross unrealized loss position",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r327",
      "r714"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of loss positions",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions",
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r328"
     ]
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFinanceCostsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt issuance costs",
        "label": "Debt Issuance Costs, Gross",
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets, net",
        "label": "Deferred Income Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r479",
      "r480"
     ]
    },
    "halo_DeferredRentPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "DeferredRentPayments",
     "crdr": "credit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Lease payments deferred",
        "label": "Deferred Rent Payments",
        "documentation": "Deferred Rent Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails",
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation and amortization",
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r256"
     ]
    },
    "us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]",
        "label": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes derivative asset."
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "us-gaap_DerivativeAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Derivative instruments",
        "label": "Derivative Asset",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r196",
      "r510",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r637",
      "r638",
      "r679",
      "r682",
      "r685",
      "r686",
      "r687",
      "r688",
      "r705",
      "r741",
      "r943"
     ]
    },
    "us-gaap_DerivativeAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeAssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative asset, current",
        "label": "Derivative Asset, Current",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r195"
     ]
    },
    "us-gaap_DerivativeAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeAssetsNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative asset, noncurrent",
        "label": "Derivative Asset, Noncurrent",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r195"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesCashFlowHedgesCurrencyRisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Contract [Domain]",
        "label": "Derivative Contract [Domain]",
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r620",
      "r622",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r644",
      "r645",
      "r646",
      "r647",
      "r658",
      "r659",
      "r660",
      "r661",
      "r664",
      "r665",
      "r666",
      "r667",
      "r679",
      "r680",
      "r685",
      "r687",
      "r739",
      "r741"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesCashFlowHedgesCurrencyRisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instrument [Axis]",
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r83",
      "r84",
      "r85",
      "r620",
      "r622",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r644",
      "r645",
      "r646",
      "r647",
      "r658",
      "r659",
      "r660",
      "r661",
      "r664",
      "r665",
      "r666",
      "r667",
      "r679",
      "r680",
      "r685",
      "r687",
      "r705",
      "r739",
      "r741"
     ]
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesCashFlowHedgesCurrencyRisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Relationship [Axis]",
        "label": "Hedging Relationship [Axis]",
        "documentation": "Information by type of hedging relationship."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r81",
      "r84"
     ]
    },
    "us-gaap_DerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative instruments",
        "label": "Derivative Liability",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r196",
      "r510",
      "r613",
      "r614",
      "r615",
      "r616",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r644",
      "r646",
      "r647",
      "r680",
      "r681",
      "r682",
      "r685",
      "r686",
      "r687",
      "r688",
      "r705",
      "r943"
     ]
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilitiesNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative liability, noncurrent",
        "label": "Derivative Liability, Noncurrent",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r195"
     ]
    },
    "us-gaap_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "label": "Derivative Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes derivative liability classified as current."
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "us-gaap_DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "label": "Derivative Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes derivative liability classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "us-gaap_DerivativeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLineItems",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesCashFlowHedgesCurrencyRisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative [Line Items]",
        "label": "Derivative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "us-gaap_DerivativeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeTable",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesCashFlowHedgesCurrencyRisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative [Table]",
        "label": "Derivative [Table]",
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r76",
      "r77",
      "r78",
      "r80",
      "r82",
      "r84",
      "r86",
      "r87",
      "r88",
      "r503"
     ]
    },
    "us-gaap_DerivativeTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeTermOfContract",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesCashFlowHedgesCurrencyRisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative, contract term",
        "label": "Derivative, Term of Contract",
        "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativesMethodsOfAccountingHedgingDerivatives",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Flow Hedges - Currency Risks",
        "label": "Derivatives, Methods of Accounting, Hedging Derivatives [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for derivatives used in hedging relationships, which may include how gains or losses are recognized and presented in the financial statements, and amortization policies for deferred amounts."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r923"
     ]
    },
    "halo_DeviceLicensingAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "DeviceLicensingAndDevelopmentMember",
     "presentation": [
      "http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Device licensing and development revenue",
        "label": "Device Licensing and Development [Member]",
        "documentation": "Device Licensing and Development"
       }
      }
     },
     "auth_ref": []
    },
    "halo_DevicePartneredProductsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "DevicePartneredProductsMember",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails",
      "http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Device partnered product sales",
        "label": "Device Partnered Products [Member]",
        "documentation": "Device Partnered Products"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DilutiveSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DilutiveSecuritiesAbstract",
     "presentation": [
      "http://www.halozyme.com/role/EarningspershareComputationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dilutive potential common stock outstanding",
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails",
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails",
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.halozyme.com/role/RevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of disaggregation of revenues",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r432",
      "r463",
      "r464",
      "r466",
      "r734"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings per share",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.halozyme.com/role/EarningspershareComputationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (USD per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r236",
      "r238",
      "r244",
      "r245",
      "r246",
      "r250",
      "r506",
      "r507",
      "r572",
      "r593",
      "r709"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.halozyme.com/role/EarningspershareComputationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (USD per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r238",
      "r244",
      "r245",
      "r246",
      "r250",
      "r506",
      "r507",
      "r572",
      "r593",
      "r709"
     ]
    },
    "us-gaap_EarningsPerShareDilutedLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDilutedLineItems",
     "presentation": [
      "http://www.halozyme.com/role/EarningspershareComputationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]",
        "label": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r242",
      "r244"
     ]
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareReconciliationAbstract",
     "presentation": [
      "http://www.halozyme.com/role/EarningspershareComputationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings per share",
        "label": "Earnings Per Share Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.halozyme.com/role/Earningspershare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings per share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r247",
      "r248",
      "r249"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective income tax rate, percent",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation and payroll taxes",
        "label": "Employee-related Liabilities",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r937"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized Expense",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r465"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining Weighted-Average Recognition Period (in years)",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r465"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ESPP",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.halozyme.com/role/EarningspershareComputationDetails",
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails",
      "http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails",
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options",
        "verboseLabel": "Stock options",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [Abstract]",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r175",
      "r205",
      "r206",
      "r207",
      "r222",
      "r223",
      "r224",
      "r226",
      "r232",
      "r234",
      "r251",
      "r315",
      "r316",
      "r394",
      "r467",
      "r468",
      "r469",
      "r487",
      "r488",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r505",
      "r515",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r532",
      "r602",
      "r603",
      "r604",
      "r611",
      "r670"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r757",
      "r768",
      "r778",
      "r803"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r754",
      "r765",
      "r775",
      "r800"
     ]
    },
    "halo_EventBasedDevelopmentAndRegulatoryMilestoneAndOtherFeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "EventBasedDevelopmentAndRegulatoryMilestoneAndOtherFeesMember",
     "presentation": [
      "http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Event-based development and regulatory milestones and other fees",
        "label": "Event -based Development And Regulatory Milestone And Other Fees [Member]",
        "documentation": "Event -based Development And Regulatory Milestone And Other Fees"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of assets measured at fair value on a recurring basis",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r147"
     ]
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByBalanceSheetGroupingTable",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r90",
      "r91"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r509",
      "r537",
      "r538",
      "r539",
      "r717",
      "r718",
      "r730",
      "r731",
      "r732"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r420",
      "r425",
      "r509",
      "r537",
      "r730",
      "r731",
      "r732"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r420",
      "r425",
      "r509",
      "r538",
      "r717",
      "r718",
      "r730",
      "r731",
      "r732"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r509",
      "r539",
      "r717",
      "r718",
      "r730",
      "r731",
      "r732"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r537",
      "r538",
      "r539",
      "r717",
      "r718",
      "r730",
      "r731",
      "r732"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair Value of Financial Instruments",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r18"
     ]
    },
    "us-gaap_FederalFundsEffectiveSwapRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FederalFundsEffectiveSwapRateMember",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fed Funds Rate",
        "label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]",
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg."
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r318",
      "r319",
      "r322",
      "r323",
      "r324",
      "r326",
      "r329",
      "r330",
      "r374",
      "r392",
      "r503",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r591",
      "r714",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r863",
      "r864",
      "r865",
      "r866"
     ]
    },
    "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities",
        "label": "Financial Instruments, Financial Liabilities, Balance Sheet Groupings [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "halo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "documentation": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r339"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remainder of 2024",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r338",
      "r339",
      "r340",
      "r567",
      "r568"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Carrying Value",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r568"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalDetails",
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r567"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r61"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails",
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Carrying Value",
        "totalLabel": "Total",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r567"
     ]
    },
    "us-gaap_ForeignExchangeForwardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignExchangeForwardMember",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesCashFlowHedgesCurrencyRisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency hedging contracts",
        "label": "Foreign Exchange Forward [Member]",
        "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate."
       }
      }
     },
     "auth_ref": [
      "r637",
      "r641",
      "r646",
      "r660",
      "r666",
      "r683",
      "r684",
      "r685",
      "r741"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r761",
      "r772",
      "r782",
      "r807"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r761",
      "r772",
      "r782",
      "r807"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r761",
      "r772",
      "r782",
      "r807"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r761",
      "r772",
      "r782",
      "r807"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r761",
      "r772",
      "r782",
      "r807"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsGoodwillRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "periodStartLabel": "Goodwill, Beginning Balance",
        "periodEndLabel": "Goodwill, Ending Balance",
        "label": "Goodwill",
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r336",
      "r569",
      "r715",
      "r736",
      "r871",
      "r878"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r56"
     ]
    },
    "us-gaap_GoodwillPurchaseAccountingAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillPurchaseAccountingAdjustments",
     "crdr": "debit",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsGoodwillRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Measurement period adjustment",
        "label": "Goodwill, Purchase Accounting Adjustments",
        "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r877"
     ]
    },
    "us-gaap_GoodwillRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillRollForward",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsGoodwillRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Roll Forward]",
        "label": "Goodwill [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_HedgingRelationshipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "HedgingRelationshipDomain",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesCashFlowHedgesCurrencyRisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Relationship [Domain]",
        "label": "Hedging Relationship [Domain]",
        "documentation": "Nature or intent of a hedge."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "halo_HelenTorleyMarch2024PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "HelenTorleyMarch2024PlanMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Helen Torley March 2024 Plan [Member]",
        "documentation": "Helen Torley March 2024 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "halo_HelenTorleyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "HelenTorleyMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Helen Torley [Member]",
        "documentation": "Helen Torley"
       }
      }
     },
     "auth_ref": []
    },
    "halo_HelenTorleyPriorPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "HelenTorleyPriorPlanMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Helen Torley Prior Plan [Member]",
        "documentation": "Helen Torley Prior Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets and Other Long-Lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r114",
      "r153",
      "r252",
      "r265",
      "r269",
      "r271",
      "r573",
      "r588",
      "r711"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r342",
      "r654"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r654"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax expense",
        "verboseLabel": "Income tax provision",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r172",
      "r233",
      "r234",
      "r257",
      "r481",
      "r489",
      "r594"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r477",
      "r478",
      "r483",
      "r484",
      "r485",
      "r486",
      "r609"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable and accrued expenses",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable, net and other contract assets",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "crdr": "credit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Deferred income taxes",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventories, net",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Changes in operating assets and liabilities",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://www.halozyme.com/role/EarningspershareComputationDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/EarningspershareComputationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dilutive potential common stock outstanding (shares)",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r240",
      "r241",
      "r246",
      "r431"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ATRS-1902 (IPR&amp;D)",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r764",
      "r772",
      "r782",
      "r799",
      "r807",
      "r811",
      "r819"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r753",
      "r823"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r753",
      "r823"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r753",
      "r823"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Total intangibles, net",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r60"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest expense",
        "label": "Interest Expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r155",
      "r208",
      "r255",
      "r522",
      "r655",
      "r747",
      "r944"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total interest expense",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r371",
      "r378",
      "r719",
      "r720"
     ]
    },
    "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Income and Interest Expense Disclosure",
        "label": "Interest Income and Interest Expense Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r700"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails",
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventories, net",
        "totalLabel": "Total inventories, net",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r697",
      "r736"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventories",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r179",
      "r191",
      "r331",
      "r332",
      "r333",
      "r565",
      "r707"
     ]
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryRawMaterialsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raw materials",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r702"
     ]
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWorkInProcessNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work-in-process",
        "label": "Inventory, Work in Process, Net of Reserves",
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r701"
     ]
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of contractual maturities of available-for-sale debt securities",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments."
       }
      }
     },
     "auth_ref": []
    },
    "halo_JanssenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "JanssenMember",
     "presentation": [
      "http://www.halozyme.com/role/OrganizationandBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Janssen",
        "label": "Janssen [Member]",
        "documentation": "Janssen Collaboration [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of leases",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r218",
      "r314",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r492",
      "r493",
      "r494",
      "r511",
      "r629",
      "r710",
      "r748",
      "r885",
      "r927",
      "r928"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r152",
      "r584",
      "r736",
      "r842",
      "r867",
      "r925"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r178",
      "r218",
      "r314",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r492",
      "r493",
      "r494",
      "r511",
      "r736",
      "r885",
      "r927",
      "r928"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current liabilities",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "halo_LicenseFeesAndEventBasedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "LicenseFeesAndEventBasedMember",
     "presentation": [
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License Fees and Event-Based",
        "label": "License Fees And Event-Based [Member]",
        "documentation": "License Fees And Event-Based [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitment fee percentage",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit facility, maximum borrowing capacity",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total carrying amount",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r151",
      "r365",
      "r376",
      "r717",
      "r718",
      "r938"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt, net",
        "verboseLabel": "Long-term debt, excluding current maturities",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r187"
     ]
    },
    "us-gaap_LongTermDebtTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtTextBlock",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Debt, Net",
        "label": "Long-Term Debt [Text Block]",
        "documentation": "The entire disclosure for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r65"
     ]
    },
    "halo_ManufacturingEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "ManufacturingEquipmentMember",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Manufacturing equipment",
        "label": "Manufacturing Equipment [Member]",
        "documentation": "Manufacturing Equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails",
      "http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails",
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails",
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Maximum",
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r345",
      "r346",
      "r347",
      "r348",
      "r426",
      "r564",
      "r601",
      "r621",
      "r622",
      "r675",
      "r676",
      "r677",
      "r678",
      "r689",
      "r692",
      "r693",
      "r713",
      "r721",
      "r733",
      "r738",
      "r887",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails",
      "http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails",
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails",
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Minimum",
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r345",
      "r346",
      "r347",
      "r348",
      "r426",
      "r564",
      "r601",
      "r621",
      "r622",
      "r675",
      "r676",
      "r677",
      "r678",
      "r689",
      "r692",
      "r693",
      "r713",
      "r721",
      "r733",
      "r738",
      "r887",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Money market funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.halozyme.com/role/OrganizationandBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Organization and Business",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r173"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r214"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r214"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r123",
      "r124"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited",
      "http://www.halozyme.com/role/EarningspershareComputationDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income",
        "verboseLabel": "Net income",
        "terseLabel": "Net Income (Loss) Attributable to Parent",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r124",
      "r154",
      "r176",
      "r200",
      "r202",
      "r207",
      "r218",
      "r225",
      "r227",
      "r228",
      "r229",
      "r230",
      "r233",
      "r234",
      "r243",
      "r252",
      "r265",
      "r269",
      "r271",
      "r314",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r507",
      "r511",
      "r589",
      "r651",
      "r668",
      "r669",
      "r711",
      "r747",
      "r885"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "presentation": [
      "http://www.halozyme.com/role/EarningspershareComputationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Adoption and Pending Adoption of Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "halo_NicoleLaBrosseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "NicoleLaBrosseMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nicole LaBrosse [Member]",
        "documentation": "Nicole LaBrosse"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r761",
      "r772",
      "r782",
      "r799",
      "r807"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating income",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r265",
      "r269",
      "r271",
      "r711"
     ]
    },
    "halo_OperatingLeaseAccretionOfLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "OperatingLeaseAccretionOfLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expense associated with accretion of lease liabilities",
        "label": "Operating Lease, Accretion Of Liability",
        "documentation": "Operating Lease, Accretion Of Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total operating lease cost",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r529",
      "r735"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Lease liability",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r525"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts related to leases",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r526",
      "r530"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails": {
       "parentTag": "halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Right of use of assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use asset amortization",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other accrued expenses",
        "label": "Other Accrued Liabilities",
        "documentation": "Amount of expenses incurred but not yet paid classified as other."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_OtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails_1": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets",
        "documentation": "Amount of assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r185",
      "r577",
      "r748"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign currency translation adjustment",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax",
        "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r113",
      "r512",
      "r513",
      "r514"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss)",
        "label": "Other Comprehensive Income (Loss), before Tax",
        "documentation": "Amount before tax, after reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r515",
      "r516",
      "r521",
      "r570",
      "r590",
      "r837",
      "r838"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax",
     "crdr": "credit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Realized gain on derivative instruments, net",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax",
        "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r199"
     ]
    },
    "halo_OtherComprehensiveIncomeLossCashFlowHedgeUnrealizedHoldingGainLossBeforeAdjustmentAfterTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeUnrealizedHoldingGainLossBeforeAdjustmentAfterTax",
     "crdr": "credit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain on derivative instruments, net",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Unrealized Holding Gain (Loss), Before Adjustment, after Tax",
        "documentation": "Other Comprehensive Income (Loss), Cash Flow Hedge, Unrealized Holding Gain (Loss), Before Adjustment, after Tax"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income",
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized (loss) gain on marketable securities",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r199",
      "r313"
     ]
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherIncomeAndExpensesAbstract",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense)",
        "label": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Investment and other income, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails_1": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other prepaid expenses",
        "label": "Other Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r835",
      "r869"
     ]
    },
    "halo_OthercollaboratorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "OthercollaboratorsMember",
     "presentation": [
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other collaborators",
        "label": "Other collaborators [Member]",
        "documentation": "Other collaborators [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r759",
      "r770",
      "r780",
      "r805"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r762",
      "r773",
      "r783",
      "r808"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r762",
      "r773",
      "r783",
      "r808"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "halo_PaymentForCappedCallTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "PaymentForCappedCallTransactions",
     "crdr": "credit",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment for capped calls",
        "label": "Payment for Capped Call Transactions",
        "documentation": "Payment for Capped Call Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repurchase of common stock",
        "label": "Payments for Repurchase of Common Stock",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment of debt issuance cost",
        "label": "Payments of Debt Issuance Costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Taxes paid related to net share settlement, net of proceeds from issuance of common stock under equity incentive plans",
        "terseLabel": "Payments for tax withholding for restricted stock units vested, net",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchases of marketable securities",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r212",
      "r281"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PSUs",
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (usd per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r380"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r631"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r380"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r631",
      "r649",
      "r945",
      "r946"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock - $0.001 par value; 20,000 shares authorized; no shares issued and outstanding",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r580",
      "r736"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total prepaid expenses and other assets",
        "label": "Prepaid Expense and Other Assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails",
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Prepaid expenses and other current assets",
        "terseLabel": "Total prepaid expenses and other assets, current",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails",
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Prepaid expenses and other assets",
        "negatedTerseLabel": "Less: Long-term portion",
        "label": "Prepaid Expense and Other Assets, Noncurrent",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r834"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails_1": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid manufacturing expenses",
        "label": "Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r334",
      "r335",
      "r699"
     ]
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of 2028 Convertible Notes",
        "label": "Proceeds from Convertible Debt",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sales and maturities of marketable securities",
        "label": "Proceeds from Sale of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r212",
      "r281",
      "r312"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net proceeds from stock options exercised",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r15"
     ]
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductMember",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails",
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product sales, net",
        "verboseLabel": "Product",
        "label": "Product [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails",
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails",
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r272",
      "r566",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r695",
      "r723",
      "r737",
      "r825",
      "r883",
      "r884",
      "r892",
      "r940"
     ]
    },
    "halo_ProductSalesOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "ProductSalesOtherMember",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other product sales",
        "label": "Product Sales, Other [Member]",
        "documentation": "Product Sales, Other"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails",
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails",
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r272",
      "r566",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r695",
      "r723",
      "r737",
      "r825",
      "r883",
      "r884",
      "r892",
      "r940"
     ]
    },
    "halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails",
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "label": "Property, Plant, and Equipment and Operating Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "documentation": "Property, Plant, and Equipment and Operating Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r181",
      "r587"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentImpairment": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentImpairment",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Long-Lived Assets",
        "label": "Property, Plant and Equipment, Impairment [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for assessing and recognizing impairments of its property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails",
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails": {
       "parentTag": "halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Subtotal",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r576",
      "r587",
      "r736"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment, Net",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r166",
      "r171",
      "r585"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of property and equipment, net",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "halo_ProprietaryProductsSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "ProprietaryProductsSalesMember",
     "presentation": [
      "http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proprietary product sales",
        "label": "Proprietary Products Sales [Member]",
        "documentation": "Proprietary Products Sales"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "halo_RSURSAandPRSUawardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "RSURSAandPRSUawardsMember",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "RSUs, PSUs and ESPP",
        "label": "RSU, RSA, and PRSU awards [Member]",
        "documentation": "Restricted Stock Unit, Restricted Stock Awards, and Performance Restricted Stock Unit awards [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails",
      "http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails",
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails",
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r345",
      "r346",
      "r347",
      "r348",
      "r419",
      "r426",
      "r458",
      "r459",
      "r460",
      "r540",
      "r564",
      "r601",
      "r621",
      "r622",
      "r675",
      "r676",
      "r677",
      "r678",
      "r689",
      "r692",
      "r693",
      "r713",
      "r721",
      "r733",
      "r738",
      "r741",
      "r881",
      "r887",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails",
      "http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails",
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails",
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r345",
      "r346",
      "r347",
      "r348",
      "r419",
      "r426",
      "r458",
      "r459",
      "r460",
      "r540",
      "r564",
      "r601",
      "r621",
      "r622",
      "r675",
      "r676",
      "r677",
      "r678",
      "r689",
      "r692",
      "r693",
      "r713",
      "r721",
      "r733",
      "r738",
      "r741",
      "r881",
      "r887",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r754",
      "r765",
      "r775",
      "r800"
     ]
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfConvertibleDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repayment of 2024 Convertible Notes",
        "label": "Repayments of Convertible Debt",
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.halozyme.com/role/OrganizationandBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r219",
      "r220",
      "r361",
      "r382",
      "r533",
      "r704",
      "r705"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r476",
      "r935"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and Development Expenses",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "halo_ResearchEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "ResearchEquipmentMember",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research equipment",
        "label": "Research Equipment [Member]",
        "documentation": "Research equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r755",
      "r766",
      "r776",
      "r801"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r756",
      "r767",
      "r777",
      "r802"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r763",
      "r774",
      "r784",
      "r809"
     ]
    },
    "halo_RestrictStockUnitsPerformanceSharesAndESPPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "RestrictStockUnitsPerformanceSharesAndESPPMember",
     "presentation": [
      "http://www.halozyme.com/role/EarningspershareComputationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs, PSUs and ESPP",
        "label": "Restrict Stock Units, Performance Shares and ESPP [Member]",
        "documentation": "Restrict Stock Units, Performance Shares and ESPP"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Domain]",
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "halo_RestrictedStockUnitsAndPerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "RestrictedStockUnitsAndPerformanceSharesMember",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs and PSUs",
        "label": "Restricted Stock Units And Performance Shares [Member]",
        "documentation": "Restricted Stock Units And Performance Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "RSUs",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Retained earnings",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r143",
      "r583",
      "r605",
      "r607",
      "r610",
      "r632",
      "r736"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Retained Earnings",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r222",
      "r223",
      "r224",
      "r226",
      "r232",
      "r234",
      "r315",
      "r316",
      "r467",
      "r468",
      "r469",
      "r487",
      "r488",
      "r497",
      "r499",
      "r500",
      "r502",
      "r505",
      "r602",
      "r604",
      "r611",
      "r945"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer [Abstract]",
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total revenues",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r254",
      "r264",
      "r267",
      "r268",
      "r272",
      "r273",
      "r274",
      "r414",
      "r415",
      "r566"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenue Recognition and Cost of Sales",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r694"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.halozyme.com/role/Revenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r404",
      "r405",
      "r418"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRemainingPerformanceObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, remaining performance obligation",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "presentation": [
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue, remaining performance obligation, expected timing",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "presentation": [
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesRevenueandCostofProductSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period of contract termination by written notice",
        "label": "Revenue, Remaining Performance Obligation, Period Of Termination By Written Notice",
        "documentation": "Revenue, Remaining Performance Obligation, Period Of Termination By Written Notice"
       }
      }
     },
     "auth_ref": []
    },
    "halo_RevenueRemainingPerformanceObligationsUnfulfilledProductPurchaseOrdersAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "RevenueRemainingPerformanceObligationsUnfulfilledProductPurchaseOrdersAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue remaining performance obligations, related to unfulfilled product purchase orders",
        "label": "Revenue Remaining Performance Obligations, Unfulfilled Product Purchase Orders, Amount",
        "documentation": "Revenue Remaining Performance Obligations, Unfulfilled Product Purchase Orders, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenues",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevolvingCreditFacilityMember",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revolving Credit Facility",
        "label": "Revolving Credit Facility [Member]",
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligation",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r531",
      "r735"
     ]
    },
    "halo_RocheMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "RocheMember",
     "presentation": [
      "http://www.halozyme.com/role/OrganizationandBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Roche",
        "label": "Roche [Member]",
        "documentation": "Roche"
       }
      }
     },
     "auth_ref": []
    },
    "halo_RoyaltiesReceivedNumberOfProductsSold": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "RoyaltiesReceivedNumberOfProductsSold",
     "presentation": [
      "http://www.halozyme.com/role/OrganizationandBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalties received, number of products sold",
        "label": "Royalties Received, Number of Products Sold",
        "documentation": "Royalties Received, Number of Products Sold"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RoyaltyMember",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails",
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalties",
        "label": "Royalty [Member]",
        "documentation": "Money for usage-based right to asset."
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "halo_SaleOfStockPremiumOverLastReportedSalePricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "SaleOfStockPremiumOverLastReportedSalePricePercentage",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock premium over last reported sale price, percentage",
        "label": "Sale of Stock Premium Over Last Reported Sale Price, Percentage",
        "documentation": "Sale of Stock Premium Over Last Reported Sale Price, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, price per share (in usd per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of accounts receivable",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of accrued expenses",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.halozyme.com/role/EarningspershareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded from calculation of diluted earnings per common share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Available-for-sale Securities",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293"
     ]
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments",
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.halozyme.com/role/OrganizationandBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of share-based compensation expense by type",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.halozyme.com/role/EarningspershareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of reconciliation of numerators and denominators of basic and diluted computations",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTable",
     "presentation": [
      "http://www.halozyme.com/role/EarningspershareComputationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]",
        "label": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]",
        "documentation": "Complete disclosure pertaining to an entity's diluted earnings per share."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r52",
      "r238",
      "r242",
      "r244"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalDetails",
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r61",
      "r567"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived Intangible Assets",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r61"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfGoodwillTextBlock",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Goodwill",
        "label": "Schedule of Goodwill [Table Text Block]",
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule."
       }
      }
     },
     "auth_ref": [
      "r715",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of inventories",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r110",
      "r111",
      "r112"
     ]
    },
    "us-gaap_ScheduleOfOtherAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfOtherAssetsTableTextBlock",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of prepaid expenses and other assets",
        "label": "Schedule of Other Assets [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails",
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails",
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r430",
      "r433",
      "r434",
      "r435",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of assumptions used in Black-Scholes model",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of unrecognized estimated compensation cost by type",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements Valuation Inputs [Line Items]",
        "label": "Schedule of Share-based Compensation Arrangements Valuation Inputs [Line Items]",
        "documentation": "[Line Items] for Schedule of Share-based Compensation Arrangements Valuation Inputs [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "ScheduleofSharebasedCompensationArrangementsValuationInputsTable",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements Valuation Inputs [Table]",
        "label": "Schedule of Share-based Compensation Arrangements Valuation Inputs [Table]",
        "documentation": "Schedule of Share-based Compensation Arrangements Valuation Inputs [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SOFR",
        "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]",
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg."
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r273",
      "r712"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Selling, general and administrative",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "label": "Selling, General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ShareBasedCompensationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Noncash Expense [Abstract]",
        "label": "Share-Based Payment Arrangement, Noncash Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails",
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r430",
      "r433",
      "r434",
      "r435",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461"
     ]
    },
    "halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum contribution amount",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum employee subscription rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum employee subscription rate",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Minimum Employee Subscription Rate",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Minimum Employee Subscription Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares available for grant (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock options granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Outstanding stock options and restricted stock units (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r437",
      "r438"
     ]
    },
    "halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase period (in months)",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period",
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.halozyme.com/role/EarningspershareComputationDetails",
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails",
      "http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails",
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r433",
      "r434",
      "r435",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock options weighted average exercise price (usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r442"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r436",
      "r455",
      "r456",
      "r457",
      "r458",
      "r461",
      "r470",
      "r471",
      "r472",
      "r473"
     ]
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareRepurchaseProgramAxis",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program [Axis]",
        "label": "Share Repurchase Program [Axis]",
        "documentation": "Information by share repurchase program."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareRepurchaseProgramDomain",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program [Domain]",
        "label": "Share Repurchase Program [Domain]",
        "documentation": "Name of the share repurchase program."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average expected term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r457"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ESPP purchase price of common stock, percent of market price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Equity, beginning balance (in shares)",
        "periodEndLabel": "Equity, ending balance (in shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Unit holders awards surrendered to pay for minimum withholding taxes (in shares)",
        "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r216"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r34",
      "r175",
      "r205",
      "r206",
      "r207",
      "r222",
      "r223",
      "r224",
      "r226",
      "r232",
      "r234",
      "r251",
      "r315",
      "r316",
      "r394",
      "r467",
      "r468",
      "r469",
      "r487",
      "r488",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r505",
      "r515",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r532",
      "r602",
      "r603",
      "r604",
      "r611",
      "r670"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r251",
      "r566",
      "r608",
      "r612",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r631",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r650",
      "r652",
      "r653",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r670",
      "r742"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Comprehensive Income [Abstract]",
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r251",
      "r566",
      "r608",
      "r612",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r631",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r650",
      "r652",
      "r653",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r670",
      "r742"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r758",
      "r769",
      "r779",
      "r804"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssued1",
     "crdr": "credit",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued for conversion of 2024 Convertible Notes",
        "label": "Stock Issued",
        "documentation": "The fair value of stock issued in noncash financing activities."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r49"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for the conversion of the 2024 Convertible Notes (in shares)",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r33",
      "r66",
      "r143",
      "r368"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock issued during period, shares, restricted stock award, net of forfeitures (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r103",
      "r104",
      "r143"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock and performance stock units, net (in shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r103",
      "r104",
      "r143"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of shares of common stock issued as a result of stock option exercises (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r103",
      "r104",
      "r143",
      "r442"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for the conversion of the 2024 Convertible Notes",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r34",
      "r143"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock and performance stock units, net",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r103",
      "r104",
      "r143"
     ]
    },
    "halo_StockOptionsAndRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "StockOptionsAndRestrictedStockUnitsMember",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options and restricted units",
        "label": "Stock Options And Restricted Stock Units [Member]",
        "documentation": "Stock Options And Restricted Stock Units [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital return program, authorized amount (in shares)",
        "label": "Stock Repurchase Program, Authorized Amount",
        "documentation": "Amount of stock repurchase plan authorized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchaseProgramPeriodInForce1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchaseProgramPeriodInForce1",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital return program, purchase period",
        "label": "Stock Repurchase Program, Period in Force",
        "documentation": "Period which shares may be purchased under a stock repurchase plan authorized by an entity's Board of Directors, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repurchase of common stock (shares)",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "documentation": "Number of shares that have been repurchased and retired during the period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r103",
      "r104",
      "r143"
     ]
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repurchase of common stock",
        "label": "Stock Repurchased and Retired During Period, Value",
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital)."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r103",
      "r104",
      "r143"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Equity, beginning balance",
        "periodEndLabel": "Equity, ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r107",
      "r108",
      "r126",
      "r633",
      "r649",
      "r671",
      "r672",
      "r736",
      "r748",
      "r842",
      "r867",
      "r925",
      "r945"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stockholders\u2019 equity",
        "terseLabel": "Stockholders' equity (deficit) (textual)",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stockholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r217",
      "r379",
      "r381",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r393",
      "r394",
      "r504",
      "r673",
      "r674",
      "r690"
     ]
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItems"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Certain Balance Sheet Items",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "halo_TakedaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "TakedaMember",
     "presentation": [
      "http://www.halozyme.com/role/OrganizationandBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Takeda",
        "label": "Takeda [Member]",
        "documentation": "Takeda"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes payable",
        "label": "Taxes Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "halo_TermLoanFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "TermLoanFacilityMember",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term Loan Facility",
        "label": "Term Loan Facility [Member]",
        "documentation": "Term Loan Facility"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable, net",
        "label": "Accounts Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r157",
      "r158",
      "r277",
      "r278",
      "r280"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r374",
      "r392",
      "r503",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r591",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r863",
      "r864",
      "r865",
      "r866"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average price paid per share (usd per share)",
        "label": "Shares Acquired, Average Cost Per Share",
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockSharesAcquired",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock repurchased (in shares)",
        "label": "Treasury Stock, Shares, Acquired",
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r104",
      "r143"
     ]
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "crdr": "debit",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock repurchased",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r68",
      "r143"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. treasury securities",
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r708",
      "r730",
      "r732",
      "r936"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54",
      "r55",
      "r164",
      "r165",
      "r167",
      "r168"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Axis]",
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": []
    },
    "halo_VariableRateComponentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "VariableRateComponentAxis",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate Component [Axis]",
        "label": "Variable Rate Component [Axis]",
        "documentation": "Variable Rate Component"
       }
      }
     },
     "auth_ref": []
    },
    "halo_VariableRateComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "VariableRateComponentDomain",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate Component [Domain]",
        "label": "Variable Rate Component [Domain]",
        "documentation": "Variable Rate Component [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "halo_VariableRateComponentOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "VariableRateComponentOneMember",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate Component One",
        "label": "Variable Rate Component One [Member]",
        "documentation": "Variable Rate Component One"
       }
      }
     },
     "auth_ref": []
    },
    "halo_VariableRateComponentTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "VariableRateComponentTwoMember",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate Component Two",
        "label": "Variable Rate Component Two [Member]",
        "documentation": "Variable Rate Component Two"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Domain]",
        "label": "Variable Rate [Domain]",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.halozyme.com/role/EarningspershareComputationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.halozyme.com/role/EarningspershareComputationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (shares)",
        "totalLabel": "Weighted average common shares outstanding for diluted earnings per share (shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r246"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.halozyme.com/role/EarningspershareComputationDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.halozyme.com/role/EarningspershareComputationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (shares)",
        "verboseLabel": "Weighted average common shares outstanding for basic earnings per share (shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r246"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.halozyme.com/role/EarningspershareComputationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average common shares outstanding",
        "verboseLabel": "Denominator",
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "halo_XYOSTEDProprietaryProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.halozyme.com/20240331",
     "localname": "XYOSTEDProprietaryProductMember",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "XYOSTED proprietary product",
        "label": "XYOSTED Proprietary Product [Member]",
        "documentation": "XYOSTED Proprietary Product"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "16",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479405/805-10-25-16"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a-c)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "e",
   "SubTopic": "470",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "((a)(1),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(a)-(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479515/805-10-05-4"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-8"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "25",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480238/815-25-50-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350/tableOfContent"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-10"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481138/505-30-25-5"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(1)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//330/tableOfContent"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12A"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EEEE",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4EEEE"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-9"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-3"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-12"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-12"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//210/tableOfContent"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-3"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-27"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480682/815-20-25-6A"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "25",
   "Name": "Accounting Standards Codification",
   "Section": "40",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480270/815-25-40-8A"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>84
<FILENAME>0001159036-24-000037-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001159036-24-000037-xbrl.zip
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M8M,>=RY.A1Z$N&*3XLX8[N U'F)' TM:VXK.HD3%+@@QK"0KK@ PF/U-'B-
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MU4DX*C4'M_+>L_N[[%-)7+_8;V()9C_+O>QTP_^2M/6-X^#9_6_1_:+0IVT
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MXJCGM;T6;_-.W^]XD\/^82_L!"'TFKS#O:/._UI[V!7%71]M%C&\WTM$6H^
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M2[$[6A+@JI]'PH^8SNECU7\."@HEY$ B=(Q)G.J!N3 1.J@S\*V!I#=#TV2
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M)P@0G"7K3)%.'CP_>U')?0>W1)3#0X7$4<.X@^4Z1(X]GBX@5G,I4*0S&<^
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MBK#KE-)T*U?"/5SS:EW7S,IU_]T6VMW(A681]K>0F':*G541U/3Q[KQ%)%E
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M(/K7@J5WC>ZZJ^$^[#L5,L06.U6K55:]P[#RQ:7Y9_(:U;YY?>L_4$L#!!0
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MNK%^"/##PA#,UTT#4&J)2<^&L#+DB!%*N]W^R'Z-+MU\$6(K0?+U[W^+WBI
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MB'^+/^,SUE.JQAVEDAAX)Z4"$)]E,D4!SL6W_E5V*M7YHE(-M'LN5 *'JH_
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M Z,Y359P%]@C*QZ)_1S1'S]^-6US'(R+LN94YRX,7T=3\EHHFG(;(<_[8=S
M_%S6EL7[%;S16\?S/D^_4.,9/-)':K$>"][(G"R%SL0;75O.C^C"+0S9:5B/
MIO=]\>77CDO-9[OWJH\0'O#Q!W&-_>=8ZNES+,U$AX!LFF[F:ML!#GQ#AX )
M_)G&SY[W&PCGO=YQCW[,[KC7N4U'S!JYS(&T% ACBY3/1 ?GL4_UP&7M60JC
M6+A-0VRE^Z7C3G"+'+VB [^ E.<VZ;"5\M_Z3RZ3[&D!R<Y=AB"]HGFFMEY$
MDG.7",B@8\9CZK(V7@2F7!2*-[@+]SFVICEN"FIP%]ES;4WSI#QW@3R_UC1/
MLG,7Z_-I3?,D.;>I *ZL:3[-T+P0'M--T6[X:_9PM\%MN(OYF*YMX']PS?&%
M6*O+C5\=FTZ_$O<[]:\#V]@F.ND!1$SW-V(%]/-T]N<7F UQ]='TEKY0:RE]
M$U]T8T\"WV-7*(7QT;B-O(L. ;4P$. V!; '"/!#=6XS $47O/WJWCQ]*&XS
M$D6'P'YU;XX0:'*;(N%.]^9)=7X3) ?0?[E"H,A)^":_V9H#Z$ !@Q@&W&:/
M3I[R_":1A!X^H#GF-@TE]/ A85#H5%2A*<]M!H@K/<SAJG&>QIC;A-1>Z,Z5
M#> '!-RFI(0F.)@YT+A-2@E-<#@0B!Q982N:<C0(&K\YLOU0_H2T09XPX#9'
M)K3!(8T"OPD[H0T."(.33M@=3AL4.7>O<9NMXRII>]H8$'G#8F(@3UO ;]I0
MZ(%#84!D#?/)7A5T:V6+WX1AH71 8?DO<H7%XW^.^K_%;Y)0R/\A^"^R@SGE
MJ JYS[]5Y*Q@%HISI7;X8;_(!A9.^O-4_OPF H7T'X#](@>89C!\=0+<DR$0
MJ4 !A0@*W&8$SX'Z[9/.QYV^3L[1/+=/.C5W^CHY3RAPFZ4["^J?=8Z,']/(
M;ZZ*^Z@Q3S:<=<Z('Z7$;^Z&>VG(DPTGG4.I%48IG73^8K]LR%,:N,L=X%$M
M#^%A</=NG[HOIIX\F A^FK@F]8D[C:[R^L3:Q_(M!V<5*3)WR04^V7.<0VP5
MF;N ?PM[/@?6=_=+\/!%E4]48+B+N[GAR+%DA+M8? M'KBA^\0#4L:E+C5B-
MG:B\<!>B<\F=8\D.=Y'[%N[T7N QGXE'C2MT@YT)JP.PC4?ZC.=&.^[TJPG>
M@._8%+YEATA?TY-UWK@+^ O)O6/)'G=Y@E2:\1;^'ZZWGX%#"2Z>J(1QET3@
MF$?'DJ.B91A"[E#4;,"?N4X\31%2N,LPQ'FUI^F$W@^[KHL+D/-Z0L8C9GMT
MQ[+( /L,.&YAMN\H2H%R!C$KHE^+0^,C90%\@*RQ&=&/H.OM@#[2,3%M4/\/
MU!TZ[IC8.KT?6.8S.R^Y]SJAND^-)W,,E]P/^_"M-R0Z_M:/E4+(GI_W\^"J
MX>!S(J:$!Q?O]TTS2"4(R!6>1 [CP 07:8F#+@,!H0I&\,N9\3=?:/?9I<Q%
M*!#"BY8<. ;!<T5X@>+YF;5UIL3RI\4!=8'B\4/2.%<<%RV>CGYBR\ L;BL,
MG%7N8F.N2)TGJE7NHN)$[ LS\:</%F')<#R4@*7K/D\Q0Y&@_B/U*!8)S:XH
M#M"Y6S7GG?JY8I^[Z#([];\2.\ (/W AXB^@ ' 7;Q:"!;E* 7<1:'867#KC
M2>!3%U='AT.PS064!.[BTL*P(5=IX"Y:S<2&^.);2CPZ<BSC9CQQG9>"Y6A4
M[L+9@C A5TG@,MY]Q$7)D,SX\:MIF^-@?)I+Q#4NP^!E#I#7$^8 M]'Q-0#?
MI[?F"S5N;!#R9W-@478PD/=Y^I7\X;B7%O&\A''N!KYS8_]!==]QGZ@^LAW+
M>49%YN-"XHGRC]OXFG_^[<FVU[@-NK.SY']_O^\_]:Y6]]Z<J#1Q&ZQSS;I]
M"1*W<3L>/K/<C2Y488HL7SKV"WC0R* ^M4W'O7-\ZET%%,C3VD+\U".X=>QG
MB$/'.))5OSPQ!+Q@KQQ7*W(K-XYSFR(X>XXOJ&?&\W3J>0D>NZEG;E,7IP6/
M=T[[D1IT/,%2O ?&U<4AO'WMO4U/!+,!&&H&6-\EAFD__\<@TQELQ^QL$!IB
M(W%!_*SX]_@S/FR3,'";0A+"L*,P//UP3DT8!H%GVM3S-@I#?,'5^X2!NU3>
MWH6!'Z^MSET6CT?B\^! U;G-]O'$J64Q41KYB FWJ3H.S&62X[+:>(OCVEXY
MKN28P*ASFPGDB?@+BI&1/YUB5'),_-6Y3?R=O6QR 0]N,Y&G!8\CQ%K[3SP<
M"[/<YE(%9KG/#QP+L]PF>#G#K%+=!%J#@;:^3Q]9:5<4I5*3\_&1BYC&/#SU
MD](9TC^5="ZS:C?IY#;))J23!WPTN,T#"GPL6_>TU37LTIRL>X/;[*/ QV(&
M3,DK ];8>\XS*_9KZ3W;/'N5-40J,!L*\RPD:W";W>.4^'GNLFAPFSOC=,TI
M5^1SFP3BE/BY(E]D,[CU=WBH-F]PF_H0^."AOVU#Y%MX]95X4!]-D6XI!#R.
MI#V:W&9;3JL^N*C:@]MJ- $/'K0'M_DJGIAS+-GE-I_%$W..)3G<YKO.WBW;
M4Y*MR6V237 \F=G+D>/<9O;.WGG:EXQSFZL3'-^3C'.;?;MTJ6'ZUT0W+1C6
M4L]Q^N)8+Z;]O'C1WG5[^+I9\_Z]<EFMR(V\N*QQFT3+B=0[2C%[XQ-\?>L0
M.R6:..(N=SFP4#/;=D"L&QBJ2SW_@4SQYF09>'3P2Q( LZM3[EH0.#LDSKA+
MIN6$L^T[#03.#HDS[K)R>>%L!-P72.,(:=RE&'-"VK43;#N[1 #MD$#C-EUZ
MQ##K-^*:! +FQ]F!G/$O?:H'\,I["*EM\WGD7YLVL748"%[:=X;N[)<;VZ"O
M_1]D@K_L.C"&L>2HL!&^8R^B?NWO_'FJNZXK,/2G[MW2R&M=0>,VR[P9K=?4
MH"ZQK@/;\'K#(=7QA+^\,,F!G)XY(KG-@A\!$N]N'%]<HR"D@$D!MRL#G$A!
MJ@,LA!047 K$:DD6K'XF'LT#?/N7M_.&=8O;Y:&S@W6^SM29PYJ[=;&3]%G>
MGS7)<=U%.$Q\BB!W2X:<B6 ^^EZ(H!#!C2+(W6HJ9R(H(HD<P<;=@BIG8!/^
M?8Y@$XNJ/$%B3S7I+6Y7!,^U,")7[G*[NG9CZ\Z8]GU03WCGK:,3[$V\+,P>
M):X^ZH(>HR_4<M@AXKW7"3QMWQVWC[0ML\7M2A#W'#O27LT6MZL6J3C6IY8%
MYO)7:F.5!?"M:XS!9P>]2[#0(F*==YK2UN8V-5\@WAU)[MK<YI^[/XAKK&YB
MZXTGEC.EP%1'_W[/6O&?J%1QFY;DAC/'DAENLU5+G&%N]V/_VV._2VSC ?XB
M>,&IFB%N\SI\L.58TL)=!N3="=:B<H"[[,2[LXY%Y0"W&80'B]AW9)S43%WL
M/-_K/SS@;WGEA=+X#'OF/3!>37_6@EI16_GPGMM<Q&GS?O$<A20[=TH&MKE-
M5.S(3F[RK:K,;3[AF)'/OHA=M 3 (_5\U]1]:C!R?[--WP,7NC@$+UI<?S""
M<Q!$JG)18ON9UJ?NT'''Q-9I?T3<?>0I]R4(18G7#TAJ+D2 NX"=&T<R5_AS
M%Y5S%*L="_K<QNEK4XAK#'/7-LY%37$;5W/,J^/DOU29VZ!Y':\281SR:!WK
M"F-EE*+$TEQ0/L<SQU1E[X%UUB18CG/C[C!1-KNTR=T%0NRDV)2]AXOOR'*G
M/U$X1T+L/9C+2@@U/2'4/ G!;?3$'(Q'.@E<?40\^N ZSRX9)[/%NDXMZA+4
MMXO7'JI(OY;ZN/3PTGR.2U<5;D,Q/GFV:#&3;-C-JNP]^MJC5<DSM%&X#6VV
MXQ%)<4DFID^L1^H'KAU=LV^/6:VH[7Q06*A8)7:1YP[R2D@)CC0N 9YF%D M
M5'S##;>.E =0N5UL7+=/:L.Y&6RGN.F;IYI84[E=H.212<>2).[6*:EN7-S8
MAOEB&@&Q$DKO"SBH]I/C6G3G#:3XCB>7&*;]W'7=]>]X "JZ^ZEWX4(ZN5LU
MS8'Q1>4%=['^&0CAGA+E*G<Y %YX^16WHB*U3UBI<K?N>R;,WY<P<Y= V<C/
M.U-W+'I+/KN.=Z+;\565NY3*T=BQ.^ _FJ\7+O6<P-6I%WX<46*P\<"$.C_#
M/XSP9J,YE&6J:7*[1>NRI@U435.;LE)K4$VFAO8?C,;G]WC^U (&C$V[,J+8
MZ.Q"U2;^IQ^FX8\N%%G^_TOLNL[/WH38G9\'[D>X._P[?,CJHXC[#$_SG<E%
M YZ$XZ\0RWRV+W2*1\'  WWLQA9?/W!<F$<%.&"1B4<OXC\^&:8WL<@4:&29
M-JVPFSY%3Q\XON^,V0M8 *@3*WH)>U_X\WP653F<B0_T\HWXS='/5?CIX^KW
M[5:U+:__2:XJ[/N/['EN_&-$P-K$+[%[8"9(J5]*M=+29*/A*Q-?\AS+-*2_
MR>S_/D6_(_'4E1\GQ$"U?2%+<./L_1\98=YF1&T#(W!X\>4P6L>]B-\U!.15
MAF1L6M.+OS^!#'G2'?TA/3IC8O^][!';JWB U6%XH6?^12\4&%7X\4=(" V>
MPU@7$491D0G?[FZ>>E=2_ZG[U.LO8BDQ>%Y&V^]=?GN\>;KI]:7NW974^]_+
M+]V[7WO2Y?W7KS?]_LW]'?=3^!?Q1@ ;W['+TE7ULBJI<J/>WCCL!&R:!X%-
M/=4LKN\?OTH_@]ZS'?LN&,-#="E2CX]TR';IE"2;H#4QJ'EQY>@L7X2YV!+3
MC$.XH*/(E7\R[3E_RDR?Y3NK9JI922MLR'D<K:5AU-<.XP-X?-^E>YO^E 86
MC5#!'52)M^O55E/)JL/K5:W1?%.%I[8&M:I<KZ>Q!IM4?ZR]U<DKZN^D8%ET
MN$H"9U):QX"YZ8CM005OOU"K:B/QG1O:\O#+Q*O^"#QPGZ;IA;CKFL22OMG@
M(AE4^MK?A'=U&]!""YQ9@/\9@+M*76OZ2">.ZY<DMG+B@Z<#<P)G\6+@.-:
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MM\=>7^BX<^-](X]])ML:]]?WUK;_'?6'>SU-0LWC[ !L+;O[X0&UYN0D#@_
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M_%0K2_# "87GOU!KNH,#+DKM<G# $\"*/*@5O#292')202? <4 /.P4X-)[
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MJFEJ4U9J#:K)U-#^HV)197C3:'9HV(0\T\K I>1[A0QA@A?$^D&F'B(O"3/
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MCRU.60I:9)^/Y8DA&^Z'OSJ.P3:Q4/?%U*G7=ZRLG7D5N5GJJ*UR3>6E"YK
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MN'")<E#=2=;<#V]FC.DROF06,3Q:2"MKS1-*#PHLI=;:.8.IP<#4JIU8@JV
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MAR]:'.H?@?$<K;4SN[M80CK"*@J7K4ZP=P*YP=>,BJ-":Q/*-'@944VC+;V
MTL#JN;"><(46/U#B+9."Y&-9)G.9/"<LIPJ !E%^SG3U8(Q'-.DXL\^L! K,
M.RLK!967F(7+"L[_8 1VD "FS0J#L: 0JVN0^>"*A?518:DQ*YU#.PY_Z'[
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MY<RIFM@3$M*@#%SQM_B'":^0E;#C?:S<(\9'+%HSL8JVA8PIP#F<-(B=SO*
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M9OPHH1R'2O.G(W)/&*WT9_EB3VG5(S\B_F=D!:!H&]KH!0M$90%^#- DDF)
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M'(V;I(0;Q<Z1:^A-*S=56E-/^@U>5\J;P@!%<0]+%0;00FS)@,!%4HZ5@E8
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MEPA-2UG[P;+4*2*RSGZR65Q4/5&<]--(9&]E1VGQ//T:PDUWPG(OL4U4!UY
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M&PIV2.YES41CB<V/0M1_V>,$,39=3",;?)3"V6<V0/35X>[;HTOY!>VWY0^
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M-VI ^M&(7=TG0_UB!]7S$WM2T$&UD96!E?#%9X+S+0M*%@<D:P, [^_;&MS
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M=Y<FB$:!C0*?FP)?%GJS>$$H@G(P]L@=OE^+])K!F<&]S,&]!.#8NTP0\V
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MQFZ'%C N*]DIJ-II]EZ!%[L+/G:7";^D1>L=3)"/J!07@?G^ZJ^=Y;.K/3;
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MOMKVL[XCT*BA4<-GJ6$#]!!@S,.NW>E7O1TU4 \;XI7(WAS/XD5O*)?L^SB
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M6@XV@RS/9<]5?O7!<3T^X,+\>-6<ZV!T=3,:M?)Q) DGL&$)G^[=V7W5Z92
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MI,:1:VHUZ:A?5S6IN1LT4*0.5$TZ&M1237J._G]9W[!.[S08*XWNW"FX)A2
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M79SS%R?B ,TH0BN"&QYL=\U3%WVS/R]P3\4[H=7[COE6;>HC5*AM$W]?,#F
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M;02I7D$:'DF0NDT3I",U5R>KK$4OQ?>OX</'Z=FYH1ET#K60R6 <Z=KS,KM
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M WD30-ZKM;,5WX1$.QZZ6?)#M^#0W5H_Y]!S%G!,2R,6IMU[; 'XX/,R$,Q
M30R**%@7LF%BPA?QGG>!/WL <<7S#SIM"GNM'_M0\ S-QSY#!\^0G>PDSY">
MN/!.%)@]0%049*/-^L;:O75L]!H4?4!:')N#C_%2%;;X/(&33)B#M2);#K[0
ML!T=)MVFV1CDS/S805(TZQMKQ![]B%B]U!J8@T9V[O26@B.:PS=H9Z%Z@<^"
M66F!-+F6(U1IEBIR 9XPCF@%W\FO#%F,"KI>@!@6' 1WZ'=?+ =-NZ_6SS]
MON&+8<_P03Y?+0Q+L '[?;/??#1L>8Q##9Z][-7-7BOKH4[><!HML##8XD57
M,UZ?24J%V)^QL'Y2]3"8Y/C/!PB$U.7G,%,Q=>,:S5LV_NKO%50QC^V"8MFM
MY90![BPG4BAPQ*,U\&BK)Q^EQ<=-4E'$HEKABL$'!1>CHZ_$@<+4,CCL(*7/
MT2)<P$E@IY]$!7!!&(+"V-^D1A0]=:->]E.#QMBKY31_R@Z/RA3)4M6G'^\
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M;XO!9@,\F><O\#L;$ '@8(I="@#@5G!T)E?*^9L4UN 0Z"C JP+H8?@%E[(
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M37#@1^LXYPUB8^(]$Q?]?;.L3BE\E;@<LU$K@\,"CJ-T!WS&,X3R0@7*2ZE
MG!T'DL A<?AZ[/2\LX IH(*FE#I3DQEX0!Q[S1:.R#N/57L2(@%3#G:X.^0E
M/N!KX(0_*( I=J>DNQ6&T8R'.SG N*^6Y[PCEL$[I2('ZW%/NG*)(I;QS'J4
MJ_J=HEMU-@>9H'3?-9QE')'/V]+&S2.&XSAP)<XY)\.K)'E.'- 4+PX970&8
M+B"&_'M!<T*7(= @@UNX3%G9UP@/XQU_B<Z3@0;8/>H2V[$[12\S'VX?D "Q
M8;66CR8PD&G >7D4W#*N0",5NQ;G%A'C.CHR#U)9,("RCL/SH@? -NL'_ !1
M2/$P--JV,[K(]4YP6R"Y>[[ACURI1L+V@'4X(3FPHSFMBI[X]<*"DE[X;SD!
MX4](A\)E;">PHQD&WFT1SD$5!Z-.L#;Z38L>8!MS8K#.6??8WM#/=RRX<]C]
MB=A!:ZV>-2XJ-$,M8^3X<W($V?0=GXF!SC.,JB!O _09.V$0S7F:!H81.%/R
MD9& B$/Q!VP+L >E0^!P/Q*G/XKX<,L<\ ^AQN4FJ)K 2IUPBNR"=@9\[U0,
MSPW^6*(/Q_- )2)."53R]M/[X:?_]_98R;N[IR+]]W\U>NT7!_8PK_<GDZXU
MAOW )I>QDK@T+H3($, 5PN(Y=Y61YA'X<T#'A84FHD=4$+R/OKQOUDT1()P!
M3MI<7(+^*@.$ L61/J3W!*0>*D$40YZ2(+<CX) ,1;C<Q\UKM06U78HP_H>K
M3'@086FZD3-& 2&=>FBUXK,! UV6POWP(:A8%N54H!X(B$U4)$B-1V1=T#V]
MD$=N-<"@$;J"JATF8OM*X[U#[5'H]K$R+32.V0CN0V*O!EBAN IU*P%H? ]F
M-_(=@C'NR]5-74.6^I*X $ (4^K%@'MWC"R"S M- N*ET+KY_K@D5#N/0JEX
M<OZ%NF^T\"_Y-:3,C%@5';,0,)]?MM3;X^UQ5QEWQ?)X,ZA4H'/&%I)@A>25
M!4E*3- 4/KU8?5[X+O Z_@%WTPC+:*QX*+P4-2:N XZGW"V_,<FL7:\]G1!Q
M9W6(N!S1WK++J,^8]2B(.DW+W)CGQA^G*,1$Y4_#=$QDDV'23$KP530T/.XL
M$R0*>#V-8-O&=&FY4>![L ;F:Q!3KLE?HS?E!QGR=&^D>?CW\8_@]Y+7OA]*
M7FNB=6(!2^%)(S8:;/A+VPI&_G0Y#CC/!C(G=6=F_<</.)/R1.H.=[XL N"5
MKANAWP>LJ,#YJ=RFKT&'AR]K!KF009$&'9=[[8E?\P@'P(*RDXC[HH^ F#S\
M"6:/)>,]$VY]<0"32>RC_0W:SQA?HXN-*=P7'!]] ?37.R#.&1/2A,Q0X/'(
MQ5"=DUQHYGN^[7(>!8;5R!]+<Y(;Z7"X6R84+A(,\ NP "*7+/\XN!/.8,OQ
M=YK0(JZ>" 8"PK@8KQ"%V_(NLT)3/QW?#I>(R%MI;7RS0,N,>)/HFA1SY$1/
M^GBYT%@K_Q 9I,0C#V[P ^Q4OIF _1DYA$"8$L0\-G'(4476- <^'O3.L21N
M!*#EDBEDC8&;..&";Z0&.G;6;S9)R$HP]P,+I(6N15Q]C[4(VI&0PN-8&F9A
M8:(]9FGU]3PQC[29B%R?4JF(1]\A+JJ5?('*2@REE0\>)1 >!^XZ\M'F,\91
MH.X>H)$$ M^S? M=0<!E[-7W#+SD8VAN,H]0G/>11RH@\O!)MNO+<#9WR?F0
M^'ZQG..-$WGB96* $LZ:>2-ZV]!GRV^)_Q:]N,&=@ Z'OU(1+!<#LTNU"@MX
MT%UI@BX7\@K$^&^D?%H,_@O0"HAUDE8XB="Q?$F2FG@EKV0)<P%!? *,]9^4
MG!Y?CDB(5PQ@2CF"R3L8871QRBQW,;4M'E"9<*\V5VST_?*L1HX"R"?A^5LD
MVIKQP<)T4%-YT70\EHAZB?08\?,D;EY#S, BT6 I9[1R?)-.Q*]$82M)$F $
M$R:YL91$([;TQ=V)I\#Z=(*E]IS:'UP];O$L[,M$(B;!-2:O!!]$5.0<E(QN
MY=7F-_.N9KSW)Q/8CG?YP8*-V5.0-!\6XQK],.<[<AE(+D6?Q2+XJ_6#C2V1
M42)9;@@_ 2+A"CK<LT@_>67]!%2TC&\WR27Y&O&:7R8 E2#Y#/\L?N8? ,@0
ML.J5XR,S3&U2?!L_/AR-OCOIH_ /XX?>NH[QP7$%,8M,(O4T?1,__"I ][5K
M?%RB[_ &V,UHE/G-JX\WFK8"$MC[:;SZ_FJH'N"?Q<]\=YSOQON88B_(1G3]
M$<8FYXP,IG!AO >\EN\BO8;"%)0+!#3_FVO]]&]F<-F_(Q8]5V_#U>-WO9Y&
MMY:3NCI8MB:P0?Z*/Z=D$V5JV*"1>.E;3X.7'I*_(ZDH:9^+'9L!Z0.&1G.0
ML43L$F<G#%U'*'AUJ9<.Z=XSXL[*D:P69<*G22$D"]08(2: *!E<FJ?RM^,
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M]3>/.C3>< XC(8;)[CK(%C1.?>R'.!8HQ%:?MXMI:!J=NC&[-8U>!_Y#RX,
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MI7!??H)ZY8\I;4=%WO5,K*89OV 5^::)E-BRI,?QTH,+LD,SU7R7;Q]7DP&
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MSX29B:!9O9LS&MC+#DTR]8&Z7 !SP,2<BR0K 5/H&&P.+YY/>7%PM/ O18X
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MO-%&J6[S.$#X>^+TI'?_0D[VTH=\UL8UOE*>K?!R.9Y6DW%/Z;C8RMS!M.#
MP1E:HZ413V_E91K1?&']8(DI\#>O\<%XWOG8^#)EX:V/GU[[-KT2*R2-6X9I
MK/,IOD^F=O"J">K@LKS#3G[X*]X=T>0#6:CPS9],<)H%?!?2Y';XR/7O62!V
MA8VYT'":PUYQ/[CZ1VM$G2?%_F@GE(#+6_^)LU,W408'Y %[?EC\.P[PYO5[
MO+L3Y=-'?)X#K4]Q0%E,+UMLRN0940P2FF+GJJNC['?HS.86/$>]::^^X[#
MT($+MP(JCX&;L&5"C$7)1*D7A#+MAU'KS,SL(4JHYJ^@O$%U6$Q=B)O2.S)/
M3E;"4QV$2(E0H-5O.J?^X3QCH;(6_@:A8,)[%D<-2!XS(EN&@.P7O5C,I/JQ
M_4=FA5.R%('9;FW0'!0.S/9J]49[3X'9=F>PG\A>O=;JMJI-/>JFZK5^I[._
M3:U?J@K,GEA@MGQ 61][K:*N5=2U]#"OHJY5U/71HJY&%78]M["K#I[C>+W
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MHT=CPZG'"<8F*R-KT \:6 E>]<^")DYAJ:FEUJ@Z61XYT)Y@X8.?[KRHT!*
MD1%D* )&1OWYE6=0<"O%1N\4I$&1TC0K:U:WS'@7-].;$SP&!H\*LL;RU L$
M+A&&0K(WVNJ3H!_8C\\+!*_*PB $YQ?;[Y?0S*V'4!06R!F,JH"C+*E-TR;A
MEO3V@HM_9[.=,#WDD3>XG6&ZD*'4[\F$5$(2,[%6(3_\,/6+,;HS/J%].&\4
MXA>2F(]U! $PM7*_T-T1,EQ!&H/B!;-7"?:-$L/GE!@RH%M#)L,( 5C +$]2
M)"C2KZ [07Y/A#+:Z<0?PV<4/UG5.2U0IY*:C5@%WXZ. 0DCN$ #O;A-HCX<
M5 "FJPEJUFJ2MZ'PP2J7Z7DTB+HU*3?*&1C7JR&%L$1 O:3[0.+X@AW%F45Z
M9QV[;\R!C!B>K!S*L,A"XBP:B_E47GK<H+F;S/' 2H9)8!T3AZ]P)4]+&B!C
M6#A@1A)G_+,R/BC83>X[7JX>4V[>;TX#6*'6$N+SF?06U2S>_&O)HHBD((^M
M?D_O/1@9:*ZHCZM1%#N:!E7A'\7,8)3U8%"7PGN;O1;VL?7&*B8R=I;X+,_8
MXO*!)3VRS!2L".8/<@(? 1LC3\-A(=%(XKF1-= @"43FPU5E/$0CUXS%&!X9
M!\68%G2QOH(1MM\@V]T3JT8\A7(K0(>(,<D(@LNQCCMO6(E/K1PD&&$5S3&
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M$5@!6LZ$<OMFLD@2F#&,ER5RAEY$$;KL5H@\:R@K&P8S\N ?CE+ ]J,*0Q>
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MR&Z9!2$DMZ*8C*GY]28M@ \IX^-/R._]27*D..JVB1PIHYSFY.@5P4KM!9/
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M;6SLO5MS6T>2+OH^O\*G]^O)=MTO'=.S0Y:E'I^0+85D3\]^8M0EB\(V"&@
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MZ1SLTX_._X$#'(4^07R5+TC,==G5&;I"&50D9N9$;,V!7%R5(4CRM%(1B;O
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M@&.Q1FP"9,^1<9%U"JU#(&N#.PF:=**)3FZ]3&BMF*\R&G-401:K1*ZE<U4
MDD[&*'0"+Z-C2I;L6.NJUN5(3H$,#63<02$KL7"$88P_XNR_/PWN1VL^#OO]
MM\/1'V&4SP26))**=-1Q3D==%."*SY"XT,XHZT7S./V&$(\C_;-#?*)+E71@
M?=P/R0IF:=E*@"G6T?E'KTHD3QO(%!**?L)D:AZ8.GSLO%.U+88C=I)Y!S;'
M_:72D1:+,#R"-K4,V_%0.[UQT%D;'S,7G,?F4:A%%"=.@]VDWH$A\2K_W\OQ
M9!KW_W6XPDJ>DK?V/,[U>"5C:%H\^Q%I >/>!.=7Q#_@J#?,'S$-SV<J^Z_0
MO\0SLI*\2]H#6=&%CN&2(-+20#$ABO!%QN8F2==K.FV.'A4CNK@>7"7WTWA\
MB?G'RQ%MQ3.8LQWZ]7 P;^7^OLR^GM2K[I\PT:].>O42HV<^:R\(O6=D*-1B
M41$4:.6D8$QY;]HG<79!?-ILW:,V.RCC7X%^^IX\#I[$%G4],,A&);E)5GU0
M&6NG-FV]DC;;U@5?.P%^EDSL0)<=W"IX\#6ZJI2]N]N?F6**3B&3CZ0C^=:L
M "W DH--7Y:4C6A>C[,%S&=)NF9ZZ^"2PT/OR0K$J+6AMR$#&EF#;=*"4UC
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MA$VW>4R#6.K.JVL48'U71_WANUD699Q&O2_SM<QI9W@T1:"%8A%I*RH)',H
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M>?Y8HD(=#206ZQ2H.MW4J@@\LIQ+XC50>@J>?S>J7!H&V$2D'7J/Z\ XO3#
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M\W*,R[\[I_4ZV#LRD7?!?1B+N14'A@=68 ?[TTYK8";8E)('[YP Q;% $,I
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M-+V'9!I[C0H<BIBUTCG?*X_JE*K/FGN[J:>[ZIF'K8^S9 UG]58=1BYJ%78
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M$2W8%)UD4CO#;.-#_@$XIT.,UK+O(*V^<NG3Y-P9^FCJ%26H?6! >9;!%R/
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MM!<) RSD!,I%A!@3!X'6%,Z84VXQ1-[VC;Z&TG9OF]U@U9@E5U8"9BWKJ2O
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MTR!(6]EW<'K<R]?%R9DK19(;:X&9*.F@C*QV]Q$@DF&,G">-JO4<A24P3H,
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M';.)!^/E\WRZW3K9]?0+5<O9@M@[4V>/Q5O_<_G-HRG_S[_^!E!+ P04
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MK^R"//5'B[_8Q2_\PB_\PB_\PO]L2$M*2RM)$?_RW%*22C(R2I)R_[",R$,
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M: :@   B _W$7UX00&=(2,G.@LDI**F(%<KH@3,@$I(SI"1D9*2DQ*LAQ.L
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MKUGKBO_U7]=::^8>Q'?$'( G)R4K!:"@H  1R'\ 8O[&A:0GR ( %!0 9@
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M/84+S!9WU.,_ZAGFGYN),P3GG--*/O+VJ&C<-63GU8'N5Q;>F]!-QC<??EP
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M4%"M</Q"5$WW E-O%;75.^NAUY3R<A',E:KT?CNGW8VF)0#+M8KR--GXW'P
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M3I65UT[:W= 630YZ+\)8E]AZ4G?_VT.-H.0)"-3<I;<.6:X*TU-U#(&'@KX
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MO?QX>T&7;!;_1QPI_C^>_G90^3+]E],*0.K/0AB69T"1S\MP.<C)R3-\!JC
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MUB;/(41'#'@%C37N9-,CQ=+)9?]SW:P,0@8:L9K;^&X'E?N?%!X<6[Y3XMK
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M[-76@0G3$G_\5>U91[$G<S+SQ042W*KJ=$JF\83QF/KM4864K?W[SI@=#@Z
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M8L^?1PQM"V%>TNVI$G#I)OM&Z0AR4HYLQ=L0<^Q9_2B@\D^)K1Z^_1/8A6>
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MSBTN$H =W9G0OL.4*=!-XY<8LY_7>H-\\5BY2-LSH,7QJ0JJTL#5,F^^U]&
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M1Y7&D@S?H TKW'I@_/J?/1>F[,&Q0CC-'W?*?O2W!;.U<9(LE\</P8<8>#^
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M7==;9^%:("KKB;/V7C$W7+64LZ!%>B9E5<OL*8_/H5Y6G1(QND]2)'.O,V>
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M!0<X0@9 D,/K2 3].O-OYB,!>.Y9W\.C/^UF9W4VX!P>%Q5_597_VIR(F:=
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MED)>I'&X+@.T=8=,:C.[30O</HNXG%!YR@3\_C=;U-0+&6T^D\BTW[9J?6Q
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M4=4ER8_#XG+96OE/ES=KZAYL^C<;6FH\T][>+;"2BBN2V.O\=)_:LYS3CQU
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M?]C,A/*;H 42?VQF? W7>1>]OZ\ODE_VBVLS0L1T$X[T3Q*FY[EK"?P\PR&
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M!IBXAEE6MW],H&L\6]SZ=PE\?W39N)'J6U[S4WKT4CA\WI'_JY'RD>"'^A=
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M6E/B_=J2W?>3AK!!)8Z,#K5J^">@L%F[3L.YZ=T$>;'-#35V>CQ?6KNJ[*R
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ME]%[T^=V(\.+O_T' +Y_UHAUVF B*?X8OVS(NR/5;"2$[E%[\AU FE7 R2]
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M*W,N?:WP85VB1>P0:U<@(H[V'DKZ? 8N7,@JQME^T"K>-'A+7GD3FQZ7PT'
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M8*V1S,L+N*'.K1XJ?3\A73D=:5(C7J^) ]QUK./ZZ/@#4?ZEJ06EC;0YJ1=
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MOACQ0LB]LN+$COY+F19O=ZM[>0C!!5Q"?FK]@C+#%U6PC)TMYJK ,M*W*=I
M\<0+\\:,6UJ+_]FB'?Q3F6.$Z?6/L6%'8[:^,YIT+$U>"+H7"X*P1"-"[N_F
M;;)2L49E=D<'!YKV9@SZI?T/_6;2K2P Z4PLV<#(*EW855@Z5U^98X6+^]2X
M(PA;8 )LXLH[KVF@(AF%K3<S[R]<>(SNZ,26K,IJKGC#LR_>NVN/VQRX;)]@
M._7TNF2EH/U)+- FG@Y-$;:O08]7L,(BR0+8/FT+]+7O_WT.WE^W4^!(9F@
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ME 1I<VFI0PH.:1[PS;NK7+/K7KPR? V+L#O,ZJ>.*E3K&';=EWOW 8W0$L/
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M>H,:]#.F7_7B9\?C@_W7FDB.OA>Q)D1)&"T;*^K0MKIG%A/QU@]$""LIE8^
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M=^!%)&*#86-G>0F,!W$=")'A^'YU1XC-L\O*7&2 S+_ZQ,EYOA-6N(Q3* 1
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MVM8.J=U/UJ:(Y-Q&]=NF!WPSA:\Q<;DI;?%JKSQJC.B>7#D).&7%[69$VU1
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M:@J6Q3C CPGY54O@@0Q:-4S(5U;XP&-+T(T/U^FH=I/NIUEK"T=@*N],#.O
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M<;2M7YQ*K_3QBXHO1A*E3<_\KCI$G^$F/0E:;ZGDOF2P$.BN7UY:U,TAWAE
M^(Y->138XW0GQ#Z=UGFY*F/"8-P8>BP&Q*?\%6D1&'<773Y55>EQ$C.&EJ5]
MP:8G%\)8F-A*&3#A1&T^8/))_=1M]%O^DP(<)(Q#TX742[KYM9^OH*X4GW4
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M%TN@:!8>]H^"=$'\1W[6.?IVA/.+1D)*CG0]W/Z9TI0. ^3J#88YX?1H@H(
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MU:#/K5:"82F&WG"3(SH.6C/Y*&KIZ,\Y T3IG)JP2&H-MVK^K$^.)-D"9SO
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M6EE_^-$<WH$<*UJ0_PW/G/\%6?7F\).Q=6GBGZO[TA1OP[KU 76IF\%OE)6
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M:(T7(^S=/SL#3_T/3L#,O;[VD(A1@#0\B:>'>S;"A'U! C@U Q+]G=!V%Q6
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MX]IB\TQ$<J8D3G]O)D)Y?)P>(?505?R</NW[P-%U8JROY/^<=5)(AL#!3W&
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M#--T"L?ZR^-U=RSY=0V JB39Q9*CD&R4M%!!(%XN7615C9#Q?Q[ C];3LM2
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M_4Z!U(L;,3O28C:\$+5()%Y0MUWHX'@C3TFON4>.=F[2N8=@Z'QRXJH3=92
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MH^+,98H*:12BF?1NRKL%<FX+?NSHFR2HL)O!E;*?P-0F_/$1:+S4=$%\6L^
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MVMQ//:>BB:@9XN1.I'&)V%428192/O0#6^/C?Y]3@.KIM-LZ@RRMH*O4B\B
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M1Q!Q1.9Q/]S2M4]/RLUPP\@N(?@)EMM *>9J0*!'7 ]@7YITPQ\SC]L0FNI
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M\%_B.)RZ0R>VO'^2=SGZ+R]:B@Z(E/P"U"[X'1593G_T*?AG9E=+;HKLTP>
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M&.9$QA,GFF&&_;2-_7T*E,<[UKE/-6]PL&!I/\ !]&Q[11&&S]!GCPO*5H0
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MZ#ZDR--FI6K][2.BH=R<O@^KTDQ^2>S%<BAOI+?X*$Y2O),'ZVNSNR4+8]V
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MJQPE9D&G/78&;X?]W#0-$NMQR:'\R9#QAU552W^$%D?Z44?._ 0FER>H)*!
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MBQ+6P-7_/",&[7!&FI=YI#[HJG!WU"9\*-56YJUEEZUUI\NJ)U]I/$&3N4^
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M@*T@(R\#P,'! 2]A?P!T&3Y!VLO&$@"4E  6  !0 40X$0 >UL(  #B%]S8
M(JP-!_O7_I3VRR] ! #P'CMD  JL#X8#B,, (-OY#>OG!0!/7IG865"IN+C9
M^,!T\G=-P5G_\O2GIOY\/0%> 2: '6 !4 $J@ O@!M@ ,*W!_!+!W-K-S4F8
M@\/!E=W$W-'4@MW,T9[#R\2)@XN=DP,0E?!R,C&SLW"C,K6PLG$08SQL:F6D
MLC$78]3A4^)4<GIJ86TCY^-BH>&CK&GF8V<F9,XH(?X03=1+V,O>R=["S83*
MR_Z5@ZNPEQC-K]R%8>U?NCEHQ$5=S"V%U9_)_(X!NQ.C^7TNGIZ>[)X\[(XN
M5AQ<0D)"')S<'-S<;# ,-E=O!S<3+S8'5]K?&3RS<#5SL7%RLW%TH/KEWL34
MT=U-C,;=W<9<V-+$DL_4W)R/S=2$QYR-B\O<A,W$G(>+S9R'QUR CTN0VY++
ME.;WX<W-_AC=R=WEU:]CFYMQ6+RRL+=P<'.%:8.+@X;COV%,<5%S,V$S%PL3
M-T>7WX;7L'#^G]/9*QOQ/RT>48[?^WYKP+C##/C@P0-1CC\/S/$/@O_> [,?
MK/6'M6&45/\?7/\G#_+W%6/A %LFGK#U  4#3P$4)"1D)$049"1D5!045#0<
M=)B.T?"QL#%PB/!)B(GPB0A)*1BI2<GIR0F):-AIZ)F861^SDE!Q\'"P<#.R
ML++\P@0.!145[0$:'CHZ'@L9$1G+OWU!OP$XJ B2",X(<#0 / X< @X<M!.@
MA$5*)+A?K[\%##AX!$0D9!34!VCH,(0:;  >#@$!'A$!"0D1ME'!^<&> X@X
M2+C47%+(C]1,4&B<\;C?1F>BTCZI:,-7'SVBXS%U"7B 1D!(1$Q"S\#(Q,S"
MR\<O("@D_/29M(RLG+R"AJ:6MLX+73TS<PM+*VL;6U<W=P]/+V^?P'=!P>\_
M? R)B8V+3TA,2D[)RL[)S<LO*"RJK*JNJ:VK;VAL[^CLZN[I[>L?&Y^8G)K^
M,3.[O+*ZMKZQN;6]<WQR>G9^<7EU??.+7'   MS?KO^A7#@PN> 1$1$047Z1
M"P[>\Q<$'$0D:BYD7"DU%!/G1S3<;U'QGD1G5K0]H.51/\(W=1E%(Z#C7:8_
M_D6T7R7[SPD6\%^2[ _!_B[7+("!  <S'@(.( &<9Y"\EH4"[Y[JA73<LNZG
M6]2G#M[*)H95L7-50P'/\A;7Q:-FT(X1%.A;A$SK4I*HW&E[9%Q@J=P3TWMO
MR);ZR1#"!1<^X8ESMVN" CRK%0T)[ DT3N]*8O=:>\_+KXPDSCE :X=0P"X;
M0AAYK[AX+0(%9G?[7,2L>\_+,O;F&$_><-P-J^R_<CR%H-]%ZD&!H%4HH'X)
M488"%XT2RUY08*(%"L2VWI<U)]).A47J250Y9?1=M9YB_:3Y2?.3YB?-3YJ?
M-#]I?M+\I/E)\[^99N\USJK$U?-2AXU;E!]?!W>23IN'9H@A6UVOMZ-WC;J.
M)#>?3T*!W6K0S8.RQQ[H6+*8FZ@SVY.78F1UG)W3G=UI\H9VHQYG8C(A3.6I
MXB7!=B)V[Q^*-:M_(4+Z_BBR.QLR^ 4*9+"";L]:E[4+\@=O8P<(OQ??)YM
M 7%M*'"Y#6J/W!O NCZI@P*MBA!\VY#78P=DT7M:?R:4O;!X?W>M#P46<Z$
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M*BL"IF:)\B.\.UWTDF[VC4JPU.KXR@G#SG[LG3=UX;347)0AUH9)>MO/<I>
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M%7?(MB0V/Z;8Y VQ#8SB4_>F*JZGB1##ELU0FB@6E?-2UVR53OGVF$"-7RQ
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M\>I=Z[-OM1YCWK-!)39KLSD@RVN\1A%,XS=[2U! X32!_5.</?GAE?Z9F&Q
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MOFYH_K"?FB&HI^J7$O\WJNBOJW[,-J0' F/^Q']?#VK@/U+:W\X;U/3OIZ%
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MK'J3CH(W7,43-7MQ8TCT&F+!QJ"%#NI<<9':"$2P49(6J(@<!],ED@5LC);
M+4QF355$.GX+?<9#D*W)#].L6P,S6D=("_.Y[*CH/-*:F%^RM)1!^SE<FU">
M0R<G(D@A":E#E/B &(U_ \$O(UPWZIS2>*/O'7-:_]BH3-N1M*;,B@S!359H
M,D8G?S M-#@DYP$P_GY^#JTOT /K%N!\T$.3NZ:>]Y^\U!5X6<,-!S+D&:=R
M4,M*^_HNGW-9YNU 1K:')>PY'7N_B'+/M8XVD3\ 2'X6!4MB E1Y:=/\4G?0
MCRB,0*0U?(^$\MY73>02)6U%\P$X^JSI/13X"/O\:A^ G^E*6,L?@#14XP<
MSO$!..:",-ERH+F3C&3<^6=Y#],_0BZHZ%O:^Y91D>\XCY5\>NY_ UH!\;>7
M5F27#&F_I0C!0F:Y.IH4.5(7^9E6A,F6=2MC ??@'=,SZ^DP^FY2D8T9H?>Q
M+.=HD0^ : '9+;S"46%].-X,)XIP2R%:RKO:.^^%_'\>"6>ME=M'(=+OPW^5
MC>UML$WV ^DG:C5YG.]/O-O:=^_)%7Z+,_1[BI._C2RW3[N?[[N+Y,>_BLZR
M1I!&\EY5-1Z[]XJ^I?]X2XVK?[I2Z+U<['U/'=E@:/*(@].M2$2^X_V:3>8"
MGL%PI;\M ;]J)!7";7UN[FC6WY8D 2%D+VZ1[1S58$5T32YM[&[6^V_=QO_>
M"R'9_^-_#.?5S^5 ^_MRX& 3XD:HGF9KDJ5\O/6@*1G]ZMUJ:/H "!-VW2-M
M/0"KEKR>^B9?E[[SMUQ-'V</[=[O,VLM&@Y)U7&)E+X+OX;[B<W9O0/^.JR*
M!^"?1?]3IQ8GDZ?_88O015VZ2,;AA576LY+(1C$-DWHC9?_3?R.G9TT _XL;
M89M&:[YQ"KOAV'P1<55#6^K'R*UJ;_CBU6/VPHOAZB2L(!Z4*W#MBOTP*5OR
M5-D4^(T^;I7<(;X8R48EF6%]K('&R*OO+;ROZYOTK*9W/<TA=:I@3_2)*Y/O
M+H_J4J,@2D_] (2W/P#V39_S+?_\_>?K]A^%/B<C9V['GF(>02T(TL%HH[3V
MUIB^+;*%<IZ8$*)Q73F$_HE38?'S:I1F9.<>@K 2.9G>AV&8\,#*B[+$17U^
MR81)]5J+SP/?WN\B[""MA=J)8,E9KWP37H#4)&X^)RZKGY<=)<"5K_<W+YE7
MVD/ Z9NQTAJ=D3N7*W#$J0J=NMF2C,RY^U&O+A"(_17LMA_L7%^TL+3-4\&T
M4)3=P,,][)4H<;=V^"9) &+WZAX>S?ZP&>$Y7L"['^+E0@M=0UATJ1OSZ6%M
M7T)3 <,SH5/5_5NL[#FW[B@]?)H@PRCX6J, 56C:,WS &,%_2*NG<NJ@<NG,
M3KQ:VV:6]YGX &,/J%\E94;\A1L"+%9]+G1N_;?Z.&0,IWR-A:!BQBV)*N7"
MC!S]<_"Z4#C9,E2MU4H?D29%/,> H&-2N+"%7+U(G'&/4+.R* D=61N_2ES9
M7)^-'OZH">*@NZS# U"R,5M&<8Q61E6(U4$5,[J#.R8'U[@0.#-N@F T'YI2
ME.PYO:UJ(ZC_]9/B3)X]:D)-HCI$ FU52CR44*G"XB4F,DHJ[PY4^3W"J+F%
MWH[<;E#VB2,G) J/]/5A.(*@(=AU=XFK(&=;[5K' 9%0$Y1PT<=Y@A<EV0Q$
M>0$ F@_2NJ=\X>+"F[J*NZ^3O<AF@;A5L8Z4\8@SBT2A\:W+Q+$7:_7_M3?A
MT@//9]EZ%I0*=3)40;;R/VRTT8ES7C.+P?A&20TO;T(8 OT,K/?(3SE8CYFZ
MV0ZN?#!?WHDLM%P;^?#3"@K&7>PS:@7LS%8.B4P_SPOQ,"F[J?\$BJZLGD^-
ME??$,3_WKACR\!!D:SGW,(F,OB,4ZIU3"8"]:R>P[D*>*C+0OORH.W8K9)RW
MJ%]T>W%M,B7)[:O&JXFC*3T+\Q2&I#DZV1X<^UH_865J-=#:3$C[#ND)&X54
M[)*'#8\A0*1P=!SIWY..UGO3AGLQI8XVY:*DO5!>M9#UME&W11&!3[GMF:B
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MPT1116CZ&1)PVYUQP[\75G>@% HSI*2<PMV^ WT[,Y?47"_1%=-H)L1CS%O
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MTLRY8.",P>-3\;Y1#<3NJ-]WS?Y65E+LT4X79,^D"$A5E+-L$KW!Q%PV=IZ
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M^<P9J18$E0KLO($2GK+1<L+JU%J"-ZPQ$PR]74QV5 C6V J@#IB47E?LWG'
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M=50(L6O!VI[,=^&-,**C/O'%Y[LJ]8[E+-ZCWBO6^U(J4MF@\ "([^?>HSP
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MCN;48 UI<>8?T\2P=SC.BDNZ^A0EV)\FH3MPZ+NKK5"L2=645%N=U%06'O$
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M='L4<G^)K?=[>V35@\;#2VJNKE!![F%670]Y&C#<J/N=I<+E2T^N1R-YQ_,
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M)7\P]5!'_?#Y'_'7O^H428'GN>X*%$<SZE:'GN#L4E\VT6^HF@7^F9-)XA$
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M;/0K8PD?Q80;>L3)5=W6.6H2SD4R>U_J6H Q-;\)3/(8GV(A^,/LXGW,HJ?
M+*^+57;,BF][/9V5H78-*2Z1G!PJ3_ P9]!Y<+NS9<Y,5:) &@,%BU9T' E;
M9P-D7M^&#R;)'D1R%+2=:NU]9#J"M#^!PX($@,434>.B1(4BC?BT38]_A[1U
ME<S.FUBH%L2;[E 0XVO(A*K&V&RL94>!+-1J)2?$QL:,R5'K2H@!8C"BM[QL
M;NBM3G25I\^EQ/)(U=O3AC,RJ:/4%)Q+EN:[O+33EB>7*+?G!.A39_@2KV,N
M5FS_,Q*"23X&!S#=">(D,G[%&"A_;UF'BD1O55K?TX=P#,C$EK[L6IIYH&C$
M?4YR0962<LK>%EP_X/N<+FE_KDJ,Y!"FI].A6M.R<F.AL;/-VMUF5<#E>LK<
MP'FUO.B.)!-D>G&A.%?JO4C[0<Q4/;*,L$K.3D[B?8;7ZZ('4M%"4%YYS"1!
M &3_<]OB 7W62584PN8[+Q?2T,Q@U;4UWH"0ABE-[ &@FCG%G!921#7=VY.0
M_@D9.AONO2%Z\;EV' 5QH.FA-5(,M_/" M]G+&X%%A?\8:+30: \K"FM763Y
M>\D2?W6RR)T!&P1Q<<3:%@+U,*LW0N@@EY'%X<&FD0-&ZIA%WB\@?3K>H3*6
M#)]0[&H6;Z0U?E/C8\^%LOL4SV>V^?%K@98O''3;A.9TP++-%#!=XFCP%1 ^
M]AQM.,RW6Y9Y%4J4NJHP],@8(SYTX6[>M%4?\4K*Z6XA3-28#)ON\;-2^%^Q
MM4I_0/$Y;'JQ?FLP,W)PWZ=S)P"ZIK$V%$RGH/_8J72E#U@GJ]_?9E4V?:"I
MJYOX]NW00>K'VCBY:U$N*X5W 50[5%\I,M=6,WL&GV NXJHHDD'0+B@;^$$B
MGC1"1R M4"<TZ595!@UQ9]8I'^Y.Z;T,8QF?TQ[_6$\XA3Y=@1S@6F)#B*#B
M/U7)J2G$,^[SS<!$2X@XD=E?^@M!41\5JJ(,WU0\ B"!CX#T9X G 0())>SN
MM/D1T.KXVSY&R2%X.O0(> 3 39'<B9DIJKDXW8&7,4Q_F828'UX0D%QO@1\!
MWGN_5,62%N"MY$? PW.(X%70>,:7]E^:94:!7Y[[^O-7WKU%AE#,K33@32+;
MG8<-J7^FI_;TW-J0]27!M4IF-JZ_=?<#0-/SE\&J_Q'PV:_[P77I$;!<]]/R
MEOE7VI4T&4>_-.;/Y7]YZ(./PJ<? <.\CX [7"WP,5;(*@%1R&W]0^H9ZB\-
M.S#B$3!1_7WDUW3@<A<\EX[>Q?$)&S"NP3$W;>_D_FSS)"K]94+??WKNF#P"
M%K"I_K^,+>Y2@+JDJC+&*>@N(+R69.8T>-DX_QU:5PW:LSNUQHD&$+;O?C"M
MI3M3S]VWP^"4>,KE4'XXMW(:0[H6='%$BB+[!$%O/L&L/58SCI=NW79X^U2!
M2!%#WUV(S-WLTS*IN/:^;Q;*8]!VMDE1-9_GCRJ*8?<Y_51^HH==W?WV&BK
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MC:].4(V=.Y3'R)A:K$LQ;$3R79?QW/774Q#PO! >EO:;ZVBBKJG^E# G'7+
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M;!@B CELK*SE]Q-\F;#4<?'"5&E)[CV<=RL[TDAX%.$[0I^6K7O0$3]_)W6
M VUEE#%5Y0#.R6S]ZUNQO!KQON4-&;1A]FCF3ZFW_!;?SHV]D;[YAESH CDQ
MH+LWN*%9;WL!7*3P.YT ;@]5JYOLG@G+99 [/M7K'@JFVXEH7)/U P$]/,+3
MH,FR8XY$CQ%*:S9E&<&9#LR68\GBC0HOEA(XNX .S-9OUW>XA-5JN+2>E,I2
MK/*8B*TG68N07(0\.!YGV.^+6/41LNL)38X1-E'9RU70['0A>#KTS@LS%&&-
M257V+5A0;H)8._8ZG<;(9;T,D?VXO3#1XJ&B!%9<;2%K)M3>;D"KQC7J$<=\
MALZBKQ&BR/:2ALTG.38_VC'$2@XIK&7;*5>3T7RR_+;>Q>VZ)XR:,KVR+J=Q
M-8CXP@U$H,DJ[3M!;+DL<ARQ;*ZFGJ"2W(B17 MQ[D(*T],/=SNM/TM#5.ZX
M,=_U:]7T7)6GZ;]P/GF;>CH\T+6P4)JT%310>;SD_TY7O6A$0Z;W17NN[$.X
M\\>C-*33\(X8"B[N5QDD:!;*'4NS@1?\?GO[OIJM+ZU9G0ZH^.$//AY(&!'J
M2W>W8TQ#(G%VEFXY9F4<^Z V$9[WGMU6 'KO+#-:7PM3#;3W2BTL5\2\#:+&
M5W-2)1-GL?-$R^9 P]-(=MJ3K5E$ML^28E"H[^(L^+JX;*G46<+BNEJ^?T=?
M.+>PT&I8V)B<V0H+-U@G::BJA!]%O6YE&U7CL#:E]H!A[EA24^%M%$2;ZZ<*
M,-8-TWU^V(;JN0V=>T>5()Z*.UN<.EQG\BX64WU:>E&+;@!&  9;T>^VF_ -
M-M\#PW>^6PU#9B8,*E!TA;.,8<1'I0-<C /E^5 T/B!\48:YIDP_@K]^0[CV
MG"O+(++-:_W:GJ%+97R"AR-4Q =B[C'_UEBI'$;OW1P"F423]''+#K*!3G+U
M1/VH$RN59RY\=J]=TYYW=P)CXD,/U.KB<Z*!O 3<!H9O+5[TP:##"S&V4&=S
MC'4\@+T$5RA<OC\",OE6E'GE6$,;3C_)6C]? &GS+X84>H9N?E@%1LY+0WS[
M/U53P,EPH-J>$OIT(=UQ,U:W]U80@/SKDRV)V1*TX".N25-FAE>$L/?O]#CO
MJ 2GJSFJ?&,,JXW\3EE=4Z3[0+WT$21<"S7W] +MW<Q4(;V58Q73/14I%Y3E
MC:<]M-YMJHCU^.6[KD.>9_*?#6JG4I5C#KB64U9YNZIOZ:Y[]E[FZ7!Q+ES#
M"Q%G<K$;>4(]G3QPBZ9U!L^I!JK"  XABED,B+!GA,9L4(VP&>XN&^\C2?6N
M@L=V>4T:OJBG/P)23'!/\/+_?;:J/"OP1.Z]@_P]HLK$^POVF'D)<G]Q1^0L
M XR(22\&10WP4; )^.S9$]=M%@F[$F>3OX'3!"^EJYDXWPDN1[A>Z(#O8)2"
M?MI\]-_^+$F3>W_SA,O>9("_TXT]W#]C1'T$^-^A-]S^##K_N/<G??XW\U04
M$^])I3K5-#(DDCKB:-*CH<"?96'D;\]H*G@?2(Y$3G^G&2G"CGT$(';]_9]_
MH:5)] A NR+[VT B'M8\Z5D?,$(P'SX!4R^WE77:>4B?\&:@:J[\]?I?NXU^
M.@*Z4P^"(DN7CX8"+->HI2N&GD M@Z_47ZC]I4WV?SH4Z/N)<0Y@Y(*V)+D?
M%M/! M:3R"./>B?^W7'?2%9@9"O4%"^N8;LMT(:7,%7NJ@@%U.K&D9VE-=.M
M#U<^B*^:P-5BP!]BTX1VI9IG^I'67V&":7^ 0\DZ6$3*%,]A2 *ZSE04=:=W
M2/.,FUZEHR!"(3197C,CB#[XX*?>@>SOAY$*Q1\1'6:_K14__9*F'P%[B6#V
M_((_W?R?/XPV&JQ="T!@ Z9 UJS5X]P8RN[#U5!JH^"M<J*,,JICCES[XOZ"
M[3'/W'>6 CIEFFOT-B-\%@=O?&K\(A"X^GSFIY0AYCP?@R[*=W%B67D%8Y_/
MS?!MX)>\B4:PLD-H5"MM'F&V7)QL+3J[_6++I]"EQ!:)_DTQ6;EL'7.LF@TJ
M*86N<6* 6C2AC1=T&Q/4=;+*$8&/P;+OM==0"DL#YP+D6\/6E,?9-?Z1_WIL
M &Z]NBZ&W4A*BSM$.GPF1#V4A83QQ,#S9O%A\.@\U6_?P7V]-%8V%!L)>[-+
M0K5[T&_Y1'@X/Q^NV=^PL:):DJV7Z<?*8!:9/HLH/MXU@JH2UQH,%E2G^L)"
M3M6H%G_A#($G8WK5''G <WS7>0/^UZX4*:QC*?5M=9T'A=DRKPI(<<.;9O2K
M1=)1O[?HEAO[M,/XP1(B+S/4A08:YW:[NL,5996);E+55[PW#V@E4X/UHZ#&
MHT2^';G/S'1QEBQWY^??7V[T:+?4,]"(CY>)*GOMVD*9 -CXP<Z[7>1@QTP%
MO3DG5YNXU6.<L!POSQ\J>6.K4M0@#!E<#G3(;8IPK._1W)T]#-FQZAM]^F*\
MT/4O^E[N.X"T7Q%!+TCG!\VR"UGK8?2^H!TP6_&BK\ (OG>?F!8/HSH%"3&\
M/Y@EH<V0]9/,Y+J6)/3ELQW+!AB[?#Q:,'<>"A[$[DQ.GNZEA'=TY"*J"3%/
MA^CNSLK[5Q9N!ZL-#9"S$+@C$1.HM^FIV3%A"\$UEIF_Y[<:G'.7(70:H'@]
MWW!\;7_M0X>[.2ROP#K'!I4NIH9[870U\SP/95I[<VF 6%='N]'V4#9,I23A
M>)^\J<H];H@8.UXF_U)K70&N@"[*G.>#>O;:+L<7<PI+J8%=C+ TB^44M VE
MI??MN3NGB_.8ZZWX$3UG,'P*<$'TR>"7.]_GM5KMS?/;&;_1L_5-O@@OZ/!M
M!Z@&DGG-RDERY38'6^A[TQ+W X$)XJ%<<O&<<1W(4=56MCY3V0#K$0V<1:JQ
M0X$.R^!09J:7TX8<>-DJQK3D5?B@9RZ=YO^^/HG*.6]>$2-0HQ_V1>Y"2-+Y
MF8*LUC_8M>(N]4=?DBO)L\-#K4? ,N'2G2S)4<3.TF+M(Z"%N_DJ83P#\MO.
M_FKL5[2OSAVEF_,E!'R$:OWP*NPO#<T4Q5;FCI_>+4[JSX#=-Q /L5SV;VGL
M0]*$X/3!G8=]23Z)7+#;UB, \,2_5\U%_LS(_]G3X,]C>#I@QYH;[9]ZM@<?
ML^>+_8NC0)C<P_GP ]3@(Z!C#-3A9BMZJO6S*MG/MI._S+M_[1W=Y8L<SO9S
MK:/,!ZV?(S&3_\L\3'Z6K*\ /_'TO_I:&#X"VOX\ 9._4I[,QGI/]#.([[<?
M!XS*<6ABCJD:9Z*5P8D^ ^:/T9RU:0,(PF1-*I*'6MU$@SQ.:MZT**%:F65@
M&K4=I\7Z"==%L6)-==#NHHQ[W*1DEA(DF 6/.*.V\7G+>Y+OYZ;,/QCBC8'D
MK!0Q&.M@1'Z>*3'N[PJ17[5O""M-5[4E:Z1 Q>?YXXIBV#U.OK]=$^[_Y)I0
M]&]=$[#9?QFHG[#.9@44^__)V-ZG"W]V,'CJ2#.+P!Y[G95C+2R:\,V=#3T\
M,Z(4<B"?@F91_UZDCCS-[3 F#MX0-Z]TL,-JW0T-S"#;$F)OT33S[.CB[NBP
M4M#BB"$);5GUU_ WNZ PFR\IWE6X[9QK2NB>?ATB=:ES77DDE[<>"P_O%QJ=
M'O9X2\NKS7YLIZ'QQK;>5+QD[/3>T03F7%;)6!G5Q865HV<[W;=IL#@CH]N!
M9JL\A-.6%K9O*('?">(9B#355\<IRXWN^ZG[Z3S:8PB=L2=&A A?;%>SN!3*
MEY[<)9H61>ZI>,O$UEBT;?7" S<NWVSQ9U T<K8W/9]@:T8'23GR18(T>BF_
M<">0+%FC)!6TD$3.\&;QA9XO/76T,.!V'A; O#5:,0>JL<9A+!MTT3^940E5
MT^LY;/W&FPIG9@/*T.PV=Z8T0HGD2X2.#HF>TZ> ;GY#P+-\) R82E,4(O:T
M7@X!,F/&A[3?Q^X?>E!KZ,'B?'#ZM.Z:!%-^;\01;,.53W8$R;%BVZ8<J8@;
MDS>U]W@E8-BU;C@$[5W_Q;"6__AGBI;-R"MZ[5NBX)'NEU+66V\9/Z0@%P@,
MO'&N-C2Z?BTI9%L=Y9/R17'4N/0*9)^#8QZX,C:#-EAO^WR,B]!IFPN2\W0J
M.S:^. 2&:=24GJS+BLI7!LV[#N(;240/#\"KD8NUHX+I\JUSS&-D#1U-LW!C
M%DUEA)TA_3;290 \*?)2PK#ZL6:W?9,T5+[IQ1 =V41%]<B36^5;F788''6*
MT(5QCPZ4;EYA+L*2'_0E_U5R:TCZEF?L/6[_J3-DB977OL:Q4S//ZN,J>.KM
MPP<O&G"G\$[.@YWB(P ;(2?QNE>S0O74%:-W<Z#X*H^?;6E(6G U[6P,S$T/
M#.)N\(D:C)L2G'L$&,8Z7UAQ$"[W[BC]K0.@[]*=Z^ O2*Z2F4VX*/Q?=Q&O
M<ZS@9MJ<]#7D$8 $WQZ1<W8>69E/<@_R1/G=+D"P^N[SW'UB2"9AK_PC(,AG
M3/9NO8@ ?'41=C^BI#BX3IABT??'WS,?Z-!D.4\C*TTR$WNX^68&KKRML4!7
M3C<@]E+6+ ;EWD6=7-5AMQ-YOYN4JD6^2AG7@U<:2?=%VOW0<=R,*6O74]_9
M@:.+B,8U+KJA',;7\>C0\\[=FCO9@0JY-%P'=L VGFA]=HYO_[$T^-M+O?+_
M)C?Y?WV)VC\4">YE@+=%<OYQ,"K CO_-R4_,\1% ; ^>XGA0I=E1U/X9+W$^
MV!PMS?/[?)5\!.S.[<C\_O$[$=5O=S:)?]BW?J\3GN"D[,^$Z]CL?T0G>+WZ
M(\+NSQQ:Y(^\@#E_2WSZTWGLOFO_X$_+2_.O00 T>0<>CX"R_@MA_%2]D[LV
MD8-N_&ZN08#B%YVQS:9Q2_*O%;-F?C4$\OA:1^YK33S$=-&IP0Y[ <3F<9"*
M,Y"M0[.YOW4\"8S=<M*)BCY$W7;06&PY_@<R+H[FUTM<,:J@=>UW'M4:=@:D
M4*U+?B0B7$-F_)PM9:95K+/M/)N2RRX0PQBI%'Q],F^]L#=66LO8?!';0O 3
MN8'[!U9P#54\OEFC9"XO-N=S4[VDGMF'3.//VGC6K7;Z-1KF:TF@Q$?,+)_.
MK5/TXW=-/>P98%07]YFS,WA(.18*N[HR-F: <@?ABO8:G!E]O/I&4+Q2I/J)
M%\\6!-LY8\(<B"_[7X:?'AI663.]K>WI#=NX_8RL>_*:)]($QK22*U93]DUF
MG/11?(QL*AE@.?CFA.LR#U,K5+UXED"FEK(TMB\2.]C:WJLECSI<%$9H=$/V
M0]_Z.X/0V9D5?0K#Z<@:?N[;7':,L4I$P:JLLABLE!M5=V<[R;!+DW@*(F$E
MVZ70KU "(45B17.#;#A3'*OX"3B@@+;D_M8NI"$T$@4)LY&"6<=@'J-DN.@2
M<BX%&LKUZGSJ6FK*5&7@OT1:_G<7S*O;#F 5,6GIJ&$H,/((<[-@@TRPC?!B
M7AAF/"CYO)&'JZ&K5CMG?3:8EOOKBV?Z1"[L_N[+]$1*JS>72@FF[/3Q,)WV
MA&7DK26;R*26N7I0M4/JI6M<N: K-070U<>)?%"O/M'6W"QE)3V%G(0@MQVT
M%>6G:GYX$RB'0Q)33DV4IFR7T3G/#"E%,IR3^@B":,:*5_LUK8S!T$*OBK1<
MZM^5Q:><7,QKUOC_V$=R-8C.4C.$4I6S0X^H2%J>D.1CS-N):'T5DC_7[1!(
MJ50YF!]!]!(8KB>:CYP=,&1C9\>C-RF +$,D,K3"=%F4_KF@P2.*4)F,>QC_
MM+QE#>^P!:X0_-+EXYZKCR+PK>^6\9L:[3R61\ ;/(;,@BV;UAYLK(_\1_.M
M[]Q"]SN@;@,%=K8? <X!0^*4M[F3Z35'IJF2(#(W7--ZWCM(DUO=V;#E]66W
M6:7CRO_J[BVCZEJV==&!DV"!X&X)[NX0$C0$=PC!=>).<'=W@KL&F#!Q0G (
MKL&=X.YVR5IKKY6U[[[GG'W?N>^]=G\,VIRS51]5U*A1U>7K7\\ RWJ2SP7=
M?R]XHP=$[EN8HNXW/0"E6WL'PO@,I6KD..;Q3QGARJT])S<)/&H26EA'*THM
M#4<JR#\MRRSG2U($!^SE!DX[ <XO['PGLP5QFGD3;_VR\8UG_#>CSZT6KK*$
MNY,;";A0IF?3CM(4M)SY!_+5ON?]" <Q$"^2,Q(X+J;BK1*XN@W#7N.$[M8T
M]I?(X3]9;DR988_ATN'J[Y*@SS1.6TWY7M4,&;?0:ZJ*D[%BW8\01B5T#3L7
MB'1=<SAX.L\9=W[^O,^R_,S..K:3&*5!\K@W1E:6OF[HO1A=I0_B7MFJ#]P3
M3 ET3'L &4H8XQ<>6:A/)3NUO"33GF #D_MYQP3KJ-P-,=BP:[2X$YG8#@T+
MWIL?)[+K\^*FY]V,S*'$=VF5JSP4(64K3&B/JK (0YPB:ZC$VS+J7I3Z; .%
M5IF.,ZS@!P#1J,C&8G11>Z8VSP%D0S2WC5ODA$CQY4N?-X:!S:@7+TA:JWIT
M@:,N7M 4B_)N)9+R60??VF$KS4;]R1&%M"!1]:1B+^=%K]4:?'.PM"0=:-IV
M&LZE]P$PN%8Z_*%1LU#,(2-O 2K@>E89L& <_]JF)+*EIYZR?M4$<.)0Z&Y+
M/&\PBK:B/.\L_3"V&E5D\=SR)H/0:2_CL>>DLW!.D((,I\"KD8,5[5$-^FU#
M$2];11XB<<O3A.O)>)="&5W3HN]#+I9/4A;H_$TIVMKF,A^G6.L,$E!#65\#
M3J;'[AK<EZX[T'>\>9L'L>Z%/%WDZ;?BJQPV#M"XU%<$80B@[B]*ADQ.3NPM
M-X?:?;O2;JS%DO,[L^"S7+-)\T)QX=?.3GVR;W\G-B9_PP.U"JZ7Q/WXQ9'?
M?5FE_*R?@,&V6[(N.F'[SL $?E34 HB2U??M+D>QXR+&FSR3KK9Q-\^9CJN\
MH=2;5(V"'* ?JW75Z40M6]NDYX,_BB[WSZLJX9PKMA-.UB95LV)?6<*&;&O"
M[#]K?,=#EB0'[R=(.;I1/T'.1?=L5%UE7[U%8CA^:('_@Y- )!;<11B[-)V,
MX,Z-V*BYN]@6*#.%+ZF/[7F8;QJA?IH*URU9XF'U &QM58_"J#[AM]F7]2&2
MZ:^Z$9XNZ"TM18.M;52R#^=O1^^J?JC/S@T4M;NP8^\/X-.;0P)HD2H!#*D*
MW5E*& >'9IJ#<OI8Q6KS$L-%?NAEI(Z6TOJ^"+=Q56+*4893QPF/1>1:)-+P
M<E(;<AH&2$S]#UG!3SNI5HAFL>HB>7T-MAK35WMP*WQXY?BO':ZFC)YE,"=\
M&*@+6S*& =T*K5]JRHY:3"+"94&NE$#"%(:4 ,(-%2:4AXS&($&^CWH\Y^Q=
M7IX>K![_ZHL&A1FS:\LL*ZS.@"QS!^1]_1 )8U5U7&BI(@38I>?>/\P3)_F1
M.':TN@V=*< F.3?\L/$LK'V4TR0(Z#&\'_9V$;\@5QWF5YOB;Q,LI2I&G#'Z
M<>$,T4K RJ*C,,4A\AE0D0LM YME@(.XQNCD-I_1>&G'<:,XH9C#W&YN@!Q;
MC @"12V*N-4*$?;^J'F)]ONO;LX$%F/BMF'1&6*D2R1E=MCW,.EB#>EW>QC;
M^X/;%)2D]3Z2&Z:X-*083=[I3[I%Y'8:L,N<=!D&SB(2D;]R,Y!#:N;Y;0N3
M->V3W_")<<NA#JNM;7CQWK@[232.&8Z#.#1I=K.&4NVPOK*;>L<F(,# 3%8?
M? 1E:JC/S.>7Z-O 38QJ4E9J=ZG:8;"EK8:1]$Q^O">>.'O"Z("4Q-[O-GK(
MKA+==RS*%-<9F+*.&6/GY4A4A["Q)0,YG"RQ*=1:7.S,G^E_7)^V(QH]^]"=
M4;;K.';H$8Z1[[Z3$N![AIRZ7:X-W)4^_TJ4#TE8AHTFK]?>K>]1[*8:5RFL
M\R]':1C 2Y:3T$?F@J/TFM[Q$=F<GF+"\?51F]:4(2J*H"LIJL 2N3M^6^7#
M:RN;Q)8AY>E5:D4^/)A5W&/4V$1A$>:O]L770ATABY8KNIO1G1IZZ\CR$]$N
M]@6Q@8Y9JQN2,5U\PFL2KG>^U@:;=1>89H),H_:]9Q*6!G$M\6:)JJ^X0T$J
M@\"9)9OW$,7DYYS#;PT=1C2:/=A.KH%49'XQ,ANBY$?36!;7P_=($Y84DHR,
M(,$I.U0.A%>S[T5M, ,MQ1S]Q.4SY"\!>P@QQ1@H=S0ZG]'!>-9$7Z&M:WXV
M,GN5,'T7P14$"0;W#Q O*M:D]8-LV*UIE'E0]Y]!\T:H>1!.(GL@MTA_VMB
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ME".V]1&UD@VR&M2,G&&.Z&J+R]8UCB5LS8.GAU^W/07J1.E0LBZ(\FXV"0&
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M;;MV@$ @*_WB/J.Z$Y(!A^,N_=D+QX]?-BLPI5%S:-XTMY8O$TK'4;P@NGT
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M!_9X[5L\ .6"&?O#<-NT%<F>C[*'GG],C\X#,-1$\L=]S$)*_O:#2^(#<'*
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M^_A8"E8T4_E);XZKS[>?/O\L'J@H%_5V%3S[01D/9O.!U6<6^9&OJZ$/A@R
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M@;XJ?;=2NM\$7[]:K]3J6A?ZMD.A7'U=+[GZF0X^J(LG\:4D.G7N-7FNPD5
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M0I"/(ENFI&5_3FP&_4D1KU^36KPE1?DWLMP8&<>1UR>V;9H.: @!TL3F-AP
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MSI+41+^-J$U^]]Z2;]:[=<, $#T'%L7M+H(VKN/>H;#3\3T46MI@2_RRGCO
M85'WSR<L;C4 1S^2/WNJ!6@JYFA=P(N#S%<CT%2>O7J!QB\Y%XEY%&7]K&^:
M:D5C._J[AT=2E/IO"\KRD&=1 F.&4XB$9)!P%,.<B%APFC,2V-:%N41S8ANW
M(Z1= ._7JWOXOG@2'-PVT<G6Y5XN0FBVG_$,C)W%ZXG?@(9\H]E;!F[  +))
M#SH6&/BKY7*1XMSE6TPA.%&QQ?A5^UODGU>/A:Y3]:5X$/SMNM2VZ6]D^79)
M[DUODD>&F%CG?_[P\=VP[%G# 9#K$@QOZ"]<MUI!,J[T'M&P4W0;(,"OFA=/
M9>$,I'6Z@AX;=[9K: /AAE?1)H\[KNB[.Y<FP*3J]I<B#:4@+(&"20&1.K'
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M,V4S4A2R1:U#K+\7S'?,F#OEFF![L?VRI?ZRVSH&:]EVP2*LUJXY]?N.]1M
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MOWY02)$@,HL0E)&D$'&*=6QJ""6+ B[3C.7(J+KL]=^!P^Y=(= 2 R\TN1_
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M4<I#B:'(PDAW%M?1:B&%>41TRSW!D]S*_W&6TL0ZW=$%0\*.&Y7S8)GM.KQ
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MG265093S!.:<)E!(A +,&)/22O.O96AB\W#K$'-S-<9FEF).Y"P= *<ZM]^
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MDT2IC&6B=J56;;+,:4^\N=Q1!5(TGMV.KF7?+ LPS;1\(HCL-%\ST=0S;]@
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M 7.62I@'6*28(Q8&5DV8O' U\8'!9)V;$'(SFS$[D'8&9LO*H+^JKJ.U_?&
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MYJKK#:%DI(7*(UQ(PC$5*L8\4@K'.8E$$J5%7#@E1[F3'-DL;'(I%W-'ERX
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M3656^OMJ)YA'\,HS")I&,("+C[]TW(D$0$$O]&>Z3B3P=E%.-YO@O(##CL0
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MXX@?__YO<1;]-8FOD#UBFB<_*-%HW;V_2JZ06?"I'?<Q \ZG./A:;OKDDF\
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MW_9,.1,_E%S/U#>]B0GOKKJ12#/..,-1RDI,24IPJ=,89UE,21'G12Y UL<
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M]JUQ0]$:4+LV\L!T1AB>;FIK-)1@"NM<Z_@=@--VCQ\ 8?0&\L=H_TEZR _
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MQ\'W&Z[HO]MM:HLVC'Z/[YKZJ*5C=2U)\T#W1,#Q\-9>-M@[XWY#JRE=(/%
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M'V]WY59%J[6KU$F@O_24J@_KS=N-X,56-TFW[^TTRH,TH1&* I^HX!)C1'%
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MPF)XIQ%QHV_XU9,Y6\)>L0='@":[S51I9O#N-&,+F%"1]=ZT#/RB%./ME70
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MXZI"Y2C+SV+[17X5I=@\BW(1!DE*F9\@3CA&.$]S1&E*42XBP2*?DCPU<IT
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MPKHLEN< _VWSSUXL/G];3L\^K7\13*BK7[OZV^4_<XLFVBB@F,1 !6_ <\>
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M 5&YNUF">[[^()2-TPND/4;'5UL7!O;7^1>BFX+GWW$]$0R%SNB C@D&RJA
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MDEM5/)DWS<VCK=UZ;2SU?4Z%9/UVN5DV;V+F=[C<-'N>L**C,#Z#P,Q I2+
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M5B\7YV$ZGS"F'"_<T]FL:9,4P2 :8J)XYDH)TF6^5W9R/V3<)V <>+31Z7V
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MG\ZG55 UHW'%5U"1]D%.M#=RJ!6Y&8+D'E(1B;M0>Y<WO[;<B[)Q*UD'0=@
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MJGA.3*A-I^^8'/@Z++I$1N>7$USZUO5$.PGI!#/'*WK16NH=0.=6K<EO6.>
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MCY+-#RZ-]ZU93G=RG\PJSYD'*Y6KN?;Z#IC<%I:$=[:(F'GK.[M#:1W7^QP
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M85%%*[4/I^TQ^Q;^?[[*3UWF]SF^.<-!A@$+A3R#$Y=[E9"C)"";.]=9$>%
M?S*JW_5C=4R8,;%46L(->,!'8HOW,FU61>$,1Q)+CK@)!&Y])U&PEN3J6^I9
M\63_$S35M8V+1V-'444#T'HBX7'W)F^UBO!_X;/]<Q*ET52:O"L5&(,AJ1P_
M2OFA3,2.>.)\Z==L \AL,ATP$">/YBZ,J[2"9MHX.?!W=KF]-L[/>S]:JF2N
M^S2=%\YO _>:^F 0UT+#+PE<0YGO0!P3Q38X8W_&_+;Q4B1P=)!S4>4'>!A9
M'S4XR-9II9B6J73+YN>?W^Z#E5[Y[3[::"-YN9>HRV<EZ!L9GSL\889!,$8A
M9ZU5@>LLM;]>?KN75I_,;_<0<1L0.11L4=HRBH&)F.#.I88B@T% 0",ABG&I
M<*=7$#]+?KN/3KOEMWL(N+;3OW5&8PY9 "-WP8Z;CJ8F2IF\0R1JG&>E6G!U
MO4?>&F:5$I'S?7OZL+]_^CO5(7&N%A?CB+0!+^QA#)];IB.#>Y=ID?N=1(YL
M;AY C2<\*>^5*VVQM)_B'@"4\Z7;1/./W%_R?7H!GL3\2[R=[L(Y')S .(J!
M6O ?<T8F"HL\U<DZN(=)\:E@!PEI.,XSQ"HI)_0&CI5[Y.<M]6XQMW<_V;3Y
M!EL_U^S?-'%G4F"E/=(B!])#[E7BX=2,1+(45&*A>*NWGB16GGAS/BCV^\:,
MJ*':5L\F3>-O@_R+Y>U,'BXM"=D8S,^<N27 !!S&*%#GC,%$6K\?K3YL[QS[
M0EV4C*K316D!-W!,[0[MCS'?]-/YEP]QF1;+J_SFZ+V;3;=G^ZL_O\4\^/'S
M]&HSCN 3_'25MI+\M+;+]:]VO?,U&'%>:[ -,(8+/G=-ML):I"*5T@I/+-T/
M#A:*<Q7BH&X]R6A7:D4U-P#R)Q,"P:@H,%PCV$6*N)9P()"@D-68,VYX4.I"
M[W#ZY?!&Z]<Q&A"+JJ(!:!V*Y![<7-O--,VM-3\LX_?IXGH%_]UT$29)6 P2
M!<M%6O"79<B#?(1 CCEN@J52I=)/9<^GNLF Z$ 4/1I]<U&5-@KBNP?PFY$(
M;^9P*\2TM%?QM"QN;QJ_^#*?_D\,$V8M2Y8&)))GN:0U()W VO*.48J5Q\:4
M?E R*D-->MWC0;\.$%K?%8^YB\%Z9[%#4E@!>Q[\42,B1SI2%P07(3RJ3QP5
MYL-P>VG3]@*X/4]5_8%HMD"<;U_97\Y+FW@E"<ZU5=$1FI^*6*3!@84_:F<$
ME9JZTB&D3H0U:<J6 5YYQ=2.''7B:/7[/%W/TG0VNWVM\.%ZZ;_:57R?U;EZ
M<;6XSBW.*!@[7$44C+;@)Q*+K(5C7V"LF,08^[1_]1^.-I6DJFY+NE'@6%=S
MK=_5$Y_R9#"A4$S6 #,\(8U-1-IJB:TTG-GRLT5/$%2WK5R]F[B7(AI U=E1
MLZT[2"8"<Y%BH,C'1! '^2)CO48&:R:5\^KQPZ?J8=$=[76[P=6_O$NKMP%8
M'ZP^S$T>_[9<K.[Z,,N<VB=@)"L-1C(V$H3J-(I:!$6-Q(&7#N5W(JQN8[:+
M'Y[G*:;Q?FHOO,_6Q@I\LSC]GH/+F[S:C1RV[9KM/-S\X%XCW?.KSPM\O&2]
M>FE97+C"/4GCC03(2YL?/Q/XQ08 OR,)2YQ,<JKTV)$+5;@_5LR[N+[9C-J;
M0$DR*-(\SL@2@ZS(@VM<8)8*;:@L?4J>HN=Y5+CWP<JCJHU2VG@V%[&,3!CF
M, +7"ZP+B@72B5*$"<'$<2MI+%V26.XB'BT.?@FLE==/HZ"[\]"X#P9;GY#$
M'HP+01D"$R:B9$22BGO84J6/\?-=Y=&"UK5 -DP?K1I[+^,2[)/Y_5;&&UOY
M\5$^C^LS[+I!WREBPIW/82%K[3X%'^,L)R#NYN'=FPP5DF:<:>3B9L8.M4B'
MP)$RGGFG'=>VM-72C;)S#[=/_FL,U[-<*;H3_;O%.J[>+NP\UP/N.E;/O]PI
M9%O2PJ.5GH,GY3&.B'MID1/,HJ2PPE)C%ESI&HR!I-:U\$; U_YY> D5MO%T
M[>$SK>"LEH8+%')32$XL1=9JNNER;&P*2DC>!8+/[G7C113^U,/'/M)O ST'
M'NJ(  :"4QXLT9 ;D/G<(YLSY#B1(3C.DNSD*?PD#Q][Z;33P\<^ JZ=R#W=
M5"X$JTU0$0D>2)X-F7O5*8.TETXH38PA??H<G=.=[\+/'GOIL'N7OCX"K0V-
MT]V?#(L@HZ!0E#F^#,<L,HE)%!G7#H2C,-E_9C]6E[X+/W0<#(UR FT@0/"P
M8;55BIKH.0HNW[):..1T9 C\7:P5MT:Q3DT7^L1U>[<#OW WQR$X.5^ZM4^-
MG3PVS8DWJ8F;AF[&):V-0<E1X"&Q_-Y;441-"OGA<$QBWW ]VNSYT ?JE(^-
M=%*4$&(#9\0#2QW$LS'6[PSTNW2HRSWM57X[SG.W/\KS%+2@D5::8:) ?&ZL
M_,A3M-6-7U_2ZQE5:PVA\8Z5!P%ZQ@)3-H] ]_F7Q%U^KQ3 /L.1^,A9L*4?
M()RFJ/(;V5%0\&2:;K!*&@!8Q\(,S30-%OQ-DX=)BSSQU"B-C':P,;'AB5[B
M!4!CB;J+P*V\@FI;6X\WT(N[VH]';/X2TV(97\QFBS]R?/;U8OD2Z)VNW][C
M7@CCL6,<<8QQGC<->RXQC)(/E%-//1B=G>RTXJ353?*-"M &=#D<R8NUG5T:
MR:?Y!D>:4.4(\BXW$!)@@5L5$Y+&849BD(9U:P)?D*BZSUM:0V\Y_55]>36$
M\P1'_VGVI:,^$D:1L9(@+K5$)C>NH9H[YX-E./HQX/LD977?Q#2'X;*:+'8
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M\Y9B@A.VCBB%'#8*<94$LA2.4*JT2T)):]6X2>H;2KIAZ#F&SPMJH-6L<^Z
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M'DL777>AJVZ'K0M K[!JBK4]NESYP.OK=<Y WC,HQBD@./Z=L4L(.G)8I8B
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MC1'F1H-?QQERSD3DJ64\>.5D\?+I8[2T]"1M##P-E'H313-[G,0;1IAC3*9
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M,3!Q<3$R,#(T+FAT;5!+ 0(4 Q0    ( #>!IUA=VE,RK 4  ,4U   1
M          "  ?D0  !E>#,R,3!Q<3$R,#(T+FAT;5!+ 0(4 Q0    ( #>!
MIU@X9%4:O7,! &K9$0 1              "  =06  !H86QO+3(P,C0P,S,Q
M+FAT;5!+ 0(4 Q0    ( #>!IUBK!.F?-Q$  +F\   1              "
M <"* 0!H86QO+3(P,C0P,S,Q+GAS9%!+ 0(4 Q0    ( #>!IU@O0,@,]1X
M )<M 0 5              "  2:< 0!H86QO+3(P,C0P,S,Q7V-A;"YX;6Q0
M2P$"% ,4    "  W@:=88IGF<O99  #E$@0 %0              @ %.NP$
M:&%L;RTR,#(T,#,S,5]D968N>&UL4$L! A0#%     @ -X&G6$.,4[ST(
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M              "  >8P!@!H86QO+3(P,C0P,S,Q7W!R92YX;6Q02P4&
/  P #  0 P  ?\D&

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>halo-20240331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:halo="http://www.halozyme.com/20240331"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="halo-20240331.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:CollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:CollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">halo:ArgenxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">halo:TakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">halo:JanssenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">halo:RocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:ProprietaryProductsSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:ProprietaryProductsSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:BulkrHuPH20Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:BulkrHuPH20Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DevicePartneredProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DevicePartneredProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:EventBasedDevelopmentAndRegulatoryMilestoneAndOtherFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:EventBasedDevelopmentAndRegulatoryMilestoneAndOtherFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DeviceLicensingAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DeviceLicensingAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:LicenseFeesAndEventBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">halo:OthercollaboratorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2024-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DevicePartneredProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DevicePartneredProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:CollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:CollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:ProductSalesOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:ProductSalesOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ResearchEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ResearchEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:AutoInjectorTechnologyPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:AutoInjectorTechnologyPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:XYOSTEDProprietaryProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:XYOSTEDProprietaryProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-15</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="halo:AnnualInterestPaymentPeriodAxis">halo:DebtInstrumentInterestPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="halo:AnnualInterestPaymentPeriodAxis">halo:DebtInstrumentInterestPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="halo:AnnualInterestPaymentPeriodAxis">halo:DebtInstrumentInterestPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="halo:AnnualInterestPaymentPeriodAxis">halo:DebtInstrumentInterestPeriodFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="halo:VariableRateComponentAxis">halo:VariableRateComponentOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="halo:VariableRateComponentAxis">halo:VariableRateComponentTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="halo:VariableRateComponentAxis">halo:VariableRateComponentTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:RSURSAandPRSUawardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:RSURSAandPRSUawardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">halo:A2021ESPPPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">halo:A2021ESPPPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">halo:A2021ESPPPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:RestrictedStockUnitsAndPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:RestrictedStockUnitsAndPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">halo:AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">halo:AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">halo:A2024CapitalReturnProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:RestrictStockUnitsPerformanceSharesAndESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:RestrictStockUnitsPerformanceSharesAndESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">halo:HelenTorleyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">halo:HelenTorleyPriorPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">halo:HelenTorleyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">halo:HelenTorleyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">halo:HelenTorleyPriorPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">halo:HelenTorleyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">halo:HelenTorleyMarch2024PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">halo:HelenTorleyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">halo:HelenTorleyMarch2024PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">halo:NicoleLaBrosseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">halo:NicoleLaBrosseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="product">
        <measure>halo:product</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>halo:segment</measure>
    </unit>
    <unit id="security">
        <measure>halo:security</measure>
    </unit>
    <unit id="trading_day">
        <measure>halo:trading_day</measure>
    </unit>
    <unit id="businessday">
        <measure>halo:businessDay</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-25">0001159036</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-26">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-27">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-28">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-29">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration contextRef="c-3" id="f-420">http://fasb.org/us-gaap/2023#PrepaidExpenseAndOtherAssetsCurrent</us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration contextRef="c-3" id="f-422">http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent</us-gaap:DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration contextRef="c-3" id="f-424">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</us-gaap:DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="c-129" id="f-557">P7Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <ecd:TrdArrDuration contextRef="c-224" id="f-821">P328D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-228" id="f-822">P460D</ecd:TrdArrDuration>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2024-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-32335</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">HALOZYME THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">88-0488686</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">12390 El Camino Real</dei:EntityAddressAddressLine1>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">92130</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">CA</dei:EntityAddressStateOrProvince>
    <dei:CityAreaCode contextRef="c-1" id="f-13">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-14">794-8889</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-15">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-16">HALO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-17">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-18">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-19">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-20">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-21">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-22">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-23">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-24" unitRef="shares">127274000</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-30" unitRef="usd">164627000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-31" unitRef="usd">118370000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-3" decimals="-3" id="f-32" unitRef="usd">298824000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-4" decimals="-3" id="f-33" unitRef="usd">217630000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <halo:AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent contextRef="c-3" decimals="-3" id="f-34" unitRef="usd">195902000</halo:AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent>
    <halo:AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent contextRef="c-4" decimals="-3" id="f-35" unitRef="usd">234210000</halo:AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent>
    <us-gaap:InventoryNet contextRef="c-3" decimals="-3" id="f-36" unitRef="usd">168541000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-4" decimals="-3" id="f-37" unitRef="usd">127601000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-38" unitRef="usd">45690000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-39" unitRef="usd">48613000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="-3" id="f-40" unitRef="usd">873584000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-41" unitRef="usd">746424000</us-gaap:AssetsCurrent>
    <halo:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-3" decimals="-3" id="f-42" unitRef="usd">78071000</halo:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <halo:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-4" decimals="-3" id="f-43" unitRef="usd">74944000</halo:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent contextRef="c-3" decimals="-3" id="f-44" unitRef="usd">17319000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-45" unitRef="usd">17816000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:Goodwill contextRef="c-3" decimals="-3" id="f-46" unitRef="usd">416821000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-4" decimals="-3" id="f-47" unitRef="usd">416821000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-3" decimals="-3" id="f-48" unitRef="usd">455116000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-4" decimals="-3" id="f-49" unitRef="usd">472879000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c-3" decimals="-3" id="f-50" unitRef="usd">616000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c-4" decimals="-3" id="f-51" unitRef="usd">4386000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:Assets contextRef="c-3" decimals="-3" id="f-52" unitRef="usd">1841527000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-53" unitRef="usd">1733270000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-3" decimals="-3" id="f-54" unitRef="usd">13325000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-55" unitRef="usd">11816000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-56" unitRef="usd">118314000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-57" unitRef="usd">100678000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-58" unitRef="usd">131639000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-59" unitRef="usd">112494000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-3" decimals="-3" id="f-60" unitRef="usd">1500879000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-4" decimals="-3" id="f-61" unitRef="usd">1499248000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-3" decimals="-3" id="f-62" unitRef="usd">31201000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-63" unitRef="usd">37720000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-3" decimals="-3" id="f-64" unitRef="usd">1663719000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-65" unitRef="usd">1649462000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-3" id="f-66" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-67" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-68"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-69"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-70" unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-71" unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c-3" decimals="INF" id="f-72" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="c-4" decimals="INF" id="f-73" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-74" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-75" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="c-3" decimals="-3" id="f-76" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-4" decimals="-3" id="f-77" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-78"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-79"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-80" unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-81" unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="-3" id="f-82" unitRef="shares">127186000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="-3" id="f-83" unitRef="shares">127186000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="-3" id="f-84" unitRef="shares">126770000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="-3" id="f-85" unitRef="shares">126770000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-3" decimals="-3" id="f-86" unitRef="usd">127000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-87" unitRef="usd">127000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-3" decimals="-3" id="f-88" unitRef="usd">11794000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-4" decimals="-3" id="f-89" unitRef="usd">2409000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-3" decimals="-3" id="f-90" unitRef="usd">-1486000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-91" unitRef="usd">-9278000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-92" unitRef="usd">167373000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-93" unitRef="usd">90550000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-94" unitRef="usd">177808000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-95" unitRef="usd">83808000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="-3" id="f-96" unitRef="usd">1841527000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-97" unitRef="usd">1733270000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="-3" id="f-98" unitRef="usd">120593000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-3" id="f-99" unitRef="usd">99640000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="-3" id="f-100" unitRef="usd">58583000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-8" decimals="-3" id="f-101" unitRef="usd">60794000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-9" decimals="-3" id="f-102" unitRef="usd">16703000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-10" decimals="-3" id="f-103" unitRef="usd">1709000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-104" unitRef="usd">195879000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-11" decimals="-3" id="f-105" unitRef="usd">162143000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-1" decimals="-3" id="f-106" unitRef="usd">28329000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-11" decimals="-3" id="f-107" unitRef="usd">35170000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-3" id="f-108" unitRef="usd">17763000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-11" decimals="-3" id="f-109" unitRef="usd">17835000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-110" unitRef="usd">19111000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-11" decimals="-3" id="f-111" unitRef="usd">17979000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-112" unitRef="usd">35134000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-11" decimals="-3" id="f-113" unitRef="usd">37357000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses contextRef="c-1" decimals="-3" id="f-114" unitRef="usd">100337000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-11" decimals="-3" id="f-115" unitRef="usd">108341000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-116" unitRef="usd">95542000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-11" decimals="-3" id="f-117" unitRef="usd">53802000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-118" unitRef="usd">4993000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-11" decimals="-3" id="f-119" unitRef="usd">2979000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestExpense contextRef="c-1" decimals="-3" id="f-120" unitRef="usd">4507000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-11" decimals="-3" id="f-121" unitRef="usd">4543000</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-122" unitRef="usd">96028000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-11" decimals="-3" id="f-123" unitRef="usd">52238000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-124" unitRef="usd">19205000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-11" decimals="-3" id="f-125" unitRef="usd">12623000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-126" unitRef="usd">76823000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-11" decimals="-3" id="f-127" unitRef="usd">39615000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-128"
      unitRef="usdPerShare">0.61</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-11"
      decimals="2"
      id="f-129"
      unitRef="usdPerShare">0.29</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-130"
      unitRef="usdPerShare">0.60</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-11"
      decimals="2"
      id="f-131"
      unitRef="usdPerShare">0.29</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-132" unitRef="shares">126941000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-11" decimals="-3" id="f-133" unitRef="shares">135027000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-134" unitRef="shares">128887000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-11" decimals="-3" id="f-135" unitRef="shares">137900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-136" unitRef="usd">76823000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-11" decimals="-3" id="f-137" unitRef="usd">39615000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-1" decimals="-3" id="f-138" unitRef="usd">-313000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-11" decimals="-3" id="f-139" unitRef="usd">924000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c-1" decimals="-3" id="f-140" unitRef="usd">8000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c-11" decimals="-3" id="f-141" unitRef="usd">22000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <halo:OtherComprehensiveIncomeLossCashFlowHedgeUnrealizedHoldingGainLossBeforeAdjustmentAfterTax contextRef="c-1" decimals="-3" id="f-142" unitRef="usd">8615000</halo:OtherComprehensiveIncomeLossCashFlowHedgeUnrealizedHoldingGainLossBeforeAdjustmentAfterTax>
    <halo:OtherComprehensiveIncomeLossCashFlowHedgeUnrealizedHoldingGainLossBeforeAdjustmentAfterTax contextRef="c-11" decimals="-3" id="f-143" unitRef="usd">0</halo:OtherComprehensiveIncomeLossCashFlowHedgeUnrealizedHoldingGainLossBeforeAdjustmentAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-1" decimals="-3" id="f-144" unitRef="usd">-518000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-11" decimals="-3" id="f-145" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-146" unitRef="usd">84615000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-11" decimals="-3" id="f-147" unitRef="usd">40561000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-148" unitRef="usd">76823000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-11" decimals="-3" id="f-149" unitRef="usd">39615000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-150" unitRef="usd">9874000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-11" decimals="-3" id="f-151" unitRef="usd">7966000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-152" unitRef="usd">2443000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-11" decimals="-3" id="f-153" unitRef="usd">2622000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-3" id="f-154" unitRef="usd">17763000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-11" decimals="-3" id="f-155" unitRef="usd">17835000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-1" decimals="-3" id="f-156" unitRef="usd">1830000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-11" decimals="-3" id="f-157" unitRef="usd">1835000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-1" decimals="-3" id="f-158" unitRef="usd">2365000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-11" decimals="-3" id="f-159" unitRef="usd">917000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss contextRef="c-1" decimals="-3" id="f-160" unitRef="usd">7000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss contextRef="c-11" decimals="-3" id="f-161" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <halo:DeferredRentPayments contextRef="c-1" decimals="-3" id="f-162" unitRef="usd">-220000</halo:DeferredRentPayments>
    <halo:DeferredRentPayments contextRef="c-11" decimals="-3" id="f-163" unitRef="usd">-320000</halo:DeferredRentPayments>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes contextRef="c-1" decimals="-3" id="f-164" unitRef="usd">-1291000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes contextRef="c-11" decimals="-3" id="f-165" unitRef="usd">-3874000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-166" unitRef="usd">-38308000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-11" decimals="-3" id="f-167" unitRef="usd">-36189000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-3" id="f-168" unitRef="usd">40233000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-11" decimals="-3" id="f-169" unitRef="usd">7250000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-170" unitRef="usd">-4795000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-11" decimals="-3" id="f-171" unitRef="usd">-8881000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-1" decimals="-3" id="f-172" unitRef="usd">18685000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-11" decimals="-3" id="f-173" unitRef="usd">-24006000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-174" unitRef="usd">129427000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-11" decimals="-3" id="f-175" unitRef="usd">86964000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-1" decimals="-3" id="f-176" unitRef="usd">198763000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-11" decimals="-3" id="f-177" unitRef="usd">109919000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt contextRef="c-1" decimals="-3" id="f-178" unitRef="usd">119627000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt contextRef="c-11" decimals="-3" id="f-179" unitRef="usd">61134000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-180" unitRef="usd">3545000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-11" decimals="-3" id="f-181" unitRef="usd">11377000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-182" unitRef="usd">-82681000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-11" decimals="-3" id="f-183" unitRef="usd">-60162000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfConvertibleDebt contextRef="c-1" decimals="-3" id="f-184" unitRef="usd">0</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt contextRef="c-11" decimals="-3" id="f-185" unitRef="usd">13483000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-1" decimals="-3" id="f-186" unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-11" decimals="-3" id="f-187" unitRef="usd">150083000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-3" id="f-188" unitRef="usd">489000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-11" decimals="-3" id="f-189" unitRef="usd">1048000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-190" unitRef="usd">-489000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-11" decimals="-3" id="f-191" unitRef="usd">-164614000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-192" unitRef="usd">46257000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-11" decimals="-3" id="f-193" unitRef="usd">-137812000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-194" unitRef="usd">118370000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-12" decimals="-3" id="f-195" unitRef="usd">234695000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-196" unitRef="usd">164627000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-13" decimals="-3" id="f-197" unitRef="usd">96883000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-198" unitRef="usd">1515000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-11" decimals="-3" id="f-199" unitRef="usd">390000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-200" unitRef="usd">1242000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-11" decimals="-3" id="f-201" unitRef="usd">406000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:StockIssued1 contextRef="c-1" decimals="-3" id="f-202" unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:StockIssued1 contextRef="c-11" decimals="-3" id="f-203" unitRef="usd">125000</us-gaap:StockIssued1>
    <us-gaap:SharesOutstanding contextRef="c-14" decimals="-3" id="f-204" unitRef="shares">126770000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-14" decimals="-3" id="f-205" unitRef="usd">127000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-15" decimals="-3" id="f-206" unitRef="usd">2409000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-16" decimals="-3" id="f-207" unitRef="usd">-9278000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-3" id="f-208" unitRef="usd">90550000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-209" unitRef="usd">83808000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-18" decimals="-3" id="f-210" unitRef="usd">9874000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-211" unitRef="usd">9874000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-19" decimals="-3" id="f-212" unitRef="shares">416000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-18" decimals="-3" id="f-213" unitRef="usd">-489000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-1" decimals="-3" id="f-214" unitRef="usd">-489000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax contextRef="c-20" decimals="-3" id="f-215" unitRef="usd">7792000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax contextRef="c-1" decimals="-3" id="f-216" unitRef="usd">7792000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:NetIncomeLoss contextRef="c-21" decimals="-3" id="f-217" unitRef="usd">76823000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-218" unitRef="usd">76823000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding contextRef="c-22" decimals="-3" id="f-219" unitRef="shares">127186000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="-3" id="f-220" unitRef="usd">127000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-3" id="f-221" unitRef="usd">11794000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-3" id="f-222" unitRef="usd">-1486000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-3" id="f-223" unitRef="usd">167373000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-224" unitRef="usd">177808000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding contextRef="c-26" decimals="-3" id="f-225" unitRef="shares">135154000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-3" id="f-226" unitRef="usd">135000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-3" id="f-227" unitRef="usd">27368000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="-3" id="f-228" unitRef="usd">-922000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-29" decimals="-3" id="f-229" unitRef="usd">143217000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-12" decimals="-3" id="f-230" unitRef="usd">169798000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-30" decimals="-3" id="f-231" unitRef="usd">7966000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-11" decimals="-3" id="f-232" unitRef="usd">7966000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c-31" decimals="-3" id="f-233" unitRef="shares">289000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-30" decimals="-3" id="f-234" unitRef="usd">-126000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-11" decimals="-3" id="f-235" unitRef="usd">-126000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-31" decimals="-3" id="f-236" unitRef="shares">384000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-31" decimals="-3" id="f-237" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-30" decimals="-3" id="f-238" unitRef="usd">-1049000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-11" decimals="-3" id="f-239" unitRef="usd">-1048000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="c-31" decimals="-3" id="f-240" unitRef="shares">4165000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="c-31" decimals="-3" id="f-241" unitRef="usd">4000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="c-30" decimals="-3" id="f-242" unitRef="usd">34159000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="c-32" decimals="-3" id="f-243" unitRef="usd">117138000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="c-11" decimals="-3" id="f-244" unitRef="usd">151301000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax contextRef="c-33" decimals="-3" id="f-245" unitRef="usd">946000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax contextRef="c-11" decimals="-3" id="f-246" unitRef="usd">946000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:NetIncomeLoss contextRef="c-32" decimals="-3" id="f-247" unitRef="usd">39615000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-11" decimals="-3" id="f-248" unitRef="usd">39615000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding contextRef="c-34" decimals="-3" id="f-249" unitRef="shares">131662000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="-3" id="f-250" unitRef="usd">132000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-35" decimals="-3" id="f-251" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-36" decimals="-3" id="f-252" unitRef="usd">24000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-37" decimals="-3" id="f-253" unitRef="usd">65694000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-13" decimals="-3" id="f-254" unitRef="usd">65850000</us-gaap:StockholdersEquity>
    <us-gaap:NatureOfOperations contextRef="c-1" id="f-255">Organization and Business &lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the innovators of ENHANZE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; drug delivery technology (&#x201c;ENHANZE&#x201d;) with our proprietary enzyme, rHuPH20, our commercially validated solution is used to facilitate the subcutaneous (&#x201c;SC&#x201d;) delivery of injected drugs and fluids with the goal of reducing the treatment burden for patients. We license our technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with our partners&#x2019; proprietary compounds. We also develop, manufacture and commercialize, for ourselves or with our partners, drug-device combination products using our advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our ENHANZE partners&#x2019; approved products and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. rHuPH20 works by breaking down hyaluronan (&#x201c;HA&#x201d;), a naturally occurring carbohydrate that is a major component of the extracellular matrix of the SC space. This temporarily reduces the barrier to bulk fluid flow allowing for improved and more rapid SC delivery of high dose, high volume injectable biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids. We refer to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as ENHANZE. We license our ENHANZE technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the SC route of administration. In the development of proprietary intravenous (&#x201c;IV&#x201d;) drugs combined with our ENHANZE technology, data has been generated supporting the potential for ENHANZE to reduce patient treatment burden, as a result of shorter duration of SC administration with ENHANZE compared to IV administration. ENHANZE may enable fixed-dose SC dosing compared to weight-based dosing typically required for IV administration, extend the dosing interval for drugs that are already administered subcutaneously and potentially allow for lower rates of infusion-related reactions.&#160;ENHANZE may enable more flexible treatment options such as home administration by a healthcare professional or potentially the patient or caregiver. Lastly, certain proprietary drugs co-formulated with ENHANZE have been granted additional exclusivity, extending the patent life of the product beyond the patent expiry of the proprietary IV drug.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We currently have ENHANZE collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (&#x201c;Roche&#x201d;), Takeda Pharmaceuticals International AG and Baxalta US Inc. (&#x201c;Takeda&#x201d;), Pfizer Inc. (&#x201c;Pfizer&#x201d;), Janssen Biotech, Inc. (&#x201c;Janssen&#x201d;), AbbVie, Inc. (&#x201c;AbbVie&#x201d;), Eli Lilly and Company (&#x201c;Lilly&#x201d;), Bristol-Myers Squibb Company (&#x201c;BMS&#x201d;), argenx BVBA (&#x201c;argenx&#x201d;), ViiV Healthcare (the global specialist HIV Company majority owned by GlaxoSmithKline) (&#x201c;ViiV&#x201d;), Chugai Pharmaceutical Co., Ltd. (&#x201c;Chugai&#x201d;) and Acumen Pharmaceuticals, Inc. (&#x201c;Acumen&#x201d;). In addition to receiving upfront licensing fees from our ENHANZE collaborations, we are entitled to receive event and sales-based milestone payments, revenues from the sale of bulk rHuPH20 and royalties from commercial sales of approved partner products co-formulated with ENHANZE. We currently earn royalties from sales of seven commercial products including sales of one commercial product from each of the Takeda, Janssen and argenx collaborations and four commercial products products from the Roche collaboration. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have commercialized auto-injector products with several pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (&#x201c;Teva&#x201d;) and Otter Pharmaceuticals, LLC (&#x201c;Otter&#x201d;). We have development programs including auto-injectors with Idorsia Pharmaceuticals Ltd. (&#x201c;Idorsia&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our commercial portfolio of proprietary products includes Hylenex&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, utilizing rHuPH20, and XYOSTED&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; utilizing our auto-injector technology.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Except where specifically noted or the context otherwise requires, references to &#x201c;Halozyme,&#x201d; &#x201c;the Company,&#x201d; &#x201c;we,&#x201d; &#x201c;our,&#x201d; and &#x201c;us&#x201d; in these notes to our condensed consolidated financial statements refer to Halozyme Therapeutics, Inc. and each of its directly and indirectly wholly owned subsidiaries as disclosed in Note 2, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <halo:RoyaltiesReceivedNumberOfProductsSold
      contextRef="c-1"
      decimals="INF"
      id="f-256"
      unitRef="product">7</halo:RoyaltiesReceivedNumberOfProductsSold>
    <halo:RoyaltiesReceivedNumberOfProductsSold
      contextRef="c-38"
      decimals="INF"
      id="f-257"
      unitRef="product">1</halo:RoyaltiesReceivedNumberOfProductsSold>
    <halo:RoyaltiesReceivedNumberOfProductsSold
      contextRef="c-39"
      decimals="INF"
      id="f-258"
      unitRef="product">1</halo:RoyaltiesReceivedNumberOfProductsSold>
    <halo:RoyaltiesReceivedNumberOfProductsSold
      contextRef="c-40"
      decimals="INF"
      id="f-259"
      unitRef="product">1</halo:RoyaltiesReceivedNumberOfProductsSold>
    <halo:RoyaltiesReceivedNumberOfProductsSold
      contextRef="c-41"
      decimals="INF"
      id="f-260"
      unitRef="product">4</halo:RoyaltiesReceivedNumberOfProductsSold>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-261">Summary of Significant Accounting Policies&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying interim unaudited condensed consolidated financial statements have been prepared for purposes of and in accordance with United States generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) and with the rules and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) related to a quarterly report on Form 10-Q. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for a complete set of financial statements. These condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December&#160;31, 2023, filed with the SEC on February&#160;20, 2024. The unaudited financial information for the interim periods presented herein reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operations for the periods presented, with such adjustments consisting only of normal recurring adjustments. Operating results for interim periods are not necessarily indicative of the operating results for an entire fiscal year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements include the accounts of Halozyme Therapeutics, Inc. and our wholly owned subsidiaries, Halozyme, Inc. and Antares Pharma, Inc., and Antares Pharma, Inc.&#x2019;s wholly owned Swiss subsidiaries, Antares Pharma IPL AG and Antares Pharma AG. All intercompany accounts and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that we believe to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash Equivalents and Marketable Securities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents consist of highly liquid investments, readily convertible to cash, which mature within 90 days or less from the date of purchase. As of March&#160;31, 2024, our cash and cash equivalents consisted of money market funds, bank certificate of deposits, U.S. treasury securities and demand deposits at commercial banks.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities are investments with original maturities of more than 90 days from the date of purchase that are specifically identified to fund current operations. Marketable securities are considered available-for-sale. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date which reflects management&#x2019;s intention to use the proceeds from the sale of these investments to fund our operations, as necessary. Such available-for-sale investments are carried at fair value with unrealized gains and losses recorded in other comprehensive income and included as a separate component of stockholders&#x2019; equity. The cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in investment and other income, net in our condensed consolidated statements of income. We use the specific identification method for calculating realized gains and losses on marketable securities sold. None of the realized gains and losses and declines in value that were judged to be as a result of credit loss on marketable securities, if any, are included in investment and other income, net in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The authoritative guidance for fair value measurements establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments include cash equivalents, available-for-sale marketable securities, accounts receivable, prepaid expenses and other assets, accounts payable, accrued expenses and long-term debt. Fair value estimates of these instruments are made at a specific point in time based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore, cannot be determined with precision. The carrying amount of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available-for-sale marketable securities consist of asset-backed securities, corporate debt securities, U.S. Treasury securities, agency bonds and commercial paper, and are measured at fair value using Level 1 and Level 2 inputs. Level 2 financial instruments are valued using market prices on less active markets and proprietary pricing valuation models with observable inputs, including interest rates, yield curves, maturity dates, issue dates, settlement dates, reported trades, broker-dealer quotes, issue spreads, benchmark securities or other market related data. We obtain the fair value of Level 2 investments from our investment manager, who obtains these fair values from a third-party pricing source. We validate the fair values of Level 2 financial instruments provided by our investment manager by comparing these fair values to a third-party pricing source.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable is recorded at the invoiced amount and is non-interest bearing. Accounts receivable is recorded net of estimated prompt pay discounts, distribution fees and chargebacks. We believe the risk of accounts being uncollectible is minimal; therefore, no significant allowances for doubtful accounts were established as of March&#160;31, 2024 and December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Inventories are reviewed periodically for potential excess, dated or obsolete status. We evaluate the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the price we expect to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into operating leases primarily for real estate and automobiles. These leases have contractual terms which range from 3 years to 12 years. We determine if an arrangement contains a lease at inception. Right of use (&#x201c;ROU&#x201d;) assets and liabilities resulting from operating leases are included in property and equipment, accrued expenses and other long-term liabilities on our condensed consolidated balance sheets. Operating lease ROU assets and liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the discount rate to calculate the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. Our leases often include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that we will exercise that option. Short-term leases with an initial term of 12 months or less are not recorded on our condensed consolidated balance sheet. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have lease agreements with lease and non-lease components, which are generally accounted for separately. For certain leases, such as automobiles, we account for the lease and non-lease components as a single lease component.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, including ROU assets are recorded at cost, less accumulated depreciation and amortization. Equipment is depreciated using the straight-line method over its estimated useful life ranging from three years to ten years and leasehold improvements are amortized using the straight-line method over the estimated useful life of the asset or the lease term, whichever is shorter. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for long-lived assets in accordance with authoritative guidance for impairment or disposal of long-lived assets. Long-lived assets are reviewed for events or changes in circumstances, which indicate that their carrying value may not be recoverable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive income is defined as the change in equity during the period from transactions and other events and circumstances from non-owner sources.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Convertible Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2024 Convertible Notes, the 2027 Convertible Notes and the 2028 Convertible Notes (collectively, the &#x201c;Convertible Notes&#x201d;) are accounted for in accordance with authoritative guidance for debt and derivatives. We evaluate all the embedded conversion options contained in the Convertible Notes to determine if there are embedded features that require bifurcation as a derivative as required by U.S. GAAP. Based on our analysis, we account for each of our Convertible Notes as single units of accounting, a liability, because we concluded that the conversion features do not require bifurcation as a derivative under embedded derivative authoritative guidance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash Flow Hedges - Currency Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in the second quarter of 2023, we entered into a cash flow hedging program to mitigate foreign currency exchange risk associated with forecasted royalty revenue denominated in Swiss francs. Under the program, we can hedge these forecasted royalties up to a maximum of four years into the future. We hedge these cash flow exposures to reduce the risk of our earnings and cash flows being adversely affected by fluctuations in exchange rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the hedge accounting treatment, all hedging relationships are formally documented at the inception of the hedge and are highly effective in offsetting changes to future cash flows on hedged transactions. Both at inception of the hedge and on an ongoing basis, we assess whether the foreign currency forward contracts are highly effective in offsetting changes in cash flows of hedged items on a prospective and retrospective basis. If we determine a (i) foreign currency forward contract is not highly effective as a cash flow hedge, (ii) foreign currency forward contract has ceased to be a highly effective hedge or (iii) forecasted transaction is no longer probable of occurring, we would discontinue hedge accounting treatment prospectively. We measure effectiveness based on the change in fair value of the forward currency forward contract and the fair value of the hypothetical foreign currency forward contract with terms that match the critical terms of the risk being hedged. No portion of our foreign currency forward contracts were excluded from the assessment of hedge effectiveness. As of March&#160;31, 2024, all hedges were determined to be highly effective. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assets or liabilities associated with our hedging contracts are recorded at fair market value in prepaid expense and other current assets, accrued expenses, or other long-term liabilities, respectively, in our condensed consolidated balance sheets. Gains and losses related to changes in the fair market value of these hedging contracts are recorded as a component of accumulated other comprehensive income (loss) (&#x201c;AOCI&#x201d;) within stockholder&#x2019;s equity in our condensed consolidated balance sheets and reclassified to royalty revenue in our condensed consolidated statements of income in the same period as the recognition of the underlying hedged transaction. In the event the underlying forecasted transaction does not occur, or it becomes probable that it will not occur, within the defined hedge period, we reclassify the gains or losses on the related cash flow hedge from AOCI to royalties revenue in our condensed consolidated statements of income. Settlements from the cash flow hedge are included in operating activities on the condensed consolidated statements of cash flows. Since the fair market value of these hedging contracts is derived from current market rates, the hedging contracts are classified as derivative financial instruments. We do not use derivatives for speculative or trading purposes. As of March&#160;31, 2024, amounts expected to be recognized as a net gain out of AOCI into our condensed consolidated statements of income during the next 12 months are not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the acquisition method of accounting, we allocate the fair value of the total consideration transferred to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the date of acquisition. These valuations require us to make estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill. Costs incurred to complete a business combination, such as legal and other professional fees, are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the initial accounting for a business combination is incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date. We record these adjustments to the provisional amounts with a corresponding offset to goodwill. Any adjustments identified after the measurement period are recorded in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill, Intangible Assets and Other Long-Lived Asset&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets acquired, including intangible assets and in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;), and liabilities assumed are measured at fair value as of the acquisition date. Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of the net assets acquired. Intangible assets acquired in a business combination that are used for IPR&amp;amp;D activities are considered indefinite lived until the completion or abandonment of the associated research and development efforts. Upon reaching the end of the relevant research and development project (i.e., upon commercialization), the IPR&amp;amp;D &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;asset is amortized over its estimated useful life. If the relevant research and development project is abandoned, the IPR&amp;amp;D asset is expensed in the period of abandonment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill and IPR&amp;amp;D are not amortized; however, they are reviewed for impairment at least annually during the second quarter, or more frequently if an event occurs indicating the potential for impairment. Goodwill and IPR&amp;amp;D are considered to be impaired if the carrying value of the reporting unit or IPR&amp;amp;D asset exceeds its respective fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We perform our goodwill impairment analysis at the reporting unit level, which aligns with our reporting and operating segment structure and availability of discrete financial information. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair values of our reporting unit is less than the carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and our overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amounts, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair value of the reporting unit with the carrying value, including goodwill. If the carrying amount of the reporting unit exceeds the fair value, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative goodwill impairment test.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our identifiable intangible assets with finite useful lives are typically comprised of acquired device technologies and product rights. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#x2019; respective estimated useful lives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We perform regular reviews to determine if any event has occurred that may indicate intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to the net book value, significant changes in the ability of a particular asset to generate positive cash flows for our strategic business objectives, and the pattern of utilization of a particular asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generate revenues from payments received (i) as royalties from licensing our ENHANZE technology and other royalty arrangements, (ii) under collaborative agreements and (iii) from sales of our proprietary and partnered products. We recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, we perform the following five steps: (i) identify the promised goods or services in the contract; (ii) identify the performance obligations in the contract, including whether they are distinct in the context of the contract; (iii) determine the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ENHANZE and Device Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of our ENHANZE collaboration and license agreements, our partners will pay us royalties at an on average mid-single digit percent rate of their sales if products under the collaboration are commercialized. All amounts owed to us are noncancelable after the underlying triggering event occurs, and nonrefundable once paid. Unless terminated earlier in accordance with its terms, collaborations generally continue in effect until the last to expire royalty payment term, as determined on a product by product and country by country basis, with each royalty term starting on the first commercial sale of that product and ending the later of: (i) a specified period or term set forth in the agreement or (ii) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration. In general, when there are no valid claims of a specified patent developed under the collaboration covering the product in a given country, the royalty rate is reduced for those sales in that country upon the expiration of our patents covering rHuPH20. Janssen&#x2019;s patents covering DARZALEX SC do not impact the timing for this royalty reduction. Partners may terminate the agreement prior to expiration for any reason in its entirety or on a target-by-target basis generally upon 90 days prior written notice to us.&#160;Upon any such termination, the license granted to partners (in total or with respect to the terminated target, as applicable) will terminate provided; however, that in the event of expiration of the agreement (as opposed to a termination), the on-going licenses granted may become perpetual, non-exclusive and fully paid. Sales-based milestones and royalties are recognized in the period the underlying sales or milestones occur. We do not receive final royalty reports from our ENHANZE partners until after we complete our financial statements for a prior quarter. Therefore, we recognize revenue based on estimates of the royalty earned, which are based on internal estimates and available preliminary reports provided by our partners. We will record adjustments in the following quarter, if necessary, when final royalty reports are received. To date, we have not recorded any material adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also earn royalties in connection with several of our licenses granted under license and development arrangements with our device partners. These royalties are based upon a percentage of commercial sales of partnered products with rates ranging from mid-single digits to low double digits and are tiered based on levels of net sales. These sales-based royalties, for which the license was deemed the predominant element to which the royalties relate, are estimated and recognized in the period in which the partners&#x2019; commercial sales occur. The royalties are generally reported and payable to us within 45 to 60 days after the end of the period in which the commercial sales are made. We base our estimates of royalties earned on actual sales information from our partners when available or estimated, prescription sales from external sources and estimated net selling price. We will record adjustments in the following quarter, if necessary, when final royalty reports are received. To date, we have not recorded any material adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue under ENHANZE and Device Collaborative Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;ENHANZE Collaboration and License Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under these agreements, we grant the collaboration partner a worldwide license to develop and commercialize products using our ENHANZE technology to combine our patented rHuPH20 enzyme with their proprietary biologics directed at up to a specified number of targets. Targets are usually licensed on an exclusive, global basis. Targets selected subsequent to inception of the arrangement generally require payment of an additional license fee. The collaboration partner is responsible for all development, manufacturing, clinical, regulatory, sales and marketing costs for any products developed under the agreement. We are responsible for supply of bulk rHuPH20 based on the collaboration partner&#x2019;s purchase orders, and may also be separately engaged to perform research and development services. While these collaboration agreements are similar in that they originate from the same framework, each one is the result of an arms-length negotiation and thus may vary from one to the other.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generally collect an upfront license payment from collaboration partners, and are also entitled to receive event-based payments subject to collaboration partners&#x2019; achievement of specified development, regulatory and sales-based milestones. In several agreements, collaboration partners pay us annual fees to maintain their exclusive license rights if they are unable to advance product development to specified stages. We earn separate fees for bulk rHuPH20 supplies and research and development services. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although these agreements are in form identified as collaborative agreements, we concluded for accounting purposes they represent contracts with customers and are not subject to accounting literature on collaborative arrangements. This is because we grant to partners licenses to our intellectual property and provide supply of bulk rHuPH20 and research and development services which are all outputs of our ongoing activities, in exchange for respective consideration. Under these collaborative agreements, our partners lead development of assets, and we do not share in significant financial risks of their development or commercialization activities. Accordingly, we concluded our collaborative agreements are appropriately accounted for pursuant to U.S. GAAP. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under all of our ENHANZE collaborative agreements, we have identified licenses to use functional intellectual property as the only performance obligation. The intellectual property underlying the license is our proprietary ENHANZE technology which represents application of rHuPH20 to facilitate delivery of drugs. Each of the licenses grants the partners rights to use our intellectual property as it exists and is identified on the effective date of the license, because there is no ongoing development of the ENHANZE technology required. Therefore, we recognize revenue from licenses at the point when the license becomes effective and the partner has received access to our intellectual property, usually at the inception of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When partners can select additional targets to add to the licenses granted, we consider these rights to be options. We evaluate whether such options contain material rights, i.e. have exercise prices that are discounted compared to what we would charge for a similar license to a new partner. The exercise price of these options includes a combination of the target selection fees, event-based milestone payments and royalties. When these amounts in aggregate are not offered at a discount that exceeds discounts available to other customers, we conclude the option does not contain a material right, and we consider grants of additional licensing rights upon option exercises to be separate contracts (target selection contracts).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Generally, we provide indemnification and protection of licensed intellectual property for our customers. These provisions are part of assurance that the licenses meet the agreements&#x2019; representations and are not obligations to provide goods or services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also fulfill purchase orders for supply of bulk rHuPH20 and perform research and development services pursuant to project authorization forms for our partners, which represent separate contracts. In addition to our licenses, we price our supply of bulk rHuPH20 and research and development services at our regular selling prices, called standalone selling prices (&#x201c;SSP&#x201d;). Therefore, our partners do not have material rights to order these items at prices not reflective of SSP. Refer to the discussion below regarding recognition of revenue for these separate contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transaction price for a contract represents the amount to which we are entitled in exchange for providing goods and services to the customer. Transaction price does not include amounts subject to uncertainties unless it is probable that there will be no significant reversal of revenue when the uncertainty is resolved. Apart from the upfront license payment (or target selection fees in the target selection contracts), all other fees we may earn under our collaborative agreements are subject to significant uncertainties of product development. Achievement of many of the event-based development and regulatory milestones may not be probable until such milestones are actually achieved. This generally relates to milestones such as obtaining marketing authorization approvals. With respect to other development milestones, e.g., dosing of a first patient in a clinical trial, achievement could be considered probable prior to its actual occurrence, based on the progress towards commencement of the trial. In order to evaluate progress towards commencement of a trial, we assess the status of activities leading up to our partner&#x2019;s initiation of a trial such as feedback received from the applicable regulatory authorities, completion of Investigational New Drug (&#x201c;IND&#x201d;) or equivalent filings, readiness and availability of drug, readiness of study sites and our partner&#x2019;s commitment of resources to the program. We do not include any amounts subject to uncertainties in the transaction price until it is probable that the amount will not result in a significant reversal of revenue in the future. At the end of each reporting period, we re-evaluate the probability of achievement of such milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When target exchange rights are held by partners, and the amounts attributed to these rights are not refundable, they are included in the transaction price. However, they are recorded as deferred revenues because we have a potential performance obligation to provide a new target upon an exchange right being exercised. These amounts are recognized in revenue when the right of exchange expires or is exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because our agreements have one type of performance obligation (licenses) which are typically all transferred at the same time at agreement inception, allocation of transaction price often is not required. However, allocation is required when licenses for some of the individual targets are subject to rights of exchange, because revenue associated with these targets cannot be recognized. When allocation is needed, we perform an allocation of the upfront amount based on relative SSP of licenses for individual targets. We determine license SSP using an income-based valuation approach utilizing risk-adjusted discounted cash flow projections of the estimated return a licensor would receive. When amounts subject to uncertainties, such as milestones and royalties, are included in the transaction price, we attribute them to the specific individual target licenses which generate such milestone or royalty amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also estimate SSP of bulk rHuPH20 and research and development services, to determine that our partners do not have material rights to order them at discounted prices. For supplies of bulk rHuPH20, because we effectively act as a contract manufacturer to our partners, we estimate and charge SSP based on the typical contract manufacturer margins consistent with all of our partners. We determine SSP of research and development services based on a fully-burdened labor rate. Our rates are comparable to those we observe in other collaborative agreements. We also have a history of charging similar rates to all of our partners. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upfront amounts allocated to licenses to individual targets are recognized as revenue when the license is transferred to the partner, as discussed above, if the license is not subject to exchange rights, or when the exchange right expires or is exercised. Development milestones and other fees are recognized in revenue when they are included in the transaction price, because by that time, we have already transferred the related license to the partner. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In contracts to provide research and development services, such services represent the only performance obligation. The fees are charged based on hours worked by our employees and the fixed contractual rate per hour, plus third-party pass-through costs, on a monthly basis. We recognize revenues as the related services are performed based on the amounts billed, as the partner consumes the benefit of research and development work simultaneously as we perform these services, and the amounts billed reflect the value of these services to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Device License, Development and Supply Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have several license, development and supply arrangements with pharmaceutical partners, under which we grant a license to our device technology and provide research and development services that often involve multiple performance obligations and highly-customized deliverables. For such arrangements, we identify each of the promised goods and services within the contract and the distinct performance obligations at inception of the contract and allocate consideration to each performance obligation based on relative SSP, which is generally determined based on the expected cost plus mark-up. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the contract includes an enforceable right to payment for performance completed to date and performance obligations are satisfied over time, we recognize revenue over the development period using either the input or output method depending on which is most appropriate given the nature of the distinct deliverable. For other contracts that do not contain an enforceable right to payment for performance completed to date, revenue is recognized when control of the product is transferred to the customer. Factors that may indicate transfer of control has occurred include the transfer of legal title, transfer of physical possession, the customer has obtained the significant risks and rewards of ownership of the assets, and we have a present right to payment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our payment terms for development contracts may include an upfront payment equal to a percentage of the total contract value with the remaining portion to be billed upon completion and transfer of the individual deliverables or satisfaction of the individual performance obligations. We record a contract liability for cash received in advance of performance, which is presented within deferred revenue and deferred revenue, long-term in our condensed consolidated balance sheets and recognized as revenue in our condensed consolidated statements of income when the associated performance obligations have been satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License fees and milestones received in exchange for the grant of a license to our functional intellectual property, such as patented technology and know-how in connection with a partnered development arrangement, are generally recognized at inception of the arrangement, or over the development period depending on the facts and circumstances, as the license is generally not distinct from the non-licensed goods or services to be provided under the contract. Milestone payments that are contingent upon the occurrence of future events are evaluated and recorded at the most likely amount, and to the extent that it is probable that a significant reversal of revenue will not occur when the associated uncertainty is resolved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 4,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for further discussion on our collaborative arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Sales, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Proprietary Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our commercial portfolio of proprietary products includes XYOSTED and Hylenex recombinant which we sell primarily to wholesale pharmaceutical distributors and specialty pharmacies, who sell the products to hospitals, retail chain drug stores and other end-user customers. Sales to wholesalers are made pursuant to purchase orders subject to the terms of a master agreement, and delivery of individual packages of products represents performance obligations under each purchase order. We use contract manufacturers to produce our proprietary products and third-party logistics (&#x201c;3PL&#x201d;) vendors to process and fulfill orders&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We concluded we are the principal in the sales to wholesalers because we control access to services rendered by both vendors and direct their activities. We have no significant obligations to wholesalers to generate pull-through sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue is recognized when control has transferred to the customer, which is typically upon delivery, at the net selling price, which reflects the variable consideration for which reserves and sales allowances are established for estimated returns, wholesale distribution fees, prompt payment discounts, government rebates and chargebacks, plan rebate arrangements and patient discount and support programs. We recognize revenue from product sales and related cost of sales upon product delivery to the wholesaler location. At that time, the wholesalers take control of the product as they take title, bear the risk of loss of ownership, and have an enforceable obligation to pay us. They also have the ability to direct sales of product to their customers on terms and at prices they negotiate. Although wholesalers have product return rights, we do not believe they have a significant incentive to return the product to us.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The determination of certain reserves and sales allowances requires us to make a number of judgements and estimates to reflect our best estimate of the transaction price and the amount of consideration to which we believe we would be ultimately entitled to receive. The expected value is determined based on unit sales data, contractual terms with customers and third-party payers, historical and estimated future percentage of rebates incurred on sales, historical and future insurance plan billings, any new or anticipated changes in programs or regulations that would impact the amount of the actual rebates, customer purchasing patterns, product expiration dates and levels of inventory in the distribution channel. The estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, rebates and customer co-pay support programs are included in accrued expenses and accounts receivable, net in our condensed consolidated balance sheets upon recognition of revenue from product sales. We monitor actual product returns, chargebacks, discounts and fees subsequent to the sale. If these amounts differ from our estimates, we make adjustments to these allowances, which are applied to increase or reduce product sales revenue and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling prices initially billed to wholesalers are subject to discounts for prompt payment and subsequent chargebacks when wholesalers sell our products at negotiated discounted prices to members of certain group purchasing organizations (&#x201c;GPOs&#x201d;), Pharmacy Benefit Managers (&#x201c;PBMs&#x201d;) and government programs. We also pay quarterly distribution fees to certain wholesalers for inventory reporting and chargeback processing, and to PBMs and GPOs as administrative fees for services and for access to their members. We concluded the benefits received in exchange for these fees are not distinct from our sales of our products, and accordingly we apply these amounts to reduce revenues. Wholesalers also have rights to return unsold product nearing or past the expiration date. Because of the shelf life of our products and our lengthy return period, there may be a significant period of time between when the product is shipped and when we issue credits on returned product. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the transaction price when we receive each purchase order taking into account the expected reductions of the selling price initially billed to the wholesaler arising from all of the above factors. We have compiled historical experience and data to estimate future returns and chargebacks of our products and the impact of the other discounts and fees we pay. When estimating these adjustments to the transaction price, we reduce it sufficiently to be able to assert that it is probable that there will be no significant reversal of revenue when the ultimate adjustment amounts are known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each purchase order contains only one type of product, and is usually shipped to the wholesaler in a single shipment. Therefore, allocation of the transaction price to individual packages is not required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the orders placed by wholesalers, we incur costs such as commissions to our sales representatives. However, as revenue from product sales is recognized upon delivery to the wholesaler, which occurs shortly after we receive a purchase order, we do not capitalize these commissions and other costs, based on application of the practical expedient allowed within the applicable guidance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Partnered Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Bulk rHuPH20&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We sell bulk rHuPH20 to partners for use in research and development and, subsequent to receiving marketing approval, we sell it for use in collaboration commercial products. Sales are made pursuant to purchase orders subject to the terms of the collaborative agreement or a supply agreement, and delivery of units of bulk rHuPH20 represent performance obligations under each purchase order. We provide a standard warranty that the product conforms to specifications. We use contract manufacturers to produce bulk rHuPH20 and have concluded we are the principal in the sales to partners. The transaction price for each purchase order of bulk rHuPH20 is fixed based on the cost of production plus a contractual markup, and is not subject to adjustments. Allocation of the transaction price to individual quantities of the product is usually not required because each order contains only one type of product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize revenue from the sale of bulk rHuPH20 as product sales and related cost of sales upon transfer of title to our partners. At that time, the partners take control of the product, bear the risk of loss of ownership, and have an enforceable obligation to pay us. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Devices&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are party to several license, development, supply and distribution arrangements with pharmaceutical partners, under which we produce and are the exclusive supplier of certain products, devices and/or components. Revenue is recognized when or as control of the goods transfers to the customer as discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are the exclusive supplier of OTREXUP&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to Otter. Because this product is custom manufactured with no alternative use and we have a contractual right to payment for performance completed to date, control is continuously transferred to the customer as the product is produced pursuant to firm purchase orders. Revenue is recognized over time using the output method based on the contractual selling price and number of units produced. The amount of revenue recognized in excess of the amount shipped/billed to the customer, if any, is recorded as contract assets in our condensed consolidated balance sheets due to the short-term nature in which the amount is ultimately expected to be billed and collected from the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other device partnered product sales are recognized at the point in time in which control is transferred to the customer, which is typically upon shipment. Sales terms and pricing are governed by the respective supply and distribution agreements, and there is generally no right of return. Revenue is recognized at the transaction price, which includes the contractual per unit selling price and estimated variable consideration, such as volume-based pricing arrangements or profit-sharing arrangements, if any. We recognize revenue, including the estimated variable consideration we expect to receive for contract margin on future commercial sales, upon shipment of the goods to our partner. The estimated variable consideration is recognized at an amount we believe is not subject to significant reversal of revenue based on historical experience and is adjusted at each reporting period if the most likely amount of expected consideration changes or becomes fixed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of sales consists primarily of raw materials, third-party manufacturing costs, fill and finish costs, freight costs, internal costs and manufacturing overhead associated with the production of proprietary and partnered products. Cost of sales also consists of the write-down of excess, dated and obsolete inventories and the write-off of inventories that do not meet certain product specifications, if any.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses include salaries and benefits, allocation of facilities and other overhead expenses, research related manufacturing services, contract services, and other outside expenses related to manufacturing, preclinical and regulatory activities and our partner development platforms. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to our research and development efforts and have no alternative future uses.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as expense as the related goods are delivered or the related services are performed or such time when we do not expect the goods to be delivered or services to be performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record compensation expense associated with stock options, restricted stock units (&#x201c;RSUs&#x201d;), performance stock units (&#x201c;PSUs&#x201d;) and shares issued under our employee stock purchase plan (&#x201c;ESPP&#x201d;) in accordance with the authoritative guidance for share-based compensation. The cost of employee services received in exchange for an award of an equity instrument is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense on a straight-line basis over the requisite service period of the award. Share-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed. Forfeitures are recognized as a reduction of share-based compensation expense as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We provide for income taxes using the liability method. Under this method, deferred income tax assets and liabilities are determined based on the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases at each reporting period. We measure deferred tax assets and liabilities using enacted tax rates for the year in which the differences are expected to reverse. Significant judgment is required by management to determine our provision for income taxes, our deferred tax assets and liabilities, and any associated valuation allowances recorded against our net deferred tax assets, which are based on complex and evolving tax regulations. Deferred tax assets (&#x201c;DTA&#x201d;) and other tax benefits are recorded when they are more likely than not to be realized. On a quarterly basis, we assess the need for valuation allowance on our DTAs, weighing all positive and negative evidence, to assess if it is more-likely-than-not that some or all of our DTAs will be realized. We recorded a provision for income taxes of $19.2 million using an effective tax rate of 20% for the three months ended March&#160;31, 2024. The difference between our effective tax rate and the U.S. federal statutory rate of 21% is primarily due to state income taxes, research and development credit generations, tax benefits on the Foreign Derived Intangible Income Deduction (&#x201c;FDII&#x201d;) (net of reserves), tax detriments on 162(m) and other share-based compensation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate our business in one operating segment, which includes all activities related to the research, development and commercialization of our proprietary enzymes and devices. This segment also includes revenues and expenses related to (i)&#160;research and development and manufacturing activities conducted under our collaborative agreements with third parties, and (ii)&#160;product sales of proprietary and partnered products. The chief operating decision-maker (&#x201c;CODM&#x201d;), our Chief Executive Officer (&#x201c;CEO&#x201d;), reviews the operating results on an aggregate basis and manages the operations as a single operating segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Adoption and Pending Adoption of Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a brief description of recently issued accounting standards, those adopted in the current period and those not yet adopted:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.852%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.570%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.570%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.154%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.570%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.688%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.878%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.787%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Standard&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Effective Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Adoption Method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Effect on the Financial&lt;br/&gt;Statements or Other Significant Matters&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In November 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The new standard is intended to improve annual and interim reportable segment disclosure requirements regardless of number of reporting units, primarily through enhanced disclosures of significant expenses. The amendment requires public entities to disclose significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit and loss.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Annual periods beginning after December 15, 2023 (our 2024 Form 10-K), and interim periods within fiscal years beginning after December 15, 2024 (our Q1 2025 Form 10-Q) - Early adoption is permitted, including adoption in an interim period&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Retrospective&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We are currently evaluating the impact of the standard on our consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The new guidance includes amendments that further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Annual periods beginning after December 15, 2024 (our 2025 Form 10-K) - Early adoption is permitted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Prospective or Retrospective&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We are currently evaluating the impact of the standard on our consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-262">&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying interim unaudited condensed consolidated financial statements have been prepared for purposes of and in accordance with United States generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) and with the rules and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) related to a quarterly report on Form 10-Q. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for a complete set of financial statements. These condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December&#160;31, 2023, filed with the SEC on February&#160;20, 2024. The unaudited financial information for the interim periods presented herein reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operations for the periods presented, with such adjustments consisting only of normal recurring adjustments. Operating results for interim periods are not necessarily indicative of the operating results for an entire fiscal year.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-263">&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements include the accounts of Halozyme Therapeutics, Inc. and our wholly owned subsidiaries, Halozyme, Inc. and Antares Pharma, Inc., and Antares Pharma, Inc.&#x2019;s wholly owned Swiss subsidiaries, Antares Pharma IPL AG and Antares Pharma AG. All intercompany accounts and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-264">&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that we believe to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from our estimates</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy contextRef="c-1" id="f-265">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents consist of highly liquid investments, readily convertible to cash, which mature within 90 days or less from the date of purchase. As of March&#160;31, 2024, our cash and cash equivalents consisted of money market funds, bank certificate of deposits, U.S. treasury securities and demand deposits at commercial banks.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:MarketableSecuritiesPolicy contextRef="c-1" id="f-266">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities are investments with original maturities of more than 90 days from the date of purchase that are specifically identified to fund current operations. Marketable securities are considered available-for-sale. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date which reflects management&#x2019;s intention to use the proceeds from the sale of these investments to fund our operations, as necessary. Such available-for-sale investments are carried at fair value with unrealized gains and losses recorded in other comprehensive income and included as a separate component of stockholders&#x2019; equity. The cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in investment and other income, net in our condensed consolidated statements of income. We use the specific identification method for calculating realized gains and losses on marketable securities sold. None of the realized gains and losses and declines in value that were judged to be as a result of credit loss on marketable securities, if any, are included in investment and other income, net in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c-1" id="f-267">&lt;div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The authoritative guidance for fair value measurements establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments include cash equivalents, available-for-sale marketable securities, accounts receivable, prepaid expenses and other assets, accounts payable, accrued expenses and long-term debt. Fair value estimates of these instruments are made at a specific point in time based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore, cannot be determined with precision. The carrying amount of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available-for-sale marketable securities consist of asset-backed securities, corporate debt securities, U.S. Treasury securities, agency bonds and commercial paper, and are measured at fair value using Level 1 and Level 2 inputs. Level 2 financial instruments are valued using market prices on less active markets and proprietary pricing valuation models with observable inputs, including interest rates, yield curves, maturity dates, issue dates, settlement dates, reported trades, broker-dealer quotes, issue spreads, benchmark securities or other market related data. We obtain the fair value of Level 2 investments from our investment manager, who obtains these fair values from a third-party pricing source. We validate the fair values of Level 2 financial instruments provided by our investment manager by comparing these fair values to a third-party pricing source.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="c-1" id="f-268">&lt;div style="margin-top:9pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable is recorded at the invoiced amount and is non-interest bearing. Accounts receivable is recorded net of estimated prompt pay discounts, distribution fees and chargebacks. We believe the risk of accounts being uncollectible is minimal; therefore, no significant allowances for doubtful accounts were established as of March&#160;31, 2024 and December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-4" decimals="INF" id="f-269" unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-3" decimals="INF" id="f-270" unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:InventoryPolicyTextBlock contextRef="c-1" id="f-271">&lt;div style="margin-top:9pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Inventories are reviewed periodically for potential excess, dated or obsolete status. We evaluate the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the price we expect to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-272">&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into operating leases primarily for real estate and automobiles. These leases have contractual terms which range from 3 years to 12 years. We determine if an arrangement contains a lease at inception. Right of use (&#x201c;ROU&#x201d;) assets and liabilities resulting from operating leases are included in property and equipment, accrued expenses and other long-term liabilities on our condensed consolidated balance sheets. Operating lease ROU assets and liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the discount rate to calculate the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. Our leases often include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that we will exercise that option. Short-term leases with an initial term of 12 months or less are not recorded on our condensed consolidated balance sheet. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have lease agreements with lease and non-lease components, which are generally accounted for separately. For certain leases, such as automobiles, we account for the lease and non-lease components as a single lease component.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-42" id="f-273">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-43" id="f-274">P12Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-275">&lt;div style="margin-top:9pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;Property and equipment, including ROU assets are recorded at cost, less accumulated depreciation and amortization. Equipment is depreciated using the straight-line method over its estimated useful life ranging from three years to ten years and leasehold improvements are amortized using the straight-line method over the estimated useful life of the asset or the lease term, whichever is shorter.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-42" id="f-276">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-43" id="f-277">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-43" id="f-278">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentImpairment contextRef="c-1" id="f-279">&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;We account for long-lived assets in accordance with authoritative guidance for impairment or disposal of long-lived assets. Long-lived assets are reviewed for events or changes in circumstances, which indicate that their carrying value may not be recoverable.</us-gaap:PropertyPlantAndEquipmentImpairment>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c-1" id="f-280">&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive income is defined as the change in equity during the period from transactions and other events and circumstances from non-owner sources.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock contextRef="c-1" id="f-281">&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Convertible Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2024 Convertible Notes, the 2027 Convertible Notes and the 2028 Convertible Notes (collectively, the &#x201c;Convertible Notes&#x201d;) are accounted for in accordance with authoritative guidance for debt and derivatives. We evaluate all the embedded conversion options contained in the Convertible Notes to determine if there are embedded features that require bifurcation as a derivative as required by U.S. GAAP. Based on our analysis, we account for each of our Convertible Notes as single units of accounting, a liability, because we concluded that the conversion features do not require bifurcation as a derivative under embedded derivative authoritative guidance.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:DerivativesMethodsOfAccountingHedgingDerivatives contextRef="c-1" id="f-282">&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash Flow Hedges - Currency Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in the second quarter of 2023, we entered into a cash flow hedging program to mitigate foreign currency exchange risk associated with forecasted royalty revenue denominated in Swiss francs. Under the program, we can hedge these forecasted royalties up to a maximum of four years into the future. We hedge these cash flow exposures to reduce the risk of our earnings and cash flows being adversely affected by fluctuations in exchange rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the hedge accounting treatment, all hedging relationships are formally documented at the inception of the hedge and are highly effective in offsetting changes to future cash flows on hedged transactions. Both at inception of the hedge and on an ongoing basis, we assess whether the foreign currency forward contracts are highly effective in offsetting changes in cash flows of hedged items on a prospective and retrospective basis. If we determine a (i) foreign currency forward contract is not highly effective as a cash flow hedge, (ii) foreign currency forward contract has ceased to be a highly effective hedge or (iii) forecasted transaction is no longer probable of occurring, we would discontinue hedge accounting treatment prospectively. We measure effectiveness based on the change in fair value of the forward currency forward contract and the fair value of the hypothetical foreign currency forward contract with terms that match the critical terms of the risk being hedged. No portion of our foreign currency forward contracts were excluded from the assessment of hedge effectiveness. As of March&#160;31, 2024, all hedges were determined to be highly effective. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assets or liabilities associated with our hedging contracts are recorded at fair market value in prepaid expense and other current assets, accrued expenses, or other long-term liabilities, respectively, in our condensed consolidated balance sheets. Gains and losses related to changes in the fair market value of these hedging contracts are recorded as a component of accumulated other comprehensive income (loss) (&#x201c;AOCI&#x201d;) within stockholder&#x2019;s equity in our condensed consolidated balance sheets and reclassified to royalty revenue in our condensed consolidated statements of income in the same period as the recognition of the underlying hedged transaction. In the event the underlying forecasted transaction does not occur, or it becomes probable that it will not occur, within the defined hedge period, we reclassify the gains or losses on the related cash flow hedge from AOCI to royalties revenue in our condensed consolidated statements of income. Settlements from the cash flow hedge are included in operating activities on the condensed consolidated statements of cash flows. Since the fair market value of these hedging contracts is derived from current market rates, the hedging contracts are classified as derivative financial instruments. We do not use derivatives for speculative or trading purposes. As of March&#160;31, 2024, amounts expected to be recognized as a net gain out of AOCI into our condensed consolidated statements of income during the next 12 months are not material.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesMethodsOfAccountingHedgingDerivatives>
    <us-gaap:DerivativeTermOfContract contextRef="c-44" id="f-283">P4Y</us-gaap:DerivativeTermOfContract>
    <us-gaap:BusinessCombinationsPolicy contextRef="c-1" id="f-284">&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the acquisition method of accounting, we allocate the fair value of the total consideration transferred to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the date of acquisition. These valuations require us to make estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill. Costs incurred to complete a business combination, such as legal and other professional fees, are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the initial accounting for a business combination is incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date. We record these adjustments to the provisional amounts with a corresponding offset to goodwill. Any adjustments identified after the measurement period are recorded in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="c-1" id="f-285">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets acquired, including intangible assets and in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;), and liabilities assumed are measured at fair value as of the acquisition date. Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of the net assets acquired. Intangible assets acquired in a business combination that are used for IPR&amp;amp;D activities are considered indefinite lived until the completion or abandonment of the associated research and development efforts. Upon reaching the end of the relevant research and development project (i.e., upon commercialization), the IPR&amp;amp;D &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;asset is amortized over its estimated useful life. If the relevant research and development project is abandoned, the IPR&amp;amp;D asset is expensed in the period of abandonment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill and IPR&amp;amp;D are not amortized; however, they are reviewed for impairment at least annually during the second quarter, or more frequently if an event occurs indicating the potential for impairment. Goodwill and IPR&amp;amp;D are considered to be impaired if the carrying value of the reporting unit or IPR&amp;amp;D asset exceeds its respective fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We perform our goodwill impairment analysis at the reporting unit level, which aligns with our reporting and operating segment structure and availability of discrete financial information. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair values of our reporting unit is less than the carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and our overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amounts, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair value of the reporting unit with the carrying value, including goodwill. If the carrying amount of the reporting unit exceeds the fair value, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative goodwill impairment test.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our identifiable intangible assets with finite useful lives are typically comprised of acquired device technologies and product rights. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#x2019; respective estimated useful lives.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock contextRef="c-1" id="f-286">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We perform regular reviews to determine if any event has occurred that may indicate intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to the net book value, significant changes in the ability of a particular asset to generate positive cash flows for our strategic business objectives, and the pattern of utilization of a particular asset.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c-1" id="f-287">&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generate revenues from payments received (i) as royalties from licensing our ENHANZE technology and other royalty arrangements, (ii) under collaborative agreements and (iii) from sales of our proprietary and partnered products. We recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, we perform the following five steps: (i) identify the promised goods or services in the contract; (ii) identify the performance obligations in the contract, including whether they are distinct in the context of the contract; (iii) determine the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ENHANZE and Device Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of our ENHANZE collaboration and license agreements, our partners will pay us royalties at an on average mid-single digit percent rate of their sales if products under the collaboration are commercialized. All amounts owed to us are noncancelable after the underlying triggering event occurs, and nonrefundable once paid. Unless terminated earlier in accordance with its terms, collaborations generally continue in effect until the last to expire royalty payment term, as determined on a product by product and country by country basis, with each royalty term starting on the first commercial sale of that product and ending the later of: (i) a specified period or term set forth in the agreement or (ii) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration. In general, when there are no valid claims of a specified patent developed under the collaboration covering the product in a given country, the royalty rate is reduced for those sales in that country upon the expiration of our patents covering rHuPH20. Janssen&#x2019;s patents covering DARZALEX SC do not impact the timing for this royalty reduction. Partners may terminate the agreement prior to expiration for any reason in its entirety or on a target-by-target basis generally upon 90 days prior written notice to us.&#160;Upon any such termination, the license granted to partners (in total or with respect to the terminated target, as applicable) will terminate provided; however, that in the event of expiration of the agreement (as opposed to a termination), the on-going licenses granted may become perpetual, non-exclusive and fully paid. Sales-based milestones and royalties are recognized in the period the underlying sales or milestones occur. We do not receive final royalty reports from our ENHANZE partners until after we complete our financial statements for a prior quarter. Therefore, we recognize revenue based on estimates of the royalty earned, which are based on internal estimates and available preliminary reports provided by our partners. We will record adjustments in the following quarter, if necessary, when final royalty reports are received. To date, we have not recorded any material adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also earn royalties in connection with several of our licenses granted under license and development arrangements with our device partners. These royalties are based upon a percentage of commercial sales of partnered products with rates ranging from mid-single digits to low double digits and are tiered based on levels of net sales. These sales-based royalties, for which the license was deemed the predominant element to which the royalties relate, are estimated and recognized in the period in which the partners&#x2019; commercial sales occur. The royalties are generally reported and payable to us within 45 to 60 days after the end of the period in which the commercial sales are made. We base our estimates of royalties earned on actual sales information from our partners when available or estimated, prescription sales from external sources and estimated net selling price. We will record adjustments in the following quarter, if necessary, when final royalty reports are received. To date, we have not recorded any material adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue under ENHANZE and Device Collaborative Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;ENHANZE Collaboration and License Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under these agreements, we grant the collaboration partner a worldwide license to develop and commercialize products using our ENHANZE technology to combine our patented rHuPH20 enzyme with their proprietary biologics directed at up to a specified number of targets. Targets are usually licensed on an exclusive, global basis. Targets selected subsequent to inception of the arrangement generally require payment of an additional license fee. The collaboration partner is responsible for all development, manufacturing, clinical, regulatory, sales and marketing costs for any products developed under the agreement. We are responsible for supply of bulk rHuPH20 based on the collaboration partner&#x2019;s purchase orders, and may also be separately engaged to perform research and development services. While these collaboration agreements are similar in that they originate from the same framework, each one is the result of an arms-length negotiation and thus may vary from one to the other.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generally collect an upfront license payment from collaboration partners, and are also entitled to receive event-based payments subject to collaboration partners&#x2019; achievement of specified development, regulatory and sales-based milestones. In several agreements, collaboration partners pay us annual fees to maintain their exclusive license rights if they are unable to advance product development to specified stages. We earn separate fees for bulk rHuPH20 supplies and research and development services. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although these agreements are in form identified as collaborative agreements, we concluded for accounting purposes they represent contracts with customers and are not subject to accounting literature on collaborative arrangements. This is because we grant to partners licenses to our intellectual property and provide supply of bulk rHuPH20 and research and development services which are all outputs of our ongoing activities, in exchange for respective consideration. Under these collaborative agreements, our partners lead development of assets, and we do not share in significant financial risks of their development or commercialization activities. Accordingly, we concluded our collaborative agreements are appropriately accounted for pursuant to U.S. GAAP. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under all of our ENHANZE collaborative agreements, we have identified licenses to use functional intellectual property as the only performance obligation. The intellectual property underlying the license is our proprietary ENHANZE technology which represents application of rHuPH20 to facilitate delivery of drugs. Each of the licenses grants the partners rights to use our intellectual property as it exists and is identified on the effective date of the license, because there is no ongoing development of the ENHANZE technology required. Therefore, we recognize revenue from licenses at the point when the license becomes effective and the partner has received access to our intellectual property, usually at the inception of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When partners can select additional targets to add to the licenses granted, we consider these rights to be options. We evaluate whether such options contain material rights, i.e. have exercise prices that are discounted compared to what we would charge for a similar license to a new partner. The exercise price of these options includes a combination of the target selection fees, event-based milestone payments and royalties. When these amounts in aggregate are not offered at a discount that exceeds discounts available to other customers, we conclude the option does not contain a material right, and we consider grants of additional licensing rights upon option exercises to be separate contracts (target selection contracts).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Generally, we provide indemnification and protection of licensed intellectual property for our customers. These provisions are part of assurance that the licenses meet the agreements&#x2019; representations and are not obligations to provide goods or services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also fulfill purchase orders for supply of bulk rHuPH20 and perform research and development services pursuant to project authorization forms for our partners, which represent separate contracts. In addition to our licenses, we price our supply of bulk rHuPH20 and research and development services at our regular selling prices, called standalone selling prices (&#x201c;SSP&#x201d;). Therefore, our partners do not have material rights to order these items at prices not reflective of SSP. Refer to the discussion below regarding recognition of revenue for these separate contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transaction price for a contract represents the amount to which we are entitled in exchange for providing goods and services to the customer. Transaction price does not include amounts subject to uncertainties unless it is probable that there will be no significant reversal of revenue when the uncertainty is resolved. Apart from the upfront license payment (or target selection fees in the target selection contracts), all other fees we may earn under our collaborative agreements are subject to significant uncertainties of product development. Achievement of many of the event-based development and regulatory milestones may not be probable until such milestones are actually achieved. This generally relates to milestones such as obtaining marketing authorization approvals. With respect to other development milestones, e.g., dosing of a first patient in a clinical trial, achievement could be considered probable prior to its actual occurrence, based on the progress towards commencement of the trial. In order to evaluate progress towards commencement of a trial, we assess the status of activities leading up to our partner&#x2019;s initiation of a trial such as feedback received from the applicable regulatory authorities, completion of Investigational New Drug (&#x201c;IND&#x201d;) or equivalent filings, readiness and availability of drug, readiness of study sites and our partner&#x2019;s commitment of resources to the program. We do not include any amounts subject to uncertainties in the transaction price until it is probable that the amount will not result in a significant reversal of revenue in the future. At the end of each reporting period, we re-evaluate the probability of achievement of such milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When target exchange rights are held by partners, and the amounts attributed to these rights are not refundable, they are included in the transaction price. However, they are recorded as deferred revenues because we have a potential performance obligation to provide a new target upon an exchange right being exercised. These amounts are recognized in revenue when the right of exchange expires or is exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because our agreements have one type of performance obligation (licenses) which are typically all transferred at the same time at agreement inception, allocation of transaction price often is not required. However, allocation is required when licenses for some of the individual targets are subject to rights of exchange, because revenue associated with these targets cannot be recognized. When allocation is needed, we perform an allocation of the upfront amount based on relative SSP of licenses for individual targets. We determine license SSP using an income-based valuation approach utilizing risk-adjusted discounted cash flow projections of the estimated return a licensor would receive. When amounts subject to uncertainties, such as milestones and royalties, are included in the transaction price, we attribute them to the specific individual target licenses which generate such milestone or royalty amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also estimate SSP of bulk rHuPH20 and research and development services, to determine that our partners do not have material rights to order them at discounted prices. For supplies of bulk rHuPH20, because we effectively act as a contract manufacturer to our partners, we estimate and charge SSP based on the typical contract manufacturer margins consistent with all of our partners. We determine SSP of research and development services based on a fully-burdened labor rate. Our rates are comparable to those we observe in other collaborative agreements. We also have a history of charging similar rates to all of our partners. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upfront amounts allocated to licenses to individual targets are recognized as revenue when the license is transferred to the partner, as discussed above, if the license is not subject to exchange rights, or when the exchange right expires or is exercised. Development milestones and other fees are recognized in revenue when they are included in the transaction price, because by that time, we have already transferred the related license to the partner. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In contracts to provide research and development services, such services represent the only performance obligation. The fees are charged based on hours worked by our employees and the fixed contractual rate per hour, plus third-party pass-through costs, on a monthly basis. We recognize revenues as the related services are performed based on the amounts billed, as the partner consumes the benefit of research and development work simultaneously as we perform these services, and the amounts billed reflect the value of these services to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Device License, Development and Supply Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have several license, development and supply arrangements with pharmaceutical partners, under which we grant a license to our device technology and provide research and development services that often involve multiple performance obligations and highly-customized deliverables. For such arrangements, we identify each of the promised goods and services within the contract and the distinct performance obligations at inception of the contract and allocate consideration to each performance obligation based on relative SSP, which is generally determined based on the expected cost plus mark-up. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the contract includes an enforceable right to payment for performance completed to date and performance obligations are satisfied over time, we recognize revenue over the development period using either the input or output method depending on which is most appropriate given the nature of the distinct deliverable. For other contracts that do not contain an enforceable right to payment for performance completed to date, revenue is recognized when control of the product is transferred to the customer. Factors that may indicate transfer of control has occurred include the transfer of legal title, transfer of physical possession, the customer has obtained the significant risks and rewards of ownership of the assets, and we have a present right to payment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our payment terms for development contracts may include an upfront payment equal to a percentage of the total contract value with the remaining portion to be billed upon completion and transfer of the individual deliverables or satisfaction of the individual performance obligations. We record a contract liability for cash received in advance of performance, which is presented within deferred revenue and deferred revenue, long-term in our condensed consolidated balance sheets and recognized as revenue in our condensed consolidated statements of income when the associated performance obligations have been satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License fees and milestones received in exchange for the grant of a license to our functional intellectual property, such as patented technology and know-how in connection with a partnered development arrangement, are generally recognized at inception of the arrangement, or over the development period depending on the facts and circumstances, as the license is generally not distinct from the non-licensed goods or services to be provided under the contract. Milestone payments that are contingent upon the occurrence of future events are evaluated and recorded at the most likely amount, and to the extent that it is probable that a significant reversal of revenue will not occur when the associated uncertainty is resolved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 4,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for further discussion on our collaborative arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Sales, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Proprietary Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our commercial portfolio of proprietary products includes XYOSTED and Hylenex recombinant which we sell primarily to wholesale pharmaceutical distributors and specialty pharmacies, who sell the products to hospitals, retail chain drug stores and other end-user customers. Sales to wholesalers are made pursuant to purchase orders subject to the terms of a master agreement, and delivery of individual packages of products represents performance obligations under each purchase order. We use contract manufacturers to produce our proprietary products and third-party logistics (&#x201c;3PL&#x201d;) vendors to process and fulfill orders&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We concluded we are the principal in the sales to wholesalers because we control access to services rendered by both vendors and direct their activities. We have no significant obligations to wholesalers to generate pull-through sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue is recognized when control has transferred to the customer, which is typically upon delivery, at the net selling price, which reflects the variable consideration for which reserves and sales allowances are established for estimated returns, wholesale distribution fees, prompt payment discounts, government rebates and chargebacks, plan rebate arrangements and patient discount and support programs. We recognize revenue from product sales and related cost of sales upon product delivery to the wholesaler location. At that time, the wholesalers take control of the product as they take title, bear the risk of loss of ownership, and have an enforceable obligation to pay us. They also have the ability to direct sales of product to their customers on terms and at prices they negotiate. Although wholesalers have product return rights, we do not believe they have a significant incentive to return the product to us.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The determination of certain reserves and sales allowances requires us to make a number of judgements and estimates to reflect our best estimate of the transaction price and the amount of consideration to which we believe we would be ultimately entitled to receive. The expected value is determined based on unit sales data, contractual terms with customers and third-party payers, historical and estimated future percentage of rebates incurred on sales, historical and future insurance plan billings, any new or anticipated changes in programs or regulations that would impact the amount of the actual rebates, customer purchasing patterns, product expiration dates and levels of inventory in the distribution channel. The estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, rebates and customer co-pay support programs are included in accrued expenses and accounts receivable, net in our condensed consolidated balance sheets upon recognition of revenue from product sales. We monitor actual product returns, chargebacks, discounts and fees subsequent to the sale. If these amounts differ from our estimates, we make adjustments to these allowances, which are applied to increase or reduce product sales revenue and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling prices initially billed to wholesalers are subject to discounts for prompt payment and subsequent chargebacks when wholesalers sell our products at negotiated discounted prices to members of certain group purchasing organizations (&#x201c;GPOs&#x201d;), Pharmacy Benefit Managers (&#x201c;PBMs&#x201d;) and government programs. We also pay quarterly distribution fees to certain wholesalers for inventory reporting and chargeback processing, and to PBMs and GPOs as administrative fees for services and for access to their members. We concluded the benefits received in exchange for these fees are not distinct from our sales of our products, and accordingly we apply these amounts to reduce revenues. Wholesalers also have rights to return unsold product nearing or past the expiration date. Because of the shelf life of our products and our lengthy return period, there may be a significant period of time between when the product is shipped and when we issue credits on returned product. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the transaction price when we receive each purchase order taking into account the expected reductions of the selling price initially billed to the wholesaler arising from all of the above factors. We have compiled historical experience and data to estimate future returns and chargebacks of our products and the impact of the other discounts and fees we pay. When estimating these adjustments to the transaction price, we reduce it sufficiently to be able to assert that it is probable that there will be no significant reversal of revenue when the ultimate adjustment amounts are known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each purchase order contains only one type of product, and is usually shipped to the wholesaler in a single shipment. Therefore, allocation of the transaction price to individual packages is not required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the orders placed by wholesalers, we incur costs such as commissions to our sales representatives. However, as revenue from product sales is recognized upon delivery to the wholesaler, which occurs shortly after we receive a purchase order, we do not capitalize these commissions and other costs, based on application of the practical expedient allowed within the applicable guidance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Partnered Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Bulk rHuPH20&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We sell bulk rHuPH20 to partners for use in research and development and, subsequent to receiving marketing approval, we sell it for use in collaboration commercial products. Sales are made pursuant to purchase orders subject to the terms of the collaborative agreement or a supply agreement, and delivery of units of bulk rHuPH20 represent performance obligations under each purchase order. We provide a standard warranty that the product conforms to specifications. We use contract manufacturers to produce bulk rHuPH20 and have concluded we are the principal in the sales to partners. The transaction price for each purchase order of bulk rHuPH20 is fixed based on the cost of production plus a contractual markup, and is not subject to adjustments. Allocation of the transaction price to individual quantities of the product is usually not required because each order contains only one type of product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize revenue from the sale of bulk rHuPH20 as product sales and related cost of sales upon transfer of title to our partners. At that time, the partners take control of the product, bear the risk of loss of ownership, and have an enforceable obligation to pay us. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Devices&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are party to several license, development, supply and distribution arrangements with pharmaceutical partners, under which we produce and are the exclusive supplier of certain products, devices and/or components. Revenue is recognized when or as control of the goods transfers to the customer as discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are the exclusive supplier of OTREXUP&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to Otter. Because this product is custom manufactured with no alternative use and we have a contractual right to payment for performance completed to date, control is continuously transferred to the customer as the product is produced pursuant to firm purchase orders. Revenue is recognized over time using the output method based on the contractual selling price and number of units produced. The amount of revenue recognized in excess of the amount shipped/billed to the customer, if any, is recorded as contract assets in our condensed consolidated balance sheets due to the short-term nature in which the amount is ultimately expected to be billed and collected from the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other device partnered product sales are recognized at the point in time in which control is transferred to the customer, which is typically upon shipment. Sales terms and pricing are governed by the respective supply and distribution agreements, and there is generally no right of return. Revenue is recognized at the transaction price, which includes the contractual per unit selling price and estimated variable consideration, such as volume-based pricing arrangements or profit-sharing arrangements, if any. We recognize revenue, including the estimated variable consideration we expect to receive for contract margin on future commercial sales, upon shipment of the goods to our partner. The estimated variable consideration is recognized at an amount we believe is not subject to significant reversal of revenue based on historical experience and is adjusted at each reporting period if the most likely amount of expected consideration changes or becomes fixed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of sales consists primarily of raw materials, third-party manufacturing costs, fill and finish costs, freight costs, internal costs and manufacturing overhead associated with the production of proprietary and partnered products. Cost of sales also consists of the write-down of excess, dated and obsolete inventories and the write-off of inventories that do not meet certain product specifications, if any.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <halo:RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice contextRef="c-1" id="f-288">P90D</halo:RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-289">&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses include salaries and benefits, allocation of facilities and other overhead expenses, research related manufacturing services, contract services, and other outside expenses related to manufacturing, preclinical and regulatory activities and our partner development platforms. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to our research and development efforts and have no alternative future uses.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as expense as the related goods are delivered or the related services are performed or such time when we do not expect the goods to be delivered or services to be performed.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-290">&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record compensation expense associated with stock options, restricted stock units (&#x201c;RSUs&#x201d;), performance stock units (&#x201c;PSUs&#x201d;) and shares issued under our employee stock purchase plan (&#x201c;ESPP&#x201d;) in accordance with the authoritative guidance for share-based compensation. The cost of employee services received in exchange for an award of an equity instrument is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense on a straight-line basis over the requisite service period of the award. Share-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed. Forfeitures are recognized as a reduction of share-based compensation expense as they occur.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-291">&lt;div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We provide for income taxes using the liability method. Under this method, deferred income tax assets and liabilities are determined based on the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases at each reporting period. We measure deferred tax assets and liabilities using enacted tax rates for the year in which the differences are expected to reverse. Significant judgment is required by management to determine our provision for income taxes, our deferred tax assets and liabilities, and any associated valuation allowances recorded against our net deferred tax assets, which are based on complex and evolving tax regulations. Deferred tax assets (&#x201c;DTA&#x201d;) and other tax benefits are recorded when they are more likely than not to be realized. On a quarterly basis, we assess the need for valuation allowance on our DTAs, weighing all positive and negative evidence, to assess if it is more-likely-than-not that some or all of our DTAs will be realized. We recorded a provision for income taxes of $19.2 million using an effective tax rate of 20% for the three months ended March&#160;31, 2024. The difference between our effective tax rate and the U.S. federal statutory rate of 21% is primarily due to state income taxes, research and development credit generations, tax benefits on the Foreign Derived Intangible Income Deduction (&#x201c;FDII&#x201d;) (net of reserves), tax detriments on 162(m) and other share-based compensation.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-292" unitRef="usd">19200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-293" unitRef="number">0.20</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c-1" id="f-294">&lt;div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate our business in one operating segment, which includes all activities related to the research, development and commercialization of our proprietary enzymes and devices. This segment also includes revenues and expenses related to (i)&#160;research and development and manufacturing activities conducted under our collaborative agreements with third parties, and (ii)&#160;product sales of proprietary and partnered products. The chief operating decision-maker (&#x201c;CODM&#x201d;), our Chief Executive Officer (&#x201c;CEO&#x201d;), reviews the operating results on an aggregate basis and manages the operations as a single operating segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-295"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-296">&lt;div style="margin-top:3pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Adoption and Pending Adoption of Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a brief description of recently issued accounting standards, those adopted in the current period and those not yet adopted:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.852%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.570%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.570%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.154%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.570%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.688%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.878%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.787%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Standard&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Effective Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Adoption Method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Effect on the Financial&lt;br/&gt;Statements or Other Significant Matters&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In November 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The new standard is intended to improve annual and interim reportable segment disclosure requirements regardless of number of reporting units, primarily through enhanced disclosures of significant expenses. The amendment requires public entities to disclose significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit and loss.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Annual periods beginning after December 15, 2023 (our 2024 Form 10-K), and interim periods within fiscal years beginning after December 15, 2024 (our Q1 2025 Form 10-Q) - Early adoption is permitted, including adoption in an interim period&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Retrospective&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We are currently evaluating the impact of the standard on our consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The new guidance includes amendments that further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Annual periods beginning after December 15, 2024 (our 2025 Form 10-K) - Early adoption is permitted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Prospective or Retrospective&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We are currently evaluating the impact of the standard on our consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-297">Fair Value Measurement&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available-for-sale marketable securities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.345%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.565%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.565%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.565%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.565%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.779%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities, available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.345%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.565%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.565%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.565%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.565%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.779%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities, available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2024, 33 available-for-sale marketable securities with a fair market value of $215.5 million were in a gross unrealized loss position of $0.2&#160;million. Based on our review of these marketable securities, we believe none of the unrealized loss is as a result of a credit loss as of&#160;March&#160;31, 2024 because we do not intend to sell these securities and it is not more-likely-than-not that we will be required to sell these securities before the recovery of their amortized cost basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of our contractual maturities of available-for-sale debt securities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.565%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.060%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.565%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.063%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year but within five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total estimated fair value of contractual maturities, available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes, by major security type, our cash equivalents and available-for-sale marketable securities measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.421%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.329%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.329%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.329%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:1.967%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.329%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.329%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.337%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Estimated Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Estimated Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale marketable &lt;br/&gt;&#160;&#160;&#160;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency hedging contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency hedging contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Based on observable market transactions of spot currency rates, forward currency rates or equivalently-termed instruments. Carrying amounts of the financial assets and liabilities are equal to the fair value. As of March&#160;31, 2024, the derivative assets and liabilities recorded within prepaid expenses and other current assets, prepaid expense and other assets and other long-term liabilities in our condensed consolidated balance sheets were $&lt;span style="-sec-ix-hidden:f-420"&gt;1.3 million&lt;/span&gt;, $&lt;span style="-sec-ix-hidden:f-422"&gt;0.3 million&lt;/span&gt; and $&lt;span style="-sec-ix-hidden:f-424"&gt;0.5 million&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had no available for sale securities that were classified within Level 3 as of March&#160;31, 2024 and December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="c-1" id="f-298">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available-for-sale marketable securities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.345%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.565%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.565%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.565%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.565%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.779%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities, available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.345%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.565%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.565%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.565%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.565%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.779%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities, available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-45" decimals="-3" id="f-299" unitRef="usd">2384000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-45" decimals="-3" id="f-300" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-45" decimals="-3" id="f-301" unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-45" decimals="-3" id="f-302" unitRef="usd">2379000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-46" decimals="-3" id="f-303" unitRef="usd">43118000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-46" decimals="-3" id="f-304" unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-46" decimals="-3" id="f-305" unitRef="usd">64000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-46" decimals="-3" id="f-306" unitRef="usd">43056000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-47" decimals="-3" id="f-307" unitRef="usd">239347000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-47" decimals="-3" id="f-308" unitRef="usd">36000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-47" decimals="-3" id="f-309" unitRef="usd">106000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-47" decimals="-3" id="f-310" unitRef="usd">239277000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-48" decimals="-3" id="f-311" unitRef="usd">9180000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-48" decimals="-3" id="f-312" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-48" decimals="-3" id="f-313" unitRef="usd">22000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-48" decimals="-3" id="f-314" unitRef="usd">9158000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-49" decimals="-3" id="f-315" unitRef="usd">4954000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-49" decimals="-3" id="f-316" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-49" decimals="-3" id="f-317" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-49" decimals="-3" id="f-318" unitRef="usd">4954000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-3" decimals="-3" id="f-319" unitRef="usd">298983000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-3" decimals="-3" id="f-320" unitRef="usd">38000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-3" decimals="-3" id="f-321" unitRef="usd">197000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-3" decimals="-3" id="f-322" unitRef="usd">298824000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-50" decimals="-3" id="f-323" unitRef="usd">3512000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-50" decimals="-3" id="f-324" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-50" decimals="-3" id="f-325" unitRef="usd">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-50" decimals="-3" id="f-326" unitRef="usd">3504000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-51" decimals="-3" id="f-327" unitRef="usd">6022000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-51" decimals="-3" id="f-328" unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-51" decimals="-3" id="f-329" unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-51" decimals="-3" id="f-330" unitRef="usd">6013000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-52" decimals="-3" id="f-331" unitRef="usd">175996000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-52" decimals="-3" id="f-332" unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-52" decimals="-3" id="f-333" unitRef="usd">12000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-52" decimals="-3" id="f-334" unitRef="usd">176184000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-53" decimals="-3" id="f-335" unitRef="usd">16119000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-53" decimals="-3" id="f-336" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-53" decimals="-3" id="f-337" unitRef="usd">16000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-53" decimals="-3" id="f-338" unitRef="usd">16103000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-54" decimals="-3" id="f-339" unitRef="usd">15826000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-54" decimals="-3" id="f-340" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-54" decimals="-3" id="f-341" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-54" decimals="-3" id="f-342" unitRef="usd">15826000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-4" decimals="-3" id="f-343" unitRef="usd">217475000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-4" decimals="-3" id="f-344" unitRef="usd">201000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-4" decimals="-3" id="f-345" unitRef="usd">46000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-4" decimals="-3" id="f-346" unitRef="usd">217630000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="c-3"
      decimals="INF"
      id="f-347"
      unitRef="security">33</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-3" decimals="-5" id="f-348" unitRef="usd">215500000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-3" decimals="-5" id="f-349" unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest contextRef="c-3" decimals="INF" id="f-350" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="c-1" id="f-351">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of our contractual maturities of available-for-sale debt securities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.565%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.060%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.565%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.063%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year but within five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total estimated fair value of contractual maturities, available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="c-3" decimals="-3" id="f-352" unitRef="usd">235059000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="c-4" decimals="-3" id="f-353" unitRef="usd">197633000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="c-3" decimals="-3" id="f-354" unitRef="usd">63765000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="c-4" decimals="-3" id="f-355" unitRef="usd">19997000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-3" decimals="-3" id="f-356" unitRef="usd">298824000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-4" decimals="-3" id="f-357" unitRef="usd">217630000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="c-1" id="f-358">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes, by major security type, our cash equivalents and available-for-sale marketable securities measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.421%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.329%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.329%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.329%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:1.967%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.329%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.329%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.337%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Estimated Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Estimated Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale marketable &lt;br/&gt;&#160;&#160;&#160;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency hedging contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency hedging contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Based on observable market transactions of spot currency rates, forward currency rates or equivalently-termed instruments. Carrying amounts of the financial assets and liabilities are equal to the fair value. As of March&#160;31, 2024, the derivative assets and liabilities recorded within prepaid expenses and other current assets, prepaid expense and other assets and other long-term liabilities in our condensed consolidated balance sheets were $&lt;span style="-sec-ix-hidden:f-420"&gt;1.3 million&lt;/span&gt;, $&lt;span style="-sec-ix-hidden:f-422"&gt;0.3 million&lt;/span&gt; and $&lt;span style="-sec-ix-hidden:f-424"&gt;0.5 million&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-55" decimals="-3" id="f-359" unitRef="usd">20276000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-56" decimals="-3" id="f-360" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-57" decimals="-3" id="f-361" unitRef="usd">20276000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-58" decimals="-3" id="f-362" unitRef="usd">22142000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-59" decimals="-3" id="f-363" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-60" decimals="-3" id="f-364" unitRef="usd">22142000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-61" decimals="-3" id="f-365" unitRef="usd">30000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-62" decimals="-3" id="f-366" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-63" decimals="-3" id="f-367" unitRef="usd">30000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-64" decimals="-3" id="f-368" unitRef="usd">2000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-65" decimals="-3" id="f-369" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-66" decimals="-3" id="f-370" unitRef="usd">2000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-67" decimals="-3" id="f-371" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-68" decimals="-3" id="f-372" unitRef="usd">2379000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-45" decimals="-3" id="f-373" unitRef="usd">2379000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-69" decimals="-3" id="f-374" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-70" decimals="-3" id="f-375" unitRef="usd">3504000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-50" decimals="-3" id="f-376" unitRef="usd">3504000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-71" decimals="-3" id="f-377" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-72" decimals="-3" id="f-378" unitRef="usd">43056000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-46" decimals="-3" id="f-379" unitRef="usd">43056000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-73" decimals="-3" id="f-380" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-74" decimals="-3" id="f-381" unitRef="usd">6013000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-51" decimals="-3" id="f-382" unitRef="usd">6013000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-75" decimals="-3" id="f-383" unitRef="usd">239277000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-76" decimals="-3" id="f-384" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-47" decimals="-3" id="f-385" unitRef="usd">239277000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-77" decimals="-3" id="f-386" unitRef="usd">176184000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-78" decimals="-3" id="f-387" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-52" decimals="-3" id="f-388" unitRef="usd">176184000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-79" decimals="-3" id="f-389" unitRef="usd">9158000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-80" decimals="-3" id="f-390" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-48" decimals="-3" id="f-391" unitRef="usd">9158000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-81" decimals="-3" id="f-392" unitRef="usd">16103000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-82" decimals="-3" id="f-393" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-53" decimals="-3" id="f-394" unitRef="usd">16103000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-83" decimals="-3" id="f-395" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-84" decimals="-3" id="f-396" unitRef="usd">4954000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-49" decimals="-3" id="f-397" unitRef="usd">4954000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-85" decimals="-3" id="f-398" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-86" decimals="-3" id="f-399" unitRef="usd">15826000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-54" decimals="-3" id="f-400" unitRef="usd">15826000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DerivativeAssets contextRef="c-87" decimals="-3" id="f-401" unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-88" decimals="-3" id="f-402" unitRef="usd">1574000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-89" decimals="-3" id="f-403" unitRef="usd">1574000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-90" decimals="-3" id="f-404" unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-91" decimals="-3" id="f-405" unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-92" decimals="-3" id="f-406" unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-93" decimals="-3" id="f-407" unitRef="usd">298711000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-94" decimals="-3" id="f-408" unitRef="usd">51963000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-3" decimals="-3" id="f-409" unitRef="usd">350674000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-95" decimals="-3" id="f-410" unitRef="usd">216429000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-96" decimals="-3" id="f-411" unitRef="usd">25343000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-4" decimals="-3" id="f-412" unitRef="usd">241772000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities contextRef="c-87" decimals="-3" id="f-413" unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-88" decimals="-3" id="f-414" unitRef="usd">478000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-89" decimals="-3" id="f-415" unitRef="usd">478000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-90" decimals="-3" id="f-416" unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-91" decimals="-3" id="f-417" unitRef="usd">9480000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-92" decimals="-3" id="f-418" unitRef="usd">9480000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeAssetsCurrent contextRef="c-3" decimals="-5" id="f-419" unitRef="usd">1300000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsNoncurrent contextRef="c-3" decimals="-5" id="f-421" unitRef="usd">300000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="c-3" decimals="-5" id="f-423" unitRef="usd">500000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-97" decimals="INF" id="f-425" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-98" decimals="INF" id="f-426" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c-1" id="f-427">Revenue&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our disaggregated revenues were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.570%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.144%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.570%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.147%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product sales, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proprietary product sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bulk rHuPH20 sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Device partnered product sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total product sales, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues under collaborative agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Event-based development and regulatory milestones and other fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Device licensing and development revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues under collaborative agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2024, we recognized revenue related to licenses granted to partners in prior periods in the amount of $134.6 million. This amount represents royalties earned in the current period in addition to $14.0&#160;million of variable consideration in the contracts where uncertainties were resolved and the development milestones are expected to be achieved or were achieved. We also recognized revenue of $0.1&#160;million during the three months ended March&#160;31, 2024 that had been included in accrued expense and other long-term liabilities in our condensed consolidated balance sheets as of December&#160;31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable, other contract assets and deferred revenues (contract liabilities) from contracts with customers, including partners, consisted of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.856%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.859%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other contract assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2024, the amounts included in the transaction price of our contracts with customers, including collaboration partners, and allocated to goods and services not yet provided were $77.3 million, of which $72.7 million relates to unfulfilled product purchase orders and $4.6&#160;million has been collected and is reported as accrued expense and other long-term liabilities in our condensed consolidated balance sheets. The unfulfilled product purchase orders are estimated to be delivered by the end of 2024. Of the total deferred revenues of $4.6&#160;million, $1.2 million is expected to be used by our customers within the next 12 months. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized contract assets of $10.6 million as of March&#160;31, 2024, which related to development milestones deemed probable of receipt for intellectual property licenses granted to partners in prior periods and for goods or services when control has transferred to the customer, and corresponding revenue is recognized on an over time basis but is not yet billable to the customer in accordance with the terms of the contract.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c-1" id="f-428">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our disaggregated revenues were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.570%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.144%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.570%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.147%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product sales, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proprietary product sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bulk rHuPH20 sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Device partnered product sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total product sales, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues under collaborative agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Event-based development and regulatory milestones and other fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Device licensing and development revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues under collaborative agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="-3" id="f-429" unitRef="usd">120593000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-3" id="f-430" unitRef="usd">99640000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-99" decimals="-3" id="f-431" unitRef="usd">35254000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-100" decimals="-3" id="f-432" unitRef="usd">27961000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-101" decimals="-3" id="f-433" unitRef="usd">10511000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-102" decimals="-3" id="f-434" unitRef="usd">22069000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-103" decimals="-3" id="f-435" unitRef="usd">12818000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-104" decimals="-3" id="f-436" unitRef="usd">10764000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="-3" id="f-437" unitRef="usd">58583000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-8" decimals="-3" id="f-438" unitRef="usd">60794000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-105" decimals="-3" id="f-439" unitRef="usd">14000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-106" decimals="-3" id="f-440" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-107" decimals="-3" id="f-441" unitRef="usd">2703000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-108" decimals="-3" id="f-442" unitRef="usd">1709000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-9" decimals="-3" id="f-443" unitRef="usd">16703000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-10" decimals="-3" id="f-444" unitRef="usd">1709000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-445" unitRef="usd">195879000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-11" decimals="-3" id="f-446" unitRef="usd">162143000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod contextRef="c-109" decimals="-5" id="f-447" unitRef="usd">134600000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized contextRef="c-1" decimals="-5" id="f-448" unitRef="usd">14000000</us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-1" decimals="-5" id="f-449" unitRef="usd">-100000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="c-1" id="f-450">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable, other contract assets and deferred revenues (contract liabilities) from contracts with customers, including partners, consisted of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.856%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.859%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other contract assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-3" decimals="-3" id="f-451" unitRef="usd">185313000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-4" decimals="-3" id="f-452" unitRef="usd">233254000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ContractWithCustomerAssetGrossCurrent contextRef="c-3" decimals="-3" id="f-453" unitRef="usd">10589000</us-gaap:ContractWithCustomerAssetGrossCurrent>
    <us-gaap:ContractWithCustomerAssetGrossCurrent contextRef="c-4" decimals="-3" id="f-454" unitRef="usd">956000</us-gaap:ContractWithCustomerAssetGrossCurrent>
    <us-gaap:ContractWithCustomerLiability contextRef="c-3" decimals="-3" id="f-455" unitRef="usd">4595000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-4" decimals="-3" id="f-456" unitRef="usd">4048000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-110" decimals="-5" id="f-457" unitRef="usd">77300000</us-gaap:RevenueRemainingPerformanceObligation>
    <halo:RevenueRemainingPerformanceObligationsUnfulfilledProductPurchaseOrdersAmount contextRef="c-111" decimals="-5" id="f-458" unitRef="usd">72700000</halo:RevenueRemainingPerformanceObligationsUnfulfilledProductPurchaseOrdersAmount>
    <us-gaap:ContractWithCustomerLiability contextRef="c-3" decimals="-5" id="f-459" unitRef="usd">4600000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-3" decimals="-5" id="f-460" unitRef="usd">4600000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-112" decimals="-5" id="f-461" unitRef="usd">1200000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 contextRef="c-112" id="f-462">P12M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:ContractWithCustomerAssetGrossCurrent contextRef="c-3" decimals="-5" id="f-463" unitRef="usd">10600000</us-gaap:ContractWithCustomerAssetGrossCurrent>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="c-1" id="f-464">Certain Balance Sheet Items&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable, net and contract assets consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.485%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.568%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.264%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.265%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable from product sales to partners&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable from revenues under collaborative agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable from royalty payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable from other product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accounts receivable and contract assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for distribution fees and discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,209)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,747)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accounts receivable, net and contract assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories, consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.485%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.568%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.264%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.265%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other assets consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.485%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.568%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.264%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.265%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid manufacturing expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total prepaid expenses and other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Long-term portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,319)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,816)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total prepaid expenses and other assets, current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid manufacturing expenses include raw materials, slot reservation fees and other amounts paid to contract manufacturing organizations.&#160;Such amounts are reclassified to work-in-process inventory as materials are used or the contract manufacturing organization services are complete.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.485%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.568%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.264%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.265%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,661)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use of assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;                            &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense was approximately $2.4 million and $2.6 million, inclusive of ROU asset amortization of $1.4 million and $1.4 million for the three months ended March&#160;31, 2024 and 2023, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.485%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.568%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.264%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.265%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and payroll taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued outsourced manufacturing expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product returns and sales allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less long-term portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,201)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,720)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses, current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expense associated with the accretion of the lease liabilities was approximately $0.6 million and $0.7 million for the three months ended March&#160;31, 2024 and 2023, respectively. Total lease expense for the three months ended March&#160;31, 2024 and 2023 was $2.0 million and $2.1 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts related to leases for the three months ended March&#160;31, 2024 and 2023 was $1.8 million and $1.7 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="c-1" id="f-465">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable, net and contract assets consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.485%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.568%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.264%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.265%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable from product sales to partners&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable from revenues under collaborative agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable from royalty payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable from other product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accounts receivable and contract assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for distribution fees and discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,209)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,747)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accounts receivable, net and contract assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableGrossCurrent contextRef="c-113" decimals="-3" id="f-466" unitRef="usd">27045000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent contextRef="c-114" decimals="-3" id="f-467" unitRef="usd">58588000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent contextRef="c-115" decimals="-3" id="f-468" unitRef="usd">2078000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent contextRef="c-116" decimals="-3" id="f-469" unitRef="usd">16183000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent contextRef="c-117" decimals="-3" id="f-470" unitRef="usd">115413000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent contextRef="c-118" decimals="-3" id="f-471" unitRef="usd">118170000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent contextRef="c-119" decimals="-3" id="f-472" unitRef="usd">46986000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent contextRef="c-120" decimals="-3" id="f-473" unitRef="usd">47060000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:ContractWithCustomerAssetGrossCurrent contextRef="c-3" decimals="-3" id="f-474" unitRef="usd">10589000</us-gaap:ContractWithCustomerAssetGrossCurrent>
    <us-gaap:ContractWithCustomerAssetGrossCurrent contextRef="c-4" decimals="-3" id="f-475" unitRef="usd">956000</us-gaap:ContractWithCustomerAssetGrossCurrent>
    <halo:AccountsReceivableAndContractWithCustomerAssetBeforeAllowanceForCreditLossCurrent contextRef="c-3" decimals="-3" id="f-476" unitRef="usd">202111000</halo:AccountsReceivableAndContractWithCustomerAssetBeforeAllowanceForCreditLossCurrent>
    <halo:AccountsReceivableAndContractWithCustomerAssetBeforeAllowanceForCreditLossCurrent contextRef="c-4" decimals="-3" id="f-477" unitRef="usd">240957000</halo:AccountsReceivableAndContractWithCustomerAssetBeforeAllowanceForCreditLossCurrent>
    <halo:AccountsReceivableAndContractWithCustomerAssetAllowanceForCreditLossCurrent contextRef="c-3" decimals="-3" id="f-478" unitRef="usd">6209000</halo:AccountsReceivableAndContractWithCustomerAssetAllowanceForCreditLossCurrent>
    <halo:AccountsReceivableAndContractWithCustomerAssetAllowanceForCreditLossCurrent contextRef="c-4" decimals="-3" id="f-479" unitRef="usd">6747000</halo:AccountsReceivableAndContractWithCustomerAssetAllowanceForCreditLossCurrent>
    <halo:AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent contextRef="c-3" decimals="-3" id="f-480" unitRef="usd">195902000</halo:AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent>
    <halo:AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent contextRef="c-4" decimals="-3" id="f-481" unitRef="usd">234210000</halo:AccountsReceivableAndContractWithCustomerAssetAfterAllowanceForCreditLossCurrent>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c-1" id="f-482">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories, consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.485%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.568%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.264%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.265%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="c-3" decimals="-3" id="f-483" unitRef="usd">29112000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="c-4" decimals="-3" id="f-484" unitRef="usd">23646000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-3" decimals="-3" id="f-485" unitRef="usd">43611000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-4" decimals="-3" id="f-486" unitRef="usd">34025000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-3" decimals="-3" id="f-487" unitRef="usd">95818000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-4" decimals="-3" id="f-488" unitRef="usd">69930000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet contextRef="c-3" decimals="-3" id="f-489" unitRef="usd">168541000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-4" decimals="-3" id="f-490" unitRef="usd">127601000</us-gaap:InventoryNet>
    <us-gaap:ScheduleOfOtherAssetsTableTextBlock contextRef="c-1" id="f-491">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other assets consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.485%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.568%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.264%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.265%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid manufacturing expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total prepaid expenses and other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Long-term portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,319)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,816)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total prepaid expenses and other assets, current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherAssetsTableTextBlock>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-3" decimals="-3" id="f-492" unitRef="usd">36211000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-4" decimals="-3" id="f-493" unitRef="usd">36850000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c-3" decimals="-3" id="f-494" unitRef="usd">13847000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c-4" decimals="-3" id="f-495" unitRef="usd">12902000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherAssets contextRef="c-3" decimals="-3" id="f-496" unitRef="usd">12951000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets contextRef="c-4" decimals="-3" id="f-497" unitRef="usd">16677000</us-gaap:OtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssets contextRef="c-3" decimals="-3" id="f-498" unitRef="usd">63009000</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssets contextRef="c-4" decimals="-3" id="f-499" unitRef="usd">66429000</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent contextRef="c-3" decimals="-3" id="f-500" unitRef="usd">17319000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-501" unitRef="usd">17816000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-502" unitRef="usd">45690000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-503" unitRef="usd">48613000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-504">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.485%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.568%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.264%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.265%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,661)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use of assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-121" decimals="-3" id="f-505" unitRef="usd">8690000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-122" decimals="-3" id="f-506" unitRef="usd">8588000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-123" decimals="-3" id="f-507" unitRef="usd">36364000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-124" decimals="-3" id="f-508" unitRef="usd">32472000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-125" decimals="-3" id="f-509" unitRef="usd">10888000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-126" decimals="-3" id="f-510" unitRef="usd">9722000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-127" decimals="-3" id="f-511" unitRef="usd">7124000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-128" decimals="-3" id="f-512" unitRef="usd">6987000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-3" decimals="-3" id="f-513" unitRef="usd">63066000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-4" decimals="-3" id="f-514" unitRef="usd">57769000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-3" decimals="-3" id="f-515" unitRef="usd">21180000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-516" unitRef="usd">19661000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-517" unitRef="usd">41886000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-518" unitRef="usd">38108000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-519" unitRef="usd">36185000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-520" unitRef="usd">36836000</us-gaap:OperatingLeaseRightOfUseAsset>
    <halo:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-3" decimals="-3" id="f-521" unitRef="usd">78071000</halo:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <halo:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-4" decimals="-3" id="f-522" unitRef="usd">74944000</halo:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-5" id="f-523" unitRef="usd">2400000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-11" decimals="-5" id="f-524" unitRef="usd">2600000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-1" decimals="-5" id="f-525" unitRef="usd">1400000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-11" decimals="-5" id="f-526" unitRef="usd">1400000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-527">&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.485%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.568%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.264%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.265%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and payroll taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued outsourced manufacturing expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product returns and sales allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less long-term portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,201)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,720)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses, current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent contextRef="c-3" decimals="-3" id="f-528" unitRef="usd">10442000</us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent contextRef="c-4" decimals="-3" id="f-529" unitRef="usd">17361000</us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent>
    <halo:AccruedOutsourcedManufacturingExpenses contextRef="c-3" decimals="-3" id="f-530" unitRef="usd">27456000</halo:AccruedOutsourcedManufacturingExpenses>
    <halo:AccruedOutsourcedManufacturingExpenses contextRef="c-4" decimals="-3" id="f-531" unitRef="usd">12361000</halo:AccruedOutsourcedManufacturingExpenses>
    <us-gaap:TaxesPayableCurrent contextRef="c-3" decimals="-3" id="f-532" unitRef="usd">19074000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c-4" decimals="-3" id="f-533" unitRef="usd">963000</us-gaap:TaxesPayableCurrent>
    <us-gaap:ContractWithCustomerRefundLiability contextRef="c-3" decimals="-3" id="f-534" unitRef="usd">39941000</us-gaap:ContractWithCustomerRefundLiability>
    <us-gaap:ContractWithCustomerRefundLiability contextRef="c-4" decimals="-3" id="f-535" unitRef="usd">41932000</us-gaap:ContractWithCustomerRefundLiability>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent contextRef="c-3" decimals="-3" id="f-536" unitRef="usd">20839000</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent contextRef="c-4" decimals="-3" id="f-537" unitRef="usd">33584000</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OperatingLeaseLiability contextRef="c-3" decimals="-3" id="f-538" unitRef="usd">31763000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability contextRef="c-4" decimals="-3" id="f-539" unitRef="usd">32197000</us-gaap:OperatingLeaseLiability>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="c-3" decimals="-3" id="f-540" unitRef="usd">149515000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="c-4" decimals="-3" id="f-541" unitRef="usd">138398000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <halo:AccruedLiabilitiesNoncurrent contextRef="c-3" decimals="-3" id="f-542" unitRef="usd">31201000</halo:AccruedLiabilitiesNoncurrent>
    <halo:AccruedLiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-543" unitRef="usd">37720000</halo:AccruedLiabilitiesNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-544" unitRef="usd">118314000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-545" unitRef="usd">100678000</us-gaap:AccruedLiabilitiesCurrent>
    <halo:OperatingLeaseAccretionOfLiability contextRef="c-1" decimals="-5" id="f-546" unitRef="usd">600000</halo:OperatingLeaseAccretionOfLiability>
    <halo:OperatingLeaseAccretionOfLiability contextRef="c-11" decimals="-5" id="f-547" unitRef="usd">700000</halo:OperatingLeaseAccretionOfLiability>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-5" id="f-548" unitRef="usd">2000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-11" decimals="-5" id="f-549" unitRef="usd">2100000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-5" id="f-550" unitRef="usd">1800000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-11" decimals="-5" id="f-551" unitRef="usd">1700000</us-gaap:OperatingLeasePayments>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="c-1" id="f-552">Goodwill and Intangible Assets&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the activity impacting goodwill is presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.592%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.577%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.431%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:22.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our acquired intangible assets are amortized using the straight-line method over their estimated useful lives of &lt;span style="-sec-ix-hidden:f-557"&gt;seven&lt;/span&gt; to ten years. The following table shows the cost, accumulated amortization and weighted average useful life in years for our acquired intangible assets as of March&#160;31, 2024 (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.581%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.118%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.581%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.993%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.893%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.993%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.893%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.998%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Useful Life &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Auto Injector technology platform&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;XYOSTED proprietary product&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangibles, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;538,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ATRS-1902 (IPR&amp;amp;D)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangibles, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;455,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated future annual amortization of finite-lived intangible assets is shown in the following table (in thousands). Actual amortization expense to be reported in future periods could differ from these estimates as a result of acquisitions, divestitures, and asset impairments, among other factors.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:82.561%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.010%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.029%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortization Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock contextRef="c-1" id="f-553">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the activity impacting goodwill is presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.592%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.577%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.431%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill contextRef="c-4" decimals="-3" id="f-554" unitRef="usd">416821000</us-gaap:Goodwill>
    <us-gaap:GoodwillPurchaseAccountingAdjustments contextRef="c-1" decimals="-3" id="f-555" unitRef="usd">0</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:Goodwill contextRef="c-3" decimals="-3" id="f-556" unitRef="usd">416821000</us-gaap:Goodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="c-130" id="f-558">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="c-1" id="f-559">The following table shows the cost, accumulated amortization and weighted average useful life in years for our acquired intangible assets as of March&#160;31, 2024 (in thousands).&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.581%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.118%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.581%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.993%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.893%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.993%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.893%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.998%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Useful Life &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Auto Injector technology platform&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;XYOSTED proprietary product&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangibles, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;538,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ATRS-1902 (IPR&amp;amp;D)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangibles, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;455,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="c-131" id="f-560">P7Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-132" decimals="-3" id="f-561" unitRef="usd">402000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-132" decimals="-3" id="f-562" unitRef="usd">106521000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-132" decimals="-3" id="f-563" unitRef="usd">295479000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="c-133" id="f-564">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-134" decimals="-3" id="f-565" unitRef="usd">136200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-134" decimals="-3" id="f-566" unitRef="usd">25263000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-134" decimals="-3" id="f-567" unitRef="usd">110937000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-3" decimals="-3" id="f-568" unitRef="usd">538200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-3" decimals="-3" id="f-569" unitRef="usd">131784000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-3" decimals="-3" id="f-570" unitRef="usd">406416000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-3" decimals="-3" id="f-571" unitRef="usd">48700000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-3" decimals="-3" id="f-572" unitRef="usd">455116000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="c-1" id="f-573">&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated future annual amortization of finite-lived intangible assets is shown in the following table (in thousands). Actual amortization expense to be reported in future periods could differ from these estimates as a result of acquisitions, divestitures, and asset impairments, among other factors.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:82.561%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.010%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.029%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortization Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear contextRef="c-3" decimals="-3" id="f-574" unitRef="usd">53286000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-3" decimals="-3" id="f-575" unitRef="usd">71049000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-3" decimals="-3" id="f-576" unitRef="usd">71049000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-3" decimals="-3" id="f-577" unitRef="usd">71049000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-3" decimals="-3" id="f-578" unitRef="usd">71049000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <halo:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour contextRef="c-3" decimals="-3" id="f-579" unitRef="usd">68934000</halo:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-3" decimals="-3" id="f-580" unitRef="usd">406416000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:LongTermDebtTextBlock contextRef="c-1" id="f-581">Long-Term Debt, Net&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;1.00% Convertible Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2022, we completed the sale of $720.0&#160;million in aggregate principal amount of 1.00% Convertible Senior Notes due 2028 (the &#x201c;2028 Convertible Notes&#x201d;). The net proceeds in connection with the issuance of the 2028 Convertible Notes, after deducting the initial purchasers&#x2019; fee of $18.0&#160;million, was approximately $702.0&#160;million. We also incurred additional debt issuance costs totaling $1.0&#160;million. Debt issuance costs and the initial purchasers&#x2019; fee are presented as a debt discount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2028 Convertible Notes pay interest semi-annually in arrears on February 15th and August 15th of each year at an annual rate of 1.00%. The 2028 Convertible Notes are general unsecured obligations and rank senior in right of payment to all indebtedness that is expressly subordinated in right of payment to the 2028 Convertible Notes, rank equally in right of payment with all existing and future liabilities that are not so subordinated, are effectively junior to any secured indebtedness to the extent of the value of the assets securing such indebtedness, and are structurally subordinated to all indebtedness and other liabilities (including trade payables) of our current or future subsidiaries. The 2028 Convertible Notes have a maturity date of August 15, 2028.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders may convert their 2028 Convertible Notes at their option only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on December 31, 2022, if the last reported sale price per share of common stock exceeds 130% of the conversion price for each of at least 20 trading days during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the five consecutive business days immediately after any five consecutive trading day period (such five consecutive trading day period, the &#x201c;measurement period&#x201d;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of our common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on our common stock, as described in the offering memorandum for the 2028 Convertible Notes; (4) if we call such notes for redemption; and (5) at any time from, and including, February 15, 2028 until the close of business on the second scheduled trading day immediately before the maturity date. As of March&#160;31, 2024, the 2028 Convertible Notes were not convertible.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon conversion, we will pay cash for the settlement of principal, and for the premium, if applicable, we will pay cash, deliver shares of common stock or a combination of cash and shares of common stock, at our election. The initial conversion rate for the 2028 Convertible Notes is 17.8517 shares of common stock per $1,000 in principal amount of 2028 Convertible Notes, equivalent to a conversion price of approximately $56.02 per share of our common stock. The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued or unpaid interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2024, we were in compliance with all covenants and there was no material adverse change in our business, operations or financial condition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Capped Call Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the offering of the 2028 Convertible Notes, we entered into capped call transactions with certain counterparties (the &#x201c;Capped Call Transactions&#x201d;). The Capped Call Transactions are expected generally to reduce potential dilution to holders of our common stock upon conversion of the 2028 Convertible Notes or at our election (subject to certain conditions) offset any cash payments we are required to make in excess of the principal amount of such converted 2028 Convertible Notes. The cap price of the Capped Call Transactions is initially $75.4075 per share of common stock, representing a premium of 75% above the last reported sale price of $43.09 per share of common stock on August 15, 2022, and is subject to certain adjustments under the terms of the Capped Call Transactions. As of March&#160;31, 2024, no capped calls had been exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to their terms, the capped calls qualify for classification within stockholders&#x2019; equity in our condensed consolidated balance sheets, and their fair value is not remeasured and adjusted as long as they continue to qualify for stockholders&#x2019; equity classification. We paid approximately $69.1&#160;million for the Capped Calls, including applicable transaction costs, which was recorded as a reduction to additional paid-in capital in our condensed consolidated balance sheets. The Capped Call Transactions are separate transactions entered into by us with the capped call Counterparties, are not part of the terms of the Convertible Notes, and do not affect any holder&#x2019;s rights under the Convertible Notes. Holders of the Convertible Notes do not have any rights with respect to the Capped Call Transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;0.25% Convertible Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2021, we completed the sale of $805.0&#160;million in aggregate principal amount of 0.25% Convertible Senior Notes due 2027 (the &#x201c;2027 Convertible Notes&#x201d;). The net proceeds in connection with the issuance of the 2027 Convertible Notes, after deducting the initial purchasers&#x2019; fee of $20.1&#160;million, was approximately $784.9&#160;million. We also incurred additional debt issuance costs totaling $0.4&#160;million. Debt issuance costs and the initial purchasers&#x2019; fee are presented as a debt discount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2027 Convertible Notes pay interest semi-annually in arrears on March 1st and September 1st of each year at an annual rate of 0.25%. The 2027 Convertible Notes are general unsecured obligations and rank senior in right of payment to all indebtedness that is expressly subordinated in right of payment to the 2027 Convertible Notes, rank equally in right of payment with all existing and future liabilities that are not so subordinated, are effectively junior to any secured indebtedness to the extent of the value of the assets securing such indebtedness and are structurally subordinated to all indebtedness and other liabilities (including trade payables) of our current or future subsidiaries. The 2027 Convertible Notes have a maturity date of March 1, 2027.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders may convert their 2027 Convertible Notes at their option only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on June 30, 2021, if the last reported sale price per share of common stock exceeds 130% of the conversion price for each of at least 20 trading days during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the five consecutive business days immediately after any five consecutive trading day period (such five consecutive trading day period, the &#x201c;measurement period&#x201d;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of our common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on our common stock, as described in the offering memorandum for the 2027 Convertible Notes; (4) if we call such notes for redemption; and (5) at any time from, and including, September 1, 2026 until the close of business on the scheduled trading day immediately before the maturity date. As of March&#160;31, 2024, the 2027 Convertible Notes were not convertible.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon conversion, we will pay cash for the settlement of principal and for the premium, if applicable, we will pay cash, deliver shares of common stock or a combination of cash and shares of common stock, at our election. The initial conversion rate for the 2027 Convertible Notes is 12.9576 shares of common stock per $1,000 in principal amount of 2027 Convertible Notes, equivalent to a conversion price of approximately $77.17 per share of our common stock. The conversion rate is subject to adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2024, we were in compliance with all covenants and there was no material adverse change in our business, operations or financial condition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;1.25% Convertible Notes due 2024&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2019, we completed the sale of $460.0 million in aggregate principal amount of 1.25% Convertible Senior Notes due 2024 (the &#x201c;2024 Convertible Notes&#x201d;). The net proceeds in connection with the issuance of the 2024 Convertible Notes, after deducting the initial purchasers&#x2019; fee of $12.7&#160;million, was approximately $447.3 million. We also incurred debt issuance cost totaling $0.3&#160;million. Debt issuance costs and the initial purchasers&#x2019; fee were presented as a debt discount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, we notified the note holders of our irrevocable election to settle the principal of the 2024 Convertible Notes in cash and for the premium, to deliver shares of common stock. The conversion rate for the 2024 Convertible Notes was 41.9208 shares of common stock per $1,000 in principal amount of 2024 Convertible Notes, equivalent to a conversion price of approximately $23.85 per share of our common stock. The conversion rate was subject to adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2023, we issued a notice for the redemption of 2024 Convertible Notes. Holders of the notes could convert their notes at any time prior to the close of the business day prior to the redemption date. In March 2023, holders of the notes elected to convert the 2024 Convertible Notes in full. In connection with the conversion, we paid approximately $13.5 million in cash which included principal and accrued interest, and issued 288,886 shares of our common stock representing the intrinsic value based on the contractual conversion rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Carrying Amounts of our Convertible Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount and fair value of our Convertible Notes were as follows (in thousands). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.570%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.580%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.472%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.474%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;805,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;805,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;720,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;720,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total principal amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,525,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,525,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,094)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,950)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,027)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,802)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total unamortized debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,752)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;794,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;794,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;705,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;705,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,499,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value based on trading levels (Level 2):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;695,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;702,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of outstanding notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,416,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,366,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining amortization per period of debt discount (in years):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of interest expense and the effective interest rates for each of our Convertible Notes (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.011%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.464%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.368%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.464%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.699%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Coupon interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;503&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;503&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,800&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,800&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total coupon interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,303&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,339&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;856&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;850&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;764&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total amortization of debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,631&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,638&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,359&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,353&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,575&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,564&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,934&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,977&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective interest rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revolving Credit and Term Loan Facilities (May 2022)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022, we entered into a credit agreement, which was subsequently amended in August 2022 (the &#x201c;Amendment&#x201d;), with Bank of America, N.A., as Administrative Agent, Swing Line Lender and an L/C Issuer, and the other lenders and L/C Issuers party thereto (the &#x201c;2022 Credit Agreement), evidencing a credit facility (the &#x201c;2022 Facility&#x201d;) that provides for (i) a $575&#160;million revolving credit facility (the &#x201c;Revolving Credit Facility&#x201d;) and (ii) a $250&#160;million term loan facility (the &#x201c;Term Facility&#x201d;). Concurrently, with the entry into the Amendment, we repaid the entire outstanding Term Loan Facility and repaid all outstanding loans under the Revolving Credit Facility under the 2022 Credit Agreement. The 2022 Facility will mature on November 30, 2026 unless either the Revolving Credit Facility or the Term Facility is extended prior to such date in accordance with the 2022 Credit Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Term Facility requires quarterly scheduled repayments of the term loans in each of the first, second, third and fourth years following the closing in annual amounts equal to 2.50%, 5.00%, 7.50% and 10.00% of the initial principal amount of the term loans, respectively. The term loans are also subject to mandatory prepayments from the proceeds of certain asset sales, subject to our right to reinvest the proceeds thereof.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the 2022 Facility bear interest, at our option, at a rate equal to an applicable margin plus: (a) the applicable Term Secured Overnight Financing Rate (&#x201c;SOFR&#x201d;) (which includes a SOFR adjustment of 0.10%), or (b) a base rate determined by reference to the highest of (1) the federal funds effective rate plus 0.50%, (2) the Bank of America prime rate, (3) the Term SOFR rate for an interest period of one month plus 1.10%, and (4) 1.00%. The margin for the 2022 Facility ranges, based on our consolidated total net leverage ratio, from 0.25% to 1.25% in the case of base rate loans and from 1.25% to 2.25% in the case of Term SOFR rate loans. In addition to paying interest on the outstanding principal under the Facility, we will pay (i) a commitment fee in respect of the unutilized commitments thereunder and (ii) customary letter of credit fees and agency fees. The commitment fees range from 0.15% to 0.35% per annum based on our consolidated net leverage ratio.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2024, the Revolving Credit Facility was undrawn. We incurred a total of $3.6&#160;million in third-party costs related to the 2022 Credit Agreement which are recorded as debt issuance cost within prepaid expenses and other assets in our condensed consolidated balance sheets. As of March&#160;31, 2024, the unamortized debt issuance cost related to the revolving credit facility was $2.1 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-135"
      decimals="INF"
      id="f-582"
      unitRef="number">0.0100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-135" decimals="-5" id="f-583" unitRef="usd">720000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-135"
      decimals="INF"
      id="f-584"
      unitRef="number">0.0100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFeeAmount contextRef="c-135" decimals="-5" id="f-585" unitRef="usd">18000000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="c-136" decimals="-5" id="f-586" unitRef="usd">702000000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-136" decimals="-5" id="f-587" unitRef="usd">1000000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-135"
      decimals="INF"
      id="f-588"
      unitRef="number">0.0100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="c-137"
      decimals="INF"
      id="f-589"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="c-137"
      decimals="INF"
      id="f-590"
      unitRef="trading_day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="c-137"
      decimals="INF"
      id="f-591"
      unitRef="trading_day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <halo:DebtInstrumentConvertibleThresholdConsecutiveBusinessDays
      contextRef="c-138"
      decimals="INF"
      id="f-592"
      unitRef="businessday">5</halo:DebtInstrumentConvertibleThresholdConsecutiveBusinessDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="c-138"
      decimals="INF"
      id="f-593"
      unitRef="trading_day">5</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="c-138"
      decimals="INF"
      id="f-594"
      unitRef="trading_day">5</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="c-138"
      decimals="INF"
      id="f-595"
      unitRef="number">0.98</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="c-136"
      decimals="INF"
      id="f-596"
      unitRef="number">17.8517</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-135"
      decimals="2"
      id="f-597"
      unitRef="usdPerShare">56.02</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <halo:DebtInstrumentCapCallTransactionCapPricePerShare
      contextRef="c-139"
      decimals="4"
      id="f-598"
      unitRef="usdPerShare">75.4075</halo:DebtInstrumentCapCallTransactionCapPricePerShare>
    <halo:SaleOfStockPremiumOverLastReportedSalePricePercentage
      contextRef="c-140"
      decimals="INF"
      id="f-599"
      unitRef="number">0.75</halo:SaleOfStockPremiumOverLastReportedSalePricePercentage>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-141"
      decimals="2"
      id="f-600"
      unitRef="usdPerShare">43.09</us-gaap:SaleOfStockPricePerShare>
    <halo:PaymentForCappedCallTransactions contextRef="c-140" decimals="-5" id="f-601" unitRef="usd">69100000</halo:PaymentForCappedCallTransactions>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-142"
      decimals="INF"
      id="f-602"
      unitRef="number">0.0025</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-142" decimals="INF" id="f-603" unitRef="usd">805000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-142"
      decimals="INF"
      id="f-604"
      unitRef="number">0.0025</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFeeAmount contextRef="c-142" decimals="-5" id="f-605" unitRef="usd">20100000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="c-143" decimals="-5" id="f-606" unitRef="usd">784900000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-144" decimals="-5" id="f-607" unitRef="usd">400000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-142"
      decimals="INF"
      id="f-608"
      unitRef="number">0.0025</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="c-145"
      decimals="INF"
      id="f-609"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="c-145"
      decimals="INF"
      id="f-610"
      unitRef="trading_day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="c-145"
      decimals="INF"
      id="f-611"
      unitRef="trading_day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <halo:DebtInstrumentConvertibleThresholdConsecutiveBusinessDays
      contextRef="c-146"
      decimals="INF"
      id="f-612"
      unitRef="businessday">5</halo:DebtInstrumentConvertibleThresholdConsecutiveBusinessDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="c-146"
      decimals="INF"
      id="f-613"
      unitRef="trading_day">5</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="c-146"
      decimals="INF"
      id="f-614"
      unitRef="trading_day">5</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="c-146"
      decimals="INF"
      id="f-615"
      unitRef="number">0.98</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1 contextRef="c-144" decimals="4" id="f-616" unitRef="number">12.9576</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-142"
      decimals="2"
      id="f-617"
      unitRef="usdPerShare">77.17</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-147"
      decimals="INF"
      id="f-618"
      unitRef="number">0.0125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-147" decimals="INF" id="f-619" unitRef="usd">460000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-147"
      decimals="INF"
      id="f-620"
      unitRef="number">0.0125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFeeAmount contextRef="c-147" decimals="-5" id="f-621" unitRef="usd">12700000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="c-148" decimals="-5" id="f-622" unitRef="usd">447300000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-149" decimals="-5" id="f-623" unitRef="usd">300000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1 contextRef="c-150" decimals="4" id="f-624" unitRef="number">41.9208</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-151"
      decimals="2"
      id="f-625"
      unitRef="usdPerShare">23.85</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c-152" decimals="-5" id="f-626" unitRef="usd">13500000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="c-152"
      decimals="INF"
      id="f-627"
      unitRef="shares">288886</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock contextRef="c-1" id="f-628">&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Carrying Amounts of our Convertible Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount and fair value of our Convertible Notes were as follows (in thousands). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.570%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.580%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.472%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.474%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;805,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;805,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;720,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;720,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total principal amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,525,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,525,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,094)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,950)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,027)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,802)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total unamortized debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,752)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;794,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;794,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;705,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;705,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,499,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value based on trading levels (Level 2):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;695,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;702,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of outstanding notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,416,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,366,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining amortization per period of debt discount (in years):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-153" decimals="-3" id="f-629" unitRef="usd">805000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-154" decimals="-3" id="f-630" unitRef="usd">805000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-155" decimals="-3" id="f-631" unitRef="usd">720000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-156" decimals="-3" id="f-632" unitRef="usd">720000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-3" decimals="-3" id="f-633" unitRef="usd">1525000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-4" decimals="-3" id="f-634" unitRef="usd">1525000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-153" decimals="-3" id="f-635" unitRef="usd">10094000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-154" decimals="-3" id="f-636" unitRef="usd">10950000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-155" decimals="-3" id="f-637" unitRef="usd">14027000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-156" decimals="-3" id="f-638" unitRef="usd">14802000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-3" decimals="-3" id="f-639" unitRef="usd">24121000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-4" decimals="-3" id="f-640" unitRef="usd">25752000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-153" decimals="-3" id="f-641" unitRef="usd">794906000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-154" decimals="-3" id="f-642" unitRef="usd">794050000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-155" decimals="-3" id="f-643" unitRef="usd">705973000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-156" decimals="-3" id="f-644" unitRef="usd">705198000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebt contextRef="c-3" decimals="-3" id="f-645" unitRef="usd">1500879000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-4" decimals="-3" id="f-646" unitRef="usd">1499248000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFairValue contextRef="c-153" decimals="-3" id="f-647" unitRef="usd">714244000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue contextRef="c-154" decimals="-3" id="f-648" unitRef="usd">695826000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue contextRef="c-155" decimals="-3" id="f-649" unitRef="usd">702403000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue contextRef="c-156" decimals="-3" id="f-650" unitRef="usd">670522000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue contextRef="c-3" decimals="-3" id="f-651" unitRef="usd">1416647000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue contextRef="c-4" decimals="-3" id="f-652" unitRef="usd">1366348000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1 contextRef="c-153" id="f-653">P2Y10M24D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1 contextRef="c-154" id="f-654">P3Y2M12D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1 contextRef="c-155" id="f-655">P4Y4M24D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1 contextRef="c-156" id="f-656">P4Y7M6D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock contextRef="c-1" id="f-657">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of interest expense and the effective interest rates for each of our Convertible Notes (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.011%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.464%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.368%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.464%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.699%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Coupon interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;503&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;503&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,800&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,800&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total coupon interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,303&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,339&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;856&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;850&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;764&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total amortization of debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,631&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,638&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,359&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,353&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,575&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,564&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,934&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,977&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective interest rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest contextRef="c-157" decimals="-3" id="f-658" unitRef="usd">0</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest contextRef="c-158" decimals="-3" id="f-659" unitRef="usd">36000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest contextRef="c-159" decimals="-3" id="f-660" unitRef="usd">503000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest contextRef="c-160" decimals="-3" id="f-661" unitRef="usd">503000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest contextRef="c-161" decimals="-3" id="f-662" unitRef="usd">1800000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest contextRef="c-162" decimals="-3" id="f-663" unitRef="usd">1800000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest contextRef="c-163" decimals="-3" id="f-664" unitRef="usd">2303000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest contextRef="c-164" decimals="-3" id="f-665" unitRef="usd">2339000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-157" decimals="-3" id="f-666" unitRef="usd">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-158" decimals="-3" id="f-667" unitRef="usd">24000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-159" decimals="-3" id="f-668" unitRef="usd">856000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-160" decimals="-3" id="f-669" unitRef="usd">850000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-161" decimals="-3" id="f-670" unitRef="usd">775000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-162" decimals="-3" id="f-671" unitRef="usd">764000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-163" decimals="-3" id="f-672" unitRef="usd">1631000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-164" decimals="-3" id="f-673" unitRef="usd">1638000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InterestExpenseDebt contextRef="c-157" decimals="-3" id="f-674" unitRef="usd">0</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-158" decimals="-3" id="f-675" unitRef="usd">60000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-159" decimals="-3" id="f-676" unitRef="usd">1359000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-160" decimals="-3" id="f-677" unitRef="usd">1353000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-161" decimals="-3" id="f-678" unitRef="usd">2575000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-162" decimals="-3" id="f-679" unitRef="usd">2564000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-163" decimals="-3" id="f-680" unitRef="usd">3934000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-164" decimals="-3" id="f-681" unitRef="usd">3977000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-165" decimals="3" id="f-682" unitRef="number">0.007</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-166" decimals="3" id="f-683" unitRef="number">0.007</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-167" decimals="3" id="f-684" unitRef="number">0.015</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-168" decimals="3" id="f-685" unitRef="number">0.015</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-169" decimals="-6" id="f-686" unitRef="usd">575000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-170" decimals="-6" id="f-687" unitRef="usd">250000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-171"
      decimals="INF"
      id="f-688"
      unitRef="number">0.0250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-172"
      decimals="INF"
      id="f-689"
      unitRef="number">0.0500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-173"
      decimals="INF"
      id="f-690"
      unitRef="number">0.0750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-174"
      decimals="INF"
      id="f-691"
      unitRef="number">0.1000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-175"
      decimals="INF"
      id="f-692"
      unitRef="number">0.0010</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-176"
      decimals="INF"
      id="f-693"
      unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-177"
      decimals="INF"
      id="f-694"
      unitRef="number">0.0110</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-178"
      decimals="INF"
      id="f-695"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-179"
      decimals="INF"
      id="f-696"
      unitRef="number">0.0025</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-180"
      decimals="INF"
      id="f-697"
      unitRef="number">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-181"
      decimals="INF"
      id="f-698"
      unitRef="number">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-182"
      decimals="INF"
      id="f-699"
      unitRef="number">0.0225</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="c-183"
      decimals="INF"
      id="f-700"
      unitRef="number">0.0015</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="c-184"
      decimals="INF"
      id="f-701"
      unitRef="number">0.0035</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:DeferredFinanceCostsGross contextRef="c-185" decimals="-5" id="f-702" unitRef="usd">3600000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet contextRef="c-186" decimals="-5" id="f-703" unitRef="usd">2100000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-704">Share-based Compensation&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarized share-based compensation expense included in our condensed consolidated statements of income related to share-based awards (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:79.143%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.559%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.018%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.559%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation expense by type of share-based award was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:79.351%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.551%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.922%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.551%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs, PSUs and ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We granted stock options to purchase approximately 0.5 million and 1.2 million shares of common stock during the three months ended March&#160;31, 2024 and 2023, respectively. The exercise price of stock options granted is equal to the closing price of the common stock on the date of grant. The fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option pricing model (&#x201c;Black-Scholes Model&#x201d;). Expected volatility is based on historical volatility of our common stock. The expected term of options granted is based on analyses of historical employee termination rates and option exercises. The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The dividend yield assumption is based on the expectation of no future dividend payments. The assumptions used in the Black-Scholes Model were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:24.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.952%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.804%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.02 - 40.08%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.68 - 39.98%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.80 - 4.28%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.48 - 4.27%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, our Board of Directors approved our 2021 ESPP and our stockholders approved the plan in May 2021. The ESPP enables eligible employees to purchase shares of our common stock at the end of each offering period at a price equal to 85% of the fair market value of the shares on the first business day or the last business day of the offering period, whichever is lower. Share purchases are funded through payroll deduction of at least 1% and up to 15% of an employee&#x2019;s compensation for each payroll period, and no employee may purchase shares under the ESPP that exceeds $25,000 worth of our common stock for a calendar year. As of March&#160;31, 2024, 2,604,222 shares were available for future purchase. The offering period is generally for a six-month period and the first offering period commenced on June 16, 2021. Offering periods shall commence on or about the sixteenth day of June and December of each year and end on or about the fifteenth day of the next December and June, respectively, occurring thereafter. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total unrecognized estimated compensation cost by type of award and the weighted-average remaining requisite service period over which such expense is expected to be recognized was as follows (in thousands, unless otherwise noted):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:24.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.643%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.158%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.606%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.606%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.030%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrecognized&lt;br/&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Recognition Period&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.70&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.05&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.30&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-705">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarized share-based compensation expense included in our condensed consolidated statements of income related to share-based awards (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:79.143%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.559%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.018%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.559%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-187" decimals="-3" id="f-706" unitRef="usd">3345000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-188" decimals="-3" id="f-707" unitRef="usd">3101000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-189" decimals="-3" id="f-708" unitRef="usd">6529000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-190" decimals="-3" id="f-709" unitRef="usd">4865000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-710" unitRef="usd">9874000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-11" decimals="-3" id="f-711" unitRef="usd">7966000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="c-1" id="f-712">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation expense by type of share-based award was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:79.351%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.551%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.922%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.551%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs, PSUs and ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-191" decimals="-3" id="f-713" unitRef="usd">4299000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-192" decimals="-3" id="f-714" unitRef="usd">3455000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-193" decimals="-3" id="f-715" unitRef="usd">5575000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-194" decimals="-3" id="f-716" unitRef="usd">4511000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-717" unitRef="usd">9874000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-11" decimals="-3" id="f-718" unitRef="usd">7966000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="-5" id="f-719" unitRef="shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-11" decimals="-5" id="f-720" unitRef="shares">1200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-721">The assumptions used in the Black-Scholes Model were as follows:&lt;div style="margin-top:5pt;text-align:center;text-indent:24.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.952%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.804%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.02 - 40.08%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.68 - 39.98%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.80 - 4.28%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.48 - 4.27%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="c-129" decimals="4" id="f-722" unitRef="number">0.4002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="c-130" decimals="4" id="f-723" unitRef="number">0.4008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="c-195" decimals="4" id="f-724" unitRef="number">0.3968</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="c-196" decimals="4" id="f-725" unitRef="number">0.3998</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-1" id="f-726">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-11" id="f-727">P4Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c-1" decimals="4" id="f-728" unitRef="number">0.0380</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c-1" decimals="4" id="f-729" unitRef="number">0.0428</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c-11" decimals="4" id="f-730" unitRef="number">0.0348</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c-11" decimals="4" id="f-731" unitRef="number">0.0427</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-1" decimals="INF" id="f-732" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-11"
      decimals="INF"
      id="f-733"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="c-197"
      decimals="INF"
      id="f-734"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <halo:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate
      contextRef="c-198"
      decimals="INF"
      id="f-735"
      unitRef="number">0.01</halo:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="c-198"
      decimals="INF"
      id="f-736"
      unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <halo:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount contextRef="c-197" decimals="-3" id="f-737" unitRef="usd">25000</halo:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-199"
      decimals="INF"
      id="f-738"
      unitRef="shares">2604222</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <halo:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod contextRef="c-197" id="f-739">P6M</halo:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod>
    <us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock contextRef="c-1" id="f-740">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total unrecognized estimated compensation cost by type of award and the weighted-average remaining requisite service period over which such expense is expected to be recognized was as follows (in thousands, unless otherwise noted):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:24.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.643%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.158%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.606%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.606%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.030%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrecognized&lt;br/&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Recognition Period&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.70&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.05&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.30&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-200" decimals="-3" id="f-741" unitRef="usd">42038000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-191" id="f-742">P2Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-201" decimals="-3" id="f-743" unitRef="usd">56513000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-202" id="f-744">P3Y18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-203" decimals="-3" id="f-745" unitRef="usd">11543000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-204" id="f-746">P2Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-205" decimals="-3" id="f-747" unitRef="usd">118000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-206" id="f-748">P0Y2M15D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-749">Stockholders&#x2019; Equity &lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2024 and 2023, we issued an aggregate of 154,556 and 143,931 shares of common stock, respectively, in connection with the exercises of stock options at a weighted average exercise price of $17.47 and $16.87 per share, respectively, for net proceeds of approximately $2.7 million and $2.4 million, respectively. For the three months ended March&#160;31, 2024 and 2023, we issued 262,195 and 239,919 shares of common stock, respectively, upon vesting of certain RSUs and PSUs for which the RSU and PSU holders surrendered 88,825 and 70,733 RSUs and PSUs, respectively, to pay for minimum withholding taxes totaling approximately $6.0 million and $6.5 million, respectively. Stock options and unvested restricted units totaling approximately 8.7 million and 7.8 million shares of our common stock were outstanding as of March&#160;31, 2024 and December&#160;31, 2023, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share Repurchases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2021, the Board of Directors authorized a second capital return program to repurchase up to $750.0&#160;million of outstanding stock over a three-year period. During 2021, we repurchased 3.9&#160;million shares of common stock for $150.0&#160;million at an average price of $38.51. During 2022, we repurchased 4.5&#160;million shares of common stock for $200.0&#160;million at an average price of $44.44. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accelerated the initiation of our planned 2024 share repurchases and in November 2023, we entered into an Accelerated Share Repurchase (&#x201c;ASR&#x201d;) agreement with Bank of America, N.A. to accelerate the remaining $250.0&#160;million of share repurchases under the approved capital return program. Pursuant to the agreement, at the inception of the ASR, we paid $250.0&#160;million to Bank of America, N.A. and took initial delivery of 5.5&#160;million shares. All shares repurchased under our capital return programs have been retired and have resumed their status of authorized and unissued shares. We continued to execute share repurchases during the three months ended March 31, 2024 under our ASR agreement with Bank of America, N.A.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2024, excluding the shares we received under the ASR, we have repurchased a total of 12.6&#160;million shares for $500.0&#160;million at an average price per share of $39.81 under our $750&#160;million 3-year share repurchase plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2024, our Board of Directors authorized a new capital return program to repurchase up to $750.0&#160;million of our outstanding common stock.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-191"
      decimals="INF"
      id="f-750"
      unitRef="shares">154556</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-192"
      decimals="INF"
      id="f-751"
      unitRef="shares">143931</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-191"
      decimals="2"
      id="f-752"
      unitRef="usdPerShare">17.47</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-192"
      decimals="2"
      id="f-753"
      unitRef="usdPerShare">16.87</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-191" decimals="-5" id="f-754" unitRef="usd">2700000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-192" decimals="-5" id="f-755" unitRef="usd">2400000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c-207"
      decimals="INF"
      id="f-756"
      unitRef="shares">262195</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c-208"
      decimals="INF"
      id="f-757"
      unitRef="shares">239919</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="c-207"
      decimals="INF"
      id="f-758"
      unitRef="shares">88825</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="c-208"
      decimals="INF"
      id="f-759"
      unitRef="shares">70733</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-207" decimals="-5" id="f-760" unitRef="usd">6000000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-208" decimals="-5" id="f-761" unitRef="usd">6500000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-209"
      decimals="-5"
      id="f-762"
      unitRef="shares">8700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-210"
      decimals="-5"
      id="f-763"
      unitRef="shares">7800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-211" decimals="-5" id="f-764" unitRef="usd">750000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramPeriodInForce1 contextRef="c-212" id="f-765">P3Y</us-gaap:StockRepurchaseProgramPeriodInForce1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-213"
      decimals="-5"
      id="f-766"
      unitRef="shares">3900000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-213" decimals="-5" id="f-767" unitRef="usd">150000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="c-213"
      decimals="2"
      id="f-768"
      unitRef="usdPerShare">38.51</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-214"
      decimals="-5"
      id="f-769"
      unitRef="shares">4500000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-214" decimals="-5" id="f-770" unitRef="usd">200000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="c-214"
      decimals="2"
      id="f-771"
      unitRef="usdPerShare">44.44</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-215" decimals="-5" id="f-772" unitRef="usd">250000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt contextRef="c-216" decimals="-5" id="f-773" unitRef="usd">-250000000</us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-215"
      decimals="-5"
      id="f-774"
      unitRef="shares">5500000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-217"
      decimals="-5"
      id="f-775"
      unitRef="shares">12600000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-217" decimals="-5" id="f-776" unitRef="usd">500000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="c-217"
      decimals="2"
      id="f-777"
      unitRef="usdPerShare">39.81</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-211" decimals="-6" id="f-778" unitRef="usd">750000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramPeriodInForce1 contextRef="c-212" id="f-779">P3Y</us-gaap:StockRepurchaseProgramPeriodInForce1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-218" decimals="-5" id="f-780" unitRef="usd">750000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-781">Earnings per share&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share is computed by dividing net income for the period by the weighted average number of common shares outstanding during the period, without consideration for common stock equivalents. Outstanding stock options, unvested RSUs, unvested PSUs, common shares expected to be issued under our ESPP and the Convertible Notes are considered common stock equivalents and are only included in the calculation of diluted earnings per common share when net income is reported and their effect is dilutive. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive common shares issuable upon vesting of stock options, RSUs and PSUs are determined using the average share price for each period under the treasury stock method. Potentially dilutive common shares issuable upon conversion of the Convertible Notes are determined using the if-converted method. Since we have committed to settle the principal amount of the Convertible Notes in cash upon conversion only, the number of shares for the conversion spread will be included as a dilutive common stock equivalent. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the numerators and the denominators of the basic and diluted earnings per share computations is as follows (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-align:center;text-indent:24.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.307%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.565%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.547%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.565%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.316%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding for basic earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive potential common stock outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs, PSUs and ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding for diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares which have been excluded from the calculation of diluted earnings per common share because their effect was anti-dilutive include the following (shares in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-indent:24.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.640%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.429%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.821%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.821%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.589%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;    The anti-dilutive securities include outstanding stock options, unvested RSUs, unvested PSUs, common shares expected to be issued under our ESPP and Convertible Notes</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-782">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the numerators and the denominators of the basic and diluted earnings per share computations is as follows (in thousands, except per share amounts):&lt;/span&gt;&lt;div style="margin-top:11pt;text-align:center;text-indent:24.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.307%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.565%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.547%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.565%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.316%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding for basic earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive potential common stock outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs, PSUs and ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding for diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-783" unitRef="usd">76823000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-11" decimals="-3" id="f-784" unitRef="usd">39615000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-785" unitRef="shares">126941000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-11" decimals="-3" id="f-786" unitRef="shares">135027000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-191"
      decimals="-3"
      id="f-787"
      unitRef="shares">1607000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-192"
      decimals="-3"
      id="f-788"
      unitRef="shares">2173000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-219"
      decimals="-3"
      id="f-789"
      unitRef="shares">339000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-220"
      decimals="-3"
      id="f-790"
      unitRef="shares">468000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-221"
      decimals="-3"
      id="f-791"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-222"
      decimals="-3"
      id="f-792"
      unitRef="shares">232000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-793" unitRef="shares">128887000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-11" decimals="-3" id="f-794" unitRef="shares">137900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-795"
      unitRef="usdPerShare">0.61</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-11"
      decimals="2"
      id="f-796"
      unitRef="usdPerShare">0.29</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-797"
      unitRef="usdPerShare">0.60</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-11"
      decimals="2"
      id="f-798"
      unitRef="usdPerShare">0.29</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-799">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares which have been excluded from the calculation of diluted earnings per common share because their effect was anti-dilutive include the following (shares in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-indent:24.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.640%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.429%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.821%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.821%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.589%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;    The anti-dilutive securities include outstanding stock options, unvested RSUs, unvested PSUs, common shares expected to be issued under our ESPP and Convertible Notes</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="-5" id="f-800" unitRef="shares">28200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-11" decimals="-5" id="f-801" unitRef="shares">26200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-802">Commitments and Contingencies&lt;div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of our business. Any of these claims could subject us to costly legal expenses and, while we generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage or our policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on our condensed consolidated statements of income and balance sheets. Additionally, any such claims, whether or not successful, could damage our reputation and business. We currently are not a party to any legal proceedings, the adverse outcome of which, in our opinion, individually or in the aggregate, would have a material adverse effect on our condensed consolidated statements of income or balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-1" id="f-803">&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the fiscal quarter ended ended March&#160;31, 2024, the following officers adopted or terminated any Rule 10b5-1 trading arrangement (as such terms are defined pursuant to Item 408(a) of Regulation S-K) as noted in the table below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.779%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.673%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.947%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.202%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.319%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.830%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.196%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.119%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Trading Arrangement&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Name and Title&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Action&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rule 10b5-1*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-Rule 10b5-1**&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Shares To Be Sold&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Helen Torley&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Termination&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1/30/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;X&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Terminated&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;President and Chief Executive Officer&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Helen Torley&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adoption&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3/22/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;X&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" rowspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td rowspan="2" style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The earlier of 02/13/2025 or date all shares are sold&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;President and Chief Executive Officer&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nicole LaBrosse&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adoption&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3/22/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;X&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The earlier of 06/25/2025 or date all shares are sold&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:35pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Vice President and Chief Financial Officer&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&#160;&#160;&#160;&#160;Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:45pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;**&#160;&#160;&#160;&#160;Non-Rule 10b5-1 trading arrangement&#x201d; as defined in Item 408(c) of Regulation S-K under the Exchange Act.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;The duration of the trading arrangement was until May 30, 2024, or earlier if all transaction under the trading arrangement had been completed. At the time of termination, no shares had been sold under the trading arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Represents a sale of common shares acquired upon exercise of stock options with ten-year term expiring in 2025.&lt;/span&gt;&lt;/div&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-1" id="f-804">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-1" id="f-805">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:TrdArrIndName contextRef="c-223" id="f-806">Helen Torley</ecd:TrdArrIndName>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-224" id="f-807">true</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:TrdArrTerminationDate contextRef="c-224" id="f-808">1/30/2024</ecd:TrdArrTerminationDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-225"
      decimals="-3"
      id="f-809"
      unitRef="shares">500000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndTitle contextRef="c-223" id="f-810">President and Chief Executive Officer</ecd:TrdArrIndTitle>
    <ecd:TrdArrIndName contextRef="c-226" id="f-811">Helen Torley</ecd:TrdArrIndName>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-226" id="f-812">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-226" id="f-813">3/22/2024</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-227"
      decimals="-3"
      id="f-814"
      unitRef="shares">110000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndTitle contextRef="c-226" id="f-815">President and Chief Executive Officer</ecd:TrdArrIndTitle>
    <ecd:TrdArrIndName contextRef="c-228" id="f-816">Nicole LaBrosse</ecd:TrdArrIndName>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-228" id="f-817">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-228" id="f-818">3/22/2024</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-229"
      decimals="-3"
      id="f-819"
      unitRef="shares">35000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndTitle contextRef="c-228" id="f-820">Senior Vice President and Chief Financial Officer</ecd:TrdArrIndTitle>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
